FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Buck, KJ Walter, NAR Belknap, JK Hitzemann, R AF Buck, K. J. Walter, N. A. R. Belknap, J. K. Hitzemann, R. TI Toward identification of an alcohol withdrawal quantitative trait gene (QTG) on mouse chromosome 1. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR USA. Oregon Hlth Sci Univ, Portland Alcohol Res Ctr, Portland, OR USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 25A EP 25A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400076 ER PT J AU Kozell, LB Belknap, JK Mayeda, A Buck, KJ AF Kozell, L. B. Belknap, J. K. Mayeda, A. Buck, K. J. TI Fine mapping of two quantitative trait loci for ethanol physical dependence and associated withdrawal on mouse chromosome 1. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 25A EP 25A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400077 ER PT J AU Denmark, DL Walter, NAR Betknap, JK Hitzemann, R Buck, KJ AF Denmark, D. L. Walter, N. A. R. Betknap, J. K. Hitzemann, R. Buck, K. J. TI Candidate gene analyses of a quantitative trait locus (QTL) on mouse chromosome 1 involved in alcohol physical dependence and withdrawal. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland Alchol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 26A EP 26A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400078 ER PT J AU Kivlahan, DR Harris, AM Malte, CA Baer, JS Hawkins, E Calsyn, DA Saxon, AJ AF Kivlahan, D. R. Harris, A. M. Malte, C. A. Baer, J. S. Hawkins, E. Calsyn, D. A. Saxon, A. J. TI Three month retention in SUD specialty care predicts better 6-month abstinence: A weighted propensity score analysis. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 VA Puget Sound, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 59A EP 59A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400211 ER PT J AU Fernandez, E Koek, W Gerhardt, GA Frazer, A France, CP Strong, R AF Fernandez, E. Koek, W. Gerhardt, G. A. Frazer, A. France, C. P. Strong, R. TI Monoamine transporters, monoamine metabolism, and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 65A EP 65A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400237 ER PT J AU Beresford, TP Alfers, J Clapp, L Martin, B Arciniegas, D Laudenslager, M AF Beresford, T. P. Alfers, J. Clapp, L. Martin, B. Arciniegas, D. Laudenslager, M. TI Evidence for cortisol/DHEA dissociation in heavy drinkers SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Denver VA Med Ctr, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400278 ER PT J AU Beresford, TP Alfers, J Clapp, L Martin, B Arciniegas, D Laudenslager, M AF Beresford, T. P. Alfers, J. Clapp, L. Martin, B. Arciniegas, D. Laudenslager, M. TI Hypercortisolism despite abstinence in heavy drinkers SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80220 USA. RI Arciniegas, David/A-3792-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400279 ER PT J AU Veateh, LM Cummings, SE AF Veateh, L. M. Cummings, S. E. TI Impact of drug treatment on sleep during alcohol withdrawal SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Charleston Alochol Res Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 79A EP 79A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400293 ER PT J AU Arciniegas, DB Hudson, C Beresford, TP AF Arciniegas, D. B. Hudson, C. Beresford, T. P. TI Comparison of the mmse and fab as screening measures for alcohol-related cognitive impairment SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80220 USA. RI Arciniegas, David/A-3792-2009 NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 94A EP 94A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400353 ER PT J AU Goldstein, G Cornelius, AMJJ AF Goldstein, Gerald Cornelius, Aaron M. Jacoby jack TI Insight and cognitive function in alcoholism comorbid with bipolar disorder SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 94A EP 94A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400350 ER PT J AU Milner, L Spofford, N Buck, KJ AF Milner, L. Spofford, N. Buck, K. J. TI Baclofen-induced hypothermia in DBA/2J, C57BU/6J and congenic mouse strains. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 122A EP 122A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299400463 ER PT J AU Conigliaro, J Gordon, AJ McGinnis, K Maisto, SA Justice, AC AF Conigliaro, J. Gordon, A. J. McGinnis, K. Maisto, S. A. Justice, A. C. TI Comparison of the temporal stability of alcohol use reported using the self-administered 30 day TLFB method to the phone interview method among clinical samples of HIV plus and HIV-patients. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Univ Kentucky, Lexington, KY 40506 USA. Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. Syracuse Univ, Syracuse, NY 13244 USA. Yale Univ, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 169A EP 169A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401099 ER PT J AU Rasmussen, DD Burke, BL Crites, NJ AF Rasmussen, D. D. Burke, B. L. Crites, N. J. TI Daily nocturnal melatonin treatment prevents the decrease in thymus size induced by chronic ethanol consumption SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 173A EP 173A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401113 ER PT J AU Beresford, TP Arciniegas, DB Alfers, J Clapp, L Martin, B Du, Y Liu, D Shen, D Davatzikos, C AF Beresford, T. P. Arciniegas, D. B. Alfers, J. Clapp, L. Martin, B. Du, Y. Liu, D. Shen, D. Davatzikos, C. TI Disulfiram adherence preserves total hippocampus volume during the first 6 months of abstinence SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO 80220 USA. RI Arciniegas, David/A-3792-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 190A EP 190A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401183 ER PT J AU Durazzo, TC Studholme, C Song, E Weiner, MW Meyerhoff, DJ AF Durazzo, T. C. Studholme, C. Song, E. Weiner, M. W. Meyerhoff, D. J. TI MRI assessment of regional brain volumes in community-based heavy drinkers: The effects of chronic cigarette smoking SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 194A EP 194A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401200 ER PT J AU Lieber, CS Cao, Q DeCarli, LM Leo, MA Mak, KM Ponomarenko, A Ren, C Wang, X AF Lieber, C. S. Cao, Q. DeCarli, L. M. Leo, M. A. Mak, K. M. Ponomarenko, A. Ren, C. Wang, X. TI Alcoholic liver disease is aggravated by diets containing both medium chain triglycerides (MCT) and long-chain triglycerides (LCT) but in the absence of LCT it is attenuated by MCT SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Mt Sinai Sch Med, Bronx, NY 10468 USA. James J Peters VA Med Ctr, Bronx, NY 10468 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 221A EP 221A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401305 ER PT J AU Hitzemann, R Belknap, J McWeeney, S AF Hitzemann, R. Belknap, J. McWeeney, S. TI On the integration of multiple strain, short-term selective breeding (STSB), QTL and gene expression data to detect candidate quantitative trait genes for ethanol preference. SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 236A EP 236A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401363 ER PT J AU Myrick, H AF Myrick, H. TI Neuroimaging and alcohol endophenotypes SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Med Univ S Carolina, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 253A EP 253A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401434 ER PT J AU Veatch, LM AF Veatch, Lynn M. TI Impact of benzodiazepine treatment on sleep during withdrawal in a mouse model of chronic alcohol exposure SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 29th Annual Meeting of the Research-Society-on-Alcoholism CY JUN 23-29, 2006 CL Baltimore, MD SP Res Soc Alcoholism C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 SU S BP 270A EP 270A PG 1 WC Substance Abuse SC Substance Abuse GA 053IS UT WOS:000238299401502 ER PT J AU Gazdzinski, S Durazzo, TC Jahng, GH Ezekiel, F Banys, P Meyerhoff, DJ AF Gazdzinski, S Durazzo, TC Jahng, GH Ezekiel, F Banys, P Meyerhoff, DJ TI Effects of chronic alcohol dependence and chronic cigarette smoking on cerebral perfusion: A preliminary magnetic resonance study SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE alcohol dependence; cigarette smoking; regional brain perfusion; cerebral blood flow; magnetic resonance (MR); neurocognition ID POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; NICOTINE DEPENDENCE; MAJOR DEPRESSION; GLUCOSE-METABOLISM; WORKING-MEMORY; TC-99M-BICISATE SPECT; COMPUTED-TOMOGRAPHY; BRAIN METABOLISM; SHORT-TERM AB Although approximately 80% of individuals with alcohol use disorders are chronic smokers and despite reported associations between chronic cigarette smoking and lower cerebral perfusion in nonalcoholics, previous brain perfusion studies with alcoholics did not account for the potential effects of concurrent chronic cigarette smoking. One-week-abstinent alcohol-dependent individuals in treatment (ALC) [19 smokers (sALC) and 10 nonsmokers (nsALC)] and 19 healthy light drinking, nonsmoking control participants (nsLD) were scanned with a pulsed arterial spin labeling method to measure cerebral perfusion without an exogenous contrast agent. Studies were performed with 2 different postlabeling delay times (time from labeling pulse to the excitation pulse; PLD=1,500 ms and PLD=1,200 ms) to assess the potential effect of arterial blood transit time on the perfusion. Average gray matter (GM) and white matter (WM) perfusion for the frontal and parietal lobes were calculated for each hemisphere from voxels containing at least 90% GM and 100% WM. At PLD=1,500 ms, multivariate analyses compared ALC (combined sALC and nsALC) with nsLD (p=0.04) and contrasted sALC, nsALC, and nsLD (p=0.006). ALC, as a group, showed 13% lower frontal GM perfusion (p=0.005) and 8% lower parietal GM perfusion than nsLD (p=0.03). With ALC separated into smokers and nonsmokers, sALC showed 19% lower frontal GM perfusion (p=0.001) and 12% lower parietal GM perfusion than nsLD (p=0.004). In sALC, a higher number of cigarettes smoked per day was associated with lower perfusion. Overall, regional perfusion did not differ significantly between nsALC and nsLD. Results obtained with PLD=1,200 ms generally confirmed the 1,500 ms findings. This study provides preliminary evidence that chronic cigarette smoking adversely affects cerebral perfusion in frontal and parietal GM of 1-week-abstinent alcohol-dependent individuals. These results are in line with our spectroscopic and structural magnetic resonance studies that suggest chronic cigarette smoking compounds the detrimental effects of alcohol dependence on brain neurobiology. C1 NCIRE, San Francisco, CA 94110 USA. San Francisco Vet Adm Med Ctr, Magnet Resonance Unit, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Gazdzinski, S (reprint author), NCIRE, 4150 Clement St 114M, San Francisco, CA 94110 USA. EM spg@itsa.ucsf.edu FU NIAAA NIH HHS [R01 AA010788-09, AA10788, R01 AA010788, R01 AA010788-08, R01 AA010788-10, R01 AA010788-11] NR 75 TC 22 Z9 22 U1 1 U2 8 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2006 VL 30 IS 6 BP 947 EP 958 DI 10.1111/j.1530-0277.2006.00108.x PG 12 WC Substance Abuse SC Substance Abuse GA 046KQ UT WOS:000237810900006 PM 16737452 ER PT J AU Sachs, G Shin, JM Howden, CW AF Sachs, G Shin, JM Howden, CW TI Review article: the clinical pharmacology of proton pump inhibitors SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article; Proceedings Paper CT 13th World Congress of Gastroenterology CY SEP, 2005 CL Montreal, CANADA ID GASTROESOPHAGEAL REFLUX DISEASE; RANDOMIZED CONTROLLED-TRIAL; ESOMEPRAZOLE 40 MG; PLASMA HALF-LIFE; GASTRIC H,K-ATPASE; ACID SUPPRESSION; INTRAGASTRIC PH; EROSIVE ESOPHAGITIS; HEALTHY-VOLUNTEERS; BINDING-SITES AB Proton pump inhibitors inhibit the gastric H+/K+-ATPase via covalent binding to cysteine residues of the proton pump. All proton pump inhibitors must undergo acid accumulation in the parietal cell through protonation, followed by activation mediated by a second protonation at the active secretory canaliculus of the parietal cell. The relative ease with which these steps occur with different proton pump inhibitors underlies differences in their rates of activation, which in turn influence the location of covalent binding and the stability of inhibition. Slow activation is associated with binding to a cysteine residue involved in proton transport that is located deep in the membrane. However, this is inaccessible to the endogenous reducing agents responsible for restoring H+/K+-ATPase activity, favouring a longer duration of gastric acid inhibition. Pantoprazole and tenatoprazole, a novel proton pump inhibitor which has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, are activated more slowly than other proton pump inhibitors but their inhibition is resistant to reversal. In addition, tenatoprazole has a greatly extended plasma half-life in comparison with all other proton pump inhibitors. The chemical and pharmacological characteristics of tenatoprazole give it theoretical advantages over benzimidazole-based proton pump inhibitors that should translate into improved acid control, particularly during the night. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA. RP Sachs, G (reprint author), WLA VAMC, 11301 Wilshire Blvd,Bldg 113,Room 324A, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu NR 34 TC 127 Z9 130 U1 4 U2 20 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUN PY 2006 VL 23 SU 2 BP 2 EP 8 DI 10.1111/j.1365-2036.2006.02943.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 057TV UT WOS:000238619000002 PM 16700898 ER PT J AU Ioannou, GN Liou, IW Weiss, NS AF Ioannou, GN Liou, IW Weiss, NS TI Serum bilirubin and colorectal cancer risk: a population-based cohort study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID COLON-CANCER; ALBUMIN; DAMAGE; ANTIOXIDANT; MORTALITY AB Background Bilirubin has antioxidant properties and has been postulated to protect against the development of malignancies. Aim To investigate whether baseline serum bilirubin concentration predicts the incidence of colorectal cancer in a nationally representative sample of the US population. Methods Participants of the first National Health and Nutrition Examination Survey were divided into four groups based on quartiles of baseline serum bilirubin concentration in mg/dL: < 0.38 (n = 1410), 0.38 to < 0.5 (n = 1287), 0.5 to < 0.6 (n = 1048) and >= 0.6 (n = 1742). The incidence of colorectal cancer during the following 20 years was determined from hospitalization records and death certificates. Results 110 cases of colorectal cancer-related death or hospitalization were identified among 5487 participants during 88 339 person-years of follow-up (12 per 10 000 person-years). There was no association between baseline serum bilirubin concentration and the incidence of colorectal cancer either in unadjusted analyses or after adjusting for age, gender, ethnicity, smoking, body mass index, alcohol consumption and educational attainment. Conclusions Baseline serum bilirubin concentration did not predict the subsequent incidence of colorectal cancer in this population-based cohort study. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, NW Hepatitis C Resource Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, S-111-Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 20 TC 10 Z9 10 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD JUN 1 PY 2006 VL 23 IS 11 BP 1637 EP 1642 DI 10.1111/j.1365-2036.2006.02939.x PG 6 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 042GN UT WOS:000237516000017 PM 16696814 ER PT J AU Boden, WE O'Rourke, RA Teo, KK Hartigan, PM Maron, DJ Kostuk, W Knudtson, M Dada, M Casperson, P Harris, CL Spertus, JA Shaw, L Chaitman, BR Mancini, J Berman, DS Weintraub, WS AF Boden, William E. O'Rourke, Robert A. Teo, Koon K. Hartigan, Pamela M. Maron, David J. Kostuk, William Knudtson, Merril Dada, Marcin Casperson, Paul Harris, Crystal L. Spertus, John A. Shaw, Leslee Chaitman, Bernard R. Mancini, John Berman, Daniel S. Weintraub, William S. CA COURAGE trial coprincipal investig TI Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424 SO AMERICAN HEART JOURNAL LA English DT Article ID CORONARY-ARTERY-DISEASE; AMERICAN-HEART-ASSOCIATION; TREATMENT PANEL-III; MEDICAL THERAPY; RANDOMIZED TRIAL; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; STABLE ANGINA; RITA-2 TRIAL; TASK-FORCE AB Background Major improvements in medical therapy and percutaneous coronary intervention (PCI) for coronary heart disease have occurred during the past decade, but no randomized trial has compared these 2 strategies for the "hard" clinical end points of death or myocardial infarction nor have earlier studies incorporated the use of coronary stents and aggressive multifaceted medical therapy during long-term follow-up. Methods The COURAGE trial is a multicenter study of patients with documented myocardial ischemia and angiographically confirmed single or multivessel coronary artery disease who are randomized to a strategy of PCI plus intensive medical therapy or intensive medical therapy alone. Medical therapy in both groups is guideline-driven and includes: aspirin, clopidogrel, simvastatin (low-density lipoprotein cholesterol target 60-85 mg/dL), long-acting metoprolol and/or amlodipine, lisinopril or losartan, and long-acting nitrates, as well as lifestyle interventions. The primary end point is a composite of all-cause mortality or acute myocardial infarction, and there will be 85% power to detect an absolute 4.6% (relative 22%) difference between strategies. The principal hypothesis is that PCI plus aggressive medical therapy (projected event rate 16.4%) will be superior to aggressive medical therapy alone (projected event rate 21%) during a 2.5- to 7-year (median of 5 years) follow-up. Conclusions COURAGE is the largest prospective randomized trial of PCI versus intensive medical therapy to date and will define the incremental benefits of PCI in the setting of contemporary optimal medical therapy for chronic coronary heart disease. A total of 2287 patients have been enrolled, and follow-up will conclude in June 2006. C1 VA Connecticut Healthcare Syst, West Haven, CT USA. Hartford Hosp, Div Cardiol, Hartford, CT 06102 USA. Univ Connecticut, Sch Med, Hartford, CT 06112 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. McMaster Univ, Hlth Sci Ctr, Hamilton, ON L8S 4L8, Canada. VA Connecticut Healthcare Syst, Vet Affairs Cooperat Studies Program Coordinating, West Haven, CT USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. London Hlth Sci Ctr, London, ON, Canada. Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. Clin Res Pharm Coordinating Ctr, Vet Affairs Cooperat Studies Program, Albuquerque, NM USA. Mid Amer Heart Inst, Kansas City, MO USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. St Louis Univ, Sch Med, St Louis, MO 63103 USA. Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. Emory Univ, Emory Ctr Outcomes Res, Atlanta, GA 30322 USA. RP Boden, WE (reprint author), Hartford Hosp, Div Cardiol, 80 Seymour St, Hartford, CT 06102 USA. EM wboden@harthosp.org NR 34 TC 59 Z9 63 U1 1 U2 5 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JUN PY 2006 VL 151 IS 6 BP 1173 EP 1179 DI 10.1016/j.ahj.2005.08.015 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 057SD UT WOS:000238614600004 PM 16781214 ER PT J AU Weintraub, WS Barnett, P Chen, S Hartigan, P Casperson, P O'Rourke, R Boden, WE Lewis, C Veledar, E Becker, E Culler, S Kolm, P Mahoney, EM Dunbar, SB Deaton, C O'Brien, B Goeree, R Blackhouse, G Nease, R Spertus, J Kaufman, S Teo, K AF Weintraub, WS Barnett, P Chen, S Hartigan, P Casperson, P O'Rourke, R Boden, WE Lewis, C Veledar, E Becker, E Culler, S Kolm, P Mahoney, EM Dunbar, SB Deaton, C O'Brien, B Goeree, R Blackhouse, G Nease, R Spertus, J Kaufman, S Teo, K TI Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial SO AMERICAN HEART JOURNAL LA English DT Article ID MULTIVARIATE PREDICTION MODEL; ST-SEGMENT ELEVATION; OF-VETERANS-AFFAIRS; COST-EFFECTIVENESS; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; RAPID ESTIMATION; MEDICAL THERAPY; ANGIOPLASTY; ANGINA AB Percutaneous coronary intervention (PCI) remains a major therapeutic option for the treatment of chronic coronary artery disease. In the COURAGE trial, 2287 patients with chronic coronary disease were randomized between PCI with medical management and medical management alone. Embedded within the COURAGE trial is a detailed economic analysis being conducted in three health care systems: the US Veterans Administration (VA), Canada, and the US non-VA. Resource use and costs are being collected for each system and overall. Survival is assessed internally in the trial with mean follow-up of 4.5 years. Long-term mean survival will be estimated by projecting survival beyond the trial period by extrapolating the in-trial hazard rates. Utility is being assessed at baseline and at 1, 3, and 6 months and annually thereafter, using a computer-administered standard gamble. Quality-adjusted life years are calculated by multiplying survival by utility. The incremental cost-effectiveness ratio of PCI will be defined as the additional cost of PCI divided by the gain in life years and quality-adjusted life years. The 95% confidence regions of efficacy and costs will be determined by bootstrap over a range of acceptability thresholds, which will then be displayed in the cost-effectiveness plane and as a cost-effectiveness acceptability curve. A multilevel regression model will assess cost-effectiveness from a net benefit perspective. These approaches should provide the most detailed assessment available of the cost-effectiveness of PCI for coronary artery disease. C1 Emory Univ, Emory Ctr Outcomes Res, Atlanta, GA 30322 USA. Atlanta VA Med Ctr, Decatur, GA USA. Stanford Univ, VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Yale Univ, New Haven, CT 06520 USA. Univ Texas, S Texas Vet Healthcare Syst, San Antonio, TX 78285 USA. Hartford Hosp, Hartford, CT 06115 USA. New England Res Inst, Watertown, MA 02172 USA. Univ Manchester, Manchester M13 9PL, Lancs, England. McMaster Univ, Hamilton, ON L8S 4L8, Canada. Washington Univ, St Louis, MO 63130 USA. Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. RP Weintraub, WS (reprint author), Emory Univ, Emory Ctr Outcomes Res, Briarcliff Campus, Atlanta, GA 30322 USA. EM wweintraub@christianacare.org RI Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 36 TC 21 Z9 21 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD JUN PY 2006 VL 151 IS 6 BP 1180 EP 1185 DI 10.1016/j.ahj.2005.07.035 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 057SD UT WOS:000238614600005 PM 16781215 ER PT J AU Saw, J Bajzer, C Casserly, IP Exaire, E Haery, C Sachar, R Lee, D Abou-Chebl, A Yadav, JS AF Saw, J Bajzer, C Casserly, IP Exaire, E Haery, C Sachar, R Lee, D Abou-Chebl, A Yadav, JS TI Evaluating the optimal activated clotting time during carotid artery stenting SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; BIVALIRUDIN AB Carotid artery stenting is an alternative to carotid endarterectomy for patients at high risk for surgery for carotid artery stenosis. Although unfractionated heparin is routinely used, there are no published data evaluating the optimal activated clotting time during carotid stenting. In a retrospective analysis of 605 patients who underwent carotid stenting using unfractionated heparin at the Cleveland Clinic Foundation, the optimal peak procedural activated. clotting time associated with the lowest combined incidence of death, stroke, or myocardial infarction was 250 to 299 seconds. (c) 2006 Elsevier Inc. All rights reserved. C1 Vancouver Gen Hosp, Vancouver, BC, Canada. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Mexico, Natl Inst Hlth, Mexico City, DF, Mexico. RP Saw, J (reprint author), Vancouver Gen Hosp, Vancouver, BC, Canada. EM jsaw@interchange.ubc.ca NR 6 TC 16 Z9 18 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUN 1 PY 2006 VL 97 IS 11 BP 1657 EP 1660 DI 10.1016/j.amjcard.2005.12.062 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 051MX UT WOS:000238166300022 PM 16728233 ER PT J AU Yaffe, K Steffens, D AF Yaffe, K Steffens, D TI Epidemiology of mental health: A keystone of geriatric psychiatry SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Editorial Material C1 Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Dept Geriatr Psychiat, San Francisco, CA USA. RP Steffens, D (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Box 3903, Durham, NC 27710 USA. EM steff001@mc.duke.edu NR 11 TC 0 Z9 0 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2006 VL 14 IS 6 BP 477 EP 479 DI 10.1097/01.JGP.0000222934.91587.86 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 047TE UT WOS:000237900800001 PM 16731715 ER PT J AU Nathan, RV Rhew, DC Murray, C Bratzler, DW Houck, PM Weingarten, SR AF Nathan, RV Rhew, DC Murray, C Bratzler, DW Houck, PM Weingarten, SR TI In-hospital observation after antibiotic switch in pneumonia: A national evaluation SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE pneumonia; antibiotics; hospital; health services research ID COMMUNITY-ACQUIRED PNEUMONIA; LOW-RISK PATIENTS; INTRAVENOUS ANTIBIOTICS; INTERVENTIONAL TRIAL; OBSERVATION PERIOD; DISCHARGE; CARE AB PURPOSE: To evaluate the clinical benefit of in-hospital observation after the switch from intravenous (IV) to oral antibiotics in a large Medicare population. Retrospective studies of relatively small size indicate that the practice of in-hospital observation after the switch from IV to oral antibiotics for patients hospitalized with community-acquired pneumonia (CAP) is unnecessary. METHODS: We performed a retrospective examination of the US Medicare National Pneumonia Project database. Eligible patients were discharged with an ICD-9-CM diagnosis consistent with community-acquired pneumonia and divided into 2 groups: 1) a "not observed" cohort, in which patients were discharged on the same day as the switch from IV to oral antibiotics and 2) an "observed for 1 day" cohort, in which patients remained hospitalized for 1 day after the switch from IV to oral antibiotics. We compared clinical outcomes between these 2 cohorts. RESULTS: A total of 39,242 cases were sampled, representing 4341 hospitals in all 50 states and the District of Columbia. There were 5248 elderly patients who fulfilled eligibility criteria involving a length of stay of no more than 7 hospital days (2536 "not observed" and 2712 "observed for 1 day" patients). Mean length of stay was 3.8 days for the "not observed" cohort and 4.5 days for the "observed for 1 day" cohort (P <.0001). There was no significant difference in 14-day hospital readmission rate (7.8% in the "not observed" cohort vs 7.2% "observed for 1 day" cohort, odds ratio 0.91; 95% confidence interval [CI] 0.74-1.12; P =. 367) and 30-day mortality rate (5.1% "not observed" cohort vs 4.4% in the "observed for 1 day" cohort, odds ratio 0.86; 95% CI, 0.67-1.11; P =. 258) between the "not observed" and "observed for 1 day" cohorts. CONCLUSIONS: Our analysis of the US Medicare Pneumonia Project database provides further evidence that the routine practice of in-hospital observation after the switch from IV to oral antibiotics for patients with CAP may be avoided in patients who are clinically stable although these findings should be verified in a large randomized controlled trial. (c) 2006 Elsevier Inc. All rights reserved. C1 Zynx Hlth Inc, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Dept Med, Los Angeles, CA USA. Cedars Sinai Med Ctr, Dept Hlth Serv Res, Los Angeles, CA 90048 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Oklahoma Fdn Med Qual, Oklahoma City, OK USA. Ctr Medicare, Seattle, WA USA. Ctr Medicaid Serv, Seattle, WA USA. RP Rhew, DC (reprint author), Zynx Hlth Inc, 10880 Wilshire Blvd,Suite 1450, Los Angeles, CA 90024 USA. EM drhew@zynx.com NR 18 TC 14 Z9 16 U1 0 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD JUN PY 2006 VL 119 IS 6 BP 512 EP 518 DI 10.1016/j.amjmed.2005.09.012 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 050TD UT WOS:000238110500012 ER PT J AU Bauman, WA Spungen, AM Wang, J Pierson, RN Schwartz, E AF Bauman, WA Spungen, AM Wang, J Pierson, RN Schwartz, E TI Relationship of fat mass and serum estradiol with lower extremity bone in persons with chronic spinal cord injury SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE bone mineral density; bone mineral content; lean mass; estrogen; paraplegia ID HORMONE-BINDING GLOBULIN; SEX STEROID-LEVELS; BODY-COMPOSITION; MINERAL DENSITY; TURNOVER MARKERS; GROWTH-HORMONE; ELDERLY MEN/; OLDER MEN; ESTROGEN; TESTOSTERONE AB In the spinal cord injury (SCI) population, a relationship between adiposity and leg bone has not been reported, nor one between serum estradiol and leg bone mass. A cross-sectional, comparative study of 10 male pairs of monozygotic twins discordant for SCI was performed. Relationships were determined among bone mineral density (BMD), bone mineral content (BMC), lean mass, fat mass, and serum sex steroids. In the twins with SCI, significant relationships were evident between leg BMD or BMC with total body percent fat (r(2) = 0.49, P < 0.05; r(2) = 0.45, P = 0.05), leg fat mass (r(2) = 0.76, P < 0.0005; r(2) = 0.69, P = 0.005), and serum estradiol (r(2) = 0.40, P = 0.05; r(2) = 0.37, P = 0.05). By stepwise regression analysis, in the twins with SCI, leg fat mass was found to be the single most significant predictor of leg BMD or BMC (F = 12.01, r(2) = 0.76, P = 0.008; F = 50.87, r(2) = 0.86, P < 0.0001). In the able-bodied twins, leg lean mass correlated with leg BMD and BMC (r(2) = 0.58, P = 0.01; r(2) = 0.87, P = 0.0001). By use of within-pair differences, significant correlations were found for leg lean mass loss with leg BMD loss (r(2) = 0.56, P = 0.01) or leg BMC loss (r(2) = 0.64, P = 0.0005). In conclusion, in twins with SCI, significant correlations were observed between fat mass and leg BMD or BMC as well as between serum estradiol values and leg BMD. The magnitude of the leg muscle mass loss was correlated with the magnitude of bone loss. C1 Vet Affairs Med Ctr, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence, Bronx, NY USA. Vet Affairs Med Ctr, Spinal Cord Damage Res Ctr, Bronx, NY USA. Vet Affairs Med Ctr, Med Serv, Bronx, NY USA. Vet Affairs Med Ctr, Spinal Cord Injury Serv, Bronx, NY USA. Vet Affairs Med Ctr, Res Serv, Bronx, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. Columbia Univ, St Lukes Roosevelt Hosp Ctr, Body Composit Unit, New York, NY 10027 USA. RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Spinal Cord Damage Res Ctr, Rm 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM wabauman@earthlink.net NR 41 TC 12 Z9 12 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUN PY 2006 VL 290 IS 6 BP E1098 EP E1103 DI 10.1152/ajpendo.00250.2005 PG 6 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 046HX UT WOS:000237803300005 PM 16418207 ER PT J AU Sweeney, TR Moser, AH Shigenaga, JK Grunfeld, C Feingold, KR AF Sweeney, TR Moser, AH Shigenaga, JK Grunfeld, C Feingold, KR TI Decreased nuclear hormone receptor expression in the livers of mice in late pregnancy SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE farnesoid X receptor; liver X receptor; peroxisome proliferator-activated receptor; retinoid X receptor; lipid metabolism ID ACUTE-PHASE RESPONSE; PROLIFERATOR-ACTIVATED RECEPTORS; COACTIVATOR 1-ALPHA PGC-1-ALPHA; ELEMENT-BINDING PROTEIN-1C; X-RECEPTOR; CHOLESTEROL-METABOLISM; FATTY-ACIDS; SIGNALING PATHWAYS; LIPID HOMEOSTASIS; STEROL SYNTHESIS AB During the third trimester of pregnancy, there is an increase in serum triglyceride and cholesterol levels. The mechanisms accounting for these changes in lipid metabolism during pregnancy are unknown. We hypothesized that, during pregnancy, the expression of nuclear hormone receptors involved in regulating lipid metabolism would decrease. In 19-day pregnant mice, serum triglyceride and non-HDL cholesterol levels were significantly increased, whereas total cholesterol was slightly decreased, because of a decrease in the HDL fraction. Peroxisome proliferator-activated receptor ( PPAR)alpha, PPAR(-/-), and PPAR gamma, liver X receptor (LXR)alpha and LXR beta, farnesoid X receptor ( FXR), and retinoid X receptor (RXR)alpha, RXR beta, and RXR gamma mRNA levels were significantly decreased in the livers of 19-day pregnant mice. Additionally, the expressions of thyroid receptor (TR)alpha, pregnane X receptor, sterol regulatory element-binding proteins ( SREBP)-1a, SREBP-1c, SREBP-2, and liver receptor homolog 1 were also decreased, whereas the expression of TR beta, constitutive androstane receptor, and hepatic nuclear factor 4 showed no significant change. mRNA levels of the PPAR target genes carnitine-palmitoyl transferase 1 alpha and acyl- CoA oxidase, the LXR target genes SREBP1c, ATP-binding cassettes G5 and G8, the FXR target gene SHP, and the TR target genes malic enzyme and Spot14 were all significantly decreased. Finally, the expressions of PPAR gamma coactivator ( PGC)-1 alpha and PGC-1 alpha, known activators of a number of nuclear hormone receptors, were also significantly decreased. The decreases in expression of RXRs, PPARs, LXRs, FXR, TRs, SREBPs, and PGC-1s could contribute to the alterations in lipid metabolism during late pregnancy. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. US Dept Vet Affairs, Med Ctr, Metab Sect, San Francisco, CA USA. RP Feingold, KR (reprint author), SFVAMC Metab Sect, 4150 Clement St,111F, San Francisco, CA 94121 USA. EM kfngld@itsa.ucsf.edu NR 62 TC 23 Z9 24 U1 1 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUN PY 2006 VL 290 IS 6 BP E1313 EP E1320 DI 10.1152/ajpendo.00071.2005 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 046HX UT WOS:000237803300032 PM 16434558 ER PT J AU Meyer, AM Dwyer-Nield, LD Hurteau, G Keith, RL Ouyang, Y Freed, BM Kisley, LR Geraci, MW Bonventre, JV Nemenoff, RA Malkinson, AM AF Meyer, AM Dwyer-Nield, LD Hurteau, G Keith, RL Ouyang, Y Freed, BM Kisley, LR Geraci, MW Bonventre, JV Nemenoff, RA Malkinson, AM TI Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A(2) null mice SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE eicosanoids; Clara cells; macrophages ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PLATELET-ACTIVATING-FACTOR; CHEMOKINE RECEPTOR; LUNG TUMORIGENESIS; EPITHELIAL-CELLS; TRANSGENIC MICE; II CELLS; EXPRESSION; CYTOKINE; MACROPHAGES AB Administration of butylated hydroxytoluene (BHT) to mice causes lung damage characterized by the death of alveolar type I pneumocytes and the proliferation and subsequent differentiation of type II cells to replace them. Herein, we demonstrate this injury elicits an inflammatory response marked by chemokine secretion, alveolar macrophage recruitment, and elevated expression of enzymes in the eicosanoid pathway. Cytosolic phospholipase A(2) (cPLA(2)) catalyzes release of arachidonic acid from membrane phospholipids to initiate the synthesis of prostaglandins and other inflammatory mediators. A role for cPLA(2) in this response was examined by determining cPLA(2) expression and enzymatic activity in distal respiratory epithelia and macrophages and by assessing the consequences of cPLA(2) genetic ablation. BHT-induced lung inflammation, particularly monocyte infiltration, was depressed in cPLA(2) null mice. Monocyte chemotactic protein-1 (MCP-1) content in bronchoalveolar lavage fluid increases after BHT treatment but before monocyte influx, suggesting a causative role. Bronchiolar Clara cells isolated from cPLA(2) null mice secrete less MCP-1 than Clara cells from wild-type mice, consistent with the hypothesis that cPLA(2) is required to secrete sufficient MCP-1 to induce an inflammatory monocytic response. C1 Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Div Pulm Sci & Crit Care Med, Dept Med, Denver, CO USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Nephrol, Charlestown, MA USA. Harvard Univ, MIT, Div Hlth Sci & Technol, Charlestown, MA USA. RP Malkinson, AM (reprint author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Box C238,4200 E 9th Ave, Denver, CO 80262 USA. EM al.malkinson@uchsc.edu FU NCI NIH HHS [CA 93641, CA 33497] NR 43 TC 11 Z9 11 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JUN PY 2006 VL 290 IS 6 BP L1260 EP L1266 DI 10.1152/ajplung.00182.2005 PG 7 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 040VG UT WOS:000237408200025 PM 16443645 ER PT J AU Fu, Y Subramanya, A Rozansky, D Cohen, DM AF Fu, Y Subramanya, A Rozansky, D Cohen, DM TI WNK kinases influence TRPV4 channel function and localization SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE hypertension; calcium balance; hypotonicity; osmoregulation ID CATION CHANNEL; LARGE FAMILY; MUTANT WNK4; HYPERTENSION; PROTEIN; EPITHELIA; KIDNEY; HYPERCALCIURIA; IDENTIFICATION; HYPERKALEMIA AB TRPV4, a renally expressed nonselective cation channel of the transient receptor potential (TRP) family, is gated by hypotonicity. Kinases of the WNK family influence expression and function of the thiazide-sensitive Na(+)-Cl(-) cotransporter, and monogenic human hypertension has been linked to mutations in the gene coding for WNK4. Along with TRPV4, WNK isoforms are highly expressed in the distal nephron. We show here that coexpression of WNK4 downregulates TRPV4 function in human embryonic kidney (HEK-293) cells and that this effect is mediated via decreased cell surface expression of TRPV4; total abundance of TRPV4 in whole cell lysates is unaffected. The effect of the related kinase WNK1 on TRPV4 function and surface expression was similar to that of WNK4. Disease-causing point mutations in WNK4 abrogate, but do not eliminate, the inhibitory effect on TRPV4 function. In contrast to wild-type WNK4, a kinase-dead WNK4 point mutant failed to influence TRPV4 trafficking; however, deletion of the entire WNK4 kinase domain did not blunt the effect of WNK4 on localization of TRPV4. Deletion of the extreme COOH-terminal putative coiled-coil domain of WNK4 abolished its effect. In immunoprecipitation experiments, we were unable to detect direct interaction between TRPV4 and either WNK kinase. In aggregate, these data indicate that TRPV4 is functionally regulated by WNK family kinases at the level of cell surface expression. Because TRPV4 and WNK kinases are coexpressed in the distal nephron in vivo and because there is a tendency toward hypercalcemia in TRPV4(-/-) mice, we speculate that this pathway may impact systemic Ca(2+) balance. In addition, because WNK kinases and TRPV4 are activated by anisotonicity, they may comprise elements of an osmosensing or osmotically responsive signal transduction cascade in the distal nephron. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Nephrol, Dept Pediat, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Mailcode PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu NR 45 TC 50 Z9 52 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUN PY 2006 VL 290 IS 6 BP F1305 EP F1314 DI 10.1152/ajprenal.00391.2005 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 040HC UT WOS:000237368600005 PM 16403833 ER PT J AU Gelasco, AK Raymond Jr AF Gelasco, AK Raymond, JR TI Indoxyl sulfate induces complex redox alterations in mesangial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE electron paramagnetic spin resonance; fluorescence; microphysiometry; superoxide; NADPH oxidase; reactive oxygen species; uremic toxins ID ORGANIC ANION TRANSPORTERS; ACTIVATED PROTEIN-KINASE; HUMAN SERUM-ALBUMIN; SUPEROXIDE RADICALS; UREMIC TOXIN; RENAL-FAILURE; DIABETIC RATS; ORAL SORBENT; SPIN-TRAP; IN-VIVO AB Indoxyl sulfate is a protein metabolite that is concentrated in the serum of patients with chronic renal insufficiency. It also is a uremic toxin that has been implicated in the progression of chronic renal disease in rodent models. We have shown previously that mesangial cell redox status is related to activation of mitogen-activated protein kinases and cell proliferation, which are factors related to glomerular damage. We used three methods to examine the ability of indoxyl sulfate to alter mesangial cell redox as a possible mechanism for its toxicity. Indoxyl sulfate increases mesangial cell reduction rate in a concentration-dependent manner as demonstrated by redox microphysiometry. Alterations occurred at concentrations as low as 100 mu M, with more marked alterations occurring at higher concentrations associated with human renal failure. We demonstrated that indoxyl sulfate induces the production of intracellular reactive oxygen species (ROS) in mesangial cells (EC(50) = 550 mu M) by using the ROS-sensitive fluorescent dye CM-DCF. ROS generation was only partially (similar to 50%) inhibited by the NADPH oxidase inhibitor diphenylene iodinium at low (<= 300 mu M) indoxyl sulfate concentrations. Diphenylene iodinium was without effect at higher concentrations of indoxyl sulfate. We also used electron paramagnetic spin resonance spectroscopy with extracellular and intracellular spin traps to show that indoxyl sulfate increases extracellular SOD-sensitive O(2)(-)center dot production and intracellular hydroxyl radical production that may derive from an initial O(2)(-)center dot burst. These results document that indoxyl sulfate, when applied to renal mesangial cells at pathological concentrations, induces rapid and complex changes in mesangial cell redox. C1 Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Gelasco, AK (reprint author), Med Univ S Carolina, Div Nephrol, Dept Med, 96 Jonathan Lucas St,829 CSB, Charleston, SC 29425 USA. EM gelascoa@musc.edu FU NCRR NIH HHS [S10RR-13005, S10RR-13656]; NIDDK NIH HHS [DK-54720, DK-59950] NR 42 TC 68 Z9 70 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUN PY 2006 VL 290 IS 6 BP F1551 EP F1558 DI 10.1152/ajprenal.00281.2004 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 040HC UT WOS:000237368600034 PM 16434574 ER PT J AU Sabol, KE Echevarria, KL Lewis, JS AF Sabol, KE Echevarria, KL Lewis, JS TI Community-associated methicillin-resistant Staphylococcus aureus: New bug, old drugs SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE methicillin resistance; community-acquired; community associated; Panton-Valentine leukocidin; Staphylococcus aureus; mec ID PANTON-VALENTINE LEUKOCIDIN; SOFT-TISSUE INFECTIONS; OF-THE-LITERATURE; CIPROFLOXACIN RESISTANCE; TRIMETHOPRIM-SULFAMETHOXAZOLE; SKIN INFECTIONS; MINOCYCLINE; EMERGENCE; STRAINS; VANCOMYCIN AB OBJECTIVE: To discuss community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections and evaluate older antibiotics as suitable therapeutic treatment options. DATA SOURCES: Searches of MEDLINE, EMBASE, and the Cochrane Library (1966-May 2006) were performed using the key terms methicillin resistance, community-acquired, community associated, treatment, Staphylococcus aureus, mec, and Panton-Valentine leukocidin. STUDY SELECTION AND DATA EXTRACTION: All articles were critically evaluated and all relevant information was included in this review. DATA SYNTHESIS: There has been a documented shift of methicillin resistance occurring in staphylococcal infections manifested within the community. Infections caused by CA-MRSA possess unique characteristics including lack of hospital-associated risk factors, improved susceptibility patterns, distinct genotypes, faster doubling times, and additional toxins. Potential therapeutic options to treat these infections include trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, tetracyclines, fluoroquinolones, and new antimicrobials. CONCLUSIONS: CA-MRSA infections can be successfully treated with older, oral antibiotic agents including TMP/SMX, clindamycin, and tetracyclines. Fluoroquinolones and linezolid should be avoided as first-line agents. C1 Univ Texas, Hlth Syst, Serv Pharm, San Antonio, TX 78229 USA. Parkland Hlth & Hosp Syst, Dallas, TX USA. S Texas Vet Healthcare Syst, Serv Pharm, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Clin Pharm, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78285 USA. RP Lewis, JS (reprint author), Univ Texas, Hlth Syst, Serv Pharm, 4502 Med Dr, San Antonio, TX 78229 USA. EM James.Lewis@uhs-sa.com NR 82 TC 31 Z9 32 U1 0 U2 1 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD JUN PY 2006 VL 40 IS 6 BP 1125 EP 1133 DI 10.1345/aph.1G404 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 054IF UT WOS:000238369300016 PM 16735661 ER PT J AU Cadle, RM Mansouri, MD Darouiche, RO AF Cadle, RM Mansouri, MD Darouiche, RO TI Vancomycin-induced elevation of liver enzyme levels SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE bioavailability; liver enzymes; vancomycin ID ORAL VANCOMYCIN; CLOSTRIDIUM-DIFFICILE; SYSTEMIC ABSORPTION; TOXICITY; THERAPY; COLITIS; DIGOXIN AB OBJECTIVE: To report a case of oral vancomycin-induced elevation of liver enzyme levels. CASE SUMMARY: A 57-year-old man with multiple medical conditions requiring systemic antibiotic therapy developed numerous Clostridium difficile-associated enterocolitis episodes. The patient did not respond adequately to oral metronidazole, as evidenced by his continuing diarrhea. He was treated with oral vancomycin on 5 separate occasions (with doses from 125 to 500 mg/day), each of which resulted in significant elevations in alanine aminotransferase (to 371 U/L) and aspartate aminotransferase (to 203 U/L) levels. The elevations resolved on each occasion with discontinuation of vancomycin. DISCUSSION: Vancomycin, a glycopepticle antibiotic, has primary activity against gram-positive bacteria. Oral vancomycin can be used for the treatment of C. difficile-associated enterocolitis in patients who fail to respond to or are intolerant to metronidazole therapy. Oral vancomycin has very poor bioavailability and, as of May 4, 2006, has not been associated with hepatic toxicity. Inflammatory bowel disease processes can result in increased absorption of oral vancomycin. CONCLUSIONS: This is the first reported case of oral vancomycin-induced elevation of hepatic enzyme levels. Use of the Naranjo probability scale indicated that this was a probable adverse drug-associated event. C1 Michael E DeBakey Vet Affairs Med Ctr, Pharm Serv 119, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Cadle, RM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Pharm Serv 119, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM cadle.richardmark@med.va.gov NR 16 TC 8 Z9 8 U1 0 U2 0 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD JUN PY 2006 VL 40 IS 6 BP 1186 EP 1189 DI 10.1345/aph.1G668 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 054IF UT WOS:000238369300028 PM 16720708 ER PT J AU Tomlinson, JS Ko, CY AF Tomlinson, JS Ko, CY TI Patient satisfaction: An increasingly important measure of quality SO ANNALS OF SURGICAL ONCOLOGY LA English DT Editorial Material ID CANCER; CARE C1 Univ Calif Los Angeles, Ctr Surg Outcomes & Qual, W Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. RP Ko, CY (reprint author), Univ Calif Los Angeles, Ctr Surg Outcomes & Qual, W Los Angeles VA Med Ctr, 8-684 Factor Bldg,Box 951781, Los Angeles, CA 90095 USA. EM cko@mednet.ucla.edu NR 7 TC 12 Z9 14 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD JUN PY 2006 VL 13 IS 6 BP 764 EP 765 DI 10.1245/ASO.2006.01.904 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 043AJ UT WOS:000237571400003 PM 16614874 ER PT J AU Bosso, JA Mauldin, PD AF Bosso, JA Mauldin, PD TI Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID FIBRONECTIN-BINDING PROTEINS; INTENSIVE-CARE UNITS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; CIPROFLOXACIN RESISTANCE; HOSPITALIZED-PATIENTS; ECONOMIC OUTCOMES; US HOSPITALS; ANTIBIOTIC-RESISTANCE AB The use of fluoroquinolones has been linked to increasing bacterial resistance and infection and/or colonization with already resistant pathogens both as a risk factor and based on volume of use. Changes in individual fluoroquinolones used in an institution may also be related to these clinical problems. Interrupted time series analysis, which allows for assessment of the associations of an outcome attributable to a specific event in time, was used to study the effect of changes in our hospital's fluoroquinolone formulary on fluoroquinolone susceptibility rates in select gram-negative pathogens and the methicillin-resistant Staphylococcus aureus (MRSA) isolation rate. Susceptibility rates to ciprofloxacin were considered for the period of 1993 through 2004, while the MRSA isolation rate was assessed from 1995 through 2004. Levofloxacin was added to the formulary in 1999, and gatifloxacin was substituted for levofloxacin in 2001. Statistically significant changes in the already declining rates of susceptibility of Pseudomonas aeruginosa (P, 0.042) and Escherichia coli (P, 0.004) to ciprofloxacin and in the already rising MRSA isolation rate (P, 0.001) were associated with the addition of levofloxacin to the formulary. Substitution of gatifloxacin for levofloxacin on the formulary was associated with reversals in the downward trend in E. coli susceptibility to ciprofloxacin and the upward trend in MRSA isolation rate. No associations were detected on susceptibility of Klebsiella pneumoniae or Proteus mirabilis to ciprofloxacin. These findings suggest that potential changes in susceptibility to fluoroquinolones and isolation of MRSA may vary by both drug and organism. C1 Med Univ S Carolina, Coll Pharm, Dept Pharm & Clin Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Coll Med, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Coll Pharm, Ctr Medicat Safety, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bosso, JA (reprint author), Med Univ S Carolina, Coll Pharm, Dept Pharm & Clin Sci, POB 250140, Charleston, SC 29425 USA. EM bossoja@musc.edu NR 51 TC 26 Z9 28 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUN PY 2006 VL 50 IS 6 BP 2106 EP 2112 DI 10.1128/AAC.01359-05 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 048FE UT WOS:000237932200028 PM 16723572 ER PT J AU Deitiker, PR Oshima, M Smith, RG Mosier, DR Atassi, MZ AF Deitiker, Philip R. Oshima, Minako Smith, R. Glenn Mosier, Dennis R. Atassi, M. Zouhair TI Subtle differences in HLA DQ haplotype-associated presentation of AChR alpha-chain peptides may suffice to mediate myasthenia gravis SO AUTOIMMUNITY LA English DT Article DE acetylcholine receptor; autoimmunity; HLA; myasthenia gravis; T-cell ID HUMAN ACETYLCHOLINE-RECEPTOR; T-CELL RECOGNITION; PERIPHERAL-BLOOD LYMPHOCYTES; IN-VITRO; EXTRACELLULAR PART; ANTIBODY; SUBUNIT; DISEASE; SUSCEPTIBILITY; IDENTIFICATION AB The HLA DQA1 and DQB1 alleles were determined on a set of 24 myasthenia gravis patients that had previously been examined for their T-cell proliferative responses to the 18 overlapping peptides representing the extracellular domain of h AChR alpha-chain. Patient responses according to assumed cis or trans haplotypes were significantly higher in most cases relative to normal controls. Comparisons of in vitro peptide-stimulated T-cell responses of patient pairs which had DQA1:DQB1 in common displayed responses in tighter distribution relative to comparisons in which patient pairs did not share the same DQA1:DQB1 haplotype. Similar haplotypes, such as DQA1*0102:DQB1*0602 and DQA1*0102:DQB1*0604, tended to exhibit similar responses and were grouped according to this similarity. Modified F -test and Student's T -test analyses on DQ isoform bearing groups revealed that high responses to peptide alpha 34-49 were associated with A1*0102:B1*0602/0604, A1*0301:B1*0302 and A1*0401/0303:B1*0301. Peptide alpha 146-162 showed higher responses in A1*0301:B1*0302 group and moderate responses in A1*0401/0303:B1*0301 groups. Differences in the age of disease onset relative to DQ haplotypes were also observed. Groups of A1*0301:B1*0302, A1*0501:B1*0201 and A1*0102:B1*0604 showed earlier ages of disease onset relative to those of A1*0102:B1*0602 or A1*0505:B1*0301. C1 Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. ME DeBakey VA Med Ctr, Neurol & Med Res Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. RP Oshima, M (reprint author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Pl, Houston, TX 77030 USA. EM moshima@bcm.tmc.edu NR 38 TC 9 Z9 11 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PD JUN PY 2006 VL 39 IS 4 BP 277 EP 288 DI 10.1080/08916930600738581 PG 12 WC Immunology SC Immunology GA 070ZS UT WOS:000239566900003 PM 16891216 ER PT J AU Weindruch, R AF Weindruch, Richard TI Will dietary restriction work in primates? SO BIOGERONTOLOGY LA English DT Editorial Material DE dietary restriction; aging; primates ID PROSTATE-CANCER RISK; CALORIC RESTRICTION; HUMANS; LONGEVITY; ENERGY; SWEDEN AB This issue of Biogerontology addresses whether dietary restriction (DR) "... can increase longevity in all species, particularly in human beings." The possibility that DR can increase longevity in all species seems a trivial issue compared to that of DR's potential efficacy in people. The striking phylogenetic breadth of DR's longevity increasing effect supports the notion of human translatability. The available evidence in primates (human and nonhuman) suggests that it is highly probable that DR will increase the span of good health (and the average lifespan) but the magnitude of this predicted increase is unknown. Robust survival data for monkeys subjected to highly controlled DR will be available in similar to 25 years; similar data for large numbers of human practitioners of DR appear to be many decades away. C1 Univ Wisconsin, Dept Med, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Weindruch, R (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53705 USA. EM rhweindr@wisc.edu NR 14 TC 12 Z9 12 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1389-5729 J9 BIOGERONTOLOGY JI Biogerontology PD JUN PY 2006 VL 7 IS 3 BP 169 EP 171 DI 10.1007/s10522-006-9007-0 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 085AY UT WOS:000240576700011 PM 16680522 ER PT J AU Dinh, P Zhou, XH AF Dinh, P Zhou, XH TI Nonparametric statistical methods for cost-effectiveness analyses SO BIOMETRICS LA English DT Article DE confidence interval; cost-effectiveness analysis; Edgeworth expansion; incremental cost-effectiveness ratio; net health benefit; skewness ID CLINICAL-TRIAL DATA; CONFIDENCE-INTERVALS; EFFECTIVENESS RATIOS; RANDOMIZED-TRIAL; CARE; UNCERTAINTY; BENEFIT; SAMPLE AB Two measures often used in a cost-effectiveness analysis are the incremental cost-effectiveness ratio (ICER) and the net health benefit (NHB). Inferences on these two quantities are often hindered by highly skewed cost data. In this article, we derive the Edgeworth expansions for the studentized t-statistics for the two measures and show how they could be used to guide inferences. In particular, we use the expansions to study the theoretical performance of existing confidence intervals based on normal theory and to derive new confidence intervals for the ICER and the NHB. We conduct a simulation study to compare our new intervals with several existing methods. The methods evaluated include Taylor's interval, Fieller's interval, the bootstrap percentile interval, and the bootstrap bias-corrected acceleration interval. We found that our new intervals give good coverage accuracy and are narrower compared to the current recommended intervals. C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Dinh, P (reprint author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU AHRQ HHS [R01HS013105] NR 28 TC 17 Z9 17 U1 0 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0006-341X J9 BIOMETRICS JI Biometrics PD JUN PY 2006 VL 62 IS 2 BP 576 EP 588 DI 10.1111/j.1541-0420.2006.00509.x PG 13 WC Biology; Mathematical & Computational Biology; Statistics & Probability SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational Biology; Mathematics GA 054NP UT WOS:000238384500028 PM 16918923 ER PT J AU Schoder, H Glass, EC Pecking, AP Harness, JK Wallace, AM Hirnle, P Alberini, JL Vilain, D Larson, SM Hoh, CK Vera, DR AF Schoder, Heiko Glass, Edwin C. Pecking, Alain P. Harness, Jay K. Wallace, Anne M. Hirnle, Peter Alberini, Jean L. Vilain, Didier Larson, Steven M. Hoh, Carl K. Vera, David R. TI Molecular targeting of the lymphovascular system for imaging and therapy SO CANCER AND METASTASIS REVIEWS LA English DT Article; Proceedings Paper CT 1st International Symposium on Cancer Metastasis and the Lymphovascular System CY APR 28-30, 2005 CL San Francisco, CA DE molecular targeting; PET; ultrasound; image fusion; endolymphatic therapy; sentinel lymph node mapping ID SENTINEL LYMPH-NODE; BREAST-CANCER PATIENTS; POSITRON-EMISSION-TOMOGRAPHY; GLUT-1 GLUCOSE-TRANSPORTER; BLEOMYCIN OIL SUSPENSION; FINE-NEEDLE-ASPIRATION; HEXOKINASE-II; AEROBIC GLYCOLYSIS; LYMPHOSCINTIGRAPHIC AGENTS; ENDOLYMPHATIC APPLICATION AB Progress toward targeting cancer cells is a multi-disciplinary endeavor. In addition to the surgical and oncology specialties, radiologists collaborate with mathematicians, computer scientists, and physicists, in a constant effort to incrementally improve upon the current imaging modalities. Recently, radiologists have formed collaborations with molecular biologists and chemists in order to develop molecular agents that target cancer cells via receptor-substrate or specific physiochemical interactions. In this review, we summarize selected efforts toward molecular targeting of the lymphovascular system. Standard imaging modalities, positron emission tomography, single photon emission tomography, and ultrasound, are reviewed as well as, the targeted introduction of substances for endolymphatic therapy. We also review the current status of sentinel lymph node mapping with radiocolloids and the application of molecular targeting for the development of a radiopharmaceutical specifically designed for sentinel lymph node mapping. C1 Moores Univ Calif San Diego Canc Ctr, La Jolla, CA 92093 USA. Mem Sloan Kettering Canc Ctr, Dept Radiol Nucl Med, New York, NY 10021 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Nucl Med, Los Angeles, CA 90073 USA. Ctr Rene Huguenin, Dept Nucl Med, F-92210 St Cloud, France. St Joseph Hosp, Comprehens Breast Ctr, Orange, CA 92868 USA. Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA. Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Vera, DR (reprint author), Moores Univ Calif San Diego Canc Ctr, 3855 Hlth Sci Dr 0819, La Jolla, CA 92093 USA. EM dvera@ucsd.edu NR 111 TC 21 Z9 21 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0167-7659 J9 CANCER METAST REV JI Cancer Metastasis Rev. PD JUN PY 2006 VL 25 IS 2 BP 185 EP 201 DI 10.1007/s10555-006-8498-0 PG 17 WC Oncology SC Oncology GA 052YA UT WOS:000238268800003 PM 16770532 ER PT J AU Cilingiroglu, M Oh, JH Sugunan, B Kemp, NJ Kim, J Lee, S Zaatari, HN Escobedo, D Thomsen, S Milner, TE Feldman, MD AF Cilingiroglu, M Oh, JH Sugunan, B Kemp, NJ Kim, J Lee, S Zaatari, HN Escobedo, D Thomsen, S Milner, TE Feldman, MD TI Detection of vulnerable plaque in a murine model of atherosclerosis with optical coherence tomography SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article; Proceedings Paper CT SCAI Meeting 2005 CY MAY, 2005 CL FL SP SCAI, Gen Elect DE vulnerable plaque; ApoE mice; OCT ID E-KNOCKOUT MOUSE; APOLIPOPROTEIN-E; ISCHEMIC DEATH; MICE; LESIONS; HYPERCHOLESTEROLEMIA; MACROPHAGE; THROMBOSIS; ARTERIES; RUPTURE AB Objectives: The aim of this study was to evaluate the feasibility of optical coherence tomography (OCT) to identify the components of vulnerable plaques in a well-established murine model of human atherosclerosis. Background: Although the pathologic features that predict plaque rupture at autopsy are well known, the development of a technology to identify these high risk features in vivo is lacking. OCT uses reflected light to provide histology-like images of plaque with higher resolution than competing imaging modalities. Whether OCT can reliably identify the features of an atherosclerotic plaque that define it as vulnerable-thin fibrous cap, large lipid core, and high percent of lipid in the artery-requires further study. Methods: OCT images of the atherosclerotic innominate artery segments from the apolipoprotein E knockout (apoE(-/-)) mice were recorded and correlated with histology in both in vivo (n = 7) and well as in ex vivo experiments (n = 12). Results: Excellent correlation between the OCT and histology measurements for fibrous cap thickness, lipid core size, and percentage lipid content was found. The fibrous cap thicknesses examined span those of human fibrous caps known to rupture (<65 mu m). Regions of greatest light reflection in OCT images were observed when calcium hydroxy-apatite was scattered in lipid, less in fibrous tissue, and least in lipid. Conclusions: These findings suggest that OCT holds promise for the identification of features defining vulnerable plaque including fibrous cap thickness, lipid core size, and the percentage of lipid content. (C) 2006 Wiley-Liss., Inc. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Res & Dev Serv, San Antonio, TX USA. RP Feldman, MD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM feldmanm@uthscsa.edu FU NHLBI NIH HHS [HL59472] NR 27 TC 47 Z9 49 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD JUN PY 2006 VL 67 IS 6 BP 915 EP 923 DI 10.1002/ccd.20717 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 050JA UT WOS:000238082300014 PM 16602128 ER PT J AU Littner, MR Leung, FW Huang, B Ballard, ED Samra, NK AF Littner, MR Leung, FW Huang, B Ballard, ED Samra, NK TI Gastroesophageal reflux disease and asthma - The role of proton pump inhibitors SO CHEST LA English DT Letter ID THERAPY; LARYNGITIS C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. Abbott Labs, Abbott Pk, IL 60064 USA. TAP Pharmaceut Inc, Lake Forest, IL USA. RP Littner, MR (reprint author), VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. EM mlittner@ucla.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2006 VL 129 IS 6 BP 1732 EP 1733 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 054BA UT WOS:000238349300055 ER PT J AU Reckamp, KL Krysan, K Morrow, JD Milne, GL Newman, RA Tucker, C Elashoff, RM Dubinett, SM Figlin, RA AF Reckamp, KL Krysan, K Morrow, JD Milne, GL Newman, RA Tucker, C Elashoff, RM Dubinett, SM Figlin, RA TI A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR RECEPTOR; MAJOR URINARY METABOLITE; TYROSINE KINASE; CYCLOOXYGENASE-2 INHIBITOR; PROSTAGLANDIN E-2; EGF RECEPTOR; GEFITINIB; MUTATIONS; THERAPY; CHEMOPREVENTION AB Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI) - resistant manner. Because preclinical data indicated that tumor COX-2 expression caused resistance to EGFR TKI, a phase I trial to establish the optimal biological dose (OBD), defined as the maximal decrease in urinary prostaglandin E-M (PGE-M), and toxicity profile of the combination of celecoxib and erlotinib in advanced non - small cell lung cancer was done. Experimental Design: Twenty-two subjects with stage IIIB and/or IV non - small cell lung cancer received increasing doses of celecoxib from 200 to 800 mg twice daily (bid) and a fixed dose of erlotinib. Primary end points included evaluation of toxicity and determination of the OBD of celecoxib when combined with erlotinib. Secondary end points investigate exploratory biological markers and clinical response. Results: Twenty-two subjects were enrolled, and 21 were evaluable for the determination of the OBD, toxicity, and response. Rash and skin-related effects were the most commonly reported toxicities and occurred in 86%. There were no dose-limiting toxicities and no cardiovascular toxicities related to study treatment. All subjects were evaluated on intent to treat. Seven patients showed partial responses (33%), and five patients developed stable disease (24%). Responses were seen in patients both with and without EGFR-activating mutations. A significant decline in urinary PGE-M was shown after 8 weeks of treatment, with an OBD of celecoxib of 600 mg bid. Conclusions: This study defines the OBD of celecoxib when combined with a fixed dose of EGFR TKI. These results show objective responses with an acceptable toxicity profile. Future trials using COX-2 inhibition strategies should use the OBD of celecoxib at 600 mg bid. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA. Univ Texas, MD Anderson Canc Ctr, Pharmaceut Dev Ctr, Houston, TX 77030 USA. OSI Pharmaceut Inc, Boulder, CO USA. RP Reckamp, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, 10945 LeConte Ave,Suite 2333, Los Angeles, CA 90095 USA. EM kreckamp@mednet.ucla.edu RI Milne, Ginger/D-7648-2014 OI Milne, Ginger/0000-0003-3890-151X; Reckamp, Karen/0000-0002-9213-0325 FU NCI NIH HHS [CA77839, P50CA90388]; NIDDK NIH HHS [DK48831]; NIEHS NIH HHS [ES13125]; NIGMS NIH HHS [GM15431] NR 42 TC 72 Z9 81 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2006 VL 12 IS 11 BP 3381 EP 3388 DI 10.1158/1078-0432.CCR-06-0112 PN 1 PG 8 WC Oncology SC Oncology GA 051OG UT WOS:000238169800022 PM 16740761 ER PT J AU Zheng, X Chang, RL Cui, XX Avila, GE Hebbar, V Garzotto, M Shih, WCJ Lin, Y Lu, SE Rabson, AB Kong, ANT Conney, AH AF Zheng, X Chang, RL Cui, XX Avila, GE Hebbar, V Garzotto, M Shih, WCJ Lin, Y Lu, SE Rabson, AB Kong, ANT Conney, AH TI Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice SO CLINICAL CANCER RESEARCH LA English DT Article ID KINASE-C-DELTA; ESTER-INDUCED APOPTOSIS; TRANS-RETINOIC ACID; N-TERMINAL KINASE; PHASE-II TRIAL; PROTEIN-KINASE; PHORBOL ESTER; ESTRAMUSTINE PHOSPHATE; CERAMIDE SYNTHASE; GENE-EXPRESSION AB Purpose: To investigate the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate cancer cells cultured in vitro or grown as tumors in immunodeficient mice. Experimental Design: Human prostate cancer LNCaP cells in culture were treated with TPA alone or in combination with paclitaxel. NCr immunodeficient mice with well-established LNCaP tumors received i.p. injections with vehicle or with TPA, paclitaxel, or TPA in combination with paclitaxel. The animals either received daily treatment for 5 consecutive days followed by a 2-day intermission, which was repeated for a total of 28 days (experiment 1), or continuous daily treatment for 28 days (experiment 2). Results: Treatment of LNCaP cells with a combination of TPA and paclitaxel synergistically inhibited the growth and induced apoptosis in cultured LNCaP cells, and this treatment also induced a marked increase in phosphorylated c-Jun-NH2-kinase (JNK). In animal experiments, tumor growth occurred in all mice treated with vehicle. When treated with TPA alone, the percentage of animals with some tumor regression was 33% in experiment 1 and 100% in experiment 2. Treatment of animals with paclitaxel alone caused some tumor regression in 17% and 57% of the animals in experiments 1 and 2, respectively. All animals treated with TPA + paclitaxel in both experiments had some tumor regression. Conclusions: TPA and paclitaxel in combination had a stronger inhibitory effect on the growth of LNCaP cells in culture or as xenograft tumors in immunodeficient mice than either agent alone. Clinical trials with TPA alone or in combination with paclitaxel in patients with prostate cancer may be warranted. C1 Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA. Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Pharmaceut, Piscataway, NJ USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA. Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Med & Dent New Jersey, Sch Publ Hlth, Div Biometr, Newark, NJ 07103 USA. Canc Inst New Jersey, New Brunswick, NJ USA. RP Conney, AH (reprint author), Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA. EM aconney@rci.rutgers.edu FU NCI NIH HHS [CA 092268] NR 35 TC 19 Z9 19 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2006 VL 12 IS 11 BP 3444 EP 3451 DI 10.1158/1078-0432.CCR-05-2823 PN 1 PG 8 WC Oncology SC Oncology GA 051OG UT WOS:000238169800030 PM 16740769 ER PT J AU Habib, GB AF Habib, GB TI Prevention of vascular events in patients with cerebrovascular disease: Efficacy and appropriate duration of antiplatelet therapy SO CLINICAL CARDIOLOGY LA English DT Review DE stroke; secondary prevention; extended-release dipyridamole; clopidogurel; antiplatelet ID TRANSIENT ISCHEMIC ATTACK; EUROPEAN STROKE PREVENTION; AMERICAN-HEART-ASSOCIATION; HIGH-RISK PATIENTS; RANDOMIZED TRIALS; 30 MG; ASPIRIN; CLOPIDOGREL; REHABILITATION; DIPYRIDAMOLE AB Antiplatelet therapy has shown consistent benefit in the prevention of secondary stroke. The paucity of head-to-head studies of different antiplatelet regimens, assessment of comparative efficacy, and optimal treatment duration requires evaluation and comparison of clinical studies that vary extensively in design and follow-up. Evidence for aspirin benefit in secondary stroke prevention is strong, but existing studies provide little guidance with regard to treatment duration. The efficacy of clopidogrel in secondary event prevention is significantly greater than that of aspirin for patients with a history of peripheral artery disease, but does not differ from that of aspirin for patients with a history of stroke or myocardial infarction. Relative to clopidogrel alone, the addition of aspirin to clopidogrel results in increased risk for life-threatening bleeding episodes similar in absolute magnitude to the reduction of secondary event risk in patients with stroke. Benefits associated with clopidogrel occur early in the course of therapy; few data support clopidogrel use for longer than I year after stroke. Monotherapy with extended-release dipytidamole (ER-DP) provides reduction in secondary stroke risk similar to aspirin; however, the combination of aspirin plus ER-DP significantly reduces risk relative to either agent alone. Compared with placebo and monotherapy with either agent, risk reduction for the aspirin plus ER-DP combination continued through 24 months, with no concomitant increase in bleeding risk. Additional clinical studies should provide needed comparisons of efficacy and guidance with regard to optimal duration of therapy. C1 Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. RP Habib, GB (reprint author), Michael E DeBakey vet Affairs Med Ctr, Cardiol Sect, Off 3C 310E, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM gabehabib@yahoo.com NR 19 TC 1 Z9 1 U1 0 U2 0 PU CLINICAL CARDIOLOGY PUBL CO PI MAHWAH PA PO BOX 832, MAHWAH, NJ 07430-0832 USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD JUN PY 2006 VL 29 IS 6 BP 244 EP 248 DI 10.1002/clc.4960290604 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 048OT UT WOS:000237957100003 PM 16796073 ER PT J AU Zhao, WG Valencia, AZ Melby, PC AF Zhao, Weiguo Valencia, Anais Z. Melby, Peter C. TI Biological activity of hamster interferon-gamma is modulated by the carboxyl-terminal tail SO CYTOKINE LA English DT Article DE interferon-gamma; hamster; Mesocricetus auratus; antiviral ID NUCLEAR-LOCALIZATION SEQUENCE; MOLECULAR PHYLOGENY; IFN-GAMMA; RECEPTOR; EXPRESSION; TRANSLOCATION; PEPTIDE; RODENTS; BINDING; CLONING AB The Syrian golden hamster (Mesocricetus auratus) is highly susceptible to a number of intracellular pathogens. Interferon-gamma (IFN-gamma), the primary macrophage-activating cytokine, plays a key role in the host defense against intracellular pathogens. The hamster IFN-gamma cDNA encodes a 174 amino acid protein that has an additional 17 amino acids at the carboxyl-terminus compared to IFN-gamma of mice and rats. A homologous C-terminal tail is also found in other non-murine rodents. The biological activity of hamster IFN-gamma had not been investigated previously so we first demonstrated the activity of native IFN-gamma in assays of IFN-gamma-induced receptor signaling and antiviral activity against vesicular stomatitis virus. We then tested the hypothesis that the C-terminal tail of hamster IFN-gamma could influence its biological activity. A truncated hamster IFN-gamma, in which the C-terminal 17 aa were removed by insertion of a stop codon at the position corresponding to the stop codon in the mouse sequence, had approximately 10-fold greater activity than the full length protein when measured in the two bioassays. Polyclonal and monoclonal anti-hamster IFN-gamma antibodies specifically inhibited this biological activity. Collectively, these data indicate that this unique structural feature influences the biological activity of hamster IFN-gamma. (c) 2006 Elsevier Ltd. All rights reserved. C1 S Texas Vet Hlth Care syst, Dept Vet Affairs, Med Ctr, Res Serv, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. RP Melby, PC (reprint author), S Texas Vet Hlth Care syst, Dept Vet Affairs, Med Ctr, Res Serv, 7400 Merton Minter Dr Mailstop 151, San Antonio, TX 78229 USA. EM melby@uthscsa.edu FU NCRR NIH HHS [RR14269] NR 25 TC 3 Z9 3 U1 0 U2 0 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD JUN PY 2006 VL 34 IS 5-6 BP 243 EP 251 DI 10.1016/j.cyto.2006.05.006 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 084MI UT WOS:000240536700002 PM 16843003 ER PT J AU Komers, R Schutzer, WE Reed, JF Lindsley, JN Oyama, TT Buck, DC Mader, SL Anderson, S AF Komers, R Schutzer, WE Reed, JF Lindsley, JN Oyama, TT Buck, DC Mader, SL Anderson, S TI Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney SO DIABETES LA English DT Article ID RENAL HEMODYNAMIC-CHANGES; GLOMERULAR HYPERFILTRATION; CARDIAC MYOCYTES; OXIDATIVE STRESS; ENOS ACTIVATION; CELLS; RATS; DYSFUNCTION; NEPHROPATHY; TETRAHYDROBIOPTERIN AB Experimental diabetes is associated with complex changes in renal nitric oxide (NO) bioavailability. We explored the effect of diabetes on renal cortical protein expression of endothelial NO synthase (eNOS) with respect to several determinants of its enzymatic function, such as eNOS expression, membrane localization, phosphorylation, and dimerization, in moderately hyperglycemic streptozotocin-induced diabetic rats compared with nondiabetic control rats and diabetic rats with intensive insulin treatment to achieve near-normal metabolic control. We studied renal cortical expression and localization of caveolin-1 (CAV-1), an endogenons modulator of eNOS function. Despite similar whole-cell eNOS expression in all groups, eNOS monomer and dimer in membrane fractions were reduced in moderately hyperglycemic diabetic rats compared with control rats; the opposite trend was apparent in the cytosol. Stimulatory phosphorylation of eNOS (Ser1177) was also reduced in moderately hyperglycemic diabetic rats. eNOS colocalized and interacted with CAV-1 in endothelial cells throughout the renal vascular tree both in control and moderately hyperglycemic diabetic rats. However, the abundance of membrane-localized CAV-1 was decreased in diabetic kidneys. Intensive insulin treatment reversed the effects of diabetes on each of these parameters. In summary, we observed diabetes-mediated alterations in eNOS and CAV-1 expression that are consistent with the view of decreased bioavailability of renal eNOS-derived NO. C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens PP262, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Inst Clin & Expt Med, Diabet Ctr, Prague, Czech Republic. Portland VA Med Ctr, Res Serv, Portland, OR USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Komers, R (reprint author), Oregon Hlth Sci Univ, Div Nephrol & Hypertens PP262, 3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU NIDDK NIH HHS [DK-63231] NR 48 TC 48 Z9 50 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD JUN PY 2006 VL 55 IS 6 BP 1651 EP 1659 DI 10.2337/db05-1595 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 049YI UT WOS:000238053400013 PM 16731827 ER PT J AU Boyko, EJ Ahroni, JH Cohen, V Nelson, KM Heagerty, PJ AF Boyko, EJ Ahroni, JH Cohen, V Nelson, KM Heagerty, PJ TI Prediction of diabetic foot ulcer occurrence using commonly available clinical information - The Seattle diabetic foot study SO DIABETES CARE LA English DT Article ID LOWER-EXTREMITY AMPUTATION; PRIMARY HEALTH-CARE; AUTONOMIC NEUROPATHY; RISK-FACTORS; MANAGEMENT; DIAGNOSIS; COMMUNITY; DISEASE AB OBJECTIVE- The ability of readily available clinical information to predict the occurrence of diabetic foot ulcer has not been extensively studied. We conducted a prospective study of the individual and combined effects of commonly available clinical information in the prediction of diabetic foot ulcer occurrence. RESEARCH DESIGN AND METHODS- We followed 1,285 diabetic veterans without foot ulcer for this outcome with annual clinical evaluations and quarterly mailed questionnaires to identify foot problems. At baseline we assessed age; race; weight; current smoking; l ation diabetes duration and treatment; HbA(1c) (AlC); visual acuity; history of laser photocoagu and amputation; foot shape; claudication; foot insensitivity to the 10-g monofilament, foot callus, pedal edema; hallux limitus, Linea pedis and onychomycosis. Cox proportional hazards modeling was used with backwards stepwise elimination to develop a prediction model for the first foot ulcer occurrence after the baseline examination. RESULTS - At baseline, subjects were 62.4 years of age on average and 981/o male. Mean follow-up duration was 3.38 years, during which time 216 foot ulcers occurred, for an incidence of 5.0/100 person-years. Significant predictors (P <= 0.05) of foot ulcer in the final model (hazard ratio, 95% CI) included A1C (1.10, 1.06-1.15), impaired vision (1.48, 1.00-2.18), prior foot ulcer (2.18, 1.50-2.95) prior amputation (2.57, 1.60-4.12), monofilament insensivity) (2.03, 1.50-2.76), tinea pedis (0. 73, 0.54-0.98), and onychomycosis (1.58, 1.16-2.16). Area under the receiver operating characteristic curve was 0.81 at 1 year and 0.76 at 5 years. CONCLUSIONS - Readily available clinical information has substantial predictive power for the development of diabetic foot ulcer and may help in accurately targeting persons at high risk of this outcome for preventive interventions. C1 VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), VA Puget Sound S152E, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eboyko@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 21 TC 112 Z9 118 U1 0 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2006 VL 29 IS 6 BP 1202 EP 1207 DI 10.2337/dc05-2031 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 049YG UT WOS:000238053200002 PM 16731996 ER PT J AU Lavery, LA Armstrong, DG Wunderlich, RP Mohler, MJ Wendel, CS Lipsky, BA AF Lavery, LA Armstrong, DG Wunderlich, RP Mohler, MJ Wendel, CS Lipsky, BA TI Risk factors for foot infections in individuals with diabetes SO DIABETES CARE LA English DT Article ID CLASSIFICATION-SYSTEM; MEXICAN-AMERICANS; PUNCTURE WOUNDS; ULCERATION; ULCERS; OSTEOMYELITIS; AMPUTATION; DISEASE; MULTICENTER; PRESSURES AB OBJECTIVE - To prospectively determine risk factors for foot infection in a cohort of people with diabetes. RESEARCH DESIGN AND METHODS - We evaluated then followed 1,666 consecutive diabetic patients enrolled in a managed care-based outpatient clinic in a 2-year longitudinal outcomes study. At enrollment, patients underwent a standardized general medical examination and detailed foot assessment and were educated about proper foot care. They were then rescreened at scheduled intervals and also seen promptly if they developed any foot problem. RESULTS - During the evaluation period, 151 (9.1%) patients developed 199 foot infections, all but one involving a wound or penetrating injury. Most patients had infections involving only the soft tissue, but 19.9% had bone culture-proven osteomyelitis. For those who developed a foot infection, compared with those who did not, the risk of hospitalization was 55.7 times greater (95% CI 30.3-102.2; P < 0.001) and the risk of amputation was 154.5 times greater (58.5-468.5; P < 0.001). Foot wounds preceded all but one infection. Significant (P < 0.05) independent risk factors for foot infection from a multivariate analysis included wounds that penetrated to bone (odds ratio 6.7), wounds with a duration > 30 days (4.7), recurrent wounds (2.4), wounds with a traumatic etiology (2.4), and presence of peripheral vascular disease (1.9). CONCLUSIONS - Foot infections occur relatively frequently in individuals with diabetes, almost always follow trauma, and dramatically increase the risk of hospitalization and amputation. Efforts to prevent infections should be targeted at people with traumatic foot wounds, especially those that are chronic, deep, recurrent, or associated with peripheral vascular disease. C1 Texas A&M Univ, Coll Med, Dept Surg, Scott & White Hosp,Hlth Sci Ctr, Temple, TX 76508 USA. Rosalind Franklin Univ Med & Sci, Dr William M Scholl Coll Podiatr Med, Chicago, IL USA. Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England. Diabetex, San Antonio, TX USA. So Arizona Vet Affairs Med Ctr, Res Serv, Tucson, AZ USA. Univ Arizona, Coll Publ Hlth, Epidemiol & Biostat Div, Tucson, AZ USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lavery, LA (reprint author), Scott & White Hosp, Dept Surg, 703 Highland Spring Ln, Georgetown, TX 78628 USA. EM llavery@swmail.sw.org OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 54 TC 200 Z9 216 U1 3 U2 19 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2006 VL 29 IS 6 BP 1288 EP 1293 DI 10.2337/dc05-2425 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 049YG UT WOS:000238053200016 PM 16732010 ER PT J AU Utzschneider, KM Trence, DL AF Utzschneider, KM Trence, DL TI Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy SO DIABETES CARE LA English DT Article ID SEVERELY OBESE SUBJECTS; OF-THE-LITERATURE; INSULIN SENSITIVITY; CLINICAL-FEATURES; WEIGHT-LOSS; RESISTANCE; DERANGEMENTS; ADIPONECTIN C1 VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu FU NCRR NIH HHS [M01 RR 00037]; NIDDK NIH HHS [T32 DK 07247] NR 15 TC 10 Z9 10 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2006 VL 29 IS 6 BP 1380 EP 1382 DI 10.2337/dc06-0130 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 049YG UT WOS:000238053200031 PM 16732025 ER PT J AU Huebschmann, AG Regensteiner, JG Vlassara, H Reusch, JEB AF Huebschmann, AG Regensteiner, JG Vlassara, H Reusch, JEB TI Diabetes and advanced glycoxidation end products SO DIABETES CARE LA English DT Review ID LOW-DENSITY-LIPOPROTEIN; ADVANCED GLYCATION ENDPRODUCTS; ALDOSE REDUCTASE INHIBITOR; ALPHA-LIPOIC ACID; NF-KAPPA-B; CULTURED ENDOTHELIAL-CELLS; MAILLARD REACTION-PRODUCTS; CONTROLLED-TRIAL ALADIN; RENAL-FAILURE PATIENTS; CROSS-LINK BREAKER C1 Univ Colorado, Dept Med, Div Cardiol, Denver, CO USA. Univ Colorado, Div Gen Internal Med, Denver, CO USA. Hlth Sci Ctr, Denver, CO USA. Mt Sinai Sch Med, Div Expt Diabet & Aging, Dept Geriatr, New York, NY USA. Univ Colorado, Dept Med, Div Endocrinol, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. RP Huebschmann, AG (reprint author), Univ Colorado, POB 6510,Mailstop F-729, Aurora, CO 80045 USA. EM amy.huebschmann@uchsc.edu NR 200 TC 136 Z9 152 U1 3 U2 13 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2006 VL 29 IS 6 BP 1420 EP 1432 DI 10.2337/dc05-2096 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 049YG UT WOS:000238053200045 PM 16732039 ER PT J AU Saunders, GH Forsline, A AF Saunders, GH Forsline, A TI The performance-perceptual test (PPT) and its relationship to aided reported handicap and hearing aid satisfaction SO EAR AND HEARING LA English DT Article ID DECISION-MAKING; INVENTORY; BENEFIT; LIFE; AGE AB Objective: Results of objective clinical tests (e.g., measures of speech understanding in noise) often conflict with subjective reports of hearing aid benefit and satisfaction. The Performance-Perceptual Test (PPT) is an outcome measure in which objective and subjective evaluations are made by using the same test materials, testing format, and unit of measurement (signal-to-noise ratio, S/N), permitting a direct comparison between measured and perceived ability to hear. Two variables are measured: a Performance Speech Reception Threshold in Noise (SRTN) for 50% correct performance and a Perceptual SRTN, which is the S/N at which listeners perceive that they can understand the speech material. A third variable is computed: the Performance-Perceptual Discrepancy (PPDIS); it is the difference between the Performance and Perceptual SRTNs and measures the extent to which listeners "misjudge" their hearing ability. Saunders et al. in 2004 examined the relation between PPT scores and unaided hearing handicap. In this publication, the relations between the PPT, residual aided handicap, and hearing aid satisfaction are described. Design: Ninety-four individuals between the ages of 47 and 86 yr participated. All had symmetrical sensorineural hearing loss and had worn binaural hearing aids for at least 6 wk before participating. All subjects underwent routine audiological examination and completed the PPT, the Hearing Handicap Inventory for the Elderly/Adults (HHIE/A), and the Satisfaction for Amplification in Daily Life questionnaire. Sixty-five subjects attended one research visit for participation in this study, and 29 attended a second visit to complete the PPT a second time. Results: Performance and Perceptual SRTN and PPDIS scores were normally distributed and showed excellent test-retest reliability. Aided SRTNs were significantly better than unaided SRTNs; aided and unaided PPDIS values did not differ. Stepwise multiple linear regression showed that the PPDIS, the Performance SRTN, and age were significant predictors of scores on the HHIE/A such that greater reported handicap is associated with underestimating hearing ability, poorer aided ability to understand speech in noise, and being younger. Scores on the Satisfaction with Amplification in Daily Life were not well explained by the PPT, age, or audiometric thresholds. When individuals were grouped by their HHIE/A scores, it was seen that individuals who report more handicap than expected based on their audiometric thresholds, have a more negative PPDIS, i.e., underestimate their hearing ability, relative to individuals who report expected handicap, who in turn have a more negative PPDIS than individuals who report less handicap than expected. No such patterns were apparent for the Performance SRTN. Conclusions: The study showed the PPT to be a reliable outcome measure that can provide more information than a performance measure and/or a questionnaire measure alone, in that the PPDIS can provide the clinician with an explanation for discrepant objective and subjective reports of hearing difficulties. The finding that self-reported handicap is affected independently by both actual ability to hear and the (mis)perception of ability to hear underscores the difficulty clinicians encounter when trying to interpret outcomes questionnaires. We suggest that this variable should be measured and taken into account when interpreting questionnaires and counseling patients. C1 Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97207 USA. RP Saunders, GH (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM gabrielle.saunders@med.va.gov NR 30 TC 12 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD JUN PY 2006 VL 27 IS 3 BP 229 EP 242 DI 10.1097/01.aud.0000215976.64444.e6 PG 14 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 041GB UT WOS:000237441200003 PM 16672792 ER PT J AU Mundinger, TO Cummings, DE Taborsky, GJ AF Mundinger, Thomas O. Cummings, David E. Taborsky, Gerald J., Jr. TI Direct stimulation of ghrelin secretion by sympathetic nerves SO ENDOCRINOLOGY LA English DT Article ID PLASMA GHRELIN; NERVOUS-SYSTEM; NEUROPEPTIDE-Y; ADIPOSE-TISSUE; COLD-EXPOSURE; ACTIVE FORM; FOOD-INTAKE; RATS; RELEASE; HUMANS AB The hormone ghrelin is secreted mainly from the gut, rises in peripheral plasma before meals, and is implicated in stimulating hunger, initiating meals, and developing obesity. We hypothesize that activation of the sympathetic nervous system contributes to preprandial ghrelin surges. The present studies in isoflurane-anesthetized Wistar rats were designed to determine whether sympathetic nerves and neurohormones are capable of stimulating ghrelin secretion. We activated gut sympathetic nerves by two methods: electrical sympathetic nerve stimulation (SNS) and chemical sympathetic nerve activation with iv tyramine (TYR) administration. Portal venous blood was sampled before and during a 10-min sympathetic stimulation. Successful activation of gut sympathetic nerves was verified by increments in portal venous norepinephrine. SNS increased portal ghrelin by 206 +/- 50%. In contrast, simply isolating gut sympathetic nerves without applying current had a minimal effect on ghrelin levels. TYR also increased portal ghrelin [change (Delta), + 52 +/- 11%], whereas saline infusion had little effect. We next determined whether the neural stimulation of ghrelin secretion was mediated indirectly via the suppression of insulin secretion during SNS and TYR. Streptozotocin-induced diabetes prevented a fall in insulin during TYR, yet the portal ghrelin response (Delta = + 47 +/- 18%) was similar to that in nondiabetic rats. Lastly, to test for humoral stimulation of ghrelin, we infused the sympathetic neurohormone, epinephrine, to achieve levels found during severe stress. Epinephrine failed to stimulate ghrelin secretion (Delta = + 4 +/- 35%). We conclude that the neural, but not the neurohumoral, branch of the sympathetic nervous system can directly stimulate ghrelin secretion. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Mundinger, TO (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM mundin@u.washington.edu FU NIDDK NIH HHS [DK-12829, DK-17047, DK-50154, DK-61516, DK-68384] NR 71 TC 79 Z9 82 U1 0 U2 5 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2006 VL 147 IS 6 SU S BP 2893 EP 2901 DI 10.1210/en.2005-1182 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 043SF UT WOS:000237621200044 PM 16527847 ER PT J AU Arufe, MC Lu, M Kubo, A Keller, G Davies, TF Lin, RY AF Arufe, Maria C. Lu, Min Kubo, Atsushi Keller, Gordon Davies, Terry F. Lin, Reigh-Yi TI Directed differentiation of mouse embryonic stem cells into thyroid follicular cells SO ENDOCRINOLOGY LA English DT Article ID IN-VITRO DIFFERENTIATION; SYSTEM CHARACTERIZATION; TRANSCRIPTION FACTORS; THYROTROPIN RECEPTOR; PLURIPOTENTIAL CELLS; EPITHELIAL-CELLS; GROWTH; FRTL-5; THYROGLOBULIN; INVITRO AB Elucidating the molecular mechanisms leading to the induction and specification of thyroid follicular cells is important for our understanding of thyroid development. To characterize the key events in this process, we previously established an experimental embryonic stem (ES) cell model system, which shows that wild-type mouse CCE ES cells can give rise to thyrocyte-like cells in vitro. We extend our analysis in this report by using a genetically manipulated ES cell line in which green fluorescent protein (GFP) cDNA is targeted to the TSH receptor (TSHR) gene, linking GFP expression to the transcription of the endogenous TSHR gene. The appearance of GFP-positive cells was dependent on the formation of embryoid bodies from undifferentiated ES cells and was greatly enhanced by TSH treatment during the first 2-4 d of differentiation. With the support of Matrigel, highly enriched ES cell-derived GFP-positive cells formed thyroid follicle-like clusters in a serum-free medium supplemented with TSH. Importantly, these clusters display the characteristics of thyroid follicular cells. Immunofluorescent studies confirmed the colocalization of TSHRwith the Na+/I- symporter in the clusters and indicated that Na+/I- symporter was expressed exclusively in the plasma membrane. In addition, I- uptake activity was observed in these cells. Our results indicate that ES cells can be induced to differentiate into thyroid follicular cells, providing a powerful tool to study embryonic thyroid development and function. C1 Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Dept Med, Beijing 100029, Peoples R China. Mt Sinai Sch Med, Dept Gene & Cell Med, Beijing 100029, Peoples R China. Nara Med Univ, Dept Publ Hlth, Nara 6348521, Japan. James J Peters Vet Adm Med Ctr, Div Endocrinol & Metab, Bronx, NY 10468 USA. RP Lin, RY (reprint author), Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Dept Med, Box 1055,1 Gustave L Levy Pl, Beijing 100029, Peoples R China. EM reigh-yi.lin@mssm.edu RI arufe gonda, maria/N-3189-2014 OI arufe gonda, maria/0000-0003-3725-0743 FU NIDDK NIH HHS [R01 DK068057, R01-DK-068057-01A1] NR 41 TC 34 Z9 44 U1 1 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2006 VL 147 IS 6 SU S BP 3007 EP 3015 DI 10.1210/en.2005-1239 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 043SF UT WOS:000237621200056 PM 16497809 ER PT J AU Karayiannis, NB Xiong, YH Tao, GZ Frost, JD Wise, MS Hrachovy, RA Mizrahi, EM AF Karayiannis, NB Xiong, YH Tao, GZ Frost, JD Wise, MS Hrachovy, RA Mizrahi, EM TI Automated detection of videotaped neonatal seizures of epileptic origin SO EPILEPSIA LA English DT Article DE motion segmentation; motion-strength signal; motion tracking; motion-trajectory signal; neonatal seizure; neural network; quantitative feature; video recording ID MOTOR-ACTIVITY SIGNALS; QUANTUM NEURAL-NETWORKS; QUANTIFYING MOTION; RECORDINGS; EEG; RISK; CONVULSIONS; EXTRACTION; NEWBORN; COUNTY AB Purpose: This study aimed at the development of a seizure-detection system by training neural networks with quantitative motion information extracted from short video segments of neonatal seizures of the myoclonic and focal clonic types and random infant movements. Methods: The motion of the infants' body parts was quantified by temporal motion-strength signals extracted from video segments by motion-segmentation methods based on optical flow computation. The area of each frame occupied by the infants' moving body parts was segmented by clustering the motion parameters obtained by fitting an affine model to the pixel velocities. The motion of the infants' body parts also was quantified by temporal motion-trajectory signals extracted from video recordings by robust motion trackers based on block-motion models. These motion trackers were developed to adjust autonomously to illumination and contrast changes that may occur during the video-frame sequence. Video segments were represented by quantitative features obtained by analyzing motion-strength and motion-trajectory signals in both the time and frequency domains. Seizure recognition was performed by conventional feed-forward neural networks, quantum neural networks, and cosine radial basis function neural networks, which were trained to detect neonatal seizures of the myoclonic and focal clonic types and to distinguish them from random infant movements. Results: The computational tools and procedures developed for automated seizure detection were evaluated on a set of 240 video segments of 54 patients exhibiting myoclonic seizures (80 segments), focal clonic seizures (80 segments), and random infant movements (80 segments). Regardless of the decision scheme used for interpreting the responses of the trained neural networks, all the neural network models exhibited sensitivity and specificity > 90%. For one of the decision schemes proposed for interpreting the responses of the trained neural networks, the majority of the trained neural-network models exhibited sensitivity > 90% and specificity > 95%. In particular, cosine radial basis function neural networks achieved the performance targets of this phase of the project (i.e., sensitivity > 95% and specificity > 95%). Conclusions: The best among the motion segmentation and tracking methods developed in this study produced quantitative features that constitute a reliable basis for detecting neonatal seizures. The performance targets of this phase of the project were achieved by combining the quantitative features obtained by analyzing motion-strength signals with those produced by analyzing motion-trajectory signals. The computational procedures and tools developed in this study to perform off-line analysis of short video segments will be used in the next phase of this project, which involves the integration of these procedures and tools into a system that can process and analyze long video recordings of infants monitored for seizures in real time. C1 Univ Houston, Dept Elect & Comp Engn, Houston, TX 77204 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Karayiannis, NB (reprint author), Univ Houston, Dept Elect & Comp Engn, N308 Engn Bldg 1, Houston, TX 77204 USA. EM karayiannis@uh.edu FU NIBIB NIH HHS [1 R01 EB00183]; NINDS NIH HHS [N01-NS-2316] NR 40 TC 13 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD JUN PY 2006 VL 47 IS 6 BP 966 EP 980 DI 10.1111/j.1528-1167.2006.00571.x PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA 047IL UT WOS:000237872900006 PM 16822243 ER PT J AU Uschakov, A Gong, H McGinty, D Szymusiak, R AF Uschakov, Aaron Gong, Hui McGinty, Dennis Szymusiak, Ronald TI Sleep-active neurons in the preoptic area project to the hypothalamic paraventricular nucleus and perifornical lateral hypothalamus SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE fos; hypothalamus; lamina terminals; rat ID WAKING DISCHARGE PATTERNS; MONOAMINERGIC CELL GROUPS; EXPRESS C-FOS; LAMINA TERMINALIS; SUBFORNICAL ORGAN; AFFERENT CONNECTIONS; GALANINERGIC NEURONS; SUPRAOPTIC NUCLEUS; GABAERGIC NEURONS; HYPERTONIC SALINE AB The lamina terminalis consists of the organum vasculosum of the lamina terminalis (OVLT), median preoptic nucleus (MnPO) and subfornical organ. The MnPO and ventrolateral preoptic area (vIPOA) are known to contain high densities of neurons that are sleep active. The prevalence of sleep-active neurons in the OVILT and subfornical organ is unknown. The vIPOA and subdivisions of the lamina terminalis project to hypothalamic regions involved in the control of behavioral, electrographic or autonomic arousal, including the lateral hypothalamic area (LHA) and paraventricular nucleus (PVN). The extent to which projection neurons are active during sleep is unknown. We quantified c-Fos protein immunoreactivity (IR) in the lamina terminalis and vIPOA in sleeping and awake rats that received injections of retrograde tracer into either the LHA or PVN. Fos IR was also examined in lamina terminalis neurons following tracer injections into the vIPOA. Significantly more projection neurons from the MnPO, OVILT and vIPOA to the LHA were Fos-immunoreactive in sleeping vs. awake animals. Waking Fos IR was more prevalent in lamina terminalis neurons projecting to the PVN although a subset of MnPO projection neurons in sleeping rats was Fos-immunoreactive. Almost 50% of vIPOA-PVN projection neurons expressed Fos IR during sleep, compared with 3% during waking. Significantly more neurons in the OVILT and MnPO projecting to the vIPOA were Fos-immunoreactive in sleeping vs. awake rats. Inhibition of LHA and PVN neurons arising from OVILT, MnPO and vIPOA neurons may contribute to suppression of behavioral, electroencephalographic and sympathetic nervous system activation during sleep. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90024 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [MH63323] NR 60 TC 31 Z9 34 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JUN PY 2006 VL 23 IS 12 BP 3284 EP 3296 DI 10.1111/j.1460-9568.2006.04860.x PG 13 WC Neurosciences SC Neurosciences & Neurology GA 070EF UT WOS:000239502400014 PM 16820018 ER PT J AU Gold, PB Glynn, SM Mueser, KT AF Gold, PB Glynn, SM Mueser, KT TI Challenges to implementing and sustaining comprehensive mental health service programs SO EVALUATION & THE HEALTH PROFESSIONS LA English DT Article DE evidence-based practice; mental health practice and policy; psychiatric disability; dissemination; implementation ID ASSERTIVE COMMUNITY TREATMENT; RESEARCH-TEAM PORT; SUPPORTED EMPLOYMENT; TREATMENT RECOMMENDATIONS; MULTISITE DEMONSTRATIONS; FAMILY PSYCHOEDUCATION; CONCEPTUAL-MODEL; RANDOMIZED-TRIAL; FEDERAL-SUPPORT; SUBSTANCE USE AB The Presidents New Freedom Commission recently concluded that the nation's mental health service delivery system is ill equipped to meet the complex needs of persons with mental illness. A major contributor to this service quality crisis has been the long-standing divergence of research efforts and clinical programs. In this article, the authors begin by describing the unique needs of persons with serious and persisting psychiatric disorders and the evolution of the mental health service system that has attempted to meet these needs. They then discuss recent efforts to upgrade services by emphasizing the use of evidence-based practices (EBPs) and the research underlying their development. Next, they describe the difficulties of using traditional research methods to develop and test interventions for persons receiving services at public mental health agencies. Finally, they outline the challenges confronted when trying to disseminate these EBPs to the wider clinical community. C1 Med Univ S Carolina, Charleston, SC 29425 USA. Univ Calif Los Angeles, Vet Affairs Greater Los Angeles, Los Angeles, CA 90024 USA. Dartmouth Coll Sch Med, Semel Inst Neurosci & Human Behav, Hanover, NH USA. RP Gold, PB (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. EM goldpb@musc.edu FU NIMH NIH HHS [MH64662, MH01903, MH62324, MH62629] NR 82 TC 28 Z9 28 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0163-2787 J9 EVAL HEALTH PROF JI Eval. Health Prof. PD JUN PY 2006 VL 29 IS 2 BP 195 EP 218 DI 10.1177/0163278706287345 PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 041KI UT WOS:000237454700003 PM 16645184 ER PT J AU Schmucker, DL AF Schmucker, D. L. TI Response to: "Age-related changes in goblet cell density of rat small bowel" by Aller MA et al SO EXPERIMENTAL GERONTOLOGY LA English DT Letter C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Schmucker, DL (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. EM coach@itsa.ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JUN PY 2006 VL 41 IS 6 BP 565 EP 565 DI 10.1016/j.exger.2006.03.008 PG 1 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 061UZ UT WOS:000238899600004 ER PT J AU Pedersen, WA McMillan, PJ Kulstad, JJ Leverenz, JB Craft, S Haynatzki, GR AF Pedersen, Ward A. McMillan, Pamela J. Kulstad, J. Jacob Leverenz, James B. Craft, Suzanne Haynatzki, Gleb R. TI Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice SO EXPERIMENTAL NEUROLOGY LA English DT Article DE glucocorticoids; insulin-degrading enzyme; insulin resistance; metyrapone; peroxisome proliferator-activated receptor-gamma; stress; thiazolidinedione ID INSULIN-DEGRADING ENZYME; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN-E GENOTYPE; TYPE-2 DIABETES-MELLITUS; MOUSE MODEL; COGNITIVE FUNCTION; CHRONIC STRESS; DISEASE; RISK; DEMENTIA AB The thiazolidinediones, such as rosiglitazone, increase peripheral insulin sensitivity and their use is proposed for the treatment of Alzheimer's disease. However, the mechanisms underlying the potential beneficial effects of rosiglitazone in Alzheimer's disease remain unclear. In previous studies, we observed that Tg2576 Alzheimer mice develop peripheral insulin resistance with age and have much higher serum corticosterone levels than wild-type mice when fasted overnight. We further showed that both of these defects can be ameliorated by rosiglitazone administration. Here, we report that during behavioral testing which involves repetitive overnight fasting, Tg2576 mice administered rosiglitazone exhibited better spatial learning and memory abilities and had lower serum corticosterone levels than untreated Tg2576 mice. When untreated Tg2576 mice were administered metyrapone, a drug that blocks glucocorticoid production, their spatial learning and memory abilities and serum corticosterone levels were similar to those of rosiglitazone-treated mice. We further report here that rosiglitazone attenuated reductions in insulin-degrading enzyme (IDE) mRNA and activity, and reduced amyloid beta-peptide (A beta)42 levels without affecting amyloid deposition, in the brains of Tg2576 mice. These results demonstrate that rosiglitazone attenuates learning and memory deficits in Tg2576 mice and suggest that the effects of the drug on learning and memory, brain IDE levels, and brain A beta 42 levels in the mice may be due to its glucocorticoid-lowering actions. (c) 2006 Elsevier Inc. All rights reserved. C1 Creighton Univ, Med Ctr, Dept Pathol, Omaha, NE 68131 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Creighton Univ, Med Ctr, Osteoporosis Res Ctr, Dept Internal Med, Omaha, NE 68131 USA. RP Pedersen, WA (reprint author), Creighton Univ, Med Ctr, Dept Pathol, 601 N 30th St,Suite 2469, Omaha, NE 68131 USA. EM wpedersen@creighton.edu FU NIA NIH HHS [AG-10880] NR 44 TC 204 Z9 216 U1 3 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD JUN PY 2006 VL 199 IS 2 BP 265 EP 273 DI 10.1016/j.expneurol.2006.01.018 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 063DB UT WOS:000238995200007 PM 16515786 ER PT J AU Sayers, SL White, T Zubritsky, C Oslin, DW AF Sayers, SL White, T Zubritsky, C Oslin, DW TI Family involvement in the care of healthy medical outpatients SO FAMILY PRACTICE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-of-Behavioral-Medicine CY MAR 19-22, 2003 CL Salt Lake City, UT SP Soc Behav Med DE emotional support; family involvement; medical care; older adults ID SOCIAL SUPPORT; PRISM-E; TRIAL; INTERVENTIONS; METAANALYSIS; BEHAVIORS; OUTCOMES; LIFE AB Background. Although the involvement of patients' family members in office visits has been examined extensively, less is known about the involvement of family members in supporting patients' medical care outside of office visits. Objective. This study examines two questions: What types of family involvement do family members have in the medical care of relatively healthy older outpatients, and does self-rated health moderate patients' reactions to this family involvement? Methods. Patients from a large sample of medical practice outpatients (N = 1572) were assessed to determine perceived emotional support, involvement of family members in their medical care, as well as the presence of depressive symptoms. Results. Approximately 50% of patients had some family involvement in their medical care (e.g. taking part in medical decisions, reminding the patient to take medication). Marital status was a stronger predictor of family involvement than self-ratings of poor physical health. Additionally, there was no evidence that older patients who report good health have less favourable reactions to family involvement in their medical care. Conclusion. Family involvement in medical care occurs routinely and is most likely to involve a spouse, and is consistent with family interaction patterns among older adults. These findings also suggest that when providers invite family members to support treatment outside the office visit, these invitations are appropriate for older adult patients across a continuum of good to poor health. C1 Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Res Educ & Clin Ctr, VISN Mental Illness 4, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. RP Sayers, SL (reprint author), Vet Affairs Med Ctr, 116,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM ssayers@mail.med.upenn.edu FU NIMH NIH HHS [1K08 MH01599]; PHS HHS [1UDISM53033] NR 24 TC 21 Z9 21 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 J9 FAM PRACT JI Fam. Pr. PD JUN PY 2006 VL 23 IS 3 BP 317 EP 324 DI 10.1093/fampra/cmi114 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 048EY UT WOS:000237931600010 PM 16461451 ER PT J AU Muller, FL Song, W Liu, YH Chaudhuri, A Pieke-Dahl, S Strong, R Huang, TT Epstein, CJ Roberts, LJ Csete, M Faulkner, JA Van Remmen, H AF Muller, FL Song, W Liu, YH Chaudhuri, A Pieke-Dahl, S Strong, R Huang, TT Epstein, CJ Roberts, LJ Csete, M Faulkner, JA Van Remmen, H TI Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE superoxide; muscle atrophy; aging; oxidative stress; CuZnSOD; free radicals ID INTERMEMBRANE SPACE; LIPID-PEROXIDATION; REACTIVE OXYGEN; DEFICIENT MICE; MOTOR-NEURONS; NULL MUTATION; HEARING-LOSS; COMPLEX-III; FIBER TYPES; DROSOPHILA AB We describe a novel phenotype in mice lacking the major antioxidant enzyme, CuZn-superoxide dismutase (Sod1(-/-) mice), namely a dramatic acceleration of age-related loss of skeletal muscle mass. Sod1(-/-) mice are 17 to 20% smaller and have a significantly lower muscle mass than wildtype mice as early as 3 to 4 months of age. Muscle mass in the Sod1(-/-) mice is further reduced with age and by 20 months, the hind-limb muscle mass in Sod1(-/-) mice is nearly 50% lower than in age-matched wild-type mice. Skeletal muscle tissue from young Sod1(-/-) mice has elevated oxidative damage to proteins, lipids, and DNA compared to muscle from young wild-type mice. The reduction in muscle mass and elevated oxidative damage are accompanied by a 40% decrease in voluntary wheel running by 6 months of age and decreased performance on the Rota-rod test at 13 months of age, but are not associated with a decline in overall spontaneous activity. In some of the old Sod1(-/-) mice, the loss in muscle mass is also associated with the presence of tremors and gait disturbances. Thus, the absence of CuZnSOD imposes elevated oxidative stress, loss of muscle mass, and physiological consequences that resemble an acceleration of normal age-related sarcopenia. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Stanford Univ, Palo Alto, CA 94304 USA. Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. Vanderbilt Univ, Dept Pharmacol & Med, Nashville, TN 37232 USA. Emory Univ, Atlanta, GA 30322 USA. Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. RP Van Remmen, H (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,MSC 7762, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu FU NIA NIH HHS [5T3-AG021890-02, P01 AG20591]; NIGMS NIH HHS [GM42056] NR 55 TC 189 Z9 195 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUN 1 PY 2006 VL 40 IS 11 BP 1993 EP 2004 DI 10.1016/j.freeradbiomed.2006.01.036 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 050QP UT WOS:000238103300012 PM 16716900 ER PT J AU Goodgame, R Graham, DY AF Goodgame, Richard Graham, David Y. TI Common gastrointestinal and hepatic infections - Preface SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 Baylor Coll Med, Houston, TX 77030 USA. Vet Affairs Med Ctr 111D, Houston, TX 77030 USA. RP Goodgame, R (reprint author), Baylor Coll Med, 1 Baylor Plaza,Room 525-D, Houston, TX 77030 USA. EM goodgame@bcm.tmc.edu; dgraham@bcm.tmc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2006 VL 35 IS 2 BP XIII EP XIV DI 10.1016/j.gtc.2006.05.004 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076PI UT WOS:000239969800001 ER PT J AU Vilaichone, RK Mahachai, V Graham, DY AF Vilaichone, Ratha-Korn Mahachai, Varocha Graham, David Y. TI Helicobacter pylori diagnosis and management SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; RANITIDINE BISMUTH CITRATE; PROTON PUMP INHIBITORS; QUADRUPLE THERAPY; UNITED-STATES; SEQUENTIAL TREATMENT; INFECTED PERSONS; GASTRIC-CANCER; ULCER DISEASE; PEPTIC-ULCER AB Helicobacter pylori is a global human pathogen and the major cause of gastritis and the gastritis-associated diseases: gastric ulcer, duodenal ulcer, gastric cancer, and primary gastric B-cell lymphoma. Although several reliable diagnostic tests are widely available, the ideal regimen for treating the infection remains to be established. The current first-line or legacy triple therapy regimens fail in 20% to 40% of patients. Recent studies have confirmed older observations that the success rate of legacy triple regimens (proton pump inhibitor plus two antibiotics) can be improved if the duration is extended to 14 days or a third antibiotic is given. Confirmation of eradication using noninvasive diagnostic tests, such as a urea breath test or stool antigen assay, is now the standard of care. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Thammasat Univ Hosp, Gastroenterol Unit, Dept Med, Pathum Thani 12120, Thailand. Chulalongkorn Univ Hosp, Dept Med, Div Gastroenterol, Bangkok 10330, Thailand. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338] NR 87 TC 43 Z9 52 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2006 VL 35 IS 2 BP 229 EP + DI 10.1016/j.gtc.2006.03.004 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076PI UT WOS:000239969800002 PM 16880064 ER PT J AU Aslam, S Musher, DM AF Aslam, Saima Musher, Daniel M. TI An update on diagnosis, treatment, and prevention of Clostridium difficile - Associated disease SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Review ID ANTIBIOTIC-ASSOCIATED COLITIS; PLACEBO-CONTROLLED TRIAL; CLINDAMYCIN-ASSOCIATED COLITIS; RANDOMIZED CONTROLLED-TRIAL; PROTON PUMP INHIBITORS; IN-VITRO ACTIVITY; TOX A/B TEST; PSEUDOMEMBRANOUS COLITIS; DOUBLE-BLIND; HOSPITALIZED-PATIENTS AB Clostridium diffiicile is an Important cause of nosocomial morbidity and mortality and is implicated in recent epidemics. Data support the treatment of colitis with oral metronidazole in a dose of 1.0 to 1.5 g/d, with oral vancomycin as a second-line agent. Given recent data regarding poorer response rates than previously described and more severe disease, alternative agents for the treatment of initial and recurrent disease are being studied. Greater attention should be paid to hospital infection control policies and restriction of broad-spectrum antibiotics. C1 Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Aslam, S (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Room 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM saslam@bcm.tmc.edu NR 179 TC 41 Z9 48 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2006 VL 35 IS 2 BP 315 EP + DI 10.1016/j.gtc.2006.03.009 PG 22 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076PI UT WOS:000239969800006 PM 16880068 ER PT J AU Graham, DY Uemura, N AF Graham, DY Uemura, N TI Natural history of gastric cancer after Helicobacter pylori eradication in Japan: After endoscopic resection, after treatment of the general population, and naturally SO HELICOBACTER LA English DT Editorial Material ID SUBSEQUENT DEVELOPMENT; BIRTH COHORT; INFECTION; EPIDEMIOLOGY; CHILDREN; REGION C1 Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Mol Virol & Microbiol, Houston, TX USA. Int Med Ctr Japan, Dept Gastroenterol, Shinjyu Ku, Tokyo, Japan. RP Graham, DY (reprint author), Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338] NR 24 TC 10 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD JUN PY 2006 VL 11 IS 3 BP 139 EP 143 DI 10.1111/j.1523-5378.2006.00391.x PG 5 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 040QK UT WOS:000237395300001 PM 16684259 ER PT J AU Sterling, RK Lissen, E Clumeck, N Sola, R Correa, MC Montaner, J Sulkowski, MS Torriani, FJ Dieterich, DT Thomas, DL Messinger, D Nelson, M AF Sterling, RK Lissen, E Clumeck, N Sola, R Correa, MC Montaner, J Sulkowski, MS Torriani, FJ Dieterich, DT Thomas, DL Messinger, D Nelson, M CA APRICOT Clinical Investigators TI Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection SO HEPATOLOGY LA English DT Article; Proceedings Paper CT 12th Conference on Retroviruses and Opportunistic Infections CY FEB 22-25, 2005 CL Boston, MA ID CHRONIC HEPATITIS-C; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; LIVER FIBROSIS; BIOCHEMICAL MARKERS; ASPARTATE-AMINOTRANSFERASE; SERUM MARKERS; BIOPSY; CIRRHOSIS AB Liver biopsy remains the gold standard in the assessment of severity of liver disease. Noninvasive tests have gained popularity to predict histology in view of die associated risks of biopsy. However, many models include tests not readily available, and there are limited data from patients with HIV/hepatitis C virus (HCV) coinfection. We aimed to develop a model using routine tests to predict liver fibrosis in patients with HIV/HCV coinfection. A retrospective analysis of liver histology was performed in 832 patients. Liver fibrosis was assessed via Ishak score; patients were categorized as 0-1, 2-3, or 4-6 and were randomly assigned to training (n = 555) or validation (n = 277) sets. Multivariate logistic regression analysis revealed that platelet count (PLT), age, AST, and M were significantly associated with fibrosis. Additional analysis revealed PLT, age, AST, and ALT as an alternative model. Based on this, a simple index (FIB-4) was developed: age ([yr] x AST [U/L])/((PLT [10(9)/L]) X (ALT [U/L])(1/2)). The AUROC of the index was 0.765 for differentiation between Ishak stage 0-3 and 4-6. At a cutoff of < 1.45 in the validation set, the negative predictive value to exclude advanced fibrosis (stage 4-6) was 90% with a sensitivity of 70%. A cutoff of > 3.25 had a positive predictive value of 65% and a specificity of 97%. Using these cutoffs, 87% of the 198 patients with FIB-4 values outside 1.45-3.25 would be correctly classified, and liver biopsy could be avoided in 71% of the validation group. In conclusion noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV-coinfected patients. C1 Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. Virgen Rocio Univ Hosp, Seville, Spain. CHU St Pierre, Brussels, Belgium. Univ Autonoma Barcelona, Hosp del Mar, Liver Sect, Barcelona, Spain. HCFMUSP Casa AIDS, Sao Paulo, Brazil. Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Univ Calif San Diego, Treatment Ctr, San Diego, CA 92103 USA. Mt Sinai Sch Med, New York, NY USA. IST GmbH, Mannheim, Germany. Chelsea & Westminster Hosp, London, England. RP Sterling, RK (reprint author), Virginia Commonwealth Univ Hlth Syst, Sect Hepatol, W Hosp, 1200 E Broad St,Room 1492, Richmond, VA 23298 USA. EM rksterli@hsc.vcu.edu RI Manzotti, Grazia/C-5985-2008; mendes correa, maria cassia /A-6779-2013 FU NIDA NIH HHS [R01DA16078]; NIDDK NIH HHS [K23 DK064578] NR 48 TC 677 Z9 694 U1 3 U2 11 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JUN PY 2006 VL 43 IS 6 BP 1317 EP 1325 DI 10.1002/hep.21178 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 048ZG UT WOS:000237984500018 PM 16729309 ER PT J AU McMurtray, AM Ringman, J Chao, SZ Licht, E Saul, RE Mendez, MF AF McMurtray, Aaron M. Ringman, John Chao, Steven Z. Licht, Eliot Saul, Ronald E. Mendez, Mario F. TI Family history of dementia in early-onset versus very late-onset Alzheimer's disease SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID RISK C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Stanford Univ Hosp, Dept Neurol, Los Angeles, CA USA. RP McMurtray, AM (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amcmurtray@mednet.ucla.edu NR 5 TC 9 Z9 9 U1 1 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JUN PY 2006 VL 21 IS 6 BP 597 EP 598 DI 10.1002/gps.1540 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 063PE UT WOS:000239031100013 PM 16783800 ER PT J AU Glahn, DC Bearden, CE Bowden, CL Soares, JC AF Glahn, DC Bearden, CE Bowden, CL Soares, JC TI Reduced educational attainment in bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; education; cognitive; socioeconomic status; matching facile; IQ ID SCHIZOPHRENIA AB Objective: To document educational attainment in relation to IQ in patients with bipolar disorder, in order to establish guidelines for matching patients with appropriate comparison subjects. Method: 60 adult patients with bipolar disorder were compared to 60 demographically matched healthy subjects on IQ measures and educational attainment. Results: Despite comparable IQ levels, patients with bipolar disorder completed fewer years of education than controls. Although over 60% of both groups entered college, only 16% of bipolar patients received a college degree. In contrast 47% of the comparison sample completed college. Educational attainment did not differ between subgroups of patients with earlier vs. later illness onset, nor as a function of comorbid substance abuse. Limitations: Other comorbidities, such as anxiety disorders or sub-clinical symptomatology prior to illness onset, were not assessed. Conclusions: Educational attainment is disrupted in bipolar disorder, and thus should not be used for matching patients and comparison subjects. Reduced educational attainment may contribute to later functional disability in this illness. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Glahn, DC (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr,Mail Code 7792, San Antonio, TX 78229 USA. EM glahn@uthscsa.edu FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH 068662, MH 01736] NR 10 TC 25 Z9 25 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUN PY 2006 VL 92 IS 2-3 BP 309 EP 312 DI 10.1016/j.jad.2006.01.025 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 050ZS UT WOS:000238130500023 PM 16524631 ER PT J AU Bush, RK Peden, DB AF Bush, RK Peden, DB TI Advances in environmental and occupational disorders SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE environment; allergens; asthma; occupational diseases; environmental controls ID AIR-POLLUTION; ALLERGEN AVOIDANCE; MAJOR ALLERGEN; PUBLIC-HEALTH; IN-VIVO; ASTHMA; CHILDREN; IGE; EXPOSURE; ENDOTOXIN AB As with the previous year, 2005 was a very active year for investigation of the effect of environmental agents on allergic disease, be they allergens, pollutants, bioaerosols, or occupationally encountered agents. There were a large number of articles on the prevalence of allergic disease in the United States, identification and characterization of a number of allergens, and the role of indoor allergens and potential mitigation of the effect of such allergens, as well as the hygiene hypothesis, air pollution, and the effect of these agents on airway disease. The Journal of Allergy and Clinical Immunology also saw very interesting case reports and mechanistic studies examining the causes of occupational immune-mediated disease. There were also reports on gene-environment interactions, highlighting the importance of such interactions in modulating the risk for development of allergic disease. That these interactions have proved to be remarkably complex comes as no surprise to the allergy and immunology community because allergists and immunologists have long appreciated the role of environmental influences on disease. C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Sect Allergy Pulm & Crit Care Med, Madison, WI 53706 USA. Univ N Carolina, Sch Med, Div Pediat Immunol & Infect Dis, Chapel Hill, NC USA. Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA. RP Bush, RK (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Robert.Bush@med.va.gov NR 48 TC 2 Z9 2 U1 1 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JUN PY 2006 VL 117 IS 6 BP 1367 EP 1373 DI 10.1016/j.jaci.2006.04.009 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 053UX UT WOS:000238332300024 PM 16750999 ER PT J AU Conard, MW Heidenreich, P Rumsfeld, JS Weintraub, WS Spertus, J AF Conard, MW Heidenreich, P Rumsfeld, JS Weintraub, WS Spertus, J CA Cardiovascular Outcomes Res Consor TI Patient-reported economic burden and the health status of heart failure patients SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE difficulty affording health care; cardiovascular disease ID CASE-FINDING INSTRUMENTS; HIGH-RISK PATIENTS; MYOCARDIAL-INFARCTION; SOCIOECONOMIC-STATUS; CARE; DEPRESSION; COSTS; READMISSION AB Background: Heart failure (HF) guidelines recommend treatment with multiple medications to improve survival, functioning, and quality of life. Yet, HF treatments can be costly, resulting in significant economic burden for some patients. To date, there are few data on the impact of patients' perceived difficulties in affording medical care on their health outcomes. Methods and Results: Comprehensive clinical data, health status, and the perceived economic burden of 539 HF outpatients from 13 centers were assessed at baseline and 1 year later. Health status was quantified with the Kansas City Cardiomyopathy Questionnaire overall summary score. Cross-sectional and longitudinal (1-year) analyses were conducted comparing the health status of patients with and without self-reported economic burden. Patients with economic burden had significantly lower health status scores at both baseline and 1 year later. Although baseline perceptions of economic burden were associated with poorer health status, patients' perceived difficulty affording medical care at 1 year was a more important determinant of lower 1-year health status. Conclusion: HF patients reporting difficulty affording their medical care had lower perceived health status than those reporting little to no economic burden. More research is needed to further evaluate this association and to determine whether addressing perceived economic difficulties affording health care can improve HF patients' health status. C1 Univ Missouri, Kansas City & Midamer Heart Inst, St Lukes Hosp, Kansas City, MO 64110 USA. Denver VA Med Ctr, Denver, CO USA. Palo Alto VA Med Ctr, Palo Alto, CA USA. Emory Univ, Atlanta, GA 30322 USA. RP Conard, MW (reprint author), St James Hosp, 20201 S Crawford Ave, Olympia Fields, IL 60461 USA. OI Heidenreich, Paul/0000-0001-7730-8490 NR 31 TC 13 Z9 13 U1 0 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JUN PY 2006 VL 12 IS 5 BP 369 EP 374 DI 10.1016/j.cardfail.2006.03.004 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 056JK UT WOS:000238518600009 PM 16762800 ER PT J AU Musher, DM Nichol, AC Rueda, AM AF Musher, DM Nichol, AC Rueda, AM TI Nontypeable Haemophilus influenzae as a cause of spontaneous bacterial peritonitis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; CIRRHOTIC ASCITES; OPSONIC ACTIVITY; FLUID; SEROTYPES; BIOTYPES; CHILDREN; TRACT; FLORA AB Haemophilus influenzae rarely causes spontaneous bacterial peritonitis. We describe a typical case of spontaneous bacterial peritonitis in which the causative organism was identified as nontypeable H. influenzae, biotype III. Infection progressed despite the presence of adequate serum bactericidal antibody, probably due to the absence of complement in ascites fluid. C1 Michael E DeBakey Vet Affairs Med Ctr, Med Care Line Infect Dis Sect, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA. Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, Room 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 23 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2006 VL 44 IS 6 BP 2304 EP 2306 DI 10.1128/JCM.02066-05 PG 3 WC Microbiology SC Microbiology GA 053VD UT WOS:000238332900067 PM 16757647 ER PT J AU Brawman-Mintzer, O Knapp, RG Rynn, M Carter, RE Rickels, K AF Brawman-Mintzer, Olga Knapp, Rebecca G. Rynn, Moira Carter, Rickey E. Rickels, Karl TI Sertraline treatment for generalized anxiety disorder: A randomized, double-blind, placebo-controlled study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 15th Congress of the European-College-of-Neuropsychopharmacology CY OCT 05-09, 2002 CL BARCELONA, SPAIN SP European Coll Neuropsychopharmacol ID DEPRESSION SCALE; EFFICACY; TRIAL; VENLAFAXINE; PAROXETINE AB Objective: This study assessed the efficacy and safety of sertraline in the treatment of generalized anxiety disorder (GAD). Method: The study was conducted from April 2000 to May 2002. Outpatients with DSM-IV GAD (N = 326) who satisfied inclusion/exclusion criteria and completed a 1-week screening phase were randomly assigned to 10-week double-blind treatment with flexible dosing of sertraline (50-200 mg/day) or placebo. The primary efficacy measure was change from baseline in Hamilton Rating Scale for Anxiety (HAM-A) total score. Response was defined as a 50% or greater decrease in HAM-A total score at endpoint. Results: Sertraline produced a statistically significant reduction in anxiety symptoms, as measured by HAM-A total change scores (p = .032), HAM-A psychic anxiety subscale (p = .011), and Hospital Anxiety and Depression Scale-anxiety subscale (p = .001). Response rates were significantly higher (p = .05) for the sertraline group (59.2%) compared to the placebo group (48.2%). Sertraline was well tolerated, with only sexual side effects reported significantly more often by subjects receiving sertraline than those receiving placebo. Conclusion: Despite the relatively small between-group differences, study findings suggest a role for sertraline in the acute treatment of GAD. C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29406 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29406 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Brawman-Mintzer, O (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 5900 Core Rd,Suite 203, Charleston, SC 29406 USA. EM mintzero@musc.edu NR 23 TC 37 Z9 39 U1 1 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2006 VL 67 IS 6 BP 874 EP 881 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 059WY UT WOS:000238764100003 PM 16848646 ER PT J AU Groeneveld, PW Sonnad, SS Lee, AK Asch, DA Shea, JE AF Groeneveld, PW Sonnad, SS Lee, AK Asch, DA Shea, JE TI Racial differences in attitudes toward innovative medical technology SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT Academy-Health Annual Research Meeting CY JUN, 2005 CL Boston, MA SP Acad Hlth DE African Americans; technology; medical; attitude; diffusion of innovation; veterans ID CORONARY-REVASCULARIZATION; ADOPTION; DISPARITIES; CARE AB BACKGROUND: New medical technologies are used at different rates among whites and blacks. This variation may be partially explained by racial differences in patient innovativeness-the propensity of patients to adopt unfamiliar therapies. OBJECTIVE: To measure how innovativeness varies among patients and how it may influence patients' attitudes toward new medical technologies. DESIGN: Cross-sectional survey. PARTICIPANTS: Primary care patients (n=171-108 blacks, 63 whites) at an urban Veterans Affairs medical center. MEASUREMENTS: Respondents answered questions about their general innovativeness and innovativeness regarding medical technology, and they responded to a vignette describing either a hypothetical new prescription drug or implantable device. RESULTS: There were no significant racial differences in general innovativeness, but whites had higher medical technology innovativeness (P=.001). Whites were also more likely to accept the new prescription drug (P =.003), but did not differ from blacks in acceptance of the new implantable device. In multivaiiate analyses, lower medical technology innovativeness scores among blacks were significantly associated with less favorable reactions to both the prescription drug (P <.001) and the medical device (P <.001). In contrast, although whites with lower medical technology innovativeness were similarly less inclined to accept the new implantable device (P=.02), there was no significant association between medical technology innovativeriess and positive attitudes to the new prescription drug among whites. CONCLUSIONS: Blacks and whites have differing attitudes toward medical innovation. These differences are associated with significant racial differences in response to particular health care technologies. These findings suggest potentially remediable causes for racial differences in the utilization of innovative medical technologies. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Groeneveld, PW (reprint author), 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM peter.groenevetd@med.va.gov OI Asch, David/0000-0002-7970-286X NR 23 TC 21 Z9 21 U1 2 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2006 VL 21 IS 6 BP 559 EP 563 DI 10.1111/j.1525-1497.2006.00453.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 051FU UT WOS:000238147800003 PM 16808736 ER PT J AU Levine, RB Haidet, P Kern, DE Beasley, BW Bensinger, L Brady, DW Gress, T Hughes, J Marwaha, A Nelson, J Wright, SM AF Levine, Rachel B. Haidet, Paul Kern, David E. Beasley, Brent W. Bensinger, Liso Brady, Donald W. Gress, Todd Hughes, Jennifer Marwaha, Ajay Nelson, Jennifer Wright, Scott M. TI Personal growth during internship - A qualitative analysis of interns' responses to key questions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE graduate medical education; personal growth; qualitative research ID MEDICINE RESIDENCY PROGRAM; PATIENT-CARE; REFLECTION; PHYSICIANS; AWARENESS; STUDENTS; DOCTORS; STRESS AB BACKGROUND: During clinical training, house officers frequently encounter intense experiences that may affect their personal growth. The purpose of this study was to explore processes related to personal growth during internship. DESIGN. Prospective qualitative study conducted over the course of internship. PARTICIPANTS: Thirty-two postgraduate year (PGY)-1 residents from 9 U.S. internal medicine training programs. APPROACH: Every 8 weeks, interns responded by e-mail to an open-ended question related to personal growth. Content analysis methods were used to analyze the interns' writings to identify triggers, facilitators, and barriers related to personal growth. RESULTS: Triggers for personal growth included caring for critically ill or dying patients, receiving feedback, witnessing unprofessional behavior, experiencing personal problems, and dealing with the increased responsibility of internship. Facilitators of personal growth included supportive relationships, reflection, and commitment to core values. Fatigue, lack of personal time, and overwhelming work were barriers to personal growth. The balance between facilitators and barriers may dictate the extent to which personal growth occurs. CONCLUSIONS: Efforts to support personal growth during residency training include fostering supportive relationships, encouraging reflection, and recognizing interns' core values especially in association with powerful triggers. C1 Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD 21224 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Missouri, Kansas City, MO 64110 USA. Mt Sinai Sch Med, New York, NY USA. Emory Univ, Atlanta, GA 30322 USA. Marshall Univ, Joan C Edwards Sch Med, Huntington, WV USA. Boston Univ, Med Ctr, Boston, MA 02215 USA. York Hosp, York, PA USA. Highland Gen Hosp, Oakland, CA USA. RP Levine, RB (reprint author), Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, 4940 Eastern Ave,Bldg B2N,Room 235, Baltimore, MD 21224 USA. EM rlevine@jhmi.edu NR 33 TC 18 Z9 18 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2006 VL 21 IS 6 BP 564 EP 569 DI 10.1111/j.1525-1497.2006.00383.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 051FU UT WOS:000238147800004 PM 16808737 ER PT J AU Bokhour, BG Berlowitz, DR Long, JA Kressin, NR AF Bokhour, BG Berlowitz, DR Long, JA Kressin, NR TI How do providers assess antihypertensive medication adherence in medical encounters? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hypertension; medication adherence; provider-patient communication ID DOCTOR-PATIENT COMMUNICATION; HIGH BLOOD-PRESSURE; DECISION-MAKING; HEALTH LITERACY; HYPERTENSION; PREVENTION; AMERICANS; ILLNESS; CARE AB BACKGROUND: Poor adherence to antihypertensives has been shown to be a significant factor in poor blood pressure (BP) control. Providers' communication with patients about their medication-taking behavior may be central to improving adherence. OBJECTIVE: The goal of this study was to characterize the ways in which providers ask patients about medication taking. DESIGN. Clinical encounters between primary care providers and hypertensive patients were audiotaped at 3 Department of Veterans' Affairs medical centers. PARTICIPANTS: Primary care providers (n=9) and African-American and Caucasian patients (n =38) who were diagnosed with hypertension (HTN). APPROACH: Transcribed audiotapes of clinical encounters were coded by 2 investigators using qualitative analysis based on sociolinguistic techniques to identify ways of asking about medication taking. Electronic medical records were reviewed after the visit to determine the BP measurement for the day of the taped encounter. RESULTS: Four different aspects of asking about medication were identified: structure, temporality, style and content. Open-ended questions generated the most discussion, while closed-ended declarative statements led to the least discussion. Collaborative style and use of lay language were also seen to facilitate discussions. In 39% of encounters, providers did not ask about medication taking. Among patients with uncontrolled HTN, providers did not ask about medications 33% of the time. CONCLUSION., Providers often do not ask about medication-taking behavior, and may not use the most effective communication strategies when they do. Focusing on the ways in which providers ask about patients' adherence to medications may improve BP control. C1 ENRM Vet Hosp 152, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. Philadelphia Va Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. RP Bokhour, BG (reprint author), ENRM Vet Hosp 152, Ctr Hlth Qual Outcomes & Econ Res, 200 Springs Rd, Bedford, MA 01730 USA. EM bokhour@bu.edu OI Bokhour, Barbara/0000-0001-8238-0745; Kressin, Nancy/0000-0003-2767-4286 NR 30 TC 39 Z9 40 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2006 VL 21 IS 6 BP 577 EP 583 DI 10.1111/j.1525-1497.2006.00397.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 051FU UT WOS:000238147800006 PM 16808739 ER PT J AU Mularski, RA White-Chu, F Overbay, D Miller, L Asch, SM Ganzini, L AF Mularski, RA White-Chu, F Overbay, D Miller, L Asch, SM Ganzini, L TI Measuring pain as the 5th vital sign does not improve quality of pain management SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE pain; quality of health care; outcome and process assessment (health care); pain measurement; quality indicators ID HEALTH-CARE-SYSTEM; CANCER PAIN; OF-CARE; VALIDATION; GUIDELINES; ADULTS AB BACKGROUND: To improve pain management, the Veterans Health Administration launched the "Pain as the 5th Vital Sign" initiative in 1999, requiring a pain intensity rating (0 to 10) at all clinical encounters. OBJECTIVE: To measure the initiative's impact on the quality of pain management. DESIGN: We retrospectively reviewed medical records at a single medical center to compare providers' pain management before and after implementing the initiative and performed a subgroup analysis of patients reporting substantial pain ( 4) during a postimplementation visit. PARTICIPANTS: Unique patient visits selected from all 15 primary care providers of a general medicine outpatient clinic. MEASUREMENTS: We used 7 process indicators of quality pain management, based on appropriately evaluating and treating pain, to assess 300 randomly selected visits before and 300 visits after implementing the pain initiative. RESULTS: The quality of pain care was unchanged between visits before and after the pain initiative (P >.05 for all comparisons): subjective provider assessment (49.3% before, 48.7% after), pain exam (26.3%, 26.0%), orders to assess pain (11.7%, 8.3%), new analgesic (8.7%, 11.0%), change in existing analgesics (6.7%, 4.3%), other pain treatment (11.7%, 13.7%), or follow-up plans (10.0%, 8.7%). Patients (n=79) who reported substantial pain often did not receive recommended care: 22% had no attention to pain documented in the medical record, 27% had no further assessment documented, and 52% received no new therapy for pain at that visit. CONCLUSIONS: Routinely measuring pain by the 5th vital sign did not increase the quality of pain management. Patients with substantial pain documented by the 5th vital sign often had inadequate pain management. C1 VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RAND Hlth, Los Angeles, CA USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Sch Nursing, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Mental Hlth Div, Portland, OR USA. RP Mularski, RA (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd,Mailcode 111G, Los Angeles, CA 90073 USA. EM Richard.Mularski@med.va.gov FU NINR NIH HHS [1P20NR0780] NR 29 TC 131 Z9 136 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2006 VL 21 IS 6 BP 607 EP 612 DI 10.1111/j.1525-1497.2006.00415.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 051FU UT WOS:000238147800011 PM 16808744 ER PT J AU Offner, H Subramanian, S Parker, SM Wang, CH Afentoulis, ME Lewis, A Vandenbark, AA Hurn, PD AF Offner, H Subramanian, S Parker, SM Wang, CH Afentoulis, ME Lewis, A Vandenbark, AA Hurn, PD TI Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESSENGER-RNA EXPRESSION; MIDDLE CEREBRAL-ARTERY; RAT ISCHEMIC CORTEX; TRANSCRIPTION FACTOR; IMMUNE PATHOLOGY; GENE-EXPRESSION; AUTOIMMUNITY; INJURY AB Induction of stroke not only produces local ischemia and brain damage, but also has profound effects on peripheral immune responses. In the current study, we evaluated effects on spleen and blood cells 4 days after stroke induction. Surprisingly, there was a less inflammatory cytokine profile in the middle cerebral artery occlusion-affected right brain hemisphere at 96 h compared with earlier time points. Moreover, our results demonstrate that stroke leads to splenic atrophy characterized by a reduction in organ size, a drastic loss of splenocyte numbers, and induction of annexin V+ and TUNEL+ cells within the spleen that are in the late stages of apoptosis. The consequence of this process was to reduce T cell proliferation responses and secretion of inflammatory cytokines, resulting in a state of profound immunosuppression. These changes produced a drastic reduction in B cell numbers in spleen and blood, and a novel increase in CD4(+)FoxP3(+) regulatory T cells. Moreover, we detected a striking increase in the percentage of nonapoptotic CD11b(+) VLA-4-negative macrophages/monocytes in blood. Immunosuppression in response to brain injury may account for the reduction of inflammatory factors in the stroke-affected brain, but also potentially could curtail protective immune responses in the periphery. These findings provide new evidence to support the contention that damage to the brain caused by cerebral ischemia provides a powerful negative signal to the peripheral immune system that ultimately induces a drastic state of immunosuppression caused by cell death as well as an increased presence of CD4(+)FoxP3(+) regulatory T cells. C1 Portland Vet Affairs Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland Vet Affairs Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NCRR NIH HHS [RR00163]; NINDS NIH HHS [NS33668, NS49210, R01 NS076013]; NINR NIH HHS [NR03521] NR 35 TC 193 Z9 200 U1 2 U2 6 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JUN 1 PY 2006 VL 176 IS 11 BP 6523 EP 6531 PG 9 WC Immunology SC Immunology GA 045PN UT WOS:000237754200016 PM 16709809 ER PT J AU Fan, JH Guan, SX Cheng, CF Cho, M Fields, JW Chen, M Denning, MF Woodley, DT Li, W AF Fan, Jianhua Guan, Shengxi Cheng, Chieh-Fang Cho, Michele Fields, Joshua W. Chen, Mei Denning, Mitchell F. Woodley, David T. Li, Wei TI PKC delta clustering at the leading edge and mediating growth factor-enhanced, but not ECM-initiated, dermal fibroblast migration SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID PROTEIN-KINASE-C; HUMAN KERATINOCYTE MIGRATION; VASCULAR SMOOTH-MUSCLE; TYROSINE PHOSPHORYLATION; CELL MOTILITY; INDUCED-DIFFERENTIATION; INDUCED APOPTOSIS; GENE-EXPRESSION; ACTIVATION; RECEPTOR AB We have previously shown that the immobilized extracellular matrices (ECMs) initiate cell migration and soluble growth factors (GFs) further enhance ECM-initiated cell migration. GFs alone cannot initiate cell migration. To further investigate the specificity of the two signaling mechanisms, we focused on the protein kinase C (PKC) family genes in primary human dermal fibroblasts (DFs). We here show that platelet-derived growth factor-BB (PDGF-BB) strongly stimulates membrane translocation and leading edge clustering of protein kinase C delta(PKC delta). In contrast, attachment to collagen matrix alone does not cause the translocation. Although the kinase function of PKC delta is dispensable for initial membrane translocation, it is critical for its sustained presence at the cells's leading edge. Blockade of endogenous PKC delta signaling with dominant-negative kinase-defective PKC (PKC delta-KD) or PKC delta-small interfering RNA (siRNA) completely inhibited PDGF-BB-stimulated DF migration. In contrast, neither PKC delta-KD nor PKC delta-siRNA affected collagen-induced initiation of DF migration. Overexpression of a constitutively activated PKC delta(PKC delta-R144/145A) partially mimics the effect of PDGF-BB. However, PKC delta-KD, PKC delta-siRNA, or PKC delta-R144/145A does not affect PDGF-BB-stimulated activation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase1/2, or c-Jun N-terminal kinase. Instead, inhibition of PKC delta blocks PDGF-BB-stimulated activation of signal transducer and activator of transcription 3 (Stat3). This study unveiled the specificity of PKC delta in the control of DF migration. C1 Univ So Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Greater Los Angeles Vet Adm Hlth Syst, Los Angeles, CA USA. Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. RP Li, W (reprint author), Univ So Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90033 USA. EM dwoodley@usc.edu; wli@usc.edu FU NIAMS NIH HHS [AR46538, GM/AR67100-01] NR 65 TC 13 Z9 14 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JUN PY 2006 VL 126 IS 6 BP 1233 EP 1243 DI 10.1038/sj.jid.5700149 PG 11 WC Dermatology SC Dermatology GA 062TZ UT WOS:000238968800012 PM 16543902 ER PT J AU Wambaugh, JL Duffy, JR McNeil, MR Robin, DA Rogers, MA AF Wambaugh, JL Duffy, JR McNeil, MR Robin, DA Rogers, MA TI Treatment guidelines for acquired apraxia of speech: A synthesis and evaluation of the evidence SO JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY LA English DT Article ID SOUND PRODUCTION TREATMENT; PERCEPTUAL CHARACTERISTICS; CONSONANT PRODUCTION; DYSARTHRIC SPEAKERS; APHASIA; THERAPY; OVERGENERALIZATION; VARIABILITY; CONSISTENCY; PATTERNS AB This report provides a summary and critical appraisal of the evidence utilized in the development of treatment guidelines for acquired apraxia of speech (AOS). This systematic review of the AOS treatment literature is a result of the efforts of the Academy of Neurologic Communication Disorders and Sciences (ANCDS) Writing Committee of Treatment Guidelines for AOS. Fifty-nine publications that met inclusion criteria were reviewed in terms of 33 variables pertaining to issues such as subject, treatment, and outcome descriptions, and scientific adequacy. Although the review revealed many weaknesses in the evidence base, findings indicated that patients with AOS can benefit from treatment. C1 VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA. Univ Utah, Salt Lake City, UT USA. Mayo Clin, Rochester, MN USA. Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. San Diego State Univ, San Diego, CA 92182 USA. Univ Washington, Seattle, WA 98195 USA. RP Wambaugh, JL (reprint author), 500 Foothill Blvd, Salt Lake City, UT 84148 USA. EM Julie.wambaugh@health.utah.edu RI Robin, Donald/F-2109-2010 NR 93 TC 59 Z9 60 U1 3 U2 23 PU DELMAR LEARNING PI CLIFTON PARK PA EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA SN 1065-1438 J9 J MED SPEECH-LANG PA JI J. Med. Speech-Lang. Pathol. PD JUN PY 2006 VL 14 IS 2 BP XV EP XXXIII PG 19 WC Audiology & Speech-Language Pathology; Clinical Neurology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology GA 047ME UT WOS:000237882600004 ER PT J AU Wambaugh, JL Duffy, JR McNeil, MR Robin, DA Rogers, MA AF Wambaugh, JL Duffy, JR McNeil, MR Robin, DA Rogers, MA TI Treatment guidelines for acquired apraxia of speech: Treatment descriptions and recommendations SO JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY LA English DT Article ID SOUND PRODUCTION TREATMENT; APHASIA; THERAPY; OVERGENERALIZATION; STIMULATION; ACCURACY; SPEAKER; ADULTS AB This article is the second of two reports from the Academy of Neurologic Communication Disorders and Sciences (ANCDS) Writing Committee of Treatment Guidelines for AOS. The first report provided a review and evaluation of the AOS treatment evidence (Wambaugh, Duffy, McNeil, Robin, & Rogers, 2006a). The current report is focused on the aspects of guidelines development that followed the review of the evidence. The major categories of AOS treatments are described in terms of treatment techniques, targets, outcomes, candidacy, and evidence quality. In addition, this report provides the committee's treatment recommendations and suggestions for future research. C1 VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA. Univ Utah, Salt Lake City, UT USA. Mayo Clin, Rochester, MN USA. Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. San Diego State Univ, San Diego, CA 92182 USA. Univ Washington, Seattle, WA 98195 USA. RP Wambaugh, JL (reprint author), 500 Foothill Blvd, Salt Lake City, UT 84148 USA. EM Julie.wambaugh@health.utah.edu RI Robin, Donald/F-2109-2010 NR 83 TC 22 Z9 23 U1 1 U2 19 PU DELMAR LEARNING PI CLIFTON PARK PA EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA SN 1065-1438 J9 J MED SPEECH-LANG PA JI J. Med. Speech-Lang. Pathol. PD JUN PY 2006 VL 14 IS 2 BP XXXV EP LXVII PG 33 WC Audiology & Speech-Language Pathology; Clinical Neurology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology GA 047ME UT WOS:000237882600005 ER PT J AU Quinones, MP Jimenez, F Martinez, H Estrada, CA Willmon, O Dudley, M Kuziel, WA Melby, PC Reddick, RL Ahuja, SK Ahuja, SS AF Quinones, MP Jimenez, F Martinez, H Estrada, CA Willmon, O Dudley, M Kuziel, WA Melby, PC Reddick, RL Ahuja, SK Ahuja, SS TI CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Article ID COLLAGEN-INDUCED ARTHRITIS; HEAT-SHOCK PROTEIN; BEIGE MOUSE MODEL; RHEUMATOID-ARTHRITIS; MOLECULAR MIMICRY; PONCETS-DISEASE; T-CELLS; NONTUBERCULOUS MYCOBACTERIA; INTRACELLULARE INFECTION; SEPTIC ARTHRITIS AB The host factors that influence autoimmune arthritides such as rheumatoid arthritis have not been fully elucidated. We previously found that genetic inactivation of CC chemokine receptor 2 (CCR2) in the arthritis-prone DBA/1j mouse strain significantly increases the susceptibility of this strain to autoimmune arthritis induced by immunization with collagen type II (CII) and complete Freund's adjuvant (CFA). Here, we show that following intradermal infection with Mycobacterium avium, a similar arthritis phenotype was detected in Ccr2-null mice in the DBA/1j, but not in the BALB/c background. The failure to develop arthritis in Ccr2-null BALB/c mice occurred in the face of high bacterial burdens and low interferon gamma (IFN gamma) production. By contrast, Ccr2-null DBA/1j mice had low bacterial burdens, produced normal amounts of IFN gamma, and had high titers of autoantibodies against CII. Thus, the Ccr2-null state in an arthritic-prone genetic background leads to increased arthritis susceptibility following infectious (M. avium) and noninfectious (CII/CFA) challenges. Because CCR2 serves as a negative regulator of murine arthritis, caution might need to be exercised while testing CCR2 blockers in human arthritis or other diseases. These findings also indicate that Ccr2-null DBA/1j mice might serve as a valuable model system to uncover the immunological determinants of arthritis and to test novel antiarthritic agents. C1 Univ Texas, Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. Prot Design Labs Inc, Fremont, CA 94555 USA. S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX USA. Vet Adm Ctr Res AIDS & HIV 1 Infect, San Antonio, TX USA. RP Ahuja, SS (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7870, San Antonio, TX 78229 USA. EM ahuja@uthscsa.edu FU NIAID NIH HHS [AI48644] NR 55 TC 8 Z9 10 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0946-2716 J9 J MOL MED-JMM JI J. Mol. Med. PD JUN PY 2006 VL 84 IS 6 BP 503 EP 512 DI 10.1007/s00109-006-0039-3 PG 10 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 048RO UT WOS:000237964400007 PM 16520943 ER PT J AU Jha, S Xu, KP Maruta, T Oshima, M Mosier, DR Atassi, MZ Hoch, W AF Jha, S Xu, KP Maruta, T Oshima, M Mosier, DR Atassi, MZ Hoch, W TI Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK) SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE antibodies; autoimmunity; muscle-specific kinase; myasthenia gravis; mouse model; agrin ID T-CELL RECOGNITION; ACETYLCHOLINE-RECEPTOR; NEUROMUSCULAR-JUNCTION; ANTI-TITIN; TYROSINE PHOSPHORYLATION; IMMUNE RESPONSIVENESS; SYNAPSE FORMATION; SKELETAL-MUSCLE; SERONEGATIVE MG; GENETIC-CONTROL AB Myasthenia gravis (MG) is mostly caused by anti-acetylcholine receptor (AChR) auto-antibodies (Abs). Such Abs are undetectable in 10-15% of MG patients, but many have anti-muscle-specific kinase (MuSK) Abs. We injected recombinant rat-MuSK extracellular domain in H-2(a), H-2(b), H-2(bm12) and H-2(d) mice. Certain strains exhibited exercise-induced fatigue, tremors, weight loss, and some died after 2-3 injections. Compound muscle action potentials showed decrement with low-frequency repetitive nerve stimulation. Miniature endplate potentials decreased, suggesting lower numbers of endplates functional AChRs. Myasthenic sera inhibited agrin-induced AChR aggregation in C2C12 myotubes. Conclusion: Anti-MuSK Abs induce MG, which might also result from blocking the agrin-signaling pathway. (c) 2006 Published by Elsevier B.V C1 Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. ME DeBakey Vet Affairs Med Ctr, Neurol & Med Res Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. RP Atassi, MZ (reprint author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA. EM matassi@bcm.edu NR 46 TC 63 Z9 66 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD JUN PY 2006 VL 175 IS 1-2 BP 107 EP 117 DI 10.1016/j.jneuroim.2006.03.016 PG 11 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 056HA UT WOS:000238511600012 PM 16697051 ER PT J AU Weintraub, D Taraborelli, D Morales, KH Duda, JE Katz, IR Stern, MB AF Weintraub, Daniel Taraborelli, Donna Morales, Knashawn H. Duda, John E. Katz, Ira R. Stern, Matthew B. TI Escitalopram for major depression in Parkinson's disease: An open-label, flexible-dosage study SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID PLACEBO-CONTROLLED TRIAL; SYMPTOMATOLOGY IDS; PAROXETINE; CITALOPRAM; SERTRALINE; ANXIETY; NORTRIPTYLINE; COMORBIDITY; INVENTORY; DOPAMINE AB Depression and antidepressant use are common in Parkinson's disease, but the benefit of selective serotonin reuptake inhibitor (SSRI) treatment in this population has not been established. The authors treated 14 Parkinson's disease patients with major depression with escitalopram in an open-label study. Although treatment was well tolerated and correlated with a significant decrease in Inventory of Depressive Symptomatology score, response and remission rates were only 21% and 14%, respectively. However, half of the subjects met Clinical Global Impression-Improvement criteria for response. In Parkinson's disease, either SSRIs may have limited antidepressant effects, or the use of existing depression diagnostic and rating instruments may be problematic. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), 3535 Market St,Rm 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH NIH HHS [K23 MH067894] NR 44 TC 27 Z9 27 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2006 VL 18 IS 3 BP 377 EP 383 DI 10.1176/appi.neuropsych.18.3.377 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 081AC UT WOS:000240288600009 PM 16963587 ER PT J AU McMurtray, AM Clark, DG Flood, MK Perlman, S Mendez, MF AF McMurtray, Aaron M. Clark, David G. Flood, Mary K. Perlman, Susan Mendez, Mario F. TI Depressive and memory symptoms as presenting features of spinocerebellar ataxia SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID OLIVOPONTOCEREBELLAR ATROPHY; DEGENERATION AB The spinocerebellar ataxias (SCA) can be manifested in neuropsychiatric symptoms. Among 76 SCA patients presenting to a university ataxia center, depressive symptoms characterized SCA3. Memory symptoms occurred across all SCA groups with relative sparing of SCA6. These differences in neuropsychiatric symptoms suggest the subtype of SCA and the corresponding neuropathological involvement. C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP McMurtray, AM (reprint author), Vet Affairs Greater Los Angeles Healthcare, 166AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM aaronmnm@hawaii.edu FU NINDS NIH HHS [R01-NS33123] NR 9 TC 16 Z9 18 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2006 VL 18 IS 3 BP 420 EP 422 DI 10.1176/appi.neuropsych.18.3.420 PG 3 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 081AC UT WOS:000240288600017 PM 16963595 ER PT J AU Panizzon, K Allen, S Wallis, RA AF Panizzon, Kimberly Allen, Suni Wallis, Roi Ann TI Modulation of the mitochondrial ATP-sensitive potassium channel by diazoxide provides protection against neuronal injury induced by trauma to cortical slices SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 24th Annual National-Neurotrauma-Society Symposium CY JUL 07-09, 2006 CL St Louis, MO SP Natl Neurotrauma Soc C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN PY 2006 VL 23 IS 6 MA P151 BP 1025 EP 1025 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 056TW UT WOS:000238549000162 ER PT J AU Wallis, RA Panizzon, K AF Wallis, Roi Ann Panizzon, Kimberly TI Pravastatin provides protection against CA1 traumatic neuronal injury SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 24th Annual National-Neurotrauma-Society Symposium CY JUL 07-09, 2006 CL St Louis, MO SP Natl Neurotrauma Soc C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN PY 2006 VL 23 IS 6 MA P193 BP 1036 EP 1036 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 056TW UT WOS:000238549000203 ER PT J AU Goudreau, KA Hardy, J AF Goudreau, KA Hardy, J TI Succession planning and individual development SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article AB The authors present a framework for a succession planning and individual development initiative implemented in a Veterans Health Administration facility. Foundational strategic goals and a conceptual framework in the Veterans Affairs system provide the structure for the 3 facility-level succession planning and individual development programs. Outcomes of the programs are promising with 2 of 3 programs demonstrating clear succession planning outcomes and the other one showing positive preliminary results. C1 Portland VA Med Ctr, P3EDUC, Portland, OR 97239 USA. RP Goudreau, KA (reprint author), Portland VA Med Ctr, P3EDUC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kagoudreau@hotmail.com NR 10 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD JUN PY 2006 VL 36 IS 6 BP 313 EP 318 DI 10.1097/00005110-200606000-00007 PG 6 WC Nursing SC Nursing GA 054II UT WOS:000238369600006 PM 16766911 ER PT J AU Goy, ER Carlson, B Simopoulos, N Jackson, A Ganzini, L AF Goy, ER Carlson, B Simopoulos, N Jackson, A Ganzini, L TI Determinants of oregon hospice chaplains' views on physician-assisted suicide SO JOURNAL OF PALLIATIVE CARE LA English DT Article ID DIGNITY ACT; SOCIAL-WORKERS; ATTITUDES; EXPERIENCES; DEATH; CARE; PSYCHIATRISTS; NURSES AB Background: Although religiousness is a strong predictor of attitudes towards physician-assisted suicide (PAS), Oregon hospice chaplains express wide variation in their opposition to or support for legalized PAS. We explored factors associated with chaplains' views on PAS. Methods: A mailed survey to chaplains from 51 Oregon hospices. Results: Fifty of 77 eligible hospice chaplains (65%) returned surveys. Views on PAS were associated with views on suicide in general. Moral and theological beliefs were the most important influences on views on PAS. Chaplains who were opposed to PAS believed that God alone may take life, that life is an absolute good, and that suffering has a divine purpose. Those who supported PAS placed emphasis on the importance of self-determination and sanctity of life as defined by quality of life. Conclusions: Oregon hospice chaplains' diverse views towards PAS are closely related to their views on suicide in general, and their personal and theological beliefs. C1 Oregon Hlth Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Oregon Episcopal Sch, Portland, OR USA. Oregon Hospice Assoc, Portland, OR USA. RP Goy, ER (reprint author), Oregon Hlth Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. NR 14 TC 1 Z9 1 U1 0 U2 1 PU CENTER BIOETHICS CLIN RES INST MONTREAL PI MONTREAL PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA SN 0825-8597 J9 J PALLIATIVE CARE JI J. Palliative Care PD SUM PY 2006 VL 22 IS 2 BP 83 EP 90 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 058PC UT WOS:000238675900004 PM 17265660 ER PT J AU Lorenz, KA Shugarman, LR Lynn, J AF Lorenz, KA Shugarman, LR Lynn, J TI Health care policy issues in end-of-life care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID CONGESTIVE-HEART-FAILURE; OBSTRUCTIVE PULMONARY-DISEASE; TERMINAL CANCER-PATIENTS; HOME-BASED INTERVENTION; LAST 6 MONTHS; NATIONAL HOSPICE; MEDICARE EXPENDITURES; PAIN MANAGEMENT; DEPRESSIVE SYMPTOMS; REGIONAL-VARIATIONS C1 VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, Los Angeles, CA 90073 USA. Rand Hlth, Santa Monica, CA USA. Rand Hlth, Arlington, VA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Div Gen Internal Med, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM karl.lorenz@med.va.gov NR 141 TC 15 Z9 15 U1 4 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JUN PY 2006 VL 9 IS 3 BP 731 EP 748 DI 10.1089/jpm.2006.9.731 PG 18 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 052OK UT WOS:000238242800019 PM 16752979 ER PT J AU Senkal, CE Ponnusamy, S Rossi, MJ Sundararaj, K Szulc, Z Bielawski, J Bielawska, A Meyer, M Cobanoglu, B Koybasi, S Sinha, D Day, TA Obeid, LM Hannun, YA Ogretmen, B AF Senkal, CE Ponnusamy, S Rossi, MJ Sundararaj, K Szulc, Z Bielawski, J Bielawska, A Meyer, M Cobanoglu, B Koybasi, S Sinha, D Day, TA Obeid, LM Hannun, YA Ogretmen, B TI Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID TELOMERE LENGTH; BREAST-CANCER; PHASE-II; TUMOR; CHEMOTHERAPY; CISPLATIN; APOPTOSIS; MITOCHONDRIA; INHIBITION; DELIVERY AB In this study, a cationic water-soluble ceramide analog L-threo-C6-pyridinium-ceramide-bromide (L-t-C-6-Pyr-Cer), which exhibits high solubility and bioavailability, inhibited the growth of various human head and neck squamous cell carcinoma (HNSCC) cell lines at low IC50 concentrations, independent of their p53 status. Consistent with its design to target negatively charged intracellular compartments, L-t-C-6-Pyr-Cer accumulated mainly in mitochondria, and nuclei- enriched fractions upon treatment of human UM-SCC-22A cells [human squamous cell carcinoma (SCC) of the hypopharynx] at 1 to 6 h. In addition to its growth-inhibitory function as a single agent, the supra-additive interaction of L-t-C(6)Pyr-Cer with gemcitabine (GMZ), a chemotherapeutic agent used in HNSCC, was determined using isobologram studies. Then, the effects of this ceramide, alone or in combination with GMZ, on the growth of UM-SCC-22A xenografts in SCID mice was assessed following the determination of preclinical parameters, such as maximum tolerated dose, clearance from the blood, and bioaccumulation. Results demonstrated that treatment with L-t-C-6-Pyr-Cer in combination with GMZ significantly prevented the growth of HNSCC tumors in vivo. The therapeutic efficacy of L-t-C-6-Pyr-Cer/GMZ combination against HNSCC tumors was approximately 2.5-fold better than that of the combination of 5-fluorouracil/cisplatin. In addition, liquid chromatography/mass spectroscopy analysis showed that the levels of L-t-C-6-Pyr-Cer in HNSCC tumors were significantly higher than its levels in the liver and intestines; interestingly, the combination with GMZ increased the sustained accumulation of this ceramide by approximately 40%. Moreover, treatment with L-t-C-6-Pyr-Cer/GMZ combination resulted in a significant inhibition of telomerase activity and decrease in telomere length in vivo, which are among downstream targets of ceramide. C1 Med Univ S Carolina, Dept Biochem, Charleston, SC 29424 USA. Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29424 USA. Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29424 USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29424 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29424 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29424 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29424 USA. RP Ogretmen, B (reprint author), Med Univ S Carolina, Dept Biochem, 173 Ashley Ave, Charleston, SC 29424 USA. EM ogretmen@musc.edu OI obeid, lina/0000-0002-0734-0847 NR 40 TC 53 Z9 54 U1 1 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD JUN PY 2006 VL 317 IS 3 BP 1188 EP 1199 DI 10.1124/jpet.106.101949 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 044AE UT WOS:000237643600032 PM 16510697 ER PT J AU Thompson, R Kane, V Cook, JM Greenstein, R Walker, P Woody, G AF Thompson, Richard Kane, Vincent Cook, Joan M. Greenstein, Robert Walker, Patricia Woody, George TI Suicidal ideation in veterans receiving treatment for opiate dependence SO JOURNAL OF PSYCHOACTIVE DRUGS LA English DT Article DE opiate; screening; suicide; veterans ID MEDICAL-CENTER; PRIMARY-CARE; LATE-LIFE; PATTERNS; RISK AB Persons with opiate use disorders, especially veterans, have a number of both chronic and acute indicators of risk for suicide, but are not typically screened for suicidal ideation on a routine basis, beyond initial evaluations. One hundred one veterans receiving treatment for opiate dependence at an urban VA medical center were screened for suicidal ideation. Over 24% reported some suicidal ideation. Current ideation was associated with severe chronic pain, ongoing problems with street drugs, firearm ownership, and with having recently enrolled in treatment. It was also associated with a variety of recent negative life events and mental health issues, especially depression, recurring troubling thoughts, hallucinations, loss of jobs, and conflicts with family members. Two veterans endorsing suicidal ideation required immediate hospitalization. The implications of these findings are discussed, and frequent screening for suicidal ideation among patients receiving treatment for opiate dependence is recommended. C1 Univ Illinois, Dept Psychiat, Juvenile Protect Assoc, Chicago, IL 60622 USA. Philadelphia VA Med Ctr, VISN 4 MIRECC, Philadelphia, PA USA. Philadelphia VA Med Ctr, Dept Behav Hlth, Philadelphia, PA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Thompson, R (reprint author), Univ Illinois, Dept Psychiat, Juvenile Protect Assoc, 1333 N Kingbury,Suite 306, Chicago, IL 60622 USA. RI Thompson, Richard/G-5408-2011 OI Thompson, Richard/0000-0003-0127-513X NR 28 TC 5 Z9 5 U1 3 U2 3 PU HAIGHT-ASHBURY PUBL PI SAN FRANCISCO PA 409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA SN 0279-1072 J9 J PSYCHOACTIVE DRUGS JI J. Psychoact. Drugs PD JUN PY 2006 VL 38 IS 2 BP 149 EP 156 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 065XX UT WOS:000239194600005 PM 16903454 ER PT J AU Hammerman, S Lam, C Caroff, SN AF Hammerman, S Lam, C Caroff, SN TI Neuroleptic malignant syndrome and aripiprazole SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Letter C1 Childrens Hosp, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Sch Med, Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Hammerman, S (reprint author), Childrens Hosp, Dept Psychiat, Philadelphia, PA 19104 USA. NR 6 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JUN PY 2006 VL 45 IS 6 BP 639 EP 641 DI 10.1097/01.chi.0000209786.29479.74 PG 3 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 046CE UT WOS:000237788200004 PM 16721313 ER PT J AU Friedlander, AH Mahler, ME Yagiela, JA AF Friedlander, AH Mahler, ME Yagiela, JA TI Restless legs syndrome - Manifestations, treatment and dental im'plications SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE neurological movement disorders; dentistry; restless legs syndrome ID LIMB MOVEMENT-DISORDER; HEART-DISEASE; BACTERIAL-ENDOCARDITIS; DOPAMINE AGONISTS; SYNDROME RLS; EPIDEMIOLOGY; POPULATION; MANAGEMENT; DIAGNOSIS; SYMPTOMS AB Background. The authors reviewed the clinical features, epidemiology, pathogenesis and risk factors, medical management, dental findings and dental management of patients with restless legs syndrome (RLS). Types of Studies Reviewed. The authors conducted a MEDLINE search for the years 2000 through 2004 using the key terms "restless legs syndrome," "epidemiology," "pathophysiology," "treatment" and "dentistry." They selected articles published in English in peer-reviewed journals for further review, and they gave preference to articles reporting randomized controlled trials. Conclusions. RLS is a neurological disorder that is characterized by unpleasant sensations in the legs that occur at rest, especially at bedtime. These symptoms cause an irresistible urge to get out of bed and move the legs to relieve the discomfort, thereby delaying sleep onset and resulting in fatigue and dysphoria the next day. Clinical Implications. The prevalence of dental disease may be extensive in patients with RLS because of diminished salivary flow resulting from the medications used to treat RLS. Patient education, saliva substitutes and anticaries agents are indicated. Special precautions must be taken when prescribing or administering sedative-hypnotic agents that are likely to have adverse reactions with the medications used to treat RLS. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM friedlander@med.va.gov NR 43 TC 1 Z9 1 U1 0 U2 4 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JUN PY 2006 VL 137 IS 6 BP 755 EP 761 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 053TZ UT WOS:000238329600016 PM 16803804 ER PT J AU Simmons, SF Schnelle, JF AF Simmons, SF Schnelle, JF TI Feeding assistance needs of long-stay nursing home residents and staff time to provide care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE staffing requirements; nursing homes; feeding assistance ID REFLECT DIFFERENCES; MEAL INTAKE; QUALITY; INCONTINENCE AB OBJECTIVES: To describe the staff time requirements to provide feeding assistance to nursing home residents who require three different types of assistance to improve oral food and fluid intake (social stimulation, verbal cuing, or both; physical guidance; or full physical assistance) and to determine whether physically dependent residents require more staff time, as defined in the national Resource Utilization Group System (RUGS) used for reimbursement. DESIGN: Descriptive. SETTING: Six skilled nursing homes. MEASUREMENTS: Ninety-one long-stay residents with low oral intake who responded to improved feeding assistance. PARTICIPANTS: Research staff conducted direct observations of usual nursing home care for 2 consecutive days (total of six meals) to measure oral food and fluid consumption (total percentage eaten) and staff time spent providing assistance (minutes and seconds). Research staff then implemented a standardized graduated-assistance protocol on 2 separate days (total of six meals) that enhanced residents' oral food and fluid intake. RESULTS: Staff time to provide feeding assistance that improved food and fluid consumption was comparable across different levels of eating dependency. Across all levels, residents required an average of 35 to 40 minutes of staff time per meal; thus, residents who needed only supervision and verbal cuing required just as much time as those who were physically dependent on staff for eating. CONCLUSION: The current RUGS system used for reimbursement likely underestimates the staff time required to provide feeding assistance care that improves oral intake. C1 Univ Calif Los Angeles, Borun Ctr Gerontol Res, Sch Med, Dept Geriatr,Jewish Home Aging, Reseda, CA 91335 USA. Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Borun Ctr Gerontol Res, Sch Med, Dept Geriatr,Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. EM ssimmons@ucla.edu FU NIA NIH HHS [AG 01026-01A1, AG 10415] NR 25 TC 48 Z9 52 U1 2 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2006 VL 54 IS 6 BP 919 EP 924 DI 10.1111/j.1532-5415.2006.00812.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 049EX UT WOS:000237999800006 PM 16776786 ER PT J AU Carnes, M Schuler, L Sarto, GE Lent, SJ Bakken, L AF Carnes, M Schuler, L Sarto, GE Lent, SJ Bakken, L TI Increasing sex and ethnic/racial diversity of researchers in aging: Some promising strategies at the postdoctoral level SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID ACADEMIC MEDICINE; GENDER; WOMEN; CAREER; FACULTY; GLASS; PRODUCTIVITY; PROMOTION; PROGRAM; TENURE AB To increase recruitment of a diverse pool of women into research careers in aging, a postdoctoral training program was designed based on the premise that women would be attracted to a research training program that focused on older women's health; offered an individualized, competency-based career development plan; could commit multiple years of financial support; and provided career mentorship by senior women faculty and that ethnic/racial minority women would be attracted to a research training program that, in addition to these other aspects, focused on the study of health differences and disparities between populations of older women. All 15 trainees have been women, and since focusing on health disparities, recruitment of underrepresented minority trainees increased from 10% to 80%. Of the nine former trainees, five continue research-based academic careers in aging with demonstrable success in achieving academic benchmarks. Focusing on areas of research with personal relevance to applicants and individualizing the program can be used to recruit diverse postdoctoral fellows in aging research. Short-term career outcomes indicate that career persistence of trainees compares favorably with that in other National Institutes of Health (NIH) postdoctoral training programs. C1 Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. Univ Wisconsin, Dept Med, Madison, WI USA. Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA. Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53706 USA. Univ Wisconsin, Women Sci & Engn Leadership Inst, Madison, WI USA. Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA. Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA. Univ Wisconsin, Ctr Study Cultural Divers Healthcare, Madison, WI USA. Univ Wisconsin, Sch Educ, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU NHLBI NIH HHS [K30 HL 04100-03]; NIA NIH HHS [K07 AG000744, K12 AG 19247, K07 AG 00744, T32 AG000265, T32 AG 00265, K12 AG019247] NR 41 TC 3 Z9 3 U1 2 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2006 VL 54 IS 6 BP 980 EP 985 DI 10.1111/j.1532-5415.2006.00739.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 049EX UT WOS:000237999800016 PM 16776796 ER PT J AU Garzotto, M AF Garzotto, M TI Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer - Editorial comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Urol & Renal Transplantat, Portland, OR 97201 USA. RP Garzotto, M (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Urol & Renal Transplantat, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JUN PY 2006 VL 175 IS 6 BP 2077 EP 2077 DI 10.1016/S0022-5347(06)00659-8 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 043FJ UT WOS:000237585100028 ER PT J AU Raghunathan, A Rapp, JH Littooy, F Santilli, S Krupski, WC Ward, HB Thottapurathu, L Moritz, T McFalls, EO Investigators, C AF Raghunathan, A Rapp, JH Littooy, F Santilli, S Krupski, WC Ward, HB Thottapurathu, L Moritz, T McFalls, EO Investigators, C TI Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: A subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the Society-for-Vascular-Surgery CY JUN 16-19, 2005 CL Chicago, IL SP Soc Vasc Surg ID PERIOPERATIVE MYOCARDIAL-INFARCTION; VASCULAR-SURGERY; INFRAINGUINAL OPERATIONS; CARDIAC MORBIDITY; DISEASE; MANAGEMENT; MORTALITY; PERIOD AB Objective: To determine the perioperative mortality, myocardial infarction rate, and long-term survival of patients with critical limb ischemia (CLI) compared with those with intermittent claudication (IC) within a cohort selected for significant coronary artery disease, a secondary analysis was conducted of a prospective, randomized, multicenter trial of Coronary Artery Revascularization Prophylaxis (CARP) before peripheral vascular surgery. This multicenter trial was sponsored by the Cooperative Studies Program of the Department of Veterans Affairs. Methods. Of the 510 patients enrolled in the CARP trial and randomized to coronary revascularization or no revascularization before elective vascular surgery, 143 had CLI and 164 had IC as an indication for lower limb revascularization; > 95% of each group were men. The presence of coronary artery disease was determined by cardiac catheterization. Eligible patients had at least one treatable coronary lesion of >= 70%. Those with significant left main disease, ejection fraction of < 20%, and aortic stenosis were excluded. Patients were randomized to coronary artery disease revascularization or no revascularization before vascular surgery and followed for mortality and morbidity perioperatively and for a median of 2.7 years postoperatively. Medical treatment of coronary artery disease was pursued aggressively. Results. Patients with IC had a longer time from randomization to vascular surgery (p =.001) and more abdominal operations (p <.001). Patients with CLI had more urgent operations (p =.006), reoperations (p <.001), and limb loss (p =.008) as well as longer hospital stays (p <.001). The IC group had more perioperative myocardial infarctions (CLI, 8.4%; IC, 17.1%; p =.024), although perioperative mortality was similar (CLI, 3.5%; IC, 1.8%; p =.360). In follow-up, the IC group also had numerically more myocardial infarctions (CLI, 16.8%; IC, 25%; p =.079), but mortality was not different (CLI, 21%; IC, 22%; p =.825). Coronary artery revascularization did not lower perioperative or long-term mortality in either group. Conclusions. Our data indicate that patients with significant coronary artery disease and either CLI or IC can undergo vascular surgery with low mortality and morbidity, and these results are not improved by coronary artery revascularization before vascular surgery. Furthermore, when selected for the presence of symptomatically stable, severe coronary artery disease, there is no difference in long-term survival between patients with CLI and IC. Finally, the better-than-predicted outcomes for these patients with advanced systemic atherosclerosis may be due to aggressive medical management with beta-blockers, statins, and acetylsalicylic acid. C1 San Francisco VA Med Ctr, Vasc Serv Serv, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Edward Hines Jr VA Med Ctr, Chicago, IL USA. Univ Minnesota, Minneapolis, MN USA. Denver VA Med Ctr, Denver, CO USA. RP Rapp, JH (reprint author), San Francisco DVA Med Ctr, Surg Serv 112G, 4150 Clement St, San Francisco, CA 94121 USA. EM rappj@surgery.ucsf.edu NR 21 TC 26 Z9 30 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2006 VL 43 IS 6 BP 1175 EP 1181 DI 10.1016/j.jvs.2005.12.069 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 049VW UT WOS:000238046700019 PM 16765234 ER PT J AU Sharma, PP Friesen, T Waites, KB AF Sharma, PP Friesen, T Waites, KB TI Influenza testing in the diagnostic laboratory SO LABMEDICINE LA English DT Article ID A H5N1; PATIENT AB Laboratory professionals need to understand the prevalence of influenza in the community, clinical manifestations and test characteristics for the proper use of rapid diagnostic tests. Rapid diagnosis of influenza is essential for reducing ancillary tests, decreasing inappropriate antibiotic use and guiding appropriate antiviral therapy. Differences in rapid influenza tests stem mainly from which type of virus is identified and whether it can differentiate between influenza A and B viral antigens. After reading this article, the reader should be able to understand the significance of viral influenza from an epidemiologic perspective, appreciate when tests to determine a microbiological diagnosis of influenza are indicated and select optimum methods for laboratory detection for use in physician offices and hospitals. Microbiology exam 70601 questions and corresponding answer form are located after the CE Update secon on p 375. C1 Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Sharma, PP (reprint author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0007-5027 J9 LABMEDICINE JI Labmedicine PD JUN PY 2006 VL 37 IS 6 BP 366 EP 370 DI 10.1309/TFED6CLTYW4A6VO6 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 047FU UT WOS:000237866000016 ER PT J AU Carver, JD Calverley, D Shen, P AF Carver, John D. Calverley, David Shen, Peter TI Chronic lymphocytic leukemia/small lymphocytic lymphoma presenting in urinary bladder without peripheral blood lymphocytosis: Case report and literature review SO LEUKEMIA & LYMPHOMA LA English DT Letter ID OF-THE-LITERATURE; PRIMARY MALIGNANT-LYMPHOMA; CELL LYMPHOMA; MALT-TYPE C1 Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA. UCHSC, Dept Med, Div Hematol, Denver, CO USA. UCHSC, Dept Med, Div Med Oncol, Denver, CO USA. Eastern Colorado Denver Vet Adm Med Ctr, Dept Pathol & Lab Med, Denver, CO USA. RP Calverley, D (reprint author), Denver VAMC, Sect Hematol Med Oncol, Box 111F,1055 Clermont St, Denver, CO 80220 USA. EM david.calverley@uchsc.edu NR 15 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JUN PY 2006 VL 47 IS 6 BP 1163 EP 1165 DI 10.1080/10428190500465283 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA 063RJ UT WOS:000239037000033 PM 16840214 ER PT J AU Paige, NM Nouvong, A AF Paige, NM Nouvong, A TI The top 10 things foot and ankle specialists wish every primary care physician knew SO MAYO CLINIC PROCEEDINGS LA English DT Review ID PLANTAR FASCIITIS; ONYCHOMYCOSIS; MANAGEMENT AB Foot and ankle problems are common complaints of patients presenting to primary care physicians. These problems range from minor disorders, such as ankle sprains, plantar fasciitis, bunions, and Ingrown toenails, to more serious conditions such as Charcot arthropathy and Achilles tendon rupture. Early recognition and treatment of foot and ankle problems are imperative to avoid associated morbidities. Primary care physicians can address many of these complaints successfully but should be cognizant of which patients should be referred to a foot and ankle specialist to prevent common short-term and long-term complications. This article provides evidence-based pearls to assist primary care physicians in providing optimal care for their patients with foot and ankle complaints. C1 VA Greater Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90073 USA. RP Paige, NM (reprint author), VA Greater Los Angeles, David Geffen Sch Med, Dept Med, 11301 Wilshire Blvd 111A, Los Angeles, CA 90073 USA. EM neil.paige@med.va.gov NR 27 TC 5 Z9 5 U1 0 U2 2 PU MAYO CLINIC PROCEEDINGS PI ROCHESTER PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JUN PY 2006 VL 81 IS 6 BP 818 EP 822 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 048SM UT WOS:000237966800014 PM 16770982 ER PT J AU Seshamani, M Zhu, JS Volpp, KG AF Seshamani, M Zhu, JS Volpp, KG TI Did postoperative mortality increase after the implementation of the medicare balanced budget act? SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Meeting of the Academy-of-Health-Services-Research-and-Health-Policy CY JUN 06-08, 2004 CL San Diego, CA SP Acad Hlth Serv Res & Hlth Policy DE health care delivery; health care reform; hospital quality; hospital reimbursement ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; HOSPITAL CHARACTERISTICS; PATIENT CHARACTERISTICS; ADMINISTRATIVE DATA; SURGICAL-PROCEDURES; OUTCOMES; COST; RATES AB Background: The Balanced Budget Act (BBA) of 1997 was a cost-saving measure designed to reduce Medicare reimbursements by $116.4 billion from 1998 to 2002. Resulting financial strain could adversely affect the quality of patient care in hospitals. Objective: We sought to determine whether 30-day mortality rates for surgical patients who developed complications changed at different rates in hospitals under different levels of financial strain from the BBA. Methods: Pennsylvania hospital discharge data, financial data, and death certificate data from 1997 to 2001 were obtained. A retrospective multivariate analysis examined whether 30-day mortality rates from 8 postoperative complications varied based on degree of hospital financial strain. Results: The average magnitude of Medicare payment reduction on overall hospital net revenues was estimated at 1.8% for hospitals with low BBA impact and 3.5% for hospitals with high impact in 1998, worsening to 2.0% and 4.8%, respectively, by 2001. Mortality rates changed at similar rates for high- and low-impact hospitals from 1997 to 1999, but from 1997 to 2000 mortality rates increased more among patients in high-impact compared with low-impact hospitals (P < 0.05). From 2000 to 2001, mortality rates among impact groups converged. There were no statistically significant differences based on BBA impact in changes in nursing-staff or length of stay. Conclusions: The mortality of surgical patients who developed postoperative complications increased to a greater degree in the short term in hospitals affected more by BBA. Measuring the quality impact of reimbursement cuts is necessary to understand cost-quality tradeoffs that may accompany cost-saving reforms. C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Johns Hopkins Sch Med, Baltimore, MD USA. Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA. RP Volpp, KG (reprint author), 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu NR 41 TC 19 Z9 19 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JUN PY 2006 VL 44 IS 6 BP 527 EP 533 DI 10.1097/01.mlr.0000215886.49343.c6 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 050FN UT WOS:000238073000006 PM 16708001 ER PT J AU Siegel, JM AF Siegel, JM TI The stuff dreams are made of: anatomical substrates of REM sleep SO NATURE NEUROSCIENCE LA English DT Editorial Material ID PARADOXICAL SLEEP; NEURONS; MEDULLA; NARCOLEPSY C1 Univ Calif Los Angeles, Sch Med, Ctr Sleep Res,Dept Psychiat, Vet Affairs Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA 91343 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Sch Med, Ctr Sleep Res,Dept Psychiat, Vet Affairs Greater Los Angeles Healthcare Syst, 16111 Plummer St,151A3, North Hills, CA 91343 USA. EM jsiegel@ucla.edu NR 15 TC 30 Z9 33 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD JUN PY 2006 VL 9 IS 6 BP 721 EP 722 DI 10.1038/nn0606-721 PG 2 WC Neurosciences SC Neurosciences & Neurology GA 047RA UT WOS:000237895200006 PM 16732200 ER PT J AU Dang, AC Warren, AP Kim, HT AF Dang, AC Warren, AP Kim, HT TI Beneficial effects of intra-articular caspase inhibition therapy following osteochondral injury SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE cartilage; apoptosis; cell death; programmed cell death; arthritis; caspase inhibition ID APOPTOTIC CHONDROCYTE DEATH; ARTICULAR-CARTILAGE; IN-VIVO; OSTEOARTHRITIC CARTILAGE; CELL-DEATH; REPAIR; DEGRADATION; FRACTURE; DEFECTS; HUMANS AB Objective: Recent studies have demonstrated that articular cartilage injury leads to chondrocyte death through a mechanism termed "apoptosis", or programmed cell death (PCD). Inhibitors of caspases, key enzymatic mediators of apoptosis, have been shown to block chondrocyte PCD. We hypothesized that short-term intra-articular administration of a potent caspase inhibitor would decrease chondrocyte PCD and subsequent cartilage degeneration following experimental osteochondral injury in rabbits. Methods: Adult New Zealand white rabbits were subjected to osteochondral injuries of their femoral condyles. Knees in the treatment group received daily intra-articular injections of the broad-spectrum caspase inhibitor Z-VAD-fmk for 7 days, while the control group received injections of Vehicle alone. Seven days postinjury, one group of rabbits was sacrificed to assess levels of chondrocyte PCD. A second group was sacrificed 42 days postinjury for histological evaluation to measure cartilage degeneration and cartilage repair. Results: Seven days postinjury, there was a 45% reduction in chondrocyte PCD in the caspase inhibitor treated knees as compared to controls (P = 0.01). Forty-two days postinjury, treated knees were found to have 17.9% greater chondrocyte survival (P < 0.01) and 7.6% greater articular cartilage thickness (P = 0.01). Conclusions: Intra-articular administration of the caspase inhibitor Z-VAD-fmk effectively blocks chondrocyte PCD following experimental osteochondral injury in this model. Inhibition of chondrocyte PCD rescues chondrocytes that would otherwise die, limiting subsequent cartilage loss. To our knowledge, this study is the first to demonstrate that short-term inhibition of chondrocyte PCD leads to long-term preservation of cartilage in vivo. (c) 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 San Francisco VA Med Ctr, Dept Orthopaed Surg, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. RP Kim, HT (reprint author), San Francisco VA Med Ctr, Dept Orthopaed Surg, 4150 Clement St 112, San Francisco, CA 94121 USA. EM kimh@orthosurg.ucsf.edu NR 26 TC 20 Z9 21 U1 1 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD JUN PY 2006 VL 14 IS 6 BP 526 EP 532 DI 10.1016/j.joca.2005.12.010 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 055QL UT WOS:000238465300003 PM 16483806 ER PT J AU Martinez, V Wang, L Tache, Y AF Martinez, V Wang, L Tache, Y TI Peripheral adrenomedullin inhibits gastric emptying through CGRP(8-37)-sensitive receptors and prostaglandins pathways in rats SO PEPTIDES LA English DT Article DE adrenomedullin; beta-adrenergic receptors; gastric emptying; CGRP; CGRP(8-37); prostaglandins ID GENE-RELATED PEPTIDE; PROADRENOMEDULLIN N-TERMINAL-20 PEPTIDE; NERVOUS-SYSTEM ACTION; GASTROINTESTINAL TRANSIT; ANESTHETIZED RATS; VASCULAR ACTIONS; CALCITONIN; CGRP; CAPSAICIN; AMYLIN AB The effects of intravenous (iv) adrenomedullin (AM) on gastric emptying were investigated in conscious rats. AM induced a maximal 50% inhibition of gastric emptying at a dose of 1.2 nmol/kg. AM was about two-fold less potent than a-calcitonin gene-related peptide (alpha-CGRP), which induced a similar 50% maximal inhibition of gastric emptying at 0.6 nmol/kg. Delayed gastric emptying induced by i.v. AM and alpha-CGRP was prevented by peripheral injection of the selective CGRP(1) antagonist, CGRP(8-37), and by pretreatment with indomethacin, while not altered by blockade of the sympathetic nervous system with propranolol. These data indicate that peripheral AM inhibits gastric emptying through the interaction with CGRP(8-37)-sensitive receptors, likely CGRP(1) receptors, and the recruitment of prostazglandin-dependent mechanisms. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, CURE, DDRC, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Neurovisceral Sci & Womens Hlt, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90007 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE, DDRC, 11301 Wilshire Blvd,Bldg 115,Room 117, Los Angeles, CA 90073 USA. EM vicente.martinez@astrazeneca.com; ytache@mednet.ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [R01 DK-33061, P30 DK-41301] NR 44 TC 4 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JUN PY 2006 VL 27 IS 6 BP 1376 EP 1382 DI 10.1016/j.peptides.2005.11.003 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 055MU UT WOS:000238455600027 PM 16337713 ER PT J AU Pekary, AE Sattin, A Stevens, SA AF Pekary, AE Sattin, A Stevens, SA TI Rapid modulation of TRH-like peptides in rat brain by thyroid hormones SO PEPTIDES LA English DT Article DE TRH; TRH-like peptides; thyroid hormones; depression; limbic system ID SYNAPTOSOMAL NOREPINEPHRINE UPTAKE; IMMATURE SECRETORY GRANULE; MESSENGER-RIBONUCLEIC-ACID; NONGENOMIC ACTIONS; STEROID-HORMONES; POTENT INHIBITOR; THYROXINE; DEIODINASE; THYROTROPIN; DESMETHYLIMIPRAMINE AB Recent identification of membrane receptors for T-4, T-3, 3,5-T-2, and 3-iodothyronamine that mediate rapid physiologic effects of thyroid hormones suggested that such receptors may supplement the regulation of TRH and TRH-like peptides by nuclear T3 receptors. For this reason 200 g male Sprague-Dawley rats received daily i.p. injections of PTU or T4. Levels of TRH and TRH-like peptides were measured 0, 2 h or 1, 2, 3, or 4 days later. Rapid increases or decreases in TRH and TRH-like peptide levels were observed in response to PTU and T4 treatments in various brain regions involved in mood regulation. Significant effects were measured within 2 h of T4 injection. Nuclear T3 receptor-mediated changes in gene expression altering translation, post-translational processing and constitutive release of peptides require more than 2 h. We conclude that non-genomic mechanisms may contribute to the psychiatric effects of thyroid disease and thyroid hormone adjuvant treatment for major depression. Published by Elsevier Inc. C1 Univ Calif Los Angeles, Res Serv, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), Univ Calif Los Angeles, Res Serv, VA Greater Los Angeles Healthcare Syst, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@med.va.gov NR 53 TC 10 Z9 10 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JUN PY 2006 VL 27 IS 6 BP 1577 EP 1588 DI 10.1016/j.peptides.2005.10.015 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 055MU UT WOS:000238455600054 PM 16310891 ER PT J AU Lipsky, BA Berendt, AR Deery, HG Embil, JM Joseph, WS Karchmer, AW LeFrock, JL Lew, DP Mader, JT Norden, C Tan, JS AF Lipsky, Benjamin A. Berendt, Anthony R. Deery, H. Gunner Embil, John M. Joseph, Warren S. Karchmer, Adolf W. LeFrock, Jack L. Lew, Daniel P. Mader, Jon T. Norden, Carl Tan, James S. TI Diagnosis and treatment of diabetic foot infections SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Review ID COLONY-STIMULATING FACTOR; SOFT-TISSUE INFECTIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; PERIPHERAL VASCULAR-DISEASE; ARTERIAL OCCLUSIVE DISEASE; LOWER-EXTREMITY INFECTIONS; CUTANEOUS OXYGEN-TENSION; OPEN-LABEL TRIAL; TERM-FOLLOW-UP; HYPERBARIC-OXYGEN AB Executive Summary: 1. Foot infections in patients with diabetes cause substantial morbidity and frequent visits to health care professionals and may lead to amputation of a lower extremity. 2. Diabetic foot infections require attention to local (foot) and systemic (metabolic) issues and coordinated management, preferably by a multidisciplinary foot-care team (A-II) (Table 1). The team managing these infections should include, or have ready access to, an infectious diseases specialist or a medical microbiologist (B-II). 3. The major predisposing factor to these infections is foot ulceration, which is usually related to peripheral neuropathy. Peripheral vascular disease and various immunological disturbances play a secondary role. 4. Aerobic Gram-positive cocci (especially Staphylococcus aureus) are the predominant pathogens in diabetic foot infections. Patients who have chronic wounds or who have recently received antibiotic therapy may also be infected with Gram-negative rods, and those with foot ischemia or gangrene may have obligate anaerobic pathogens. 5. Wound infections must be diagnosed clinically on the basis of local (and occasionally systemic) signs and symptoms of inflammation. Laboratory (including microbiological) investigations arc of limited use for diagnosing infection, except in cases of osteomyelitis (B-II). 6. Send appropriately obtained specimens for culture before starting empirical antibiotic therapy in all cases of infection, except perhaps those that are mild and previously untreated (B-III). Tissue specimens obtained by biopsy, ulcer curettage, or aspiration are preferable to wound swab specimens (A-I). 7. Imaging studies may help diagnose or better define deep, soft-tissue purulent collections and are usually needed to detect pathological findings in bone. Plain radiography may be adequate in many cases, but MRI (in preference to isotope scanning) is more sensitive and specific, especially for detection of soft-tissue lesions (A-I). 8. Infections should be categorized by their severity on the basis of readily assessable clinical and laboratory features (B-II). Most important among these are the specific tissues involved, the adequacy of arterial per-fusion, and the presence of systemic toxicity or metabolic instability. Categorization helps determine the degree of risk to the patient and the limb and, thus, the urgency and venue of management. 9. Available evidence does not support treating clinically uninfected ulcers with antibiotic therapy (D-III). Antibiotic therapy is necessary for virtually all infected wounds, but it is often insufficient without appropriate wound care. 10. Select an empirical antibiotic regimen on the basis of the severity of the infection and the likely etiologic agent(s) (B-II). Therapy aimed solely at aerobic Gram-positive cocci may be sufficient for mild-to-moderate infections in patients who have not recently received antibiotic therapy (A-II). Broad-spectrum empirical therapy is not routinely required but is indicated for severe infections, pending culture results and antibiotic susceptibility data (B-III). Take into consideration any recent antibiotic therapy and local antibiotic susceptibility data, especially the prevalence of methicillin-resistant S. aureus (MRSA) or other resistant organisms. Definitive therapy should be based on both the culture results and susceptibility data and the clinical response to the empirical regimen (C-III). 11. There is only limited evidence with which to make informed choices among the various topical, oral, and parenteral antibiotic agents. Vitually all severe and some moderate infections require parenteral therapy, at least initially (C-III). Highly bioavailable oral antibiotics can be used in most mild and in many moderate infections, including some cases of osteomyelitis (A-II). Topical therapy may be used for some mild superficial infections (B-I). 12. Continue antibiotic therapy until there is evidence that the infection has resolved but not necessarily until a wound has healed. Suggestions for the duration of antibiotic therapy are as follows: for mild infections, 12 weeks usually suffices, but some require an additional 12 weeks; for moderate and severe infections, usually 24 weeks is sufficient, depending on the structures involved, the adequacy of debridement, the type of soft-tissue wound cover, and wound vascularity (A-II); and for osteomyelitis, generally at least 46 weeks is required, but a shorter duration is sufficient if the entire infected bone is removed, and probably a longer duration is needed if infected bone remains (B-II). 13. If an infection in a clinically stable patient fails to respond to I antibiotic courses, consider discontinuing all antimicrobials and, after a few days, obtaining optimal culture specimens (C-III). 14. Seek surgical consultation and, when needed, intervention for infections accompanied by a deep abscess, extensive bone or joint involvement, crepitus, substantial necrosis or gangrene, or necrotizing fasciitis (A-II). Evaluating the limb's arterial supply and revascularizing when indicated are particularly important. Surgeons with experience and interest in the field should be recruited by the foot-care team, if possible. 15. Providing optimal wound care, in addition to appropriate antibiotic treatment of the infection, is crucial for healing (A-I). This includes proper wound cleansing, debridement of any callus and necrotic tissue, and, especially, off-loading of pressure. There is insufficient evidence to recommend use of a specific wound dressing or any type of wound healing agents or products for infected foot wounds. 16. Patients with infected wounds require early and careful follow-up observation to ensure that the selected medical and surgical treatment regimens have been appropriate and effective (B-III). 17. Studies have not adequately defined the role of most adjunctive therapies for diabetic foot infections, but systematic reviews suggest that granulocyte colony stimulating factors and systemic hyperbaric oxygen therapy may help prevent amputations (B-I). These treatments may be useful for severe infections or for those that have not adequately responded to therapy, despite correcting for all amenable local and systemic adverse factors. 18. Spread of infection to bone (osteitis or osteomyelitis) may be difficult to distinguish from noninfectious osteoarthropathy. Clinical examination and imaging tests may suffice, but bone biopsy is valuable for establishing the diagnosis of osteomyelitis, for defining the pathogenic organism(s), and for determining the antibiotic susceptibilities of such organisms (B-II). 19. Although this field has matured, further research is much needed. The committee especially recommends that adequately powered prospective studies be undertaken to elucidate and validate systems for classifying infection, diagnosing osteomyelitis, defining optimal antibiotic regimens in various situations, and clarifying the role of surgery in treating osteomyelitis (A-III). C1 Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. Nuffield Orthopaed Ctr, Bone Infect Unit, Oxford, England. Univ Manitoba, Dept Med, Infect Dis Sect, Winnipeg, MB R3T 2N2, Canada. Harvard Univ, Sch Med, Dept Med, Div Infect Dis, Cambridge, MA 02138 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Hosp Geneva, Dept Med, Infect Dis Serv, Geneva, Switzerland. Univ Texas, Med Branch, Inst Marine Biomed, Dept Internal Med, Galveston, TX USA. Univ Texas, Med Branch, Dept Orthopaed & Rehabil, Galveston, TX USA. New Jersey Med Sch & Dent, Dept Med, Newark, NJ USA. Univ Med & Dent New Jersey, Cooper Hosp, Camden, NJ 08103 USA. Northeastern Ohio Univ Coll Med & Pharm, Summa Hlth Syst, Dept Internal Med, Rootstown, OH USA. RP Lipsky, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Med Serv, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 296 TC 75 Z9 83 U1 2 U2 28 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JUN PY 2006 VL 117 IS 7 SU S BP 212S EP 238S DI 10.1097/01.prs.0000222737.09322.77 PG 27 WC Surgery SC Surgery GA 056UA UT WOS:000238549400022 PM 16799390 ER PT J AU Russell, JA Conforti, ML Connor, NP Hartig, GK AF Russell, JA Conforti, ML Connor, NP Hartig, GK TI Cutaneous tissue flap viability following partial venous obstruction SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID LEECH HIRUDO-MEDICINALIS; SKIN FLAPS; MECHANICAL DEVICE; ISLAND FLAPS; ISCHEMIA; CONGESTION; ARTERIAL; FLOW; OXYGENATION; OCCLUSION AB Background: Venous outflow obstruction is the most common cause of tissue failure after microvascular reconstructive surgery. If it is not recognized early, there is an increased risk of tissue damage and loss. Currently, however, there are no adequate models for the study of this clinical problem. The purpose of this study was to develop a partial congestion model for the study of skin flap physiology in response to varying levels of occluded venous outflow. Methods: Nine mixed-breed pigs were equally divided into three experimental groups (0 percent, 20 percent, and 50 percent venous outflow) to determine the effects of varying venous outflow on cutaneous flap color, oxygen tension, and edema. A cutaneous pedicle flap model and a partial congestion system were used to observe changes in variable venous obstruction. Results: Only 0 percent venous outflow resulted in progressive color change across time. In addition, 0 percent venous outflow demonstrated significantly different oxygen tension levels relative to the other groups. Twenty percent venous outflow resulted in significant edema formation relative to the other groups. The 50 percent group showed an increase in oxygen tension from, the second hour of venous obstruction to the end of the experiment. Conclusions: Tissue flap color is the clinical standard on which flap health is measured. After 8 hours, only complete venous occlusion resulted in significant color change. However, physiological changes that could affect tissue flap health were noted with only partial venous occlusion, including the development of edema formation. Accordingly, subtle color change could indicate partial venous congestion and may warrant intervention by the surgeon. C1 Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Dept Commun Disorders, Madison, WI 53792 USA. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. EM connor@surgery.wisc.edu NR 22 TC 16 Z9 16 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JUN PY 2006 VL 117 IS 7 BP 2259 EP 2266 DI 10.1097/01.prs.0000225472.57337.2e PG 8 WC Surgery SC Surgery GA 055DZ UT WOS:000238431500023 PM 16772926 ER PT J AU Robertson, RH Burkhardt, JH Powell, MP Eloubeidi, MA Pisu, M Weissman, NW AF Robertson, RH Burkhardt, JH Powell, MP Eloubeidi, MA Pisu, M Weissman, NW TI Trends in colon cancer screening procedures in the US Medicare and Tricare populations: 1999-2001 SO PREVENTIVE MEDICINE LA English DT Article DE colorectal cancer; Medicare; Tricare; colonoscopy; flexible sigmoidoscopy; double contrast barium enema ID COLORECTAL-CANCER AB Background. This study examined trends in the numbers of double contrast barium enemas, flexible sigmoidoscopies, and colonoscopies and trends in the choices of colorectal cancer screening service providers. Methods. Descriptive statistics were used to examine Medicare and Tricare data for the years 1999 to 2001. Results. The total volume of procedures increased 5% and 14%, respectively, in Tricare and Medicare. Tricare and Medicare, respectively, saw 32% and 33% reductions in barium enemas and 28% and 41% reductions in flexible sigmoidoscopies. Colonoscopies increased by 45% and 34% in Tricare and Medicare, respectively. Gastroenterologists provided the majority of colonoscopies for both groups each year. Conclusions. The volume of colonoscopies increased from 1999 to 2001 for both groups while the volumes of barium enemas and flexible sigmoidoscopies decreased. Gastroenterologists appear to be the preferred providers of colonoscopies. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Alabama, Sch Hlth Related Profess, Dept Hlth Serv Adm, Birmingham, AL 35294 USA. Univ Alabama, Sch Med, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Prevent Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. RP Robertson, RH (reprint author), Univ Alabama, Sch Hlth Related Profess, Dept Hlth Serv Adm, Webb 603,1530 3rd Ave S, Birmingham, AL 35294 USA. EM randal78@uab.edu NR 4 TC 28 Z9 28 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JUN PY 2006 VL 42 IS 6 BP 460 EP 462 DI 10.1016/j.ypmed.2006.01.014 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 059RV UT WOS:000238750800012 PM 16563479 ER PT J AU Wang, JH Weng, JS Cai, Y Penland, R Liu, MY Ittmann, M AF Wang, JH Weng, JS Cai, Y Penland, R Liu, MY Ittmann, M TI The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase SO PROSTATE LA English DT Article DE marker expression; quantitative RT-PCR; in situ hybridization; prostate-specific G-protein coupled receptors; PSGR; PSGR2 ID NEEDLE-BIOPSY SPECIMENS; COENZYME-A RACEMASE; BASAL-CELL MARKERS; RADICAL PROSTATECTOMY; NEPHROGENIC ADENOMA; DIAGNOSTIC UTILITY; EXPRESSION; P504S; FOCI; CARCINOMA AB BACKGROUND. Immunohistochemistry (IHC) to detect alpha-methylacyl-CoA racemase (AMACR) expression can be useful in the diagnosis of small foci of prostate cancer on needle biopsy specimens, although it still has limitations in terms of both sensitivity and specificity. We have previously described the increased expression of two prostate-specific G-protein coupled receptors (PSGR and PSGR2) in human prostate cancer. To examine their potential usefulness as cancer biomarkers, we have evaluated their expression relative to AMACR in prostate cancer tissues. METHODS. Expression of PSGR, PSGR2, and AMACR were examined by quantitative reverse-transcriptase PCR in mRNAs from benign prostate and prostate cancer tissues. Expression of PSGR2 and AMACR was also examined by in situ hybridization using a prostate cancer tissue microarray. RESULTS. By in situ hybridization, 24 of 40 prostate cancer cases showed concordant expression of PSGR2 and AMACR. However, in 16 cases there was significant discordance between expression levels of these two markers. By quantitative RT-PCR all three markers were substantially increased in cancer, with AMACR the most overexpressed (30-fold), followed by PSGR2 (13-fold) and PSGR (10-fold). AMACR was the best single marker of prostate cancer but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while PSGR and/or PSGR2 were substantially elevated. CONCLUSION. All three biomarkers are increased in prostate cancer but their expression is not completely concordant. There is a subset of cases in which analysis of expression of PSGR and/or PSGR2, in addition to AMACR, would be diagnostically useful. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. Texas A&M Univ, Ctr Canc Biol & Nutr, Inst Biosci & Technol, Syst Hlth Sci Ctr, Houston, TX USA. RP Ittmann, M (reprint author), VAMC, Res Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU NCI NIH HHS [1R21CA104318, P50CA058204] NR 33 TC 31 Z9 33 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD JUN 1 PY 2006 VL 66 IS 8 BP 847 EP 857 DI 10.1002/pros.20389 PG 11 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 042RC UT WOS:000237545600007 PM 16491480 ER PT J AU Singh, H Petersen, LA Thomas, EJ AF Singh, H Petersen, LA Thomas, EJ TI Understanding diagnostic errors in medicine: a lesson from aviation SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID SHARED MENTAL MODELS; SITUATION AWARENESS; COGNITIVE ERRORS; DYNAMIC-SYSTEMS; ADVERSE EVENTS; PERFORMANCE; CARE; CONSEQUENCES; STRATEGIES; COLORADO AB The impact of diagnostic errors on patient safety in medicine is increasingly being recognized. Despite the current progress in patient safety research, the understanding of such errors and how to prevent them is inadequate. Preliminary research suggests that diagnostic errors have both cognitive and systems origins. Situational awareness is a model that is primarily used in aviation human factors research that can encompass both the cognitive and the systems roots of such errors. This conceptual model offers a unique perspective in the study of diagnostic errors. The applicability of this model is illustrated by the analysis of a patient whose diagnosis of spinal cord compression was substantially delayed. We suggest how the application of this framework could lead to potential areas of intervention and outline some areas of future research. It is possible that the use of such a model in medicine could help reduce errors in diagnosis and lead to significant improvements in patient care. Further research is needed, including the measurement of situational awareness and correlation with health outcomes. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Texas, Ctr Excellence Patient Safety Res & Practice, Houston, TX USA. Univ Texas, Sch Med, Dept Med, Div Gen Med, Houston, TX 77030 USA. RP Singh, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu FU AHRQ HHS [1PO1HS1154401]; NCRR NIH HHS [K12 K12RR17665, K12 RR017665] NR 43 TC 66 Z9 67 U1 0 U2 13 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD JUN PY 2006 VL 15 IS 3 BP 159 EP 164 DI 10.1136/qshc.2005.016444 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 049PL UT WOS:000238028400007 PM 16751463 ER PT J AU Dransfield, MT Davis, JJ Gerald, LB Bailey, WC AF Dransfield, MT Davis, JJ Gerald, LB Bailey, WC TI Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease SO RESPIRATORY MEDICINE LA English DT Article DE chronic obstructive; pulmonary disease; smoking; race ID CIGARETTE-SMOKING; AFRICAN-AMERICANS; LUNG-FUNCTION; COPD; MORTALITY; VALUES; ADULTS; HEALTH; ASTHMA AB Background: Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. Methods: Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with >= 20 pack-years of smoking, FEV1/FVC (forced expiratory volume forced vital capacity) < 0.70, and a race-adjusted post-bronchoditator FEV1 < 80%. The primary outcome was the toss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV1-100)/pack-years. Results: A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P = 0.0003) and had more pack-years of smoking (57 vs. 43, P = 0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans (SI = -1.02% vs. -1.34%, P = 0.007) and men less than women (SI = -0.98% vs. -1.21%, P = 0.001). Caucasian mates appeared relatively protected from tobacco smoke (SI = -0.93%), while African-American women appeared most susceptible (SI = -1.42%). Conclusions: There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation. (c) 2005 Elsevier Ltd. All rights reserved. C1 Univ Alabama, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Pulm Sect, Birmingham, AL 35233 USA. RP Dransfield, MT (reprint author), 215 THT,1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 26 TC 61 Z9 63 U1 0 U2 5 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD JUN PY 2006 VL 100 IS 6 BP 1110 EP 1116 DI 10.1016/j.rmed.2005.09.019 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 049KZ UT WOS:000238016500022 PM 16236491 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Acute renal failure in the intensive care unit SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE acute renal failure; renal replacement therapy ID CRITICALLY-ILL PATIENTS; CONTRAST-INDUCED NEPHROPATHY; CONTINUOUS VENOVENOUS HEMOFILTRATION; RANDOMIZED CONTROLLED-TRIAL; ACUTE TUBULAR-NECROSIS; LOW-DOSE DOPAMINE; REPLACEMENT THERAPY; CARDIAC-SURGERY; CLINICAL-TRIAL; PROPHYLACTIC DIALYSIS AB Acute renal failure (ARF) is a common complication in critically ill patients, with ARF requiring renal replacement therapy (RRT) developing in similar to 5 to 10% of intensive care unit (ICU) patients. Epidemiological studies have demonstrated that ARF is an independent risk factor for mortality. Interventions to prevent the development of ARF are currently limited to a small number of settings, primarily radiocontrast nephropathy and rhabdomyolysis. There are no effective pharmacological agents for the treatment of established ARF. Renal replacement therapy remains the primary treatment for patients with severe ARF; however, the data guiding selection of modality of RRT and the optimal timing of initiation and dose of therapy are inconclusive. This review focuses on the epidemiology and diagnostic approach to ARF in the ICU and summarizes our current understanding of therapeutic approaches including RRT. C1 VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Rm 7E123 111F-U,Univ Dr Div, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 100 TC 14 Z9 16 U1 0 U2 2 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PD JUN PY 2006 VL 27 IS 3 BP 262 EP 273 DI 10.1055/s-2006-945527 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 061ZK UT WOS:000238913200007 PM 16791759 ER PT J AU Fan, J Levy, R Li, Y Vodovotz, Y Billiar, T Wilson, M AF Fan, J. Levy, R. Li, Y. Vodovotz, Y. Billiar, T. Wilson, M. TI TLR4 mediates hemorrhagic shock-induced NADPH oxidase activation in neutrophil. SO SHOCK LA English DT Meeting Abstract CT 29th Annual Conference of the Shock-Society CY JUN 03-06, 2006 CL Broomfield, CO SP Shock Soc, Novo Nordisk, USN, Off Naval REs, Def Adv Res Projects Agcy C1 Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD JUN PY 2006 VL 25 SU 1 BP 62 EP 62 DI 10.1097/00024382-200606001-00188 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 047AA UT WOS:000237851000189 ER PT J AU Mathews, RE McGuire, BM Estrada, CA AF Mathews, Ronnie E., Jr. McGuire, Brendan M. Estrada, Carlos A. TI Outpatient management of cirrhosis: A narrative review SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE cirrhosis; outpatient management; esophageal varices; ascites; hepatocellular carcinoma ID SPONTANEOUS BACTERIAL PERITONITIS; SUBCLINICAL HEPATIC-ENCEPHALOPATHY; HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; HEPATORENAL-SYNDROME; VARICEAL HEMORRHAGE; HEPATOPULMONARY SYNDROME; ESOPHAGEAL-VARICES; PROGNOSTIC FACTORS; COMPENSATED CIRRHOSIS AB Cirrhosis is the 12th leading cause of death in the United States. Individuals with cirrhosis are at risk for many potential complications. Complications can be managed or detected early with proper outpatient management. The most lethal of these complications is bleeding esophageal varices. All patients with cirrhosis should be screened for the presence of varices and treated when indicated. The most common complication seen in these patients is ascites. Ascites can be treated with dietary modifications and a diuretic regimen. Other potential complications include spontaneous bacteria peritonitis, hepatocellular carcinoma, hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome. The outpatient management of these complications will be discussed in this paper, along with the use of vaccinations, educating patients about the avoidance of hepatotoxic drugs, and when to refer a patient for liver transplant. C1 Univ Alabama, Div Gen Internal Med, Birmingham, AL USA. Univ Alabama, Div Gastroenterol & Hepatol, Birmingham, AL USA. Univ Alabama, Dept Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP McGuire, BM (reprint author), 1530 3rd Ave S,MCLM 262A, Birmingham, AL 35294 USA. EM bmcguire@uab.edu NR 57 TC 7 Z9 7 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD JUN PY 2006 VL 99 IS 6 BP 600 EP 606 DI 10.1097/01.smj.0000220889.36995.54 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 095NW UT WOS:000241315600009 PM 16800415 ER PT J AU Hopp, F Woodbridge, P Subramanian, U Copeland, L Smith, D Lowery, J AF Hopp, Faith Woodbridge, Peter Subramanian, Usha Copeland, Laurel Smith, David Lowery, Julie TI Outcomes associated with a home care telehealth intervention SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article ID HEALTH-CARE; HOSPITAL ADMISSIONS; TELEMEDICINE AB To determine whether adding telehealth technology to traditional home care services increases health-related quality of life (HRQOL) and home care satisfaction, and decreases resource utilization among home care patients. This trial included 37 home care patients receiving services in a Veterans Affairs medical center, randomized into intervention and control groups. Outcome measures included patient satisfaction and HRQOL at baseline and 6-month follow-up, and the use of inpatient and outpatient services before and during the 6-month study period. Intervention group patients reported greater improvement in the mental health component of HRQOL, (t = 2.27; df = 15; p = 0.04). Satisfaction with the telehealth equipment was high ( means exceeded 4.0 on six measures ranging from 1 - 5). However, no statistically significant differences were observed between intervention and control groups in terms of changes in physical health, inpatient admissions, bed days of care, emergency department visits, or general satisfaction with home care services. Intervention group members did show a trend ( p = 0.10) toward fewer overall outpatient visits ( mean = 29.1; standard deviation [SD] +/- 30.1) compared to those receiving traditional home care services ( mean = 38.9; SD +/- 28.9) The use of telehealth services as an adjunct to traditional home care is associated with greater improvements in mental health status and a trend toward lower use of inpatient and outpatient healthcare services. Further work, utilizing larger sample sizes, is needed to investigate the relationship between telehealth services, the use of healthcare resources, and other outcomes. C1 VA Ann Arbor Healthcare Syst, HSR&D Ctr Practice Management & Outcomes Res, Ann Arbor, MI 48113 USA. Richard L Roudebush Vet Affairs Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA. Regenstrief Inst Healthcare, Indianapolis, IN USA. Univ Michigan, Sch Publ Hlth, Dept Hlth Policy & Management, Ann Arbor, MI 48109 USA. S Texas Vet Hlth Care Syst VERDICT HSR&D, Dept Vet Affairs, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Indiana Ctr Aging Res, Indianapolis, IN USA. RP Hopp, F (reprint author), VA Ann Arbor Healthcare Syst, HSR&D Ctr Practice Management & Outcomes Res, POB 130170, Ann Arbor, MI 48113 USA. EM Faith.Hopp@med.va.gov OI Hopp, Faith/0000-0002-4536-3089; Copeland, Laurel/0000-0002-9478-0209 NR 31 TC 22 Z9 22 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD JUN PY 2006 VL 12 IS 3 BP 297 EP 307 DI 10.1089/tmj.2006.12.297 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 060XL UT WOS:000238835100019 PM 16796497 ER PT J AU Buchanan, DM Jones, PG Rumsfeld, JS Amin, AA Ho, PM Masoudi, FA Havranek, EP Mallik, S Spertus, JA AF Buchanan, Donna M. Jones, Philip G. Rumsfeld, John S. Amin, Alpesh A. Ho, P. M. Masoudi, Frederick A. Havranek, Edward P. Mallik, Susmita Spertus, John A. TI Trajectories of depression severity following acute myocardial infarction: A latent-class analysis SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Mid Amer Heart Inst, Kansas City, MO USA. Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. St Lukes Hosp, Ctr Innovat & Res, Kansas City, MO USA. Univ Missouri, Kansas City, MO 64110 USA. Denver Hlth Med Ctr, Denver, CO USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E798 EP E798 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600081 ER PT J AU Fihn, S Lowy, E Rumsfeld, J Sales, A Sun, HL Fleming, B Jesse, R Maynard, C AF Fihn, Stephan Lowy, Elliott Rumsfeld, John Sales, Anne Sun, Haili Fleming, Barbara Jesse, Robert Maynard, Chuck TI The prevalence and outcomes of in-hospital acute myocardial infarction in the department of veterans affairs health system SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound HCS, Seattle, WA USA. Denver VA Med Ctr, Denver, CO USA. Dept Vet Affairs, Washington, DC USA. Richmond VA Med Ctr, Richmond, VA USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E804 EP E804 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600109 ER PT J AU Greiner, G Lowy, E Maynard, C Sales, A Fihn, S AF Greiner, Gwen Lowy, Elliott Maynard, Chuck Sales, Anne Fihn, Stephan TI Comparison of six mortality risk adjustment models for acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound HCS, Seattle, WA USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E807 EP E807 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600123 ER PT J AU Groeneveld, PW Kruse, GB Schwartz, JS Kimberly, JB Pauly, MV AF Groeneveld, Peter W. Kruse, Gregory B. Schwartz, J. Sanford Kimberly, John B. Pauly, Mark V. TI Small area variation in the diffusion of percutaneous coronary intervention, 1991-2003 SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E813 EP E813 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600152 ER PT J AU Groeneveld, PW Kruse, GB AF Groeneveld, Peter W. Kruse, Gregory B. TI Costs of cardiac procedures in the veterans health administration SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E789 EP E790 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600040 ER PT J AU Ho, PM Magid, DJ Masoudi, FA McClure, DL Rumsfeld, JS AF Ho, P. Michael Magid, David J. Masoudi, Frederick A. McClure, David L. Rumsfeld, John S. TI The association between cardioprotective medications, medication adherence, and mortality among patients with chronic ischemic heart disease SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Denver VA Med Ctr, Denver, CO USA. Kaiser Permanente Colorado, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E808 EP E808 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600127 ER PT J AU Lowy, E Greiner, G Sales, A Maynard, C Fihn, S AF Lowy, Elliott Greiner, Gwen Sales, Anne Maynard, Chuck Fihn, Stephan TI Race, race, and mortality among veterans with acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound HCS, Seattle, WA USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E819 EP E820 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600183 ER PT J AU Mallavarapu, V Shalaby, A Raitt, M Groeneweld, P Hickey, K Kochar, A Marchlinski, F Verdino, R Callans, D Dixit, S AF Mallavarapu, Vamshi Shalaby, Alaa Raitt, Merritt Groeneweld, Peter Hickey, Kelly Kochar, Arshneel Marchlinski, Francis Verdino, Ralph Callans, David Dixit, Sanjay TI Outcomes in veterans with ischemic cardiomyopathy undergoing prophylactic implantable cardioverter defibriilator implantation SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Pittsburgh VA Med Ctr, Pittsburgh, PA USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E820 EP E821 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600187 ER PT J AU Pineros, SL Sales, AE Pineros, VM McDonell, M Maynard, C Lehmann, KG Fihn, SD AF Pineros, Sandra L. Sales, Anne E. Pineros, Vanessa M. McDonell, Mary Maynard, Charles Lehmann, Kenneth G. Fihn, Stephan D. TI An evaluation of a patient education initiative in VHA: Time is life for heart attack SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E825 EP E825 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600208 ER PT J AU Rumsfeld, JS Box, T Gethoffer, H Gillespie, B McDonell, M Ho, M Jesse, RL Fihn, SD AF Rumsfeld, John S. Box, Tamara Gethoffer, Hans Gillespie, Brian McDonell, Mary Ho, Michael Jesse, Robert L. Fihn, Stephan D. TI The VA cardiovascular assessment reporting and tracking system for cardiac catheterization laboratories (CART-CL) SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Denver VA Med Ctr, Denver, CO USA. VA Puget Sound HCS, Seattle, WA USA. Richmond VA Med Ctr, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E828 EP E828 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600220 ER PT J AU Sales, A McDermott, K Helfrich, C Lowy, E Greiner, G Lehmann, K Fihn, S AF Sales, Anne McDermott, Kelly Helfrich, Christian Lowy, Elliott Greiner, Gwen Lehmann, Kenneth Fihn, Stephan TI Factors associated with reperfusion for ST segment elevation myocardial infarction patients in VHA facilities SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound HCS, Seattle, WA USA. RI Sales, Anne/D-9678-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E816 EP E816 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600166 ER PT J AU Sales, A Maynard, C Sun, HL Fihn, S AF Sales, Anne Maynard, Chuck Sun, Haili Fihn, Stephan TI Race and the use of percutaneous coronary intervention in veterans with acute myocardial infarction SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 VA Puget Sound HCS, Seattle, WA USA. RI Sales, Anne/D-9678-2012; Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E793 EP E793 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600056 ER PT J AU Schelbert, EB Rumsfeld, JS Krumholz, HM Canto, JG Magid, DJ Masoudi, FA Weintraub, WS Reid, KJ Spertus, JA AF Schelbert, Erik B. Rumsfeld, John S. Krumholz, Harlan M. Canto, John G. Magid, David J. Masoudi, Frederick A. Weintraub, William S. Reid, Kimberly J. Spertus, John A. TI Ischemic symptoms during acute myocardial infarction, quality of care, and subsequent mortality SO CIRCULATION LA English DT Meeting Abstract CT 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY MAY 07-09, 2006 CL Washington, DC SP Amer Heart Assoc, Qual Care & Outcomes Res Interdisciplinary Working Grp, Amer Coll Cardiol Fdn, Ctr Dis Control & Prevent, Dept Vet Affairs C1 Denver VA Med Ctr, Denver, CO USA. Yale Univ, New Haven, CT 06520 USA. Watson Clin, Lakeland, FL USA. Colorado Permanente Med Grp, Denver, CO USA. Denver Hlth Med Ctr, Denver, CO USA. Emory Univ, Atlanta, GA 30322 USA. Mid Amer Heart Inst, Kansas City, MO USA. Univ Missouri, Kansas City, MO 64110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAY 30 PY 2006 VL 113 IS 21 BP E828 EP E829 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 048RQ UT WOS:000237964600224 ER PT J AU Kulstad, JJ Green, PS Cook, DG Watson, GS Reger, MA Baker, LD Plymate, SR Asthana, S Rhoads, K Mehta, PD Craft, S AF Kulstad, JJ Green, PS Cook, DG Watson, GS Reger, MA Baker, LD Plymate, SR Asthana, S Rhoads, K Mehta, PD Craft, S TI Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease SO NEUROLOGY LA English DT Article ID DEGRADING ENZYME; PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; HUMAN PLATELETS; A-BETA-42 LEVELS; APOLIPOPROTEIN-E; IN-VIVO; RECEPTOR; PEPTIDE; BRAIN AB Background: Hyperinsulinemia and insulin resistance are risk factors for memory impairment and Alzheimer disease ( AD). Insulin regulates levels of the amyloid beta-peptide (A beta) in vitro in neuronal cultures and in vivo in the CSF of normal older adults. Objective: To determine whether insulin affected plasma A beta levels and whether such effects differed for patients with AD compared with normal older adults. Methods: Fifty-nine patients with AD and 50 healthy older adults each received infusions of saline and of insulin (1.0 mU (.) kg(-1) (.) min(-1)) with accompanying dextrose to maintain euglycemia. A subset of participants (19 AD, 12 normal) received two additional conditions, in which insulin was infused at a lower (0.33 mU (.) kg(-1) (.) min(-1)) and higher (1.67 mU (.) kg(-1) (.) min(-1)) rate. Plasma insulin and A beta were measured after 120 minutes of infusion. Results: Adults with AD had higher plasma insulin vs normal adults at the two higher infusion rates, despite receiving comparable amounts of insulin. For normal adults, insulin reduced plasma A beta levels at the middle (1.0 mU (.) kg(-1) (.) min(-1)) dose, with attenuated effects at lower and higher doses. In contrast, for patients with AD, insulin raised plasma A beta levels at the two higher doses (1.0 and 1.67 mU (.) kg(-1) (.) min(-1)). Conclusions: These results suggest that patients with Alzheimer disease ( AD) have reduced insulin clearance and insulin-provoked plasma amyloid beta-peptide (A beta) elevation. Abnormal regulation of peripheral A beta by insulin may contribute to AD risk. C1 VAPSHCS, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI USA. Univ Wisconsin, Dept Med, Madison, WI USA. Inst Basic Res Dev Disabil, Staten Isl, NY USA. RP Craft, S (reprint author), VAPSHCS, Geriatr Res Educ & Clin Ctr, S-182 GRECC,1600 S Columbian Way, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU NIA NIH HHS [R01 AG-10880] NR 41 TC 56 Z9 59 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 23 PY 2006 VL 66 IS 10 BP 1506 EP 1510 DI 10.1212/01.wnl.0000216274.58185.09 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 044XM UT WOS:000237706900010 PM 16717209 ER PT J AU Wang, L Larson, EB Bowen, JD van Belle, G AF Wang, L Larson, EB Bowen, JD van Belle, G TI Performance-based physical function and future dementia in older people SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; INCIDENT DEMENTIA; COGNITIVE DECLINE; AGED 65; GAIT; PREDICTORS; HEALTH; RISK AB Background: The association of physical function with progression to dementia has not been well investigated. We aimed to determine whether physical function is associated with incident dementia and Alzheimer disease (AD). Methods: We performed a prospective cohort study of 2288 persons 65 years and older without dementia. Patients were enrolled from 1994 to 1996 and followed up through October 2003. Main outcome measures included incident dementia and AD. Results: During follow-up 319 participants developed dementia (221 had AD). The age-specific incidence rate of dementia was 53.1 per 1000 person-years for participants who scored lower on a performance-based physical function test at baseline (<= 10 points) compared with 17.4 per 1000 person-years for those who scored higher (< 10 points). A 1-point lower performance-based physical function score was associated with an increased risk of dementia (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P <.001), an increased risk of AD (hazard ratio, 1.06; 95% confidence interval, 1.01-1.12; P=.01), and an increased rate of decline in the Cognitive Ability Screening Instrument scores (0.11 point per year; 95% confidence interval, 0.08-0.14; P <.001) after adjusting for age, sex, years of education, baseline cognitive function, APOE epsilon 4 allele, family history of AD, depression, coronary heart disease, and cerebrovascular disease. Conclusions: Lower levels of physical performance were associated with an increased risk of dementia and AD. The study suggests that poor physical function may precede the onset of dementia and AD and higher levels of physical function may be associated with a delayed onset. C1 Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Larson, EB (reprint author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM larson.e@ghc.org FU NIA NIH HHS [UO1 AG06781] NR 28 TC 127 Z9 135 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 22 PY 2006 VL 166 IS 10 BP 1115 EP 1120 DI 10.1001/archinte.166.10.1115 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 045CP UT WOS:000237720500011 PM 16717174 ER PT J AU Smith, GL Shlipak, MG Havranek, EP Foody, JM Masoudi, FA Rathore, SS Krumholz, HM AF Smith, GL Shlipak, MG Havranek, EP Foody, JM Masoudi, FA Rathore, SS Krumholz, HM TI Serum urea nitrogen, creatinine, and estimators of renal function - Mortality in older patients with cardiovascular disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ACUTE MYOCARDIAL-INFARCTION; CHRONIC KIDNEY-DISEASE; DECOMPENSATED HEART-FAILURE; ACUTE CORONARY SYNDROMES; TIMI RISK SCORE; PREDICTIVE PERFORMANCE; HOSPITALIZATION; INSUFFICIENCY; TRIAL AB Background: Renal dysfunction predicts increased mortality in cardiovascular patients, but the best renal estimator for quantifying risks is uncertain. We compared admission serum urea nitrogen (SUN) level, creatinine level, Modification of Diet in Renal Disease (MDRD) rate, and Mayo estimated glomerular filtration rate (eGFR) for predicting mortality. Methods: In a retrospective cohort of Medicare patients (aged >= 65 years) hospitalized for myocardial infarction (n=44 437) and heart failure (n=56 652), renal estimators were compared for linearity with 1-year mortality risk, magnitude of risk, and relative importance for predicting risk (percentage variance explained) in proportional hazards models. Results: The SUN level, creatinine level, and Mayo eGFR had linear associations with mortality. These measures predicted steadily increased risk in patients who experienced a myocardial infarction with a SUN level greater than 17 mg/dL (> 6.1 mmol/L), a creatinine level greater than 1.0 mg/dL (> 88.4 mu mol/L), and a Mayo eGFR of less than 100 mL/min per 1.73 m(2); and in patients who experienced heart failure with a SUN level greater than 16 mg/dL (> 5.7 mmol/L), a creatinine level greater than 1.1 mg/dL (> 97.2 mu mol/L), and a Mayo eGFR of 90 mL/min per 1.73 m(2) or less. In contrast, the MDRD eGFR had a J-shaped association and failed to identify increased risks in 50.0% of patients who experienced a myocardial infarction (with an MDRD eGFR > 55 mL/min per 1.73 m(2)) and 60.0% of patients who experienced heart failure (with an MDRD eGFR > 44 mL/min per 1.73 m(2)). The SUN level and Mayo eGFR had the greatest magnitude of risks. In myocardial infarction and heart failure patients, adjusted mortality increased by 3% and 7%, respectively, per 5-U increase in SUN, and by 3% and 9%, respectively, per 10-U decrease in Mayo eGFR (P <.001), based on models including both renal measures. Of all the measures, SUN had the greatest magnitude of relative importance for predicting mortality. Conclusions: In older cardiovascular patients, SUN- and creatinine-based measures were powerful predictors of postdischarge mortality. Only MDRD eGFR was less adequate in quantifying risks for patients with mild impairment. Novel estimators, such as the Mayo eGFR, may play an important role in outcomes' prognostication for these patients. C1 Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver Hlth Med Ctr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Div Geriatr Med, Denver, CO 80262 USA. Colorado Fdn Med Care, Aurora, CO USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, 333 Cedar St,Sterling Hall Med,1 Wing,Suite 456, New Haven, CT 06520 USA. EM harlan.krumholz@yale.edu FU NIA NIH HHS [K08-AG20623-01, K08-AG01011]; NIGMS NIH HHS [GM07205] NR 44 TC 59 Z9 61 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 22 PY 2006 VL 166 IS 10 BP 1134 EP 1142 DI 10.1001/archinte.166.10.1134 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 045CP UT WOS:000237720500014 PM 16717177 ER PT J AU Cui, XY Yang, SC Sharma, S Heuze-Vourc'h, N Dubinett, SM AF Cui, XY Yang, SC Sharma, S Heuze-Vourc'h, N Dubinett, SM TI IL-4 regulates COX-2 and PGE2production in human non-small cell lung cancer SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE NSCLC; IL-4; COX-2; PGE(2); mPEGES-1; 15-PGDH ID ACTIVATED PROTEIN-KINASES; PROSTAGLANDIN-E SYNTHASE; SMOOTH-MUSCLE-CELLS; CYCLOOXYGENASE-2 EXPRESSION; KAPPA-B; E-2 BIOSYNTHESIS; UP-REGULATION; PATHWAYS; IDENTIFICATION; INTERLEUKIN-4 AB IL-4 is a type 2 cytokine that may mediate pleiotropic effects in the NSCLC microenvironment. Here, we investigated whether IL-4 regulates PGE(2) production in NSCLC cells. We found that IL-4 inhibited constitutive COX-2 expression and PGE(2) production in A427 and H2122 NSCLC cell lines, and also suppressed IL-1 beta-induced COX-2 expression in A549 and RH2 NSCLC cell lines. COX-2 mRNA was decreased in response to IL-4, and promoter analysis indicated that IL-4 inhibited both constitutive and IL-1 beta-induced COX-2 transcription. IL-4 inhibited IL-1 beta-stimulated ERK phosphorylation, which may mediate the inhibition of IL-1 beta-induced COX-2 by IL-4. IL-4 did not modulate additional arachidonic acid pathway enzymes mPGES-1 and 15-PGDH, which could potentially be responsible for regulating PGE2 production. Overall, our Studies demonstrate that IL-4 has the capacity to inhibit COX-2 mRNA transcription in NSCLC cells and the inhibition of PGE(2) appears to be predominately COX-2 dependent. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. EM sdubinett@mednet.ucla.edu RI HEUZE-VOURC'H, Nathalie/P-8081-2016 FU NCI NIH HHS [R01 CA111851, P50 CA90388] NR 32 TC 19 Z9 23 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAY 19 PY 2006 VL 343 IS 4 BP 995 EP 1001 DI 10.1016/j.bbrc.2006.03.073 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 038ZQ UT WOS:000237269000001 PM 16574063 ER PT J AU Drain, PK Baeten, JM Overbaugh, J Wener, MH D Bankson, D Lavreys, L Mandaliya, K O Ndinya-Achola, J McClelland, RS AF Drain, PK Baeten, JM Overbaugh, J Wener, MH D Bankson, D Lavreys, L Mandaliya, K O Ndinya-Achola, J McClelland, RS TI Low serum albumin and the acute phase response predict low serum selenium in HIV-1 infected women SO BMC INFECTIOUS DISEASES LA English DT Article ID VITAMIN-A-DEFICIENCY; HIV DISEASE PROGRESSION; RANDOMIZED-TRIAL; MICRONUTRIENT SUPPLEMENTATION; MORTALITY; INFECTION; PLASMA; BLOOD; RISK AB Background: Low serum selenium has been associated with lower CD4 counts and greater mortality among HIV-1-seropositive individuals, but most studies have not controlled for serum albumin and the presence of an acute phase response. Methods: A cross-sectional study was conducted to evaluate relationships between serum selenium concentrations and CD4 count, plasma viral load, serum albumin, and acute phase response markers among 400 HIV-1-seropositive women. Results: In univariate analyses, lower CD4 count, higher plasma viral load, lower albumin, and the presence of an acute phase response were each significantly associated with lower serum selenium concentrations. In multivariate analyses including all four of these covariates, only albumin remained significantly associated with serum selenium. For each 0.1 g/dl increase in serum albumin, serum selenium increased by 0.8 mu g/l ( p < 0.001). Women with an acute phase response also had lower serum selenium ( by 5.6 mu g/l, p = 0.06). Conclusion: Serum selenium was independently associated with serum albumin, but not with CD4 count or plasma viral load, in HIV-1-seropositive women. Our findings suggest that associations between lower serum selenium, lower CD4 count, and higher plasma viral load may be related to the frequent occurrence of low serum albumin and the acute phase response among individuals with more advanced HIV-1 infection. C1 Univ Washington, Dept Med, Seattle, WA 98105 USA. Univ Washington, Sch Med, Seattle, WA 98105 USA. Univ Washington, Dept Lab Med, Seattle, WA 98105 USA. Univ Washington, Clin Nutr Res Unit Lab Core, Seattle, WA 98105 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98105 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA. Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. Coast Prov Gen Hosp, Dept Pathol, Mombasa, Kenya. Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. RP McClelland, RS (reprint author), Univ Washington, Dept Med, 1959 NE Pacific,Box 356340, Seattle, WA 98105 USA. EM pkdrain@u.washington.edu; jbaeten@partners.org; joverbau@fhcrc.org; wener@u.washington.edu; daniel.bankson@med.va.gov; llavreys@africaonline.co.ke; kishor@ikenya.com; ndinya-achola@kaviuon.org; mcclell@africoonline.co.ke OI Drain, Paul/0000-0003-3300-3817 FU FIC NIH HHS [D43 TW000007, D43-TW00007]; NIAID NIH HHS [R01 AI043844, K23-AI52480, AI43844, K23 AI052480, AI39996]; NIDDK NIH HHS [P30 DK035816, DK35816] NR 28 TC 14 Z9 14 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD MAY 19 PY 2006 VL 6 AR 85 DI 10.1186/1471-2334-6-85 PG 6 WC Infectious Diseases SC Infectious Diseases GA 054IB UT WOS:000238368900001 PM 16712720 ER PT J AU Brown, JS Bradley, CS Subak, LL Richter, HE Kraus, SR Brubaker, L Lin, F Vittinghoff, E Grady, D AF Brown, JS Bradley, CS Subak, LL Richter, HE Kraus, SR Brubaker, L Lin, F Vittinghoff, E Grady, D CA Diagnost Aspects Incontinence Stu TI The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID EPIDEMIOLOGIC SURVEY; CONFIDENCE-INTERVALS; SEVERITY INDEX; WOMEN; QUESTIONNAIRE; VALIDITY; HISTORY; PREVALENCE; COMMUNITY; DIAGNOSIS AB Background: Urinary incontinence is common in women. Because treatments differ, urge incontinence should be distinguished from stress incontinence. To make this distinction, current guidelines recommend an extensive evaluation that is too time-consuming for primary care practice. Objective: To test the accuracy of a simple questionnaire to categorize type of urinary incontinence in women. Design: Multicenter, prospective study of the accuracy of the 3 Incontinence Questions (3IQ) compared with an extended evaluation to distinguish between urge incontinence and stress incontinence. Setting: 5 academic medical centers in the United States. Participants: 301 women enrolled from April to December 2004 who were older than 40 years of age (mean age, 56 years [SD, 11]) with untreated incontinence for an average of 7 years (SD, 7) and a broad range of incontinence severity. Measurements: All participants included in the analyses answered the 31Q questionnaire, and a urologist or urogynecologist who was blinded to the responses performed the extended evaluation. Sensitivity, specificity, and likelihood ratios were determined for the 3IQ. Results: For classification of urge incontinence and with the extended evaluation as the gold standard, the 3IQ had a sensitivity of 0.75 (95% CI, 0.68 to 0.81), a specificity of 0.77 (CI, 0.69 to 0.84), and a positive likelihood ratio of 3.29 (CI, 2.39 to 4.51). For classification of stress incontinence, the sensitivity was 0.86 (CI, 0.79 to 0.90), the specificity was 0.60 (CI, 0.51 to 0.68), and the positive likelihood ratio was 2.13 (CI, 1.71 to 2.66). Limitations: Participants were enrolled by urologists and urogynecologists at academic medical centers. Conclusions: The 31Q questionnaire is a simple, quick, and noninvasive test with acceptable accuracy for classifying urge and stress incontinence and may be appropriate for use in primary care settings. Similar studies are needed in other populations. We also need a clinical trial comparing the outcomes of treatments based on the 31Q and the extended evaluation. C1 Univ Calif San Francisco, San Francisco, CA 94115 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Univ Iowa, Iowa City, IA 52242 USA. Univ Alabama, Birmingham, AL 35487 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Loyola Univ, Maywood, IL 60153 USA. RP Brown, JS (reprint author), Univ Calif San Francisco, 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM brownj@obgyn.ucsf.edu FU FIC NIH HHS [D43 TW000909]; NCI NIH HHS [R01 CA094107]; NIDDK NIH HHS [P50 DK064538-04, P50 DK064538-02, P50 DK064538-01, P50 DK064538-03S1, P50 DK064538, P50 DK064538-03, P50 DK064538-010003, P50 DK064538-02S1] NR 30 TC 67 Z9 67 U1 2 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 16 PY 2006 VL 144 IS 10 BP 715 EP 723 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 043XO UT WOS:000237636400002 PM 16702587 ER PT J AU Chaudhry, B Wang, J Wu, SY Maglione, M Mojica, W Roth, E Morton, SC Shekelle, PG AF Chaudhry, B Wang, J Wu, SY Maglione, M Mojica, W Roth, E Morton, SC Shekelle, PG TI Systematic review: Impact of health information technology on quality, efficiency, and costs of medical care SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID PHYSICIAN ORDER ENTRY; ADVERSE DRUG EVENTS; RANDOMIZED CONTROLLED-TRIALS; COMPUTER-BASED INTERVENTION; DECISION-SUPPORT-SYSTEMS; HOSPITALIZED-PATIENTS; PREVENTIVE CARE; CLINICAL GUIDELINES; IMPROVE TREATMENT; TIME UTILIZATION AB Background: Experts consider health information technology key to improving efficiency and quality of health care. Purpose: To systematically review evidence on the effect of health information technology on quality, efficiency, and costs of health care. Data Sources: The authors systematically searched the English-language literature indexed in MEDLINE (1995 to January 2004), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Abstracts of Reviews of Effects, and the Periodical Abstracts Database. We also added studies identified by experts up to April 2005. Study Selection: Descriptive and comparative studies and systematic reviews of health information technology. Data Extraction: Two reviewers independently extracted information on system capabilities, design, effects on quality, system acquisition, implementation context, and costs. Data Synthesis: 257 studies met the inclusion criteria. Most studies addressed decision support systems or electronic health records. Approximately 25% of the studies were from 4 academic institutions that implemented internally developed systems; only 9 studies evaluated multifunctional, commercially developed systems. Three major benefits on quality were demonstrated: increased adherence to guideline-based care, enhanced surveillance and monitoring, and decreased medication errors. The primary domain of improvement was preventive health. The major efficiency benefit shown was decreased utilization of care. Data on another efficiency measure, time utilization, were mixed. Empirical cost data were limited. Limitations: Available quantitative research was limited and was done by a small number of institutions. Systems were heterogeneous and sometimes incompletely described. Available financial and contextual data were limited. Conclusions: Four benchmark institutions have demonstrated the efficacy of health information technologies in improving quality and efficiency. Whether and how other institutions can achieve similar benefits, and at what costs, are unclear. C1 Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90095 USA. RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Greater Los Angeles Vet Affairs Syst, Los Angeles, CA 90048 USA. RP Chaudhry, B (reprint author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Ave,2nd Floor, Los Angeles, CA 90095 USA. EM BChaudhry@mednet.ucla.edu RI Tao, Youyou/D-2367-2014 NR 106 TC 1154 Z9 1174 U1 29 U2 247 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 16 PY 2006 VL 144 IS 10 BP 742 EP 752 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 043XO UT WOS:000237636400005 PM 16702590 ER PT J AU Smith, GL Lichtman, JH Bracken, MB Shlipak, MG Phillips, CO DiCapua, P Krumholz, HM AF Smith, GL Lichtman, JH Bracken, MB Shlipak, MG Phillips, CO DiCapua, P Krumholz, HM TI Renal impairment and outcomes in heart failure - Systematic review and meta-analysis SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID VENTRICULAR SYSTOLIC DYSFUNCTION; SERUM CREATININE; NEUROHORMONAL ACTIVATION; PROGNOSTIC IMPORTANCE; KIDNEY-DISEASE; RISK-FACTORS; CYSTATIN-C; INSUFFICIENCY; MORTALITY; ASSOCIATION AB OBJECTIVES We estimated the prevalence of renal impairment in heart failure (HF) patients and the magnitude of associated mortality risk using a systematic review of published studies. BACKGROUND Renal impairment in HF patients is associated with excess mortality, although precise risk estimates are unclear. METHODS A systematic search of MEDLINE (through May 2005) identified 16 studies characterizing the association between renal impairment and mortality in 80,098 hospitalized and non-hospitalized HF patients. All-cause mortality risks associated with any renal impairment (creatinine > 1.0 mg/dl, creatinine clearance [CrCl] or estimated glomerular filtration rate [eGFR] < 90 ml/min, or cystatin-C > 1.03 mg/dl) and moderate to severe impairment (creatinine >= 1.5, CrCl or eGFR < 53, or cystatin-C >= 1.56) were estimated using fixed-effects meta-analysis. RESULTS A total of 63% of patients had any renal impairment, and 29% had moderate to severe impairment. After follow-up >= 1 year, 38% of patients with any renal impairment and 51% with moderate to severe impairment died versus 24% without impairment. Adjusted all-cause mortality was increased for patients with any impairment (hazard ratio [HR] = 1.56; 95% confidence interval [CI] 1.53 to 1.60, p < 0.001) and moderate to severe impairment (HR = 2.31; 95% CI 2.18 to 2.44, p < 0.001). Mortality worsened incrementally across the range of renal function, with 15% (95% CI 14% to 17%) increased risk for every 0.5 mg/dl increase in creatinine and 7% (95% CI 4% to 10%) increased risk for every 10 ml/min decrease in eGFR. CONCLUSIONS Renal impairment is common among HF patients and confers excess mortality. Renal function should be considered in risk stratification and evaluation of therapeutic strategies for HF patients. (J Am Coll Cardiol 2006;47:1987-96) (c) 2006 by the American College of Cardiology Foundation. C1 Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, SHM, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. San Francisco Vet Affairs Med Ctr, Gen Internal Med Sect, Med Serv, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA. Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, SHM, I Wing,Suite 456,333 Cedar St, New Haven, CT 06510 USA. EM harlan.krumholz@yale.edu FU NIGMS NIH HHS [GM07205] NR 36 TC 379 Z9 420 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 16 PY 2006 VL 47 IS 10 BP 1987 EP 1996 DI 10.1016/j.jacc.2005.11.084 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 045OG UT WOS:000237750800010 PM 16697315 ER PT J AU Whittle, J Kressin, NR Peterson, ED Orner, MB Glickman, M Mazzella, M Petersen, LA AF Whittle, J Kressin, NR Peterson, ED Orner, MB Glickman, M Mazzella, M Petersen, LA TI Racial differences in prevalence of coronary obstructions among men with positive nuclear imaging studies SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID INVASIVE CARDIOVASCULAR PROCEDURES; ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART-DISEASE; ASSOCIATION TASK-FORCE; ARTERY BYPASS-SURGERY; OF-VETERANS-AFFAIRS; REVASCULARIZATION PROCEDURES; CARDIAC-CATHETERIZATION; PRACTICE GUIDELINES; STABLE ANGINA AB OBJECTIVES The purpose of this research was to compare coronary obstruction between clinically similar African Americans (AA) and white persons undergoing coronary angiography. BACKGROUND African Americans have higher rates of coronary death than whites, but are less likely to undergo coronary revascularization. Although differences in coronary anatomy do not explain racial difference in revascularization rates, several studies of clinically diverse persons undergoing coronary angiography have found less obstructive coronary disease in AA than clinically similar whites. METHODS We studied 52 AA and 259 white male veterans who had both a positive nuclear perfusion imaging study and coronary angiography within 90 days of that study in five Department of Veterans Affairs hospitals. We used chart review and patient interview to collect demographics, clinical characteristics, and coronary anatomy results. Before angiography, we asked physicians to estimate the likelihood of coronary obstruction. RESULTS The treating physicians' estimates of coronary disease likelihood were similar for AA (79.5%) and whites (83.0%); AA were less likely to have any coronary obstruction (63.5% vs. 76.5%, p = 0.05) and had significantly less severe coronary disease (p = 0.01) than whites. African Americans continued to be less likely to have coronary obstruction in analyses controlling for clinical features, including the physician's estimate of the likelihood of coronary obstruction. CONCLUSIONS These results suggest that AA have less coronary obstruction than apparently clinically similar whites. Further studies are required to confirm our findings and better understand the paradox that AA are less likely to have obstructive coronary disease and more likely to suffer mortality from coronary disease. (J Am Coll Cardiol 2006;47:2034-41) (c) 2006 by the American College of Cardiology Foundation. C1 Zablocki Vet Adm Med Ctr, Primary Care Div, Milwaukee, WI 53295 USA. Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Milwaukee, WI 53226 USA. Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA 02215 USA. Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. Univ Kansas, Med Ctr, Div Cardiol, Kansas City, KS 66103 USA. Houston VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Div Hlth Policy & Qual, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Whittle, J (reprint author), Zablocki Vet Adm Med Ctr, Primary Care Div, Mailstop 00 PC,5000 W Natl Ave, Milwaukee, WI 53295 USA. EM jeffirey.whittle@va.gov OI Glickman, Mark/0000-0003-3993-2801; Kressin, Nancy/0000-0003-2767-4286 NR 41 TC 18 Z9 18 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 16 PY 2006 VL 47 IS 10 BP 2034 EP 2041 DI 10.1016/j.jacc.2005.12.059 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 045OG UT WOS:000237750800017 PM 16697322 ER PT J AU Wu, JY Lu, H Sun, Y Graham, DY Cheung, HS Yamaoka, Y AF Wu, JY Lu, H Sun, Y Graham, DY Cheung, HS Yamaoka, Y TI Balance between polyoma enhancing activator 3 and activator protein 1 regulates Helicobacter pylori - Stimulated matrix metalloproteinase 1 expression SO CANCER RESEARCH LA English DT Article ID GASTRIC EPITHELIAL-CELLS; COLLAGENASE MATRIX METALLOPROTEINASE-1; C-FOS; PATHOGENICITY ISLAND; INTERSTITIAL COLLAGENASE; GENE-EXPRESSION; MAP KINASE; TRANSCRIPTION FACTORS; PROMOTER ACTIVATION; SIGNAL-TRANSDUCTION AB Helicobacter pylori infection and elevated expression of tissue matrix metalloproteinase I (I IMP-l) are both associated with gastric cancer. We investigated the regulation of MMP-1 expression during H. pylori infection. Real-time reverse transcription-PCR was used to examine mucosal MMP-1 mRNA levels in 55 patients with gastric cancers and 61 control patients. Increased MMP-1 mRNA levels in the gastric mucosa and epithelial cells were observed in H. pylori infections in which both the cag pathogenicity island (PAI) and outer inflammatory protein A (OipA) were expressed. The combined induction of c-fos, c-jun, and Polyoma enhancing activator-3 (pea-3) by H. pylori caused maximal increase in MMP-1 expression. Activation of the MMP-1 promoter by H. pylori involved occupation of the activator protein 1 (AP-1) sites at -72 and -181 and, surprisingly, vacancy of the -88 PEA-3 site. Electrophoretic mobility shift, supershift, and chromatin immunoprecipitation assays showed increased binding of c-Fos and c-Jun to the -72 and -181 AP-1 sites during H. pylori infection. Importantly, during wild-type H. pylori infection, we detected increased PEA-3 binding to the -72 AP-1 site and decreased PEA-3 binding to the -88 PEA-3 site. However, during infection with the cag PAI and oipA mutants, PEA-3 binding to the-88 site was detected. MMP-1 and pea-3 activities are increased in gastric cancers. Maximal activation of MMP-1 transcription requires the cag PAI and OipA, which regulate AP-1 and PEA-3 binding. Thus, cag PAI and OipA provide a possible link between bacterial virulence factors and important host factors related to disease pathogenesis. C1 DeBakey Vet Affairs Med Ctr 111D, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Kaohsiung Med Univ Hosp, Dept Med, Kaohsiung, Taiwan. Shanghai Renji Hosp, Shanghai, Peoples R China. Shanghai Inst Digest Dis, Shanghai, Peoples R China. Miami Univ, Sch Med, Dept Med, Miami, FL USA. RP Yamaoka, Y (reprint author), DeBakey Vet Affairs Med Ctr 111D, Dept Med, Room 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [DK62813, R01 DK062813, R01 DK062813-03, DK56338, P30 DK056338] NR 45 TC 29 Z9 30 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2006 VL 66 IS 10 BP 5111 EP 5120 DI 10.1158/0008-5472.CAN-06-0383 PG 10 WC Oncology SC Oncology GA 044NS UT WOS:000237679900019 PM 16707434 ER PT J AU Dohadwala, M Yang, SC Luo, J Sharma, S Batra, RK Huang, M Lin, Y Goodglick, L Krysan, K Fishbein, MC Hong, L Lai, C Cameron, RB Gemmill, RM Drabkin, HA Dubinett, SM AF Dohadwala, M Yang, SC Luo, J Sharma, S Batra, RK Huang, M Lin, Y Goodglick, L Krysan, K Fishbein, MC Hong, L Lai, C Cameron, RB Gemmill, RM Drabkin, HA Dubinett, SM TI Cyclooxygenase-2-dependent regulation of E-cadherin: Prostaglandin E-2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer SO CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; PROGNOSTIC-SIGNIFICANCE; BETA-CATENIN; GENE-EXPRESSION; DOWN-REGULATION; TUMOR-CELLS; INHIBITION; ADHESION; SENSITIVITY AB Elevated tumor cyclooxygenase-2 (COX-2) expression is associated with tumor invasion, metastasis, and poor prognosis in non-small cell lung cancer (NSCLC). Here, we report that COX-2-dependent pathways contribute to the modulation of E-cadherin expression in NSCLC. First, whereas genetically modified COX-2-sense (COX-2-S) NSCLC cells expressed low E-cadherin and showed diminished capacity for cellular aggregation, genetic or pharmacologic inhibition of tumor COX-2 led to increased E-cadherin expression and resulted in augmented homotypic cellular aggregation among NSCLC cells in vitro. An inverse relationship between COX-2 and E-cadherin was shown in situ by double immunohistochemical staining of human lung adenocarcinoma tissue sections. Second, treatment of NSCLC cells with exogenous prostaglandin E-2 (PGE(2)) significantly decreased the expression of E-cadherin, whereas treatment of COX-2-S cells with celecoxib (1 mu mol/L) led to increased E-cadherin expression. Third, the transcriptional suppressors of E-cadherin, ZEB1 and Snail, were up-regulated in COX-2-S cells or PGE(2)-treated NSCLC cells but decreased in COX-2-antisense cells. PGE(2) exposure led to enhanced ZEB1 and Snail binding at the chromatin level as determined by chromatin immunoprecipitation assays. Small interfering RNA-mediated knockdown of ZEB1 or Snail interrupted the capacity of PGE(2) to downregulate E-cadherin. Fourth, an inverse relationship between E-cadherin and ZEB1 and a direct relationship between COX-2 and ZEB1 were shown by immunohistochemical staining of human lung adenocarcinoma tissue sections. These findings indicate that PGE(2), in autocrine or paracrine fashion, modulates transcriptional repressors of E-cadherin and thereby regulates COX-2-dependent E-cadherin expression in NSCLC. Thus, blocking PGE(2) production or activity may contribute to both prevention and treatment of NSCLC. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Los Angeles Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Care Ctr, Los Angeles, CA USA. Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80202 USA. Univ Colorado, Ctr Canc, Div Med Oncol, Denver, CO 80202 USA. RP Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu OI Batra, Raj K./0000-0002-1126-543X FU NCI NIH HHS [CA58187, P50 CA90388] NR 51 TC 177 Z9 191 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2006 VL 66 IS 10 BP 5338 EP 5345 DI 10.1158/0008-5472.CAN-05-3635 PG 8 WC Oncology SC Oncology GA 044NS UT WOS:000237679900045 PM 16707460 ER PT J AU Meeran, SM Mantena, SK Elmets, CA Katiyar, SK AF Meeran, SM Mantena, SK Elmets, CA Katiyar, SK TI (-)-Epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interieukin-12-dependent DNA repair SO CANCER RESEARCH LA English DT Article ID SUNBURN CELL-FORMATION; GREEN TEA POLYPHENOLS; SKIN-CANCER; CONTACT HYPERSENSITIVITY; ULTRAVIOLET-RADIATION; INDUCED IMMUNOSUPPRESSION; PYRIMIDINE DIMERS; TUMOR-REGRESSION; UVB RADIATION; IN-VIVO AB We have shown previously that topical application of epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, prevents photocarcinogenesis in mice. EGCG prevents UVB-induced immunosuppression by inducing interleukin-12 (IL-12). As immunosuppression is a risk factor for photocarcinogenesis, we investigated the possibility that EGCG also prevents UVB-induced photocarcinogenesis through an IL-12-dependent DNA repair mechanism. To investigate this possibility, we determined the effects of EGCG on photocarcinogenesis in IL-12 knockout (KO) mice using the formation of cyclobutane pyrimidine dimers (CPD) as an indicator of the extent of UVB-induced DNA damage. Topical application of EGCG (1 mg/cm(2) skin) prevented photocarcinogenesis in wild-type (C3H/HeN) mice in terms of tumor incidence and tumor multiplicity but did not prevent photocarcinogenesis in IL-12 KO mice. UVB-induced DNA damage, as determined by the formation of CPDs and the number of sunburn cells, was resolved more rapidly in the skin of wild-type mice treated with EGCG than untreated control mice. In contrast, the extent of UVB-induced DNA damage and the numbers of sunburn cells were not significantly different in the EGCG-treated IL-12 KO mice and untreated control mice. In addition, treatment of XPA-proficient human fibroblast cells with EGCG promoted repair of UVB-induced CPDs in a dose-dependent manner but not in an XPA-deficient cells, indicating that the nucleotide excision repair mechanism is involved in EGCG-mediated DNA repair. Taken together, these results indicate for the first time that EGCG can prevent photocarcinogenesis through an EGCG-induced IL-12-dependent DNA repair mechanism. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [1 R01 AT002536]; NCRR NIH HHS [C06 RR15490]; NIAMS NIH HHS [AR050948-01] NR 38 TC 59 Z9 65 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2006 VL 66 IS 10 BP 5512 EP 5520 DI 10.1158/0008-5472.CAN-06-0218 PG 9 WC Oncology SC Oncology GA 044NS UT WOS:000237679900066 PM 16707481 ER PT J AU Leung, WK Man, EPS Yu, J Go, MYY To, KF Yamaoka, Y Cheng, VYY Ng, EK Sung, JJY AF Leung, WK Man, EPS Yu, J Go, MYY To, KF Yamaoka, Y Cheng, VYY Ng, EK Sung, JJY TI Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach SO CLINICAL CANCER RESEARCH LA English DT Article ID TUMOR-RELATED GENES; DIFFUSE GASTRIC-CANCER; PROMOTER HYPERMETHYLATION; INTESTINAL METAPLASIA; CARCINOMA; MUTATIONS; CDH1; EXPRESSION; INFECTION AB Purpose: Promoter hypermethylation of E-cadherin plays an important role on gastric cancer development. Whereas E-cadherin methylation was frequently detected in the stomach of Helicobacter pylori - infected individuals, we tested whether eradication of H pylori alters the methylation status of the noncancerous gastric epithelium. Experimental Design: Endoscopic biopsies were taken from the antrum and corpus of H pylori - infected subjects without gastric cancer. Presence of methylated E-cadherin sequences in the gastric specimens was detected by methylation-specific PCR. Bisulfite DNA sequencing was done to determine the topographical distribution and changes in methylation profiles with H pylori eradication. Results: Among the 28 H pylori - infected subjects (median age, 44.5 years), 15 (53.6%) had E-cadherin methylation detected in stomach at baseline. Discordant methylation patterns between the antrum and corpus were noted in six patients. One year after successful H pylori eradication, there was a significant reduction in the methylation density of the promoter region and exon 1 of the E-cadherin gene as detected by bisulfite DNA sequencing (P < 0.001). Conclusion: Promoter methylation in E-cadherin was frequently detected in the stomach of H. pylori-infected individuals. Eradication of H pylori might possibly reduce the methylation density in E-cadherin gene and the chance of subsequent neoplastic transformation. C1 Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Inst Digest Dis,Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China. Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Leung, WK (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Inst Digest Dis,Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China. EM wkleung@cuhk.edu.hk RI Hossain, Sarah /C-7332-2009; Leung, Wai Keung/B-8140-2011; Cheng, Yuen Yee/G-4406-2016; Yu, Jun /D-8569-2015 OI Hossain, Sarah /0000-0003-1355-0979; Cheng, Yuen Yee/0000-0001-7060-0624; NR 23 TC 73 Z9 77 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2006 VL 12 IS 10 BP 3216 EP 3221 DI 10.1158/1078-0432.CCR-05-2442 PG 6 WC Oncology SC Oncology GA 044PX UT WOS:000237685800037 PM 16707623 ER PT J AU Zhang, F Signore, AP Zhou, ZG Wang, SP Cao, GD Chen, J AF Zhang, F Signore, AP Zhou, ZG Wang, SP Cao, GD Chen, J TI Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: Potential signaling mechanisms SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE EPO; AKT; GSK-3 beta; BDNF; CA1 ID GLYCOGEN-SYNTHASE KINASE-3; OXYGEN-GLUCOSE DEPRIVATION; NEUROTROPHIC FACTOR; BRAIN-INJURY; FOREBRAIN ISCHEMIA; APOPTOSIS; EXPRESSION; PREVENTS; HYPOXIA; PATHWAY AB Erythropoietin (EPO) is a hormone that is neuroprotective in models of neurodegenerative diseases. This study examined whether EPO can protect against neuronal death in the CA1 region of the rat hippocampus following global cerebral ischemia. Recombinant human EPO was infused into the intracerebral ventricle either before or after the induction of ischemia produced by using the four-vessel-occlusion model in rat. Hippocampal CA1 neuron damage was ameliorated by infusion of 50 U EPO. Administration of EPO was neuroprotective if given 20 hr before or 20 min after ischemia, but not 1 hr following ischemia. Coinjection of the phosphoinositide 3 kinase inhibitor LY294002 with EPO inhibited the protective effects of EPO. Treatment with EPO induced phosphorylation of both AKT and its substrate, glycogen synthase kinase-3 beta, in the CA1 region. EPO also enhanced the CA1 level of brain-derived neurotrophic factor. Finally, we determined that ERK activation played minor roles in EPO-mediated neuroprotection. These studies demonstrate that a single injection of EPO ICV up to 20 min after global ischemia is an effective neuroprotective agent and suggest that EPO is a viable candidate for treating global ischemic brain injury. (c) 2006 Wiley-Liss, Inc. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507,Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu FU NINDS NIH HHS [NS38560, NS45048, NS43802, NS36736] NR 67 TC 77 Z9 90 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAY 15 PY 2006 VL 83 IS 7 BP 1241 EP 1251 DI 10.1002/jnr.20816 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 041WY UT WOS:000237488500010 PM 16511866 ER PT J AU Oram, S Cai, XY Haleem, R Cyriac, J Wang, Z AF Oram, S Cai, XY Haleem, R Cyriac, J Wang, Z TI Regulation of calcium homeostasis by S100RVP, an androgen-regulated S100 protein in the rat ventral prostate SO PROSTATE LA English DT Article DE androgens; prostate; S100; calcium ID EF-HAND TYPE; BINDING PROTEINS; MODULATED PROTEINS; FUNCTIONAL ROLES; CELL-LINES; EXPRESSION; CANCER; FAMILY; ACTIVATION; CLONING AB BACKGROUND. S100RVP was previously identified as an androgen-response gene in the rat ventral prostate RVP Characterization of S100RVP is important for elucidating the function of S100 proteins in androgen action. METHODS. The expression and subcellular localization of S100RVP were determined by Northern blot, in situ hybridization, and fluorescent microscopy. Calcium overlay and calcium ionophore sensitivity assays were performed to investigate the calcium binding and function of S100RVP. RESULTS. S100RVP is abundantly expressed in the RVP epithelial cells. A green fluorescent protein(GFP)-S100RVP fusion protein is present in both the cytoplasm and nucleus of transfected cells. A GST-S100RVP fusion protein bound calcium in vitro at levels similar to known S100 proteins. Furthermore, GFP-S100RVP transfected LNCaP and PC3 cells exhibited reduced sensitivity to calcium ionophore-induced cell death, but not to UV-induced cell death. CONCLUSION. The results of this study argue for a role of S100RVP in calcium homeostasis in the prostate. C1 Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA. Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA. Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Wang, Z (reprint author), Northwestern Univ, Sch Med, Dept Urol, Tarry 16-763, Chicago, IL 60611 USA. EM wangz@northwestern.edu FU NCI NIH HHS [P50-CA90386]; NIDDK NIH HHS [R01-DK51193] NR 37 TC 1 Z9 2 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-4137 J9 PROSTATE JI Prostate PD MAY 15 PY 2006 VL 66 IS 7 BP 768 EP 778 DI 10.1002/pros.20395 PG 11 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 031ZU UT WOS:000236744500010 PM 16444689 ER PT J AU Jatana, M Giri, S Ansari, MA Elango, C Singh, AK Singh, I Khan, M AF Jatana, Manu Giri, Shailendra Ansari, Mubeen A. Elango, Chinnasamy Singh, Avtar K. Singh, Inderjit Khan, Mushfiquddin TI Inhibition of NF-kappa B activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia SO JOURNAL OF NEUROINFLAMMATION LA English DT Article ID NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REDUCES INFLAMMATION; EXPERIMENTAL STROKE; ARTERY OCCLUSION; GENE-EXPRESSION; PUTATIVE ROLE; CELL-DEATH; ALPHA; CYCLOOXYGENASE AB Background: Stroke is one of the leading causes of death worldwide and a major cause of morbidity and mortality in the United States of America. Brain ischemia-reperfusion (IR) triggers a complex series of biochemical events including inflammation. Leukotrienes derived from 5-lipoxygenase (5-LOX) cause inflammation and are thus involved in the pathobiology of stroke injury. Methods: To test the neuroprotective efficacy of 5-LOX inhibition in a rat model of focal cerebral IR, ischemic animals were either pre- or post-treated with a potent selective 5-LOX inhibitor, (N[ 3-[3-(-fluorophenoxy) phenyl]-1-methyl-2-propenyl]-N-hydroxyurea (BW-B 70C). They were evaluated at 24 h after reperfusion for brain infarction, neurological deficit score, and the expression of 5-LOX. Furthermore, the mechanism and the anti-inflammatory potential of BW-B 70C in the regulation of nuclear factor kappa B ( NF-kappa B) and inflammatory inducible nitric oxide synthase ( iNOS) were investigated both in vivo and in vitro. Results and discussion: Both pre- and post-treatment with BW-B 70C reduced infarctions and improved neurological deficit scores. Immunohistochemical study of brain sections showed IR-mediated increased expression of 5-LOX in the neurons and microglia. BW-B 70C down-regulated 5-LOX and inhibited iNOS expression by preventing NF-kappa B activation. Two other structurally different 5-LOX inhibitors were also administered post IR: caffeic acid and 2, 3, 5-trimethyl-6-[12-hydroxy-5, 10-dodecadiynyl]- 1, 4-benzoquinone (AA-861). As with BW-B 70C, they provided remarkable neuroprotection. Furthermore, in vitro, BW-B 70C inhibited lipopolysaccharide (LPS) mediated nitric oxide production, iNOS induction and NF-kappa B activation in the BV2 microglial cell line. Treating rat primary microglia with BW-B70C confirmed blockage of LPS-mediated translocation of the p65 subunit of NF-kappa B from cytosol to nucleus. Conclusion: The study demonstrates the neuroprotective potential of 5-LOX inhibition through down-regulation of NF-kappa B in a rat model of experimental stroke. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM manujatana@gmail.com; giris@musc.edu; ansarim@musc.edu; elangoc@musc.edu; singha@musc.edu; singhi@musc.edu; khanm@musc.edu FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NINDS NIH HHS [R01 NS034741, R01 NS040810, R01 NS040144, R37 NS022576, R01 NS037766, R01 NS022576] NR 54 TC 52 Z9 57 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD MAY 11 PY 2006 VL 3 AR 12 DI 10.1186/1742-2094-3-12 PG 13 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 174US UT WOS:000246968900001 PM 16689995 ER PT J AU Hansen, JE Sohn, W Kim, C Chang, SS Huang, NC Santos, DG Chan, G Weisbart, RH Nishimura, RN AF Hansen, JE Sohn, W Kim, C Chang, SS Huang, NC Santos, DG Chan, G Weisbart, RH Nishimura, RN TI Antibody-mediated Hsp70 protein therapy SO BRAIN RESEARCH LA English DT Article DE Hsp70; protein therapy; protein transduction; Tat; neuroprotection; antibody ID RAT CORTICAL-NEURONS; INTRACELLULAR DELIVERY; IN-VIVO; CANCER-CELLS; TRANSDUCTION; HEAT-SHOCK-PROTEIN-70; MECHANISMS; INDUCTION; PEPTIDE; BRAIN AB Intracellular Hsp70 provides cytoprotection against a variety of stressful stimuli, and an effective means of increasing intracellular Hsp70 levels could prove beneficial in the prevention and treatment of a variety of human diseases. A novel protein transduction domain consisting of the single chain Fv fragment of an anti-DNA antibody known to penetrate into living cells and tissues, mAb 3E10, has recently been used to deliver functional proteins to cells. The ability of the single chain Fv fragment to deliver Hsp70 into living cells was tested by generating an Fv-Hsp70 fusion protein. Fv-Hsp70 was produced as a secreted protein in both COS-7 cells and the methylotropic yeast strain Pichia pastoris and was shown capable of penetrating into COS-7 cells and primary rat cortical neurons. Pretreatment with Fv-Hsp70 protected both COS-7 cells and primary rat cortical neurons against subsequent exposure to hydrogen peroxide. These results provide the first evidence that the Fv fragment of mAb 3E10 is capable of delivering proteins to neurons and indicate its potential in the development of Hsp70 protein therapy. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, San Fernando Valley Program, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA 91343 USA. RP Hansen, JE (reprint author), Univ Calif Los Angeles, San Fernando Valley Program, Dept Med, 16111 Plummer St, H Nills, CA 91343 USA. EM jameshansen2004@hotmail.com NR 29 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAY 9 PY 2006 VL 1088 BP 187 EP 196 DI 10.1016/j.brainres.2006.03.025 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 056HM UT WOS:000238512900020 PM 16630585 ER PT J AU Beeri, MS Rapp, M Silverman, JM Schmeidler, J Grossman, HT Fallon, JT Purohit, DP Perl, DP Siddiqui, A Lesser, G Rosendorff, C Haroutunian, V AF Beeri, MS Rapp, M Silverman, JM Schmeidler, J Grossman, HT Fallon, JT Purohit, DP Perl, DP Siddiqui, A Lesser, G Rosendorff, C Haroutunian, V TI Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers SO NEUROLOGY LA English DT Article ID APOLIPOPROTEIN-E GENOTYPES; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; RISK-FACTOR; ATHEROSCLEROSIS; DEMENTIA; HYPERTENSION; CHOLESTEROL; POPULATION; PREVALENCE AB Objective: To examine the associations between postmortem Alzheimer disease (AD) neuropathology and autopsy-verified cardiovascular disease. Methods: The authors examined 99 subjects (mean age at death = 87.6; SD = 8.7) from the Mount Sinai School of Medicine Department of Psychiatry Brain Bank who were devoid of cerebrovascular disease-associated lesions or of non-AD-related neuropathology. Density of neuritic plaques (NPs) and neurofibrillary tangles (NFTs) as well as coronary artery and aortic atherosclerosis, left ventricular wall thickness, and heart weight were measured. Partial correlations were used to assess the associations of the four cardiovascular variables with NPs and NFTs in the hippocampus, entorhinal cortex, and multiple regions of the cerebral cortex after controlling for age at death, sex, dementia severity, body mass index, and ApoE genotype. These analyses were also repeated separately for ApoE4 carriers and noncarriers. Results: The extent of coronary artery disease and to a lesser extent atherosclerosis were significantly associated with the density of cardinal neuropathologic lesions of AD in this autopsy sample (significant correlations between 0.22 and 0.29). These associations were more pronounced for the ApoE4 allele carriers (n = 42; significant correlations between 0.34 and 0.47). Conclusions: The degree of coronary artery disease is independently associated with the cardinal neuropathological lesions of Alzheimer disease. These associations are primarily attributable to individuals with the ApoE4 allele. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Dept Biostat, New York, NY USA. Mt Sinai Sch Med, Dept Pathol, New York, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Jewish Home & Hosp, New York, NY USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, 4F-33B,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu FU NIA NIH HHS [K01 AG023515, 1 K01 AG023515-01A2, AG02219, AG05138, K01 AG023515-01A2, P01 AG002219, P50 AG005138] NR 39 TC 60 Z9 62 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 9 PY 2006 VL 66 IS 9 BP 1399 EP 1404 DI 10.1212/01.wnl.0000210447.19748.0b PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 040FS UT WOS:000237365000020 PM 16682673 ER PT J AU Swarztrauber, K Koudelka, C Brodsky, MA AF Swarztrauber, K Koudelka, C Brodsky, MA TI Initial pharmacotherapy in a population of veterans with Parkinson disease SO NEUROLOGY LA English DT Article ID LEVODOPA; BEGIN AB The authors analyzed patient and prescribing provider characteristics for 530 veterans identified from VA pharmacy records with Parkinson disease (PD) and initial pharmacotherapy. Neurologists prescribed 29% of initial therapy. While a patient being younger and seeing a movement disorder specialist predicted receiving dopamine agonists, only 20% of patients younger than age 65 years received dopamine agonists. Initial pharmacotherapy is strongly influenced by the provider's specialty but mostly initiated by providers without PD expertise. C1 Portland VA Med Ctr, Portland, OR USA. Parkinson Dis Res Educ & Clin Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Biostat & Bioinformat Shared Resources, Portland, OR USA. Oregon Hlth Sci Univ, Ctr Biostat Comp & Informat Biol & Med, Portland, OR USA. RP Swarztrauber, K (reprint author), P-3-PADRECC,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM swarztra@ohsu.edu NR 7 TC 6 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY 9 PY 2006 VL 66 IS 9 BP 1425 EP 1426 DI 10.1212/01.wnl.0000210433.49727.40 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 040FS UT WOS:000237365000025 PM 16682678 ER PT J AU Armstrong, K Hughes-Halbert, C Asch, DA AF Armstrong, K Hughes-Halbert, C Asch, DA TI Patient preferences can be misleading as explanations for racial disparities in health care SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CARDIAC-CATHETERIZATION; RENAL-TRANSPLANTATION; ETHNIC DISPARITIES; TRUST; RACE; COMMUNICATION; HYSTERECTOMY; SATISFACTION; INFORMATION; PHYSICIANS AB Addressing racial differences in US health care is difficult, in part because the origins of these differences are complex and poorly understood and also because only some differences may represent legitimate agendas for reform. For example, racial differences that result from differences in access or from clinician prejudices are symptoms of a problem that must be addressed; in contrast, racial differences that arise from different preferences for health care might be seen as acceptable consequences of variation in personal or cultural values that are worth respecting and preserving. However, we believe that this distinction is sometimes overstated. We present several fictitious clinical stories to illustrate how what appear to be individual or cultural preferences are often substantially shaped by modifiable practices of the health care system. True differences in preference that are worthy of respect surely exist between individuals or demographic groups, but some apparent differences in preference may actually reflect problems with the health care system that are worthy of remediation. Uncovering the hidden constraints that we impose on health care choice may help us reduce unwanted disparities in health care. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Abramson Canc Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Armstrong, K (reprint author), Univ Penn, Sch Med, Dept Med, 1204 Blockley Hall, Philadelphia, PA 19104 USA. EM karmstro@mail.med.upenn.edu NR 50 TC 29 Z9 29 U1 4 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 8 PY 2006 VL 166 IS 9 BP 950 EP 954 DI 10.1001/archinte.166.9.950 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 039VF UT WOS:000237334900001 PM 16682567 ER PT J AU Valiyeva, E Russell, LB Miller, JE Safford, MM AF Valiyeva, E Russell, LB Miller, JE Safford, MM TI Lifestyle-related risk factors and risk of future nursing home admission SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID MORTALITY; OBESITY; CARE AB Background: While risks of disease, hospitalization, and death attributable to lifestyle-related factors such as smoking, inactivity, and obesity have been well studied, their associations with nursing home admission are less well known. These risk factors are usually established by middle age, but nothing is known about how they relate to long-term risk of nursing home admission in this age group. Methods: Cox proportional hazards regressions were used to analyze risk of nursing home admission over 2 decades of follow-up (1971-1975 to 1992) in a nationally representative, longitudinal survey of community-dwelling adults aged 45 to 74 years at baseline. Middle-aged (45-64 years at baseline) and elderly persons ( aged 65-74 years at baseline) were analyzed separately: 230 (6.5%) of 3526 middle-aged respondents and 728 (24.7%) of 2936 elderly ones had 1 or more nursing home admissions. Baseline risk factors included smoking, inactivity, obesity, elevated blood pressure, elevated total cholesterol level, and diabetes mellitus, which were defined according to national guidelines. Results: All lifestyle-related factors, except total cholesterol level, were associated with higher risk of nursing home admission during follow-up in one or both age groups. Risk ratios were higher in middle-aged than in elderly persons. In those aged 45 to 64 years at baseline, diabetes more than tripled the risk of nursing home admission ( relative risk, 3.25; 95% confidence interval, 2.04-5.19); smoking, inactivity, and elevated systolic blood pressure had relative risks of 1.56, 1.40, and 1.35, respectively. Obesity was a risk factor for those aged 65 to 74 years at baseline, but not for the middle-aged subjects. Persons with 2 lifestyle-related factors were at greatly increased risk, especially if 1 was diabetes. Conclusions: Lifestyle factors are important contributors to the long-term risk of nursing home admission. Modifying lifestyle, especially in middle age, may reduce the risk of admission. C1 Rutgers State Univ, Inst Hlth, New Brunswick, NJ 08901 USA. Rutgers State Univ, Dept Econ, New Brunswick, NJ 08901 USA. Rutgers State Univ, Bloustein Sch Planning & Publ Policy, New Brunswick, NJ 08901 USA. Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharm Practice & Adm, Piscataway, NJ USA. Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Univ Alabama, Sch Med, Birmingham, AL USA. RP Russell, LB (reprint author), Rutgers State Univ, Inst Hlth, 30 Coll Ave, New Brunswick, NJ 08901 USA. EM lrussell@ifh-mail1.rutgers.edu FU AHRQ HHS [HS 11477] NR 31 TC 35 Z9 35 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAY 8 PY 2006 VL 166 IS 9 BP 985 EP 990 DI 10.1001/archinte.166.9.985 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 039VF UT WOS:000237334900006 PM 16682571 ER PT J AU Houston, TK Person, SD Pletcher, MJ Liu, K Iribarren, C Kiefe, CI AF Houston, TK Person, SD Pletcher, MJ Liu, K Iribarren, C Kiefe, CI TI Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study SO BRITISH MEDICAL JOURNAL LA English DT Article ID DEPENDENT DIABETES-MELLITUS; CIGARETTE-SMOKING; RISK DEVELOPMENT; MEN; RECRUITMENT; PATTERNS; ALCOHOL AB Objective To assess whether active and passive smokers are more likely than non-smokers to develop clinically relevant glucose intolerance or diabetes. Design Coronary artery risk development in Young adults (CARDIA) is a prospective cohort study begun in 1985-6 with 15 years of follow-up. Setting Participants recruited from Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California, USA. Participants Black and white men and women aged 18-30 years with no glucose intolerance at baseline, including 1386 current smokers, 621 previous smokers, 1452 never smokers with reported exposure to secondhand smoke (validated by serum cotinine concentrations 1-15 ng/ml), and 1113 never smokers with no exposure to secondhand smoke. Main outcome measure Time to development of glucose intolerance (glucose >= 100 mg/dl or taking antidiabetic drugs) during 15 years of follow-up. Results Median age at baseline was 25, 55% of participants were women, and 50% were African-American. During follow-up, 16.7% of participants developed glucose intolerance. A graded association existed between smoking exposure and the development of glucose intolerance. The 15 year incidence of glucose intolerance was highest among smokers (21.8%), followed by never smokers with passive smoke exposure (17.2%), and then previous smokers (14.4%); it was lowest for never smokers with no passive smoke exposure (11.5%). Current smokers (hazard ratio 1.65, 95% confidence interval 1.27 to 2.13) and never smokers with passive smoke exposure (1.35, 1.06 to 1.71) remained at higher risk than never smokers without passive smoke exposure after adjustment for multiple baseline sociodemographic, biological, and behavioural factors, but risk in previous smokers was similar to that in never smokers without passive smoke exposure. Conclusion These findings support a role of both active and passive smoking in the development of glucose intolerance in young adulthood. C1 Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. Kaiser Permanente, Oakland, CA USA. Northwestern Univ, Evanston, IL USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness Res, Birmingham, AL USA. RP Houston, TK (reprint author), Univ Alabama, Div Gen Internal Med, 510 20th St S,FOT 720, Birmingham, AL 35294 USA. EM thouston@uabmc.edu RI Houston, Thomas/F-2469-2013 FU NHLBI NIH HHS [N01-HC-45134, N01-HC-05187, N01-HC-48047, N01-HC-48050, N01-HC-95095, N01-HC48048] NR 25 TC 102 Z9 110 U1 1 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-8146 J9 BRIT MED J JI Br. Med. J. PD MAY 6 PY 2006 VL 332 IS 7549 BP 1064 EP 1067 DI 10.1136/bmj.38779.584028.55 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 042HI UT WOS:000237518400017 PM 16603565 ER PT J AU Ho, PM Rumsfeld, JS AF Ho, PM Rumsfeld, JS TI Cardiac risk management in severe mental illness SO LANCET LA English DT Editorial Material ID DISEASE; SCHIZOPHRENIA C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Cardiol Sect, Denver, CO 80220 USA. RP Ho, PM (reprint author), Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Cardiol Sect, 4200 E 9th Ave, Denver, CO 80220 USA. EM Michael.ho@uchsc.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD MAY 6 PY 2006 VL 367 IS 9521 BP 1469 EP 1471 DI 10.1016/S0140-6736(06)68628-5 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 039RJ UT WOS:000237324200009 PM 16679146 ER PT J AU Tice, JA Grady, D AF Tice, JA Grady, D TI Alternatives to estrogen for treatment of hot flashes - Are they effective and safe? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; BREAST-CANCER; DOUBLE-BLIND; SOY PHYTOESTROGENS; PLUS PROGESTIN; SYMPTOMS; FLUSHES; LIFE C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Tice, JA (reprint author), Univ Calif San Francisco, Dept Med, 1701 Divisadero St,Suite 554, San Francisco, CA 94143 USA. EM jeff.tice@ucsf.edu NR 28 TC 10 Z9 10 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 3 PY 2006 VL 295 IS 17 BP 2076 EP 2078 DI 10.1001/jama.295.17.2076 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 038MF UT WOS:000237225100025 PM 16670417 ER PT J AU Dobie, SA Baldwin, LM Dominitz, JA Matthews, B Billingsley, K Barlow, W AF Dobie, SA Baldwin, LM Dominitz, JA Matthews, B Billingsley, K Barlow, W TI Completion of therapy by medicare patients with stage III colon cancer SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID ADVANCED COLORECTAL-CANCER; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; PROCEDURE VOLUME; PLUS LEVAMISOLE; RECTAL-CANCER; TOXICITY; FLUOROURACIL; OUTCOMES; CARCINOMA AB Background. Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. Results: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. Conclusions: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates. C1 Univ Washington, Dept Family Med, Seattle, WA 98195 USA. Univ Washington, Dept Family Med, Seattle, WA 98195 USA. NW Ctr Outcomes Res Older Adults, Ctr Excellence, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. Canc Res & Biostat, Seattle, WA USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Dobie, SA (reprint author), Univ Washington, Dept Family Med, Box 356390, Seattle, WA 98195 USA. EM dob@u.washington.edu OI Dominitz, Jason/0000-0002-8070-7086 FU NCI NIH HHS [R01 CA089544, R01 CA089544-01, R01CA089544] NR 53 TC 80 Z9 81 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD MAY 3 PY 2006 VL 98 IS 9 BP 610 EP 619 DI 10.1093/jnci/djj159 PG 10 WC Oncology SC Oncology GA 043UP UT WOS:000237628000010 PM 16670386 ER PT J AU Chang, JT Hays, RD Shekelle, PG MacLean, CH Solomon, DH Reuben, DB Roth, CP Kamberg, CJ Adams, J Young, RT Wenger, NS AF Chang, JT Hays, RD Shekelle, PG MacLean, CH Solomon, DH Reuben, DB Roth, CP Kamberg, CJ Adams, J Young, RT Wenger, NS TI Patients' global ratings of their health care are not associated with the technical quality of their care SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CONSUMER ASSESSMENT; VULNERABLE ELDERS; OLDER PATIENTS; OF-CARE; SATISFACTION; PLANS; COMMUNICATION; DEPRESSION; COMMUNITY; OUTCOMES AB Background: Patient global ratings of care are commonly used to assess health care. However, the extent to which these assessments of care are related to the technical quality of care received is not well understood. objective: To investigate the relationship between patient-reported global ratings of health care and the quality of providers' communication and technical quality of care. Design: Observational cohort study. Setting: 2 managed care organizations, Patients: Vulnerable older patients identified by brief interviews of a random sample of community-dwelling adults 65 years of age or older who received care in 2 managed care organizations during a 13-month period. Measurements: Survey questions from the second stage of the Consumer Assessment of Healthcare Providers and Systems program were used to determine patients' global rating of health care and provider communication. A set of 236 quality indicators, defined by the Assessing Care of Vulnerable Elders project, were used to measure technical quality of care given for 22 clinical conditions; 207 quality indicators were evaluated by using data from chart abstraction or patient interview. Results: Data on the global rating item, communication scale, and technical quality of care score were available for 236 vulnerable older patients. In a multivariate logistic regression model that included patient and clinical factors, better communication was associated with higher global ratings of health care. Technical quality of care was not significantly associated with the global rating of care. Limitations: Findings were limited to vulnerable elders who were enrolled in managed care organizations and may not be generalizable to other age groups or types of insurance coverage. Conclusions: Vulnerable elders' global ratings of care should not be used as a marker of technical quality of care. Assessments of quality of care should include both patient evaluations and independent assessments of technical quality. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. RAND Hlth, Arlington, VA USA. RP Chang, JT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, 911 Broxton Ave,3rd Floor, Los Angeles, CA 90095 USA. EM johnchang@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 FU BHP HRSA HHS [PE-19001]; NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 38 TC 118 Z9 118 U1 3 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 2 PY 2006 VL 144 IS 9 BP 665 EP 672 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 039GJ UT WOS:000237293700006 PM 16670136 ER PT J AU Mohanty, SA Washington, DL Lambe, S Fink, A Asch, SM AF Mohanty, SA Washington, DL Lambe, S Fink, A Asch, SM TI Predictors of on-call specialist response times in California emergency departments SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc Gen Internal Med DE on-call specialist; emergency department; health services research ID INCOME; CARE AB Objectives: To assess waiting times in emergency departments (EDs) for on-call specialist response and how these might vary by facility or neighborhood characteristics. Limited availability of on-call specialists is thought to contribute to ED overcrowding. Methods: Direct observational data from a random sample of 1,798 patients visiting 30 California EDs during a six-month period provided specialist waiting times. The authors used multivariate logistic regression and survival analysis to analyze predictors of time to on-call specialists' telephone response. Results: Eighty-six percent of on-call specialists who were paged responded by telephone within 30 minutes. Ten percent of specialists did not respond at all. After controlling for the annual percentage of non-urgent ED patients at each facility, near closure status, and hospital ownership status, for every $10,000 increase in hospital zip code income, the odds of on-call specialist response within 30 minutes increased by 123% (adjusted odds ratio = 2.23; 95% confidence interval = 1.24 to 4.02; p = 0.01). Conclusions: Although the majority of on-call specialists met the federal recommendation of a 30-minute response, those in poor neighborhoods were less likely to do so. One in ten on-call specialists did not respond at all. State and federal policies should focus on making more funding available for on-call specialist panels in poor areas. C1 Univ So Calif, Keck Sch Med, Dept Med & Emergency Med, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med & Publ Hlth, Los Angeles, CA USA. Univ Calif San Francisco, Dept Med, Div Emergency Med, San Francisco, CA USA. RP Mohanty, SA (reprint author), Univ So Calif, Dept Med, Div Geriatr & Gen Internal Med, 2020 Zonal Ave,IRD 627, Los Angeles, CA 90033 USA. EM samohant@usc.edu NR 28 TC 9 Z9 9 U1 0 U2 0 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAY PY 2006 VL 13 IS 5 BP 505 EP 512 DI 10.1197/j.aem.2005.12.018 PG 8 WC Emergency Medicine SC Emergency Medicine GA 041VN UT WOS:000237484500005 PM 16609102 ER PT J AU Leff, B Harper, GM AF Leff, B Harper, GM TI The reading habits of medicine clerks at one medical school: Frequency, usefulness, and difficulties SO ACADEMIC MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Clerkship Directors in Internal Medicine CY OCT, 2003 CL Savannah, GA ID STUDENTS AB Purpose To describe the reading habits of medicine clerks, which previously have not been well described. Understanding issues related to student reading habits may provide insights and opportunities for medical educators to develop methods to improve clerks' clinical clerkship experiences and their information literacy skills. Method The authors administered an 18-item survey tool to 120 students on their first inpatient internal medicine clerkships at the Johns Hopkins University School of Medicine in 2002-03. The questionnaire focused on issues related to what and how often they read during their basic medicine clerkship. Data were explored mainly with descriptive statistics. Results One hundred twelve of 120 (93%) medicine clerks completed the survey. Clerks reported reading for an average of 10.8 (SD 5.6) hours per week (median ten hours per week, range one to 30 hours per week). The most commonly used and useful reading sources were UpToDate(R) and test preparation textbooks. Approximately 30% of students reported substantial problems in reading about their patients. Limited data suggest that reading habits and learning methods vary by year of medical school. Clerks are given disparate advice on appropriate reading sources to consult by attending physicians, resident physicians, and fellow students. Conclusions Students spend significant amounts of time reading online sources during their medicine clerkship, especially UpToDate. Medical educators should become familiar with these sources and contribute to maximizing their effectiveness for students. Additional research focused on understanding how students build skills in information literacy and how educational programs can facilitate the development of those skills is needed. C1 Johns Hopkins Univ, Sch Med, Johns Hopkins Care Ctr, Johns Hopkins Bayview Med Ctr,Dept Med, Baltimore, MD 21224 USA. Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Leff, B (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Care Ctr, Johns Hopkins Bayview Med Ctr,Dept Med, John R Burton Pavil,5505 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM bleff@jhmi.edu NR 13 TC 10 Z9 12 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAY PY 2006 VL 81 IS 5 BP 489 EP 494 DI 10.1097/01.ACM.0000222273.90705.a6 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 039HK UT WOS:000237296400014 PM 16639211 ER PT J AU Liu, CF Campbell, DG Chaney, EF Li, YF McDonell, M Fihn, SD AF Liu, CF Campbell, DG Chaney, EF Li, YF McDonell, M Fihn, SD TI Depression diagnosis and antidepressant treatment among depressed VA primary care patients SO ADMINISTRATION AND POLICY IN MENTAL HEALTH LA English DT Article DE primary care patients; veterans; depression; antidepressant treatment; depression diagnosis ID RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; CASE-MIX MEASURES; COLLABORATIVE CARE; MAJOR DEPRESSION; MENTAL-DISORDERS; VETERANS HEALTH; LATE-LIFE; OUTCOMES; MANAGEMENT AB This study examined the extent to which 3559 VA primary care patients with depression symptomatology received depression diagnoses and/or antidepressant prescriptions. Symptomatology was classified as mild (13%), moderate (42%) or severe (45%) based on SCL-20 scores. Diagnosis and treatment was related to depression severity and other patient characteristics. Overall, 44% were neither diagnosed nor treated. Only 22% of those neither diagnosed nor treated for depression received treatment for other psychopathology. Depression treatment performance measures dependent on diagnoses and antidepressant prescriptions from administrative databases exclude undiagnosed patients with significant, treatable, symptomatology. C1 VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Liu, CF (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. NR 48 TC 21 Z9 21 U1 1 U2 1 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD MAY PY 2006 VL 33 IS 3 BP 331 EP 341 DI 10.1007/s10488-006-0043-5 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 055RE UT WOS:000238467200008 PM 16755394 ER PT J AU Durazzo, TC Rothlind, JC Gazdzinski, S Banys, P Meyerhoff, DJ AF Durazzo, Timothy C. Rothlind, Johannes C. Gazdzinski, Stefan Banys, Peter Meyerhoff, Dieter J. TI A comparison of neurocognitive function in nonsmoking and chronically smoking short-term abstinent alcoholics SO ALCOHOL LA English DT Article DE alcoholism; alcohol dependence; chronic cigarette smoking; neurocognition; abstinence ID CEREBRAL BLOOD-FLOW; CHRONIC CIGARETTE-SMOKING; COGNITIVE PERFORMANCE; ALZHEIMERS-DISEASE; FEMALE ALCOHOLICS; MAJOR DEPRESSION; CONSUMPTION; DEPENDENCE; RISK; EFFICIENCY AB Approximately 70-90% of individuals in North America seeking treatment for alcoholism are chronic smokers. A growing body of evidence suggests chronic cigarette smoking alone adversely affects neurocognition in adults. However, few studies on the neurocognitive function of short-term abstinent alcoholics have specifically considered the potential effects of chronic cigarette smoking. In this study, 20 nonsmoking recovering alcoholics (nsRA) and 22 actively smoking recovering alcoholics (sRA) participants, matched on age and education, were contrasted on a comprehensive neurocognitive battery after 34 +/- 9 days of abstinence. nsRA were superior to sRA on measures of auditory-verbal learning and memory, processing speed, cognitive efficiency, and static postural stability. These group differences were not a function of group disparities in age, education, estimated premorbid verbal intelligence, lifetime alcohol consumption, or other measured comorbid psychiatric or medical factors. In sRA, longer smoking duration was negatively correlated with executive skills, visuospatial learning, general cognitive efficiency, and static postural stability. These results indicate that greater consideration of the potential neurobiological effects of current chronic smoking on neurocognitive functioning is warranted in studies of alcoholism and other conditions where smoking is a common comorbid factor. (c) 2006 Elsevier Inc. All rights reserved. C1 San Francisco Vet Adm Med Ctr, Ctr Imaging & Neurodegenerat Dis 114M, San Francisco, CA 94116 USA. No Calif Inst Res & Educ, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging & Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94116 USA. EM timothy.durazzo@ucsf.edu FU NIAAA NIH HHS [AA10788] NR 76 TC 36 Z9 36 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 J9 ALCOHOL JI Alcohol PD MAY PY 2006 VL 39 IS 1 BP 1 EP 11 DI 10.1016/j.alcohol.2006.06.006 PG 11 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 083RF UT WOS:000240475200001 PM 16938624 ER PT J AU Cavusoglu, E Ruwende, C Chopra, V Yanamadala, S Eng, C Clark, LT Pinsky, DJ Marmur, JD AF Cavusoglu, E Ruwende, C Chopra, V Yanamadala, S Eng, C Clark, LT Pinsky, DJ Marmur, JD TI Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction SO AMERICAN HEART JOURNAL LA English DT Article ID SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; ATHEROSCLEROTIC LESIONS; ENDOTHELIAL-CELLS; EXPRESSION; PLAQUE; GELATINASE; HEART; GENE; MICE AB Background Matrix metalloproteinases and their inhibitors have been implicated in both vascular and ventricular remodeling, and in atherosclerotic plaque rupture. The prognostic value of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) levels in patients with established or suspected coronary artery disease is unknown. Methods Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 (MMP-9) levels, along with a number of other established biomarkers, were measured in 389 male patients undergoing coronary angiography at a Veterans Administration Medical Center. The patients were then followed prospectively for the occurrence of all-cause mortality, cardiac mortality, and myocardial infarction (MI). Results Follow-up data at 24 months were available for 97% of the patients. For the entire cohort of patients, TIMP-1 was the only biomarker to independently predict all-cause mortality and MI. In addition, the ratio of TIMP-1 to matrix metalloproteinase-9 was independently predictive of cardiac mortality at 24 months. The 24-month survival rates for patients in the lower quartile (< 66.5 ng/mL), interquartile (66.5-100 ng/mL), and upper quartile (> 100 ng/mL) of plasma TIMP-1 values were 95.3%, 89.3%, and 72.2%, respectively (P < .001). Furthermore, when patients with chest pain were risk stratified into those with and without an acute coronary syndrome, TIMP-1 remained an independent predictor of all-cause mortality in both subgroups. Conclusions In a cohort of male patients undergoing coronary angiography, a single baseline determination of plasma TIMP-1 is independently predictive of the subsequent risk of death and MI. C1 SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. Bronx Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Marmur, JD (reprint author), SUNY Hlth Sci Ctr, Dept Med, 450 Clarkson Ave,Box 1257, Brooklyn, NY 11203 USA. EM jonathan@marmur.com NR 26 TC 17 Z9 17 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAY PY 2006 VL 151 IS 5 AR e8 DI 10.1016/j.ahj.2006.02.029 PG 15 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 043YF UT WOS:000237638200034 ER PT J AU Chang, L Chey, WD Harris, L Olden, K Surawicz, C Schoenfeld, P AF Chang, L Chey, WD Harris, L Olden, K Surawicz, C Schoenfeld, P TI Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; RECEPTOR ANTAGONIST ALOSETRON; 5-HT3 ANTAGONIST; COLON ISCHEMIA; EFFICACY; WOMEN; SAFETY; IMPROVEMENT; SYNDROME/; FEMALE AB BACKGROUND: Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies. This systematic review calculated the incidence of these adverse events in alosetron-using patients in clinical trials and post-marketing surveillance. METHODS: A panel of experts in epidemiology and functional bowel disorders reviewed clinical trial report forms and FDA MedWatch forms of each reported case of ischemic colitis or serious complications of constipation. Experts were blinded about whether patients used alosetron or placebo. Using pre-specified criteria, experts rated the likelihood of an accurate diagnosis and an association between medication use and adverse events. Cases that were not consistent with the reported diagnosis or not possibly associated with medication use were eliminated from calculation of incidence rates of adverse events. RESULTS: Pooled data from clinical trials indicate an increased rate of ischemic colitis among alosetron-using patients compared to placebo-using patients (0.15% vs 0.0%, respectively, p = 0.03), but there was no significant difference in the rate of serious complications of constipation. All (19/19) alosetron-using patients with ischemic colitis had reversible colitis without long-term sequelae. Based on post-marketing surveillance data, the post-adjudication rate of ischemic colitis is 1.1 per 1,000 patient-years of alosetron use and the rate of serious complications of constipation is 0.66 per 1,000 patient-years of alosetron use. CONCLUSION: The incidence of ischemic colitis and serious complications of constipation is very low and is rarely associated with long-term sequelae or serious morbidity. C1 Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI 48109 USA. Mayo Clin Scottsdale, Dept Gastroenterol, Scottsdale, AZ USA. Univ S Alabama, Sch Med, Div Gastroenterol, Mobile, AL 36688 USA. Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA 98195 USA. Vet Affairs Ctr Excellence Hlth Serv Res, Ann Arbor, MI USA. RP Schoenfeld, P (reprint author), VA Ann Arbor Healthcare Syst 111D, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. NR 31 TC 75 Z9 77 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2006 VL 101 IS 5 BP 1069 EP 1079 DI 10.1111/j.1572-0241.2006.00459.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 041NQ UT WOS:000237463300024 PM 16606352 ER PT J AU Sherman, SE Yano, EM York, LS Lanto, AB Chernof, BA Mittman, BS AF Sherman, SE Yano, EM York, LS Lanto, AB Chernof, BA Mittman, BS TI Assessing the structure of smoking cessation care in the veterans health administration SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE smoking cessation; health care quality assessment; practice guidelines; organizational structure; survey methods; questionnaires; structure of care; quality measurement; veterans; guidelines; prevention research; manuscript format : research; research purpose : instrument development; study design : quasi-experimental; outcome measure : behavioral; setting : clinical/health care; health focus : smoking control; strategy : policy; target population : adults in a health care system AB Purpose. National smoking cessation practice guidelines offer recommendations regarding the processes and structure of care. Facilities routinely measure the processes of care but not the structure of care. This pilot study assessed the structure of smoking cessation care at Veterans Health Administration facilities. Methods. Key informants at 18 sites completed a brief checklist survey adapted from national smoking cessation guidelines. Responses were compared with detailed, site surveys. Results. Guideline adherence was seen in identifying smokers and treating inpatient smokers. Areas of low adherence include offering incentives and defining staff responsibilities. The checklist survey showed poor correspondence with the detailed survey with low agreement on systematic screening (kappa = .21) and higher agreement on primary care prescribing authority (kappa = .53). Discussion. This pilot survey provides a potential rapid method for assessing adherence to systems recommendations from the national smoking cessation guidelines. The relatively low agreement with a more detailed. survey suggests that the two surveys may have been. measuring different aspects of smoking cessation care. C1 VA Greater Los Angeles HSR&D Ctr Excellence, Vet Adm Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. HealthNet, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. RP Sherman, SE (reprint author), VA Greater Los Angeles HSR&D Ctr Excellence, Vet Adm Greater Los Angeles Healthcare Syst, 16111 Plummer St,Mailstop 152, Sepulveda, CA 91343 USA. EM ssherman@ucla.edu NR 7 TC 3 Z9 3 U1 0 U2 0 PU AMER J HEALTH PROMOTION INC PI KEEGO HARBOR PA 1660 CASS LAKE RD, STE 104, KEEGO HARBOR, MI 48320 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD MAY-JUN PY 2006 VL 20 IS 5 BP 313 EP 318 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 041WL UT WOS:000237487100003 PM 16706001 ER PT J AU Sales, AE Helfrich, CD AF Sales, AE Helfrich, CD TI Value in development of complex interventions SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Editorial Material ID QUALITY IMPROVEMENT; SCIENCE C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. RP Sales, AE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1880 S Columbia Way, Seattle, WA 98108 USA. EM ann.sales@med.va.gov RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 NR 10 TC 1 Z9 1 U1 1 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAY PY 2006 VL 12 IS 5 BP 253 EP 254 PG 2 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 041WS UT WOS:000237487800001 PM 16686581 ER PT J AU Adams, SG Pugh, JA Kazis, LE Lee, S Anzueto, A AF Adams, SG Pugh, JA Kazis, LE Lee, S Anzueto, A TI Characteristics associated with sustained abstinence from smoking among patients with COPD SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE chronic obstructive pulmonary disease; tobacco use disorder; former and current smokers; mental health; cardiovascular disease ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; PRIMARY-CARE; VETERANS-HEALTH; MENTAL-ILLNESS; LUNG HEALTH; EX-SMOKERS; CESSATION; POPULATION; PREDICTORS AB PURPOSE: Smoking cessation is the mainstay of recommended treatment for chronic obstructive pulmonary disease (COPD), yet many continue smoking. This study seeks to understand the characteristics of patients with COPD who have quit and those who have not quit to identify important factors to evaluate in smoking-cessation interventions. SUBJECTS/METHODS: A cross-sectional survey of a random sample of 1.5 million, predominantly male Veterans Administration enrollees. Of the respondents (63% [n = 887 775]), those with at least 1 COPD visit, a smoking history, and aged more than 34 years were included in this analysis (n = 89 337). Differences in demographics, functional status, comorbidities, and provider-patient interactions were evaluated for current and former smokers. RESULTS: Ninety-seven percent of the cohort with COPD was male. Former smokers (n = 58 482) were older (mean age of 69.6 vs 62.8, P <. 001) and had more cardiac comorbidities, but better mental health ( Mean Mental Component Summary score from the Veterans Short Form-36 +/- standard deviation of 43.4 +/- 13.2 vs 39.9 +/- 13.7, P < .001) than current smokers (n = 25 595), respectively. In addition, former smokers more actively participated in their health care and had a better relationship with their provider than current smokers. CONCLUSION: Former smokers with COPD were older, had more cardiac comorbidities, better mental health, and better perceived provider - patient interactions than active smokers. This study highlights the importance of screening participants with COPD who are enrolling in forthcoming smoking cessation trials for mental illnesses. In addition, developing interventions that address psychiatric comorbidities and potentially improve provider-patient communication may be other key areas to evaluate in future smoking cessation trials in patients with COPD. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Pulm Div Critical Care Med, Dept Med, San Antonio, TX USA. S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. Boston Univ, Sch Publ Hlth, VAMC, Ctr Hlth Qual Outcomes & Econ Res, Boston, MA USA. Boston Univ, Sch Publ Hlth, Hlth Outcomes Technol, Boston, MA USA. RP Adams, SG (reprint author), Audie L Murphys Mem Vet Hosp, Pulm Dis Sect, 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM adamssg@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X NR 43 TC 7 Z9 7 U1 1 U2 2 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY PY 2006 VL 119 IS 5 BP 441 EP 447 DI 10.1016/jamjmed.2005.09.055 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 038LO UT WOS:000237221900012 PM 16651057 ER PT J AU Spiegel, BMR Farid, M Dulai, GS Gralnek, IM Kanwal, F AF Spiegel, BMR Farid, M Dulai, GS Gralnek, IM Kanwal, F TI Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: A meta-analysis SO AMERICAN JOURNAL OF MEDICINE LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/106th Annual Meeting of the American-Gastroenterological-Association CY MAY 14-19, 2005 CL Chicago, IL SP Amer Gastroenterol Assoc DE Cox-2 inhibitors; proton pump inhibitors; dyspepsia; meta-analysis ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; GASTRODUODENAL ULCERS; GASTROINTESTINAL TOXICITY; CYCLOOXYGENASE-2 INHIBITOR; REDUCED INCIDENCE; CLINICAL-TRIAL AB PURPOSE: Because dyspeptic symptoms are far more prevalent than ulcer complications in users of nonsteroidal anti-inflammatory drugs (NSAIDs), economic models indicate that dyspepsia rates (not ulcer complications) are the major determinant of cost-effectiveness in treating arthritis. We performed a meta-analysis to compare rates of dyspepsia for two common therapies in high-risk patients with arthritis: cyclooxygenase-2 inhibitor (Coxib) alone and combination therapy with a nonselective NSAID and a proton pump inhibitor (PPI) (NSAID+PPI). METHODS: We performed a systematic review to identify trials comparing either a Coxib versus NSAID or NSAID+PPI versus NSAID in chronic arthritis. We selected studies that report incident dyspepsia, defined a priori as "epigastric pain," "dyspepsia," and "nausea." We then performed meta-analysis to compare the relative risk reduction and absolute risk reduction of dyspepsia for Coxib versus NSAID and NSAID + PPI versus NSAID. RESULTS: Meta-analysis of 26 studies comparing dyspepsia between Coxibs and NSAIDs revealed a 12% relative risk reduction for Coxibs with an absolute risk reduction of 3.7%. Meta-analysis of four studies comparing dyspepsia between the NSAID + PPI combination and NSAIDs alone revealed a 66% relative risk reduction for NSAID + PPI with an absolute risk reduction of 9%. Compared with the NSAID strategy, the number needed to treat to prevent dyspepsia was 27 for Coxibs and 11 for NSAID + PPI. CONCLUSION: NSAID + PPI affords greater risk reduction for dyspepsia than Coxibs when compared with the common baseline of NSAIDs. Because there are limited head-to-head data comparing Coxibs versus NSAID + PPI, these data provide the best indirect evidence that NSAID + PPI may be superior to Coxibs in minimizing incident dyspepsia. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CORE,Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Vet Affairs Ctr Outcomes Res & Educ, Los Angeles, CA USA. CURE, Digest Dis Res Ctr, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, CORE,Div Gastroenterol & Hepatol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu NR 51 TC 2 Z9 2 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAY PY 2006 VL 119 IS 5 DI 10.1016/j.amjmed.2005.11.020 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 038LO UT WOS:000237221900015 ER PT J AU Chiou-Tan, FY Keng, MJ Graves, DE Chan, KT Rintala, DH AF Chiou-Tan, FY Keng, MJ Graves, DE Chan, KT Rintala, DH TI Racial/ethnic differences in FIM (TM) scores and length of stay for underinsured patients undergoing stroke inpatient rehabilitation SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE stroke; race; ethnicity; FIM; underinsured; rehabilitation ID NORTHERN MANHATTAN STROKE; WHITE; BLACK; RACE AB Objective: To explore racial/ethnic differences in FIM (TM) data from admission to discharge in underinsured patients undergoing inpatient stroke rehabilitation. Design: This is a retrospective analysis of the Uniform Data System for Medical Rehabilitation (UDSMR (R)) database of an inpatient rehabilitation unit of a county hospital in a large urban city. Data included 171 adult patients admitted to the stroke rehabilitation unit between January 2000 and October 2003. Main outcome measures included admission and discharge total FIM (TM) score, FIM (TM) gain, FIM (TM) efficiency, and length of stay (LOS). Data were analyzed using chi(2) analyses, t tests, univariate analysis of variance, binary logistic regression, and hierarchical multiple regression. Results: Data from 68 Hispanic, 83 black, and 20 white patients were included in the study. Univariate tests revealed that race/ethnicity groups differed significantly on admission FIM (TM) score (F = 5.38, P < 0.005), FIM (TM) gain (F = 4.35, P < 0.014), and FIM (TM) efficiency (F = 3.42, P < 0.035). Post hoc pairwise comparisons revealed that Hispanics had lower admission FIM (TM) scores than blacks (58.9 vs. 68.9). However, Hispanics had higher FIM (TM) gain scores than blacks (26.8 vs. 21.5). Race/ethnicity was not significantly related to age, gender, side of stroke, type of stroke, time from onset of stroke to rehabilitation admission, discharge FIM (TM) score, or LOS. Multiple regression analyses revealed that after controlling for all other available factors, race/ethnicity accounted for a significant amount of additional variance in admission FIM (TM) score (5.8%) and FIM (TM) efficiency (4.6%), but not in discharge FIM (TM) score, FIM (TM) gain, or LOS. Race/ethnicity was not predictive of discharge disposition. Conclusions: Differences in functional independence at admission to poststroke rehabilitation and the average daily improvement in function are related, in part, to patients' race/ethnicity. Differences in change in functional independence from admission to discharge (FIM (TM) gain) are not related to race/ethnicity once other factors, particularly admission FIM (TM) score, are taken into account. Future studies should identify reasons why Hispanics have lower admission FIM (TM) scores because demographic and stroke-related variables were not related to ethnicity yet have outcomes similar to blacks and whites at discharge. C1 Quentin Mease Hosp, Dept Phys Med & Rehabil, Harris Cty Hosp Dist, Ctr Trauma Rehabil Res, Houston, TX 77004 USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Inst Rehabil Res, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Chiou-Tan, FY (reprint author), Quentin Mease Hosp, Dept Phys Med & Rehabil, Harris Cty Hosp Dist, Ctr Trauma Rehabil Res, Suite 240,3601 N MacGregor Way, Houston, TX 77004 USA. NR 10 TC 19 Z9 20 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAY PY 2006 VL 85 IS 5 BP 415 EP 423 DI 10.1097/01.phm.0000214320.99729.f3 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 037QG UT WOS:000237161300001 PM 16628148 ER PT J AU Zhang, BX Ma, XY Zhang, WK Yeh, CK Lin, A Luo, J Sprague, EA Swerdlow, RH Katz, MS AF Zhang, BX Ma, XY Zhang, WK Yeh, CK Lin, A Luo, J Sprague, EA Swerdlow, RH Katz, MS TI Polyunsaturated fatty acids mobilize intracellular Ca(2+) in NT2 human teratocarcinoma cells by causing release of Ca(2+) from mitochondria SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE arachidonic acid; mitochondrial Ca(2+) uniporter; G protein-coupled receptor; IP(3) receptor ID ARACHIDONIC-ACID; PERMEABILITY TRANSITION; NADPH OXIDASE; GROWTH-FACTOR; 2-AMINOETHOXYDIPHENYL BORATE; EICOSAPENTAENOIC ACID; ENDOPLASMIC-RETICULUM; DOCOSAHEXAENOIC ACID; SYMPATHETIC NEURONS; CARDIAC MYOCYTES AB In a variety of disorders, overaccumulation of lipid in nonadipose tissues, including the heart, skeletal muscle, kidney, and liver, is associated with deterioration of normal organ function, and is accompanied by excessive plasma and cellular levels of free fatty acids (FA). Increased concentrations of FA may lead to defects in mitochondrial function found in diverse diseases. One of the most important regulators of mitochondrial function is mitochondrial Ca(2+)([Ca2(+)](m)), which fluctuates in coordination with intracellular Ca(2+)([Ca(2+)](i)). Polyunsaturated FA (PUFA) have been shown to cause [Ca(2+)](i) mobilization albeit by unknown mechanisms. We have found that PUFA but not monounsaturated or saturated FA cause [Ca(2+)](i) mobilization in NT2 human teratocarcinoma cells. Unlike the [Ca(2+)](i) response to the muscarinic G protein-coupled receptor agonist carbachol, PUFA-mediated [Ca(2+)](i) mobilization in NT2 cells is independent of phospholipase C and inositol-1,4,5-trisphospate (IP(3)) receptor activation, as well as IP(3)-sensitive internal Ca(2+) stores. Furthermore, PUFA-mediated [Ca(2+)](i) mobilization is inhibited by the mitochondria uncoupler carboxyl cyanide m-chlorophenylhydrozone. Direct measurements of [Ca(2+)](m) with X-rhod-1 and (45)Ca(2+) indicate that PUFA induce Ca(2+) efflux from mitochondria. Further studies show that ruthenium red, an inhibitor of the mitochondrial Ca(2+) uniporter, blocks PUFA-induced Ca(2+) efflux from mitochondria, whereas inhibitors of the mitochondrial permeability transition pore cyclosporin A and bongkrekic acid have no effect. Thus PUFA-gated Ca(2+) release from mitochondria, possibly via the Ca(2+) uniporter, appears to be the underlying mechanism for PUFA-induced [Ca(2+)](i) mobilization in NT2 cells. C1 GRECC 182, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Virginia, Hlth Sci Ctr, Dept Neurol, Charlottesville, VA 22908 USA. RP Zhang, BX (reprint author), GRECC 182, S Texas Vet Hlth Care Syst, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM zhangb2@uthscsa.edu FU NHLBI NIH HHS [R01 HL 75011] NR 79 TC 16 Z9 17 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD MAY PY 2006 VL 290 IS 5 BP C1321 EP C1333 DI 10.1152/ajpcell.00335.2005 PG 13 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 037JN UT WOS:000237143000006 PM 16601147 ER PT J AU Page, ST Plymate, SR Bremner, WJ Matsumoto, AM Hess, DL Lin, DW Amory, JK Nelson, PS Wu, JD AF Page, ST Plymate, SR Bremner, WJ Matsumoto, AM Hess, DL Lin, DW Amory, JK Nelson, PS Wu, JD TI Effect of medical castration on CD4(+) CD25(+) T cells, CD8(+) T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE testosterone replacement; gonadotropin; releasing hormone antagonist; regulatory T cells; interferon-gamma ID NATURAL-KILLER-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMMUNOLOGICAL FEATURES; KLINEFELTERS-SYNDROME; AUTOIMMUNE-DISEASES; HORMONE ANTAGONIST; INTERFERON-GAMMA; SEX STEROIDS; ESTROGEN; IMMUNE AB The higher prevalence of autoimmune disease among women compared with men suggests that steroids impact immune regulation. To investigate how sex steroids modulate cellular immune function, we conducted a randomized trial in 12 healthy men aged 35 - 55 yr treated for 28 days with placebo, a GnRH antagonist, acyline to induce medical castration, or acyline plus daily testosterone (T) gel to replace serum T, followed by a 28-day recovery period. Serum hormones were measured weekly and peripheral blood lymphocytes (PBLs) were collected biweekly for analyses of thymus-derived lymphocyte (T cell) subtypes and natural killer (NK) cells. Compared with the other groups and to baseline throughout the drug exposure period, men receiving acyline alone had significant reductions in serum T ( near or below castrate levels), dihydrotestosterone, and estradiol (P < 0.05). Medical castration significantly reduced the percentage of CD4(+) CD25(+) T cells (P < 0.05), decreased mitogen-induced CD8(+) T cell IFN-gamma expression, and increased the percentage of NK cells without affecting the ratio of CD4(+) to CD8(+) T cells and the expression of NK cell-activating receptor NKG2D or homing receptor CXCR1. No changes in immune composition were observed in subjects receiving placebo or acyline with replacement T. These data suggest that T and/or its metabolites may help maintain the physiological balance of autoimmunity and protective immunity by preserving the number of regulatory T cells and the activation of CD8(+) T cells. In addition, sex steroids suppress NK cell proliferation. This study supports a complex physiological role for T and/or its metabolites in immune regulation. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Natl Oregon Primate Res Ctr, Beaverton, OR USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Wu, JD (reprint author), 325 9th Ave,Box 359625, Seattle, WA 98104 USA. EM wuj@u.washington.edu FU NCI NIH HHS [K01 CA116002, P01 CA-85859, CA-97186]; NCRR NIH HHS [RR-00163]; NIA NIH HHS [K23 AG027238, K23 AG027238-01A1]; NICHD NIH HHS [U54 HD-12629, U54 HD-42454] NR 49 TC 53 Z9 58 U1 0 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAY PY 2006 VL 290 IS 5 BP E856 EP E863 DI 10.1152/ajpendo.00484.2005 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 036EJ UT WOS:000237053500012 PM 16352669 ER PT J AU Xu, Y Lu, L Greyson, C Rizeq, M Nunley, K Wyatt, B Bristow, MR Long, CS Schwartz, GG AF Xu, Y Lu, L Greyson, C Rizeq, M Nunley, K Wyatt, B Bristow, MR Long, CS Schwartz, GG TI The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE nuclear receptor; fibric acid derivative; energy metabolism; cytokine; ventricular function ID RECEPTOR-ALPHA; ISCHEMIA/REPERFUSION INJURY; PEROXISOME PROLIFERATION; ENERGY-METABOLISM; GAMMA; RAT; LIGAND; CELLS; HEART; RESPONSIVENESS AB Rodent studies suggest that peroxisome proliferator-activated receptor-alpha ( PPAR-alpha) activation reduces myocardial ischemia-reperfusion (I/R) injury and infarct size; however, effects of PPAR-alpha activation in large animal models of myocardial I/R are unknown. We determined whether chronic treatment with the PPAR-alpha activator fenofibrate affects myocardial I/R injury in pigs. Domestic farm pigs were assigned to treatment with fenofibrate 50 mg . kg(-1) . day(-1) orally or no drug treatment, and either a low-fat (4% by weight) or a high-fat (20% by weight) diet. After 4 wk, 66 pigs underwent 90 min low-flow regional myocardial ischemia and 120 min reperfusion under anesthetized open-chest conditions, resulting in myocardial stunning. The high-fat group received an infusion of triglyceride emulsion and heparin during this terminal experiment to maintain elevated arterial free fatty acid (FFA) levels. An additional 21 pigs underwent 60 min no-flow ischemia and 180 min reperfusion, resulting in myocardial infarction. Plasma concentration of fenofibric acid was similar to the EC50 for activation of PPAR-alpha in vitro and to maximal concentrations achieved in clinical use. Myocardial expression of PPAR-alpha mRNA was prominent but unaffected by fenofibrate treatment. Fenofibrate increased expression of carnitine palmitoyltransferase (CPT)-I mRNA in liver and decreased arterial FFA and lactate concentrations ( each P < 0.01). However, fenofibrate did not affect myocardial CPT-I expression, substrate uptake, lipid accumulation, or contractile function during low-flow I/R in either the low-or high-fat group, nor did it affect myocardial infarct size. Despite expression of PPAR-alpha in porcine myocardium and effects of fenofibrate on systemic metabolism, treatment with this PPAR-alpha activator does not alter myocardial metabolic or contractile responses to I/R in pigs. C1 Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 111B,1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@med.va.gov RI bristow, michael/G-7850-2011 FU NHLBI NIH HHS [HL-49944, HL-68606, R01 HL049944, R01 HL049944-09, R01 HL068606, R56 HL049944] NR 38 TC 13 Z9 13 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAY PY 2006 VL 290 IS 5 BP H1798 EP H1807 DI 10.1152/ajpheart.00631.2005 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 030WD UT WOS:000236664900012 PM 16339839 ER PT J AU Kaunitz, JD AF Kaunitz, JD TI Membrane transport proteins: not just for transport anymore SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Editorial Material ID NA+/K+-ATPASE; OUABAIN; PLASMA; CFTR C1 Univ Calif Los Angeles, Sch Med, Dept Med, W Los Angeles Vet Affairs Med Ctr,Med Serv, Los Angeles, CA 90073 USA. CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, W Los Angeles Vet Affairs Med Ctr,Med Serv, Bldg 114,Suite 217, Los Angeles, CA 90073 USA. EM jake@ucla.edu NR 16 TC 7 Z9 7 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAY PY 2006 VL 290 IS 5 BP F995 EP F996 DI 10.1152/ajprenal.00515.2005 PG 2 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 029YT UT WOS:000236601000005 PM 16601299 ER PT J AU Xu, HS Fu, Y Tian, W Cohen, DM AF Xu, HS Fu, Y Tian, W Cohen, DM TI Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 on Asn-651 influences membrane trafficking SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE cell volume regulation; hypotonicity; ion channel ID SHAKER POTASSIUM CHANNEL; REGULATING FACTOR NHERF2; CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; SMOOTH-MUSCLE-CELLS; SODIUM-CHANNELS; CATION CHANNEL; PLASMA-MEMBRANE; XENOPUS-OOCYTES; TRPC6 CHANNEL AB We identified a consensus N-linked glycosylation motif within the pore-forming loop between the fifth and sixth transmembrane segments of the osmoresponsive transient receptor potential (TRP) channel TRPV4. Mutation of this residue from Asn to Gln (i.e., TRPV4(N651Q)) resulted in loss of a slower migrating band on anti-TRPV4 immunoblots and a marked reduction in lectin-precipitable TRPV4 immunoreactivity. HEK293 cells transiently transfected with the mutant TRPV4(N651Q) exhibited increased calcium entry in response to hypotonic stress relative to wild-type TRPV4 transfectants. This increase in hypotonicity responsiveness was associated with an increase in plasma membrane targeting of TRPV4(N651Q) relative to wild-type TRPV4 in both HEK293 and COS-7 cells but had no effect on overall channel abundance in whole cell lysates. Residue N651 of TRPV4 is immediately adjacent to the pore-forming loop. Although glycosylation in this vicinity has not been reported for a TRP channel, the structurally related hexahelical hyperpolarization-activated cyclic nucleotide-gated channel, HCN2, and the voltage-gated potassium channel, human ether-a-go-go-related ( HERG), share a nearly identically situated and experimentally confirmed N-linked glycosylation site which promotes rather than limits channel insertion into the plasma membrane. These data point to a potentially conserved structural and functional feature influencing membrane trafficking across diverse members of the voltage-gated-like ion channel superfamily. C1 Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Mailcode PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu NR 57 TC 38 Z9 40 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAY PY 2006 VL 290 IS 5 BP F1103 EP F1109 DI 10.1152/ajprenal.00245.2005 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 029YT UT WOS:000236601000017 PM 16368742 ER PT J AU Wright, T Myrick, H Henderson, S Peters, H Malcolm, R AF Wright, T Myrick, H Henderson, S Peters, H Malcolm, R TI Risk factors for delirium tremens: A retrospective chart review SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Review ID ALCOHOL-WITHDRAWAL DELIRIUM; PRACTICE GUIDELINE; USE DISORDERS; DETOXIFICATION; MANAGEMENT; DIAGNOSIS; DRINKING; DRUGS AB A retrospective chart review was performed within an inpatient VA hospital setting in an attempt to identify risk factors for delirium tremens (DTs). Cases of delirium tremens were compared to cases where patients' alcohol withdrawal during hospitalization did not progress to DTs. Significant differences were found in regard to prior histories of DTs and laboratory values at admission. The amount and duration of benzodiazepine use during hospitalization, antipsychotic use during hospitalization, and length of hospitalization were also statistically different between the groups. While not reaching statistical significance, there were differences in reason for admission and relapse rate upon follow-up between the groups. C1 Med Univ S Carolina, Inst Psychiat 4N, Alcohol Res Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affiars Med Ctr, Res & Dev Serv, Charleston, SC USA. RP Wright, T (reprint author), Med Univ S Carolina, Inst Psychiat 4N, Alcohol Res Ctr, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA. EM wright@musc.edu FU NIAAA NIH HHS [K23 AA00314, K24 AA013314, P50 AA10761] NR 36 TC 17 Z9 18 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAY-JUN PY 2006 VL 15 IS 3 BP 213 EP 219 DI 10.1080/10550490600625798 PG 7 WC Substance Abuse SC Substance Abuse GA 038LI UT WOS:000237221100003 PM 16923667 ER PT J AU Williams, EC Kivlaban, DR Saitz, R Merrill, JO Achtmeyer, CE McCormick, KA Bradley, KA AF Williams, EC Kivlaban, DR Saitz, R Merrill, JO Achtmeyer, CE McCormick, KA Bradley, KA TI Readiness to change in primary care patients who screened positive for alcohol misuse SO ANNALS OF FAMILY MEDICINE LA English DT Article DE alcohol drinking; alcoholism/diagnosis; patient acceptance of health care ID BEHAVIORAL-COUNSELING INTERVENTIONS; PROBLEM DRINKING; GENERAL-PRACTITIONERS; CONSUMPTION QUESTIONS; INTEGRATIVE MODEL; AUDIT; CAGE; DRINKERS; VALIDITY; HEALTH AB PURPOSE Readiness to change drinking may influence the content or effectiveness of brief alcohol counseling. This study was designed to assess readiness to change and its relationship to alcohol misuse severity among primary care patients whose screening questionnaire was positive for alcohol misuse. METHODS This study was a cross-sectional analysis of data collected from 2 consecutive mailed questionnaires. Male outpatients at 7 Veterans Affairs (VA) general medicine clinics were eligible if they returned both questionnaires, screened positive for alcohol misuse (augmented CAGE Questionnaire >= 1 point), responded to 3 readiness-to-change questions, and completed the Alcohol Use Disorders Identification Test (AUDIT). A validated algorithm based on 3 standardized questions categorized participants into 3 readiness groups (precontemplation, contemplation, action). Measures of alcohol misuse severity included AUDIT, CAGE, and the 3 consumption questions from the AUDIT (AUDIT-C). Analyses were descriptive; linear-by-linear associations between alcohol misuse severity and readiness were tested with chi(2) statistics. RESULTS Response rates to the first and second surveys were 59% and 55%, respectively. Of the 6,419 eligible outpatients who screened positive for alcohol misuse, 4,797 (75%) reported any readiness to change (contemplation 24%, action 51%). Among patients with AUDIT scores > 8, more than 90% indicated that they drank more than they should and/or had contemplated drinking less. Greater readiness was significantly associated with greater alcohol misuse severity (P <.001 for all measures). CONCLUSIONS Most primary care patients who screen positive for alcohol misuse indicate some readiness to change. Contrary to stereotypes of denial, those with greater alcohol misuse severity are more likely to report readiness to change. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. Univ Washington, Dept Behav Sci, Seattle, WA 98195 USA. Boston Univ, Sch Med, Dept Med, Clin Addict Res & Educ Unit, Boston, MA 02118 USA. Boston Med Ctr, Boston, MA USA. Boston Univ, Sch Publ Hlth, Youth Alcohol Prevent Ctr, Boston, MA USA. Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98101 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emwilli@u.washington.edu OI /0000-0002-2535-1427 FU NIAAA NIH HHS [K23AA00313] NR 45 TC 31 Z9 31 U1 0 U2 2 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672, UNITED STATES SN 1544-1709 J9 ANN FAM MED JI Ann. Fam. Med. PD MAY-JUN PY 2006 VL 4 IS 3 BP 213 EP 220 DI 10.1370/afm.542 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 053VT UT WOS:000238334700005 PM 16735522 ER PT J AU Gray, SL Odegard, PS Sales, AE Young, HM Sullivan, JH Hedrick, SC AF Gray, SL Odegard, PS Sales, AE Young, HM Sullivan, JH Hedrick, SC TI Quality of medication records and use of pharmacy resources in community residential care facilities SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE cohort study; community residential care; medication management ID DRUG; MANAGEMENT; BOARD AB BACKGROUND: In community residential care (CRC) facilities, medication administration is often performed by unlicensed personnel with minimal knowledge in medication use. Medication management is one of the top 3 quality-of-care issues facing these facilities. OBJECTIVE: To examine the type of medication assistance residents received, determine the proportion of facilities that used pharmacy resources, and examine the quality of facility medication records in CRC facilities (eg, adult family homes, adult residential care, assisted living facilities). METHODS: Baseline in-person interviews were conducted with 349 residents and 299 facility providers in the Puget Sound region of Washington. Information was also obtained from facility medication records at enrollment and state databases. A pharmacist determined quality of the records using a standardized form. RESULTS: The average resident was a 78-year-old white female taking 7 drugs. Medication records that were computer generated were significantly less likely to have misspelled names of drugs and errors in or absence of dose, directions for use, and route of administration. Overall, 26.3% of facilities reported that a consultant pharmacist reviewed residents' medication lists, 52.0% reported the use of preprinted lists, and 75.6% received prepackaged medications from the pharmacy. Adult family homes, the smallest facility type, were the least likely to use pharmacy-related services. CONCLUSIONS: The quality of handwritten medication records was a concern in CRC facilities. These facilities may benefit from services offered by pharmacies that may enhance medication management, many of which were underutilized. C1 Univ Washington, Sch Pharm, Geriatr Pharm Program, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Sch Nursing, Ashland, OR USA. RP Gray, SL (reprint author), Univ Washington, Sch Pharm, Geriatr Pharm Program, Box 357630, Seattle, WA 98195 USA. EM slgray@u.washington.edu RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 NR 22 TC 3 Z9 3 U1 2 U2 6 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAY PY 2006 VL 40 IS 5 BP 894 EP 899 DI 10.1345/aph.1G585 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 043KW UT WOS:000237600900011 PM 16638918 ER PT J AU Molitoris, D Vaeisanen, ML Bolanos, M Finegold, SM AF Molitoris, D Vaeisanen, ML Bolanos, M Finegold, SM TI In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID DES-FLUORO(6) QUINOLONE; GARENOXACIN; DES-F(6)-QUINOLONE AB The activity of DX-619 was evaluated against 376 anaerobic isolates using the reference CLSI agar dilution method. Overall, 90% of the strains were susceptible to DX-619 at <= 1 mu g/ml. It was more active than the other four compounds tested except for meropenem, which showed virtually identical overall activity. C1 VA Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA. RP Finegold, SM (reprint author), Greater Los Angeles VAMC, 11301 Wilshire Blvd,Bldg 304,Rm E3-237, Los Angeles, CA 90073 USA. EM sidfinegol@aol.com NR 10 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2006 VL 50 IS 5 BP 1887 EP 1889 DI 10.1128/AAC.50.5.1887-1889.2006 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 040FV UT WOS:000237365300045 PM 16641470 ER PT J AU Morasco, BJ Gfeller, JD Chibnall, JT AF Morasco, Benjamin J. Gfeller, Jeffrey D. Chibnall, John T. TI The relationship between measures of psychopathology, intelligence, and memory among adults seen for psychoeducational assessment SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE cognitive functioning; depression; MMPI-2; WMS-III; WAIS-III; assessment ID TEST-PERFORMANCE; TEST-SCORES; DEPRESSION; METAANALYSIS; ATTENTION; ANXIETY; TESTS AB This study assessed the relationship between symptoms of psychopathology and cognitive functioning in clients completing comprehensive psychoeducational assessments at a university-based outpatient mental health clinic. Seventy clients (36 women, 34 men, mean age = 28.8) completed the Wechsler Memory Scale - Third Edition (WMS-III), Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), and Minnesota Multiphasic Personality Inventory - Second Edition (MMPI-2). Partial correlations between the MMPI-2 clinical scales, WMS-III Index scores, WAIS-III Index scores, and WAIS-III IQ scores were not significant. Memory and Intelligence scores for clients with comorbid symptoms of depression and anxiety were comparable to scores for clients without comorbid symptomatology. Psychopathology factors accounted for 22% of the variance in the WAIS-III Full Scale IQ and 6.5% of the variance in the WMS-III General Memory Index. The results suggest that psychopathology as measured by the MMPI-2 may be minimally associated with intelligence and memory test performance in adults seen for psychoeducational assessment. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved. C1 Portland VA Med Ctr, Dept Behav Hlth & Clin Neurosci, Portland, OR 97239 USA. St Louis Univ, St Louis, MO 63103 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr, Dept Behav Hlth & Clin Neurosci, 3710 SW US Vet Hosp Rd,P3MHDC, Portland, OR 97239 USA. EM benjamin.morasco@med.va.gov NR 17 TC 5 Z9 5 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAY PY 2006 VL 21 IS 4 BP 297 EP 301 DI 10.1016/j.acn.2006.03.005 PG 5 WC Psychology, Clinical; Psychology SC Psychology GA 067GI UT WOS:000239289500006 PM 16777372 ER PT J AU Khachaturian, AS Zandi, PP Lyketsos, CG Hayden, KM Skoog, I Norton, MC Tschanz, JT Mayer, LS Welsh-Bohmer, KA Breitner, JCS AF Khachaturian, AS Zandi, PP Lyketsos, CG Hayden, KM Skoog, I Norton, MC Tschanz, JT Mayer, LS Welsh-Bohmer, KA Breitner, JCS CA Cache Cty Study Grp TI Antihypertensive medication use and incident Alzheimer disease - The Cache County Study SO ARCHIVES OF NEUROLOGY LA English DT Article ID AGED 75 YEARS; BLOOD-PRESSURE; COGNITIVE DECLINE; SYSTOLIC HYPERTENSION; VASCULAR DEMENTIA; POPULATION; POTASSIUM; OLDER; PREVENTION; STROKE AB Background: Recent reports suggest that antihypertensive (AH) medications may reduce the risk of dementing illnesses. Objectives: To examine the relationship of AH medication use with incidence of Alzheimer disease (AD) among the elderly population (aged 65 years and older) of Cache County, Utah, and to examine whether the relationship varies with different classes of AH medications. Methods: After an initial (wave 1) multistage assessment (1995 through 1997) to identify prevalent cases of dementia, we used similar methods 3 years later (wave 2) to identify 104 incident cases of AD among the 3308 survivors. At the baseline assessment, we obtained a detailed drug inventory from the study participants. We carried out discrete time survival analyses to examine the association between the use of AH medications (including angiotensin converting enzyme inhibitors, beta-blockers, calcium channel blockers, and diuretics) at baseline with subsequent risk of AD. Results: Use of any AH medication at baseline was associated with lower incidence of AD (adjusted hazard ratio, 0.64; 95% confidence interval, 0.41-0.98). Examination of medication subclasses showed that use of diuretics (adjusted hazard ratio, 0.57; 95% confidence interval, 0.33-0.94), and specifically potassium-sparing diuretics (adjusted hazard ratio, 0.26; 95% confidence interval, 0.08-0.64), was associated with the greatest reduction in risk of AD. Corresponding analysis with a fully examined subsample controlling for blood pressure measurements did not substantially change our findings. Conclusions: These data suggest that AH medications, and specifically potassium-sparing diuretics, are associated with reduced incidence of AD. Because the latter association is a new finding, it requires confirmation in further study. C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. Khachaturian & Associates Inc, Potomac, MD USA. Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Div Geriatr Psychiat, Baltimore, MD 21205 USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Ctr Study Aging & Human Dev, Durham, NC USA. Univ Gothenburg, Inst Clin Neurosci, Gothenburg, Sweden. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Utah State Univ, Dept Family Human & Consumer Sci, Logan, UT 84322 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Zandi, PP (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Hampton House,Room 857,624 N Broadway, Baltimore, MD 21205 USA. EM pzandi@jhsph.edu RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [AG 11380, R01 AG011380]; NIMH NIH HHS [MH 14592] NR 39 TC 187 Z9 192 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAY PY 2006 VL 63 IS 5 BP 686 EP 692 DI 10.1001/archneur.63.5.noc60013 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 041XQ UT WOS:000237490600007 PM 16533956 ER PT J AU Bogaert, YE Reusch, J Nemenoff, R AF Bogaert, YE Reusch, J Nemenoff, R TI Disruption of vascular calcification by PPAR gamma SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Meeting Abstract CT 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology CY APR 27-29, 2006 CL Denver, CO C1 UCHSC, Denver, CO USA. Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAY PY 2006 VL 26 IS 5 BP E97 EP E97 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 034PF UT WOS:000236942400339 ER PT J AU Bogaert, YE Grippa, J Nemenoff, R Reusch, J AF Bogaert, YE Grippa, J Nemenoff, R Reusch, J TI PI-3K dependent alterations in vascular smooth muscle cell (VSMC) function in response to type 1 collagen SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Meeting Abstract CT 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology CY APR 27-29, 2006 CL Denver, CO C1 UCHSC, Denver, CO USA. Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAY PY 2006 VL 26 IS 5 BP E76 EP E76 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 034PF UT WOS:000236942400225 ER PT J AU Green, DM Noble, PC Ahuero, JS Birdsall, HH AF Green, DM Noble, PC Ahuero, JS Birdsall, HH TI Cellular events leading to chondrocyte death after cartilage impact injury SO ARTHRITIS AND RHEUMATISM LA English DT Article ID NITRIC-OXIDE; ARTICULAR-CARTILAGE; TNF-ALPHA; TRANSENDOTHELIAL MIGRATION; GENE-EXPRESSION; IN-VITRO; APOPTOSIS; OXYGEN; INTERLEUKIN-1-BETA; ADHESION AB Objective. We undertook this study to test our postulate that leukocytes extend the zone of injury in cartilage after acute mechanical trauma. Methods. Fresh cadaveric canine femoral condyles were subjected to 20-25-MPa impact injury. Condyle explants or dispersed chondrocytes were cultured with autologous blood mononuclear leukocytes (MNLs). Viability of chondrocytes at varying distances from the impact site was assessed by trypan blue exclusion. Results. Mechanical injury caused a significant loss of viable chondrocytes over 7 days, even in cartilage > 10 mm from the impact site. After biomechanical stress, death of cells within 10 mm of the impact could be largely prevented by addition of N-G-monomethyl-Larginine to inhibit nitric oxide (NO) generation. Chondrocytes within 10 mm of the impact were also susceptible to killing by living MNLs, but not by incubation with the supernatants of endotoxin-activated MNLs. Chondrocytes in this vulnerable zone expressed intercellular adhesion molecule 1 (ICAM-1) (CD54), facilitating attachment of MNLs that localized adjacent to the chondrocytes. Leukocytes killed dispersed chondrocytes harvested from the impact zone by generation of reactive oxygen species. Leukocyte-mediated killing could be blocked by desferoxamine or by antibodies to CD18, which prevent attachment of leukocytes to ICAM1-expressing chondrocytes. Conclusion. Our data suggest that after mechanical injury, chondrocytes distant from the site may be killed through the generation of NO. Inflammatory leukocytes further extend the zone of chondrocyte death by adhering to chondrocytes expressing ICAM-1 and by inducing the accumulation of free oxygen radicals in the chondrocyte cytoplasm. Patients may benefit from therapies that reduce infiltration of inflammatory leukocytes into acutely injured cartilage. C1 Baylor Coll Med, Houston, TX 77030 USA. Methodist Hosp, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Res Off, Houston, TX 77030 USA. RP Birdsall, HH (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Res Off, MS 151,2002 Holcombe, Houston, TX 77030 USA. EM birdsall@bcm.tmc.edu FU NHLBI NIH HHS [HL-42550] NR 42 TC 28 Z9 30 U1 3 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD MAY PY 2006 VL 54 IS 5 BP 1509 EP 1517 DI 10.1002/art.21812 PG 9 WC Rheumatology SC Rheumatology GA 042MV UT WOS:000237533100020 PM 16649187 ER PT J AU Martinez-Juarez, IE Alonso, ME Medina, MT Duron, RM Bailey, JN Lopez-Ruiz, M Ramos-Ramirez, R Leon, L Pineda, G Castroviejo, IP Silva, R Mija, L Perez-Gosiengfiao, K Machado-Salas, J Delgado-Escueta, AV AF Martinez-Juarez, IE Alonso, ME Medina, MT Duron, RM Bailey, JN Lopez-Ruiz, M Ramos-Ramirez, R Leon, L Pineda, G Castroviejo, IP Silva, R Mija, L Perez-Gosiengfiao, K Machado-Salas, J Delgado-Escueta, AV TI Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up SO BRAIN LA English DT Article DE juvenile myoclonic epilepsy; subtypes; follow-up; classification ID IDIOPATHIC GENERALIZED EPILEPSY; ABSENCE EPILEPSY; PERSISTING ABSENCES; SEIZURES; CLASSIFICATION; LINKAGE; LOCUS; CHILDHOOD; PROGNOSIS; HETEROGENEITY AB The 2001 classification subcommittee of the International League Against Epilepsy (ILAE) proposed to 'group JME, juvenile absence epilepsy, and epilepsy with tonic clonic seizures only under the sole heading of idiopathic generalized epilepsies (IGE) with variable phenotype'. The implication is that juvenile myoclonic epilepsy (JME) does not exist as the sole phenotype of family members and that it should no longer be classified by itself or considered a distinct disease entity. Although recognized as a common form of epilepsy and presumed to be a lifelong trait, a long-term follow-up of JME has not been performed. To address these two issues, we studied 257 prospectively ascertained JME patients and encountered four groups: (i) classic JME (72%), (ii) CAE (childhood absence epilepsy) evolving to JME (18%), (iii) JME with adolescent absence (7%), and (iv) JME with astatic seizures (3%). We examined clinical and EEG phenotypes of family members and assessed clinical course over a mean of 11 +/- 6 years and as long as 52 years. Forty per cent of JME families had JME as their sole clinical phenotype. Amongst relatives of classic JME families, JME was most common (40%) followed by grand mal (GM) only (35%). In contrast, 66% of families with CAE evolving to JME expressed the various phenotypes of IGE in family members. Absence seizures were more common in family members of CAE evolving to JME than in those of classic JME families (P < 0.001). Female preponderance, maternal transmission and poor response to treatment further characterized CAE evolving to JME. Only 7% of those with CAE evolving to JME were seizure-free compared with 58% of those with classic JME (P < 0.001), 56% with JME plus adolescent pyknoleptic absence and 62% with JME plus astatic seizures. Long-term follow-up (1-40 years for classic JME; 5-52 years for CAE evolving to JME, 5-26 years for JME with adolescent absence and 3-18 years for JME with astatic seizures) indicates that all subsyndromes are chronic and perhaps lifelong. Seven chromosome loci, three epilepsy-causing mutations and two genes with single nucleotide polymorphisms (SNPs) associating with JME reported in literature provide further evidence for JME as a distinct group of diseases. C1 Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA. VA Los Angeles VA Med Ctr, VA GLAHS W Los Angeles, Epilepsy Ctr Excellence, Epilepsy Genet Genom Labs,Comprehens Epilepsy Pro, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci, Los Angeles, CA 90073 USA. Mexico Gen Hosp, Natl Inst Neurol & Neurosurg, Mexico City, DF, Mexico. Mexico Gen Hosp, Neurol & Neurosurg Unit, Mexico City, DF, Mexico. Angel Leanos Hosp, Guadalajara, Jalisco, Mexico. Natl Autonomous Univ Honduras, Tegucigalpa, Honduras. Univ Hosp La Paz, Madrid, Spain. Nuestra Senora La Paz Hosp, San Miguel, El Salvador. Inst Neurol Sci, Lima, Peru. RP Delgado-Escueta, AV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Comprehens Epilepsy Program, Epilepsy Genet Genom Labs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM escueta@ucla.edu OI Duron, Reyna M./0000-0002-9425-2289; Delgado-Escueta, Antonio V./0000-0002-1581-6999; Martinez-Juarez, Iris E./0000-0001-6512-5312 FU NINDS NIH HHS [R01-NS42376] NR 48 TC 71 Z9 72 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD MAY PY 2006 VL 129 BP 1269 EP 1280 DI 10.1093/brain/awl048 PN 5 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 035JV UT WOS:000236998000021 PM 16520331 ER PT J AU Martinez, V Wang, LX Tache, Y AF Martinez, Vicente Wang, Lixin Tache, Yvette TI Proximal colon distension induces Fos expression in the brain and inhibits gastric emptying through capsaicin-sensitive pathways in conscious rats SO BRAIN RESEARCH LA English DT Article DE proximal colon distension; Fos; brain; visceral pain; gastric emptying; capsaicin ID CORTICOTROPIN-RELEASING-FACTOR; IRRITABLE-BOWEL-SYNDROME; NOXIOUS VISCERAL STIMULUS; LUMBOSACRAL SPINAL-CORD; LOCUS-COERULEUS NEURONS; DORSAL MOTOR NUCLEUS; C-FOS; COLORECTAL DISTENSION; RECTAL DISTENSION; SOLITARY TRACT AB We assessed brain nuclei activated during noxious mechanical distension of the proximal colon in conscious rats, using Fos as a marker of neuronal activation, and functional reflex changes in gastric emptying associated to colon distension. The role of capsaicin-sensitive afferents in Fos and gastric: responses to distension was also investigated. Compared with sham distension, isovolumetric phasic distension of the proximal colon (10 ml, 30 s on/off for 10 min) increased significantly Fos expression 1 h after distension in selective brain areas, most prominently, the paraventricular and supraoptic nuclei of the hypothalamus (13-fold and 80-fold, respectively), the locus coeruleus-Barrington's nucleus complex (2-fold), area postrema (7-fold) and the nucleus tractus solitarius (4-fold). Increased Fos expression was also observed in the cingulate cortex, posterior paraventricular nucleus of the thalamus, periaqueductal gray and ventrolateral medulla. Distension of the proximal colon significantly inhibited gastric emptying by 82% and 34%, as measured 30 and 60 min after the distension respectively, compared with control. Pretreatment with systemic capsaicin prevented both the brain increase in Fos expression and the inhibition of gastric emptying induced by the colon distension. These results show that visceral pain arising from the proximal colon activates a complex neuronal network that includes specific brain nuclei involved in the integration of autonomic, neuroendocrine and behavioral responses to pain and an inhibitory motor reflex in other gut areas (delayed gastric emptying). Capsaicin-sensitive afferent pathways are involved in mediating brain neuronal activation and functional changes associated with noxious visceral stimulation. (c) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE,Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Wang, LX (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, CURE,Digest Dis Res Ctr, Los Angeles, CA 90073 USA. EM lixinw@ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [R01 DK-33061]; PHS HHS [DDK-P30 41301] NR 78 TC 25 Z9 27 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAY 1 PY 2006 VL 1086 BP 168 EP 180 DI 10.1016/j.brainres.2006.02.063 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 049FN UT WOS:000238001500020 PM 16626641 ER PT J AU Young, MRI Cigal, M AF Young, MRI Cigal, M TI Tumor skewing of CD34(+) cell differentiation from a dendritic cell pathway into endothelial cells SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE angiogenesis; angiopoietins; endothelial cells; tumor; vasculogenesis; VEGF ID COLONY-STIMULATING FACTOR; HEMATOPOIETIC PROGENITOR CELLS; IMMUNE SUPPRESSOR CELLS; LEWIS LUNG-CARCINOMA; NECK-CANCER PATIENTS; GROWTH-FACTOR; PERIPHERAL-BLOOD; CLINICAL-SIGNIFICANCE; INDUCED MOBILIZATION; HEAD AB Patients and animals bearing tumors have increased levels of CD34(+) progenitor cells, which are capable of developing into dendritic cells. However, addition of medium conditioned by murine Lewis lung carcinoma cells increases the cellularity of the CD34(+) cell cultures and redirects their differentiation into endothelial cells. The resulting cells resemble endothelial cells phenotypically as well as functionally by their capacity to reorganize into cord structures. Mechanisms by which tumors induced the increased cellularity and skewing toward endothelial cells were examined. Tumor-derived VEGF contributed to the increase in cellularity, but not to the redirection of differentiation. Differentiation into endothelial cells was blocked with sTie-2, suggesting tumor-derived angiopoietins in skewing differentiation. These studies show the capacity of tumors to skew progenitor cell development toward endothelial cells and define the mediators that contribute to endothelial cell development. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29401 USA. RP Young, MRI (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@med.va.gov FU NCI NIH HHS [CA85266, CA97813] NR 37 TC 13 Z9 16 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-7004 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD MAY PY 2006 VL 55 IS 5 BP 558 EP 568 DI 10.1007/s00262-005-0036-3 PG 11 WC Oncology; Immunology SC Oncology; Immunology GA 021HD UT WOS:000235973400008 PM 16025265 ER PT J AU Beer, TM Garzotto, M Park, B Mori, M Myrthue, A Janeba, N Sauer, D Eilers, K AF Beer, TM Garzotto, M Park, B Mori, M Myrthue, A Janeba, N Sauer, D Eilers, K TI Effect of calcitriol on prostate-specific antigen in vitro and in humans SO CLINICAL CANCER RESEARCH LA English DT Article ID CANCER CELL-LINES; VITAMIN-D ANALOGS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ANDROGEN RECEPTOR; GROWTH-INHIBITION; LNCAP CELLS; CARCINOMA; PROLIFERATION; EXPRESSION; INDUCTION AB Background: Calcitriol, the natural ligand for the vitamin D receptor, has significant potential in Prostate cancer treatment. Measurement of its antineoplastic activity in prostate cancer clinical trials may be complicated by effects of calcitriol on prostate-specific antigen (PSA) production. We examined the effects of calcitriol at similar concentration on cell proliferation, androgen receptor (AR) expression, and PSA production in vitro and on PSA concentrations in prostate cancer patients. Experimental Design: LNCaP prostate cancer cell proliferation was examined by cell counts 6 days after exposure to a range of concentrations of calcitriol. AR and PSA protein was quantified in LNCaP cells over 96 hours after exposure to 1 nmol/L calcitriol. Serum PSA and free PSA was serially measured by immunoassay over a period of 8 days in patients with hormone-naive prostate cancer after a single dose of 0.5 mu g/kg calcitriol. Results: Calcitriol treatment resulted in dose-dependent growth inhibition of LNCaP with similar to 50% growth inhibition at the clinically achievable concentration of 1 nmol/L. Time-dependent up-regulation of AR expression and of PSA production in LNCaP cells was shown at the same concentration. No significant change in serum PSA or free PSA over 8 days was seen in eight subjects treated with a single dose of 0.5 mu g/kg calcitriol. The analysis was powered to detect a 1.23-fold change between the baseline and day 8 serum PSA. Conclusions: At clinically achievable concentrations, calcitriol inhibits growth and induces AR and PSA expression in LNCaP cells. We did not detect similar changes in serum PSA or free PSA in patients exposed to similar concentrations of calcitriol. Thus, a PSA flare, predicted by preclinical systems, is unlikely to occur in patients and therefore unlikely to complicate interpretation of clinical trial outcomes. C1 Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Div Urol, Portland, OR USA. Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. RP Beer, TM (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, CR-145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu OI /0000-0003-3516-7516 FU NCI NIH HHS [5 R21 CA85585-02]; NCRR NIH HHS [5 M01 RR00334-33S2] NR 26 TC 8 Z9 8 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2006 VL 12 IS 9 BP 2812 EP 2816 DI 10.1158/1078-0432.CCR-05-2310 PG 5 WC Oncology SC Oncology GA 041GI UT WOS:000237441900021 PM 16675575 ER PT J AU Wilkinson, CW Raff, H AF Wilkinson, CW Raff, H TI Comparative evaluation of a new immunoradiometric assay for corticotropin SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE LA English DT Article DE corticotropin; diagnostic techniques and procedures; immunoradiometric assay (IRMA); sensitivity and specificity AB We have characterized the performance of a commercial two-site immunoradiometric assay for manual in vitro diagnostic measurement of plasma corticotropin from Scantibodies Laboratory. We compared the results with those of a similar commonly used assay from Nichols Institute Diagnostics that has recently been withdrawn from production. The lower detection limit, range of the standard curve, cross-reactivity, and intra-assay and inter-assay imprecision of the two assays are very similar. Measurement of clinical samples and a series of samples from an experimental subject demonstrate high correlations between the two assays. These factors, together with recent clearance by the United States Food and Drug Administration for manual in vitro diagnostic measurement, make the Scantibodies corticotropin immunoradiometric assay an appropriate replacement for the Nichols assay. C1 VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Med Coll Wisconsin, St Lukes Med Ctr, Endocrine Res Lab, Milwaukee, WI 53226 USA. RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, GRECC, S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM wilkinso@u.washington.edu NR 2 TC 13 Z9 13 U1 0 U2 0 PU WALTER DE GRUYTER & CO PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 1434-6621 J9 CLIN CHEM LAB MED JI Clin. Chem. Lab. Med. PD MAY PY 2006 VL 44 IS 5 BP 669 EP 671 DI 10.1515/CCLM.2006.113 PG 3 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 050YB UT WOS:000238125300027 PM 16681443 ER PT J AU Mortensen, EM Restrepo, MI Anzueto, A Pugh, J AF Mortensen, EM Restrepo, MI Anzueto, A Pugh, J TI Queen of punt - Reply to Bodi et al. SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 UTHSCSA, VERDICT, ALMD, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Div Pulm Crit Care Med, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Div Gen Internal Med, San Antonio, TX USA. RP Mortensen, EM (reprint author), UTHSCSA, VERDICT, ALMD, Vet Evidence Based Res Disseminat & Implementat C, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM mortensen@verdict.uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563 NR 3 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2006 VL 42 IS 9 BP 1345 EP 1345 DI 10.1086/503307 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 029JD UT WOS:000236557600022 PM 16586400 ER PT J AU Silbert, LC Nelson, C Holman, S Eaton, R Oken, BS Lou, JS Kaye, JA AF Silbert, LC Nelson, C Holman, S Eaton, R Oken, BS Lou, JS Kaye, JA TI Cortical excitability and age-related volumetric MRI changes SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE aging; TMS; white matter; atrophy; cortical excitability ID TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY MOTOR CORTEX; INTRACORTICAL INHIBITION; ALZHEIMERS-DISEASE; CARDIOVASCULAR-HEALTH; PARKINSONS-DISEASE; DEPENDENT CHANGES; DEMENTIA; STROKE; BRAIN AB Objective: Normative data on transcranial magnetic stimulation (TMS)-derived measures of cortical excitability in the elderly is sparse. Nevertheless, elderly subjects are included as controls in studies utilizing TMS to investigate disease states. Age-associated increased ventricular cerebrospinal fluid CSF (vCSF) and white matter hyperintensity (WMH) MRI volumes have uncertain significance in non-demented elderly. Information regarding cortical excitability in neurologically intact elderly would augment our understanding of the pathophysiology of aging and assist in the interpretation of TMS studies involving elderly subjects. Methods: Twenty-four healthy elderly subjects underwent TMS testing to determine outcomes of resting motor threshold (RMT) cortical silent period (cSP) and central motor conduction time for examination in relation to WMH, vCSF, and CNS volumes. Results: Increased vCSF and WMH volumes were associated with decreased right and left hemisphere RMT. Smaller CNS volumes were associated with decreased right hemisphere RMT and shorted cSP. Conclusions: Commonly observed age-associated MRI changes are associated with findings consistent with increased cortical excitability. Significance: Age-related MRI findings likely reflect changes at a cellular level, and may influence cognitive and motor integrity in the elderly. Future TMS studies investigating cortical excitability may wish to consider neuroimaging markers of neurodegeneration prior to enrolling elderly subjects as controls. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Layton Aging & Alheimers Dis Ctr, Dept Neurol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Silbert, LC (reprint author), Oregon Hlth & Sci Univ, Layton Aging & Alheimers Dis Ctr, Dept Neurol, CR-131,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM silbertl@ohsu.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [M01 RR000334]; NIA NIH HHS [K23 AG 24826-01, P30 AG 08017] NR 38 TC 19 Z9 19 U1 0 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD MAY PY 2006 VL 117 IS 5 BP 1029 EP 1036 DI 10.1016/j.clinph.2006.02.003 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 044DF UT WOS:000237651900013 PM 16564739 ER PT J AU Cristian, A AF Cristian, A TI Geriatric rehabilitation SO CLINICS IN GERIATRIC MEDICINE LA English DT Editorial Material C1 James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. RP Cristian, A (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Room 3D-16,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM acristianmd@msn.com NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP XIII EP XIV DI 10.1016/j.cger.2006.01.001 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200001 ER PT J AU Cristian, A AF Cristian, A TI The assessment of the older adult with a physical disability: A guide for clinicians SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID SPINAL-CORD-INJURY; PARKINSONS-DISEASE; STROKE PATIENTS; SLEEP DISTURBANCES; SEXUAL DYSFUNCTION; FUNCTIONAL-CHANGES; FATIGUE; REHABILITATION; DEPRESSION; SPOUSES AB As the population of older adults increases, so does the number of people aging with a disability. It is more important than ever that clinicians caring for these individuals ask appropriate questions and focus on key areas of the physical examination that are pertinent to the care of this population. This article is meant to provide clinicians with a framework for evaluating the older adult aging with a physical disability in a clinic or hospital setting. C1 James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. RP Cristian, A (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, 3D-16,526-117,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM acristianmd@msn.com NR 41 TC 3 Z9 3 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 221 EP + DI 10.1016/j.cger.2005.12.001 PG 19 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200002 PM 16627075 ER PT J AU Richards, S Cristian, A AF Richards, S Cristian, A TI The role of the physical therapist in the care of the older adult SO CLINICS IN GERIATRIC MEDICINE LA English DT Article AB Physical therapists play an important role in the care of older adults who have physical disabilities. Proper patient selection, a thorough medical, social, and functional history, and a physical examination emphasizing the neuromusculoskeletal system are the cornerstones of the evaluation process. Treatment is individualized and goal driven, with appropriate precautions being followed. Gait training is an integral part of the treatment process for many older adults with disabilities, and various assistive devices may be used to ensure safe mobility. C1 James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. RP Richards, S (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Room 3D-16,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM shana.richards@med.va.gov NR 4 TC 5 Z9 5 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 269 EP + DI 10.1016/j.cger.2005.12.003 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200005 PM 16627078 ER PT J AU Daley, T Cristian, A Fitzpatrick, M AF Daley, T Cristian, A Fitzpatrick, M TI The role of occupational therapy in the care of the older adult SO CLINICS IN GERIATRIC MEDICINE LA English DT Article AB Older adults who have physical disabilities often require the services of an occupational therapist. This article reviews the role of the occupational therapist in the care of the geriatric population. C1 James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Daley, T (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM teina.daley@bronx.va.gov NR 2 TC 0 Z9 1 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 281 EP + DI 10.1016/j.cger.2005.12.004 PG 11 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200006 PM 16627079 ER PT J AU Ashley, J Duggan, M Sutcliffe, N AF Ashley, J Duggan, M Sutcliffe, N TI Speech, language, and swallowing disorders in the older adult SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID LOUDNESS MANIPULATIONS; PARKINSONS-DISEASE; IMPACT; TUBE; REHABILITATION; DYSARTHRIA; DYSPHAGIA AB The geriatric population has become a major component in the practice of medical speech-language pathology. This article discusses normal and abnormal functions of speech, voicing, language, cognition, and swallowing. Particular attention is given to disorders affecting the geriatric population. Evaluation, treatment, and ethical issues are explored in addition to the role of the speech-language pathologist on the interdisciplinary team. C1 James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Sutcliffe, N (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM natalie.sutcliffe@med.va.gov NR 44 TC 8 Z9 9 U1 1 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 291 EP + DI 10.1016/j.cger.2005.12.008 PG 21 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200007 PM 16627080 ER PT J AU Perret, DM Rim, J Cristian, A AF Perret, DM Rim, J Cristian, A TI A geriatrician's guide to the use of the physical modalities in the treatment of pain and dysfunction SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID LOW-BACK-PAIN; ELECTRICAL NERVE-STIMULATION; DOUBLE-BLIND TRIAL; ULTRASOUND THERAPY; MUSCULOSKELETAL DISORDERS; COLD THERAPY; EFFICACY; TENS; HEAT; REHABILITATION AB The use of the physical modalities in the treatment of musculoskeletal conditions has a long and rich history. This article explores the various physical modalities and their indications, precautions, and contraindications, especially in their applied use in pain management. It also highlights the role of the physical modalities as agents for the management of pain in the geriatric population. C1 James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Bronx, NY 10468 USA. Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA. SUNY Hlth Sci Ctr, Dept Anesthesiol, Brooklyn, NY 11203 USA. RP Cristian, A (reprint author), James J Peters Vet Affairs Med Ctr, Dept Rehabil Med, Room 3D-16,Route 526-117,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM acristianmd@msn.com NR 92 TC 6 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 331 EP + DI 10.1016/j.cger.2005.12.005 PG 25 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200009 PM 16627082 ER PT J AU Sabol, TP Haley, ES AF Sabol, TP Haley, ES TI Wheelchair evaluation for the older adult SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID SPINAL-CORD-INJURY; PRESSURE; PROPULSION; MOBILITY; RELIABILITY; EFFICIENCY; CUSHION; PEOPLE; SYSTEM; USERS AB This article focuses on basic principles of seating and wheelchair evaluation for the general population. The discussion includes wheelchair options, components, and accessories. Basic principles to guide the clinician in the process of selection for maximum function are addressed. C1 James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Unit, Bronx, NY 10468 USA. RP Sabol, TP (reprint author), James J Peters Vet Affairs Med Ctr, Spinal Cord Injury Unit, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM timothy.sabel@med.va.gov NR 31 TC 8 Z9 8 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 355 EP + DI 10.1016/j.cger.2005.12.013 PG 22 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200010 PM 16627083 ER PT J AU MacDonald, DE AF MacDonald, DE TI Principles of geriatric dentistry and their application to the older adult with a physical disability SO CLINICS IN GERIATRIC MEDICINE LA English DT Review ID ROOT SURFACE CARIES; SQUAMOUS-CELL CARCINOMA; ORAL LICHEN-PLANUS; SALIVARY FLOW-RATE; PERIODONTAL-DISEASE; PROSTHODONTIC TREATMENT; APHTHOUS STOMATITIS; NUTRITIONAL-STATUS; CARE UTILIZATION; OROFACIAL PAIN AB The older adult living with a physical disability faces many daily challenges. Limited hand function or impaired cognition often has profound effects on activities of daily life including oral hygiene. This article explores age-related changes in dentition and common causes of pathology of the oral cavity with special emphasis in populations with impaired hand function or cognition. This article will also assist the treating physician as it relates to oral diagnosis and patient management. C1 Columbia Univ, Sch Dent & Oral Surg, Div Periodontol, New York, NY 10032 USA. Columbia Univ, Fu Sch Grad Engn, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA. Hosp Special Surg, Div Mineralized Tissue Res, New York, NY 10021 USA. James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP MacDonald, DE (reprint author), Columbia Univ, Sch Dent & Oral Surg, Div Periodontol, 630 W 168th St,PH-7-E-110, New York, NY 10032 USA. EM dem14@columbia.edu NR 138 TC 5 Z9 6 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2006 VL 22 IS 2 BP 413 EP + DI 10.1016/j.cger.2005.12.009 PG 23 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 044VX UT WOS:000237702200013 PM 16627086 ER PT J AU Shin, JM Sachs, G AF Shin, Jai Moo Sachs, George TI Gastric H,K-ATPase as a drug target SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article ID PROTON-PUMP INHIBITORS; K+-COMPETITIVE INHIBITOR; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; AMINO-ACID-SEQUENCE; BETA-SUBUNIT; H+/K+-ATPASE; ALPHA-SUBUNIT; PARIETAL-CELL; SUBSTITUTED BENZIMIDAZOLES C1 Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, Los Angeles, CA 90073 USA. RP Sachs, G (reprint author), Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu NR 90 TC 16 Z9 17 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2006 VL 51 IS 5 BP 823 EP 833 DI 10.1007/s10620-005-9042-8 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 061CA UT WOS:000238847600001 PM 16645899 ER PT J AU Morasco, BJ Petry, NM AF Morasco, BJ Petry, NM TI Gambling problems and health functioning in individuals receiving disability SO DISABILITY AND REHABILITATION LA English DT Article DE disability; disordered gambling; pathological gambling; health functioning; mental health ID DISORDERS; PREVALENCE; GAMBLERS; ADULTS; CARE AB Purpose. This study evaluated the rates and correlates of disordered gambling, with a focus on gambling behavior among participants receiving disability. Method. The sample consisted of 723 patients seeking free or reduced-cost dental care. Participants completed the South Oaks Gambling Screen (SOGS), Short Form-12 Health Survey, Second Edition (SF-12v2), and questions assessing demographic characteristics and frequency and intensity of current gambling behaviors. Results. Results indicate a significantly higher prevalence of disordered gambling among participants receiving disability (26%) than in the remainder of the sample (14%; p < 0.001). Of the 135 individuals receiving disability, disordered gambling was associated with decreased physical and mental health functioning. Conclusions. These data indicate that individuals receiving disability have high rates of disordered gambling, and gambling behavior in this population is associated with poorer health functioning. Results suggest that disordered gamblers who receive disability have an increased need for interventions to reduce gambling and associated problems. C1 Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06030 USA. Portland VA Med Ctr, Portland, OR USA. RP Petry, NM (reprint author), Univ Connecticut, Ctr Hlth, Dept Psychiat, 263 Farmington Ave, Farmington, CT 06030 USA. EM petry@psychiatry.uchc.edu FU NIAAA NIH HHS [P50-AA03510]; NIDA NIH HHS [R01-DA13444, P50-DA09241, R01-DA14618]; NIMH NIH HHS [R01-MH60417, R01-MH60417-SUPP] NR 21 TC 19 Z9 19 U1 1 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PD MAY PY 2006 VL 28 IS 10 BP 619 EP 623 DI 10.1080/09638280500242507 PG 5 WC Rehabilitation SC Rehabilitation GA 041QO UT WOS:000237471000004 PM 16690574 ER PT J AU Reilly, CM Olgun, S Goodwin, D Gogal, RM Santo, A Romesburg, JW Ahmed, SA Gilkeson, GS AF Reilly, CM Olgun, S Goodwin, D Gogal, RM Santo, A Romesburg, JW Ahmed, SA Gilkeson, GS TI Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE interferon regulatory; factor-1; kidney; lupus; mouse; MRL ID NITRIC-OXIDE SYNTHASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE KIDNEY-DISEASE; GAMMA-INDUCED APOPTOSIS; PERIPHERAL-BLOOD CELLS; IFN-GAMMA; T-CELLS; MRL-FAS(LPR) MICE; DEFICIENT MICE; AUTOANTIBODY PRODUCTION AB To investigate the role of interferon regulatory factor-1 (IRF-1) in the development of lupus nephritis, IRF-1(-/-) genotype mice were bred onto the MRL/1pJfas(1pr) (MRL/1pr) background. We examined kidney mesangial cell function and disease progression. Endpoints evaluated included inflammatory mediators, autoantibody production, immune complex deposition, renal pathology, T cell subset analysis, and duration of survival. Mesangial cells cultured from IRF-1(-/-) mice produced significantly lower levels of nitric oxide and IL-12 but not TNF-alpha when stimulated with LPS + IFN-gamma. IRF-/- mice showed less aggravated dermatitis compared to the wild-type mice. Anti-double-stranded DNA production and proteinuria were significantly decreased in IRF-1(-/-) mice compared to lRF-1(+/+) mice. IgG and C3 deposition as well as glomerulonephritis were decreased in IRF-1(-/-) mice at 26 wk of age compared to the IRF-1(+/+) mice. Splenic CD4(-)CD8(-)CD44(+) T cells were decreased while CD4(+)CD25(+) T cells were increased in the IRF-1(-/-) mice when compared to IRF-1(+/+) mice. Survival rates (ED50) were 22 wk for IRF-1(+/+) mice and 45 wk for IRF-1(-/-) mice. These findings suggest an important role of IRF-1 in mediating renal disease in MRL/1pr mice. C1 Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24060 USA. Via Coll Osteopath Med, Blacksburg, VA USA. Ralph H Johnson VA Med Ctr, Med Res Serv, Charleston, SC USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Reilly, CM (reprint author), Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Virginia Maryland Reg Coll Vet Med, 2265 Kraft Dr, Blacksburg, VA 24060 USA. EM chreilly@vcom.vt.edu FU NIAMS NIH HHS [AR0493190-03] NR 71 TC 29 Z9 29 U1 1 U2 4 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY SN 0014-2980 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD MAY PY 2006 VL 36 IS 5 BP 1296 EP 1308 DI 10.1002/eji.200535245 PG 13 WC Immunology SC Immunology GA 046BB UT WOS:000237785300024 PM 16541466 ER PT J AU Park, KI Himes, BT Stieg, PE Tessler, A Fischer, I Snyder, EY AF Park, Kook In Himes, B. Timothy Stieg, Philip E. Tessler, Alan Fischer, Itzhak Snyder, Evan Y. TI Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury SO EXPERIMENTAL NEUROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CEREBRAL-ARTERY OCCLUSION; CLARKES NUCLEUS NEURONS; SPINAL-CORD-INJURY; ADULT-RAT CNS; GROWTH-FACTOR; PROGENITOR CELLS; NEUROTROPHIC FACTOR; FUNCTIONAL RECOVERY; GRANULE NEURONS AB Previously, we reported that, when clonal neural stem cells (NSCs) were transplanted into brains of postnatal mice subjected to unilateral hypoxic-ischemic (HI) injury (optimally 3-7 days following infarction), donor-derived cells homed preferentially (from even distant locations) to and integrated extensively within the large ischemic areas that spanned the hemisphere. A subpopulation of NSCs and host cells, particularly in the penumbra, "shifted" their differentiation towards neurons and oligodendrocytes, the cell types typically damaged following asphyxia and least likely to regenerate spontaneously and in sufficient quantity in the "post-developmental" CNS. That no neurons and few oligodendrocytes were generated from the NSCs in intact postnatal cortex suggested that novel signals are transiently elaborated following HI to which NSCs might respond. The proportion of "replacement" neurons was similar to 5%. Neurotrophin-3 (NT-3) is known to play a role in inducing neuronal differentiation during development and perhaps following injury. We demonstrated that NSCs express functional TrkC receptors. Furthermore, the donor cells continued to express a foreign reporter transgene robustly within the damaged brain. Therefore, it appeared feasible that neuronal differentiation of exogenous NSCs (as well as endogenous progenitors) might be enhanced if donor NSCs were engineered prior to transplantation to (over)express a bioactive gene such as NT-3. A subclone of NSCs transduced with a retrovirus encoding NT-3 (yielding > 90% neurons in vitro) was implanted into unilaterally asphyxiated postnatal day 7 mouse brain (emulating one of the common causes of cerebral palsy). The subclone expressed NT-3 efficiently in vivo. The proportion of NSC-derived neurons increased to similar to 20% in the infarction cavity and > 80% in the penumbra. The neurons variously differentiated further into cholinergic, GABAergic, or glutamatergic subtypes, appropriate to the cortex. Donor-derived glia were rare, and astroglial scarring was blunted. NT-3 likely functioned not only on donor cells in an autocrine/paracrine fashion but also on host cells to enhance neuronal differentiation of both. Taken together, these observations suggest (1) the feasibility of taking a fundamental biological response to injury and augmenting it for repair purposes and (2) the potential use of migratory NSCs in some degenerative conditions for simultaneous combined gene therapy and cell replacement during the same procedure in the same recipient using the same cell (a unique property of cells with stem-like attributes). (c) 2006 Elsevier Inc. All rights reserved. C1 Burnham Inst Med Res, La Jolla, CA 92037 USA. Yonsei Univ, Coll Med, Dept Pediat, Seoul 120749, South Korea. Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120749, South Korea. Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Cornell Univ, Weil Sch Med, Dept Neurosurg, New York, NY 10021 USA. RP Snyder, EY (reprint author), Burnham Inst Med Res, La Jolla, CA 92037 USA. EM esnyder@bumham.org RI Fischer, Itzhak/D-1080-2012 OI Fischer, Itzhak/0000-0003-3187-8740 NR 64 TC 98 Z9 120 U1 1 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD MAY PY 2006 VL 199 IS 1 BP 179 EP 190 DI 10.1016/j.expneurol.2006.03.016 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 060KI UT WOS:000238800700020 PM 16714016 ER PT J AU Mantena, SK Katiyar, SK AF Mantena, SK Katiyar, SK TI Grape seed proanthocyanidins inhibit UV-radiation-induced oxidative stress and activation of MAPK and NF-kappa B signaling in human epidermal keratinocytes SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE grape seed proanthocyanidins; oxidative stress; ultraviolet radiation; mitogen-activated protein kinases; hydrogen peroxide; glutathione peroxidase; glutathione; NF-kappa B; free radicals ID POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT; GREEN TEA POLYPHENOLS; PROTEIN-KINASE; MOUSE SKIN; ANTIOXIDANT ENZYMES; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ULTRAVIOLET-LIGHT; SUPEROXIDE ANION; CELL-SURVIVAL AB Solar ultraviolet (UV) radiation-induced oxidative stress has been implicated in various skin diseases. Here, we report the photoprotective effect of grape seed proanthocyanidins (GSPs) on UV-induced oxidative stress and activation of mitogen-activated protein kinase (MAPK) and NF-kappa B signaling pathways using normal human epidermal keratinocytes (NHEK). Treatment of NHEK with GSPs inhibited UVB-induced hydrogen peroxide (H2O2), lipid peroxidation, protein oxidation, and DNA damage in NHEK and scavenged hydroxyl radicals and superoxide anions in a cell-free system. GSPs also inhibited UVB-induced depletion of antioxidant defense components,. such as glutathione peroxidase, catalase, superoxide dismutase, and glutathione. As UV-induced oxidative stress mediates activation of MAPK and NF-kappa B signaling pathways, we determined the effects of GSPs on these pathways. Treatment of NHEK with GSPs inhibited UVB-induced phosphorylation of ERK1/2, JNK, and p38 proteins of the MAPK family at the various time points studied. As UV-induced H2O2 plays a major role in activation of MAPK proteins, NHEK were treated with H2O2 with or without GSPs and other known antioxidants, viz. (-)-epigallocatechin-3 -gallate, silymarin, ascorbic acid, and N-acetylcysteine. It was observed that H2O2,induced phosphorylation of ERK1/2, JNK, and p38 was decreased by these antioxidants. Under identical conditions, GSPs also inhibited UVB-induced activation of NF-kappa B/p65, which was mediated through inhibition of degradation and activation Of I kappa B alpha and IKK alpha, respectively. Together, these results Suggest that GSPs could be useful in the attenuation of UV-radiation-induced oxidative stress-mediated skin diseases in human skin. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, Volker Hall 557,1670 Univ Blvd,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCI NIH HHS [CA104428] NR 56 TC 97 Z9 107 U1 5 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAY 1 PY 2006 VL 40 IS 9 BP 1603 EP 1614 DI 10.1016/j.freeradbiomed.2005.12.032 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 041DP UT WOS:000237433900012 PM 16632120 ER PT J AU Anand, BS Currie, S Dieperink, E Bin, EJ Shen, H Ho, SB Wright, T AF Anand, BS Currie, S Dieperink, E Bin, EJ Shen, H Ho, SB Wright, T CA VA HCV 001 Study Grp TI Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study SO GASTROENTEROLOGY LA English DT Article ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; LIVER-DISEASE; ANTIVIRAL THERAPY; UNITED-STATES; PEGINTERFERON ALPHA-2B; INITIAL TREATMENT; RANDOMIZED-TRIAL; NATURAL-HISTORY; INFECTION; VETERANS AB Background & Aims: Patients with hepatitis C virus (HCV) infection who use alcohol have been excluded from clinical trials; therefore, outcomes with antiviral therapy are unknown. The aim of the study was to determine the impact of alcohol use on HCV treatment outcomes. Methods: Subjects using alcohol were categorized as follows: no alcohol versus regular alcohol use, quantity consumed (none, < 6 drinks/ day, >= 6 drinks/day), CAGE score < 2 or >= 2, and recent alcohol use (past 12 months). Patients were treated with interferon plus ribavirin. Results: A total of 4061 subjects were enrolled, and 726 (18%) received treatment. Alcohol use (past and within 12 months) reduced treatment candidacy. Past alcohol use did not affect the end-of-treatment response, sustained virologic response (SVR), and treatment discontinuation rates. However, recent alcohol use resulted in higher treatment discontinuation (40% vs 26%; P =.0002) and tended to reduce the SVR (14% vs 20%; P =.06), but when patients who discontinued treatment were excluded from analysis, the trend in favor of nondrinkers for SVR disappeared (25% vs 23%). These findings were also consistent in subgroup analyses on race and genotype. Conclusions: Eligibility for anti-HCV treatment was reduced in past and recent drinkers. Recent alcohol use was associated with increased treatment discontinuation and lower SVR. However, patients who use alcohol and completed the treatment had a response comparable to that of nondrinkers. Patients with a history of alcohol use should not be excluded from HCV therapy. Instead, additional support should be provided to these patients to ensure their ability to complete treatment. C1 Michael E DeBakey VA Med Ctr, Digest Dis Sect, Dept Med, Houston, TX 77030 USA. San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. Minneapolis VA Med Ctr, Dept Med, Minneapolis, MN USA. VA New York Harbor Healthcare Syst, Dept Med, Brooklyn, NY USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Anand, BS (reprint author), Michael E DeBakey VA Med Ctr, Digest Dis Sect, Dept Med, 2002 Holcombe Blvd,111D, Houston, TX 77030 USA. EM anaO@flash.net NR 34 TC 85 Z9 86 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2006 VL 130 IS 6 BP 1607 EP 1616 DI 10.1053/j.gastro.2006.02.023 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 044QG UT WOS:000237686700011 PM 16697724 ER PT J AU Bradesi, S Kokkotou, E Simeonidis, S Patierno, S Ennes, HS Mittal, Y McRoberts, JA Ohning, G McLean, P Marvizon, JC Sternini, C Pothoulakis, C Mayer, EA AF Bradesi, S Kokkotou, E Simeonidis, S Patierno, S Ennes, HS Mittal, Y McRoberts, JA Ohning, G McLean, P Marvizon, JC Sternini, C Pothoulakis, C Mayer, EA TI The role of neurokinin 1 receptors in the maintenance of visceral hyperalgesia induced by repeated stress in rats SO GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Digestive Disease Week Meeting/106th Annual Meeting of the American-Gastroenterological-Association CY MAY 14-19, 2005 CL Chicago, IL SP Amer Gastroenterol Assoc ID SUBSTANCE-P RECEPTOR; CLOSTRIDIUM-DIFFICILE TOXIN; IRRITABLE-BOWEL-SYNDROME; SPINAL-CORD SLICES; NK1 RECEPTOR; TACHYKININ NK1; GASTROINTESTINAL-TRACT; DORSAL-HORN; LAMINA-I; MUCOSAL INFLAMMATION AB Background & Aims: The neurokinin 1 receptors (NK(1)Rs) and substance P (SP) have been implicated in the stress and/or pain pathways involved in chronic pain conditions. Here we examined the participation of NK(1)Rs in sustained visceral hyperalgesia observed in rats exposed to chronic psychological stress. Methods: Male Wistar rats were exposed to daily 1-hour water avoidance stress (WA) or sham WA for 10 consecutive days. We tested intraperitoneal or intrathecal injection of the NK1R antagonist SR140333 on the visceromotor reflex to colorectal distention in both groups at day 11. Real-time reverse-transcription polymerase chain reaction, Western blot, and immunohistochemistry were used to assess the expression of NK(1)Rs and/or SP in samples of colon, spinal cord, and dorsal root ganglia. Results: Both intraperitoneal and intrathecal SR140333 injection diminished the enhanced visceromotor reflex to colorectal distention at day 11 in stressed rats but did not affect the response in control animals. Realtime polymerase chain reaction and Western blotting demonstrated stress-induced up-regulation of spinal NK(1)LRs. Immunohistochemistry showed an increased number of NK1R-expressing neurons in the laminae I of the dorsal horn in stressed rats. The expression of NK(1)Rs was decreased in colon from stressed rats compared with control. The expression of SP gene precursor in dorsal root ganglia was unchanged in stressed rats compared with controls. Conclusions: Stress-induced increased NK1R expression on spinal neurons and the inhibitory effect of intrathecal NK1R antagonist on visceral hyperalgesia support the key contribution of spinal NK(1)Rs in the molecular pathways involved in the maintenance of visceral hyperalgesia observed after chronic WA. C1 Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Inst Brain Res, Dept Neurobiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Gastrointestinal Neuropeptide C, Boston, MA 02115 USA. GlaxcoSmithKline, Neurol & G1 Ctr Excellence Drug Discovery, Harlow, Essex, England. RP Mayer, EA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Neurovisceral Sci & Womens Hlth, Room 223,VAGLAHS,11301 Willshire Blvd,CURE Bldg, Los Angeles, CA 90073 USA. EM emayer@ucla.edu FU NCCIH NIH HHS [R24 AT00281]; NIDDK NIH HHS [R21 DK071767, DK41301, DK47343, DK54155, DK57037, P50 DK64539, R21 DK071767-01] NR 69 TC 35 Z9 37 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAY PY 2006 VL 130 IS 6 BP 1729 EP 1742 DI 10.1053/j.gastro.2006.01.037 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 044QG UT WOS:000237686700024 PM 16697737 ER PT J AU Bordelon, SJ AF Bordelon, SJ TI A monthly review of one aspect of advanced cardiac life support SO GASTROENTEROLOGY NURSING LA English DT Letter C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Bordelon, SJ (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1042-895X J9 GASTROENTEROL NURS JI Gastroenterol. Nurs. PD MAY-JUN PY 2006 VL 29 IS 3 BP 254 EP 255 DI 10.1097/00001610-200605000-00012 PG 2 WC Gastroenterology & Hepatology; Nursing SC Gastroenterology & Hepatology; Nursing GA 052ZU UT WOS:000238273600010 PM 16770146 ER PT J AU Young, MRI AF Young, MRI TI Protective mechanisms of head and neck squamous cell carcinomas from immune assault SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Review DE head and neck cancer; HNSCC; immune; immunosuppression; suppressor cells ID REGULATORY T-CELLS; GROWTH-FACTOR-BETA; MACROPHAGE SUPPRESSOR ACTIVITY; COLONY-STIMULATING FACTOR; CD34(+) PROGENITOR CELLS; BLOOD MONONUCLEAR-CELLS; TUMOR-BEARING MICE; HLA CLASS-I; CANCER-PATIENTS; PERIPHERAL-BLOOD AB Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy that is the sixth most common neoplasm in the world. Despite advances in treatments involving surgery, radiation, and chemotherapy, the 5-year survival has remained at less than 50% for the past 30 years, primarily because of local recurrences, Thus, the possibility of immunotherapeutic approaches for patients with HNSCC has gained interest. Unfortunately, patients with HNSCC have profound immune defects that are associated with increased recurrence. This review aims to provide an overview of both the defensive and immune subversive mechanisms by which patients with HNSCC can protect themselves from immune antitumor assault. (c) 2005 Wiley Periodicals, Inc. C1 Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. NR 92 TC 41 Z9 43 U1 0 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1043-3074 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD MAY PY 2006 VL 28 IS 5 BP 462 EP 470 DI 10.1002/hed.20331 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 039HP UT WOS:000237296900011 PM 16284974 ER PT J AU Levine, AJ Hinkin, CH Marion, S Keuning, A Castellon, SA Lam, MN Robinet, M Longshore, D Newton, T Myers, H Durvasula, RS AF Levine, AJ Hinkin, CH Marion, S Keuning, A Castellon, SA Lam, MN Robinet, M Longshore, D Newton, T Myers, H Durvasula, RS TI Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring SO HEALTH PSYCHOLOGY LA English DT Article DE adherence; electronic monitoring; self-report; HAART; HIV ID PROTEASE INHIBITORS; VIRAL LOAD; THERAPY; PREDICTORS; ADULTS AB Controversy remains regarding the reliability of methods used to determine adherence to antiretroviral medication in HIV. In this study the authors compared adherence rates of 119 HIV-positive participants during a 6-month study, as estimated via electronic monitoring (EM) and self-report (SR). Adherence for both short (4-day) and long (4-week, or intervisit) periods was examined, as well as factors that underlie discrepancies between EM and SR. Results showed that intervisit EM estimates were consistently lower than those of SR. SR estimates based on shorter periods (4 days) were closer to those of EM. Higher discrepancies between EM and SR estimates were associated with lower cognitive functioning and externalized focus of control. These findings lend support for using both EM and SR methods; however, study design (e.g., length) and other factors (e.g., cognitive status, cost) should be considered. C1 Univ Calif Los Angeles, Dept Neurol, Natl Neurol AIDS Bank, Inst Neuropsychiat, Los Angeles, CA 90025 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Calif State Univ Los Angeles, Dept Psychol, Los Angeles, CA 90032 USA. RP Levine, AJ (reprint author), Univ Calif Los Angeles, Dept Neurol, Natl Neurol AIDS Bank, Inst Neuropsychiat, 11645 Wilshire Blvd,Suite 770, Los Angeles, CA 90025 USA. EM ajlevine@mednet.ucla.edu OI newton, thomas/0000-0002-3198-5901 FU NIDA NIH HHS [R01 DA013799, R01 DA13799]; NIMH NIH HHS [T32 MH19535] NR 29 TC 40 Z9 41 U1 1 U2 2 PU AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD MAY PY 2006 VL 25 IS 3 BP 329 EP 335 DI 10.1037/0278-6133.25.3.329 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 045SB UT WOS:000237761300009 PM 16719604 ER PT J AU Ioannou, GN Weiss, NS Boyko, EJ Mozaffarian, D Lee, SP AF Ioannou, GN Weiss, NS Boyko, EJ Mozaffarian, D Lee, SP TI Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States SO HEPATOLOGY LA English DT Article ID FATTY LIVER-DISEASE; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; METABOLIC SYNDROME; ASSOCIATION; PREVALENCE; POPULATION; PREDICTION; FRAMINGHAM; CIRRHOSIS AB In the United States, elevated serum alanine aminotransferase (ALT) activity in the absence of viral hepatitis of excessive alcohol consumption is most commonly attributed to nonalcoholic fatty liver disease (NAFLD). NAFLD is related to predictors of coronary heart disease (CHD) such as insulin resistance and central obesity. We examined the association between elevated serum ALT activity and the 10-year risk of CHD as estimated using the Framingham risk score (FRS). We performed a cross-sectional analysis comparing participants in the Third National Health and Nutrition Examination Survey with normal and elevated ALT activity (> 43 IU/L), examining the mean levels of FRS. Among participants without viral hepatitis or excessive alcohol consumption, those with elevated ALT activity (n = 267) had a higher FRS than those with normal ALT activity (n = 7,259), both among men (mean difference in FRS 0.25, 95% CI 0.07-0.4; hazard ratio for CHD 1.28, 95% CI 1.07-1.5) and women (mean difference in FRS 0.76, 95% CI 0.4-1.1; hazard ratio for CHD 2.14, 95% CI 1.5-3.0). The ALT threshold for increased risk of CHD was higher in men (> 43 IU/L) than in women (> 30 IU/L). Elevated ALT activity was not associated with higher FRS among nonobese participants with viral hepatitis or excessive alcohol consumption. In conclusion, individuals with elevated serum ALT activity in the absence of viral hepatitis or excessive alcohol consumption, most of whom have NAFLD, have an increased calculated risk of CHD. This association is more prominent in women. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu RI Mozaffarian, Dariush/B-2276-2008; Lee, Sum Ping/C-4333-2009 OI Boyko, Edward/0000-0002-3695-192X NR 32 TC 120 Z9 125 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAY PY 2006 VL 43 IS 5 BP 1145 EP 1151 DI 10.1002/hep.21171 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 039SM UT WOS:000237327200031 PM 16628637 ER PT J AU Kraemer, BC Burgess, JK Chen, JH Thomas, JH Schellenberg, GD AF Kraemer, BC Burgess, JK Chen, JH Thomas, JH Schellenberg, GD TI Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans SO HUMAN MOLECULAR GENETICS LA English DT Article ID GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; AXONAL-TRANSPORT DEFECTS; PROTEIN PHOSPHATASE 2A; TRANSGENIC MICE; FRONTOTEMPORAL DEMENTIA; C-ELEGANS; TRANSCRIPTION FACTORS; ALZHEIMERS-DISEASE; NEURONAL POLARITY AB Mutations in the gene encoding tau cause frontotemporal dementia with parkinsonism-chromosome 17 type (FTDP-17). In FTDP-17, Alzheimer's disease, and other tauopathies, aggregated hyper-phosphorylated tau forms the neurofibrillary tangles characteristic of these disorders. We previously reported a Caenorhabditis elegans model for tauopathies using human normal and FTDP-17 mutant tau as transgenes. Neuronal transgene expression caused insoluble phosphorylated tau accumulation, neurodegeneration and uncoordinated (Unc) movement. Here we describe a genome-wide RNA-mediated interference (RNAi) screen for genes that modify the tau-induced Unc phenotype. We tested RNAi sequences for 16 757 genes and found 75 that enhanced the transgene-induced Unc phenotype. Forty-six of these genes have sequence similarity to known human genes and fall into a number of broad classes including kinases, chaperones, proteases and phosphatases. The remaining 29 modifiers have sequence similarity only with other nematode genes. To determine if the enhancers are specific for the tau-induced Unc behavior, we exposed several non-tau Unc mutants to tau RNAi enhancer clones. Fifteen enhancers modified phenotypes in multiple Unc mutants, whereas 60 modified only the Unc phenotype in the tau transgenic lines. We also introduced the tau transgene into the background of genetic loss-of-function mutations for a subset of the enhancer genes. Tau transgenic animals homozygous for loss of these enhancer genes exhibited increased impaired motility relative to the tau transgene line alone. This work uncovers novel candidate genes that prevent tau toxicity, as well as genes previously implicated in tau-mediated neurodegeneration. C1 Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Div Neurogenet, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Schellenberg, GD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle Div, 1660 S Columbian Ave, Seattle, WA 98108 USA. EM zachdad@u.washington.edu FU NIA NIH HHS [AG017586] NR 94 TC 72 Z9 91 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 1 PY 2006 VL 15 IS 9 BP 1483 EP 1496 DI 10.1093/hmg/ddl067 PG 14 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 035LL UT WOS:000237002400010 PM 16600994 ER PT J AU Sterling, TR Zhao, Z Khan, A Chaisson, RE Schluger, N Mangura, B Weiner, M Vernon, A AF Sterling, TR Zhao, Z Khan, A Chaisson, RE Schluger, N Mangura, B Weiner, M Vernon, A CA Tuberculosis Trials Consortium TI Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; mortality; HIV; malignancy ID HIV-RELATED TUBERCULOSIS; CASE-FATALITY RATE; PULMONARY TUBERCULOSIS; DEATH CERTIFICATE; NETHERLANDS; RIFAPENTINE; DIAGNOSIS; THERAPY; TWICE; CITY AB SETTING: North America. OBJECTIVES: Tuberculosis (TB) patients in North America often have characteristics that may increase overall mortality. Identifying modifiable risk factors would allow for improvements in outcome. DESIGN: We evaluated mortality in a large TB treatment trial conducted in the United States and Canada. Persons with culture-positive pulmonary TB were enrolled after 2 months of treatment, treated for 4 more months under direct observation, and followed for 2 years (total observation: 28 months). Cause of death was determined by death certificate, autopsy, and/or clinical observation. RESULTS: Of 1075 participants, 71 (6.6%) died: 15/71 (21.1%) HIV-infected persons, and 56/1004 (5.6%) non-HIV-infected persons (P < 0.001). Only one death was attributed to TB. Cox multivariate regression analysis identified four independent risk factors for death after controlling for age: malignancy (hazard ratio [HR] 5.28, P < 0.0001), HIV (HR 3.89, P < 0.0001), daily alcohol (HR 2.94, P < 0.0001), and being unemployed (HR 1.99, P = 0.01). The risk of death increased with the number of independent risk factors present (P < 0.0001). Extent of disease and treatment failure/relapse were not associated with an increased risk of death. CONCLUSIONS: Death due to TB was rare. Interventions to treat malignancy, HIV, and alcohol use in TB patients are needed to reduce mortality in this patient population. C1 Vanderbilt Univ, Med Ctr, Div Infect Dis, Nashville, TN 37232 USA. Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD USA. Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07103 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. RP Sterling, TR (reprint author), Vanderbilt Univ, Med Ctr, Div Infect Dis, A2209 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM timothy.sterling@vanderbilt.edu NR 30 TC 54 Z9 54 U1 0 U2 3 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2006 VL 10 IS 5 BP 542 EP 549 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 038JT UT WOS:000237216500012 PM 16704037 ER PT J AU Kellogg, DL AF Kellogg, DL TI In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE thermoregulation; heat stress; cold stress; skin blood flow; cotransmission ID SKIN BLOOD-FLOW; VASOACTIVE INTESTINAL POLYPEPTIDE; NITRIC-OXIDE CONCENTRATION; COLD-INDUCED CONSTRICTION; HEAT-STRESS; ACTIVE VASODILATION; NEUROPEPTIDE-Y; SWEAT GLANDS; LOCAL TEMPERATURE; CARDIOVASCULAR ADJUSTMENTS AB This review focuses on the neural and local mechanisms that have been demonstrated to effect cutaneous vasodilation and vasoconstriction in response to heat and cold stress in vivo in humans. First, our present understanding of the mechanisms by which sympathetic cholinergic nerves mediate cutaneous active vasodilation during reflex responses to whole body heating is discussed. These mechanisms include roles for cotransmission as well as nitric oxide ( NO). Next, the mechanisms by which sympathetic noradrenergic nerves mediate cutaneous active vasoconstriction during whole body cooling are reviewed, including cotransmission by neuropeptide Y ( NPY) acting through NPY Y1 receptors. Subsequently, current concepts for the mechanisms that effect local cutaneous vascular responses to direct skin warming are examined. These mechanisms include the roles of temperature-sensitive afferent neurons as well as NO in causing vasodilation during local heating of skin. This section is followed by a review of the mechanisms that cause local cutaneous vasoconstriction in response to direct cooling of the skin, including the dependence of these responses on intact sensory and sympathetic, noradrenergic innervation as well as roles for nonneural mechanisms. Finally, unresolved issues that warrant further research on mechanisms that control cutaneous vascular responses to heating and cooling are discussed. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Geronterol, San Antonio, TX 78229 USA. Audie L Murphys Mem Vet Hosp Div, S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Kellogg, DL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Geronterol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu FU NHLBI NIH HHS [HL-65599] NR 96 TC 167 Z9 172 U1 6 U2 37 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAY PY 2006 VL 100 IS 5 BP 1709 EP 1718 DI 10.1152/japplphysiol.01071.2005 PG 10 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 040DE UT WOS:000237358400040 PM 16614368 ER PT J AU Offner, H Subramanian, S Parker, SM Afentoulis, ME Vandenbark, AA Hurn, PD AF Offner, H Subramanian, S Parker, SM Afentoulis, ME Vandenbark, AA Hurn, PD TI Experimental stroke induces massive, rapid activation of the peripheral immune system SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE chemokines; cytokines; peripheral immunity; receptors; stroke ID MIDDLE CEREBRAL-ARTERY; CENTRAL-NERVOUS-SYSTEM; INTERFERON-INDUCIBLE PROTEIN-10; CHEMOKINE RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; RAT ISCHEMIC CORTEX; SPINAL-CORD; PERMANENT OCCLUSION; GENE-EXPRESSION; FOCAL STROKE AB Clinical experimental stroke induces injurious local brain inflammation. However, effects on the peripheral immune system have not been well characterized. We quantified mRNA and protein levels for cytokines, chemokines, and chemokine receptors (CCR) in brain, spinal cord, peripheral lymphoid organs (spleen, lymph node, blood, and cultured mononuclear cells from these sources), and blood plasma after reversible middle cerebral artery occlusion (MCAO) or sham treatment in male C57BL/6 mice. Middle cerebral artery occlusion induced a complex, but organ specific, pattern of inflammatory factors in the periphery. At both 6 and 22 h after MCAO, activated spleen cells from stroke-injured mice secreted significantly enhanced levels of TNF-alpha, IFN-gamma, IL-6, MCP-1, and IL-2. Unstimulated splenocytes expressed increased chemokines and CCR, including MIP-2 and CCR2, CCR7 & CCR8 at 6 h; and MIP-2, IP-10, and CCR1 & CCR2 at 22 h. Also at 22 h, T cells from blood and lymph nodes secreted increased levels of inflammatory cytokines after activation. As expected, there were striking proinflammatory changes in postischemic brain. In contrast, spinal cord displayed suppression of all mediators, suggesting a compensatory response to intracranial events. These data show for the first time that focal cerebral ischemia results in dynamic and widespread activation of inflammatory cytokines, chemokines, and CCR in the peripheral immune system. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NINDS NIH HHS [NS33668, NS49210, R01 NS076013]; NINR NIH HHS [NR03521] NR 40 TC 254 Z9 267 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAY PY 2006 VL 26 IS 5 BP 654 EP 665 DI 10.1038/sj.jcbfm.9600217 PG 12 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 038RA UT WOS:000237239500007 PM 16121126 ER PT J AU Molitch, ME Clemmons, DR Malozowski, S Merriam, GR Shalet, SM Vance, ML AF Molitch, ME Clemmons, DR Malozowski, S Merriam, GR Shalet, SM Vance, ML CA Endocrine Societys Clinical Guidel TI Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Review ID GH-REPLACEMENT THERAPY; BONE-MINERAL DENSITY; CARDIOVASCULAR RISK-FACTORS; INTIMA-MEDIA THICKNESS; QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; RECOMBINANT HUMAN GH; BENIGN INTRACRANIAL HYPERTENSION; MIMICKING DIABETIC-RETINOPATHY; RANDOMIZED CONTROLLED TRIAL AB Objective: The objective is to provide guidelines for the evaluation and treatment of adults with GH deficiency (GHD). Participants: The chair of the Task Force was selected by the Clinical Guidelines Subcommittee of The Endocrine Society (TES). The chair selected five other endocrinologists and a medical writer, who were approved by the Council. One closed meeting of the group was held. There was no corporate funding, and members of the group received no remuneration. Evidence: Only fully published, peer-reviewed literature was reviewed. The Grades of Evidence used are outlined in the Appendix. Consensus Process: Consensus was achieved through one group meeting and e-mailing of drafts that were written by the group with grammatical/style help from the medical writer. Drafts were reviewed successively by the Clinical Guidelines Subcommittee, the Clinical Affairs Committee, and TES Council, and a version was placed on the TES web site for comments. At each level, the writing group incorporated needed changes. Conclusions: GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks of GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual. C1 Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA. NIDDKD, NIH, Bethesda, MD 20892 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98432 USA. Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England. Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22908 USA. RP Molitch, ME (reprint author), Endocrine Soc, 8401 Connecticut Ave,Suite 900, Chevy Chase, MD 20815 USA. NR 166 TC 219 Z9 229 U1 0 U2 9 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2006 VL 91 IS 5 BP 1621 EP 1634 DI 10.1210/jc.2005-2227 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 039TL UT WOS:000237330000001 PM 16636129 ER PT J AU Sontag, SJ Sonnenberg, A Schnell, TG Leya, J Metz, A AF Sontag, SJ Sonnenberg, A Schnell, TG Leya, J Metz, A TI The long-term natural history of gastroesophageal reflux disease SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Review DE natural history; gastroesophageal reflux diseases ID RISK-FACTORS; FOLLOW-UP; ESOPHAGITIS AB Introduction: Long-term gastric acid suppression has been suggested as a means to prevent complications of reflux esophagitis. We report on the 20-year follow-up of 2,306 patients with at least two endoscopic examinations who were taking no antisecretory medication before baseline endoscopy and whose long-term treatment was determined by reflux symptoms. Methods: From 1979 through 1998, endoscopy and biopsy were performed in the Hines Veterans Affairs Hospital endoscopy clinic by three endoscopists. Antireflux treatment was symptom-driven, and endoscopies were repeated mostly for symptomatic recurrence due to cessation of therapy. Results: Of 4,633 patients undergoing endoscopy for reflux symptoms, 2,306 had at least one follow-up endoscopy and biopsy. Over a mean follow-up period of 7.6 years (range, 1-20 years), the esophageal mucosa of 67% of patients remained unchanged, that of 21% improved, and that of 11% worsened. Esophageal stricture requiring dilation developed from a normal baseline mucosa in one of 1,313 patients (0.08%) and from an erosive baseline mucosa in 18 of 957 patients (1.9%). The overall incidence of stricture in patients with gastroesophageal reflux (GER) disease was < 1/1,000 per year. Nonsteroidal antiinflammatory drug (NSAID) consumption was associated with less mucosal improvement (odds ration [OR] = 0.67; confidence interval [CI] = 0.46-0.98). Use of histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) was associated with mucosal improvement (OR for PPIs = 1.49, CI = 1.14-2.17). Cohn's kappa was 42%, confirming the results that demonstrate stability of esophageal mucosal disease in the majority of patients. Conclusions: Symptom-driven treatment of GER disease after a thorough endoscopic examination to exclude premalignant or malignant esophageal mucosal disease is practical and safe for the vast majority of patients with uncomplicated GER symptoms. C1 Hines Vet Affairs Hosp, Hines, IL 60141 USA. Loyola Univ, Sch Med, Maywood, IL 60153 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Sontag, SJ (reprint author), Hines Vet Affairs Hosp, Bldg 1,Room B321 151B3, Hines, IL 60141 USA. EM Stephen.Sontag@med.va.gov NR 16 TC 35 Z9 36 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAY-JUN PY 2006 VL 40 IS 5 BP 398 EP 404 DI 10.1097/00004836-200605000-00007 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 045LF UT WOS:000237742900007 PM 16721220 ER PT J AU Haidet, P Kelly, PA Bentley, S Blatt, B Chou, CL Fortin, AH Gordon, G Gracey, C Harrell, H Hatem, DS Helmer, D Paterniti, DA Wagner, D Inui, TS AF Haidet, P Kelly, PA Bentley, S Blatt, B Chou, CL Fortin, AH Gordon, G Gracey, C Harrell, H Hatem, DS Helmer, D Paterniti, DA Wagner, D Inui, TS CA Communication Curriculum Culture TI Not the same everywhere - Patient-centered learning environments at nine medical schools SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE physician-patient relations; patient-centered care; schools, medical; students; medical; culture; organizational culture; education, medical, undergraduate; curriculum ID INTERVIEWING SKILLS; STUDENTS; CURRICULUM; EDUCATION; CARE; COMMUNICATION; ACQUISITION; RETENTION; ATTITUDES; CONTEXT AB BACKGROUND: Learning environments overtly or implicitly address patient-centered values and have been the focus of research for more than 40 years, often in studies about the "hidden curriculum." However, many of these studies occurred at single medical schools and used time-intensive ethnographic methods. This field of inquiry lacks survey methods and information about how learning environments differ across medical schools. OBJECTIVE: To examine patient-centered characteristics of learning environments at 9 U.S. medical schools. DESIGN: Cross-sectional internet-based survey. PARTICIPANTS: Eight-hundred and twenty-three third- and fourth-year medical students in the classes of 2002 and 2003. MEASUREMENTS: We measured the patient-centeredness of learning environments with the Communication, Curriculum, and Culture (C-3) Instrument, a 29-item validated measure that characterizes the degree to which a medical school's environment fosters patient-centered care. The C-3 Instrument contains 3 content areas (role modeling, students' experiences, and support for students' patient-centered behaviors), and is designed to measure these areas independent of respondents' attitudes about patient-centered care. We also collected demographic and attitudinal information from respondents. RESULTS: The variability of C-3 scores across schools in each of the 3 content areas of the instrument was striking and statistically significant (P values ranged from .001 to .004). In addition, the patterns of scores on the 3 content areas differed from school to school. CONCLUSIONS: The 9 schools demonstrated unique and different learning environments both in terms of magnitude and patterns of characteristics. Further multiinstitutional study of hidden curricula is needed to further establish the degree of variability that exists, and to assist educators in making informed choices about how to intervene at their own schools. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. Yale Univ, Sch Med, New Haven, CT USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Univ Rochester, Sch Med & Dent, Rochester, NY USA. Univ Florida, Coll Med, Gainesville, FL USA. Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, E Orange, NJ USA. Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Sacramento, CA 95817 USA. Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA. Regenstrief Inst Hlth Care, Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. RP Haidet, P (reprint author), Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM phaidet@bcm.tmc.edu NR 37 TC 31 Z9 31 U1 1 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2006 VL 21 IS 5 BP 405 EP 409 DI 10.1111/j.1525-1497.2006.00417.x PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 040ZL UT WOS:000237422300001 PM 16704378 ER PT J AU Harrison, R Allen, E AF Harrison, R Allen, E TI Teaching internal medicine residents in the new era - Inpatient attending with duty-hour regulations SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE resident education; inpatient teaching; duty hours ID WORK HOURS; SLEEP AB BACKGROUND: Little is known about the impact of resident duty-hour regulations on the inpatient teaching experience. OBJECTIVE: Provide descriptive information on the effect of resident duty-hour regulations on attendings and the educational environment. DESIGN: Qualitative analysis of attending focus groups and e-mail survey of residents in Internal Medicine. PARTICIPANTS: Inpatient attending physicians at 2 academic centers and residents at the affiliated university-based Internal Medicine residency program in Portland, OR. RESULTS: Seventy-two percent of eligible attendings participated in 2 focus groups. Three themes were generated: increased clinical role, altered time management, and altered teaching. Attending physicians report performing more clinical work, teaching less, using more focused teaching methods, and experiencing an increased perception of intensity. Forty percent of eligible residents completed our e-mail survey. We organized residents data using the same 3 themes as attending physician data. Residents observed attending physicians performing increased clinical work, being more time aware, delivering more focused teaching, and having less time to teach. Participants noted changes in autonomy and professionalism. Strategies to enhance teaching effectiveness in the new environment were described. CONCLUSION: Duty-hour regulations have increased attending clinical responsibility and decreased teaching time in 1 residency program, leading to the perception of a more intense attending experience. Duty-hour regulations encourage educators to determine what is critical to preserve in the educational experiences of learners and challenge us to reexamine autonomy and professionalism in training. C1 Oregon Hlth Sci Univ, Div Hospitalist Med, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Harrison, R (reprint author), Oregon Hlth Sci Univ, Div Hospitalist Med, BTE 119,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM harrisor@ohsu.edu NR 21 TC 22 Z9 22 U1 0 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2006 VL 21 IS 5 BP 447 EP 452 DI 10.1111/j.1525-1497.2006.00425.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 040ZL UT WOS:000237422300009 PM 16704386 ER PT J AU Butt, AA Evans, R Skanderson, M Shakil, AO AF Butt, AA Evans, R Skanderson, M Shakil, AO TI Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis SO JOURNAL OF HEPATOLOGY LA English DT Article DE HCV; dialysis; comorbidities; treatment ID CHRONIC HEPATITIS-C; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; HUMAN-IMMUNODEFICIENCY-VIRUS; HEMOLYTIC-ANEMIA; HEPATOCELLULAR-CARCINOMA; INITIAL TREATMENT; RANDOMIZED-TRIAL; VETERANS; HIV; COINFECTION AB Background/Aims: The burden of comorbidity in the Hepatitis C virus (HCV) infected persons on dialysis is unknown. Methods: We identified all HCV infected and uninfected subjects in the United States Renal Data System in the years 1997-1998 using ICD-9 codes. Controls were matched on the date of first dialysis. ICD-9 codes and claims data was used to identify medical and psychiatric comorbidities. Results: We identified 5,737 HCV infected persons and 11,228 HCV uninfected subjects. HCV infected subjects were younger, more likely to be black race and male and more likely to have the following comorbidities: hypertension; hepatitis B; cirrhosis; wasting; anemia; human immunodeficiency virus (HIV) infection; major depression; mild depression; bipolar disorder; schizophrenia; post-traumatic stress disorder; drug use; alcohol use; smoking and less likely to have the following comorbidities: coronary artery disease; stroke; peripheral vascular disease; diabetes; cancer; erythropoietin use. After adjusting for age, gender and race, HCV infected subjects were more likely to have hypertension, hepatitis B, cirrhosis, wasting, anemia and HIV infection and less likely to have coronary artery disease and stroke. Conclusions: HCV infected persons on dialysis are more likely to have psychiatric comorbidities and substance abuse, as well as certain medical comorbidities. These factors should be considered when developing future intervention strategies. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 Univ Pittsburgh, Med Ctr, Sch Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, Falk Med Bldg,3601 5th Ave,Suite 3A, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu RI Langan Martin, Julie/M-4658-2015 FU NIDA NIH HHS [DA016175-01A1] NR 26 TC 24 Z9 24 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD MAY PY 2006 VL 44 IS 5 BP 864 EP 868 DI 10.1016/j.jhep.2006.01.024 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 039SS UT WOS:000237327800006 PM 16516332 ER PT J AU Leykum, L Pugh, J Diuguid, D Papadopoulos, K AF Leykum, Luci Pugh, Jacqueline Diuguid, David Papadopoulos, Kyriakos TI Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE heparin-induced thrombocytopenia; VTE prophylaxis; cast-utility ID MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; LOW-DOSE HEPARIN; INDUCED THROMBOCYTOPENIA; DOUBLE-BLIND; PHARMACOECONOMIC EVALUATION; COLORECTAL SURGERY; RANDOMIZED-TRIAL; RISK-FACTORS AB BACKGROUND: Both heparin and enoxaparin are effective for the prevention of venous thromboembolism (VTE) in medical patients. On the basis of price, heparin appears preferable because it is less expensive. However, choosing enoxaparin may have greater cost utility when the outcomes of heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITT) are considered. OBJECTIVE: To determine the cost utility of substituting enoxaparin for heparin from payer and institutional perspectives. DESIGN: A decision analysis model was used. Cost data were based on Medicare reimbursement and the medication and laboratory costs for a multi-institutional healthcare system. Quality-adjusted life years (QALYs) saved by preventing HIT/HITT through the use of enoxaparin were based on published data. Costs are expressed on a per-day basis, and the incremental cost of enoxaparin over that of heparin was used in the calculation of cost/QALY. A sensitivity analysis also was performed. SETTING: inpatient medicine. PATIENTS: All medical patients for whom VTE prophylaxis was appropriate. INTERVENTIONS: Substitution of enoxaparin for heparin. MEASUREMENT: Cost/QALY. RESULTS: From a payer perspective, using enoxaparin resulted in a decrease in cost of $28.61 over that of heparin and saved 0.00629 QALYs in the base case, resulting in a savings of $4550.17/QALY. The sensitivity analysis showed this finding of decreased cost and increased effectiveness to be consistent. From an institutional perspective, the use of heparin generally appeared less costly but was dependent on medication price, length of stay required, and bed utilization. CONCLUSIONS: From a payer and, by extrapolation, a societal perspective, cost-utility analysis supports the use of enoxaparin in place of heparin for the prevention of VTE in medical inpatients. From an institutional perspective, the decision is more complicated, but in most cases, the use of enoxaparin also is supported. C1 [Leykum, Luci; Pugh, Jacqueline; Papadopoulos, Kyriakos] S Texas Veterans Hlth Care Syst, San Antonio, TX USA. [Leykum, Luci; Pugh, Jacqueline] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Diuguid, David] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Papadopoulos, Kyriakos] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA. RP Leykum, L (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Ambulatory Care 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM leykum@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X NR 34 TC 12 Z9 13 U1 3 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAY-JUN PY 2006 VL 1 IS 3 BP 168 EP 176 DI 10.1002/jhm.97 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 291PS UT WOS:000255209900006 PM 17219491 ER PT J AU Perez, LE Chandrasekar, B Saldarriaga, OA Zhao, WG Arteaga, LT Travi, BL Melby, PC AF Perez, Luis E. Chandrasekar, Bysani Saldarriaga, Omar A. Zhao, Weiguo Arteaga, Lourdes T. Travi, Bruno L. Melby, Peter C. TI Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen SO JOURNAL OF IMMUNOLOGY LA English DT Article ID NITRIC-OXIDE SYNTHASE; EXPERIMENTAL VISCERAL LEISHMANIASIS; REGULATORY FACTOR-I; INTERFERON-GAMMA; PROINFLAMMATORY CYTOKINE; MESOCRICETUS-AURATUS; MURINE MACROPHAGES; IMMUNE-RESPONSE; GOLDEN-HAMSTER; MESSENGER-RNA AB Progressive disease in the hamster model of visceral leishmaniasis, caused by Leishmania donovani, in contrast to infection in mice, mimics the progressive disease observed in untreated humans. During progressive infection in hamsters, there was a vigorous type 1 cellular immune response, which is typically associated with control of infection, suggesting that there was ineffective IFN-gamma-mediated macrophage activation. Indeed, at the site of infection, hamsters did not express NO synthase 2 (NOS2), which is the primary mechanism for control of infection in mice. Furthermore, in striking contrast to mouse macrophages, IFN-gamma-activated hamster macrophages did not did not express NOS2 nor generate NO, and were unable to restrict the replication of intracellular L. donovani. The absent hamster NOS2 expression was not the result of NOS2 gene deletion and the NOS2 cDNA had an intact open reading frame. Furthermore, the impaired transcription of NOS2 mRNA was selective and not due to global impairment of IFN-gamma signaling (members of the IFN-gamma-signaling pathway were expressed and functional and IFN-gamma up-regulated several primary and secondary response genes). Strikingly, the proximal hamster NOS2 promoter, like the human ortholog, had > 20-fold less basal and IFN-gamma/LPS-inducible activity than the corresponding mouse promoter. Thus, reduced basal and IFN-gamma-induced activity of the hamster NOS2 transcriptional unit, which is unique to this small animal and similar to the human counterpart, accompanies the inability of the animal to control an intracellular pathogen. C1 Dept Vet Affairs Med Ctr, Res Serv, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA. Univ Texas, Dept Microbiol & Immunol, Hlth Sci Ctr, San Antonio, TX 78229 USA. Ctr Int Entrenamiento & Invest Med, Cali, Colombia. RP Melby, PC (reprint author), Dept Vet Affairs Med Ctr, Res Serv, S Texas Vet Hlth Care Syst, 7400 Merton Minter Dr,Mailstop 151, San Antonio, TX 78229 USA. EM melby@uthscsa.edu FU NCRR NIH HHS [RR 12469]; NIAID NIH HHS [AI 61624] NR 51 TC 31 Z9 31 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2006 VL 176 IS 9 BP 5519 EP 5528 PG 10 WC Immunology SC Immunology GA 059YS UT WOS:000238768700050 PM 16622021 ER PT J AU Houben, E Holleran, WM Yaginuma, T Mao, CG Obeid, LM Rogiers, V Takagi, Y Elias, PM Uchida, Y AF Houben, E Holleran, WM Yaginuma, T Mao, CG Obeid, LM Rogiers, V Takagi, Y Elias, PM Uchida, Y TI Differentiation-associated expression of ceramidase isoforms in cultured keratinocytes and epidermis SO JOURNAL OF LIPID RESEARCH LA English DT Article DE ceramide; sphingolipid; sphingosine ID HUMAN ACID CERAMIDASE; NEUTRAL CERAMIDASE; STRATUM-CORNEUM; PERMEABILITY BARRIER; MOLECULAR-CLONING; INDUCED APOPTOSIS; ALKALINE CERAMIDASE; ATOPIC-DERMATITIS; GLUCOSYLCERAMIDE; PURIFICATION AB Ceramides (Cers) accumulate within the interstices of the outermost epidermal layers, or stratum corneum (SC), where they represent critical components of the epidermal permeability barrier. Although the SC contains substantial sphingol, indicative of ceramidase (CDase) activity, which CDase isoforms are expressed in epidermis remains unresolved. We hypothesized here that CDase isoforms are expressed within specific epidermal compartments in relation to functions that localize to these layers. Keratinocytes/epidermis express all five known CDase isoforms, of which acidic and alkaline CDase activities increase significantly with differentiation, persisting into the SC. Conversely, neutral and phytoalkaline CDase activities predominate in proliferating keratinocytes. These differentiation-associated changes in isoform activity/protein are attributed to corresponding, differentiation-associated changes in mRNA levels (by quantitative RT-PCR). Although four of the five known CDase isoforms are widely expressed in cutaneous and extracutaneous tissues, alkaline CDase-1 occurs almost exclusively in epidermis. These results demonstrate large, differentiation-associated, and tissue-specific variations in the expression and activities of all five CDase isoforms. Because alkaline CDase-1 and acidic CDase are selectively upregulated in the differentiated epidermal compartment, they could regulate functions that localize to the distal epidermis, such as permeability barrier homeostasis and antimicrobial defense. C1 Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. Vrije Univ Brussels, Dept Toxicol DermatoCosmetol & Pharmacognosy, Brussels, Belgium. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA. Kao Corp, Biol Sci Lab, Haga, Tochigi, Japan. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Uchida, Y (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. EM uchiday@itsa.ucsf.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [CA-104834]; NIAMS NIH HHS [AR-050629, AR-19098, AR-39448] NR 46 TC 33 Z9 34 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAY PY 2006 VL 47 IS 5 BP 1063 EP 1070 DI 10.1194/jlr.M600001-JLR200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 048GQ UT WOS:000237936000020 PM 16477081 ER PT J AU Minzenberg, MJ Poole, JH Vinogradov, S AF Minzenberg, Michael J. Poole, John H. Vinogradov, Sophia TI Adult social attachment disturbance is related to childhood maltreatment and current symptoms in borderline personality disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat DE borderline personality disorder; social attachment; childhood maltreatment; impulsivity; affect ID SUICIDAL-BEHAVIOR; SEXUAL ABUSE; WOMEN; PSYCHOPATHOLOGY; PREDICTORS; SEVERITY; STYLES; SAMPLE AB We characterized borderline personality disorder (BPD) along two fundamental dimensions of adult social attachment and evaluated attachment associations with childhood maltreatment and current symptoms using self-report measures in 40 outpatients with DSM-IV BPD. The BPD group had significantly greater dimensional attachment impairment and rate of fearful attachment type compared with a healthy control group. Among BPD subjects, dimensional attachment-anxiety was specifically associated with sexual abuse, whereas attachment-avoidance was associated with all five maltreatment types. The two attachment dimensions showed divergent associations with current interpersonal problems, impulsivity subtypes and mood symptoms. We conclude that (1) BPD is characterized by adult attachment disturbance; (2) these attachment problems are strongly related to childhood maltreatment, and to current interpersonal problems and clinical symptoms that are considered core features of BPD; and (3) the diverse problems of BPD patients may arise from two basic mechanisms, each tied to a different type of attachment disturbance, developmental history, and clinical outcome. C1 Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Minzenberg, MJ (reprint author), Univ Calif Davis, Imaging Res Ctr, UC Davis Hlth Syst, 4701 10 St, Sacramento, CA 95817 USA. NR 44 TC 24 Z9 27 U1 5 U2 27 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAY PY 2006 VL 194 IS 5 BP 341 EP 348 DI 10.1097/01.nmd.0000218341.54333.4e PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 044RH UT WOS:000237689500006 PM 16699383 ER PT J AU Yoshimura, M Fueki, K Garrettt, N Ohyama, T AF Yoshimura, M Fueki, K Garrettt, N Ohyama, T TI Influence of food platform width of mandibular removable partial denture on food mixing ability SO JOURNAL OF ORAL REHABILITATION LA English DT Article DE removable partial denture; food platform; tooth width; masticatory function; food mixing ability ID MASTICATORY FUNCTION; CHEWING GUM; PERFORMANCE; TEETH; SIZE AB The aim of this study was to clarify the influence of food platform width on food mixing ability in patients with mandibular removable partial dentures (RPDs). Twelve subjects (six males and six females, mean age 56(.)8 years) with intact dentition except for unilaterally missing mandibular first and second molars participated in the study. The food platforms of their RPDs were made of light polymerized composite and three platform conditions were evaluated. A food platform (Control condition) had 7 mm width with a central focus on the top of the residual ridge. Narrowed platforms (5 mm) were created by trimming a lingual portion (Buccally oriented occlusion, Buccal condition) or a buccal portion (Lingually oriented occlusion, Lingual condition) from the control. Subjects chewed a standardized wax cube which provided an estimate of food mixing ability [Mixing Ability Index (MAI)] for each of the three platforms. A significant effect (P < 0(.)001) on the MAI was found for food platform type (repeated measures one-way analysis of variance). Tukey multiple comparisons found significant differences of MAI between Control condition (1(.)05 +/- 0(.)26) and Buccal condition (0(.)86 +/- 0(.)23) (P = 0(.)032), and between Control and Lingual condition (0(.)54 +/- 0(.)37) (P < 0(.)001). Furthermore, MAI with Lingual condition was significantly smaller than that with Buccal condition (P < 0(.)001). These results suggest that reduction in the width of the food platform may impair masticatory function and the buccal portion of mandibular food platform of RPD is more critical for food mixing than the lingual portion of the platform. C1 Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan. Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fueki, K (reprint author), Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan. EM kunfu.rpro@tmd.ac.jp RI Fueki, Kenji/A-9909-2008 OI Fueki, Kenji/0000-0002-5885-2447 NR 28 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0305-182X J9 J ORAL REHABIL JI J. Oral Rehabil. PD MAY PY 2006 VL 33 IS 5 BP 335 EP 340 DI 10.1111/j.1365-2842.2005.01570.x PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 045YB UT WOS:000237777500004 PM 16629891 ER PT J AU Avansino, JR Chen, DC Woolman, JD Hoagland, VD Stelzner, M AF Avansino, JR Chen, DC Woolman, JD Hoagland, VD Stelzner, M TI Engraftment of mucosal stem cells into murine jejunum is dependent on optimal dose of cells SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE intestinal stem cell transplantation; GFP; neo-mucosa; mucosal restitution; intestinal stem cell seeding density; jejunal debridment time ID SMALL-BOWEL; TRANSPLANTATION; ENTEROCYTES; MOUSE AB Background. Transplantation of intestinal mucosal stem cells is an important step in the development of intestinal gene therapy and treatment of intestinal mucosal diseases. We hypothesized that engraftment rates increase proportionally with increasing doses of seeded stem cells and increasing jejunal debridment. Materials and methods. Intestinal mucosal organoids were harvested from neonatal mice carrying a green-fluorescent protein (GFP) transgene and transplanted into adult GFP(-) mice (n = 66). In recipients, two jejunal segments (1.5 cm) were isolated with their blood circulation left intact with anastomosis of the distal and proximal segments to restore continuity. Debridement of native enterocytes was performed by perfusing luminally with ethylene diamine tetraacetc acid solutions for 20 min. A total of 5,000, 10,000, or 25,000 organoids were then seeded. Three weeks later, cross sections (n = 398) of the segments were evaluated for the presence of GFP(+) neomucosa using fluorescence microscopy. Additional segments were debrided for 30 and 40 min (n = 83). Other conditions were not tested because of the rate of high mortality in these experiments. Results. The group seeded with 10,000 organoid units at 20 min showed the highest engraftment of GFP(+) epithelium. Engraftment was improved by increasing debridment times at this seeding density. Overall mortality was 70%. Conclusions. These findings suggest that there is an optimal seeding density of stem cell clusters for enhanced engraftment in this model. Mortality prohibited complete testing of all combinations of seeding density and debridement times. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Surg, Seattle, WA 98105 USA. Vet Adm Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Avansino, JR (reprint author), Univ Washington, Dept Surg, Box 356410, Seattle, WA 98105 USA. EM javansin@u.washington.edu NR 12 TC 9 Z9 9 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD MAY PY 2006 VL 132 IS 1 BP 74 EP 79 DI 10.1016/j.jss.2005.09.009 PG 6 WC Surgery SC Surgery GA 035CH UT WOS:000236977100013 PM 16297408 ER PT J AU Rosen, S Weintraub, N AF Rosen, Sonja Weintraub, Nancy TI The efficacy of performing screening mammograms in the frail elderly population SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article ID BREAST-CANCER; OLDER WOMEN; AGE; SURVIVAL; COMORBIDITY; OPPORTUNITY; CARCINOMA; DIAGNOSIS; MORTALITY; BARRIERS C1 VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Sepulveda Vet Affairs Acad Nursing Home, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Multicampus Program Geriatr & Gerontol, Los Angeles, CA USA. RP Weintraub, N (reprint author), VA Greater Los Angeles Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Sepulveda Vet Affairs Acad Nursing Home, 11E,16111 Plummer St, Sepulveda, CA 91343 USA. EM nancy.weintraub@med.va.gov NR 35 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2006 VL 7 IS 4 BP 230 EP 233 DI 10.1016/j.jamda.2006.01.026 PG 4 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 081JW UT WOS:000240314900006 PM 16698509 ER PT J AU Rosenbloom, ST Miller, RA Johnson, KB Elkin, PL Brown, SH AF Rosenbloom, ST Miller, RA Johnson, KB Elkin, PL Brown, SH TI Interface terminologies: Facilitating direct entry of clinical data into electronic health record systems SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Review ID CONTROLLED MEDICAL TERMINOLOGY; DECISION-SUPPORT; KNOWLEDGE REPRESENTATION; INFORMATION-TECHNOLOGY; COMPUTER; LANGUAGE; VOCABULARIES; GUIDELINE; CARE; CLASSIFICATIONS AB Previous investigators have defined clinical interface terminology as a systematic collection of health care-related phrases (terms) that supports clinicians' entry of patient-related information into computer programs, such as clinical "note capture" and decision support tools. Interface terminologies also can facilitate display of computer-stored patient information to clinician-users. Interface terminologies "interface" between clinicians' own unfettered, colloquial conceptualizations of patient descriptors and the more structured, coded internal data elements used by specific health care application programs. The intended uses of a terminology determine its conceptual underpinnings, structure, and content. As a result, the desiderata for interface terminologies differ from desiderata for health care-related terminologies used for storage (e.g., SNOMED-CT (R)), information retrieval (e.g., MeSH), and classification (e.g., ICD9-CM (R)). Necessary but not sufficient attributes for an interface terminology include adequate synonym coverage, presence of relevant assertional knowledge, and a balance between pre- and post-coordination. To place interface terminologies in context, this article reviews historical goals and challenges of clinical terminology development in general and then focuses on the unique features of interface terminologies. C1 Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37240 USA. Vanderbilt Univ, Dept Pediat, Nashville, TN USA. Vanderbilt Univ, Sch Nursing, Nashville, TN USA. Mayo Fdn Med Educ & Res, Rochester, MN USA. US Dept Vet Affairs, Nashville, TN USA. RP Rosenbloom, ST (reprint author), Vanderbilt Univ, Dept Biomed Informat, 221 Kirkland Hall, Nashville, TN 37240 USA. EM trent.rosenbloom@vanderbilt.edu FU NLM NIH HHS [1K22 LM008576-01, 5R01 LM007995] NR 97 TC 95 Z9 96 U1 2 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY-JUN PY 2006 VL 13 IS 3 BP 277 EP 288 DI 10.1197/jamia.M1957 PG 12 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 052WI UT WOS:000238264200006 PM 16501181 ER PT J AU La Fontaine, J Harkless, LB Davis, CE Allen, MA Shireman, PK AF La Fontaine, J Harkless, LB Davis, CE Allen, MA Shireman, PK TI Current concepts in diabetic microvascular dysfunction SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Review ID ENDOTHELIAL DYSFUNCTION; VASCULAR-DISEASE; NITRIC-OXIDE; CARDIOVASCULAR EVENTS; BASEMENT-MEMBRANE; OXIDATIVE STRESS; FOOT ULCERATION; BLOOD-VISCOSITY; LOWER-EXTREMITY; MELLITUS AB Microvascular dysfunction is an important component of the pathologic processes that occur in diabetic foot disease. The endothelial abnormalities observed in patients with diabetes mellitus are poorly understood, and evidence suggests that endothelial dysfunction could be involved in the pathogenesis of diabetic macroangiopathy and microangiopathy. With the advent of insulin replacement in the early 1900s and increased efforts toward metabolic control of diabetes, long-term complications of this disease have become apparent. These late-term complications are primarily disorders of the vascular system. This article reviews the process of microvascular dysfunction and how it may relate to the pathogenesis of diabetic foot problems. C1 Univ Texas, Hlth Sci Ctr, Dept Orthoped, Podiatry Div, San Antonio, TX 78229 USA. Assoc Podiatrist Connecticut, Manchester, CT USA. Sports Med Assoc San Antonio, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Surg, Div Vasc Surg, San Antonio, TX 78229 USA. S Texas Vet Healthcare Syst, San Antonio, TX USA. RP La Fontaine, J (reprint author), Univ Texas, Hlth Sci Ctr, Dept Orthoped, Podiatry Div, 7703 Floyd Curl Dr,MSC 7776, San Antonio, TX 78229 USA. FU NHLBI NIH HHS [HL 070158, HL 074236] NR 73 TC 12 Z9 12 U1 0 U2 2 PU AMER PODIATRIC MED ASSN PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD MAY-JUN PY 2006 VL 96 IS 3 BP 245 EP 252 PG 8 WC Orthopedics SC Orthopedics GA 047PH UT WOS:000237890700010 PM 16707637 ER PT J AU Inagami, S Borrell, LN Wong, MD Fang, J Shapiro, MF Asch, SM AF Inagami, S Borrell, LN Wong, MD Fang, J Shapiro, MF Asch, SM TI Residential segregation and Latino, black and white mortality in New York City SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Hispanic; Latino; morality; New York City; race; segregation ID DISPARITIES GEOCODING PROJECT; LOW-BIRTH-WEIGHT; UNITED-STATES; ETHNIC DENSITY; SOCIOECONOMIC-FACTORS; INFANT-MORTALITY; HEALTH RESEARCH; SMALL-AREA; LONDON; SCHIZOPHRENIA AB Although racial segregation is associated with health status, few studies have examined this relationship among Latinos. We examined the effect of race/ethnic group concentration of Latinos, blacks and whites on all-cause mortality rates within a highly segregated metropolitan area, New York City (NYC). We linked NYC mortality records from 1999 and 2000 with the 2000 U.S. Census data by zip code area. Age-adjusted mortality rates by race/ethnic concentration were calculated. Linear regression was used to determine the association between population characteristics and mortality. Blacks living in predominantly black areas had lower all-cause mortality rates than blacks living in other areas regardless of gender (16161100,000 vs. 20141100,000 for men; 10321100,000 vs. 13621100 000 for women). Amongst whites, those living in predominantly white areas had the lowest mortality rates. Latinos living in predominantly Latino areas had lower mortality rates than those in predominantly black areas (1187/100,000 vs. 1950/100,000 for men; 760/100,000 vs. 7791100,000 for women). After adjustment for socioeconomic conditions, whites, older blacks, and young Latino men experienced decreasing mortality rates when living in areas with increasing similar race/ethnic concentrations. Increasing residential concentration of blacks is independently associated with lower mortality in older blacks; similarly, increasing residential concentration of Latinos and whites is associated with lower mortality in young Latino men and whites, respectively. C1 VA Greater Los Angeles Hlth Care Syst, Div Gen Internal Med 111G, Los Angeles, CA 90073 USA. Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RAND Hlth, Div Gen Internal Med 111G, Los Angeles, CA 90073 USA. RP Inagami, S (reprint author), VA Greater Los Angeles Hlth Care Syst, Div Gen Internal Med 111G, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM sinagami@ucla.edu OI Wong, Mitchell/0000-0002-4800-8410 FU NCI NIH HHS [F32 CA090073] NR 54 TC 36 Z9 36 U1 3 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD MAY PY 2006 VL 83 IS 3 BP 406 EP 420 DI 10.1007/s11524-006-9035-8 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 054CY UT WOS:000238355600008 PM 16739044 ER PT J AU Wolff, RA Malinowski, RL Heaton, NS Hullett, DA Hoch, JR AF Wolff, RA Malinowski, RL Heaton, NS Hullett, DA Hoch, JR TI Transforming growth factor-beta 1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID GROWTH-FACTOR-BETA; SMOOTH-MUSCLE-CELLS; INTIMAL HYPERPLASIA; GENE-EXPRESSION; TGF-BETA; MATRIX METALLOPROTEINASES; ALLOGRAFT-REJECTION; TISSUE INHIBITORS; SAPHENOUS-VEIN; BYPASS GRAFTS AB Background: The main cause of occlusion and vein graft failure after peripheral and coronary arterial reconstruction is intimal hyperplasia. Transforming growth factor beta-1 (TGF-beta 1) is a pleiotropic cytokine known to have powerful effects on cell growth, apoptosis, cell differentiation, and extracellular matrix synthesis. Methods: To investigate the role of TGF-beta 1 in intimal hyperplasia, we used adenovirus to deliver to superficial epigastric vein messenger RNA (mRNA) antisense to TGF-beta 1 (Ad-AST) or the sequence encoding the bioactive form of TGF-beta 1 (Ad-BAT). Infection with "empty" virus was used as a control (Ad-CMVpLpA). The treated vein was then used for an interposition graft into rat femoral artery. Grafts were harvested at 1, 2, 4, and 12 weeks and formalin-fixed for histologic studies or placed in liquid nitrogen for mRNA studies. Results. Ad-AST treatment resulted in an overall reduction of TGF-beta 1 expression (P = .001), and Ad-BAT treatment resulted in an overall increase in TGF-beta 1 expression (P = .007). Histologic analysis showed Ad-AST caused reduced collagen build up in the neointima at 12 weeks (P = .0001.). Immunohistochemical staining for h-caldesmon at 12 weeks indicated Ad-AST increased smooth muscle cells throughout the vessel wall compared with Ad-CMVpLpA (P = .0024) or Ad-BAT (P = .04). Ad-AST also resulted in reduced CD68-positive cells in the media/adventitia (P = .005 vs Ad-CMVpLpA, P = .01 vs Ad-BAT). To further understand how Ad-AST was influencing the build up of collagen, we performed quantitative polymerase chain reaction on complimentary DNA (cDNA) from homogenates of the vein grafts. Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) was increased at 1 week by Ad-BAT (P = .048 vs AdCMVpLpA) and decreased by Ad-AST at all time points (P <= .038). The mRNA for collagen-1 alpha-1 was decreased by Ad-AST at 2, 4, and 12 weeks (P <= .05) and increased by Ad-BAT at 1 week (P = .01). Conclusions: TGF-beta 1 antisense treatment of vein grafts prevents the accumulation of collagen in the neointima in part by (1) changing the proportions of the cell types populating the vein graft wall, (2) reducing the mRNA for TIMPs, and (3) reducing the amount of collagen mRNA. With the Ad-AST and Ad-BAT treatments, we have been able to tip the maturation of the vein graft toward positive remodeling (artery-like phenotype) or toward negative remodeling (fibroproliferation and stenosis), respectively. C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53792 USA. Univ Wisconsin, Sch Med, Madison, WI 53792 USA. RP Wolff, RA (reprint author), William S Middleton Mem Vet Adm Med Ctr, H5-3 CSC,VA G-Wing,600 Highland Ave, Madison, WI 53792 USA. EM wolff@surgery.wisc.edu NR 47 TC 15 Z9 17 U1 1 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2006 VL 43 IS 5 BP 1028 EP 1036 DI 10.1016/j.jvs.2006.01.016 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 038WY UT WOS:000237261400030 PM 16678700 ER PT J AU Crawford, SE Patel, DG Cheng, E Berkova, Z Hyser, JM Ciarlet, M Finegold, MJ Conner, ME Estes, MK AF Crawford, SE Patel, DG Cheng, E Berkova, Z Hyser, JM Ciarlet, M Finegold, MJ Conner, ME Estes, MK TI Rotavirus viremia and extraintestinal viral infection in the neonatal rat model SO JOURNAL OF VIROLOGY LA English DT Article ID RESPIRATORY-TRACT; HISTOLOGIC DISTRIBUTION; ACUTE GASTROENTERITIS; BILIARY ATRESIA; YOUNG-CHILDREN; ANIMAL-MODEL; SIALIC-ACID; ASSOCIATION; INFANT; SPREAD AB Rotaviruses infect mature, differentiated enterocytes of the small intestine and, by an unknown mechanism, escape the gastrointestinal tract and cause viremia. The neonatal rat model of rotavirus infection was used to determine the kinetics of viremia, spread, and pathology of rotavirus in extraintestinal organs. Five-day-old rat pups were inoculated intragastrically with an animal (RRV) or human (HALI 166) rotavirus or phosphate-buffered saline. Blood was collected from a subset of rat pups, and following perfusion to remove residual blood, organs were removed and homogenized to analyze rotavirus-specific antigen by enzyme-linked immunosorbent assay and infectious rotavirus by fluorescent focus assay or fixed in formalin for histology and immunohistochemistry. Viremia was detected following rotavirus infection with RRV and HAL1166. The RRV 50% antigenemia dose was 1.8 x 10(3) PFU, and the 50% diarrhea dose was 7.7 x 10(5) PFU, indicating that infection and viremia occurred in the absence of diarrhea and that detecting rotavirus antigen in the blood was a more sensitive measure of infection than diarrhea. Rotavirus antigens and infectious virus were detected in multiple organs (stomach, intestines, liver, lungs, spleen, kidneys, pancreas, thymus. and bladder). Histopathological changes due to rotavirus infection included acute inflammation of the portal tract and bile duct, microsteatosis, necrosis, and inflammatory cell infiltrates in the parenchymas of the liver and lungs. Colocalization of structural and nonstructural proteins with histopathology in the liver and lungs indicated that the histological changes observed were due to rotavirus infection and replication. Replicating rotavirus was also detected in macrophages in the lungs and blood vessels, indicating a possible mechanism of rotavirus dissemination. Extraintestinal infectious rotavirus, but not diarrhea, was observed in the presence of passively or actively acquired rotavirus-specific antibody. These findings alter the previously accepted concept of rotavirus pathogenesis to include not only gastroenteritis but also viremia, and they indicate that rotavirus could cause a broad array of systemic diseases in a number of different organs. C1 Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Merck & Co Inc, Clin Res Dept, Blue Bell, PA 19422 USA. RP Estes, MK (reprint author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. EM mestes@bcm.tmc.edu FU NIAID NIH HHS [AI 24998, R01 AI024998, R21 AI024998]; NIDDK NIH HHS [T32 DK007664, DK 07664, DK 30144, DK 56338, P30 DK056338, R01 DK030144, R56 DK030144] NR 56 TC 77 Z9 86 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAY PY 2006 VL 80 IS 10 BP 4820 EP 4832 DI 10.1128/JVI.80.10.4820-4832.2006 PG 13 WC Virology SC Virology GA 041LK UT WOS:000237457500018 PM 16641274 ER PT J AU Cabelof, DC Raffoul, JJ Ge, YB Van Remmen, H Matherly, LH Heydari, AR AF Cabelof, DC Raffoul, JJ Ge, YB Van Remmen, H Matherly, LH Heydari, AR TI Age-related loss of the DNA repair response following exposure to oxidative stress SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID BASE EXCISION-REPAIR; IN-VIVO; APURINIC/APYRIMIDINIC ENDONUCLEASE; CALORIC RESTRICTION; AP ENDONUCLEASE-1; STRAND BREAKS; UP-REGULATION; MOUSE-BRAIN; P53; INDUCTION AB Young (4- to 6-month-old) and aged (24- to 28-month-old) mice were exposed to 2-nitropropane (2-NP), a DNA oxidizing agent, and the ability to induce DNA polymerase beta (beta-pol) and AP endonuclease (APE) was determined. In contrast to the inducibility of these gene products in response to oxidative damage in young mice, aged mice showed a lack of inducibility of beta-pol and APE. APE protein level and endonuclease activity were both reduced 40% (p <.01) in response to 2-NP. Accordingly, the accumulation of DNA repair intermediates in response to 2-NP differed with age. Young animals accumulated 3'OH-containing DNA strand breaks, whereas the aged animals did not. A role for p53 in the difference in DNA damage response with age is suggested by the observation that the accumulation of p53 protein ill response to DNA damage in young animals was absent in the aged animals. Our results are consistent with a reduced ability to process DNA damage with age. C1 Wayne State Univ, Barbara Ann Karmanos Canc Inst, Sch Med, Dev Therapeut Program, Detroit, MI 48201 USA. Wayne State Univ, Dev Therapeut Program, Detroit, MI 48201 USA. Wayne State Univ, Dept Nutr & Food Sci, Detroit, MI 48201 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA. RP Cabelof, DC (reprint author), Wayne State Univ, Barbara Ann Karmanos Canc Inst, Sch Med, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA. EM d.cabelof@wayne.edu FU NIDDK NIH HHS [1R21-DK62256]; NIEHS NIH HHS [ES06639, 1F32-ES013643] NR 40 TC 30 Z9 33 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2006 VL 61 IS 5 BP 427 EP 434 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 046NL UT WOS:000237818200002 PM 16720738 ER PT J AU Young, BA Rudser, K Kestenbaum, B Seliger, SL Andress, D Boyko, EJ AF Young, BA Rudser, K Kestenbaum, B Seliger, SL Andress, D Boyko, EJ TI Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS SO KIDNEY INTERNATIONAL LA English DT Article DE race; ESRD; transplant; dialysis; mortality; myocardial infarction ID CORONARY-ARTERY CALCIFICATION; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; REVASCULARIZATION PROCEDURES; DIABETIC-NEPHROPATHY; UNITED-STATES; MORTALITY; RISK; POPULATION; RACE AB African Americans have a greater risk of cardiovascular disease (CVD) than Caucasians in early chronic kidney disease; however, limited data describe racial and ethnic differences in the risk of incident myocardial infarction (MI) among patients with end-stage renal disease ( ESRD). We conducted a prospective, observational cohort study among 271 102 incident dialysis patients receiving renal replacement therapy enrolled in the United States Renal Data System (USRDS) for whom Medicare was the primary insurer between 1995 and 2000. The incidence and risk of any MI (non-fatal or fatal) estimated by Cox proportional hazards models was the primary outcome of interest. Of those with prevalent CVD at baseline ( 118 708), 14 849 had an incident non-fatal MI compared with 9926 events for those without prevalent CVD ( 152 394). Patients with prevalent CVD had higher crude rates of combined fatal and non-fatal MI (99.3/1000 person-years vs 42.9/1000 person-years) compared with those without prevalent CVD. Among those with prevalent CVD, African Americans ( adjusted relative risk (aRR) 0.65, 95% confidence interval (CI): 0.62 - 0.68), Asian Americans (aRR = 0.74, 95% CI: 0.66 - 0.83), and Hispanics (aRR 0.72, 95% CI: 0.68 - 0.77) were 26 - 35% less likely to have an incident MI compared to Caucasians. Similarly, among those without prevalent CVD, racial/ethnic minorities were 26 - 42% less likely to have an incident MI compared to Caucasians. We conclude that in a national setting where comparable access to dialysis and associated medical care, exist, racial/ ethnic minorities were found to have a lower risk of non- fatal and fatal MI than Caucasians. C1 VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Special Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. NW Kidney Ctr, Seattle, WA USA. Univ Washington, Dept Biostat, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, 1600 S Columbian Way,152-E, Seattle, WA 98108 USA. EM youngb@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 36 TC 34 Z9 34 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAY PY 2006 VL 69 IS 9 BP 1691 EP 1698 DI 10.1038/sj.ki.5000346 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 038QP UT WOS:000237238400034 PM 16598201 ER PT J AU Gross, RD Steinhauer, KM Zajac, DJ Weissler, MC AF Gross, RD Steinhauer, KM Zajac, DJ Weissler, MC TI Direct measurement of subglottic air pressure while swallowing SO LARYNGOSCOPE LA English DT Article DE swallowing; deglutition; subglottic air pressure; tracheostomy tube ID PASSY-MUIR VALVE; NORMAL ADULTS; PHASE-RELATIONSHIPS; BOLUS VOLUME; LUNG-VOLUME; TRACHEOSTOMY; ASPIRATION; COORDINATION; RESPIRATION; PHYSIOLOGY AB Objective: The subglottic pressure theory for swallowing asserts that laryngeal mechanoreceptors have a role in the regulation of swallowing function. The primary purpose of this study was to determine if subglottic air pressure is generated during swallowing in a healthy, nontracheostomized person. Methods. This pilot investigation used a prospective, repeated-measures design in a single subject. Direct measurement of subglottic air pressure was obtained through percutaneous puncture of the cricothyroid membrane. Swallows were timed with four randomly assigned lung volumes: total lung capacity, tidal volume, functional residual capacity (FRC), and residual volume. Results: Lung volumes above FRC generated positive subglottic pressure during the swallow, whereas lung volumes below FRC generated consistently negative subglottic pressures. The degree and polarity of the pressure was directly related to lung volume at the time of the swallow. Conclusion. These findings illustrate that during normal swallowing, positive subglottic air pressure is likely present. Previously, subglottic air pressure during swallowing had been measured in tracheostomy patients only. C1 Univ Pittsburgh, Sch Med, Dept Otolaryngol, Inst Eye & Ear, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Think Voice Int LLC, Pittsburgh, PA USA. Univ N Carolina, Dept Dent Ecol, Craniofacial Ctr, Chapel Hill, NC USA. Univ N Carolina, Dept Otolaryngol, Chapel Hill, NC USA. RP Gross, RD (reprint author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, Inst Eye & Ear, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM Grossrd@upmc.edu FU NIDCR NIH HHS [R01-DE10175] NR 24 TC 20 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD MAY PY 2006 VL 116 IS 5 BP 753 EP 761 DI 10.1097/01.mlg.0000205168.39446.12 PG 9 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 040KB UT WOS:000237376300013 PM 16652083 ER PT J AU Clever, SL Ford, DE Rubenstein, LV Rost, KM Meredith, LS Sherbourne, CD Wang, NY Arbelaez, JJ Cooper, LA AF Clever, SL Ford, DE Rubenstein, LV Rost, KM Meredith, LS Sherbourne, CD Wang, NY Arbelaez, JJ Cooper, LA TI Primary care patients' involvement in decision-making is associated with improvement in depression SO MEDICAL CARE LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 30-MAY 03, 2003 CL VANCOUVER, CANADA SP Soc Gen Internal Med DE depression; primary care; shared decision-making; patient involvement in care; patient-centered care ID QUALITY IMPROVEMENT; OUTCOMES; INTERVENTION; INTERVIEW; PROVIDER; HEALTH; COMMUNICATION; PHYSICIANS; IMPACT; MODEL AB Background: Depression is undertreated in primary care settings. Little research investigates the impact of patient involvement in decisions on guideline-concordant treatment and depression outcomes. Objective: The objective of this study was to determine whether patient involvement in decision-making is associated with guideline-concordant care and improvement in depression symptoms. Design: Prospective cohort study Setting: Multisite, nationwide randomized clinical trial of quality improvement strategies for depression in primary care. Subjects: Primary care patients with current symptoms and probable depressive disorder. Measurements: Patients rated their involvement in decision-making (IDM) about their care on a 5-point scale from poor to excellent 6 months after entry into the study. Depressive symptoms were measured every 6 months for 2 years using a modified version of the Center for Epiderniologic Studies-Depression (CES-D) scale. We examined probabilities (Pr) of receipt of guideline-concordant care and resolution of depression across IDM groups using multi-variate logistic regression models controlling for patient and provider factors. Results: For each 1-point increase in IDM ratings, the probability of patients' report of receiving guideline-concordant care increased 4% to 5% (adjusted Pr 0.31 vs. 0.50 for the lowest and highest IDM ratings, respectively, P < 0.001). Similarly, for each 1-point increase in IDM ratings, the probability of depression resolution increased 2% to 3% (adjusted Pr 0.10 vs. 0.19 for the lowest and highest IDM ratings respectively, P = 0.004). Conclusions: Depressed patients with higher ratings of involvement in medical decisions have a higher probability of receiving guideline-concordant care and improving their symptoms over an 18-month period. Interventions to increase patient involvement in decision-making may be an important means of improving care for and outcomes of depression. C1 Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA. Johns Hopkins Sch Med, Div Gen Internal Med, Dept Med, Baltimore, MD USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. RAND Corp, Hlth Program, Santa Monica, CA USA. Univ Colorado, Hlth Sci Ctr, Dept Family Med, Denver, CO 80202 USA. RP Cooper, LA (reprint author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-500, Baltimore, MD 21287 USA. EM lisa.cooper@jhmi.edu OI Wang, Nae-Yuh/0000-0001-6513-9730 FU NIMH NIH HHS [R01 MH5443, R01 MH5444, R01 MH57992] NR 42 TC 90 Z9 90 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAY PY 2006 VL 44 IS 5 BP 398 EP 405 DI 10.1097/01.mlr.0000208117.15531.da PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 037MC UT WOS:000237150000003 PM 16641657 ER PT J AU Weinberger, M Mahrshak, I Keller, N Goldscmied-Reuven, A Amariglio, N Kramer, M Tobar, A Samra, Z Pitlik, SD Rinaldi, MG Thompson, E Sutton, D AF Weinberger, M. Mahrshak, I. Keller, N. Goldscmied-Reuven, A. Amariglio, N. Kramer, M. Tobar, A. Samra, Z. Pitlik, S. D. Rinaldi, M. G. Thompson, E. Sutton, D. TI Isolated endogenous endophthalmitis due to a sporodochial-forming Phialemonium curvatum acquired through intracavernous autoinjections SO MEDICAL MYCOLOGY LA English DT Article DE Phialemonium curvatum; endophthalmitis; injections; contamination; outbreak ID DEXTROSE INFUSION FLUID; FUNGAL ENDOPHTHALMITIS; ENDOCARDITIS; INJECTION; INFECTION; OBOVATUM; THERAPY; ASPERGILLUS; IMPOTENCE; OUTBREAK AB We report a case of endogenous endophthalmitis due to a sporodochial-forming species of Phialemonium curvatum. The infection led to the enucleation of the affected eye, but there was no evidence of systemic dissemination. The isolated P. curvatum produced aggregates of phialides, many occurring on coils or in verticils, which eventually develop into sporodochia. The initial and post-enucleation isolates revealed they were identical to strains of P. curvatum from Israel causing disseminated disease in patients practicing intracavernous auto-injections for the treatment of erectile dysfunction. The reported case had unusual clinical and microbiological features. Despite the route of acquisition and the lack of systemic antifungal therapy, the infection did not spread beyond the eye. The morphology of the phialides aggregates was also unique, and the distinction between Volutella and Acremonium is discussed. This case expands the spectrum of infections due to Phialemonium species, and reveals a novel way of developing fungal endophthalmitis. C1 Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel. Chaim Sheba Med Ctr, Microbiol Lab, IL-52621 Tel Hashomer, Israel. Chaim Sheba Med Ctr, Hematol Lab, IL-52621 Tel Hashomer, Israel. Rabin Med Ctr, Inst Pathol, Petah Tiqwa, Israel. Rabin Med Ctr, Clin Microbiol Lab, Petah Tiqwa, Israel. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel. RP Weinberger, M (reprint author), Assaf Harofeh Med Ctr, Infect Dis Unit, IL-70300 Zerifin, Israel. EM miriw@netvision.net.il NR 30 TC 10 Z9 10 U1 0 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD MAY PY 2006 VL 44 IS 3 BP 253 EP 259 DI 10.1080/13693780500411097 PG 7 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 061NA UT WOS:000238878100008 PM 16702105 ER PT J AU Anstead, GM Martinez, M Graybill, JR AF Anstead, G. M. Martinez, M. Graybill, J. R. TI Control of a Candida glabrata prosthetic endovascular infection with posaconazole SO MEDICAL MYCOLOGY LA English DT Article DE Candida glabrata; infection; posaconazole; transjugular intrahepatic portosystemic shunt ID INTRAHEPATIC PORTOSYSTEMIC SHUNT; IN-VITRO ACTIVITIES; ANTIFUNGAL AGENTS; TORULOPSIS-GLABRATA; FLUCONAZOLE; FUNGEMIA; SUSCEPTIBILITY; ITRACONAZOLE; VORICONAZOLE; BACTEREMIA AB A 63-year-old man with a history of cirrhosis of the liver developed Candida glabrata fungemia after undergoing transjugular intrahepatic portosystemic shunt ( TIPS) placement. Treatment with oral fluconazole was initially effective, but when the patient became neutropenic, subsequent blood cultures grew C. glabrata and a thrombus developed, which partially occluded the stent. Despite treatment with fluconazole, blood cultures remained positive for C. glabrata. Treatment with posaconazole resulted in clinical improvement and the patient had only intermittently positive fungal cultures for 6 weeks. A CT scan showed resolution of the inferior vena cava thrombus. Subsequently, the patient developed hepatocellular carcinoma and hepatic encephalopathy and became noncompliant with posaconazole. Blood cultures again became positive for C. glabrata. The patient died a few weeks after the diagnosis of hepatocellular carcinoma, but the cause of death was believed to be worsening liver dysfunction, not C. glabrata infection. Posaconazole had controlled the infection for about 3 months prior to his death. In conclusion, posaconazole may be a useful option in the management of prosthetic endovascular infections caused by C. glabrata. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Vet Affairs, Med Ctr, Med Serv, San Antonio, TX USA. David Powell Clin, Austin, TX USA. RP Graybill, JR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM graybill@uthscsa.edu NR 30 TC 10 Z9 10 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD MAY PY 2006 VL 44 IS 3 BP 273 EP 277 DI 10.1080/13693780500049152 PG 5 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 061NA UT WOS:000238878100011 PM 16702108 ER PT J AU Bammert, CS O'Connell, S Miskevics, S Collins, EG Budiman-Mak, E AF Bammert, Christine S. O'Connell, Susan Miskevics, Scott Collins, Eileen G. Budiman-Mak, Elly TI Increased Mobility in Obese Elderly with Knee Osteoarthritis - A Home-Based Walking and Strength Program SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Bammert, Christine S.; O'Connell, Susan; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Collins, Eileen G.] Univ Illinois, Chicago, IL USA. [Budiman-Mak, Elly] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. EM christine.maloney@med.va.gov NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2006 VL 38 IS 5 SU S BP S419 EP S420 PG 2 WC Sport Sciences SC Sport Sciences GA V19KH UT WOS:000208070803163 ER PT J AU Grady, D AF Grady, D TI Helping women stop postmenopausal hormone therapy SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; REPLACEMENT THERAPY; DEMENTIA C1 Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94143 USA. RP Grady, D (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. NR 15 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD MAY-JUN PY 2006 VL 13 IS 3 BP 323 EP 324 DI 10.1097/01.gme.0000222473.16217.0f PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 050VD UT WOS:000238116100001 PM 16735925 ER PT J AU Friedberg, SJ Lam, YWF Blum, JJ Gregerman, RI AF Friedberg, SJ Lam, YWF Blum, JJ Gregerman, RI TI Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID ISOPHANE NPH INSULIN; TIME-ACTION PROFILES; SUBCUTANEOUS-INSULIN; FEEDBACK INHIBITION; OBESE SUBJECTS; GLUCOSE RESPONSES; REGULAR INSULIN; INJECTION-SITE; SECRETION; PHARMACOKINETICS AB Our experience over many years from 2 diabetes clinics with large patient populations indicated that, apparently, excessive doses of intermediate-acting insulin preparations (150-300 U of NPH insulin), alone or in combination with rapid-acting insulin, generally did not result in acceptable control of fasting blood glucose. We hypothesized that insulin resistance at the tissue level and the known variability of insulin absorption were not satisfactory explanations. To deal with the ambiguities of available data on insulin absorption, we elected to measure insulin bioavailability via a different approach. Thirteen publications provided plasma insulin concentrations after the subcutaneous administration of defined doses of insulin. These data were then analyzed by noncompartmental analysis and by standard pharmacokinetic methods. Analyses required only knowledge of the areas under the plasma insulin curve and the metabolic clearance rate of insulin. Both of these are parameters measurable with considerable accuracy. Quantitative pharmacokinetic analysis of published insulin absorption curves for insulin administered subcutaneously revealed mean absorption levels for regular and lispro insulin of 70 to 80%, 30% or less for NPH insulin, and 30 to 40% for lente insulin. In conclusion, poor absorption of intermediate-acting insulin preparations, or combinations of intermediate and rapid-acting insulin preparations, explains the difficulty in lowering blood glucose in patients with type 2 diabetes mellitus who have had long-standing disease, are insulin resistant, and have a flat insulin response to a glucose load. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27705 USA. RP Friedberg, SJ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM sjfriedberg@sbcglobal.net NR 49 TC 8 Z9 8 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD MAY PY 2006 VL 55 IS 5 BP 614 EP 619 DI 10.1016/j.metabol.2005.12.004 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 040SM UT WOS:000237400700009 PM 16631437 ER PT J AU Liang, TW Truax, AC Trojanowski, JQ Lee, VMY Stern, MB Kotzbauer, PT AF Liang, TW Truax, AC Trojanowski, JQ Lee, VMY Stern, MB Kotzbauer, PT TI Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor-predominant neurodegeneration with brain iron accumulation SO MOVEMENT DISORDERS LA English DT Article DE Hallervorden-Spatz syndrome; neurodegeneration with brain iron accumulation; pantothenate kinase; pantothenate kinase-associated neurodegeneration; tremor ID HALLERVORDEN-SPATZ-SYNDROME; KINASE-ASSOCIATED NEURODEGENERATION AB We describe an atypical case of pantothenate kinase-associated neurodegeneration (PKAN) in which slowly progressive arm tremor was the predominant symptom beginning at the age of 25, with late-onset dystonia and dysarthria developing at the age of 50. Compound heterozygous mutations resulting in missense amino acid substitutions G521R and I529V were identified in the pantothenate kinase (PANK2) gene. We demonstrate that while the G521R mutation results in an unstable and inactive protein, the previously unreported I529V substitution has no apparent effect on the stability or catalytic activity of PanK2. The phenotype that results from this combination of mutations suggests that atypical presentations of PKAN may arise from partial deficits in PanK2 catalytic activity. (C) 2006 Movement Disorder Society. C1 Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. RP Liang, TW (reprint author), Jefferson Hosp Neurosci, 900 Walnut St,Suite 200, Philadelphia, PA 19107 USA. EM tsao-wei.liang@jefferson.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2006 VL 21 IS 5 BP 718 EP 722 DI 10.1002/mds.20797 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 044ZP UT WOS:000237712700024 PM 16450344 ER PT J AU Malkani, R D'Souza, I Gwinn-Hardy, K Scheenberg, GD Hardya, J Momeni, P AF Malkani, R D'Souza, I Gwinn-Hardy, K Scheenberg, GD Hardya, J Momeni, P TI A MAPT mutation in a regulatory element upstream of exon 10 causes frontotemporal dementia SO NEUROBIOLOGY OF DISEASE LA English DT Article DE MAPT; frontotemporal dementia; splicing ID TAU; CHROMOSOME-17; ASSOCIATION; EXPRESSION; GENE AB We report here the genetic analysis of a newly ascertained kindred in which frontotemporal dementia occurs in an apparent autosomal dominant fashion, and in which a novel MAPT gene mutation cosegregates with disease. Sequencing the MAPT gene in affected individuals revealed a change in intron 9. This finding supports earlier studies on the effect of a splice-accepting element in inclusion of exon 10 in the MAPT transcript. This mutation sheds light on a novel mechanism by which over-expression of 4-repeat tau leads to disease. Based on our current findings, we propose a novel mechanism by which intronic mutations can lead to frontotemporal dementia. (c) 2005 Elsevier Inc. All rights reserved. C1 Natl Inst Aging, Lab Neurogenet, Bethesda, MD 20892 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. Natl Inst Neurol Disorders & Stroke, Neurogenet Cluster, Bethesda, MD 20892 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Momeni, P (reprint author), Natl Inst Aging, Lab Neurogenet, Porter Neurosci Bldg,35,Convent Dr, Bethesda, MD 20892 USA. EM momeni@mail.nih.gov RI Gwinn, Katrina/C-2508-2009; Hardy, John/C-2451-2009 FU Intramural NIH HHS; Medical Research Council [G0701075]; NIA NIH HHS [R01 AG1176] NR 9 TC 19 Z9 20 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD MAY PY 2006 VL 22 IS 2 BP 401 EP 403 DI 10.1016/j.nbd.2005.12.001 PG 3 WC Neurosciences SC Neurosciences & Neurology GA 040KS UT WOS:000237378000019 PM 16503405 ER PT J AU Bowler, RM Koller, W Schulz, PE AF Bowler, RM Koller, W Schulz, PE TI Parkinsonism due to manganism in a welder: Neurological and neuropsychological sequelae SO NEUROTOXICOLOGY LA English DT Article; Proceedings Paper CT Conference on Health Effects of Manganese, Research, Industrial Hygiene and Clinical Issues in Occupational Exposures CY APR 17-18, 2004 CL New Orleans, LA SP Tulane Univ Med Sch, SAn Francisco State Univ, Assoc Occupat & Environm Clin DE manganese exposure; manganism; parkinsonism; neurological status; MRI; L-dopa; neuropsychological assessment; mood changes; motor slowing ID NERVOUS-SYSTEM; EXPOSURE; WORKERS; SERUM; UTILITY AB A 33-year-old welder with 3 years of exposure to manganese (Mn) bearing welding fumes was seen by neurologists for cognitive and motor complaints. He exhibited signs and symptoms of Parkinson's disease, including tremor, bradykinesia, gait disturbance and cogwheel rigidity. However, he was young and had significant inattention and forgetfulness, had found levodopa unhelpful and moved with a cock-walk gait, all of which suggested manganism. His serum and urine levels of Mn were, in fact, elevated, and his brain MRI had increased T1-weighted signal intensities in the basal ganglia bilaterally (globus pallidus) consistent with Mn deposition. Two years later, he underwent comprehensive neuropsychological testing. Clinical history indicated a mild tremor and emotional dysfunction with irritability, anxiety, and depression with psychotic features. He showed deficits in cognitive flexibility, information processing and speed, and greatly reduced motor speed, which are consistent with a fronto-subcortical process. These findings support a diagnosis of early onset parkinsonism from welding, (c) 2006 Elsevier Inc. All rights reserved. C1 San Francisco State Univ, San Francisco, CA 94132 USA. Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. RP Bowler, RM (reprint author), 8371 Kent Dr, El Cerrito, CA 94530 USA. EM rbowl@sfsu.edu NR 39 TC 53 Z9 55 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X J9 NEUROTOXICOLOGY JI Neurotoxicology PD MAY PY 2006 VL 27 IS 3 BP 327 EP 332 DI 10.1016/j.neuro.2005.10.011 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 046WF UT WOS:000237841100006 PM 16457889 ER PT J AU Robbins, LB Gretebeck, KA Kazanis, AS Pender, NJ AF Robbins, LB Gretebeck, KA Kazanis, AS Pender, NJ TI Girls on the move program to increase physical activity participation SO NURSING RESEARCH LA English DT Article DE female adolescents; intervention; physical activity ID ADOLESCENT GIRLS; PRIMARY-CARE; SEDENTARY BEHAVIORS; AFRICAN-AMERICAN; SELF-EFFICACY; WHITE GIRLS; OBESITY; QUESTIONNAIRES; VALIDATION; OVERWEIGHT AB Background: Because physical inactivity poses serious health risks, interventions are urgently needed to reverse the increasingly sedentary lifestyles of adolescent girls. Objective: The aim of this study was to determine the feasibility of "Girls on the Move," an individually tailored computerized physical activity (PA) program plus nurse counseling intervention, in increasing PA. Methods: A pretest-posttest control group design was used with 77 racially diverse sedentary girls in Grades 6, 7, and 8 from two middle schools. Each of the instructional grades was randomly assigned to either an intervention or control condition. After completing computerized questionnaires, each girl in the control group received a handout listing the PA recommendations. To encourage PA, each girl in the intervention group received computerized, individually tailored feedback messages based on her responses to the questionnaires, individual counseling from the school's pediatric nurse practitioner (PNP), and telephone calls and mailings from a trained research assistant. At 12 weeks, girls in both groups responded to the questionnaires. Results: No differences in self-reported PA emerged between the intervention and control groups at Weeks 1 (baseline) and 12 (postintervention). Repeated measures ANOVA showed a significant interaction between group and time for social support for PA, F(1, 69) = 5.73, p = .019, indicating that the intervention group had significantly greater social support across time than did the control group. From baseline to postintervention, social support increased for the intervention group but decreased for the control group. Discussion: Reasons for the lack of significant differences between the groups on the PA measures were cited. Important information that could inform subsequent studies that test interventions to increase youth PA was acquired from conducting this study. Future efforts to increase PA participation might include this approach for enhancing social support for PA. C1 Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA. Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. US Dept Vet Affairs, Ann Arbor, MI USA. RP Robbins, LB (reprint author), Michigan State Univ, Coll Nursing, A203 Life Sci, E Lansing, MI 48824 USA. EM robbin76@msu.edu NR 45 TC 46 Z9 47 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-6562 J9 NURS RES JI Nurs. Res. PD MAY-JUN PY 2006 VL 55 IS 3 BP 206 EP 216 DI 10.1097/00006199-200605000-00007 PG 11 WC Nursing SC Nursing GA 046WI UT WOS:000237841400007 PM 16708045 ER PT J AU King, DE Mainous, AG Geesey, ME Egan, BM Rehman, S AF King, Dana E. Mainous, Arch G., III Geesey, Mark E. Egan, Brent M. Rehman, Shakeib TI Magnesium supplement intake and C-reactive protein levels in adults SO NUTRITION RESEARCH LA English DT Article DE magnesium; C-reactive protein; diet; supplement; inflammation; adult ID METABOLIC SYNDROME; CHOLESTEROL; ATHEROSCLEROSIS; INFLAMMATION; DISEASE; HEALTH; RISK; CARE AB Previous research has indicated that dietary magnesium may be a key component in the association between diet and inflammation; however, the role of intake from magnesium supplements has not been elucidated. The objective of this study was to determine the likelihood of elevated C-reactive protein (CRP) in people taking magnesium-containing supplements of 50 mg/d or more. We examined this issue in a study sample derived from the National Health and Nutrition Examination Survey 1999-2002, a nationally representative, survey of the civilian, noninstitutionalized population of the United States. Among US adults, 25.6% were taking a magnesium supplement of at least 50 mg daily. Only 21.9% of individuals not taking supplemental magnesium met or exceeded the recommended daily allowances (RDA) for magnesium intake compared with 60.2% of adults who were taking magnesium supplements. In adjusted logistic regression analyses, people whose total daily magnesium intake was below the RDA were significantly 40% more likely to have elevated CRP regardless of whether they were taking magnesium supplements (P < .05). Among people with dietary magnesium intake less than 50% RDA, individuals taking magnesium supplements were 22% less likely to have elevated CRP. Magnesium supplement intake is associated with a lower likelihood of elevated CRP in people with low dietary magnesium intake. Prospective studies are needed to examine whether magnesium supplementation can reduce levels of CRP. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Family Med, Charleston, SC 29464 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29464 USA. Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC 29403 USA. RP King, DE (reprint author), Med Univ S Carolina, Dept Family Med, Charleston, SC 29464 USA. EM kingde@musc.edu OI King, Dana/0000-0001-5494-3467; Mainous, Arch/0000-0002-2535-7685 NR 18 TC 10 Z9 10 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0271-5317 J9 NUTR RES JI Nutr. Res. PD MAY PY 2006 VL 26 IS 5 BP 193 EP 196 DI 10.1016/j.nutres.2006.05.001 PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 073BA UT WOS:000239716100001 ER PT J AU Sitzman, BT Gallagher, RM AF Sitzman, BT Gallagher, RM TI Effectiveness of electrical neuromodulation: An economic paradigm SO PAIN MEDICINE LA English DT Article DE electrical neuromodulation; cost; economic; effectiveness; efficacy ID SPINAL-CORD STIMULATION; COST-EFFECTIVENESS ANALYSIS; CHRONIC PAIN AB The last 10-15 years has witnessed a rapid growth and advancement of electrical neuromodulation technologies: spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation, and motor cortex stimulation. As the manuscripts in this Pain Medicine supplement attest, there is strong evidence documenting the efficacy and safety of electrical neuromodulation in the treatment of many chronic, refractory pain conditions, including complex regional pain syndromes, intractable angina pectoris, neuropathic extremity pain, axial low back pain, atypical facial pain, certain visceral pain syndromes, and others. Along with the growth in utilization of electrical neuromodulation therapies, competitive pressures within the healthcare industry have created the need for other healthcare decision makers, specifically the government and third-party insurance payers, to examine the overall effectiveness and costs of electrical neuromodulation. Our objective was not to summarize the results of cost analysis studies involving neuromodulation. Doing so would be relatively simple. It is more important for the clinician to understand the underlying problems in our current reimbursement system. In doing so, we as physicians can better understand the true "value" of electrical neuromodulation therapy from the perspectives of the individual patient, the hospital administrator, and the healthcare payer. C1 Forrest Gen Canc Ctr, Hattiesburg, MS 39401 USA. Univ Penn, Sch Med, Dept Psychiat, Ctr Pain Med Res & Policy, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Anesthesiol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Sitzman, BT (reprint author), Forrest Gen Canc Ctr, 301 S 28th Ave, Hattiesburg, MS 39401 USA. EM toddsitzman@msn.com NR 6 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1526-2375 J9 PAIN MED JI Pain Med. PD MAY PY 2006 VL 7 SU 1 BP S185 EP S190 DI 10.1111/j.1526-4637.2006.00133.x PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 030YY UT WOS:000236672500020 ER PT J AU Wang, YL Hu, R Lugea, A Gukovsky, I Smoot, D Gukovskaya, AS Pandol, SJ AF Wang, Yan-Ling Hu, Richard Lugea, Aurelia Gukovsky, Ilya Smoot, Duane Gukovskaya, Anna S. Pandol, Stephen J. TI Ethanol feeding alters death signaling in the pancreas SO PANCREAS LA English DT Article DE ethanol; apoptosis; necrosis; signal transduction ID NECROTIC CELL-DEATH; INDUCED LIVER APOPTOSIS; KAPPA-B ACTIVATION; ACINAR-CELLS; CATHEPSIN-B; TRYPSINOGEN ACTIVATION; MITOCHONDRIAL DYSFUNCTION; TRANSCRIPTION FACTORS; STAT PROTEINS; IFN-GAMMA AB Objectives: Alcohol abuse is a major cause of pancreatitis, which is associated with death of parenchymal cells. The goal of this study was to explore the effects of ethanol on cell death pathways in the pancreas. Methods: Adult male Wistar rats were fed with ethanol diets using the Lieber-DeCarli method. Caspase-8, caspase-3, and cathepsin B expression and activity in the pancreas of these animals as well as the signals that regulate their expression were studied using Western blot analysis and specific assays for biochemical enzyme activity. Results: In the pancreas from rats fed with ethanol, the protein expression and activity of caspase-8 decreased by 48% and 45%, respectively, and caspase-3 activity decreased by 39%. In contrast, cathepsin B protein expression and activity increased with ethanol feeding by 189% and 143%, respectively. Evaluation of the transcriptional regulatory system for caspase-8 and cathepsin B showed that the ethanol effects on these pathways were largely transcriptional. Conclusions: Our findings show effects of ethanol on the expression of several signals involved in cell death in the pancreas through alteration of transcriptional regulators. The decrease in caspase expression and increase in cathepsin B expression indicate that ethanol feeding may prevent apoptosis and promote necrosis of pancreatic tissue with stresses that cause pancreatitis. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. Howard Univ, Sch Med, Washington, DC 20059 USA. RP Pandol, SJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA 90073 USA. EM Stephen.pandol@med.va.gov FU NIAAA NIH HHS [1 U56 AA0114643, T32 AA07578]; NIDDK NIH HHS [DK-59508] NR 70 TC 25 Z9 25 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAY PY 2006 VL 32 IS 4 BP 351 EP 359 DI 10.1097/01.mpa.0000220859.93496.e1 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 101AJ UT WOS:000241711000004 PM 16670617 ER PT J AU Jatana, M Singh, I Singh, AK Jenkins, D AF Jatana, M Singh, I Singh, AK Jenkins, D TI Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats SO PEDIATRIC RESEARCH LA English DT Article ID FOCAL CEREBRAL-ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; PERINATAL ASPHYXIA; ENCEPHALOPATHY; DAMAGE; MODEL; NEUROPROTECTION; APOPTOSIS; PROTECTS AB Hypoxic ischemic (HI) injury in neonates may have devastating, long-term consequences. Recently completed clinical trials in HI neonates indicate that hypothermia within 6 h of birth results in modest improvement in the combined outcome of death or severe disability. The aim of this study was to investigate the effects of combining hypothermia and N-acetyleysteine (NAC) off brain injury, neonatal reflexes and myelination after neonatal HI. Seven-day-old rats were subjected to right common carotid artery ligation and hypoxia (8% oxygen) for 2 h. Systemic hypothermia (30 + 0.5 degrees C) was induced immediately after the period of HI and was maintained for 2 h. NAC (50 mg/kg) was administered by intraperitoneal injection daily until sacrifice. Brain infarct Volumes were significantly reduced at 48 h post-HI in the hypothermia plus NAC Group (21.5 +/- 3.84 mm(3)) compared with vehicle (240.85 +/- 4.08 mm(3)). Neonatal reflexes were also significantly improved by combination therapy at days 1 and 7. There was a significant loss of right hemispheric brain volume in the untreated group at 2 and 4 wk after HI insult. Brain volumes were preserved in hypothermia plus NAC group and were not significantly different when compared with the sham group. Similarly, increased myelin expression was seen in brain sections from hypothermia Plus NAC group, when stained for Luxol Fast Blue (LFB), Myelin Basic Protein (MBP) and Proteolipid protein (PLP). These results indicate that hypothermia plus NAC combination therapy improves infarct volume, myelin expression and functional outcomes after focal HI injury. C1 Med Univ S Carolina, Childrens Hosp, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Jenkins, D (reprint author), Med Univ S Carolina, Childrens Hosp, Dept Pediat, Room 662,POB 250917,165 Ashley Ave, Charleston, SC 29425 USA. EM eicherdj@musc.edu FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 32 TC 61 Z9 61 U1 0 U2 3 PU INT PEDIATRIC RESEARCH FOUNDATION, INC PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA SN 0031-3998 J9 PEDIATR RES JI Pediatr. Res. PD MAY PY 2006 VL 59 IS 5 BP 684 EP 689 DI 10.1203/01.pdr.0000215045.91122.44 PG 6 WC Pediatrics SC Pediatrics GA 035LX UT WOS:000237003800012 PM 16627882 ER PT J AU Weissman, EM Moot, DM Essock, SM AF Weissman, EM Moot, DM Essock, SM TI What do people with schizophrenia think about weight management? SO PSYCHIATRIC SERVICES LA English DT Letter C1 Bronx Vet Adm Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Weissman, EM (reprint author), Bronx Vet Adm Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. NR 5 TC 10 Z9 10 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAY PY 2006 VL 57 IS 5 BP 724 EP 725 DI 10.1176/appi.ps.57.5.724 PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 039JJ UT WOS:000237301500027 PM 16675776 ER PT J AU Yehuda, R Yang, RK Buchsbaum, MS Golier, JA AF Yehuda, R Yang, RK Buchsbaum, MS Golier, JA TI Alterations in cortisol negative feedback inhibition as examined using the ACTH response to cortisol administration in PTSD SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE PTSD; cortisol; ACTH; hypothalamic-pituitary-adrenal axis; negative feedback inhibition; glucocorticoid receptor ID POSTTRAUMATIC-STRESS-DISORDER; DEXAMETHASONE-SUPPRESSION; RAT-BRAIN; RECEPTOR; CORTICOSTERONE; PITUITARY AB Objective: Studies using the dexamethasone suppression test (DST) have demonstrated an enhanced negative feedback inhibition at the pituitary in PTSD, but have not provided information about central feedback effects, since dexamethasone (DEX) does not penetrate the brain well. The authors therefore examined the change in ACTH and cortisol before and after cortisol administration, which acts at central feedback sites in addition to peripheral targets. Method: Blood was obtained from 31 mate veterans (18 with PTSD) before, and 8, 40 and 95 min following injection of 17.5 mg cortisol and placebo. Results: A greater decline in ACTH was observed after cortisol injection in PTSD. Conclusions: Central as well as peripheral negative feedback inhibition may be altered in PTSD. Published by Elsevier Ltd. C1 Bronx Vet Affairs Med Ctr, Bronx VA OOMH, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, Bronx, NY USA. RP Yehuda, R (reprint author), Bronx Vet Affairs Med Ctr, Bronx VA OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@med.va.gov FU NCRR NIH HHS [5M01 RR 00071] NR 19 TC 51 Z9 52 U1 4 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD MAY PY 2006 VL 31 IS 4 BP 447 EP 451 DI 10.1016/j.psyneuen.2005.10.007 PG 5 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 029XJ UT WOS:000236597400004 PM 16364555 ER PT J AU Dai, L Pessler, F Chen, LX Clayburne, G Schumacher, HR AF Dai, L Pessler, F Chen, LX Clayburne, G Schumacher, HR TI Detection and initial characterization of synovial lining fragments in synovial fluid SO RHEUMATOLOGY LA English DT Article DE CD68; rice bodies; synovial lining; synovial fluid; synovial fluid analysis; synovium ID RHEUMATOID-ARTHRITIS; RICE BODIES; FIBROBLASTS; KNEE; LAVAGE AB Objective. Free fragments of synovium have occasionally been seen in synovial fluid but have not been studied systematically. We wished to establish a method for the reliable detection of these fragments in joint and bursa effusions and begin to characterize them by histochemical and immunohistochemical methods. Methods. Cell smears, wet drop preparations and cytospins were prepared from 39 consecutive joint and bursa effusions. Paraffin cell blocks were prepared from a subset. Analysis encompassed standard and polarized light microscopy, histochemistry, immunohistochemistry and transmission electron microscopy (EM). Synovial biopsy tissue from one different patient was examined for comparison. Results. Tissue fragments were not seen in Wright-stained cell smears and only rarely in wet drop preparations. In contrast, variously sized fragments with the histological appearance of hyperplastic synovial lining were detected in ethanol-fixed, haematoxylin/eosin-stained cytospins from bursitis and all arthropathies studied [17/24 (71%) of non-inflammatory and 12/15 (80%) of inflammatory specimens]. Immunostaining revealed CD68 expression in a subset of cells in a pattern characteristic of hyperplastic synovial lining. Juxtaposed cells with morphological features of macrophage-like and fibroblast-like synoviocytes were seen by EM. Conclusions. Synovial lining fragments can be detected in effusions from diverse arthropathies and bursitis. They maintain important properties of the synovial lining and can be analysed by immunohistochemistry. They may afford the opportunity to study a relatively pure preparation of synovial lining cells without the need for cell culture, and to evaluate their possible role in augmenting or perpetuating synovitis or joint damage. C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Presbyterian Med Ctr, Philadelphia, PA USA. Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou, Peoples R China. RP Dai, L (reprint author), Univ Penn, Philadelphia, PA 19104 USA. EM liedai2004@hotmail.com; schumacr@mail.med.upenn.edu FU NCI NIH HHS [T32-CA09140]; NIAMS NIH HHS [T32-AR007442] NR 16 TC 8 Z9 8 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD MAY PY 2006 VL 45 IS 5 BP 533 EP 537 DI 10.1093/rheumatology/kei206 PG 5 WC Rheumatology SC Rheumatology GA 035KA UT WOS:000236998500007 PM 16352640 ER PT J AU Zhong, Z Ksiezak-Reding, H Riggio, S Haroutunian, V Pasinetti, GM AF Zhong, Z Ksiezak-Reding, H Riggio, S Haroutunian, V Pasinetti, GM TI Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; prefrontal cortex; insulin resistance; insulin receptor; Akt; glycogen synthase kinase 3 alpha; glycogen synthase kinase 3 beta ID GLYCOGEN-SYNTHASE KINASE-3; ATYPICAL ANTIPSYCHOTIC-DRUGS; LONG-TERM POTENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; PSYCHIATRIC-PATIENTS; GLUCOSE-HOMEOSTASIS; DIABETES-MELLITUS; GENE-EXPRESSION; FRONTAL-CORTEX; PC12 CELLS AB Schizophrenia is associated with abnormalities in glucose metabolism that may lead to insulin resistance and a 3 fold higher incidence of type H diabetes mellitus. The goal of the present studies was to assess the role of insulin-dependent Akt signaling in schizophrenia and in animal and cellular models of insulin resistance. Our studies revealed a functional decrease in insulin receptor (IR)-mediated signal transduction in the dorsolateral prefrontal cortex (BA46) of medicated schizophrenics relative to control patients using post-mortem brain material. We found similar to 50% decreases in the content and autophosphorylation levels of IR beta and similar to 76-78% decreases in Akt content and activity (pSer(473)-Akt). The inhibition of IR beta signaling was accompanied by an elevated content of glycogen synthase kinase (GSK)-3 alpha and GSK-3 beta without significant changes in phospho-Ser(21/9) GSK-3 alpha/beta levels. A cellular model of insulin resistance was induced by IR beta knockdown (siRNA). As in schizophrenia, the IR beta knockdown cells demonstrated a reduction in the Akt content and activity. Total GSK-3 alpha/beta content remained unaltered, but phospho-Ser(21/9) GSK-3 alpha/beta levels were reduced indicating a net increase in the overall enzyme activity similar to that in schizophrenia. Insulin resistance phenotype was induced in mice by treatment with antipsychotic drug, clozapine. Behavioral testing showed decreases in startle response magnitude in animals treated with clozapine for 68 days. The treatment resulted in a functional inhibition of IR beta but the Akt activation status remained unaltered. Changes in GSK-3 alpha/beta were consistent with a net decrease in the enzyme activity, as opposed to that in schizophrenia. The results suggest that alterations in insulin-dependent Akt signaling in schizophrenia are similar to those observed in our cellular but not animal models of insulin resistance. In animal model, clozapine ameliorates IR beta deficits at the GSK-3 alpha/beta level, which may justify its role in treatment of schizophrenia. Our studies suggest that aberrant IR function may be important in the pathophysiology of schizophrenia. (c) 2006 Elsevier B.V. All rights reserved. C1 Bronx Vet Adm Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. Mt Sinai Sch Med, Neuroinflammat Res Labs, Bronx, NY USA. Mt Sinai Sch Med, Dept Psychiat, Bronx, NY USA. RP Ksiezak-Reding, H (reprint author), Bronx Vet Adm Med Ctr, Dept Psychiat, Rm 3F-24,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM hanna.reding@mssm.edu NR 66 TC 1 Z9 2 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2006 VL 84 IS 1 BP 1 EP 14 DI 10.1016/j.schres.2006.02.009 PG 14 WC Psychiatry SC Psychiatry GA 051KP UT WOS:000238160300001 ER PT J AU Garzotto, M Myrthue, A Higano, CS Beer, TM AF Garzotto, M Myrthue, A Higano, CS Beer, TM TI Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-Urologic-Oncology CY MAY, 2005 CL San Antonio, TX SP Soc Urol Oncol DE chemotherapy; neoadjuvant; advanced prostate cancer; docetaxel; mitoxantrone ID RANDOMIZED CONTROLLED-TRIAL; RADICAL PROSTATECTOMY; ANDROGEN SUPPRESSION; RADIATION-THERAPY; HORMONAL-THERAPY; PROGNOSTIC VARIABLES; DISEASE RECURRENCE; PLUS PREDNISONE; RADIOTHERAPY; CHEMOTHERAPY AB Purpose: Currently available treatment modalities for high-risk clinically localized prostate cancer have limited chances of achieving complete tumor elimination because of either inadequate local or metastatic tumor eradication. The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy. Materials and Methods: A total of 22 men with high-risk clinically localized prostate cancer underwent weekly treatment with docetaxel (35 mg/m(2)), with increasing doses of mitoxantrone (2-5 mg/m(2)) for a 12 of 16-week treatment cycle before prostatectomy. Testosterone and prostate-specific antigen (PSA) measurements were made before and after chemotherapy. Results: The maximally tolerated dose for mitoxantrone was 4 mg/m(2), and the primary toxicity was neutropenia. Testosterone levels were maintained throughout treatment. PSA reductions were observed in 95% of patients, with a median reduction of 41%. The surgery was well tolerated after chemotherapy, without any major complications. Negative surgical margins were attained in 76% of patients. Conclusions: Administration of multi-agent chemotherapy before prostatectomy was safe in this population. This regimen appeared to have antineoplastic activity as evidenced by PSA reductions in the absence of significant testosterone changes. The benefit of chemotherapy for improving surgical margin rates could not be determined outside of a phase III trial because the effect of patient or surgeon factors could not be dissected from the potential effect of neoadjuvant therapy. Continued study of novel agents in the neoadjuvant setting is warranted because this approach allows for the rapid identification of active agents and for molecular investigation into the mechanism of drug activity. Published by Elsevier Inc. C1 Portland VA Med Ctr, Urol Sect, Surg Serv, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Urol & Renal Transplantat, Portland, OR 97239 USA. Univ Washington, Div Urol, Seattle, WA 98109 USA. Univ Washington, Div Oncol, Seattle, WA 98109 USA. RP Garzotto, M (reprint author), Portland VA Med Ctr, Urol Sect, Surg Serv, Portland, OR 97239 USA. EM garzotto@ohsu.edu NR 31 TC 25 Z9 25 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD MAY-JUN PY 2006 VL 24 IS 3 BP 254 EP 259 DI 10.1016/j.urolonc.2005.11.034 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 048KA UT WOS:000237944800016 PM 16678060 ER PT J AU Harrington, P Barner, JC Crismon, ML Lawson, KA Mascarenas, C Rascati, KL AF Harrington, P Barner, JC Crismon, ML Lawson, KA Mascarenas, C Rascati, KL TI Demographic and clinical characteristics of patients prescribed antipsychotic (AP) monotherapy in Texas Medicaid SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Univ Texas, Austin, TX 78712 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2006 VL 9 IS 3 BP A74 EP A74 DI 10.1016/S1098-3015(10)64534-2 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 038MC UT WOS:000237224200231 ER PT J AU Harrington, P Barner, JC Crismon, ML Lawson, KA Mascarenas, C Rascati, KL AF Harrington, P Barner, JC Crismon, ML Lawson, KA Mascarenas, C Rascati, KL TI Incident diabetes associated with use of second-generation antipsychotic (SGA) therapy: An evaluation of the impact of dose and treatment indication SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Univ Texas, Austin, TX 78712 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2006 VL 9 IS 3 BP A65 EP A65 DI 10.1016/S1098-3015(10)64506-8 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 038MC UT WOS:000237224200203 ER PT J AU Yang, M Barner, JC Lawson, KA Rascati, KL Crismon, ML Wilson, JP Worchel, J Mascarenas, J AF Yang, M Barner, JC Lawson, KA Rascati, KL Crismon, ML Wilson, JP Worchel, J Mascarenas, J TI Antipsychotic utilization and treatment-emergent diabetes - Comparison of results with and without propensity scoring SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Univ Texas, Austin, TX 78712 USA. Cent Texas Vet Hlth Care Syst, Austin, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2006 VL 9 IS 3 BP A39 EP A39 DI 10.1016/S1098-3015(10)64425-7 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 038MC UT WOS:000237224200122 ER PT J AU Yang, M Barner, JC Rascati, KL Lawson, KA Wilson, JP Crismon, ML Worchel, J Mascarenas, C AF Yang, M Barner, JC Rascati, KL Lawson, KA Wilson, JP Crismon, ML Worchel, J Mascarenas, C TI Antipsychotic utilization and treatment-emergent diabetes - A methodological comparison using a claims database SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Univ Texas, Austin, TX 78712 USA. Cent Texas Vet Hlth Care Syst, Austin, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2006 VL 9 IS 3 BP A38 EP A39 DI 10.1016/S1098-3015(10)64424-5 PG 2 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 038MC UT WOS:000237224200121 ER PT J AU Washington, DL Yano, EM Goldzweig, C Simon, B AF Washington, DL Yano, EM Goldzweig, C Simon, B TI VA emergency health care for women: Condition - Critical or stable? SO WOMENS HEALTH ISSUES LA English DT Article ID AFFAIRS MEDICAL-CENTER; VETERANS; DEPARTMENTS AB Background. Veteran's Affairs (VA) facilities have reconfigured themselves to address the health care needs of the growing number of women veterans. However, the challenge of providing comprehensive care to a group that is an extreme minority within VA may still leave gaps in the delivery of necessary health care services. Objectives and methods. We sought to assess the availability of women's health care specialists for emergency gynecologic problems (emergency-GYN) and for emergency mental health conditions specific to women (emergency-WMH), we surveyed the Chief of Staff and senior clinician at each VA site serving 400 or more women veterans. Results. Emergency-GYN expertise was usually available at all times for 39.8% of sites, and only during usual clinic hours for 24.6% of sites. An emergency-WMH specialist was available at all times for 51.7% of sites, and only during usual clinic hours for 31.0% of sites. VA sites that had a separate women's health clinic were more likely to have emergency-GYN expertise available. Sites in regions with higher managed care penetration were less likely to have emergency-WMH specialist availability. Conclusions. Our data suggest a limited availability of specialists for gynecologic and women's mental health emergencies at some VA sites. How this may affect overall quality of care for women in the VA system is unknown. Further work is needed to determine actions clinicians take when expertise is emergently needed for health care issues unique to women. Options for expanding VA availability of such expertise include internal development of women's health expertise and telemedicine access to experts to aid in emergency women's health care decision making. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA. Va Greater Los Angeles HSR&D Ctr Excellence, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov NR 18 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2006 VL 16 IS 3 BP 133 EP 138 DI 10.1016/j.whi.2005.12.003 PG 6 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 054TL UT WOS:000238401400005 PM 16765289 ER PT J AU Tache, Y Yang, H Miampamba, M Martinez, V Yuan, PQ AF Tache, Y Yang, H Miampamba, M Martinez, V Yuan, PQ TI Role of brainstem TRH/TRH-R1 receptors in the vagal gastric cholinergic response to various stimuli including sham-feeding SO AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL LA English DT Article; Proceedings Paper CT Pavlov Centenary Symposium on Integrative Physiology and Behaviour CY JUN, 2004 CL IP Pavlov Inst Physiol, St Petersburg, RUSSIA HO IP Pavlov Inst Physiol DE TRH; vagus; pChAT; myenteric neurons; gastric acid secretion; dorsal motor nucleus ID THYROTROPIN-RELEASING-HORMONE; DORSAL MOTOR NUCLEUS; ENTERIC NERVOUS-SYSTEM; ACID SECRETORY RESPONSE; RAPHE PALLIDUS NEURONS; TRH ANALOG; INTRACISTERNAL TRH; RAT-BRAIN; FOS EXPRESSION; SUBSTANCE-P AB Pavlov's pioneering work established that sham-feeding induced by sight or smell of food or feeding in dogs with permanent esophagostomy stimulates gastric acid secretion through vagal pathways. Brain circuitries and transmitters involved in the central vagal regulation of gastric function have recently been unraveled. Neurons in the dorsal vagal complex including the dorsal motor nucleus of the vagus (DMN) express thyrotropin-releasing hormone (TRH) receptor and are innervated by TRH fibers originating from TRH synthesizing neurons in the raphe pallidus, raphe obscurus and the parapyramidal regions. TRH injected into the DMN or cisterna, magna increases the firing of DMN neurons and gastric vagal efferent discharge, activates cholinergic neurons in gastric submucosal and myenteric plexuses and induces a vagal-dependent, atropine-sensitive stimulation of gastric secretory (acid, pepsin) and motor functions. TRH antibody or TRH-R1 receptor oligodeoxynucleotide antisense pretreatment in the cisterna magna or DMN abolished vagal-dependent gastric secretory and motor responses to sham-feeding, 2-deoxy-D-glucose, cold exposure and chemical activation of cell bodies in medullary raphe nuclei. TRH excitatory action in the DMN is potentiated by co-released prepro-TRH-(160-169) flanking peptide, Ps4 and 5-HT, and inhibited by a number of peptides involved in the stress/immune response and inhibition of food-intake. These neuroanatomical, electrophysiological and neuropharmacological data are consistent with a physiological role of brainstem TRH in the central vagal stimulation of gastric myenteric cholinergic neurons in response to several vagal dependent stimuli including sham-feeding. (c) 2006 Elsevier B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, CURE, DDR, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Digest Dis Div, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE, DDR, Digest Dis Res Ctr, Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM yTache@mednet.ucla.edu RI Martinez, Vicente/N-1189-2014 FU NIDDK NIH HHS [DK 50255, DK 33061, DK 41301]; PHS HHS [R01 30110] NR 122 TC 22 Z9 22 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1566-0702 J9 AUTON NEUROSCI-BASIC JI Auton. Neurosci-Basic Clin. PD APR 30 PY 2006 VL 125 IS 1-2 BP 42 EP 52 DI 10.1016/j.autneu.2006.01.014 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 045PT UT WOS:000237754800007 PM 16520096 ER PT J AU Brown, M AF Brown, M TI Toxicological assessments of Gulf War veterans SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Review DE veterans; pesticides; uranium; pyridostigimine bromide; sarin ID AMYOTROPHIC-LATERAL-SCLEROSIS; POSTTRAUMATIC-STRESS-DISORDER; NEUROLOGIC SYMPTOM COMPLEXES; CHRONIC MULTISYMPTOM ILLNESS; CHRONIC-FATIGUE-SYNDROME; SELF-REPORTED EXPOSURES; CHEMICAL WARFARE AGENTS; PERSIAN-GULF; TOKYO SUBWAY; PYRIDOSTIGMINE BROMIDE AB Concerns about unexplained illnesses among veterans of the 1991 Gulf War appeared soon after that conflict ended. Many environmental causes have been suggested, including possible exposure to depleted uranium munitions, vaccines and other drugs used to protect troops, deliberate or accidental exposure to chemical warfare agents and pesticides and smoke from oil-well fires. To help resolve these issues, US and UK governments have sought independent expert scientific advice from prestigious, independent scientific and public health experts, including the US National Academies of Science and the UK Royal Society and Medical Research Council. Their authoritative and independent scientific and medical reviews shed light on a wide range of Gulf War environmental hazards. However, they have added little to our understanding of Gulf War veterans' illnesses, because identified health effects have been previously well characterized, primarily in the occupational health literature. This effort has not identified any new health effects or unique syndromes associated with the evaluated environmental hazards. Nor do their findings provide an explanation for significant amounts of illnesses among veterans of the 1991 Gulf War. Nevertheless, these independent and highly credible scientific reviews have proven to be an effective means for evaluating potential health effects from deployment-related environmental hazards. C1 US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA. RP Brown, M (reprint author), US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA. EM mbrown1@va.gov NR 104 TC 16 Z9 16 U1 2 U2 4 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8436 EI 1471-2970 J9 PHILOS T R SOC B JI Philos. Trans. R. Soc. B-Biol. Sci. PD APR 29 PY 2006 VL 361 IS 1468 BP 649 EP 679 DI 10.1098/rstb.2006.1825 PG 31 WC Biology SC Life Sciences & Biomedicine - Other Topics GA 030YU UT WOS:000236672100012 PM 16687269 ER PT J AU Haq, E Contreras, MA Giri, S Singh, I Singh, AK AF Haq, E Contreras, MA Giri, S Singh, I Singh, AK TI Dysfunction of peroxisomes in twitcher mice brain: A possible mechanism of psychosine-induced disease SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE psychosine; Krabbe disease; peroxisomes; twitcher mice; neuroinflammation ID BETA-OXIDATION ENZYMES; PROLIFERATOR-ACTIVATED RECEPTORS; GLOBOID-CELL LEUKODYSTROPHY; RAT-LIVER PEROXISOMES; CHAIN FATTY-ACIDS; C6 GLIAL-CELLS; TNF-ALPHA; INFLAMMATORY DISEASE; MURINE MODEL; BIOSYNTHESIS AB Psychosine (galactosylsphingosine) accumulates in the brain of Krabbe disease (KD) patients as well as twitcher mice, a murine model of KD, resulting in loss of oligodendrocytes and myelin. This study documents progressive loss of peroxisomal proteins/functions and induction of expression of inflammatory cytokine TNF-alpha in twitcher brain. The observed decrease in peroxisomal proteins was accompanied by decreased level of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), one of the transcription factors required for expression of peroxisomal protein genes. The role of psychosine in down-regulation of PPAR-alpha activity was further supported by decreased PPAR-alpha mediated PPRE transcriptional activity in cells transfected with PPAR-alpha and PPRE reporters. The psychosine-induced down-regulation of PPAR activity and cell death was attenuated by sPLA(2) inhibitor. Therefore, this study provides the first evidence of peroxisomal abnormality in a lysosomal disorder, suggesting that such dysfunction of peroxisomes may play a role in the pathogenesis of Krabbe disease. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Childrens Res Inst, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. EM singha@musc.edu OI Haq, Ehtishamul/0000-0002-4195-0606 FU NCRR NIH HHS [C06 RR015455, C06 RR018823]; NIA NIH HHS [AG25307]; NINDS NIH HHS [NS-22576, NS-40810, NS34741, NS37766] NR 42 TC 28 Z9 28 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 28 PY 2006 VL 343 IS 1 BP 229 EP 238 DI 10.1016/j.bbrc.2006.02.131 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 030UC UT WOS:000236659300033 PM 16530726 ER PT J AU Swenson, ER AF Swenson, ER TI Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE carbonic anhydrase; inhibition; hypoxia; acute mountain sickness; pulmonary artery smooth muscle; high altitude pulmonary edema; acetazolamide; benzolamide; ethoxzolamide ID ARTERIAL SMOOTH-MUSCLE; ACUTE MOUNTAIN-SICKNESS; INTRACELLULAR PH; TEMPORAL HETEROGENEITY; ACETAZOLAMIDE; EDEMA; VENTILATION; INCREASES; PERFUSION; PRESSURE AB Acetazolamide and other related carbonic anhydrase (CA) inhibitors have had a long history of effectiveness in prevention and treatment of acute mountain sickness (AMS) and remain the standard of care for this indication. Despite many decades of CA inhibitor use for AMS, the possibility has never been seriously entertained that these drugs might also afford protection against high altitude pulmonary edema (HAPE). In this paper, I will present our evidence and supporting data of others, that acetazolamide has inhibitory effects on the hypoxic response of the Pulmonary circulation that may be useful in HAPE. Data from pulmonary artery smooth muscle cells, isolated perfused lungs, and live unanethetized animals all point to a potent reduction in hypoxic pulmonary vasoconstriction (HPV) by acetazolamide that may have clinical utility in HAPE and possibly other pulmonary hypertensive disorders. Astonishingly, the efficacy of acetazolamide as a HPV inhibitor does not appear to be related to carbonic anhydrase inhibition, since other potent CA inhibitors have no effect on HPV either in the conscious dog or on hypoxic calcium (Ca2+) signalling in rat Pulmonary artery smooth muscle cells, despite enzyme presence in these cells. Although we have not yet determined the mechanism of action for acetazolamide in HPV, we have ruled out actions on membrane L-type Ca2+ channels, normoxic and hypoxic membrane potential and rho-kinase activation. Based upon these negative findings in isolated pulmonary artery smooth muscle cells and preliminary data in Ca2+ free media we propose that acetazolamide may act at the level of Ca2+ release from the sarcoplasmic reticulum, a process which initiates and amplifies cell membrane Ca2+ channel opening. In further work, we have developed and will use a methylated analog of acetazolamide to yield a molecule lacking CA inhibiting activity, but which in most other respects (size, pK(a), heterocyclic ring structure, electrostatic charge distribution) is equivalent to acetazolamide. Published by Elsevier B.V. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Swenson, ER (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM eswenson@umashington.edu FU NHLBI NIH HHS [HL-67191, HL-24163] NR 31 TC 26 Z9 26 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD APR 28 PY 2006 VL 151 IS 2-3 BP 209 EP 216 DI 10.1016/j.resp.2005.10.011 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 041ZQ UT WOS:000237496600012 PM 16376158 ER PT J AU Grafton, ST Turner, RS Desmurget, M Bakay, R Delong, M Vitek, J Crutcher, M AF Grafton, ST Turner, RS Desmurget, M Bakay, R Delong, M Vitek, J Crutcher, M TI Normalizing motor-related brain activity - Subthalamic nucleus stimulation in Parkinson disease SO NEUROLOGY LA English DT Article ID HIGH-FREQUENCY STIMULATION; INTERNAL GLOBUS-PALLIDUS; ASSOCIATION-CORTEX; BASAL GANGLIA; FLOW CHANGES; MOVEMENTS; PET; PALLIDOTOMY; PERFORMANCE; INHIBITION AB Objective: To test whether therapeutic unilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson disease (PD) leads to normalization in the pattern of brain activation during movement execution and control of movement extent. Methods: Six patients with PD were imaged off medication by PET during performance of a visually guided tracking task with the DBS voltage programmed for therapeutic (effective) or subtherapeutic (ineffective) stimulation. Data from patients with PD during ineffective stimulation were compared with a group of 13 age-matched control subjects to identify sites with abnormal patterns of activation. Conjunction analysis was used to identify those areas in patients with PD where activity normalized when they were treated with effective stimulation. Results: For movement execution, effective DBS caused an increase of activation in the supplementary motor area (SMA), superior parietal cortex, and cerebellum toward a more normal pattern. At rest, effective stimulation reduced overactivity of SMA. Therapeutic stimulation also induced reductions of movement related "overactivity" compared with healthy subjects in prefrontal, temporal lobe, and basal ganglia circuits, consistent with the notion that many areas are recruited to compensate for ineffective motor initiation. Normalization of activity related to the control of movement extent was associated with reductions of activity in primary motor cortex, SMA, and basal ganglia. Conclusions: Effective subthalamic nucleus stimulation leads to task-specific modifications with appropriate recruitment of motor areas as well as widespread, nonspecific reductions of compensatory or competing cortical activity. C1 Dartmouth Coll, Ctr Cognit Neurosci, Hanover, NH 03755 USA. Univ Calif San Francisco, Sch Med, Dept Neurosurg, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. INSERM, Unite 534, Lyon, France. Chicago Inst Neurosurg & Neurores, Chicago, IL 60614 USA. Emory Univ, Sch Med, Dept Neurol, Atlanta, GA USA. Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA. RP Grafton, ST (reprint author), Dartmouth Coll, Ctr Cognit Neurosci, 6162 Moore Hall, Hanover, NH 03755 USA. EM scott.t.grafton@dartmouth.edu RI Turner, Robert/A-9695-2008 OI Turner, Robert/0000-0002-6074-4365 FU NINDS NIH HHS [NS33504, NS37470, R01 NS044551, R01 NS044551-01] NR 44 TC 92 Z9 93 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 25 PY 2006 VL 66 IS 8 BP 1192 EP 1199 DI 10.1212/01.wnl.0000214237.58321.c3 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 036ER UT WOS:000237054300013 PM 16636237 ER PT J AU Mallik, S Spertus, JA Reid, KJ Krumholz, HM Rumsfeld, JS Weintraub, WS Agarwal, P Santra, M Bidyasar, S Lichtman, JH Wenger, NK Vaccarino, V AF Mallik, S Spertus, JA Reid, KJ Krumholz, HM Rumsfeld, JS Weintraub, WS Agarwal, P Santra, M Bidyasar, S Lichtman, JH Wenger, NK Vaccarino, V CA PREMIER Registry Investigators TI Depressive symptoms after acute myocardial infarction - Evidence for highest rates in younger women SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID SEX-DIFFERENCES; MORTALITY; EVENTS; HEALTH; PREVALENCE; RECOVERY; DISEASE; GENDER; IMPACT; HEART AB Background: Depression is common in patients hospitalized with acute myocardial infarction ( AMI). In the community, younger women are uniquely prone to depression. Whether younger women are also more likely to have depression during hospitalization with AMI is unknown. Methods: A total of 2498 AMI patients ( 1284 patients <= 60 years; 814 women and 1684 men) were enrolled from 19 US centers in the Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery ( PREMIER) study between January 2003 and June 2004. Depression was assessed at the time of hospitalization and was defined as a Primary Care Evaluation of Mental Disorders Brief Patient Health Questionnaire (PHQ) score of 10 or higher. Results: Younger ( <= 60 years) patients had higher mean PHQ scores than older patients ( 6.4 vs 5.0; P <. 001) and women had higher mean PHQ scores than men ( 6.8 vs 5.2; P <. 001). When stratified by both age and sex, younger women had the highest PHQ scores ( 8.2; P <. 001 for the sex-age interaction). The prevalence of depression was 40% in women 60 years or younger, 21% in women older than 60, 22% in men 60 or younger, and 15% in men older than 60. In a logistic model adjusted for study center, race, medical history, and coronary heart disease risk factors, the odds of depression for women 60 years or younger were significantly higher than for the other sex-age groups and were 3.1 times higher than the reference group of men older than 60 years. Conclusions: The prevalence of depression is high in younger women with AMI. Because depression after AMI has been associated with adverse outcomes, younger women, a high-risk group compared with men, may particularly benefit from aggressive screening and treatment of post-AMI depression. C1 Emory Univ, Sch Med, Dept Med, Div Gen Med, Atlanta, GA 30303 USA. Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30303 USA. Mid Amer Heart Inst, Kansas City, MO USA. Yale Univ, Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT 06520 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Mallik, S (reprint author), Emory Univ, Sch Med, Dept Med, Div Gen Med, Room 473,Fac Off Bldg,49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA. FU NCCDPHP CDC HHS [K01-DP000085-01]; NCRR NIH HHS [MO1-RR00039, K12RR17643]; NHLBI NIH HHS [K24HL077506, R01 HL68630]; NIA NIH HHS [R01 AG026255] NR 22 TC 80 Z9 85 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 24 PY 2006 VL 166 IS 8 BP 876 EP 883 DI 10.1001/archinte.166.8.876 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 035UA UT WOS:000237026000007 PM 16636213 ER PT J AU Gesty-Palmer, D Chen, MY Reiter, E Ahn, S Nelson, CD Wang, ST Eckhardt, AE Cowan, CL Spurney, RF Luttrell, LM Lefkowitz, RJ AF Gesty-Palmer, D Chen, MY Reiter, E Ahn, S Nelson, CD Wang, ST Eckhardt, AE Cowan, CL Spurney, RF Luttrell, LM Lefkowitz, RJ TI Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SIGNAL-REGULATED KINASES; COUPLED RECEPTOR; INDEPENDENT FUNCTIONS; ADRENERGIC-RECEPTOR; KIDNEY-CELLS; PEPTIDE; PTH; BONE; DESENSITIZATION; INTERMITTENT AB Parathyroid hormone (PTH) regulates calcium homeostasis via the type I PTH/PTH-related peptide (PTH/PTHrP) receptor (PTH1R). The purpose of the present study was to identify the contributions of distinct signaling mechanisms to PTH-stimulated activation of the mitogen-activated protein kinases (MAPK) ERK1/2. In Human embryonic kidney 293 (HEK293) cells transiently transfected with hPTH1R, PTH stimulated a robust increase in ERK activity. The time course of ERK1/2 activation was biphasic with an early peak at 10 min and a later sustained ERK1/2 activation persisting for greater than 60 min. Pretreatment of HEK293 cells with the PKA inhibitor H89 or the PKC inhibitor GF109203X, individually or in combination reduced the early component of PTH-stimulated ERK activity. However, these inhibitors of second messenger dependent kinases had little effect on the later phase of PTH-stimulated ERK1/2 phosphorylation. This later phase of ERK1/2 activation at 30-60 min was blocked by depletion of cellular beta-arrestin 2 and beta-arrestin 1 by small interfering RNA. Furthermore, stimulation of hPTH1R with PTH analogues, [Trp(1)] PTHrp-(1-36) and [D-Trp(12), Tyr(34)] PTH-(7-34), selectively activated G(s)/PKA-mediated ERK1/2 activation or G protein-independent/beta-arrestin-dependent ERK1/2 activation, respectively. It is concluded that PTH stimulates ERK1/2 through several distinct signal transduction pathways: an early G protein-dependent pathway meditated by PKA and PKC and a late pathway independent of G proteins mediated through beta-arrestins. These findings imply the existence of distinct active conformations of the hPTH1R responsible for the two pathways, which can be stimulated by unique ligands. Such ligands may have distinct and valuable therapeutic properties. C1 Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA. Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA. Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA. INRA, F-37380 Nouzilly, France. Xsira Pharmaceut, Morrisville, NC 27709 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Lefkowitz, RJ (reprint author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA. EM lefko001@receptor-biol.duke.edu FU NHLBI NIH HHS [HL16037, HL70631]; NICHD NIH HHS [HD043446]; NIDDK NIH HHS [DK64353] NR 47 TC 277 Z9 285 U1 3 U2 11 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 21 PY 2006 VL 281 IS 16 BP 10856 EP 10864 DI 10.1074/jbc.M513380200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 033BV UT WOS:000236822200025 PM 16492667 ER PT J AU Yan, LJL Liu, K Daviglus, ML Colangelo, LA Kiefe, CI Sidney, S Matthews, KA Greenland, P AF Yan, LJL Liu, K Daviglus, ML Colangelo, LA Kiefe, CI Sidney, S Matthews, KA Greenland, P TI Education, 15-year risk factor progression, and coronary artery calcium in young adulthood and early middle age - The Coronary Artery Risk Development in Young Adults study SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID AMERICAN-HEART-ASSOCIATION; INTIMA-MEDIA THICKNESS; ALL-CAUSE MORTALITY; OF-THE-LITERATURE; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC-STATUS; CAROTID ATHEROSCLEROSIS; SUBCLINICAL ATHEROSCLEROSIS; POSTMENOPAUSAL WOMEN; COMPUTED-TOMOGRAPHY AB Context The inverse association between education and cardiovascular disease is well established, but little is known about the relationship between education and subclinical disease, which is free from medical access and treatment-related influences, or about possible mediating pathways for these relationships. Objective To examine the association of education with coronary artery calcium (CAC), an indicator of subclinical atherosclerosis, and cardiovascular risk factors, and their changes as potential mediators. Design, Setting, and Participants A population-based, prospective, observational study ( Coronary Artery Risk Development in Young Adults [ CARDIA]) of 2913 eligible participants (44.9% black; 53.9% women) recruited from 4 metropolitan areas ( Birmingham, Ala; Chicago, Ill; Minneapolis, Minn; and Oakland, Calif) in both the baseline (1985-1986, ages 18-30 years) and year 15 examinations (2000-2001, ages 33-45 years). Education ( year 15) was classified into less than high school (n= 128), high school graduate ( n= 498), some college ( n= 902), college graduate ( n= 764), and more than college ( n= 621). Main Outcome Measure Presence of CAC, measured twice by computed tomography ( mean total Agatston score > 0) at year 15. Results Overall CAC prevalence in this sample was 9.3%. After adjusting for age, race, and sex, the odds ratios (ORs) for having CAC were 4.14 (95% confidence interval [CI], 2.33- 7.35) for less than high school education, 1.89 ( 95% CI, 1.23- 2.91) for high school graduate, 1.47 ( 95% CI, 0.99-2.19) for some college, and 1.24 ( 95% CI, 0.84-1.85) for college graduate compared with those participants with more than a college education ( P for trend <. 001). This was also consistent within each of the 4 race-sex groups. Adjustment for baseline systolic blood pressure, smoking, waist circumference, physical activity, and total cholesterol reduced the ORs to 2.61 ( 95% CI, 1.40-4.85) for less than high school, 1.38 ( 95% CI, 0.88-2.17) for high school graduate, 1.17 ( 95% CI, 0.78-1.77) for some college, and 1.13 ( 95% CI, 0.76-1.69) for college graduate compared with more than a college education ( P for trend=. 01), and only slightly attenuated by further adjustment for 15-year changes in risk factors. Conclusion Education was inversely associated with the prevalence of CAC, an association partially explained by baseline risk factors and minimally by 15-year changes in risk factors. C1 Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. Peking Univ, Dept Hlth Econ & Management, Guanghua Sch Management, Beijing 100871, Peoples R China. Univ Alabama, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Kaiser Permanente, Div Res, Oakland, CA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Yan, LJL (reprint author), Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA. EM lijing@northwestern.edu FU NHLBI NIH HHS [N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-95095] NR 51 TC 54 Z9 58 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 19 PY 2006 VL 295 IS 15 BP 1793 EP 1800 DI 10.1001/jama.295.15.1793 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 033XG UT WOS:000236886900022 PM 16622141 ER PT J AU Smith-Bindman, R Miglioretti, DL Lurie, N Abraham, L Barbash, RB Strzelczyk, J Dignan, M Barlow, WE Beasley, CM Kerlikowske, K AF Smith-Bindman, R Miglioretti, DL Lurie, N Abraham, L Barbash, RB Strzelczyk, J Dignan, M Barlow, WE Beasley, CM Kerlikowske, K TI Does utilization of screening mammography explain racial and ethnic differences in breast cancer? SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID WHITE WOMEN; BLACK-WOMEN; SOCIOECONOMIC-FACTORS; CARCINOMA SURVIVAL; AMERICAN WOMEN; UNITED-STATES; RACE; DIAGNOSIS; STAGE; DISPARITIES AB Background: Reasons for persistent differences in breast cancer mortality rates among various racial and ethnic groups have been difficult to ascertain. Objective: To determine reasons for disparities in breast cancer outcomes across racial and ethnic groups. Design: Prospective cohort. Setting: The authors pooled data from 7 mammography registries that participate in the National Cancer Institute-funded'Breast Cancer Surveillance Consortium. Cancer diagnoses were ascertained through linkage with pathology databases; Surveillance, Epidemiology, and End Results programs; and state tumor registries. Participants: 1010515 women 40 years of age and older who had at least 1 mammogram between 1996 and 2002; 17558 of these women had diagnosed breast cancer. Measurements: Patterns of mammography and the probability of inadequate mammography screening were examined. The authors evaluated whether overall and advanced cancer rates were similar across racial and ethnic groups and whether these rates were affected by the use of mammography. Results: African-American, Hispanic, Asian, and Native American women were more likely than white women to have received inadequate mammographic screening (relative risk, 1.2 [95% Cl, 1.2 to 1.2], 1.3 [Cl, 1.2 to 1.3], 1.4 [Cl, 1.3 to 1.4], and 1.2 [Cl, 1.1 to 1.2) respectively). African-American women were more likely than white, Asian, and Native American women to have large, advanced-stage, high-grade, and lymph node-positive tumors of the breast. The observed differences in advanced cancer rates between African American and white women were attenuated or eliminated after the cohort was stratified by screening history. Among women who were previously screened at intervals of 4 to 41 months, African -American women were no more likely to have large, advanced-stage tumors or lymph node involvement than white women with the same screening history. African-American women had higher rates of high-grade tumors than white women regardless of screening history. The lower rates of advanced cancer among Asian and Native American women persisted when the cohort was stratified by mammography history. Limitations: Results are based on a cohort of women who had received mammographic evaluations. Conclusions: African-American women are less likely to receive adequate mammographic screening than white women, which may explain the higher prevalence of advanced breast tumors among African-American women. Tumor characteristics may also contribute to differences in cancer outcomes because African-American women have higher-grade tumors than white women regardless of screening. These results suggest that adherence to recommended mammography screening intervals may reduce breast cancer mortality rates. C1 Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94115 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. RAND Corp, Arlington, VA USA. NCI, Bethesda, MD 20892 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Kentucky, Prevent Res Ctr, Lexington, KY USA. Canc Res & Biostat, Seattle, WA USA. Univ N Carolina, Pembroke, NC USA. RP Smith-Bindman, R (reprint author), Univ Calif San Francisco, Dept Radiol, 1600 Divisadero St, San Francisco, CA 94115 USA. EM Rebecca.Smith-Bindman@Radiology.UCSF.edu FU NCI NIH HHS [K07 CA86032, U01CA63736, U01CA63731, U01CA63740, U01CA69976, U01CA70013, U01CA70040, U01CA86076, U01CA86082] NR 49 TC 181 Z9 185 U1 3 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 18 PY 2006 VL 144 IS 8 BP 541 EP 553 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 035QZ UT WOS:000237017900001 PM 16618951 ER PT J AU Smetana, GW Lawrence, VA Cornell, JE AF Smetana, GW Lawrence, VA Cornell, JE TI Preoperative pulmonary risk stratification for noncardiothoracic surgery: Systematic review for the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID UPPER ABDOMINAL-SURGERY; MAJOR NONCARDIAC SURGERY; EARLY POSTOPERATIVE COMPLICATIONS; THORACOABDOMINAL AORTIC-ANEURYSM; COLORECTAL-CANCER SURGERY; HIP FRACTURE REPAIR; SURGICAL-PATIENTS; PERIOPERATIVE COMPLICATIONS; BLOOD-TRANSFUSION; VASCULAR-SURGERY AB Background: The importance of clinical risk factors for postoperative pulmonary complications and the value of preoperative testing to stratify risk are the subject of debate. Purpose: To systematically review the literature on preoperative pulmonary risk stratification before noncardiothoracic surgery. Data Sources: MEDLINE search from 1 January 1980 through 30 June 2005 and hand search of the bibliographies of retrieved articles. Study Selection: English -language studies that reported the effect of patient- and procedure- related risk factors and laboratory predictors on postoperative pulmonary complication rates after noncardiothoracic surgery and that met predefined inclusion criteria. Data Extraction: The authors used standardized abstraction instruments to extract data on study characteristics, hierarchy of research design, study quality, risk factors, and laboratory predictors. Data Synthesis: The authors determined random-effects pooled estimate odds ratios and, when appropriate, trim-and-fill estimates for patient- and procedure- related risk factors from studies that used multivatiable analyses. They assigned summary strength of evidence scores for each factor. Good evidence supports patient-related risk factors for postoperative pulmonary complications, including advanced age, American Society of Anesthesiologists class 2 or higher, functional dependence, chronic obstructive pulmonary disease, and congestive heart failure. Good evidence supports procedure-related risk factors for postoperative pulmonary complications, including aortic aneurysm repair, nonresective thoracic surgery, abdominal surgery, neurosurgery, emergency surgery, general anesthesia, head and neck surgery, vascular surgery, and prolonged surgery. Among laboratory predictors, good evidence exists only for serum albumin level less than 30 g/L. Insufficient evidence supports preoperative spirometry as a tool to stratify risk. Limitations: For certain risk factors and laboratory predictors, the literature provides only unadjusted estimates of risk. Prescreening, variable selection algorithms, and publication bias limited reporting of risk factors among studies using multivariable analysis. Conclusions: Selected clinical and laboratory factors allow risk stratification for postoperative pulmonary complications after noncardiothoracic surgery. C1 Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Sch Med, Boston, MA 02215 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Smetana, GW (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Sch Med, 330 Brookline Ave, Boston, MA 02215 USA. EM gsmetana@bidmc.harvard.edu NR 152 TC 243 Z9 267 U1 2 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 18 PY 2006 VL 144 IS 8 BP 581 EP 595 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 035QZ UT WOS:000237017900006 PM 16618956 ER PT J AU Lawrence, VA Cornell, JE Smetana, GW AF Lawrence, VA Cornell, JE Smetana, GW TI Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: Systematic review for the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID MAJOR ABDOMINAL-SURGERY; RANDOMIZED CONTROLLED TRIAL; PARENTERAL-NUTRITION; EPIDURAL-ANESTHESIA; INCENTIVE SPIROMETRY; OPEN CHOLECYSTECTOMY; AORTIC-SURGERY; CLINICAL-TRIAL; NASOGASTRIC DECOMPRESSION; GASTROINTESTINAL CANCER AB Background: Postoperative pulmonary complications are as frequent and clinically important as cardiac complications in terms of morbidity, mortality, and length of stay. However, there has been much less research and no previous systematic reviews of the evidence of interventions to prevent pulmonary complications. Purpose: To systematically review the literature on interventions to prevent postoperative pulmonary complications after noncardiothoracic surgery. Data Sources: MEDLINE English -language literature search, 1 January 1980 through 30 June 2005, plus bibliographies of retrieved publications. Study Selection: Randomized, controlled trials (RCTs); systematic reviews; or meta-analyses that met predefined inclusion criteria. Data Extraction: Using standardized forms, the authors abstracted data on study methods, quality, intervention and control groups, patient characteristics, surgery, postoperative pulmonary complications, and adverse events. Data Synthesis: The authors qualitatively synthesized, without meta-analysis, evidence from eligible studies. Good evidence (2 systematic reviews, 5 additional RCTs) indicates that lung expansion interventions (for example, incentive spirometry, deep breathing exercises, and continuous positive airway pressure) reduce pulmonary risk. Fair evidence suggests that selective, rather than routine, use of nasogastric tubes after abdominal surgery (2 meta-analyses) and short-acting rather than long-acting intraciperative neuromuscular blocking agents (1 RCT) reduce risk. The evidence is conflicting or insufficient for preoperative smoking cessation (1 RCT), epidural anesthesia (2 meta-analyses), epidural analgesia (6 RCTs, 1 meta-analysis), and laparoscopic (vs. open) operations (1 systematic review, 1 meta-analysis, 2 additional RCTs), although laparoscopic operations reduce pain and pulmonary compromise as measured by spirometry. While malnutrition is associated with increased pulmonary risk, routine total enteral or parenteral nutrition does not reduce risk (1 meta-analysis, 3 additional RCTs). Enteral formulations designed to improve immune status (immunonutrition) may prevent postoperative pneumonia (1 meta-analysis, 1 additional RCT). Limitations: The overall quality of the literature was fair: Ten of 20 RCTs and 6 of 11 systematic reviews were good quality. Conclusions: Few interventions have been shown to clearly or possibly reduce postoperative pulmonary complications. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. RP Lawrence, VA (reprint author), Univ Texas, Hlth Sci Ctr, 7703 Floyd Curl Dr,Mail Code 7879, San Antonio, TX 78229 USA. EM vlawrence@uthscsa.edu NR 69 TC 169 Z9 182 U1 1 U2 22 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 18 PY 2006 VL 144 IS 8 BP 596 EP 608 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 035QZ UT WOS:000237017900007 PM 16618957 ER PT J AU Chodosh, J Morton, SC Suttorp, MJ Shekelle, PG AF Chodosh, J Morton, SC Suttorp, MJ Shekelle, PG TI Self-management education for osteoarthritis - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID ARTHRITIS; METAANALYSIS; PROGRAMS C1 Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Res Triangle Inst, Res Triangle Pk, NC 27709 USA. RAND Corp, Vet Affairs Hlth Serv Res & Dev Serv, Santa Monica, CA 90401 USA. RP Chodosh, J (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 18 PY 2006 VL 144 IS 8 BP 617 EP 618 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 035QZ UT WOS:000237017900011 ER PT J AU Deswal, A Bozkurt, B AF Deswal, A Bozkurt, B TI Comparison of morbidity in women versus men with heart failure and preserved ejection fraction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID HYPERTENSIVE HYPERTROPHIC CARDIOMYOPATHY; GENDER-DIFFERENCES; MORTALITY; PREVALENCE; SURVIVAL AB Patients with heart failure (HF) and preserved ejection fraction (HF-PEF) constitute up to 30% to 50% of patients with HF, and HF-PEF affects women more often than men. Not much is known about the role of gender in the clinical presentation, symptoms, or disease severity of HF-PEF or about the contribution of these differences to gender differences in morbidity and mortality in patients with HF-PEF. This study examined gender differences in clinical presentation, hospitalization, and mortality in patients with HF-PEF (ejection fraction >= 50%) enrolled in the ancillary arm of the Digitalis Investigation Group trial. Time-to-event analysis was performed using Cox proportional-hazards modeling. The study cohort included 719 patients (378 men, 341 women). At baseline, compared with men, women were older and had greater clinical severity of HF, as evidenced by worse New York Heart Association functional class, more frequent symptoms and signs of HF, and more treatment with diuretics. Ischemia was identified as the primary cause of HF in 46% of women and 56% of men (p = 0.01). During a median follow-up of 39 months, crude mortality was similar in women and men (24.6% and 24.3%, p = 0.93), but more, women were hospitalized for HF (26.7% vs 15.9%, p < 0.001). After adjustment for baseline differences, female gender was an independent predictor of lower mortality (hazard ratio 0.59, 95% confidence interval 0.43 to 0.82), but HF hospitalization rates were similar between men and women (hazard ratio 1.09, 95% confidence interval 0.77 to 1.53). In conclusion, although the clinical manifestations of HF appear to be more severe in women with HF-PEF, after adjustment for baseline clinical differences, HF hospitalizations are not increased and survival expectancy is better for women compared with men. (c) 2006 Elsevier Inc. All rights reserved. C1 Michael E DeBakey Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, Dept Med, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Deswal, A (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, Dept Med, Houston, TX USA. EM adeswal@bcm.tmc.edu NR 20 TC 30 Z9 33 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2006 VL 97 IS 8 BP 1228 EP 1231 DI 10.1016/j.amjcard.2005.11.042 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 038XO UT WOS:000237263000020 PM 16616031 ER PT J AU Covinsky, K AF Covinsky, K TI Aging, arthritis, and disability SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Editorial Material ID FUNCTIONAL STATUS; DISABLEMENT PROCESS; OLDER PERSONS; DEPENDENCE; ADULTS; ELDERS; RISK C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Covinsky, K (reprint author), 4150 Clement 181G, San Francisco, CA 94121 USA. EM covinsky@medicine.ucsf.edu NR 13 TC 14 Z9 14 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2006 VL 55 IS 2 BP 175 EP 176 DI 10.1002/art.21861 PG 2 WC Rheumatology SC Rheumatology GA 033EV UT WOS:000236830400003 PM 16583390 ER PT J AU Ganz, DA Chang, JT Roth, CP Guan, N Kamberg, CJ Niu, F Reuben, DB Shekelle, PG Wenger, NS Maclean, CH AF Ganz, DA Chang, JT Roth, CP Guan, N Kamberg, CJ Niu, F Reuben, DB Shekelle, PG Wenger, NS Maclean, CH TI Quality of osteoarthritis care for community-dwelling older adults SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE osteoarthritis; quality of care; quality improvement; primary care; health status ID VULNERABLE ELDERS; UNITED-STATES; RISK-FACTORS; HEALTH; INTERVENTION; PREVALENCE; VALIDATION; ARTHRITIS; KNEE; HIP AB Objective. To describe the quality of osteoarthritis care provided to community-dwelling elderly patients and to characterize arthritis-related function in these patients. Methods. Two medical groups in the western United States participated in a practice-redesign intervention targeted at falls and mobility disorders, incontinence, and cognitive impairment, but not osteoarthritis. From 339 individuals reporting a diagnosis of arthritis, we collected information on demographics, functional status, and quality of care via patient interviews and mailed questionnaires. Eight quality indicators measured osteoarthritis care: 4 indicators measuring the provision of effective osteoarthritis care (osteoarthritis treatment indicators) and 4 measuring the provision of safe osteoarthritis care (medication safety indicators). Results. The mean +/- SD Short Form 12 physical component summary score was 35 +/- 11 points, indicating a physically frail population. The overall indicator pass rate was 57.0% (95% confidence interval [95% CI] 53.9-60.2). Pass rates were higher for indicators of osteoarthritis treatment (63.5%, 95% CI 59.8-67.2) than for indicators of medication safety (43.8%, 95% CI 38.2-49.4). Patients with hip or knee pain had mean +/- SD Western Ontario and McMaster Universities Osteoarthritis Index pain, stiffness, and function scores of 6.0 +/- 4.0, 3.1 +/- 1.7, and 25 +/- 12 points, respectively. Conclusion. Quality of osteoarthritis care for older adults is suboptimal, particularly with regard to medication safety. Given the high prevalence of osteoarthritis in older age groups, the population impact of any improvement in quality would be substantial. Quality improvement efforts for osteoarthritis should target appropriate use of and counseling regarding medications, as well as underuse of efficacious therapy for osteoarthritis. C1 Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Vet Affairs Greater Los Angeles Hlth Care Syst, STAR Program, Los Angeles, CA 90024 USA. RAND Hlth, Santa Monica, CA USA. RP Ganz, DA (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Vet Affairs Greater Los Angeles Hlth Care Syst, STAR Program, 911 Broxton Plaza,3rd Floor, Los Angeles, CA 90024 USA. EM dganz@mednet.ucla.edu NR 19 TC 53 Z9 53 U1 1 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2006 VL 55 IS 2 BP 241 EP 247 DI 10.1002/art.21844 PG 7 WC Rheumatology SC Rheumatology GA 033EV UT WOS:000236830400012 PM 16583414 ER PT J AU Spiegel, BMR Chiou, CF AF Spiegel, BMR Chiou, CF TI Cost-effectiveness of nonsteroidal antiinflammatory drug strategies: comment on the article by Spiegel et al - Reply SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Letter ID OSTEOARTHRITIS; ROFECOXIB; CELECOXIB; INHIBITORS; ARTHRITIS; TRIAL C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, VA Greater Outcomes Res & Educ, Los Angeles, CA 90024 USA. Cerner Hlth Insights, Beverly Hills, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, VA Greater Outcomes Res & Educ, Los Angeles, CA 90024 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2006 VL 55 IS 2 BP 339 EP 340 DI 10.1002/art.21847 PG 2 WC Rheumatology SC Rheumatology GA 033EV UT WOS:000236830400027 ER PT J AU Kennedy, A Wood, AE Saxon, A Harvey, M Jurik, J Kilzieh, N Lofgreen, C Sorem, C Crandall, DA Graunke, B Tapp, A AF Kennedy, A Wood, AE Saxon, A Harvey, M Jurik, J Kilzieh, N Lofgreen, C Sorem, C Crandall, DA Graunke, B Tapp, A TI Quetiapine for the treatment of cocaine dependence SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Tacoma, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 75 BP 23S EP 24S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300077 ER PT J AU Boyd, JA Pierre, JM Adamson, CF Guzik, LH Mahgerefteh, S Wirshing, DA Wirshing, WC AF Boyd, JA Pierre, JM Adamson, CF Guzik, LH Mahgerefteh, S Wirshing, DA Wirshing, WC TI Aripiprazole-associated new-onset diabetes SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 76 BP 24S EP 24S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300078 ER PT J AU Marder, SR Crandall, D Pultz, J Carson, W Gutierrez-Esteinou, R Van Tran, Q Marcus, R AF Marder, SR Crandall, D Pultz, J Carson, W Gutierrez-Esteinou, R Van Tran, Q Marcus, R TI The effectiveness of aripiprazole in patients with schizophrenia experiencing high or low agitation SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Greater LA Hlth Care Syst, Los Angeles, CA USA. Bristol Myers Squibb, Neurosci, Plainsboro, NJ USA. Bristol Myers Squibb, Biostat & Data Management, Plainsboro, NJ USA. Otsuka Pharmaceut Co Ltd, Global Med Affairs, Princeton, NJ USA. Bristol Myers Squibb Co, GLobal Med Affairs, Lawrenceville, NJ USA. Otsuka Pharmaceut Co Ltd, US Med Affairs, Rockville, MD USA. Bristol Myers Squibb Co, Pharmaceut Res Inst, Global Clin Res, Wallingford, CT 06492 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 101 BP 32S EP 32S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300103 ER PT J AU McClure, MM Romero, MJ Zegarelli, GL Harvey, PD Siever, LJ AF McClure, MM Romero, MJ Zegarelli, GL Harvey, PD Siever, LJ TI Guanfacine treatment of context processing impairments in schizotypal personality disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. James J Peters VAMC, MIRECC, VA VISN3, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 151 BP 46S EP 47S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300153 ER PT J AU Frey, BN Nery, FG Stanley, JA Chen, HH Nicoletti, MA Hatch, JP Monkul, ES Caetano, SC Ortiz, O Soares, JC AF Frey, BN Nery, FG Stanley, JA Chen, HH Nicoletti, MA Hatch, JP Monkul, ES Caetano, SC Ortiz, O Soares, JC TI Lower creatine plus phosphocreatine in the left dorsolateral prefrontal cortex in unmedicated bipolar disorder subjects: A magnetic resonance spectroscopy study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil. Hosp Clin Porto Alegre, Bipolar Disorders Program, Porto Alegre, RS, Brazil. S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 185 BP 58S EP 58S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300187 ER PT J AU Nery, FG Hatch, JP Glahn, D Nicoletti, M Monkul, ES Sanches, M Najt, P Koji, M Bowden, C Cloninger, CR Soares, JC AF Nery, FG Hatch, JP Glahn, D Nicoletti, M Monkul, ES Sanches, M Najt, P Koji, M Bowden, C Cloninger, CR Soares, JC TI Chronicity and severity in major depressive disorder and their relationship with personality traits SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, MOOD CNS Program, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Washington, Sch Med, Dept Psychiat, St Louis, MO USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX USA. RI Cloninger, Claude/F-5357-2012 OI Cloninger, Claude/0000-0003-3096-4807 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 212 BP 66S EP 66S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300214 ER PT J AU Chen, HH Jeffrey, SA Caetano, SC Nicoletti, M Hatch, HP Monkul, SE Nery, FG Manoela, F Osvaldo, O Soares, JC AF Chen, HH Jeffrey, SA Caetano, SC Nicoletti, M Hatch, HP Monkul, SE Nery, FG Manoela, F Osvaldo, O Soares, JC TI A multi-voxel 1H magnetic resonance spectroscopy investigation in bipolar disorder patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Wayne State Univ, Sch Med, Detroit, MI 78284 USA. UTHSCSA, Dept Psychiat, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 214 BP 67S EP 67S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300216 ER PT J AU Goodman, M Flory, J Koenigsberg, H Siever, L New, A AF Goodman, M Flory, J Koenigsberg, H Siever, L New, A TI Aggressive responding in borderline personality disorder - Baseline differences and treatment effects of a cognitive behavioral therapy SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 275 BP 86S EP 86S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300277 ER PT J AU Chen, HH Jeffrey, SA Nicoletti, M Hatch, J Sanches, M Caetano, SC Fonseca, M Najt, P Matsuo, K Monkul, SE Peluso, M Silva, LP Osvaldo, O Soares, JC AF Chen, HH Jeffrey, SA Nicoletti, M Hatch, J Sanches, M Caetano, SC Fonseca, M Najt, P Matsuo, K Monkul, SE Peluso, M Silva, LP Osvaldo, O Soares, JC TI Gender effects on brain metabolite levels in unipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 UTHSCSA, Dept Psychiat, San Antonio, TX USA. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 375 BP 115S EP 115S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300371 ER PT J AU Fonseca, M Caetano, SC Chen, HH Nicoletti, M Stanley, JA Hatch, JP Olvera, RL Hunter, K Ortiz, O Pliszka, S Soares, JC AF Fonseca, M Caetano, SC Chen, HH Nicoletti, M Stanley, JA Hatch, JP Olvera, RL Hunter, K Ortiz, O Pliszka, S Soares, JC TI A proton chemical shift Imaging study in pediatric major depressive disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Mood CNS Program, Dept Psychiat,Div Mood & Anxiety Disorders, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Psychiat Serv, Audie L Murphy Div, San Antonio, TX USA. Univ Fed Rio Grande Sul, Psychiat Res Unit, Porto Alegre, RS, Brazil. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Child & Adolescent Psychiat, San Antonio, TX 78284 USA. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 397 BP 122S EP 122S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300393 ER PT J AU Mintzer, JE Crandall, D Pultz, J Carson, W Gutierrez-Esteinou, R Whitehead, R Breader, C AF Mintzer, JE Crandall, D Pultz, J Carson, W Gutierrez-Esteinou, R Whitehead, R Breader, C TI Efficacy of aripiprazole in highly agitated patients with psychosis of Alzheimer's disease SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Med Univ S Carolina, Alzheimers Res & Clin Program, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. Bristol Myers Squibb Co, Neurosci, Plainsboro, NJ USA. Bristol Myers Squibb Co, Biostat & Data Management, Clin Res, Wallingford, CT 06492 USA. Otsuka Pharmaceut Co Ltd, Global Med Affairs, Princeton, NJ USA. Bristol Myers Squibb Co, Global Med Affairs, Lawrenceville, NJ USA. Otsuka Pharmaceut Co Ltd, US Med Affairs, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 417 BP 128S EP 129S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767300413 ER PT J AU Boyd, JA Daigdigan, DM Wirshing, DA Guzik, LH Mahgerefteh, S Wirshing, WC AF Boyd, JA Daigdigan, DM Wirshing, DA Guzik, LH Mahgerefteh, S Wirshing, WC TI Assessment of pharmacist-run medication education group for inpatients in a schizophrenia ward SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 450 BP 139S EP 139S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301027 ER PT J AU Frey, BN Nery, FG Stanley, JA Chen, HH Nicoletti, MA Hatch, JP Monkul, ES Caetano, SC Ortiz, O Soares, JC AF Frey, BN Nery, FG Stanley, JA Chen, HH Nicoletti, MA Hatch, JP Monkul, ES Caetano, SC Ortiz, O Soares, JC TI Lower creatine plus phosphocreatine in the left dorsolateral prefrontal cortex in unmedicated bipolar disorder subjects: A magnetic resonance spectroscopy study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil. Hosp Clin Porto Alegre, Bipolar Disorders Program, Porto Alegre, RS, Brazil. S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 458 BP 141S EP 141S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301035 ER PT J AU Zunta, GB Caetano, SC Nlcoletti, M Hatch, JP Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Soares, JC AF Zunta, GB Caetano, SC Nlcoletti, M Hatch, JP Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Soares, JC TI Illness duration and total brain gray matter in bipolar disorder: Evidence for neurodegeneration? SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Univ Sao Paulo Med, Sao Paulo, Brazil. Univ Udine, Pathol & Expt & Clin Med Sect Psychiat, I-33100 Udine, Italy. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RI brambilla, paolo/B-4184-2010; Caetano, Sheila/H-5010-2012 OI brambilla, paolo/0000-0002-4021-8456; Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 487 BP 150S EP 150S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301064 ER PT J AU Nery, FG Stanley, JA Chen, HH Nicoletti, M Hatch, JP Monkul, ES Caetano, SC Sanches, M Najt, P Peluso, M Silva, LP Ortiz, O Soares, JC AF Nery, FG Stanley, JA Chen, HH Nicoletti, M Hatch, JP Monkul, ES Caetano, SC Sanches, M Najt, P Peluso, M Silva, LP Ortiz, O Soares, JC TI Glutamatergic abnormalities in dorsolateral prefrontal cortex of patients with major depressive disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, MOOD CNS Program,Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Psychiat Serv, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 505 BP 155S EP 156S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301082 ER PT J AU Adler, LE Cawthra, E Pincus, SS Woodward, L Wald, MC Staves, P House, R AF Adler, LE Cawthra, E Pincus, SS Woodward, L Wald, MC Staves, P House, R TI P50 gaiting: Differences between non combat-deployed and combat-deployed groups SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Denver VAMC, MIRECC, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Madigan Army Hosp, Tacoma, WA USA. Denver VA Med Ctr, MIRECC, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Psychiat, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 559 BP 172S EP 172S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301136 ER PT J AU Goodman, M Flory, J Koenigsberg, H Siever, L New, A AF Goodman, M Flory, J Koenigsberg, H Siever, L New, A TI Aggressive responding in borderline personality disorder-baseline differences and treatment effects of a cognitive behavioral therapy SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 564 BP 173S EP 173S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301141 ER PT J AU Bearden, CE Glahn, DC Caetano, SC Fonseca, M Olvera, RL Najt, P Hunter, K Pliszka, SR Soares, JC AF Bearden, CE Glahn, DC Caetano, SC Fonseca, M Olvera, RL Najt, P Hunter, K Pliszka, SR Soares, JC TI Deficits in working memory and executive function in juvenile bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Div Child & Adolescent Psychiat, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 616 BP 189S EP 189S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301188 ER PT J AU Koenigsberg, HW Prohovnik, I Fan, J Lee, H Osowsky, J New, A Goodman, M Guo, XD Pizzarello, S Siever, LJ AF Koenigsberg, HW Prohovnik, I Fan, J Lee, H Osowsky, J New, A Goodman, M Guo, XD Pizzarello, S Siever, LJ TI Patterns of neural activation during the processing of emotional pictures in affectively unstable borderline patients and normal controls SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 CUNY Mt Sinai Sch Med, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 659 BP 201S EP 201S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301231 ER PT J AU Wirshing, WC Mahgerefteh, S Guzik, LH Boyd, JA Pierre, JM Wirshing, DA AF Wirshing, WC Mahgerefteh, S Guzik, LH Boyd, JA Pierre, JM Wirshing, DA TI Pharmacoeconomics: Divalproex sodium and schizophrenia spectrum disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 671 BP 205S EP 205S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301243 ER PT J AU Glahn, DC Bearden, CE Barrett, J Barguil, M Nery, FG Velligan, DI Soares, JC AF Glahn, DC Bearden, CE Barrett, J Barguil, M Nery, FG Velligan, DI Soares, JC TI Declarative memory impairment accentuated by history of psychosis in bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 UTHSCSA, San Antonio, TX USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 675 BP 206S EP 206S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301247 ER PT J AU Mena, SJ Guzik, LH Mahgerefteh, S Pierre, JM Wirshing, DA Wirshing, WC AF Mena, SJ Guzik, LH Mahgerefteh, S Pierre, JM Wirshing, DA Wirshing, WC TI Aripiprazole: Effects on metabolic risk factors and sexual satisfaction SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 676 BP 206S EP 206S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301248 ER PT J AU Caetano, SC Fonseca, M Chen, HH Nicoletti, M Stanley, JA Hatch, JP Olvera, RL Hunter, K Ortiz, O Pliszka, SR Soares, JC AF Caetano, SC Fonseca, M Chen, HH Nicoletti, M Stanley, JA Hatch, JP Olvera, RL Hunter, K Ortiz, O Pliszka, SR Soares, JC TI Proton chemical shift imaging in pediatric bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, MOOD CNS Program, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Psychiat Serv, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Inst Psychiat, BR-05508 Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Psychiat Res Unit, Sch Med, BR-90046900 Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA. Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Childl & Adolescent Psychiat, San Antonio, TX 78229 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 682 BP 208S EP 208S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301254 ER PT J AU Olvera, RL Caetano, SC Fonseca, M Nicoletti, M Stanley, JA Chen, HH Hatch, JP Hunter, K Pliszka, SR Soares, JC AF Olvera, RL Caetano, SC Fonseca, M Nicoletti, M Stanley, JA Chen, HH Hatch, JP Hunter, K Pliszka, SR Soares, JC TI N-acetyl aspartate reduction in the dorsolateral prefrontal cortex of pediatric bipolar patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 UTHSCSA, MOOD, CNS Program, Div Mood & Anxiety Disorders, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Res Unit, Porto Alegre, RS, Brazil. Wayne State Univ, Sch Med, Detroit, MI USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 729 BP 223S EP 223S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301301 ER PT J AU McClure, MM Romero, MJ Zegarelli, GL Harvey, PD Siever, LJ AF McClure, MM Romero, MJ Zegarelli, GL Harvey, PD Siever, LJ TI Visual learning and memory in schizotypal personality disorder: Evidence of unidimensional episodic memory deficits in the schizophrenia spectrum SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 James J Peters VAMC, VICN3 MIRECC, Bronx, NY USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 751 BP 229S EP 230S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301323 ER PT J AU Katsel, PL Davis, KL Haroutunian, V AF Katsel, PL Davis, KL Haroutunian, V TI Oligodendrocytes associated cell cycle gene expression abnormalities in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Mt Sinai Med Ctr, New York, NY 10029 USA. James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 771 BP 236S EP 236S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301343 ER PT J AU Dracheva, S Patel, N Woo, D Siever, LJ Haroutunian, V AF Dracheva, S Patel, N Woo, D Siever, LJ Haroutunian, V TI The role of the serotonin 2C receptor mRNA editing in suicidal behaviour SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 775 BP 237S EP 237S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301347 ER PT J AU Byne, W Dracheva, S Chu, THT AF Byne, W Dracheva, S Chu, THT TI Analysis of gene expression in the interstitial nuclei of the human anterior hypothalamus SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 Bronx Vet Affairs Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 815 BP 249S EP 249S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301387 ER PT J AU Yao, JK Reddy, RD Keshavan, MS AF Yao, JK Reddy, RD Keshavan, MS TI Altered membrane lipids in first-episode psychoses SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 61st Annual Convention of the Society-of-Biological-Psychiatry CY MAY 18-20, 2006 CL Toronto, CANADA SP Soc Biol Psychiat C1 VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 SU S MA 822 BP 251S EP 251S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 032IE UT WOS:000236767301394 ER PT J AU Caetano, SC Kaur, S Brambilla, P Nicoletti, M Hatch, JP Sassi, RB Mallinger, AG Keshavan, MS Kupfer, DJ Frank, E Soares, JC AF Caetano, SC Kaur, S Brambilla, P Nicoletti, M Hatch, JP Sassi, RB Mallinger, AG Keshavan, MS Kupfer, DJ Frank, E Soares, JC TI Smaller cingulate volumes in unipolar depressed patients SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 59th Annual Meeting of the Society-of-Biological-Psychiatry CY APR 29-MAY 01, 2004 CL NEW YORK, NY SP Soc Biol Psychiat DE magnetic resonance imaging; cingulate; neuroimaging; depression; unipolar disorder; mood disorders ID SUBGENUAL PREFRONTAL CORTEX; CEREBRAL BLOOD-FLOW; ANTERIOR CINGULATE; MAJOR DEPRESSION; MOOD DISORDERS; BIPOLAR-DISORDER; ABNORMALITIES; BRAIN; MRI; DEFICITS AB Background: The, anterior cingulate cortex is a key structure in brain networks involved in mood regulation. Abnormalities in this brain region are possibly implicated in the pathophysiology of depression. This anatomical magnetic resonance imaging (MRI) study compared cingulate cortex volumes in unipolar depressed patients and age- and gender-matched healthy control subjects. Methods: Thirty-one unmedicated DSM-IV unipolar patients (24 female, aged 39.2 +/- 11.9 years [mean +/- SD]) and 31 healthy control subjects (24 female, aged 36.7 +/- 10.7 years) were studied in a 1.5-T GE Signa magnet (General Electric Medical systems, Milwaukee, Wisconsin). Cingulate volumes were compared by analysis of covariance with intracranial volume as the covariate. Results: The unipolar patients bad significantly smaller anterior and posterior cingulate volumes bilaterally compared with, healthy control subjects. When patients were divided into currently depressed (n = 27) and remitted (n = 10) subgroups. currently depressed patients bad significantly smaller anterior and Posterior cingulate volumes bilaterally compared with healthy control subjects, whereas remitted patients bad significantly smaller left anterior cingulate volumes compared with healthy individuals. Conclusions: Gray matter abnormalities in the cingulate cortex are implicated in the pathophysiology of unipolar depression. Smaller cingulate volumes in currently depressed patients support the hypothesis that cingulate cortex abnormalities are state dependent, whereas changes in left anterior cingulate might be trait related. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Psychiat, BR-05508 Sao Paulo, Brazil. Univ Udine, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. Univ Pittsburgh, Med Ctr, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010; Caetano, Sheila/H-5010-2012 OI brambilla, paolo/0000-0002-4021-8456; Caetano, Sheila/0000-0001-8403-7078 FU NCRR NIH HHS [RR 020571]; NIMH NIH HHS [MH 01736, MH 30915, MH 49115] NR 45 TC 85 Z9 94 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 BP 702 EP 706 DI 10.1016/j.biopsych.2005.10.011 PG 5 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 031HN UT WOS:000236695400005 PM 16414029 ER PT J AU Tanabe, J Tregellas, JR Martin, LF Freedman, R AF Tanabe, J Tregellas, JR Martin, LF Freedman, R TI Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE nicotine; smooth pursuit eye movement; schizophrenia; fMRI; hippocampus; cingulate ID CIGARETTE-SMOKING; ANTICIPATORY SACCADES; TRACKING DYSFUNCTION; BRAIN ACTIVATION; LEADING SACCADES; TOBACCO SMOKING; FMRI; PERFORMANCE; TASK; PARAHIPPOCAMPAL AB Background: Abnormal smooth pursuit eye movement (SPEM) in schizophrenic patients is a well known phenomenon, but the neurophysiological mechanisms underlying the deficit are unknown. Nicotine temporarily improves SPEM and has been associated with reduced hippocampal hemodynamic activity in schizophrenics. Nicotine's effect on brain activity in control subjects performing SPEM has not been studied. The purpose of this work was to determine if nicotine differentially affects brain activity in schizophrenic and control subjects during pursuit eye tracking. Methods: 16 subjects with schizophrenia and 16 control subjects underwent functional MR imaging during SPEM after receiving placebo or nicotine gum. Four brain regions were analyzed for main effects of group, drug, and interactions: hippocampus, cingulate gyrus, frontal eye fields, and area MT. Results: Nicotine reduced hippocampal activity in both groups, but the effect was greater in control subjects. A group by drug interaction was observed in the anterior cingulate gyrus, where nicotine decreased activity in control subjects and increased activityin schizophrenic subjects. There were no significant effectsof group, drug, or interactions in frontal eye fields or area MT. Conclusion: Nicotine may improve SPEM performance in people with schizophrenia through cholinergic stimulation of the hippocampus and cingulate gyrus. Potential mechanisms include improved inhibitory function and attention. C1 Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tanabe, J (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Radiol, Campus Box A034,4200 E 9th Ave, Denver, CO 80262 USA. EM jody.tanabe@uchsc.edu RI Tregellas, Jason/J-3637-2015 FU NIDA NIH HHS [K08DA1505] NR 57 TC 33 Z9 34 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2006 VL 59 IS 8 BP 754 EP 761 DI 10.1016/j.biopsych.2005.09.004 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 031HN UT WOS:000236695400012 PM 16259965 ER PT J AU Goldman, DC Berg, LK Heinrich, MC Christian, JL AF Goldman, DC Berg, LK Heinrich, MC Christian, JL TI Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus SO BLOOD LA English DT Article ID C-KIT RECEPTOR; VENTRAL BLOOD ISLAND; EMBRYONIC BLOOD; EXPRESSION PATTERNS; HEMATOPOIETIC-CELLS; REGULATES LINEAGE; GASTRULA EMBRYO; SI-LOCUS; MESODERM; MOUSE AB Signals derived from nonhematopoietic tissues are essential for normal primitive erythropoiesis in vertebrates, but little is known about the nature of these signals. In Xenopus, unidentified factors secreted by ectodermal cells during gastrulation are required to enable the underlying ventral mesoderm to form blood. Steel is expressed in the ectoderm of early Xenopus embryos and is known to regulate definitive erythroid progenitor survival and differentiation in other organisms, making it an excellent candidate regula-tor of primitive erythropoiesis. In this study, we tested whether steel signaling is required for primitive red blood cell differentiation in mice and frogs. We show that Xsl is expressed in the ectoderm in Xenopus gastrulae and that c-kit homologs are expressed in the underlying mesoderm at the same stages of development. We present loss of function data in whole Xenopus embryos and explants that demonstrate a requirement for ectodermally derived steel to signal through c-kit in the mesoderm to support early steps in the differentiation of primitive erythroid but not myeloid cells. Finally, we show that primitive erythropoiesis is not disrupted in mouse embryos that lack c-kit function. Our data suggest a previously unrecognized and unique function of steel/c-kit during primitive erythropoiesis in Xenopus. C1 Oregon Hlth Sci Univ, Dept Dev & Cell Biol, Div Hematol & Oncol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med, Div Hematol & Oncol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Christian, JL (reprint author), Oregon Hlth Sci Univ, Dept Dev & Cell Biol, Div Hematol & Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM christia@ohsu.edu FU NICHD NIH HHS [R03 HD050242] NR 62 TC 6 Z9 6 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 15 PY 2006 VL 107 IS 8 BP 3114 EP 3121 DI 10.1182/blood-2005-093930 PG 8 WC Hematology SC Hematology GA 033FY UT WOS:000236833500025 PM 16357321 ER PT J AU Fieber, CB Eldridge, J Taha, TA Obeid, LM Muise-Helmericks, RC AF Fieber, CB Eldridge, J Taha, TA Obeid, LM Muise-Helmericks, RC TI Modulation of total Akt kinase by increased expression of a single isoform: Requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells SO EXPERIMENTAL CELL RESEARCH LA English DT Article ID PROTEIN-COUPLED RECEPTORS; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; SPHINGOSINE 1-PHOSPHATE; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; CANCER-CELLS; PATHWAY; SURVIVAL; APOPTOSIS AB Akt kinase is an important downstream effector of VEGF in primary endothelial cells (EC), promoting angiogenesis by increased cellular survival, motility and tubulogenesis. Akt1 is the founding member of a family of serine threonine kinases thought to have overlapping function. We sought to determine if other Akt family members were also regulated by VEGF in EC. We show that treatment of EC with the angiogenic inducers VEGF or sphingosine-1-phosphate (SIP) results in an increased stabilization of Akt3 mRNA, concur-rent with a PI3 kinase-dependent, Akt1-independent increase in both the protein and its phosphorylation. Given the similarity of Akt3 regulation by VEGF and S1P, the sensitivity of VEGF stimulation to the Gi-protein uncoupling reagent, pertussis toxin was tested and shows that VEGF stimulation requires Gi-protein signaling. We show that the VEGF stimulates the expression of Edg3/S1P3 (S1P3) and that expression of this Gi-protein-coupled receptor is both sufficient and necessary for the expression of Akt3. Blockade of a single isoform. does not overtly affect cellular function, whereas inhibition of both kinases results in an increase in apoptosis and a down-regulation of cyclin D3. These results suggest a model whereby extracellular cues maintain total Akt kinase levels through the regulation of specific isoform expression providing a fail-safe mechanism to maintain necessary levels of Akt kinase activity. (c) 2006 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. RP Muise-Helmericks, RC (reprint author), Univ S Carolina, Hollings Canc Ctr, Rm 320,86 Jonathan Lucas St, Charleston, SC 29403 USA. EM musehelm@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01CA097132]; NCRR NIH HHS [P20 RR16434] NR 49 TC 21 Z9 21 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495, UNITED STATES SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD APR 15 PY 2006 VL 312 IS 7 BP 1164 EP 1173 DI 10.1016/j.yexcr.2006.01.022 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 031UE UT WOS:000236728900019 PM 16527273 ER PT J AU Sanders, NM Figlewicz, DP Taborsky, GJ Wilkinson, CW Daumen, W Levin, BE AF Sanders, NM Figlewicz, DP Taborsky, GJ Wilkinson, CW Daumen, W Levin, BE TI Feeding and neuroendocrine responses after recurrent insulin-induced hypoglycemia SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE hypoglycemia; hypoglycemia counterregulation; hypoglycemia-associated autonomic failure; glucoprivation; food intake ID DEPENDENT DIABETES-MELLITUS; NEUROPEPTIDE-Y; COUNTERREGULATORY RESPONSES; ANTECEDENT HYPOGLYCEMIA; GLUCOSE-UTILIZATION; PERIPHERAL FACTORS; ARCUATE NUCLEUS; WEIGHT-GAIN; FOOD-INTAKE; SUBSEQUENT HYPOGLYCEMIA AB Prior exposure to hypoglycemia impairs neuroendocrine counterregulatory responses (CRR) during subsequent hypoglycemia. Defective CRR to hypoglycemia is a component of the clinical syndrome hypoglycemia-associated autonomic failure (HAAF). Hypoglycemia also potently stimulates food intake, an important behavioral CRR. Because the increased feeding response to hypoglycemia is behavioral and not hormonal, we hypothesized that it may be regulated differently with recurrent bouts of hypoglycemia. To test this hypothesis, we simultaneously evaluated neuroendocrine CRR and food intake in rats experiencing one or three episodes of insulin-induced hypoglycemia. As expected, recurrent hypoglycemia significantly reduced neuroendocrine hypoglycemic CRR. Epinephrine (E), norepinephrine (NE) and glucagon responses 120 min after insulin injection were significantly reduced in recurrent hypoglycemic rats, relative to rats experiencing hypoglycemia for the first time. Despite these neuroendocrine impairments, food intake was significantly elevated above baseline saline intake whether rats were experiencing a first (hypoglycemia: 3.4 +/- 0.4 g vs. saline: 0.94 +/- 0.3 g, P < 0.05) or third hypoglycemic episode (hypoglycerma: 3.8 +/- 0.3 g vs. saline: 1.2 +/- 0.3 g, P < 0.05). These findings demonstrate that food intake elicited in response to hypoglycemia is not impaired as a result of recurrent hypoglycemia. Thus, neuroendocrine and behavioral (stimulation of food intake) CRR are differentially regulated by recurrent hypoglycemia experience. (c) 2006 Elsevier Inc. All rights reserved. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab, Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Div Geriatr Res, Educ & Clin Ctr, Seattle, WA USA. Seattle Inst Biomed & Clin Res & Neurol Serv, Dept Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA. RP Sanders, NM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab, Educ & Clin Ctr, S-151,1660 So Columbian Way, Seattle, WA 98108 USA. EM sandersn@u.washington.edu FU NIDDK NIH HHS [DK 50154, DK 40963, DK 53181] NR 53 TC 20 Z9 21 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD APR 15 PY 2006 VL 87 IS 4 BP 700 EP 706 DI 10.1016/j.physbeh.2006.01.007 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 035HN UT WOS:000236991600008 PM 16492385 ER PT J AU Saidarriaga, OA Perez, LE Travi, BL Melby, PC AF Saidarriaga, OA Perez, LE Travi, BL Melby, PC TI Selective enhancement of the type 1 cytokine response by expression of a canine interleukin (IL)-12 fused heterodimeric DNA SO VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY LA English DT Article DE canine; interleukin-12; vaccine adjuvant; IFN-gamma ID BLOOD MONONUCLEAR-CELLS; STIMULATORY FACTOR INTERLEUKIN-12; CELLULAR IMMUNE-RESPONSE; IN-VIVO; LEISHMANIA-MAJOR; PROTECTIVE IMMUNITY; VISCERAL LEISHMANIASIS; INTERFERON-GAMMA; MESSENGER-RNA; TH1 RESPONSE AB Interleukin-12 (IL-12) is a heterodimeric cytokine that is a principal mediator of the innate immune response and modulator of acquired cell-mediated immunity. Administration of exogenous IL-12 can direct the host adaptive T cell response toward a type I phenotype. The co-administration of IL-12 with vaccine antigen, has been shown to augment the vaccine-induced T(H)1 response and protection against intracellular pathogens. We show here that a canine IL-12 DNA, constructed by fusing the p35 and p40 Subunit cDNAs with an interspacing linker, generated stable IL-12 transcripts when placed under control of a strong constitutive promoter. The protein expressed from this fused cDNA wag fully functional in promoting a type 1 (IFN-gamma) and Suppressing a type 2 (IL-4) cytokine response following both in vitro transfection of a canine cell line and in vivo delivery to dogs. This DNA construct may be useful as an adjuvant for vaccines that target tumors or intracellular pathogens of the dog. (c) 2005 Elsevier B.V. All rights reserved. C1 S Texas Vet Hlth Care Syst, Res Serv, Dept Vet Affairs, Med Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78284 USA. Ctr Int Entrenamiento & Invest Med, Cali AA53909, Colombia. RP Melby, PC (reprint author), S Texas Vet Hlth Care Syst, Res Serv, Dept Vet Affairs, Med Ctr, 7400 Merton Minter Dr,Mailstop 151, San Antonio, TX 78229 USA. EM melby@uthscsa.edu NR 40 TC 0 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-2427 J9 VET IMMUNOL IMMUNOP JI Vet. Immunol. Immunopathol. PD APR 15 PY 2006 VL 110 IS 3-4 BP 377 EP 388 DI 10.1016/j.vetimm.2005.11.003 PG 12 WC Immunology; Veterinary Sciences SC Immunology; Veterinary Sciences GA 023VQ UT WOS:000236154700019 ER PT J AU Musher, DM AF Musher, DM TI Pneumococcal vaccine - Direct and indirect ("herd") effects SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DAY-CARE-CENTERS; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; CARRIAGE; EFFICACY C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX 77211 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX 77211 USA. NR 11 TC 54 Z9 55 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 6 PY 2006 VL 354 IS 14 BP 1522 EP 1524 DI 10.1056/NEJMe068038 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 029DP UT WOS:000236539000012 PM 16598050 ER PT J AU Perlin, JB Pogach, LM AF Perlin, JB Pogach, LM TI Improving the outcomes of metabolic conditions: Managing momentum to overcome clinical inertia SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID HEALTH-CARE-SYSTEM; DIABETES CARE; QUALITY; PROVIDERS; TRIAL C1 Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ 07018 USA. US Dept Vet Affairs, Vet Hlth Adm, Washington, DC 20420 USA. RP Pogach, LM (reprint author), Vet Affairs New Jersey Hlth Care Syst, 385 Tremont Ave, E Orange, NJ 07018 USA. EM leonard.pogach@med.va.gov NR 19 TC 13 Z9 13 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 4 PY 2006 VL 144 IS 7 BP 525 EP 527 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 031DU UT WOS:000236685100008 PM 16585667 ER PT J AU Trivedi, MA Coover, GD AF Trivedi, MA Coover, GD TI Neurotoxic lesions of the dorsal and ventral hippocampus impair acquisition and expression of trace-conditioned fear-potentiated startle in rats SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article; Proceedings Paper CT Annual Meeting of the International-Behavioral-Neuroscience-Society CY JUN 16-20, 2004 CL Key West, FL SP Int Behav Neurosci Soc DE startle; trace conditioning; fear; ventral hippocampus; dorsal hippocampus ID MEDIAL PREFRONTAL CORTEX; NICTITATING-MEMBRANE RESPONSE; LONG-TERM POTENTIATION; CONTEXTUAL FEAR; INHIBITORY AVOIDANCE; MEMORY; DELAY; AMYGDALA; ANXIETY; RABBITS AB Pavlovian delay conditioning, in which a conditioned stimulus (CS) and unconditioned stimulus (US) co-terminate, is thought to reflect nondeclarative memory. In contrast, trace conditioning, in which the CS and US are temporally separate, is thought to reflect declarative memory. Hippocampal lesions impair acquisition and expression of trace conditioning measured by the conditioned freezing and eyeblink responses, while having little effect on the acquisition of delay conditioning. Recent evidence suggests that lesions of the ventral hippocampus (VH) impair conditioned fear under conditions in which dorsal hippocampal (DH) lesions have little effect. In the present study, we examined the time-course of fear expression after delay and trace conditioning using the fear-potentiated startle (FPS) reflex, and the effects of pre- and post-training lesions to the VH and DH on trace-conditioned FPS. We found that both delay- and trace-conditioned rats displayed significant FPS near the end of the CS relative to the unpaired control group. In contrast, trace-conditioned rats displayed significant FPS throughout the duration of the trace interval, whereas FPS decayed rapidly to baseline after CS offset in delay-conditioned rats. In experiment 2, both DH and VH lesions were found to significantly reduce the overall magnitude of FPS compared to the control group, however, no differences were found between the DH and VH groups. These findings support a role for both the DH and VH in trace fear conditioning, and suggest that the greater effect of VH lesions on conditioned fear might be specific to certain measures of fear. (c) 2005 Elsevier B.V. All rights reserved. C1 No Illinois Univ, Dept Psychol, De Kalb, IL 60115 USA. RP Trivedi, MA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace 11G,GRECC, Madison, WI 53705 USA. EM mt2@medicine.wisc.edu NR 65 TC 15 Z9 15 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD APR 3 PY 2006 VL 168 IS 2 BP 289 EP 298 DI 10.1016/j.bbr.2005.11.029 PG 10 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 018JT UT WOS:000235761200015 PM 16413066 ER PT J AU Loberg, EM Jorgensen, HA Green, MF Rund, BR Lund, A Diseth, A Oie, M Hugdahl, K AF Loberg, EM Jorgensen, HA Green, MF Rund, BR Lund, A Diseth, A Oie, M Hugdahl, K TI Positive symptoms and duration of illness predict functional laterality and attention modulation in schizophrenia SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Article DE attention; dichotic listening tests; laterality; schizophrenia; symptoms ID TRANSCRANIAL MAGNETIC STIMULATION; DICHOTIC-LISTENING PERFORMANCE; SUPERIOR TEMPORAL GYRUS; AUDITORY VERBAL HALLUCINATIONS; POSITRON EMISSION TOMOGRAPHY; LEFT TEMPOROPARIETAL CORTEX; FORMAL THOUGHT-DISORDER; CEREBRAL BLOOD-FLOW; GRAY-MATTER VOLUME; HOMO-SAPIENS PAYS AB Objective: Dichotic listening (DL) performance in schizophrenia. reflecting hemispheric asymmetry and the functional integrity of the left temporal lobe, can vary with clinical characteristics. Previous studies have not taken the co-linearity of clinical variables into account. The aim of the present study was to evaluate the roles of positive symptoms and duration of illness in DL through structural Equation Modeling (SEM), thus allowing for complex relationships between the variables. Method: We pooled patients from four previous DL Studies to create a heterogeneous group Of 129 schizophrenic patients, all tested with a consonant-vowel syllables DL procedure that Included attentional Instructions. Results: A model where positive symptoms predicted a laterality component and duration of illness predicted an attention component in DL was confirmed. Conclusion: Positive symptoms predicted reduced functional laterality, suggesting involvement or left temporal lobe language processing. Duration of illness predicted impaired attention modulation. possibly reflecting the Involvement of frontotemporal networks. C1 Univ Bergen, Dept Psychiat, Bergen Mental Hlth Res Ctr, N-5035 Bergen, Norway. Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway. Univ Calif Los Angeles, Inst Neuropsychiat, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Oslo, Inst Psychol, Oslo, Norway. Univ Bergen, Dept Psychosocial Sci, Bergen, Norway. Oppland Hosp, Child & Adolescent Psychiat Outpatient Clin, Lillehammer, Norway. RP Loberg, EM (reprint author), Univ Bergen, Dept Psychiat, Bergen Mental Hlth Res Ctr, N-5035 Bergen, Norway. EM else.marie.loeberg@psych.uib.no NR 90 TC 21 Z9 21 U1 1 U2 7 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0001-690X J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD APR PY 2006 VL 113 IS 4 BP 322 EP 331 DI 10.1111/j.1600-0447.2005.00627.x PG 10 WC Psychiatry SC Psychiatry GA 028GK UT WOS:000236474800010 PM 16638077 ER PT J AU Krahn, D Grossman, J Henk, H Mussey, M Crosby, R Gosnell, B AF Krahn, D Grossman, J Henk, H Mussey, M Crosby, R Gosnell, B TI Sweet intake, sweet-liking, urges to eat, and weight change: Relationship to alcohol dependence and abstinence SO ADDICTIVE BEHAVIORS LA English DT Article DE sweet-liking; alcohol; dependence; abstinence; diet; urges ID RATS; PREFERENCE; ETHANOL; DEPRIVATION; CONSUMPTION; LINES AB Introduction: Linkages between alcohol dependence (AD) and abstinence and aspects of food ingestion and preference have been described in animals and humans, including (1) eating sweets decreases urges to drink alcohol; (2) preferences for highly sweet tastants is associated with alcohol dependence; and (3) food deprivation leads to increased alcohol intake. Methods: We randomly assigned AD subjects in early abstinence to 3 different sets of dietary instructions (eat sweets for alcohol urges; eat a balanced diet; avoid sweets). We compared the groups on urges for alcohol, alcohol consumption, weight, and sweet preference at baseline, one, and six months. We also compared these AD subjects with light-drinking C's and compared AD subjects who remained abstinent for 6 month follow-up with nonabstinent AD subjects. Results: Recruited AS subjects, 38 of 68, completed 6 month follow-up; 27 of 36 C's completed the follow-up. 21 AD's were abstinent while 17 were non-abstinent. There was no effect of dietary recommendations on urges to drink or alcohol consumption. AD's were more likely than C's to prefer highly sweet tastants. The proportion of AD's preferring the sweetest tastant decreased over time. AD's gained more weight than C's over the 6-month follow-up. Discussion: While the use of sweets did not affect urges to drink or drinking, important relationships between sweet preference, weight gain, and alcohol dependence or abstinence were identified. (c) 2005 Elsevier Ltd. All rights reserved. C1 William S Middleton Mem Vet Adm Med Ctr, Psychiat Serv, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Madison, WI USA. NRI, Fargo, ND USA. RP Krahn, D (reprint author), William S Middleton Mem Vet Adm Med Ctr, Psychiat Serv, 2500 Overlook Terrace, Madison, WI 53705 USA. EM dean.krahn@med.va.gov OI Crosby, Ross/0000-0001-9131-1629 NR 30 TC 24 Z9 26 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD APR PY 2006 VL 31 IS 4 BP 622 EP 631 DI 10.1016/j.addbeh.2005.05.056 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 032BQ UT WOS:000236749300006 PM 15990241 ER PT J AU Sonnenberg, A AF Sonnenberg, A TI Personal view: the paradox of runaway competitions in gastroenterology SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID SYSTEMATIC REVIEWS; HEALTH; CARE AB Occasionally, gastroenterologists harbour reservations about the appropriateness of various procedures and management options, yet find themselves drawn into a competition and forced by outside exigencies to provide such services. The aim of the present analysis was to describe patterns of runaway competitions and factors that influence their occurrence in gastroenterology. The interactions between two physicians or physician and patient are modelled as non-zero-sum games of two players. The outcomes associated with two behavioural strategies of two players are arranged in a two-by-two game matrix. Many scenarios of clinical gastroenterology and social interactions among gastroenterologists are characterized by the underlying game of prisoner's dilemma, where two players can choose to co-operate or compete with each other. Although from their joint perspective co-operation results in a higher joint utility, the perspective of each individual favours competition. Following the inescapable logic of their individual perspective, the players end up with a worse outcome than through co-operation. A runaway competition ensues if the game is played repeatedly with players successively increasing their stakes. Ultimately, each player tries to outdo the opponent while heading in the wrong direction. Recognizing the hallmarks of the game of prisoner's dilemma may help gastroenterologists to avoid such competitions. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 15 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD APR 1 PY 2006 VL 23 IS 7 BP 871 EP 878 DI 10.1111/j.1365-2036.2006.02833.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 022PS UT WOS:000236068700003 PM 16573789 ER PT J AU Lee, JG Lum, D Urayama, S Mann, S Saavedra, S Vigil, H Vilaysak, C Leung, JW Leung, FW AF Lee, JG Lum, D Urayama, S Mann, S Saavedra, S Vigil, H Vilaysak, C Leung, JW Leung, FW TI Extended flexible sigmoidoscopy performed by colonoscopists for colorectal cancer screening: a pilot study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; GASTROINTESTINAL ENDOSCOPY; CONSCIOUS SEDATION; ASYMPTOMATIC ADULTS; SELECTIVE SEDATION; COMPLICATIONS; INSERTION AB Background Caecal intubation can be achieved by extended flexible sigmoidoscopy in 32% of patients. Aim To assess the feasibility of extended flexible sigmoidoscopy performed by colonoscopists for colorectal cancer screening. Methods We enrolled 41 patients referred for screening flexible sigmoidoscopy. After purging, examination was performed with a colonoscope. All patients completed sigmoidoscopy (success in meeting referral goal); 93% and 71% had examination to the transverse or ascending colon, and caecum, respectively. Overall yield and right-sided polyps was 56% and 27%, respectively. Caecal intubation and complete examination with polypectomy took 6.0 +/- 2.5 and 18.3 +/- 5.1 min, respectively; with no complications. Twelve patients requested colonoscope withdrawal because of discomfort. Although 46% reported moderate to severe discomfort, 39% and 36%, respectively, were definitely or probably willing to repeat flexible sigmoidoscopy. Results Unsedated colonoscopy introduced as extended flexible sigmoidoscopy emphasizes the benefits of added yield rather than the negative image of withholding of discomfort relief. The patient can choose to accept the equivalent of an unsedated colonoscopy or reject the option based on perceived discomfort during extended flexible sigmoidoscopy performed by the colonoscopist. Conclusion Extended flexible sigmoidoscopy is a feasible option in carefully selected patients, fully prepared and by an experienced colonoscopist. C1 Univ Calif Davis, Med Ctr, Res & Med Serv, Sacramento, CA 95817 USA. Univ Calif Davis, Med Ctr, Vet Affairs No Calif Hlth Care Syst, Sacramento, CA 95817 USA. Sepulveda Ambulatory Care Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Leung, FW (reprint author), VA Sepulveda Ambulatory Care Ctr & Nursing Home, Div Gastroenterol, 16111 Plummer St,111G, Sepulveda, CA 91343 USA. EM felix.leung@med.va.gov NR 42 TC 8 Z9 8 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD APR 1 PY 2006 VL 23 IS 7 BP 945 EP 951 DI 10.1111/j.1365-2036.2006.02838.x PG 7 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 022PS UT WOS:000236068700011 PM 16573797 ER PT J AU Merriman, NA Porter, SB Brensinger, CM Reddy, KR Chang, KM AF Merriman, NA Porter, SB Brensinger, CM Reddy, KR Chang, KM TI Racial difference in mortality among US veterans with HCV/HIV coinfection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSE; ALPHA-2A PLUS RIBAVIRIN; HIV-INFECTED PATIENTS; LIVER-DISEASE; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY; PROTEASE INHIBITORS; DRUG-USERS AB OBJECTIVES: This study was performed to examine the impact of viral coinfections and race on clinical and virological outcome of hepatitis C virus (HCV) infection. METHODS: Three groups of patients (265 HCV/HIV coinfected, 251 HCV monoinfected, 227 HIV monoinfected) were identified between 2000 and 2002 from the computerized patient record system at the Philadelphia VA Medical Center and analyzed for clinical and virological parameters. RESULTS: HCV/HIV coinfection was associated with higher frequency of liver function abnormalities (37% vs 21% vs 20%; p < 0.0003) and greater mortality (17% vs 6% vs 9% over 3 yr period, p = 0.0003, p = 0.027) compared to HCV or HIV monoinfection, respectively. However, HCV/HIV coinfection was not associated with worsened HIV-related parameters (CD4 count, HIV titer, and use of antiretroviral therapy) or increased HCV titers compared to HIV or HCV monoinfection in our population, respectively. Interestingly, mortality among HCV/HIV coinfected patients was significantly greater in white than in black patients (31% vs 15%, p = 0.011). This racial disparity in mortality was not apparent in the monoinfected groups and not explained by HBV coinfection or history of alcohol use disorder. CONCLUSIONS: We conclude that HCV/HIV coinfection is associated with worsened liver disease and higher mortality than HCV- or HIV-monoinfection without directly influencing CD4 count and HCV or HIV titers. Furthermore, we demonstrated a racial disparity in survival of HCV/HIV-coinfected patients that needs further investigation. C1 Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Chang, KM (reprint author), Univ Penn, Sch Med, Dept Med, Div Gastroenterol, 600 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA. FU NCRR NIH HHS [M01-RR00040]; NIAAA NIH HHS [AA12849]; NIAID NIH HHS [AI47519]; NIDDK NIH HHS [P30DK50306] NR 41 TC 13 Z9 14 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2006 VL 101 IS 4 BP 760 EP 767 DI 10.1111/j.1572-0241.2006.00531.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 030WT UT WOS:000236666800016 PM 16494582 ER PT J AU McFarland, LV AF McFarland, LV TI Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; LACTOBACILLUS-RHAMNOSUS GG; SHORT GUT SYNDROME; SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; HEALTH-CARE; NOSOCOMIAL DIARRHEA; RANDOMIZED-TRIAL; PUBLICATION BIAS; CLINICAL-TRIALS AB CONTEXT: Antibiotic-associated diarrhea (AAD) is a common complication of most antibiotics and Clostridium difficile disease (CDD), which also is incited by antibiotics, is a leading cause of nosocomial outbreaks of diarrhea and colitis. The use of probiotics for these two related diseases remains controversial. OBJECTIVE: To compare the efficacy of probiotics for the prevention of AAD and the treatment of CDD based on the published randomized, controlled clinical trials. DATA SOURCES: PubMed, Medline, Google Scholar, NIH registry of clinical trials, metaRegister, and Cochrane Central Register of Controlled Trials were searched from 1977 to 2005, unrestricted by language. Secondary searches of reference lists, authors, reviews, commentaries, associated diseases, books, and meeting abstracts. STUDY SELECTION: Trials were included in which specific probiotics given to either prevent or treat the diseases of interest. Trials were required to be randomized, controlled, blinded efficacy trials in humans published in peer-reviewed journals. Trials that were excluded were pre-clinical, safety, Phase I studies in volunteers, reviews, duplicate reports, trials of unspecified probiotics, trials of prebiotics, not the disease being studied, or inconsistent outcome measures. Thirty-one of 180 screened studies (totally 3,164 subjects) met the inclusion and exclusion criteria. DATA EXTRACTION: One reviewer identified studies and abstracted data on sample size, population characteristics, treatments, and outcomes. DATA SYNTHESIS: From 25 randomized controlled trials (RCTs), probiotics significantly reduced the relative risk of AAD (RR = 0.43, 95% CI 0.31, 0.58, p < 0.001). From six randomized trials, probiotics had significant efficacy for CDD (RR = 0.59, 95% CI 0.41, 0.85, p = 0.005). CONCLUSION: A variety of different types of probiotics show promise as effective therapies for these two diseases. Using meta-analyses, three types of probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus GG, and probiotic mixtures) significantly reduced the development of antibiotic-associated diarrhea. Only S. boulardii was effective for CDD. C1 VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA. Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. RP VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, S-152,Metropolitan Pk W,1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. NR 78 TC 358 Z9 400 U1 13 U2 72 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2006 VL 101 IS 4 BP 812 EP 822 DI 10.1111/j.1572-0241.2006.00465.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 030WT UT WOS:000236666800024 PM 16635227 ER PT J AU Baker, JF Chen, L Krishnan, E Schumacher, HR AF Baker, JF Chen, L Krishnan, E Schumacher, HR TI Clinical trials of uric acid lowering for coronary heart disease risk reduction - Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID MYOCARDIAL-INFARCTION; ALLOPURINOL; DYSFUNCTION; PREVENTION; ASPIRIN; FAILURE C1 Univ Penn, Presbyterian Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Stanford Univ, Dept Med, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA. RP Baker, JF (reprint author), Univ Penn, Presbyterian Med Ctr, Philadelphia, PA 19104 USA. NR 13 TC 0 Z9 0 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2006 VL 119 IS 4 DI 10.1016/j.amjmed.2005.09.016 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 026BN UT WOS:000236311800026 ER PT J AU Simon, JA AF Simon, JA TI Clinical trials of uric acid lowering for coronary heart disease risk reduction SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID MYOCARDIAL-INFARCTION; SULFINPYRAZONE C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Simon, JA (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2006 VL 119 IS 4 DI 10.1016/j.amjmed.2005.08.031 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 026BN UT WOS:000236311800025 ER PT J AU Rumbaut, RE Bellera, RV Randhawa, JK Shrimpton, CN Dasgupta, SK Dong, JF Burns, AR AF Rumbaut, RE Bellera, RV Randhawa, JK Shrimpton, CN Dasgupta, SK Dong, JF Burns, AR TI Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a TLR4-dependent, neutrophil-independent mechanism SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE microcirculation; platelets; endothelium; endotoxemia ID TOLL-LIKE RECEPTOR-4; ENDOTHELIAL CELL-ADHESION; VON-WILLEBRAND-FACTOR; IN-VIVO; BACTERIAL LIPOPOLYSACCHARIDE; PLATELET-AGGREGATION; VONWILLEBRAND-FACTOR; INTESTINAL VENULES; P-SELECTIN; IFN-GAMMA AB Endotoxemia promotes adhesive interactions between platelets and microvascular endothelium in vivo. We sought to determine whether endotoxin (lipopolysaccharide, LPS) modified platelet thrombus formation in mouse cremaster venules and whether Toll-like receptor 4 (TLR4) and neutrophils were involved in the response. Intravital videomicroscopy was performed in the cremaster microcirculation of pentobarbital-anesthetized mice; venular platelet thrombi were induced with a light/dye endothelial injury model. C57BL/6 mice treated with Escherichia coli endotoxin had enhanced rates of venular platelet thrombus formation: the time to microvessel occlusion was reduced by similar to 50% (P < 0.005) compared with saline-treated animals. Enhanced microvascular thrombosis was evident as early as 2 h after LPS administration. LPS had no effect on thrombosis in either of two mouse strains with altered TLR4 signaling (C57BL/10ScNJ or C3H/HeJ), whereas it enhanced thrombosis in the control strains (C57BL/10J and C3H/HeN). LPS also enhanced platelet adhesion to endothelium in the absence of light/dye injury. Platelet adhesion, but not enhanced thrombosis, was inhibited by depletion of circulating neutrophils. LPS failed to enhance platelet aggregation ex vivo and did not influence platelet P-selectin expression, a marker of platelet activation. These findings support the notion that endotoxemia promotes platelet thrombus formation independent of neutrophils and without enhancement of platelet aggregation, via a TLR4-dependent mechanism. C1 Baylor Coll Med, Childrens Nutr Res Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Rumbaut, RE (reprint author), Baylor Coll Med, Childrens Nutr Res Ctr, Dept Med, 1100 Bates,Rm 6014, Houston, TX 77030 USA. EM rrumbaut@bcm.tmc.edu FU NHLBI NIH HHS [R01 HL079368, R01 HL079368-01A1, HL-070537, HL-42550, HL-64721]; NIAID NIH HHS [AI-46773] NR 47 TC 48 Z9 48 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2006 VL 290 IS 4 BP H1671 EP H1679 DI 10.1152/ajpheart.00305.2005 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 021GU UT WOS:000235972500044 PM 16284241 ER PT J AU Sohn, M Tan, Y Wang, B Klein, RL Trojanowska, M Jaffa, AA AF Sohn, M Tan, Y Wang, B Klein, RL Trojanowska, M Jaffa, AA TI Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE transforming growth factor-beta; mitogen-activated protein kinase; collagen IV ID SMOOTH-MUSCLE-CELLS; ANGIOGENESIS IN-VIVO; MESANGIAL CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; ATHEROSCLEROTIC LESIONS; SIGNAL-TRANSDUCTION; ARTERIAL INJURY; GENE-REGULATION; FACTOR-BETA; TGF-BETA AB Hyperlipidemia is a recognized risk factor for atherosclerotic vascular disease. The underlying mechanisms that link lipoproteins and vascular disease are undefined. Connective tissue growth factor (CTGF) is emerging as a key determinant of progressive fibrotic diseases, and its expression is upregulated by diabetes. To define the mechanisms through which low-density lipoproteins (LDL) promote vascular injury, we evaluated whether LDL can modulate the expression of CTGF and collagen IV in human aortic endothelial cells (HAECs). Treatment of HAECs with LDL (50 mu g/ml) for 24 h produced a significant increase in the mRNA and the protein levels of CTGF and collagen IV compared with unstimulated controls. To explore the mechanisms by which LDL regulates CTGF and collagen IV expression in HAECs, we determined first if CTGF and collagen IV are downstream targets for regulation by transforming growth factor-beta (TGF-beta). The results demonstrated that TGF-beta produced a concentration-dependent increase in the protein levels of CTGF. To assess whether the induction of CTGF in response to LDL is mediated via autocrine activation of TGF-beta, HAECs were treated with LDL for 24 h in the presence and absence of anti-TGF-beta neutralizing antibodies (anti-TGF- beta NA). The results demonstrated that the increase in CTGF induced by LDL was significantly inhibited by the anti-TGF-beta NA. To investigate the upstream mediators of TGF-beta on activity of CTGF in response to LDL, HAECs were treated with LDL for 24 h in the presence and absence of cell-permeable MAPK inhibitors. Inhibition of p38(mapk) activities did not affect LDL-induced TGF-beta 1, CTGF, and collagen IV expression. On the other hand, SP-600125, a specific inhibitor of c-Jun NH2-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression. These findings are the first to implicate the MAPK pathway and TGF-beta as key players in LDL signaling, leading to CTGF and collagen IV expression in HAECs. The data also point to a potential mechanistic pathway through which lipoproteins may promote vascular injury. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Diabet Med Genet, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet Med Genet, 114 Doughty St,POB 250776, Charleston, SC 29425 USA. EM jaffaa@musc.edu OI Trojanowska, Maria/0000-0001-9550-7178 FU NHLBI NIH HHS [HL-55782]; NIDDK NIH HHS [DK-46543] NR 43 TC 18 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2006 VL 290 IS 4 BP H1624 EP H1634 DI 10.1152/ajpheart.01233.2004 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 021GU UT WOS:000235972500039 PM 16272194 ER PT J AU Fan, J Li, YH Vodovotz, Y Billiar, TR Wilson, MA AF Fan, J Li, YH Vodovotz, Y Billiar, TR Wilson, MA TI Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE acute lung injury; lipopolysaccharide; innate immunity; peptidoglycan; Toll-like receptor ID TOLL-LIKE RECEPTOR-2; NF-KAPPA-B; MULTIPLE ORGAN FAILURE; TUMOR-NECROSIS-FACTOR; CUTTING EDGE; ENDOTHELIAL-CELLS; DIFFERENTIAL EXPRESSION; SELECTIVE EXPRESSION; CELLULAR ACTIVATION; DENDRITIC CELLS AB Hemorrhagic shock renders patients susceptible to the development of acute lung injury in response to a second inflammatory stimulus by as yet unclear mechanisms. We investigated the role of neutrophils (PMN) in alveolar macrophage (AM phi) priming, specifically, the role in mediating Toll-like receptor (TLR)4 and TLR2 cross talk in AM phi. Using a mouse model of hemorrhagic shock followed by intratracheal administration of LPS, we explored a novel function of shock-activated PMN in the mechanism of TLR2 upregulation induced by LPS-TLR4 signaling in AM phi. We showed that antecedent hemorrhagic shock enhanced LPS-induced TLR2 upregulation in AM phi. In neutropenic mice subjected to shock, the LPS-induced TLR2 expression was significantly reduced, and the response was restored upon repletion with PMN obtained from shock-resuscitated mice but not by PMN from sham-operated mice. These findings were recapitulated in mouse AM phi cocultured with PMN. The enhanced TLR2 upregulation in AM phi augmented the expression of macrophage inflammatory protein-2, TNF-alpha, and macrophage migration inhibitory factor in the AM phi in response to sequential challenges of LPS and peptidoglycan, a prototypical TLR2 ligand, which physiologically associated with amplified AM phi-induced PMN migration into air pouch and lung alveoli. Thus TLR2 expression in AM phi, signaled by TLR4 and regulated by shock-activated PMN, is an important positive-feedback mechanism responsible for shock-primed PMN infiltration into the lung after primary PMN sequestration. C1 VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), VA Pittsburgh Healthcare Syst, Dept Surg, CHERP Bldg 28,Univ Dr C, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU NHLBI NIH HHS [HL-079669] NR 39 TC 53 Z9 55 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD APR PY 2006 VL 290 IS 4 BP L738 EP L746 DI 10.1152/ajplung.00280.2005 PG 9 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 029ON UT WOS:000236573100013 PM 16272176 ER PT J AU Friedman, MJ AF Friedman, MJ TI Posttraumatic stress disorder among military returnees from Afghanistan and Iraq SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID MENTAL-HEALTH; WAR; INFORMATION; EXPOSURE; TRAUMA; CARE C1 Dartmouth Coll, Sch Med, Dept Psychiat, Hanover, NH USA. Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA. Natl Ctr PTSD, US Dept Vet Affairs, Hanover, NH USA. RP Friedman, MJ (reprint author), VA Med Ctr, Natl Ctr PTSD, 215 N Main St, White River Jct, VT 05009 USA. EM matthew.j.friedman@dartmouth.edu NR 37 TC 70 Z9 72 U1 4 U2 10 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2006 VL 163 IS 4 BP 586 EP 593 DI 10.1176/appi.ajp.163.4.586 PG 8 WC Psychiatry SC Psychiatry GA 029EF UT WOS:000236541200008 PM 16585431 ER PT J AU Jett, JR Miller, YE AF Jett, JR Miller, YE TI Update in lung cancer 2005 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article ID GROWTH-FACTOR RECEPTOR; POSITRON-EMISSION-TOMOGRAPHY; SPIRAL COMPUTED-TOMOGRAPHY; ENDOSCOPIC ULTRASOUND; EXHALED BREATH; GEFITINIB; MUTATIONS; CHEMOTHERAPY; ASPIRATION; RESISTANCE C1 Denver Vet Affairs Med Ctr, Pulm & Crit Care Med Sect, Denver, CO 80220 USA. Mayo Coll Med, Rochester, MN USA. Univ Colorado, Denver, CO 80202 USA. Hlth Sci Ctr, Denver, CO USA. RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, Pulm & Crit Care Med Sect, 111A,1055 Clermot St, Denver, CO 80220 USA. EM miller@uchsc.edu NR 35 TC 5 Z9 5 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2006 VL 173 IS 7 BP 695 EP 697 DI 10.1164/rccm.2601008 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 029AQ UT WOS:000236530600002 PM 16556699 ER PT J AU Sun, BC Mohanty, SA Weiss, R Tadeo, R Hasbrouck, M Koenig, W Meyer, C Asch, S AF Sun, BC Mohanty, SA Weiss, R Tadeo, R Hasbrouck, M Koenig, W Meyer, C Asch, S TI Effects of hospital closures and hospital characteristics on emergency department ambulance diversion, Los Angeles County, 1998 to 2004 SO ANNALS OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT National Meeting of the Robert Wood Johnson Clinical Scholars Program CY NOV, 2005 CL Ft Lauderdale, FL ID CONSEQUENCES; CAPACITY; TRENDS; DELAYS AB Study objective: We assess the effects of nearby hospital closures and other hospital characteristics on emergency department (ED) ambulance diversion. Methods: The study design was a retrospective, multiple interrupted time series with control group. We studied all ambulance-receiving hospitals with EDs in Los Angeles County from 1998 to 2004. The main outcome measure was monthly ambulance diversion hours because of ED saturation. Results: Our sample included 80 hospitals, of which 9 closed during the study period. There were increasing monthly diversion hours over time, from an average of 57 hours (95% confidence interval [CI] 51 to 63 hours) in 1998 to 190 hours (95% CI 180 to 200 hours) in 2004. In multivariate modeling, hospital closure increased ambulance monthly diversion hours by an average of 56 hours (95% CI 28 to 84 hours) for 4 months at the nearest ED. County-operated hospitals had 150 hours (95% Cl 90 to 200 hours) and trauma centers had 48 hours (95% CI 9 to 87 hours) more diversion than other hospitals. Diversion hours for a given facility were positively correlated with diversion hours of the nearest ED (0.3; 95% CI 0.28 to 0.32). There was a significant and positive interaction between diversion hours of the nearest ED and time, suggesting that the effects of an adjacent facility's diversion hours increased during the study period. Conclusion: Hospital closure was associated with a significant but transient increase in ambulance diversion for the nearest ED. The temporal trend toward more diversion hours, as well as increasing effects of the nearest facility's diversion hours over time, implies that the capacity to absorb future hospital closures is declining. C1 Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90024 USA. Univ So Calif, Dept Med, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA. Los Angeles Cty Emergency Med Serv Agcy, Los Angeles, CA USA. W Los Angeles Vet Affairs Local Ctr, Dept Med, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. RP Sun, BC (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM bsun@post.harvard.edu NR 23 TC 38 Z9 38 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2006 VL 47 IS 4 BP 309 EP 316 DI 10.1016/j.annemergmed.2005.12.003 PG 8 WC Emergency Medicine SC Emergency Medicine GA 029IH UT WOS:000236555300001 PM 16546614 ER PT J AU Margenthaler, JA Longo, WE Virgo, KS Johnson, FE Grossmann, EM Schifftner, TL Henderson, WG Khuri, SF AF Margenthaler, JA Longo, WE Virgo, KS Johnson, FE Grossmann, EM Schifftner, TL Henderson, WG Khuri, SF TI Risk factors for adverse outcomes following surgery for small bowel obstruction SO ANNALS OF SURGERY LA English DT Article ID SMALL INTESTINAL-OBSTRUCTION; AFFAIRS SURGICAL RISK; NONOPERATIVE TREATMENT; VETERAN POPULATION; HOSPITAL VOLUME; MORTALITY-RATE; ADHESIVE; QUALITY; CARE; ADJUSTMENT AB Objective: To construct risk indices predicting adverse outcomes following surgery for small bowel obstruction (SBO). Methods: The VA National Surgical Quality Improvement Program contains prospectively collected data oil more than I million patients. Patients undergoing adhesiolysis only or small bowel resection for SBO from 1991 to 2002 were selected. Independent variables included 68 presurgical and 12 intraoperative risk factors; dependent variables were 21 adverse Outcomes including death. Stepwise logistic regression was used to construct models predicting 30-day morbidity and mortality and to derive risk index values. Patients were then divided into risk classes. Results: Of the 2002 patients, 1650 underwent adhesiolysis only and 352 underwent small bowel resection. Thirty-seven percent undergoing adhesiolysis only and 47% undergoing small bowel resection had more than I complication (P < 0.001). The overall 30-day mortality was 7.7% and did not differ significantly between the groups. Odds of death were highest for dirty or infected Wounds, ASA class 4 or 5, age > 80 years, and dyspnea at rest. Morbidity ranged from 22%, among patients with 0 to 7 risk points, to 62% for those with > 19 risk points. Mortality ranged from 2% among patients with 0 to 12 risk points to 28% for those with > 31 risk points. Conclusions: Morbidity and mortality after surgery for SBO in VA hospitals are comparable with those in other large series. The morbidity rate, but not the mortality rate, is significantly higher in patients requiring small bowel resection compared with those requiring adhesiolysis only (P < 0.001). The risk indices presented provide all easy-to-use tool for clinicians to predict outcomes for patients undergoing surgery for SBO. C1 Yale Univ, Med Ctr, Dept Surg, New Haven, CT 06520 USA. Washington Univ, Sch Med, St Louis, MO USA. St Louis Univ, Sch Med, St Louis, MO USA. St Louis VA Med Ctr, St Louis, MO USA. Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. Denver VA Med Ctr, Denver, CO USA. Harvard Univ, Sch Med, Boston, MA USA. Brockton W Roxbury Vet Affairs Med Ctr, Boston, MA USA. RP Longo, WE (reprint author), Yale Univ, Med Ctr, Dept Surg, 330 Cedar St, New Haven, CT 06520 USA. EM walter.longo@yale.edu NR 39 TC 49 Z9 52 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 2006 VL 243 IS 4 BP 456 EP 464 DI 10.1097/01.sla.0000205668.58519.76 PG 9 WC Surgery SC Surgery GA 029AN UT WOS:000236530300005 PM 16552195 ER PT J AU Pessler, F Dai, L Einhorn, E Cron, RQ Schumacher, HR AF Pessler, F. Dai, L. Einhorn, E. Cron, R. Q. Schumacher, H. R. TI Overexpression of the calcium-calcineurin-NFAT signaling pathway in rheumatoid arthritis synovium SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Meeting Abstract CT 26th European Workshop for Rheumatology Research CY APR 23, 2006 CL Glasgow, SCOTLAND C1 Childrens Hosp Philadelphia, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD APR PY 2006 VL 65 SU 1 MA 069 BP A23 EP A23 PG 1 WC Rheumatology SC Rheumatology GA 210XV UT WOS:000249489800070 ER PT J AU Kirkpatrick, WR Coco, BJ Patterson, TF AF Kirkpatrick, WR Coco, BJ Patterson, TF TI Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID EFFICACY; ITRACONAZOLE; ANTAGONISM AB We evaluated combinations of voriconazole (VRC) and liposomal amphotericin B (L-AMB) in a guinea pig invasive aspergillosis model. Simultaneous VRC and L-AMB was most effective, although VRC monotherapy was also effective. These regimens as well as sequential L-AMB followed by VRC were more effective than L-AMB alone or VRC followed by L-AMB. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie Murphys Div, San Antonio, TX 78284 USA. RP Kirkpatrick, WR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,Mail Code 7881, San Antonio, TX 78229 USA. EM kirkpatrick@uthscsa.edu NR 12 TC 21 Z9 22 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2006 VL 50 IS 4 BP 1567 EP 1569 DI 10.1128/AAC.50.4.1567-1569.2006 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 031EA UT WOS:000236685700069 PM 16569887 ER PT J AU Freeman, S Francis, S Lundahl, K Bowland, T Dellavalle, RP AF Freeman, S Francis, S Lundahl, K Bowland, T Dellavalle, RP TI UV tanning advertisements in high school newspapers SO ARCHIVES OF DERMATOLOGY LA English DT Article; Proceedings Paper CT 66th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2005 CL St Louis, MO SP Soc Investigat Dermatol ID BASAL-CELL; POPULATION; CANCERS; RISK AB Objective: To examine the increasing use of UV tanning parlors by adolescents, despite the World Health Organization recommendation that no one under the age of 18 years use UV tanning devices. Design: We examined tanning advertisements in a sample of public high school newspapers published between 2001 and 2005 in 3 Colorado counties encompassing the Denver metropolitan area. Results: Tanning advertisements appeared in newspapers from 11 (48%) of 23 schools. Newspaper issues (N= 131) contained 40 advertisements placed by 18 tanning parlors. Advertisements commonly offered discounts ( 19 of 40) including unlimited tanning offers ( 15 of 40). Thirteen advertisements featured non-UV tanning treatments, and 2 advertisements mentioned parental consent or accompaniment for UV tanning. Conclusions: UV radiation, a classified carcinogen, is commonly and specifically marketed to adolescents through high school newspaper advertising. Public health skin cancer prevention policies should include the prohibition of UV tanning advertising to minors. C1 Denver Vet Affairs Med Ctr, Dermatol Serv, Denver, CO 80220 USA. Univ Colorado Denver, Hlth Sci Ctr, Dept Dermatol, Aurora, CO USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Code 165, Denver, CO 80220 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [K-07CA92550] NR 9 TC 22 Z9 22 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2006 VL 142 IS 4 BP 460 EP 462 DI 10.1001/archderm.142.4.460 PG 3 WC Dermatology SC Dermatology GA 033NG UT WOS:000236854700007 PM 16618865 ER PT J AU Johnson, KR Heilig, LF Hester, EJ Francis, SO Deakyne, SJ Dellavalle, RP AF Johnson, KR Heilig, LF Hester, EJ Francis, SO Deakyne, SJ Dellavalle, RP TI Indoor tanning attitudes and practices of US dermatologists compared with other medical specialists SO ARCHIVES OF DERMATOLOGY LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the American-Society-of-Preventive-Oncology CY MAR 13-15, 2005 CL San Francisco, CA SP Amer Soc Prevent Oncol ID CUTANEOUS MALIGNANT-MELANOMA; SUN PROTECTION; RISK; PEDIATRICIANS; BEHAVIOR; EXPOSURE; CHILDREN AB Objective: To compare the indoor tanning attitudes and practices of dermatologists with physicians in other medical specialties ( internal medicine, pediatrics, and family medicine) commonly providing sun safety counseling to patients. Design: Cross-sectional study. Setting: Questionnaire mailed to randomly selected US dermatologists, internists, family practitioners, and pediatricians. Results: The overall response rate was 38% (364/949): 71% indicated that patients had asked their opinions about indoor UV tanning, 80% believed that UV tanning was unsafe, and 90% agreed they would counsel patients against nonmedical indoor UV tanning. Many supported increased UV tanning legislation, including minimum age restrictions (91%) and parental consent requirements ( 90%). Dermatologists were significantly more likely than other physicians to respond to the survey (52% vs 31%, P <. 001), speak with patients about indoor UV tanning ( odds ratio [ OR], 26.5; 95% confidence interval [CI], 9.5-74.1]), believe that indoor UV tanning is unsafe OR, 14.0; 95% CI, 5.0- 39.4), and support increased regulation ( OR, 11.7; 95% CI, 1.5- 88.5). Women discouraged indoor UV tanning more than men ( OR, 5.2; 95% CI, 1.8-15.2). Physicians who had used indoor UV tanning (19%) more often agreed that non-UV tanning lotion ( OR, 2.0; 95% CI, 1.1-3.8) and airbrush tanning ( OR, 1.9; 95% CI, 1.1-3.4) were safe but did not differ in attitudes regarding UV tanning safety. Physicians practicing in the Northeast and Midwest were more likely to support UV tanning to improve mood ( OR, 2.0; 95% CI, 1.1-3.5) and more commonly believed that UV tanning could help treat depression ( OR, 2.6; 95% CI, 1.5-4.6) or prevent vitamin D deficiency ( OR, 1.7; 95% CI, 1.0-2.8). Conclusions: Physicians, especially dermatologists, are frequently asked about and generally discourage indoor UV tanning. Dermatologists regard indoor UV tanning more negatively compared with other physicians. Physician sex and geographic location were associated with specific indoor UV tanning attitudes. C1 Univ Colorado, Dept Dermatol, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Code 165, Denver, CO 80220 USA. EM robert.dellavalle@uchsc.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X FU NCI NIH HHS [CA92550]; NIAMS NIH HHS [T32 AR07411] NR 18 TC 10 Z9 10 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2006 VL 142 IS 4 BP 465 EP 470 DI 10.1001/archderm.142.4.465 PG 6 WC Dermatology SC Dermatology GA 033NG UT WOS:000236854700008 PM 16618866 ER PT J AU Primack, BA Gold, MA Switzer, GE Hobbs, R Land, SR Fine, MJ AF Primack, BA Gold, MA Switzer, GE Hobbs, R Land, SR Fine, MJ TI Development and validation of a smoking media literacy scale for adolescents SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID TOBACCO USE; CIGARETTE-SMOKING; UNITED-STATES; PROMOTION; SUSCEPTIBILITY; PREVENTION; INITIATION; INDUSTRY; TRIAL; FILMS AB Objectives: To develop a smoking media literacy (SML) scale by using empiric survey data from a large sample of high school students and to assess reliability and criterion validity of the scale. Design: On the basis of an established theoretical framework, 120 potential items were generated, and items were eliminated or altered on the basis of input from experts and students. Cross-sectional responses to scale items, demographics, smoking-related variables, and multiple covariates were obtained to refine the scale and determine its reliability and validity. Setting: One large Pittsburgh, Pa, high school. Participants: A total of 1211 high school students aged 14 to 18 years. Main Outcome Measures: Current smoking, susceptibility to smoking, attitudes toward smoking, and smoking norms. Results: Factor analysis demonstrated a strong 1-factor scale with 18 items (alpha=0.87). After controlling for all co-variate data, SML had a statistically significant and independent association with current smoking (P=.01), susceptibility (P<.001), and attitudes (P<.001), but not norms (P=.42). Controlling for all covariates, an increase of 1 point on the 10-point SML scale was associated with a 22% decrease in the odds of being a smoker and a 31% decrease in the odds of being susceptible to smoking. Conclusions: Smoking media literacy can be measured with excellent reliability and concurrent criterion validity. Given the independent association between SML and smoking, media literacy may be a promising tool for future tobacco control interventions. C1 Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. Temple Univ, Sch Commun & Theater, Philadelphia, PA 19122 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. Vet Affairs Pittsburgh Hlth Care Syst, Ctr Hlth Equin Res & Promot, Pittsburgh, PA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 230 McKee Pl,Suite 600,Room 4, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315-01A1, K07 CA114315] NR 37 TC 32 Z9 32 U1 6 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2006 VL 160 IS 4 BP 369 EP 374 DI 10.1001/archpedi.160.4.369 PG 6 WC Pediatrics SC Pediatrics GA 028VI UT WOS:000236516500005 PM 16585481 ER PT J AU Sepahpanah, F Burns, SP McKnight, B Yang, CC AF Sepahpanah, F Burns, SP McKnight, B Yang, CC TI Role of creatinine clearance as a screening test in persons with spinal cord injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 31st Annual Meeting of the American-Spinal-Injury-Association CY MAY 13, 2005 CL Dallas, TX SP Amer Spinal Injury Assoc DE bladder; neurogenic; creatinine; kidney function tests; rehabilitation; reproducibility of results; spinal cord injuries ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; RENAL-FUNCTION; CYSTATIN-C AB Objectives: To determine (1) the variability of annual creatinine clearance (C-Cr) testing for subjects with chronic spinal cord injury (SCI) and (2) whether decisions to change neurogenic bladder management are made based on C-Cr. measurements. Design: Retrospective chart review. Setting: Inpatient Veterans Affairs SCI unit. Participants: The medical records of 70 men were consecutively selected for review from among 664 veterans enrolled in the SCI clinic. All patient charts had to have at least 5 C-Cr tests performed within 10 years preceding the review. Interventions: Not applicable. Main Outcome Measures: Development of renal insufficiency and change in medical or bladder management of the patient, based on the results of the C-Cr test. Results: For individual patients, the results of 24-hour C-Cr were highly variable from 1 evaluation to the next; the within-subject standard deviation (SD) for C-Cr was 25.9mL/min. The within-subject SD for serum creatinine was 0.12mg/dL. For all comparisons of repeatability, variability, and reliability, serum creatinine was superior to C-Cr. No medical management decisions were made based on the result of the 24-hour creatinine clearance. Renal ultrasound results and postvoid bladder residuals were the major factors in changing medical management with regard to renal function preservation. Conclusions: The Cc, test has little value as a screening measure for renal disease in SCI patients because of its variability in serial testing. C1 VA Puget Sound Hlth Care Syst, Urol Sect, Spinal Cord Injury Unit, Seattle, WA 98108 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Yang, CC (reprint author), VA Puget Sound Hlth Care Syst, Urol Sect, Spinal Cord Injury Unit, 1660 S Columbian Way,S112-UR, Seattle, WA 98108 USA. EM cyang@u.washington.edu FU NCIPC CDC HHS [R49/CE000197] NR 20 TC 14 Z9 16 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2006 VL 87 IS 4 BP 524 EP 528 DI 10.1016/j.apmr.2005.11.032 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 036BL UT WOS:000237045800010 PM 16571392 ER PT J AU Cohen, PL AF Cohen, PL TI Stopping traffic in Sjogren's syndrome SO ARTHRITIS AND RHEUMATISM LA English DT Editorial Material ID CHEMOKINES C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Cohen, PL (reprint author), Univ Penn, 421 Curie Blvd,Room 757, Philadelphia, PA 19104 USA. EM philipco@mail.med.upenn.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD APR PY 2006 VL 54 IS 4 BP 1061 EP 1062 DI 10.1002/art.21746 PG 2 WC Rheumatology SC Rheumatology GA 033EZ UT WOS:000236830800006 PM 16572440 ER PT J AU Mao, HZ Roussos, EI Peterfy, M AF Mao, HZ Roussos, EI Peterfy, M TI Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Article DE type 2 diabetes mellitus; animal model; C57BLKS mouse strain; leptin receptor mutation; microsatellite marker ID EXPRESSION; LOCUS; MUTATIONS; MICE; ATHEROSCLEROSIS; SUSCEPTIBILITY; HAPLOTYPE; C57BL/6J; OBESITY AB The C57BLKS/J (BKS) inbred mouse strain is a widely used animal model of type 2 diabetes. In the presence of the diabetes (db) mutation, obese BKS-db mice develop severe diabetes. Genetic studies of diabetes-susceptibility in this strain are facilitated by the fact that BKS is a genetic composite between the diabetes-resistant C57BL/6J (136) and susceptible DBA/2J (DBA) strains. On this basis, it has been hypothesized that diabetes-susceptibility in BKS is conferred by DBA-derived alleles. However, recent studies revealed non-B6/non-DBA genetic material in BKS. To identify the origin of this genetic component, we generated a genomic map of BKS using 537 microsatellite markers. Our results demonstrate that, in addition to B6 and DBA, BKS contains alleles from at least three other strains, including 129, C57BL/10 and an unidentified mouse strain. We also analyzed two congenic strains, B6-db and BKS-db, which are widely used for the genetic mapping of diabetes-susceptibility loci. We identified several donor-derived genomic regions introduced during the generation of these congenic strains. In summary, our study reveals novel aspects of the genetic fine-structure of BKS and related strains and facilitates the identification of diabetes-susceptibility loci in this mouse model. (C) 2006 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Peterfy, M (reprint author), Univ Calif Los Angeles, Dept Med, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA. EM mpeterfy@ucla.edu FU NIDDK NIH HHS [R01-DK071673] NR 20 TC 16 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD APR PY 2006 VL 1762 IS 4 BP 440 EP 446 DI 10.1016/j.bbidis.2006.01.002 PG 7 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 026CM UT WOS:000236314300007 PM 16481151 ER PT J AU Taylor, FB Lowe, K Thompson, C McFall, MM Peskind, ER Kanter, ED Allison, N Williams, J Martin, P Raskind, MA AF Taylor, FB Lowe, K Thompson, C McFall, MM Peskind, ER Kanter, ED Allison, N Williams, J Martin, P Raskind, MA TI Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE posttraumatic stress disorder; PTSD; prazosin; emotional Stroop; norepinephrine; alpha-1 adrenoceptor ID CORTICOTROPIN-RELEASING-FACTOR; AMYGDALA; VETERANS; STIMULATION; NIGHTMARES; ACTIVATION; REDUCTION; RECEPTORS; SYMPTOMS; THREAT AB Background: Persons with posttraumatic stress disorder (PTSD) whose trauma-related nightmare improve or resolve with bedtime administration of the alpha-1 adrenergic antagonist prazosin often continue to experience PTSD symptoms during the day. This study addressed whether daytime prazosin compared to placebo would alleviate psychological distress provoked experimentally by a trauma-related word list included in the emotional Stroop (E-Strop) paradigm. Methods: Eleven persons with civilian trauma PTSD who continued to experience daytime PTSD symptoms despite a stable bedtime prazosin dose that suppressed trauma-related nightmares were studied. Prazosin and placebo were administered on two different occasions in the early afternoon followed two hours later by the E-Stroop. Effects of drug on psychological distress were assessed by the Profile of Mood States (POMS). Results: POMS total score and an "emotional distress" POMS subscale score following trauma-related words were significantly lower in the prazosin than placebo condition. There were no treatment effects on E-Stroop completion time. In 10 subjects who continued open label daytime prazosin; there was a reduction in global PTSD illness severity at 2-week follow-up. Conclusions: Daytime prazosin pretreatment reduced pyschological distress specifically to trauma cues. Adding daytime prazosin to bedtime prazosin may further reduce overall PTSD illness severity and distress. C1 Rainer Associates, Tacoma, WA 98467 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NW Network Vet Integrated Serv Network 20 Mental, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA USA. RP Taylor, FB (reprint author), Rainer Associates, 5909 Orchard W, Tacoma, WA 98467 USA. EM tfletcher2@uswest.net FU NIMH NIH HHS [R01 MH069867] NR 27 TC 68 Z9 70 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2006 VL 59 IS 7 BP 577 EP 581 DI 10.1016/j.biopsych.2005.09.023 PG 5 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 026DA UT WOS:000236315700001 PM 16460691 ER PT J AU Yehuda, R Brand, S Yang, RK AF Yehuda, R Brand, S Yang, RK TI Plasma neuropeptide y concentrations in combat exposed veterans: Relationship to trauma exposure, recovery from PTSD, and coping SO BIOLOGICAL PSYCHIATRY LA English DT Article DE coping; neuropeptide Y; neurotransmitters; posttraumatic stress disorder; resilience ID BASE-LINE; STRESS; NPY; DEPRESSION; INJECTION; CORTISOL; HORMONE; ANXIETY; BRAIN AB Background: There is emerging interest in examining the role of plasma neuropeptide Y (NPY) as a protective stress factor. Methods: To further investigate this possibility, plasma NPY was measured in 11 nonexposed veterans, 11 combat-exposed veterans without posttraumatic stress disorder (PTSD), and 12 veterans with current PTSD. Results: A significant group difference in plasma NPY (F-2.31=5.16, p=.012) was observed, reflecting higher NPY levels in exposed veterans without PTSD than in nonexposed but comparable levels in veterans with current PTSD. Among those without current PTSD, veterans with past PTSD bad higher NPY levels than Those without past PTSD (t(9)=2.71, p=.024). After controlling for all other variables, NPY levels were significantly predicted by extent of symptom improvement and lower combat exposure and significant at a trend level with positive coping. Conclusions: Plasma NPY levels may represent a biologic correlate of resilience to or recovery from the adverse effects of stress. C1 Mt Sinai Sch Med, Dept Psychiat, Traumat Stress Studies Program, New York, NY USA. Bronx Vet Affairs Med Ctr, New York, NY USA. RP Yehuda, R (reprint author), Bronx VA OOMH, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@med.va.gov FU NCRR NIH HHS [5 M01 RR00071] NR 23 TC 108 Z9 112 U1 4 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2006 VL 59 IS 7 BP 660 EP 663 DI 10.1016/j.biopsych.2005.08.027 PG 4 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 026DA UT WOS:000236315700012 PM 16325152 ER PT J AU Glahn, DC Bearden, CE Cakir, S Barrett, JA Najt, P Monkul, ES Maples, N Velligan, DI Soares, JC AF Glahn, DC Bearden, CE Cakir, S Barrett, JA Najt, P Monkul, ES Maples, N Velligan, DI Soares, JC TI Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; delayed response task; digit span; psychotic features; schizoaffective disorder; schizophrenia; working memory ID 1ST-DEGREE RELATIVES; RATING-SCALE; FAMILY; DYSFUNCTION; SYMPTOMS; SUSCEPTIBILITY; ASSOCIATION; PERFORMANCE; PEDIGREES; REMISSION AB Background: Although bipolar disorder and schizophrenia have long been viewed as distinct illnesses, there is growing evidence that these two complex diseases share some common genes, which may manifest as overlapping neuropsychological impairments. Although working memory dysfunction has been proposed to be central to the pathophysiology of schizophrenia, it has received less attention in studies of bipolar disorder. Method: We applied measures of working memory to patients with schizophrenia (n = 15), patients with schizoaffective disorder (n = 15), patients with psychotic (n = 11) and non-psychotic (n = 15) bipolar disorder, and demographically matched healthy subjects (n = 32), in order to determine the extent to which these groups show common or unique impairments. Results: While patients with bipolar disorder (with and without psychotic features) and those with schizophrenia/schizoaffective disorder were impaired on backward digit span, only patients with a lifetime history of psychotic features, regardless of diagnosis, were impaired on spatial delayed response task. Conclusions: Backward digit span performance is comparable in bipolar disorder and schizophrenia, and may be an appropriate endophenotypic marker that cuts across diagnostic categories. In contrast, spatial working memory performance clearly distinguishes non-psychotic bipolar disorder patients from patients with functional psychosis. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Schizophrenia & Related Disorders, San Antonio, TX 78229 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. RP Glahn, DC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Schizophrenia & Related Disorders, Mail Code 7792,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM glahn@uhscsa.edu FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH 068662, MH 01736] NR 44 TC 109 Z9 112 U1 1 U2 10 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD APR PY 2006 VL 8 IS 2 BP 117 EP 123 DI 10.1111/j.1399-5618.2006.00296.x PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 021YS UT WOS:000236022400002 PM 16542181 ER PT J AU Gatza, E Okada, CY AF Gatza, E Okada, CY TI Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE dendritic cells; tumor immunity; vaccination; interleukin-15 ID INTERLEUKIN-15 TRANSGENIC MICE; MOLONEY LEUKEMIA-CELLS; NATURAL KILLER CELLS; IN-VIVO; ANTITUMOR-ACTIVITY; CYTOTOXIC CELLS; FATAL LEUKEMIA; IMMUNITY; SPECIFICITY; LYMPHOCYTES AB There has been a recent interest in using IL-15 to enhance antitumor activity in several models because of its ability to stimulate CD8(+) stop T cell expansion, inhibit apoptosis and promote memory T cell survival and maintenance. Previously, we reported that C6VL tumor lysate-pulsed dendritic cell vaccines significantly enhanced the survival of tumor-bearing mice by stimulating a potent tumor-specific CD8(+) T cell response. In this study, we determined whether IL-15 used as immunologic adjuvant would augment vaccine-primed CD8(+) T cell immunity against C6VL and further improve the survival of tumor-bearing mice. We report that IL-15 given after C6VL lysate-pulsed dendritic cell vaccines stimulated local and systemic expansion of NK, NKT and CD8(+) CD44(hi) T cells. IL-15 did not, however, augment innate or cellular responses against the tumor. T cells from mice infused with IL-15 following vaccination did not secrete increased levels of tumor-specific TNF-alpha or IFN-gamma or have enhanced C6VL-specific CTL activity compared to T cells from recipients of the vaccine alone. Lastly, IL-15 did not enhance the survival of tumor-bearing vaccinated mice. Thus, while activated- and memory-phenotype CD8(+) T cells were dramatically expanded by IL-15 infusion, vaccine-primed CD8(+) T cell specific for C6VL were not significantly expanded. This is the first account of using IL-15 as an adjuvant in a therapeutic model of active immunotherapy where there was not a preexisting pool of tumor-specific CD8(+) T cells. Our results contrast the recent studies where IL-15 was successfully used to augment tumor-reactivity of adoptively transferred transgenic CD8(+) T cells. This suggests that the adjuvant potential of IL-15 may be greatest in settings where it can augment the number and activity of preexisting tumor-specific CD8(+) T cells. C1 Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA. Oregon Hlth & Sci Univ, Div Hematol Oncol, Dept Internal Med, Portland, OR 97239 USA. RP Portland VA Med Ctr, Div Hosp & Specialty Med, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM okadac@ohsu.edu FU NCI NIH HHS [T32CA88784]; NIAID NIH HHS [T32AI07413] NR 46 TC 2 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7004 EI 1432-0851 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD APR PY 2006 VL 55 IS 4 BP 420 EP 432 DI 10.1007/s00262-005-0006-9 PG 13 WC Oncology; Immunology SC Oncology; Immunology GA 001VV UT WOS:000234571700008 PM 16025264 ER PT J AU Venkatesan, BA Mahimainathan, L Ghosh-Choudhury, N Gorin, Y Bhandari, B Valente, AJ Abboud, HE Choudhury, GG AF Venkatesan, BA Mahimainathan, L Ghosh-Choudhury, N Gorin, Y Bhandari, B Valente, AJ Abboud, HE Choudhury, GG TI PI 3 kinase-dependent Akt kinase and PKC epsilon independently regulate interferon-gamma-induced STAT1 alpha serine phosphorylation to induce monocyte chemotactic protein-1 expression SO CELLULAR SIGNALLING LA English DT Article DE mesangial cell; MCP-1; PI 3 kinase; PKC-epsilon; STAT1-alpha ID HUMAN MESANGIAL CELLS; FACTOR-KAPPA-B; EPITHELIAL ICAM-1 EXPRESSION; CHEMOATTRACTANT PROTEIN-1; IFN-GAMMA; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; DIFFERENTIAL ROLE AB Monocyte chemotactic protein-1 (MCP-1) recruits activated phagocytes to the site of tissue injury. Interferon-gamma (IFN-gamma) present in the microenvironment of glomerulus acts on mesangial cells to induce local production of MCP-1. The mechanism by which IFN-gamma stimulates expression of MCP-1 is not clear. We therefore examined the role of PI 3 kinase signaling in regulating the IFN-gamma-induced MCP-1 expression in mesangial cells. Blocking PI 3 kinase activity with Ly294002 attenuated IFN-gamma-induced MCP-1 protein and mRNA expression. IFN-gamma increased Akt kinase activity in a PI 3 kinase-dependent manner. Expression of dominant negative Akt kinase inhibited serine phosphorylation of STAT1 alpha, without any effect on its tyrosine phosphorylation, and decreased IFN-gamma-induced expression of MCP-1. These data for the first time indicate a role for PI 3 kinase-dependent Akt kinase in MCP-1 expression. We have recently shown that along with Akt, PKC epsilon is a downstream target of PI 3 kinase in IFN-gamma signaling. Similar to dominant negative Akt kinase, dominant negative PKC epsilon also inhibited serine phosphorylation of STAT1 alpha without any effect on tyrosine phosphorylation. Dominant negative PKC epsilon also abrogated MAPK activity, resulting in decrease in IFN-gamma-induced MCP-1 expression. Furthermore, Akt and PKC epsilon are present together in a signaling complex. IFN-gamma had no effect on this complex formation, but did increase PKC epsilon-associated Akt kinase activity. PKC epsilon did not regulate IFN-gamma-induced Akt kinase. Finally, expression of dominant negative Akt kinase blocked IFN-gamma-stimulated MAPK activation. These data provide the first evidence that PI 3 kinase-dependent Akt and PKCF activation independently regulate MAPK activity and serine phosphorylation of STAT1 alpha. to increase expression of MCP-1. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78220 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78220 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Med Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78220 USA. EM choudhuryg@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU NIDDK NIH HHS [R01 DK50190, P50 DK061597, R01 DK33665, R01 DK55815] NR 56 TC 23 Z9 23 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 J9 CELL SIGNAL JI Cell. Signal. PD APR PY 2006 VL 18 IS 4 BP 508 EP 518 DI 10.1016/j.cellsig.2005.05.022 PG 11 WC Cell Biology SC Cell Biology GA 001PU UT WOS:000234549600012 PM 16157472 ER PT J AU Casserly, IP AF Casserly, IP TI The optimal revascularization strategy for multivessel coronary artery disease: The debate continues SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Review ID BYPASS GRAFT-SURGERY; RANDOMIZED-TRIAL; STENT IMPLANTATION; ADVERSE OUTCOMES; RISK-FACTORS; INTERVENTION; ANGIOPLASTY; MULTICENTER AB Mortality rates were lower among patients with multivessel coronary artery disease who underwent coronary artery bypass grafting (CABG) than among similar patients who underwent percutaneous coronary intervention (PCI) in an analysis of data from New York State registries (N Engl J Med 2005; 352:2174-2183). This finding appears to run counter to the results of randomized controlled trials, which found both procedures equivalent with regard to mortality. What are we to believe? C1 Denver Vet Affairs Med Ctr, Dept Cardiol 111B, Denver, CO 80220 USA. Univ Colorado, Boulder, CO 80309 USA. RP Casserly, IP (reprint author), Denver Vet Affairs Med Ctr, Dept Cardiol 111B, 1055 Clermont St, Denver, CO 80220 USA. EM ivan.casserly@med.va.gov NR 13 TC 6 Z9 6 U1 0 U2 0 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD APR PY 2006 VL 73 IS 4 BP 317 EP + PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 030QY UT WOS:000236650600004 PM 16610392 ER PT J AU Meeran, SM Mantena, SK Katiyar, SK AF Meeran, SM Mantena, SK Katiyar, SK TI Prevention of ultraviolet radiation-induced immunosuppression by (-)-epigallocatechin-3-gallate in mice is mediated through interleukin 12-dependent DNA repair SO CLINICAL CANCER RESEARCH LA English DT Article ID CYCLOBUTANE PYRIMIDINE DIMERS; GREEN TEA POLYPHENOLS; IFN-GAMMA PRODUCTION; CONTACT HYPERSENSITIVITY; TUMOR-REGRESSION; SKIN-CANCER; IMMUNE SUPPRESSION; IRRADIATED MICE; T-CELLS; IN-VIVO AB Purpose: Solar UV radiation - induced immunosuppression is considered to be a risk factor for melanoma and nonmelanoma skin cancers. We previously have shown that topical application of (-) -epigallocatechin-3-gallate (EGCG) prevents UV-induced immunosuppression in mice. We studied whether prevention of UV-induced immunosuppression by EGCG is mediated through interleukin 12 (IL-12) - dependent DNA repair. Experimental Design: IL-12 knockout (KO) mice on C3H/HeN background and DNA repair-deficient cells from xeroderma pigmentosum complementation group A (XPA) patients were used in this study. The effect of EGCG was determined on UV-induced suppression of contact hypersensitivity and UV-induced DNA damage in the form of cyclobutane pyrimidine dimers (CPD) in mice and XPA-deficient cells using immunohistochemistry and dot-blot analysis. Results: Topical treatment with EGCG prevented UV-induced suppression of the contact hypersensitivity in wild-type (WT) mice but did not prevent it in IL-12 KO mice. Injection of anti-IL-12 monoclonal antibody to WT mice blocked the preventive effect of EGCG on UV-induced immunosuppression. EGCG reduced or repaired UV-induced DNA damage in skin faster in WT mice as shown by reduced number of CPDs(+) cells and reduced the migration of CPD+ antigen-presenting cells from the skin to draining lymph nodes. In contrast, this effect of EGCG was not seen in IL-12 KO mice. Further, EGCG was able to repair UV-induced CPDs in XPA-proficient cells obtained from healthy person but did not repair in XPA-deficient cells, indicating that nucleotide excision repair mechanism is involved in DNA repair. Conclusions: These data identify anew mechanism by which EGCG prevents UV-induced immunosuppression, and this may contribute to the chemopreventive activity of EGCG in prevention of photocarcinogenesis. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [1 R01 AT002536] NR 36 TC 37 Z9 38 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 1 PY 2006 VL 12 IS 7 BP 2272 EP 2280 DI 10.1158/1078-0432.CCR-05-2672 PN 1 PG 9 WC Oncology SC Oncology GA 034BI UT WOS:000236899000046 PM 16609044 ER PT J AU McKeever, VM McWhirter, BT Huff, ME AF McKeever, Victoria M. McWhirter, Benedict T. Huff, Maureen E. TI Relationships between attribution style, child abuse history, and PTSD symptom severity in Vietnam veterans SO COGNITIVE THERAPY AND RESEARCH LA English DT Article; Proceedings Paper CT 109th Annual Convention of the American-Psychological-Association CY AUG 24-28, 2001 CL SAN FRANCISCO, CA SP Amer Psychol Assoc DE learned helplessness; internal-external control; child abuse; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; I-E SCALE; LEARNED HELPLESSNESS; EXTERNAL CONTROL; COMBAT VETERANS; CAUSAL MODEL; RISK-FACTORS; LOCUS; IMPACT; SAMPLE AB Relationships between learned helplessness, locus of control, child abuse histories, adult trauma exposure and subsequent PTSD symptom severity in a clinical sample of male Vietnam veterans were examined. Learned helplessness and external locus of control were not only reliably associated with each other, but also differentially associated with childhood abuse and PTSD symptom severity. Learned helplessness, in particular, evidenced significant relationships with both childhood trauma and current distress. Contrary to expectations, child abuse history was not reliably associated with combat-related PTSD. Overall results suggested that learned helplessness and external locus of control are correlated, but independent constructs with compelling links to adult psychopathology. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Oregon, Conseling Psychol & Human Serv, Eugene, OR 97403 USA. N Range Behav Hlth, Greeley, CO USA. RP McKeever, VM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S116 ATC, Seattle, WA 98108 USA. EM Victoria.McKeever@med.va.gov NR 49 TC 6 Z9 6 U1 2 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD APR PY 2006 VL 30 IS 2 BP 123 EP 133 DI 10.1007/s10608-006-9018-9 PG 11 WC Psychology, Clinical SC Psychology GA 109CC UT WOS:000242284500001 ER PT J AU Krouse, RS Mohler, MJ Wendel, CS Grant, M Baldwin, CM Rawl, SM McCorkle, R Rosenfeld, KE Ko, CY Schmidt, CM Coons, SJ AF Krouse, RS Mohler, MJ Wendel, CS Grant, M Baldwin, CM Rawl, SM McCorkle, R Rosenfeld, KE Ko, CY Schmidt, CM Coons, SJ TI The VA ostomy health-related quality of life study: objectives, methods, and patient sample SO CURRENT MEDICAL RESEARCH AND OPINION LA English DT Article DE focus groups; ostomy; quality of life; stomas ID INFLAMMATORY BOWEL-DISEASE; VETERANS-HEALTH; COLORECTAL-CANCER; SURVEY SF-36; SURGERY; FORM; QUESTIONNAIRE; DYSFUNCTION; COLOSTOMY; AFFAIRS AB Objective: To present the design and methods of a multisite study of health-related quality of life (HR-QOL) in veterans living with ostomies. Research design and methods: Veterans from Tucson, Indianapolis, and Los Angeles VA Medical Centers were surveyed using the validated City of Hope ostomy-specific tool (mCOH-QOL-Ostomy) and the SF-36V. Cases (ostomates) had a major gastrointestinal procedure that required an intestinal stoma, while controls had similar procedures for which an ostomy was not required. Ostomy subjects were recruited for four focus groups in each of two sites divided by ostomy type (colostomy versus ileostomy) and overall mCOH-QOL-Ostomy HR-QOL score (highest versus lowest quartile). The focus groups further evaluated barriers, concerns, and adaptation methods and skills. Main outcome measures: This report presents recruitment results, reliability of survey instruments, and demographic characteristics of the sample. Results: The overall response (i.e., recruitment) rate across all sites was 48% and by site was 53%, 57%, and 37%, respectively (p < 0.001). Internal consistency reliability estimates indicated that both instruments remain reliable in this population (Cronbach's alpha for HR-QOL domains/scales: 0.71-0.96). Cases and controls were similar in demographic characteristics. Proportions of minority subjects matched projections from the site patient populations. Subjects with ostomies had significantly longer time since surgery than controls (p < 0.001). Focus groups were comprised of two to six subjects per group and demonstrated racial diversity at the Los Angeles site. Conclusions; The unique design of our study of VA patients with ostomies is an illustration of a successful mixed methods approach to HR-QOL-research. We collected meaningful quantitative and qualitative data that will be used in the development of new approaches to care that will lead to improved functioning and well-being in persons living with ostomies. Subsequent reports will provide the results of this research project. C1 So Arizona Vet Affairs Hlth Care Syst, Surg Care Line, Tucson, AZ 85723 USA. Univ Arizona, Coll Med, Tucson, AZ USA. Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. Arizona State Univ, Coll Nursing SW Borderlands, Tempe, AZ USA. Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. Yale Univ, New Haven, CT USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Indiana Univ, Dept Surg, Indianapolis, IN 46204 USA. Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. RP Krouse, RS (reprint author), So Arizona Vet Affairs Hlth Care Syst, Surg Care Line, 2-112,3601 S 6th Ave, Tucson, AZ 85723 USA. EM robert.krouse@va.gov OI Baldwin, Carol/0000-0002-0732-2307; Rawl, Susan/0000-0003-2052-2853 NR 53 TC 24 Z9 24 U1 0 U2 3 PU LIBRAPHARM PI NEWBURY PA 29-35 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND SN 0300-7995 J9 CURR MED RES OPIN JI Curr. Med. Res. Opin. PD APR PY 2006 VL 22 IS 4 BP 781 EP 791 DI 10.1185/030079906X96380 PG 11 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 048LM UT WOS:000237948600018 PM 16684439 ER PT J AU Hart, PJ AF Hart, PJ TI Pathogenic superoxide dismutase structure, folding, aggregation and turnover SO CURRENT OPINION IN CHEMICAL BIOLOGY LA English DT Review ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; COPPER-BINDING-SITE; LINKED MUTANT SOD1; CU,ZN-SUPEROXIDE DISMUTASE; TRANSGENIC MICE; FAMILIAL ALS; SPINAL-CORD; CELL-DEATH; PROTEASOMAL DEGRADATION AB Significant advances have been made during the past two years toward an understanding of the molecular basis for how mutations in human cytosolic copper-zinc superoxide dismutase (SOD1) cause the inherited form of amyotrophic lateral sclerosis (ALS). Biophysical studies suggest that the pathogenic mutations destabilize loop or beta-barrel structural elements of the protein. With few exceptions, the loss of metal ions and reduction of the intrasubunit disulfide bond enhance this destabilization. In mouse models of the disease, the formation of visible aggregates containing mutant SOD1 occurs relatively late in the lifespan, hinting that the quality control and protein turnover systems of motor neurons eventually become overwhelmed or compromised. Studies probing SOD1 turnover have suggested the possibility that proteolytic breakdown products may play a role in pathogenesis. C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Biochem,Xray Crystallog Core Lab, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr,Dept Vet Affairs, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Biochem,Xray Crystallog Core Lab, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu FU NINDS NIH HHS [R01 NS039112] NR 56 TC 76 Z9 78 U1 0 U2 5 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1367-5931 J9 CURR OPIN CHEM BIOL JI Curr. Opin. Chem. Biol. PD APR PY 2006 VL 10 IS 2 BP 131 EP 138 DI 10.1016/j.cbpa.2006.02.034 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 035KU UT WOS:000237000700007 PM 16516535 ER PT J AU Rincon-Choles, H Vasylyeva, TL Pergola, PE Bhandari, B Bhandari, K Zhang, JH Wang, W Gorin, Y Barnes, JL Abboud, HE AF Rincon-Choles, H Vasylyeva, TL Pergola, PE Bhandari, B Bhandari, K Zhang, JH Wang, W Gorin, Y Barnes, JL Abboud, HE TI ZO-1 expression and phosphorylation in diabetic nephropathy SO DIABETES LA English DT Article ID JUNCTION PROTEIN ZO-1; GLOMERULAR EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCAN; TIGHT JUNCTION; SLIT DIAPHRAGM; HIGH GLUCOSE; GENE-EXPRESSION; MESANGIAL CELLS; ADHERENS JUNCTION; PERMEABILITY AB Cellular mechanisms responsible for the loss of capillary wall permselectivity in diabetic nephropathy are not well characterized. ZO-1 is a junctional protein involved in the assembly and proper function of a number of tight junctions and is also expressed at the junction of podocytes with the slit diaphragm. We investigated the effect of diabetes and high glucose concentration on the expression of ZO-1 in animal models of both type I and 2 diabetes and in rat glomerular epithelial cells. In diabetic animals, immunohistochemistry and Western blotting showed decreased expression of ZO-1 in glomeruli. Immunogold electron microscopy revealed redistribution of ZO-1 from the podocyte membrane to the cytoplasm in the diabetic animals. Exposure of rat glomerular epithelial cells to high glucose resulted in a decrease in the intensity of ZO-1 staining and redistribution of ZO-1 from the membrane to the cytoplasm, changes that are attenuated by blockade of the angiotensin 11 type 1 receptor. ZO-1 protein expression and serine and tyrosine phosphorylation of ZO-1 were also decreased in cells exposed to high glucose. These findings suggest that alterations in the content and localization of ZO-1 may be relevant to the pathogenesis of proteinuria in diabetes. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Rincon-Choles, H (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, MSC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choles@uthscsa.edu FU NIDDK NIH HHS [P50-DK-061597] NR 42 TC 40 Z9 48 U1 2 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2006 VL 55 IS 4 BP 894 EP 900 DI 10.2337/diabetes.55.04.06.db05-0355 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 028MK UT WOS:000236491400004 PM 16567508 ER PT J AU Zickmund, SL Bryce, CL Blasiole, JA Shinkunas, L LaBrecque, DR Arnold, RM AF Zickmund, Susan L. Bryce, Cindy L. Blasiole, Julie A. Shinkunas, Laura LaBrecque, Douglas R. Arnold, Robert M. TI Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE adherence; antiviral therapy; depression; fatigue; hepatitis C; quality of life ID RECEIVING INTERFERON-ALPHA; QUALITY-OF-LIFE; PEGINTERFERON ALPHA-2A; COMBINATION THERAPY; RIBAVIRIN; ADHERENCE; DEPRESSION; MORBIDITY; ANXIETY; IMPACT AB Objective The hepatitis C virus can be successfully treated in up to 60% of infected patients. However, treatment is long and is associated with significant side-effects. We investigated difficulties with this treatment as it is an important factor in patient adherence. Methods Patients receiving hepatitis C treatment in a tertiary referral center were enrolled in a cross-sectional study. Demographic data, functional and emotional status, and co-morbidities were collected from patients or abstracted from the medical records. All participants underwent a semistructured interview, which was analysed by blinded coders. Results A total of 65 patients (mean age 46.1 years; 38.5% women) were enrolled. Fifty-two (80%) described moderate to severe problems attributed to treatment, with a predominance of physical difficulties (fatigue 74% of cases; flu-like symptoms 32%). Approximately one third of patients (38%) experienced depression during treatment. In 31% of cases, physical or emotional problems forced patients to quit their jobs or reduce employment. One fifth attributed deteriorating relationships with friends and family to adverse treatment effects. Necessary lifestyle adjustments, such as alcohol abstinence, caused frictions with friends in 22% of the participants. Conclusions Our findings show a high prevalence of significant adverse effects in patients undergoing antiviral therapy. Whereas the nature and severity of these adverse reactions is consistent with earlier reports, we identified implications with worsening private and professional relationships. To encourage appropriate levels of adherence, healthcare providers should seek information about these indirect treatment effects as they monitor their patients on therapy. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. Univ Iowa, Sch Publ Hlth, Dept Epidemiol, Iowa City, IA USA. Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA. RP Zickmund, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C-U Univ Dr C, Pittsburgh, PA 15240 USA. EM susan.zickmund@med.va.gov OI Bryce, Cindy/0000-0001-6356-6675 FU NHLBI NIH HHS [HL07121] NR 27 TC 16 Z9 19 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD APR PY 2006 VL 18 IS 4 BP 381 EP 388 DI 10.1097/00042737-200604000-00011 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 126AI UT WOS:000243484200011 PM 16538109 ER PT J AU Evans, DC Nichol, WP Perlin, JB AF Evans, Dwight C. Nichol, W. Paul Perlin, Jonathan B. TI Effect of the implementation of an enterprise-wide Electronic Health Record on productivity in the Veterans Health Administration SO HEALTH ECONOMICS POLICY AND LAW LA English DT Article AB Since 1995, the Veterans Health Administration (VHA) has had an ongoing process of systems improvement that has led to dramatic improvement in the quality of care delivered. A major component of the redesign of the VHA has been the creation of a fully developed enterprise-wide Electronic Health Record (EHR). VHA's Health Information Technology was developed in a collaborative fashion between local clinical champions and central software engineers. Successful national EHR implementation was achieved by 1999, since when the VHA has been able to increase its productivity by nearly 6 per cent per year. C1 [Perlin, Jonathan B.] Vet Hlth Adm, Washington, DC 20240 USA. [Nichol, W. Paul] Univ Washington, Sch Med, Seattle, WA USA. [Nichol, W. Paul] VA Puget Sound HCS, Seattle, WA USA. [Evans, Dwight C.] VA Loma Linda HCS, Loma Linda, CA USA. [Evans, Dwight C.] Loma Linda Univ, Sch Med, Loma Linda, CA USA. RP Perlin, JB (reprint author), Vet Hlth Adm, 810 Vermont St, Washington, DC 20240 USA. EM jonathan.perlin@va.gov NR 15 TC 52 Z9 52 U1 2 U2 6 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1744-1331 J9 HEALTH ECON POLICY L JI Health Econ. Policy Law PD APR PY 2006 VL 1 IS 2 BP 163 EP 169 DI 10.1017/S1744133105001210 PG 7 WC Health Policy & Services SC Health Care Sciences & Services GA V18XW UT WOS:000208038500005 PM 18634688 ER PT J AU Nugalieva, ZZ Opekun, AR Graham, DY AF Nugalieva, ZZ Opekun, AR Graham, DY TI Problem of distinguishing false-positive tests from acute or transient Helicobacter pylori infections SO HELICOBACTER LA English DT Article DE Helicobacter pylori; acute infection; transient infection; pepsinogens; predictive values; urea breath test ID SERUM PEPSINOGEN-I; TERM FOLLOW-UP; ERADICATION THERAPY; CHILDREN; GASTRITIS; TRANSMISSION; POPULATION; PREVALENCE; COMMUNITY; ULCER AB Background: Reliable detection of acute Helicobacter pylori infections remains problematic. The high prevalence of false-positive non-invasive tests in low H. pylori prevalence populations makes identification of acute and transient infections difficult. Methods: We explored the use of serum pepsinogens (PG) for diagnosis of acute infection in patients following H. pylori challenge such that the onset of the infection was known. We then compared those findings to a group of children with presumed acute infections defined as a positive urea breath test (UBT) and negative IgG serology. Results: We examined the pattern and calculated cut-off values of PG levels in 18 adult volunteers with known acute H. pylori infection. We then compared the results with sera from nine symptomatic children with presumed acute H. pylori infection and a matched control group of nine children who did not meet criteria for acute H. pylori infection. In acute infection, both PGI and II levels increased following H. pylori infection reaching a peak by 2 weeks post-infection. The frequency of a positive test defined as a value > mean +2 SD was 17, 71, and 94% at week 1, 2, and 4 post-infection, respectively. Only one child with presumed acute H. pylori infection had an elevated serum PGI and one had an elevated PGII. Five of the children had follow-up UBTs and four were negative consistent with the diagnosis of false-positive UBT. H. pylori infection was confirmed in the child with an elevated PGI level. Conclusions: These data suggest that a single positive noninvasive test in populations of low prevalence is most likely a false-positive result. This suggests that a single positive test requires confirmation preferably using a test that measures a different parameter (e.g., UBT confirmed by stool antigen test). It appears that most "transient"H. pylori infections are diagnosed on the basis of false-positive tests. PG levels are possible candidates as the confirmatory test. C1 Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Vet Affairs Med Ctr, Dept Pediat, Houston, TX 77030 USA. Vet Affairs Med Ctr, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu NR 42 TC 9 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD APR PY 2006 VL 11 IS 2 BP 69 EP 74 DI 10.1111/j.1523-5378.2006.00380.x PG 6 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 020EX UT WOS:000235892300001 ER PT J AU Karayiannis, NB Mukherjee, A Glover, JR Ktonas, PY Frost, JD Hrachovy, RA Mizrahi, EA AF Karayiannis, NB Mukherjee, A Glover, JR Ktonas, PY Frost, JD Hrachovy, RA Mizrahi, EA TI Detection of pseudo sinusoidal epileptic seizure segments in the neonatal EEG by cascading a rule-based algorithm with a neural network SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE electroencephalography; epileptic seizure segment; feedforward neural network (FFNN); neonatal seizure; quantum neural network (QNN) ID NEWBORN EEG; INFANTS AB This paper presents an approach to detect epileptic seizure segments in the neonatal electroencephalogram (EEG) by characterizing the spectral features of the EEG waveform using a rule-based algorithm cascaded with a neural network. A rule-based algorithm screens out short segments of pseudosinusoidal EEG patterns as epileptic based on features in the power spectrum. The output of the rule-based algorithm is used to train and compare the performance of conventional feedforward neural networks and quantum neural networks. The results indicate that the trained neural networks, cascaded with the rule-based algorithm, improved the performance of the rule-based algorithm acting by itself. The evaluation of the proposed cascaded scheme for the detection of pseudosinusoidal seizure segments reveals its potential as a building block of the automated seizure detection system under development. C1 Univ Houston, Dept Elect & Comp Engn, Houston, TX 77204 USA. Baylor Coll Med, Peter Kellaway Sect Neurophysiol, Dept Neurol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Karayiannis, NB (reprint author), Univ Houston, Dept Elect & Comp Engn, N308 Engn Bldg 1, Houston, TX 77204 USA. EM karayiannis@uh.edu FU NINDS NIH HHS [N01-NS-2316, 1 R01 NS040577] NR 27 TC 24 Z9 24 U1 1 U2 3 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD APR PY 2006 VL 53 IS 4 BP 633 EP 641 DI 10.1109/TBME.2006.870249 PG 9 WC Engineering, Biomedical SC Engineering GA 029IY UT WOS:000236557100007 PM 16602569 ER PT J AU Obrosky, DS Edick, SM Fine, MJ AF Obrosky, DS Edick, SM Fine, MJ TI The emergency department triage of community-acquired pneumonia project data and documentation systems: A model for multicenter clinical trials SO IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE LA English DT Article DE clinical trials; data dictionary; data management systems; documentation; quality assurance AB Multicenter clinical trials are complex undertakings that require significant resources to ensure efficient, high quality research. This paper describes the goals, design, and implementation of a multicenter clinical trial database management system to support this aim. A large number of study sites or patients, and the goal of automatically generating large portions of data management infrastructure from common metadata, motivated the development of the system. This paper also describes extensions for a generalized project documentation system, and discusses plans for further extensions and improvements based on observed strengths, limitations, and anticipated technological change. C1 Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15240 USA. VA Healthcare Syst, Pittsburgh, PA 15240 USA. VA Pittsburgh Healthcare Syst, Off Res & Dev, Pittsburgh, PA 15206 USA. RP Obrosky, DS (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15240 USA. EM obroskyds@msx.upmc.edu; Stacey.Edick@va.gov; Michael.Fine@va.gov FU AHRQ HHS [R01-HS10049] NR 11 TC 0 Z9 0 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1089-7771 J9 IEEE T INF TECHNOL B JI IEEE T. Inf. Technol. Biomed. PD APR PY 2006 VL 10 IS 2 BP 377 EP 384 DI 10.1109/TITB.2005.864369 PG 8 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Medical Informatics SC Computer Science; Mathematical & Computational Biology; Medical Informatics GA 030ZR UT WOS:000236674400018 PM 16617626 ER PT J AU Casini, G Rickman, DW Brecha, NC AF Casini, G Rickman, DW Brecha, NC TI Expression of the gamma-aminobutyric acid (GABA) plasma membrane transporter-1 in monkey and human retina SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID INHIBITORY SYNAPTIC POTENTIALS; DECARBOXYLASE MESSENGER-RNA; GAD-LIKE IMMUNOREACTIVITY; RAT HIPPOCAMPAL SLICE; IN-SITU HYBRIDIZATION; GLUTAMIC-ACID; CEREBRAL-CORTEX; RABBIT RETINA; PRIMATE RETINA; AMACRINE CELLS AB PURPOSE. To determine the expression pattern of the predominant gamma-aminobutyric acid (GNBA) plasma membrane transporter GAT-1 in Old World monkey (Macaca mulatta) and human retina. METHODS. GAT-I was localized in retinal sections by using immunohistochemical techniques with fluorescence and confocal microscopy. Double-labeling studies were performed with the GAT-I antibody using antibodies to GABA, vasoactive intestinal polypeptide (VIP), tyrosine hydroxylase (TH), and the bipolar cell marker Mab115A10. RESULTS. The pattern of GAT-1 immunostaining was similar in human and monkey retinas. Numerous small immunoreactive somata were in the inner nuclear layer (INL) and were present rarely in the inner plexiform layer (IPL) of all retinal regions. Medium GAT-1 somata were in the ganglion cell layer in the parafoveal and peripheral retinal regions. GAT-1 fibers were densely distributed throughout the IPL. Varicose processes, originating from both the IPL and somata in the INL, arborized in the outer plexiform layer (OPL), forming 4 sparse network in all retinal regions, except the fovea. Sparsely occurring GAT-1 processes were in the nerve fiber layer in parafoveal regions and near the optic nerve head but not in the optic nerve. In the INL, 99% of the GAT-1 somata contained GABA, and 66% of the GABA immunoreactive somata expressed GAT-1. GAT-1 immunoreactivity was in all VIP-containing cells, but it was absent in TH-immunoreactive amacrine cells and in Mab115A10 immunoreactive bipolar cells. CONCLUSIONS. GAT-1 in primate retinas is expressed by amacrine and displaced amacrine cells. The predominant expression of GAT-1 in the inner retina is consistent with the idea that GABA transporters influence neurotransmission and thus participate in visual information processing in the retina. C1 Univ Tuscia, Dipartimento Sci Ambientali, I-01100 Viterbo, Italy. Duke Univ, Dept Ophthalmol, Durham, NC USA. Duke Univ, Dept Neurobiol, Durham, NC USA. Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Neurobiol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Casini, G (reprint author), Univ Tuscia, Dipartimento Sci Ambientali, Largo Univ D, I-01100 Viterbo, Italy. EM gcasini@unitus.it FU NEI NIH HHS [R01 EY015573-02, EY04067, R01 EY004067-26, R01 EY004067, R01 EY015573, R56 EY004067, EY15573]; NIDDK NIH HHS [P30 DK041301, DK41301] NR 88 TC 14 Z9 16 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2006 VL 47 IS 4 BP 1682 EP 1690 DI 10.1167/iovs.05-1117 PG 9 WC Ophthalmology SC Ophthalmology GA 029KI UT WOS:000236560800056 PM 16565409 ER PT J AU Sarawate, CA Patel, PA Schumacher, HR Yang, WY Brewer, KK Bakst, AW AF Sarawate, CA Patel, PA Schumacher, HR Yang, WY Brewer, KK Bakst, AW TI Serum urate levels and gout flares - Analysis from managed care data SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE gout; retrospective; serum urate ID HYPERURICEMIA AB Background: The desired serum urate level (SUA) for prevention of gout attacks is widely recommended to be in the subsaturating range, < 6.0 mg/dL. Objectives: The objectives of this study were to evaluate attainment of this target SUA among gout patients on allopurinol in a naturalistic setting and to assess its impact on gout flare risk. Methods: This was a retrospective, observational study in a southeastern U.S. managed care organization of approximately 2.2 million members. The first gout claim/prescription within the intake period (January 1, 2000-December 31, 2002) was the index date. Included patients had >= 2 visits with gout International Classification of Diseases, 9th Revision code (274.xx) or >= 1 pharmacy script(s) for allopurinol, colchicine, probenecid, or sulfinpyrazone. Excluded patients were < 18 years and/or did not have a 1-year continuous eligibility pre-/postindex date. Gout flares were defined by office/emergency room visit with gout or joint pain code(s) and >= 1 of the following within 7 days of the visit: intraarticular aspiration/injection, joint fluid microscopy, or pharmacy claim for nonsteroidal anti inflammatory drug, colchicine, corticosteroid, or ACTH. Multivariable regression analyses were conducted to evaluate gout flare risk/rate and association with target SUA. Results: Approximately 40% of 5942 gout patients identified used allopurinol postindex. Among allopurinol users with pre-/postindex SUA data (n = 162), mean SUA was lowered from 8.7 mg/dL to 7.1 mg/dL; reduction was significant (P < 0.001). Among allopurinol users who did not have SUA < 6.0 mg/dL preindex (n = 147), only 25% reached target levels during postindex. Despite pharmacotherapy, patients with nontarget levels were 59% more likely to flare than those at target. Allopurinol users who were not at target were 75% more likely to flare. Conclusion: The failure of allopurinol users to achieve target SUA levels of < 6.0 mg/dL may be attributed to lack of awareness of optimal SUA, allopurinol dosing, compliance, and efficacy. Patients who did not achieve target SUA were at increased flare risk. C1 HealthCore Inc, Analyt Hlth Outcomes Res, Wilmington, DE 19801 USA. Pharmaceut Prod Inc, Lake Forest, IL USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Sarawate, CA (reprint author), HealthCore Inc, Analyt Hlth Outcomes Res, 800 Delaware Ave,5th Floor, Wilmington, DE 19801 USA. EM csartwate@healthcore.com NR 9 TC 108 Z9 109 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD APR PY 2006 VL 12 IS 2 BP 61 EP 65 DI 10.1097/01.rhu.0000209882.50228.9f PG 5 WC Rheumatology SC Rheumatology GA 035VC UT WOS:000237028800003 PM 16601538 ER PT J AU Chinman, M Young, AS Hassell, J Davidson, L AF Chinman, M Young, AS Hassell, J Davidson, L TI Toward the implementation of mental health consumer provider services SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Review ID SELF-HELP GROUPS; ONE-YEAR OUTCOMES; QUALITY-OF-CARE; CASE-MANAGEMENT; RANDOMIZED TRIAL; CONCEPTUAL-FRAMEWORK; FOCUS GROUPS; ILLNESS; SCHIZOPHRENIA; COMMUNITY AB Encouraged by the New Freedom Commission, mental health systems such as the Veteran Administration (VA) are now becoming more recovery-oriented. Consumer providers (CPs)-those with serious mental illness who are further along in recovery who provide services to others with similar mental health problems-are viewed as a key part of this change. However, organizational change theories suggest that careful consideration of implementation issues is critical when disseminating new and sometimes controversial services into existing organizations. Therefore, to guide the dissemination of CP set-vices, the literature on the effectiveness of CPs was reviewed, and interviews, focus groups, and a brief survey of 110 administrators, providers, and patients were conducted at three large VA clinics in Southern California. Questions focused on their perceptions of feasibility and acceptability of CP services. Using literature and study findings, an organizational change framework and other strategies to overcome potential implementation challenges of CP set-vices are suggested. C1 W LA VA Healthcare Ctr, MIRECC, VISN 22, Hlth Serv Unit, Los Angeles, CA 90073 USA. Yale Univ, Sch Med, Dept Psychiat, Yale Program Recovery & Community Hlth, New Haven, CT 06511 USA. RP Chinman, M (reprint author), W Los Angeles VA MIRECC, Hlth Serv Unit, 11301 Wilshire Blvd,210A, Los Angeles, CA 90073 USA. EM chinman@rand.org; ayoung@ucla.edu; jhassell@alliant.edu RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 NR 119 TC 50 Z9 51 U1 2 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD APR PY 2006 VL 33 IS 2 BP 176 EP 195 DI 10.1007/s11414-006-9009-3 PG 20 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 041PG UT WOS:000237467500004 PM 16645906 ER PT J AU Ratcliffe, MB AF Ratcliffe, MB TI The treatment of ischemic heart failure with surgical ventricular restoration (SVR): New evidence of benefit SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material ID FINITE-ELEMENT MODEL; VOLUME REDUCTION SURGERY; ENDOVENTRICULAR PATCH PLASTY; MYOCARDIAL-INFARCTION; MITRAL REGURGITATION; ANEURYSM; DYSFUNCTION; SURVIVAL; SIZE; ENLARGEMENT C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Dept Vet Affairs Med Ctr, San Francisco, CA USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, Div Surg Serv 112D, 4150 Clement St, San Francisco, CA 94121 USA. FU NHLBI NIH HHS [R01-HL-63348] NR 38 TC 2 Z9 2 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2006 VL 12 IS 3 BP 195 EP 198 DI 10.1016/j.cardfail.2006.01.007 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 039KV UT WOS:000237305400005 PM 16624684 ER PT J AU Durvasula, RS Myers, HF Mason, K Hinkin, C AF Durvasula, RS Myers, HF Mason, K Hinkin, C TI Relationship between alcohol use/abuse, HIV infection and neuropsychological performance in African American men SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTRAVENOUS-DRUG-USERS; AIDS DEMENTIA COMPLEX; ABUSE; MEMORY; BRAIN; CONSUMPTION; COGNITION; COFACTOR; DISEASE AB This study examines the impact of alcohol use and HIV infection on neuropsychological performance in a sample of 497 community-resident African American men. HIV serostatus and alcohol use ( during the past 12 months) exerted an interactive effect on psychomotor speed, reaction time, and motor speed, and in general, HIV infected heavy drinkers evidenced significantly poorer performance than other HIV positive subjects. Main effects for HIV serostatus were noted for reaction time, with seronegative men performing better than seropositives. This study examines a sample of men who continue to show increases in HIV infection, however, sample specific issues such as comorbid substance use, past histories of head injury, and lack of data on alcohol abuse and dependence require caution in definitively attributing the findings solely to alcohol and HIV. However, these findings suggest that relatively recent heavy alcohol use may represent a potential risk factor for more rapid or pronounced cognitive decline in HIV positive individuals, and that these patterns may be even more pronounced in persons with comorbid substance use. C1 Calif State Univ Los Angeles, Dept Psychol, Los Angeles, CA 90032 USA. Charles R Drew Univ Med & Sci, Res Ctr Ethn Hlth & Behav, Los Angeles, CA 90059 USA. Charles R Drew Univ Med & Sci, Dept Psychiat, Los Angeles, CA 90059 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Durvasula, RS (reprint author), Calif State Univ Los Angeles, Dept Psychol, King Hall,5151 State Univ Dr, Los Angeles, CA 90032 USA. EM rdurvas@calstatela.edu FU NIAAA NIH HHS [R21 AA011912-02, U24AA-11899, AA11912, U24 AA011899-04, U24 AA011899]; NIDA NIH HHS [DA06597] NR 62 TC 19 Z9 20 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD APR PY 2006 VL 28 IS 3 BP 383 EP 404 DI 10.1080/13803390590935408 PG 22 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 025RP UT WOS:000236284900008 PM 16618627 ER PT J AU Castellon, SA Hardy, DJ Hinkin, CH Satz, P Stenquist, PK Van Gorp, WG Myers, HF Moore, L AF Castellon, SA Hardy, DJ Hinkin, CH Satz, P Stenquist, PK Van Gorp, WG Myers, HF Moore, L TI Components of depression in HIV-1 infection: Their differential relationship to neurocognitive performance SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; BASE-LINE ASSESSMENT; NEUROPSYCHOLOGICAL PERFORMANCE; PSYCHIATRIC-DISORDERS; HOMOSEXUAL MEN; PSYCHOLOGICAL DISTRESS; NEUROPSYCHIATRIC AIDS; SOMATIC SYMPTOMS; BISEXUAL MEN AB Both depression and neurocognitive compromise are commonly observed among persons infected with the Human Immunodeficiency Virus (HIV). To date, the majority of studies have failed to find a consistent relationship between mood and cognition among HIV-seropositive (HIV+) individuals, suggesting that these constructs are independent of one another. However, depression is a multi-dimensional syndrome and its measurement often utilizes multi-factorial instruments containing cognitive, affective, somatic, and motivational components. The degree to which various symptoms or dimensions of depression might be related to neuropsychological performance in HIV-1 infection is not typically explored and was a main objective of the current study. A sample of 247 HIV+ persons completed both a comprehensive neurocognitive battery and the Beck Depression Inventory (BDI) as part of a standard clinical evaluation at a major community hospital. To examine the dimensionality of the BDI, a principal components analysis was conducted which suggested a three-factor solution comprised of factors representing Self-Reproach (SR), Mood-Motivation Disturbance ( MM), and Somatic Disturbance (SOM). The relationship between each of these three factors and neurocognitive performance was examined using both regression and analysis of variance techniques. These analyses showed the MM factor, more so than either the SR or SOM factors, to be associated with several aspects of neurocognitive performance, including verbal memory, executive functioning, and motor speed. These findings suggest that certain items on depression rating scales may be more indicative of central nervous system (CNS) involvement than others. The association between disturbance in mood and motivation and neurocognitive compromise may suggest that each are sequelae of disease specific mechanisms. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Cornell Univ, Weill Med Coll, Ithaca, NY USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Castellon, SA (reprint author), 760 Westwood Plaza,C8-747, Los Angeles, CA 90024 USA. EM scastell@ucla.edu FU NIMH NIH HHS [R01 MH058552, R01 MH058552-05, R01MH58552, T32 MH019535, T32 MH019535-18, T32MH19535] NR 95 TC 32 Z9 34 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD APR PY 2006 VL 28 IS 3 BP 420 EP 437 DI 10.1080/13803390590935444 PG 18 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 025RP UT WOS:000236284900010 PM 16618629 ER PT J AU Fang, P Kofoed, EM Little, BM Wang, XD Ross, RJM Frank, SJ Hwa, V Rosenfeld, RG AF Fang, P Kofoed, EM Little, BM Wang, XD Ross, RJM Frank, SJ Hwa, V Rosenfeld, RG TI A mutant signal transducer and activator of transcription 5b, associated with growth hormone insensitivity and insulin-like growth factor-I deficiency, cannot function as a signal transducer or transcription factor SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PERIPHERAL T-CELLS; GENE-TRANSCRIPTION; STAT5 ACTIVATION; C-SRC; RECEPTOR; DNA; EXPRESSION; PROLACTIN; MUTATION; KINASES AB Context: A natural missense mutation in the signal transducer and activator of transcription ( STAT) 5b gene was recently identified in association with a female patient presenting with severe growth failure and immune dysfunction. The mutation results in an alanine to proline substitution at residue 630 (A630P) in the src-homology-2 domain, a region essential for docking of STATs to phospho-tyrosines on activated receptors, STAT dimerization, and stabilization of phospho-STAT-DNA interactions. Objective: The purpose of this study was to explore the molecular mechanisms underlying the GH insensitivity and IGF-I deficiency caused by the A630P-mutated STAT5b. Results: In reconstitution experiments using HEK293 cells, both GH and interferon-gamma were unable to activate mutant STAT5b ( A630P), as demonstrated by lack of immunodetectable phospho-tyrosyl-STAT5b A630P) and inability to drive luciferase reporter activity. However, the Src family of nonreceptor kinases [ constitutively active v-src and epithelial growth factor-induced c-src] tyrosine-phosphorylated STAT5b(A630P). The v-src-induced phospho-STAT5b(A630P) translocated to the nucleus but, unlike wild-type Stat5b, was unable to bind DNA. Conclusions: The A630P mutation disrupts the src-homology-2 architecture such that: 1) mutant STAT5b most likely cannot dock to phospho-tyrosines on ligand-activated receptors; and 2) stable interactions with DNA are prevented. Because STAT5b ( A630P) is an inefficient signal transducer and transcription factor, the detrimental impact on signaling pathways important for normal growth and immunity explains, in part, the complex clinical phenotype of GH insensitivity and immune dysfunction. C1 Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA. Univ Sheffield, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. Univ Alabama, Dept Physiol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. Lucile Packard Fdn Childrens Hlth, Palo Alto, CA 94304 USA. Stanford Univ, Dept Pediat, Stanford, CA 94305 USA. RP Hwa, V (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, NRC5,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM hwav@ohsu.edu RI Ross, Richard/B-2672-2012 OI Ross, Richard/0000-0001-9222-9678 FU NCI NIH HHS [CA 58110]; NIDDK NIH HHS [DK 46395] NR 33 TC 19 Z9 21 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2006 VL 91 IS 4 BP 1526 EP 1534 DI 10.1210/jc.2005-2558 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 029YW UT WOS:000236601300055 PM 16464942 ER PT J AU O'Connell, TD Swigart, PM Rodrigo, MC Ishizaka, S Joho, S Turnbull, L Tecott, LH Baker, AJ Foster, E Grossman, W Simpson, PC AF O'Connell, TD Swigart, PM Rodrigo, MC Ishizaka, S Joho, S Turnbull, L Tecott, LH Baker, AJ Foster, E Grossman, W Simpson, PC TI alpha(1)-adrenergic receptors prevent a maladaptive cardiac response to pressure overload SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID LIPID-LOWERING TREATMENT; HEART-ATTACK TRIAL; VENTRICULAR EJECTION FRACTIONS; ATRIAL-NATRIURETIC-PEPTIDE; IN-VIVO; STIMULATED HYPERTROPHY; PLASMA NOREPINEPHRINE; MESSENGER-RNAS; BLOOD-PRESSURE; KNOCKOUT MOUSE AB An alpha(1)-adrenergic receptor (alpha(1)-AR) antagonist increased heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), but it is unknown whether this adverse result was due to alpha(1)-AR inhibition or a nonspecific drug effect. We studied cardiac pressure overload in mice with double KO of the 2 main alpha(1)-AR subtypes in the heart, alpha(1A) (Adra1a) and alpha(1B) (Adra1b). At 2 weeks after transverse aortic constriction (TAC), KO mouse survival was only 60% of WT, and surviving KO mice had lower ejection fractions and larger end-diastolic volumes than WT mice. Mechanistically, final heart weight and myocyte cross-sectional area were the same after TAC in KO and WT mice. However, KO hearts after TAC had increased interstitial fibrosis, increased apoptosis, and failed induction of the fetal hypertrophic genes. Before TAC, isolated KO myocytes were more susceptible to apoptosis after oxidative and beta-AR stimulation, and beta-ARs were desensitized. Thus, alpha(1)-AR deletion worsens dilated cardiomyopathy after pressure overload, by multiple mechanisms, indicating that alpha(1)-signaling is required for cardiac adaptation. These results suggest that the adverse cardiac effects of alpha(1)-antagonists in clinical trials are due to loss of alpha(1)-signaling in myocytes, emphasizing concern about clinical use of alpha(1)-antagonists, and point to a revised perspective on sympathetic activation in heart failure. C1 San Francisco Vet Affairs Med Ctr, Div Cardiol, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Simpson, PC (reprint author), San Francisco Vet Affairs Med Ctr, Div Cardiol, San Francisco, CA USA. EM paul.simpson@ucsf.edu RI Turnbull, Lynne/A-2605-2012; O'Connell, Timothy/D-5048-2013 OI Turnbull, Lynne/0000-0002-9255-9033; FU NHLBI NIH HHS [R01 HL031113, T32 HL007731, T32HL07731] NR 86 TC 84 Z9 87 U1 0 U2 2 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2006 VL 116 IS 4 BP 1005 EP 1015 DI 10.1172/JCI22811 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 029IP UT WOS:000236556100022 PM 16585965 ER PT J AU Fung, CH Tsai, J Lulejian, A Patterson, E Asch, S AF Fung, C. H. Tsai, J. Lulejian, A. Patterson, E. Asch, S. TI A national survey of clinical reminder use and barriers to clinical reminder use in an integrated healthcare system SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, David Geffen Sch Med, RAND VA Greater Los Angeles Healthcare Syst, Santa Monica, CA USA. VA Greater Los Angeles Syst, Los Angeles, CA USA. Columbia Univ, New York, NY USA. Ohio State Univ, Columbus, OH 43210 USA. Vet Adm Greater W Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 3 EP 3 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000008 ER PT J AU Hess, R McTigue, K Bryce, CL Fitzgerald, K Zickmund, S Sacco, D Olshansky, E Fischer, GS AF Hess, R. McTigue, K. Bryce, C. L. Fitzgerald, K. Zickmund, S. Sacco, D. Olshansky, E. Fischer, G. S. TI A pamphlet's just a pamphlet SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 4 EP 4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000012 ER PT J AU Hsiao, A Wong, M Goldstein, MS Becerra, L Wenger, NS Cheng, E AF Hsiao, A. Wong, M. Goldstein, M. S. Becerra, L. Wenger, N. S. Cheng, E. TI Acculturation and access to conventional care are not related to complementary and alternative medicine use among Asian American subgroups SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Irvine, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Greater Los Angeles Vet Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 8 EP 8 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000025 ER PT J AU Rodriguez, KL Barnato, AE Gambino, FJ Arnold, RM AF Rodriguez, K. L. Barnato, A. E. Gambino, F. J. Arnold, R. M. TI Acute care hospital provider utilization and perceptions of palliative care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 8 EP 8 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000026 ER PT J AU Barrett, TW Mori, M De Boer, D AF Barrett, T. W. Mori, M. De Boer, D. TI Association of perioperative statins and beta-blockers with long term mortality after vascular surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 18 EP 18 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000063 ER PT J AU Aujesky, D Stone, RA Sartorius, J Obrosky, DS Fine, MJ Ibrahim, SA AF Aujesky, D. Stone, R. A. Sartorius, J. Obrosky, D. S. Fine, M. J. Ibrahim, S. A. TI Black patients with pulmonary embolism have a higher 30-day mortality than white patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Lausanne, Lausanne, Switzerland. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 22 EP 22 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000077 ER PT J AU Singh, H Thomas, EJ Petersen, LA AF Singh, H. Thomas, E. J. Petersen, L. A. TI Can computerized screening detect diagnostic errors in primary care? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Texas Hlth Sci Ctr, Houston, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 23 EP 24 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000083 ER PT J AU Houston, TK Heudebert, GR Kiefe, CI Willett, LL Palonen, KP Allison, JJ AF Houston, T. K. Heudebert, G. R. Kiefe, C. I. Willett, L. L. Palonen, K. P. Allison, J. J. TI Can residents audit their own performance accurately? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 24 EP 24 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000085 ER PT J AU Spencer, AL Bost, JE McNeil, MA AF Spencer, A. L. Bost, J. E. McNeil, M. A. TI Do women's health residency tracks make a difference?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, VA Pittsburgh Hlthcare Syst, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 38 EP 39 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000138 ER PT J AU Bean-Mayberry, B Brucker, NJ Bayliss, N Xu, X Crick, E Mor, M Yano, E Fine, MJ AF Bean-Mayberry, B. Brucker, N. J. Bayliss, N. Xu, X. Crick, E. Mor, M. Yano, E. Fine, M. J. TI Effect of gender and race on receipt of pneumococcal and influenza immunizations in VA SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 44 EP 44 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000158 ER PT J AU Frank, D Debenedetti, A Volk, RJ Williams, E Kivlahan, DR Bradley, K AF Frank, D. Debenedetti, A. Volk, R. J. Williams, E. Kivlahan, D. R. Bradley, K. TI Effectiveness of AUDIT-C as a screening test for alcohol misuse in three racial/ethnic groups SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 45 EP 46 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000162 ER PT J AU Mohanty, SA Diamant, AL Gelberg, L Anglin, D Perez, LR Asch, SM AF Mohanty, S. A. Diamant, A. L. Gelberg, L. Anglin, D. Perez, L. R. Asch, S. M. TI Effectiveness of community health workers in facilitating insurance enrollment among patients in a public sector emergency department. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ So Calif, Keck Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 46 EP 46 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000164 ER PT J AU Dowell, D Schwartz, MD Blustein, J Dubovsky, A Gourevitch, MN AF Dowell, D. Schwartz, M. D. Blustein, J. Dubovsky, A. Gourevitch, M. N. TI Effects of medication cost-sharing on LDL cholesterol in elderly patients with diabetes or vascular disease attending an urban clinic from 1999-2004 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 NYU, New York, NY USA. US Dept Vet Affairs, New York, NY USA. NYU, Wagner Grad Sch, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 47 EP 48 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000169 ER PT J AU Volpp, KG Konetzka, RT Sochalski, J Zhu, J AF Volpp, K. G. Konetzka, R. T. Sochalski, J. Zhu, J. TI Effects of hospital price competition on quality of care for 4 high-mortality conditions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Chicago, Chicago, IL 60637 USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 47 EP 47 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000166 ER PT J AU Kaboli, PJ Barrett, TW Vazirani, S Osterberg, L Auerbach, AD AF Kaboli, P. J. Barrett, T. W. Vazirani, S. Osterberg, L. Auerbach, A. D. TI Growth of hospitalists in the Veterans Administration (VA) health-care system: 1997-2005. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Iowa City VAMC, Iowa City, IA USA. Univ Iowa, Iowa City, IA USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Greater Los Angeles VAMC, Los Angeles, CA USA. Stanford Univ, Palo Alto VA Med Ctr, Palo Alto, CA 94304 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 62 EP 62 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000219 ER PT J AU Nicolaidis, C Gregg, J Galian, H McFarland, B Curry, M Gerrity, M AF Nicolaidis, C. Gregg, J. Galian, H. McFarland, B. Curry, M. Gerrity, M. TI Health care beliefs and needs of depressed women with a history of intimate partner violence. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 62 EP 62 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000220 ER PT J AU Polsky, D Lave, JR Jha, A Pauly, MV Chen, Z Cen, L Klusaritz, H Volpp, K AF Polsky, D. Lave, J. R. Jha, A. Pauly, M. V. Chen, Z. Cen, L. Klusaritz, H. Volpp, K. TI Is lower hospital mortality among blacks unique to the veterans administration? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VAMC, CHERP, Philadelphia, PA USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. Harvard Univ, Boston, MA 02115 USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. VA Med Ctr, CHERP, Philadelphia, PA USA. Univ Penn, VAMC, CHERP, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 77 EP 77 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000273 ER PT J AU Petersen, LA Woodard, L Urech, T Daw, C Sookanan, S AF Petersen, L. A. Woodard, L. Urech, T. Daw, C. Sookanan, S. TI Is pay for performance effective in improving the quality of health care? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 78 EP 78 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000275 ER PT J AU Eisenman, D Cordasco, K Asch, SM Golden, J Glik, D AF Eisenman, D. Cordasco, K. Asch, S. M. Golden, J. Glik, D. TI Leveraging social networks for protecting vulnerable communities' health during disasters SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. W Los Angeles VA, RAND, Los Angeles, CA USA. W Los Angeles VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 80 EP 80 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000284 ER PT J AU Simpson, SA Nacke, EP Long, JA AF Simpson, S. A. Nacke, E. P. Long, J. A. TI Medical education at a student-run health clinic SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 85 EP 85 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000300 ER PT J AU Simpson, SA Long, JA AF Simpson, S. A. Long, J. A. TI Medical student-run health clinics - A growing trend in community activism and medical education SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 85 EP 86 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000301 ER PT J AU Steinman, MA Landefeld, CS Rosenthal, GE Bertenthal, D Sen, S Kaboli, P AF Steinman, M. A. Landefeld, C. S. Rosenthal, G. E. Bertenthal, D. Sen, S. Kaboli, P. TI Polypharmacy and prescribing quality in elders SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Iowa, Iowa City, IA 52242 USA. Iowa City VAMC, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 103 EP 104 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000368 ER PT J AU Hsu, DJ Obrosky, D Stone, RA Crick, E Fine, MJ AF Hsu, D. J. Obrosky, D. Stone, R. A. Crick, E. Fine, M. J. TI Predictors of timely initiation of antibiotic therapy for patients hospitalized with pneumonia SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healtcare Syst, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 106 EP 106 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000379 ER PT J AU Rosenfeld, KE Lorenz, K Steckart, M Riopelle, D Wagner, G AF Rosenfeld, K. E. Lorenz, K. Steckart, M. Riopelle, D. Wagner, G. TI Relationships among patient perception of prognosis, treatment and documented and communicated care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 123 EP 123 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000440 ER PT J AU Binswanger, I Stern, MF Deyo, RA Heagerty, PJ Cheadle, A Elmore, JG Koepsell, TD AF Binswanger, I. Stern, M. F. Deyo, R. A. Heagerty, P. J. Cheadle, A. Elmore, J. G. Koepsell, T. D. TI Release from prison: A high-risk time for death? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Washington, Vet Affairs Puget Sound, Seattle, WA 98195 USA. State Washington Dept Corrections, Olympia, WA USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 124 EP 124 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000442 ER PT J AU Weissmann, PF Branch, WT Gracey, CF Haidet, PM Frankel, RM AF Weissmann, P. F. Branch, W. T. Gracey, C. F. Haidet, P. M. Frankel, R. M. TI Role modeling humanistic behavior: Learning bedside manner from the experts SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Minnesota, Minneapolis, MN 55455 USA. Emory Healthcare, Atlanta, GA USA. Univ Rochester, Rochester, NY 14627 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. Indiana Univ Purdue Univ, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 127 EP 127 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000454 ER PT J AU Higashi, T Adams, JL Wenger, NS McGlynn, E Chiang, L Asch, S Kerr, EA Reuben, DB Fung, C Shekelle, PG AF Higashi, T. Adams, J. L. Wenger, N. S. McGlynn, E. Chiang, L. Asch, S. Kerr, E. A. Reuben, D. B. Fung, C. Shekelle, P. G. TI Sicker, more complex patients get better, not worse, quality of care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Kyoto Univ, Dept Epidemiol & Healthcare Res, Kyoto, Japan. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 130 EP 131 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000466 ER PT J AU Long, JA Armstrong, K Chang, VW Chen, Z Metlay, JP AF Long, J. A. Armstrong, K. Chang, V. W. Chen, Z. Metlay, J. P. TI Social capital, race, and glucose control SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Philadelphia VA CHERP, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 131 EP 131 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000469 ER PT J AU Shacter, HE Long, JA AF Shacter, H. E. Long, J. A. TI The effect of state policy on access to emergency contraception SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA CHERP, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 141 EP 141 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000502 ER PT J AU Cordasco, KM Eisenman, D Asch, S Golden, J Glik, D AF Cordasco, K. M. Eisenman, D. Asch, S. Golden, J. Glik, D. TI "They blew the levee'': Distrust among hurricane Katrina evacuees SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Los Angeles, CA USA. Vet Adm Greater W Los Angeles Healthcare Syst, Los Angeles, CA USA. W Los Angeles VA, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 150 EP 150 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000536 ER PT J AU Wheeler, S Maynard, C Bowen, J AF Wheeler, S. Maynard, C. Bowen, J. TI Women Veterans and outcomes after acute myocardial infarction SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Dept Vet Affairs, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 165 EP 166 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000591 ER PT J AU Draganescu, M Kapo, J Egan, K Seng, L Streim, J AF Draganescu, M. Kapo, J. Egan, K. Seng, L. Streim, J. TI "Hello,doc... tell me this is not true!'' Or how to teach death notification over the phone SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 Philadelphia VAMC, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 173 EP 174 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000618 ER PT J AU Tabibian, PA Fung, C AF Tabibian, P. A. Fung, C. TI Emergence of community acquired methicillin-resistant staphyloccocus aureus (CA-MRSA) pneumonia in healthy individuals. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 234 EP 235 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000836 ER PT J AU Tabibian, PA Chahal, P AF Tabibian, P. A. Chahal, P. TI HIV/AIDS infections among the elderly: A need for implementing new screening and educational measures. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 SU 4 BP 242 EP 243 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA V43VG UT WOS:000202962000864 ER PT J AU Armstrong, K Rose, A Peters, N Long, JA McMurphy, S Shea, JA AF Armstrong, K Rose, A Peters, N Long, JA McMurphy, S Shea, JA TI Distrust of the health care system and self-reported health in the United States SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE distrust; health status ID RATED HEALTH; PATIENTS TRUST; MEDICAL-PROFESSION; AFRICAN-AMERICAN; PATIENT TRUST; PHYSICIANS; MORTALITY; SATISFACTION; SCALE; INSTITUTIONS AB Despite theoretical concerns that health care related distrust may lead to poor health outcomes by interfering with effective health care, little is currently known about the prevalence or outcomes of distrust of the health care system in the United States. To investigate the association between distrust of the health care system and self-reported health status among the general population in the United States. Random-digit-dialing telephone survey. Nine hundred and sixty-one adult residents of the continental U.S. Distrust of the health care system and self-reported health status. Distrust of the health care system is relatively high in the United States, with between 20% and 80% of respondents reporting distrust for each item on the Health Care System Distrust scale and a median scale score of 31 (potential range from 10 to 50). Distrust of the health care system is strongly associated with self-reported fair/poor health (odds ratio [OR] 1.40%, 95% confidence interval [CI] 1.12 to 1.75 for each standard deviation increase in distrust), even after adjusting for sociodemographic characteristics, access to health care and trust in primary physicians. In contrast, low trust in one's primary physician is much lower (only 10% to 20% of respondents reported distrust for each item) and is not associated with health status. Distrust of the health care system is relatively high in the general population in the United States and is strongly associated with worse self-reported health. Further studies are needed to assess the direction of this association and the mechanisms involved. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Armstrong, K (reprint author), 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM karmstro@mail.med.upenn.edu FU PHS HHS [R01 2689-01] NR 46 TC 54 Z9 54 U1 4 U2 13 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 IS 4 BP 292 EP 297 DI 10.1111/j.1525-1497.2006.00396.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 036ZT UT WOS:000237117200002 PM 16686803 ER PT J AU Shrank, WH Fox, SA Kirk, A Ettner, SL Cantrell, CH Glassman, P Asch, SM AF Shrank, WH Fox, SA Kirk, A Ettner, SL Cantrell, CH Glassman, P Asch, SM TI The effect of pharmacy benefit design on patient-physician communication about costs SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE pharmacy benefit design; prescription drugs; doctor patient communication; incentive-based ID CARE; INCENTIVES; DRUGS AB Incentive-based formularies have been widely instituted to control the rising costs of prescription drugs. To work properly, such formularies depend on patients to be aware of financial incentives and communicate their cost preferences with prescribing physicians. The impact of financial incentives on patient awareness of and communication about those costs is unknown. To evaluate the relationship between enrollment in incentive-based pharmacy benefit plans and awareness of out-of-pocket costs and rates of communication about out-of-pocket costs. A matched telephone survey of patients and their primary care physicians. Los Angeles County. One thousand nine hundred and seventeen patients aged 53 to 82 (73% response rate). Patient-reported pharmacy benefit design, knowledge of out-of-pocket costs, and discussion of out-of-pocket costs with physicians. Sixty-two percent of patients who had prescription drug coverage and were aware of their pharmacy benefit design reported being enrolled in incentive-based plans. The majority of these (54%) were "never" or only "sometimes" aware of their out-of-pocket cost requirements at the time of the physician visit. After controlling for numerous physician and patient level variables, we found that patients enrolled in pharmacy benefit designs requiring no copayments were more likely to report they "never" discuss out-of-pocket costs with physicians compared with patients enrolled in incentive-based pharmacy benefit designs (81% vs 67%, P = .001) and patients with no prescription drug insurance (57%, P < .001). Incentive-based pharmacy benefit plans and lack of insurance are associated with increased rates of discussions about out-of-pocket costs. Nonetheless, most incentive-based enrollees are unaware of out-of-pocket costs when prescriptions are written and never discuss out-of-pocket costs with their physicians, likely mitigating the effectiveness of financial incentives to guide decision making. Considering that out-of-pocket costs are associated with adherence to medical therapy, interventions to improve patient access to out-of-pocket cost information and the frequency of patient-physician discussions about costs are needed. C1 Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Community Partnerships Hlth Promot, Los Angeles, CA USA. RP Shrank, WH (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM wshrank@partners.org FU NCI NIH HHS [R01 CA 74322] NR 23 TC 30 Z9 30 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 IS 4 BP 334 EP 339 DI 10.1111/j.1525-1497.2006.00402.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 036ZT UT WOS:000237117200009 PM 16686808 ER PT J AU Davis, KS Magruder, KM Lin, Y Powell, CK Clancy, DE AF Davis, KS Magruder, KM Lin, Y Powell, CK Clancy, DE TI Brief report: Trainee provider perceptions of group visits SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE group visits; health care delivery system; provider perceptions ID CARE; PHYSICIANS; SATISFACTION; QUALITY AB To evaluate the effect of observing group visits on trainees' perceptions of group visits as a method of health care delivery. Thirty-two trainees assigned to month-long rotations at an academic Internal Medicine Primary Care Clinic serving underinsured patients were recruited to observe between 1 and 4 group visits. Prior to observation of their first, and subsequent to observation of their last group visit, each trainee completed the Patient-Physician Orientation Scale (PPOS), a validated survey evaluating their tendencies toward being patient-centered or provider-centered. Additionally, they completed a Group Visit Questionnaire (GVQ) evaluating their perceptions of group visits as a method of health care delivery. Trainee gender, type, and level of training were similarly represented across the study population of trainees. While there were no significant differences noted on pre- and postobservation PPOS scores, the postobservation GVQs scores were significantly improved after observing at least one group visit (P < .0001). Trainees' perceptions of group visits as a method of health care delivery improved significantly after observation of at least 1 group as measured by the GVQ. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Hlth Care Res, Charleston, SC USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Davis, KS (reprint author), McClennan Banks Ambulat Care Ctr, Adult Primary Care Ctr Adm Serv, 326 Calhoun St,POB 250104, Charleston, SC 29425 USA. EM davisks@musc.edu FU AHRQ HHS [5 P01 HS10871, P01 HS010871] NR 8 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2006 VL 21 IS 4 BP 357 EP 359 DI 10.1111/j.1525-1497.2006.00350.x PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 036ZT UT WOS:000237117200013 PM 16686812 ER PT J AU Paintlia, AS Paintlia, MK Singh, I Singh, AK AF Paintlia, Ajaib S. Paintlia, Manjeet K. Singh, Inderjit Singh, Avtar K. TI IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappa B trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: Implication for CNS-demyelinating diseases SO JOURNAL OF IMMUNOLOGY LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; MULTIPLE-SCLEROSIS; T-CELL; GENE-EXPRESSION; EXTRACELLULAR DOMAIN; IMMUNE-DEVIATION; INTERFERON-GAMMA; ANIMAL-MODEL AB Th2 phenotype cytokine, IL-4, plays an important role in the regulation of Th1 cell responses and spontaneous remission of inflammatory CNS demyelinating diseases such as multiple sclerosis (MS). In this study we demonstrate IL-4-induced down-regulation of inducible NO synthase (iNOS) expression and survival of differentiating oligodendrocyte progenitors (OPs) in proinflammatory cytokine (Cyt-Mix)-treated CNS glial cells, which is a condition similar to that observed in the brain of a patient with MS. IL-4 treatment of Cyt-Mix-treated CNS glial cells significantly decreased iNOS expression/NO release with a parallel increase in survival of differentiating OPs. IL-4 effects were concentration-dependent and could be reversed by anti-IL-4R Abs. The use of inhibitors for Akt, p38 MAPK, and peroxisome proliferator-activated receptor gamma (PPAR-gamma) antagonist revealed that inhibition of Cyt-Mix-induced MOS expression and survival of differentiating OPs by IL-4 is via PPAR-gamma activation. There was a coordinate increase in the expression of both PPAR-gamma and its natural ligand-producing enzyme 12/15-lipoxygenase (12/15-LOX) in IL-4-treated cells. Next, EMSA, immunoblots, and transient cotransfection studies with reporter plasmids (pNF-kappa B-Luc and pTK-PPREx3-Luc) and 12/15-LOX small interfering RNA revealed that IL-4-induced PPAR-gamma activation antagonizes NF-kappa B transactivation in Cyt-Mix-treated astrocytes. In support of this finding, similarly treated 12/15-LOX-/- CNS glial cells further corroborated the result. Furthermore, there was reversal of IL-4 inductive effects in the brain of LPS-challenged 12/15-LOX-/mice when compared with LPS-challenged wild-type mice. Together, these data for the first time demonstrate the inhibition of Cyt-Mix-induced NF-kappa B transactivation in CNS glial cells by IL-4 via PPAR-gamma activation, hence its implication for the protection of differentiating OPs during MS and other CNS demyelinating diseases. C1 Med Univ S Carolina, Childrens Res Inst, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Childrens Res Inst, Dept Pediat, 504-D,173 Ashley Ave, Charleston, SC 29425 USA. EM singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NCRR NIH HHS [C06-RR015455, C06-RR018823]; NIA NIH HHS [AG-025307]; NINDS NIH HHS [NS-22576, NS-37766, NS-34741, NS-40810] NR 61 TC 41 Z9 42 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 IS 7 BP 4385 EP 4398 PG 14 WC Immunology SC Immunology GA 059YY UT WOS:000238769300066 PM 16547277 ER PT J AU Hsu, HC Yang, P Wu, Q Wu, YL Chen, J Accavitti-Loper, MAV Mountz, JD AF Hsu, Hui-Chen Yang, PingAr Wu, Qi Wu, Yalei Chen, Jian Accavitti-Loper, Mary Ann V. Mountz, John D. TI Over-expression of activation-induced cytidine deaminase in BXD2 B cells requires stimulation by BXD2 CD4 T cells SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S153 EP S153 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837101203 ER PT J AU Konopa, JL Lathers, DMR Young, MRI AF Konopa, Jennifer Lynn Lathers, Deanne M. R. Young, M. Rita I. TI Tumor secreted factors induce normal endothelial cells to inhibit immune cell function SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Med Univ S Carolina, Charleston, SC 29403 USA. Ralph Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. MUSC, STB 502, Dept Med, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S276 EP S276 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837102278 ER PT J AU Macklin, MD Zuleger, CL Breunig, A Newton, MA Albertini, MR AF Macklin, Michael D. Zuleger, Cindy L. Breunig, Adam Newton, Michael A. Albertini, Mark R. TI Analysis of T-cell receptor genes in wild-type and 6-thioguanine-resistant T-cells from melanoma patients SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53792 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S271 EP S271 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837102256 ER PT J AU Nath, N Prasad, R Giri, S Singh, AK Singh, I AF Nath, Narender Prasad, Ratna Giri, Shailendra Singh, Avtar K. Singh, Inderjit TI T-bet is essential for the progression of experimental autoimmune encephalomyelitis SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S250 EP S250 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837102156 ER PT J AU Prasad, R Giri, S Nath, N Singh, I Singh, AK AF Prasad, Rama Giri, Shailendra Nath, Narender Singh, Inderjit Singh, Avtar K. TI GSNO attenuates EAE disease by S-nitrosylation mediated modulation of endothelial-monocyte interactions SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S2 EP S2 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837100009 ER PT J AU Wang, J Mountz, JD Chen, J Wu, Q Yang, PA Hsu, HC AF Wang, John Mountz, John D. Chen, Jian Wu, Qi Yang, PingAr Hsu, Hui-Chen TI Autoantigen responsible for augmenting activated IL-17 producing T-cell in BXD2 autoinamune mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S160 EP S161 PG 2 WC Immunology SC Immunology GA 060YD UT WOS:000238837101237 ER PT J AU You, YY Carter, RH AF You, Yuying Carter, Robert H. TI The role of CD19 in the development of the marginal zone SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists CY MAY 12-16, 2006 CL Boston, MA SP Amer Assoc Immunologists C1 Univ Alabama, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35233 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 2006 VL 176 SU S BP S162 EP S162 PG 1 WC Immunology SC Immunology GA 060YD UT WOS:000238837101245 ER PT J AU David, WS Simpson, TL Cotton, AJ AF David, WS Simpson, TL Cotton, AJ TI Taking charge - A pilot curriculum of self-defense and personal safety training for female veterans with PTSD because of military sexual trauma SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE posttraumatic stress disorder; women veterans; personal safety; self-defense ID WOMEN; EFFICACY; AGGRESSION; ASSAULT; STRESS AB The authors describe an overview of the pilot project Taking Charge, a 36-hour comprehensive behavioral intervention involving psychoeducation, personal safety, and self-defense training for 12 female veterans with posttraumatic stress disorder (PTSD) from military sexual trauma. Self-defense training can incorporate the benefits of repeated exposure while teaching proactive cognitive and behavioral responses to the feared stimuli, and thus facilitate emotional and physical rescripting of and mastery over the trauma. Results up to 6 months follow-up indicate significant reductions in behavioral avoidance, PTSD hyperarousal, and depression, with significant increases in interpersonal, activity, and self-defense self-efficacy. The authors propose that this therapeutic self-defense curriculum provides an enhanced exposure therapy paradigm that may be a potent therapeutic tool in the treatment of PTSD. C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP David, WS (reprint author), VA Puget Sound Hlth Care Syst, 116-MHC,1660 S Columbian Way, Seattle, WA 98108 USA. EM wendy.david@med.va.gov NR 20 TC 16 Z9 16 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD APR PY 2006 VL 21 IS 4 BP 555 EP 565 DI 10.1177/0886260505285723 PG 11 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 023EL UT WOS:000236108400007 PM 16501219 ER PT J AU Meeran, SM Mantena, SK Elmets, CA Katiyar, SK AF Meeran, S. M. Mantena, S. K. Elmets, C. A. Katiyar, S. K. TI Interleukin-12-deficient mice are at greater risk for the development of UV radiation-induced skin cancers SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 91 BP 16 EP 16 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500092 ER PT J AU Cha, X Naylor, T Bansal, A Lu, H Seykora, J Weber, B Fakharzadeh, S AF Cha, X. Naylor, T. Bansal, A. Lu, H. Seykora, J. Weber, B. Fakharzadeh, S. TI Identification of putative basal cell carcinoma genes by array-based comparative genomic hybridization SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 112 BP 19 EP 19 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500114 ER PT J AU Chamlin, S Cella, D Lai, J Williams, M Frieden, I Mancini, A Chren, M AF Chamlin, S. Cella, D. Lai, J. Williams, M. Frieden, I. Mancini, A. Chren, M. TI Childhood Atopic Dermatitis Index (CADIS): reliability, discriminative and concurrent validity, and responsiveness SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Childrens Mem Hosp, Div Pediat Dermatol, Chicago, IL USA. Evanston NW Healthcare, Ctr Outcomes Res & Educ, Evanston, IL USA. Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 287 BP 48 EP 48 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500285 ER PT J AU Chren, M Sahay, A Bertenthal, D Sen, S AF Chren, M. Sahay, A. Bertenthal, D. Sen, S. TI Patient-reported outcomes of nonmelanoma skin cancer treated in different practice settings SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VAMC, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 329 BP 55 EP 55 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500327 ER PT J AU Li, W Fedesco, M Fan, J Cheng, J Bandyopadhay, B Li, Y Feilds, J Han, Y Chen, M Woodley, D AF Li, W. Fedesco, M. Fan, J. Cheng, J. Bandyopadhay, B. Li, Y. Feilds, J. Han, Y. Chen, M. Woodley, D. TI Heat shock protein-90: an abundant extracellular molecule in epidermis and a potent stimulus of keratinocyte re-epithelialization SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Univ So Calif, Los Angeles, CA USA. Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 524 BP 88 EP 88 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500525 ER PT J AU Katiyar, SK Mantena, SK Meeran, SM Elmets, CA AF Katiyar, S. K. Mantena, S. K. Meeran, S. M. Elmets, C. A. TI (-)-Epigallocatechin-3-gallate from green tea prevents photocarcinogenesis in mice through augmentation of repair of UV-damaged DNA via interleukin-12-dependent mechanisms SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 03-06, 2006 CL Philadelphia, PA SP Soc Investigat Dermatol C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2006 VL 126 SU 1 MA 788 BP 132 EP 132 PG 1 WC Dermatology SC Dermatology GA 117RU UT WOS:000242891500785 ER PT J AU Beigneux, AP Vergnes, L Qiao, X Quatela, S Davis, R Watkins, SM Coleman, RA Walzem, RL Philips, M Reue, K Young, SG AF Beigneux, AP Vergnes, L Qiao, X Quatela, S Davis, R Watkins, SM Coleman, RA Walzem, RL Philips, M Reue, K Young, SG TI Agpat6 - a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium SO JOURNAL OF LIPID RESEARCH LA English DT Article DE acyltransferase; transacylase; milk fat ID LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; INSERTIONAL MUTATIONS; ENDOPLASMIC-RETICULUM; GLYCEROL 3-PHOSPHATE; BARTH SYNDROME; CLONING; MOUSE; CELLS; LIVER AB In analyzing the sequence tags for mutant mouse embryonic stem (ES) cell lines in BayGenomics (a mouse gene-trapping resource), we identified a novel gene, 1-acylglycerol-3-phosphate O-acyltransferase (Agpat6), with sequence similarities to previously characterized glycerolipid acyltransferases. Agpat6's closest family member is another novel gene that we have provisionally designated Agpat8. Both Agpat6 and Agpat8 are conserved from plants, nematodes, and flies to mammals. AGPAT6, which is predicted to contain multiple membrane-spanning helices, is found exclusively within the endoplasmic reticulum (ER) in mammalian cells. To gain insights into the in vivo importance of Agpat6, we used the Agpat6 ES cell line from BayGenomics to create Agpat6-deficient ( gpat6(-/-)) mice. Agpat6(-/-) mice lacked full-length Agpat6 transcripts, as judged by northern blots. One of the most striking phenotypes of Agpat6(-/-) mice was a defect in lactation. Pups nursed by Agpat6(-/-) mothers die perinatally. Normally, Agpat6 is expressed at high levels in the mammary epithelium of breast tissue, but not in the surrounding adipose tissue. Histological studies revealed that the aveoli and ducts of Agpat6(-/-) lactating mammary glands were underdeveloped, and there was a dramatic decrease in the size and number of lipid droplets within mammary epithelial cells and ducts. Also, the milk from Agpat6(-/-) mice was markedly depleted in diacylglycerols and triacylglycerols. Thus, we identified a novel glycerolipid acyltransferase of the ER, AGPAT6, which is crucial for the production of milk fat by the mammary gland. - Beigneux, A. P., L. Vergnes, X. Qiao, S. Quatela, R. Davis, S. M. Watkins, R. A. Coleman, R. L. Walzem, M. Philips, K. Reue, and S. G. Young. Agpat6 - a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Human Genet, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. NYU, Sch Med, Dept Med Cell Biol & Pharmacol, New York, NY 10016 USA. Lipom Technol, W Sacramento, CA 95691 USA. Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. RP Beigneux, AP (reprint author), Univ Calif Los Angeles, Div Cardiol, Dept Internal Med, Los Angeles, CA 90095 USA. EM abeigneux@mednet.ucla.edu FU NHLBI NIH HHS [R01 HL094732, U01 HL066621, UO1 HL-66621] NR 33 TC 67 Z9 70 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD APR PY 2006 VL 47 IS 4 BP 734 EP 744 DI 10.1194/jlr.M50056-JLR200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 024VF UT WOS:000236223700006 PM 16449762 ER PT J AU Vergnes, L Beigneux, AP Davis, R Watkins, SM Young, SG Reue, K AF Vergnes, L Beigneux, AP Davis, R Watkins, SM Young, SG Reue, K TI Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity SO JOURNAL OF LIPID RESEARCH LA English DT Article DE acyltransferase; gene-trap; adipose tissue.; energy expenditure; 1-acylglycerol-3-phosphate; O-acyltransferase ID LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE; CONGENITAL GENERALIZED LIPODYSTROPHY; TRIGLYCERIDE SYNTHESIS; MICE; GENE; CLONING; MOUSE; EXPRESSION; LIPIN; ABNORMALITIES AB Triglyceride synthesis in most mammalian tissues involves the sequential addition of fatty acids to a glycerol backbone, with unique enzymes required to catalyze each acylation step. Acylation at the sn-2 position requires 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) activity. To date, seven Agpat genes have been identified based on activity and/or sequence similarity, but their physiological functions have not been well established. We have generated a mouse model deficient in AGPAT6, which is normally expressed at high levels in brown adipose tissue ( BAT), white adipose tissue (WAT), and liver. Agpat6-deficient mice exhibit a 25% reduction in body weight and resistance to both diet-induced and genetically induced obesity. The reduced body weight is associated with increased energy expenditure, reduced triglyceride accumulation in BAT and WAT, reduced white adipocyte size, and lack of adipose tissue in the subdermal region. In addition, the fatty acid composition of triacylglycerol, diacylglycerol, and phospholipid is altered, with proportionally greater polyunsaturated fatty acids at the expense of monounsaturated fatty acids. Thus, Agpat6 plays a unique role in determining triglyceride content and composition in adipose tissue and liver that cannot be compensated by other members of the Agpat family. - Vergnes, L., A. P. Beigneux, R. Davis, S. M. Watkins, S. G. Young, and K. Reue. Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Cardiol, Dept Internal Med, Los Angeles, CA 90095 USA. Lipom Technol, W Sacramento, CA 95691 USA. RP Reue, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM reuek@ucla.edu FU NHLBI NIH HHS [U01 HL066621, R01 HL094732-01S1, R01 HL094732-02, R01 HL094732-03, R01 HL094732-01, U01 HL-66621, R01 HL094732] NR 29 TC 68 Z9 71 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD APR PY 2006 VL 47 IS 4 BP 745 EP 754 DI 10.1194/jlr.M500553-JLR200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 024VF UT WOS:000236223700007 PM 16436371 ER PT J AU Starr, PA Turner, RS Rau, G Lindsey, N Heath, S Volz, M Ostrem, JL Marks, WJ AF Starr, PA Turner, RS Rau, G Lindsey, N Heath, S Volz, M Ostrem, JL Marks, WJ TI Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes SO JOURNAL OF NEUROSURGERY LA English DT Article DE deep brain stimulation; dystonia; globus pallidus internus; microelectrode recording ID PRIMARY GENERALIZED DYSTONIA; PARKINSONS-DISEASE; CERVICAL DYSTONIA; BASAL GANGLIA; ELECTRICAL-STIMULATION; INTRATHECAL BACLOFEN; SUBTHALAMIC NUCLEUS; SECONDARY DYSTONIA; TECHNICAL APPROACH; NEURONAL-ACTIVITY AB Object. Deep brain stimulation (DBS) of the globus pallidus internus (GPI) is a promising new procedure for the treatment of dystonia. The authors describe their technical approach for placing electrodes into the GPI in awake patients with dystonia, including methodology for electrophysiological mapping of the GPI in the dystonic state, clinical outcomes and complications, and the location of electrodes associated with optimal benefit. Methods. Twenty-three adult and pediatric patients with various forms of dystonia were included in this study. Baseline neurological status and DBS-related improvement in motor function were measured using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). The implantation of DBS leads was performed using magnetic resonance (MR) imaging-based stereotaxy, single-cell microelectrode recording, and intraoperative test stimulation to determine thresholds for stimulation-induced adverse effects. Electrode locations were measured on computationally reformatted postoperative MR images according to a prospective protocol. Conclusions. Physiologically guided implantation of DBS electrodes in patients with dystonia was technically feasible in the awake state in most patients, and the morbidity rate was low. Spontaneous discharge rates of GPI neurons in dystonia were similar to those of globus pallidus extemus neurons, such that the two nuclei must be distinguished by neuronal discharge patterns rather than rates. Active electrode locations associated with robust improvement (> 70% decrease in BFMDRS score) were located near the intercommissural plane, at a mean distance from the pallidocapsular border of 3.6 mm. C1 Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, PADRECC, San Francisco, CA USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurosurg, 505 Parnassus,779 Moffitt, San Francisco, CA 94143 USA. EM starrp@itsa.ucsf.edu FU NINDS NIH HHS [R01 NS039146, R01 NS039146-01] NR 53 TC 105 Z9 108 U1 0 U2 2 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD APR PY 2006 VL 104 IS 4 BP 488 EP 501 DI 10.3171/jns.2006.104.4.488 PG 14 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 029VM UT WOS:000236592500007 PM 16619651 ER PT J AU Datto, CJ Thompson, R Knott, K Katz, IR AF Datto, CJ Thompson, R Knott, K Katz, IR TI Older adult report of change in depressive symptoms as a treatment decision tool SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE primary care; older adult; depression; treatment decision-making ID MEMORY-CONCENTRATION TEST; MENTAL-HEALTH-SERVICES; PRIMARY-CARE PATIENTS; RANDOMIZED-TRIAL; PERSPECTIVE; DISORDERS; DISEASE; SAMPLE; STATE AB OBJECTIVES: To evaluate patient reports of changes in depressive symptoms as information that can be used in treatment decision-making. DESIGN: Longitudinal cohort study. SETTING: The Prevention of Suicide in Primary Care Elderly: Collaborative Trial and the Primary Care Research in Substance Abuse and Mental Health for the Elderly trial, multisite studies investigating the effect of depression interventions on outcomes in primary care. PARTICIPANTS: Fifty-six patients aged 60 and older. MEASUREMENTS: Patient demographics were collected from patient reports. Symptoms of depression were measured using the Centers for Epidemiologic Studies Depression Scale (CES-D) and Hamilton Depression Scale (HAM-D). Changes in depressive symptoms were also measured using the Clinical Global Impressions of Change (CGI-C) as rated by patients in ongoing treatment. RESULTS: Patient ratings of CGI-C were significantly correlated with percentage improvement on the HAM-D as rated by the depression care manager (correlation coefficient (r)=0.44, P <.001) and percentage improvement on the CES-D (r=0.38, P=.005). The patient report of at least "much improved" predicted at least 50% treatment response based on HAM-D scale scores, with a sensitivity of 87.5% and a specificity of 74.2%. CONCLUSION: These findings suggest that patients are able to accurately report their degree of improvement in depressive symptoms. Patient report of at least "much improved" can be used as an estimate of at least 50% depression treatment response. In an era of increasingly fragmented clinical care, these findings demonstrate that older adult primary care patients can accurately self-report overall change in depressive symptoms. When results of repeated depression instruments are not available, patient report of depression treatment response can be used to inform depression treatment decision-making. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. JPA, Res & Training Inst, Chicago, IL USA. RP Datto, CJ (reprint author), 3535 Market St,Room 3055, Philadelphia, PA 19104 USA. EM cdatto@mail.med.upenn.edu RI Thompson, Richard/G-5408-2011 OI Thompson, Richard/0000-0003-0127-513X FU CMHS SAMHSA HHS [1UD1SM53033]; NIMH NIH HHS [5P30MH52129, P30-MH066270] NR 19 TC 7 Z9 7 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 BP 627 EP 631 DI 10.1111/j.1532-5415.2006.00660.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 029SQ UT WOS:000236585100009 PM 16686873 ER PT J AU Williams, BA Lindquist, K Sudore, RL Strupp, HM Willmott, DJ Walter, LC AF Williams, BA Lindquist, K Sudore, RL Strupp, HM Willmott, DJ Walter, LC TI Being old and doing time: Functional impairment and adverse experiences of geriatric female prisoners SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE prisoners; geriatrics; activities of daily living; women ID HEALTH LITERACY; INMATES; RISK; CARE; PERFORMANCE; LIMITATIONS; PREVALENCE; DISABILITY; MORTALITY; DISEASE AB The number of older prisoners is increasing exponentially. For example, the number of geriatric female prisoners in California has increased 350% in the past decade. Despite an increasing population of geriatric female prisoners, the degree of functional impairment in this population is unknown. Therefore, the goals of this study were to describe the prevalence and nature of functional impairment in geriatric female prisoners in California and to identify aspects of the prison environment that may exacerbate functional impairments. Questionnaires were analyzed from 120 geriatric women in California state prisons. Functional impairment was defined as impairment in activities of daily living (ADLs) or in prison ADLs (PADLs), including dropping to the floor for alarms, standing for count, getting to meals, hearing orders, and climbing onto the top bunk. The mean age of participants was 62; 16% were dependent in one ADL, and 69% reported one PADL impairment. Increasing severity of functional impairment was associated with worse health status and more adverse prison experiences. For example, fall rates ranged from 33% in women without impairment to 57% with PADL impairment to 63% with ADL dependence (P=.02). Several prison environmental stressors were identified that likely exacerbate functional impairment. For example, 29% of geriatric women were assigned to a top bunk. Geriatric female prisoners report high rates of functional impairment. ADL and PADL impairment were associated with worse health status and adverse prison experiences. Therefore, the evaluation of functional impairment in geriatric female prisoners needs to consider the unique demands of the prison environment. C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Legal Serv Prisoners Childrens, San Francisco, CA USA. RP Williams, BA (reprint author), 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM brie.williams@ucsf.edu FU NIA NIH HHS [T32-AG00212] NR 27 TC 25 Z9 25 U1 2 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 BP 702 EP 707 DI 10.1111/j.1532-5415.2006.00662.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 029SQ UT WOS:000236585100022 PM 16686886 ER PT J AU Berlowitz, D Hickey, E Czarnowski, E Saliba, D AF Berlowitz, D Hickey, E Czarnowski, E Saliba, D TI Can administrative data identify active diagnoses for the minimum data set? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Bedford VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, VA USA. Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA 02215 USA. VA Greater Los Angeles Hlth Care Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S91 EP S91 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300264 ER PT J AU Ganz, DA Wenger, NS Roth, CP Kamberg, CJ Chang, JT MacLean, CH Young, RT Solomon, DH Higashi, T Min, L Reuben, DB Shekelle, PG AF Ganz, DA Wenger, NS Roth, CP Kamberg, CJ Chang, JT MacLean, CH Young, RT Solomon, DH Higashi, T Min, L Reuben, DB Shekelle, PG TI The effect of the ACOVE-2 quality improvement initiative on the quality of other aspects of health care: The law of unintended consequences? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RAND Hlth, Santa Monica, CA USA. Kyoto Univ, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S42 EP S42 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300119 ER PT J AU O'Neill, SM Lorenz, KA Ettner, SL AF O'Neill, SM Lorenz, KA Ettner, SL TI Are rural hospices financially disadvantaged? Evidence from California. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S181 EP S181 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300529 ER PT J AU Raducha-Grace, L Kwoh, C AF Raducha-Grace, L Kwoh, C TI The knee pain map: Pain localization in knee osteoarthritis. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S103 EP S103 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300299 ER PT J AU Ruzicka, SA Sanchez-Reilly, SE AF Ruzicka, SA Sanchez-Reilly, SE TI Exploring the role of the spiritual dimension in chronic pain assessment among older adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Univ Texas, Hlth Sci Ctr, Dept Geriatr Med, Sch Nursing,Med Sch, San Antonio, TX USA. S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S32 EP S32 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300090 ER PT J AU Shaw, A Boal, J Penrod, J Hochman, T Ornstein, K DeCherrie, L AF Shaw, A Boal, J Penrod, J Hochman, T Ornstein, K DeCherrie, L TI Risk factors for hospitalization in the first year of enrollment in a home-based primary care program. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Mt Sinai Sch Med, Sch Med, New York, NY USA. Mt Sinai Sch Med, Brookdale Dept Geriatr, New York, NY USA. Mt Sinai Sch Med, Dept Med, New York, NY USA. Bronx Vet Adm Med Ctr, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S186 EP S186 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300543 ER PT J AU Sims, RV Ahmed, A Baker-Sawyer, P Allman, RM AF Sims, RV Ahmed, A Baker-Sawyer, P Allman, RM TI Diabetes predicts driving cessation in community dwelling older drivers: A propensity score analysis. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Birmingham VAMC, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S84 EP S84 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300244 ER PT J AU Stone, C Sanchez-Reilly, SE Gore, T AF Stone, C Sanchez-Reilly, SE Gore, T TI Cognitive assessment at the end of life: Is it being done? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S32 EP S32 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300091 ER PT J AU Wielert, CA Jaffe, EJ AF Wielert, CA Jaffe, EJ TI Integration of chaplain residents into a palliative care interdisciplinary team. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 03-07, 2006 CL Chicago, IL SP Amer Geriatr Soc C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2006 VL 54 IS 4 SU S BP S98 EP S98 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 036KF UT WOS:000237069300284 ER PT J AU Freedland, SJ Kane, CJ Amling, CL Aronson, WJ Presti, JC Terris, MK AF Freedland, SJ Kane, CJ Amling, CL Aronson, WJ Presti, JC Terris, MK CA SEARCH Database Study Grp TI Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; prostatectomy; biopsy; prostate-specific antigen ID RADIATION-THERAPY; SEARCH DATABASE; RECURRENCE; PSA; PREDICTOR; MORTALITY; ANTIGEN; BIOPSY; IMPACT AB Purpose: Men newly diagnosed with prostate cancer are faced with multiple treatment options. Understanding these options and their associated side effects, and making a decision often requires time, resulting in a delay before receiving treatment. This is particularly pertinent in men with low risk disease who may be considered candidates for watchful waiting and, thus, may not experience strong pressure to undergo treatment promptly. Whether delays and especially prolonged delays, eg greater than 180 days, before RP negatively impact the disease outcome is unclear. Materials and Methods: We examined the association between time from diagnosis to surgery, and pathological features of the RP specimen and risk of biochemical progression in 895 men with low risk prostate cancer (prostate specific antigen less than 10 ng/ml and biopsy Gleason sum 6 or less) treated with RP between 1988 and 2004 in the Shared-Equal Access Regional Cancer Hospital Database using logistic regression and Cox proportional hazards, respectively. Results: Time from biopsy to surgery was not significantly related to high grade disease in the RP specimen, positive surgical margins or extraprostatic extension (all p-trend > 0.05). After adjustment for multiple clinical covariates a longer time from biopsy to surgery was significantly associated with an increased risk of biochemical progression (p-trend = 0.002). However, this increased risk of progression was only apparent in men with delays greater than 180 days (median 263, vs 90 or fewer days RR 2.73, 95% CI 1.51 to 4.94). Conclusions: Our data suggest that patients with low risk prostate cancer can be reassured that immediate treatment is not necessary. Whether long delays (greater than 180 days) decrease the likelihood of curability in some patients requires further study. C1 Duke Univ, Med Ctr, Dept Surg & Pathol, Div Urol Surg, Durham, NC 27719 USA. Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA. Univ Calif San Francisco, Sch Med, Vet Adm Med Ctr, Urol Sect,Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Univ Calif Los Angeles, Sch Med, Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA. Vet Adm Med Ctr, Dept Surg, Urol Sect, Palo Alto, CA 94304 USA. Univ Alabama, Dept Urol, Birmingham, AL USA. Med Coll Georgia, Vet Adm Med Ctr, Dept Surg, Augusta, GA 30912 USA. Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Dept Surg & Pathol, Div Urol Surg, Box 3850, Durham, NC 27719 USA. EM steve.freedland@duke.edu FU NCI NIH HHS [P50 CA92131-01A1, R01CA100938] NR 15 TC 45 Z9 47 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD APR PY 2006 VL 175 IS 4 BP 1298 EP 1302 DI 10.1016/S0022-5437(05)00646-4 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 022EX UT WOS:000236038900030 PM 16515984 ER PT J AU Brau, N Bini, EJ Currie, S Shen, H Schmidt, WN King, PD Ho, SB Cheung, RC Hu, KQ Anand, BS Simon, FR Aytaman, A Johnson, DP Awad, JA Ahmad, J Mendenhall, CL Pedrosa, MC Moseley, RH Hagedorn, CH Waters, B Chang, KM Morgan, TR Rossi, SJ Jeffers, LJ Wright, TL AF Brau, N Bini, EJ Currie, S Shen, H Schmidt, WN King, PD Ho, SB Cheung, RC Hu, KQ Anand, BS Simon, FR Aytaman, A Johnson, DP Awad, JA Ahmad, J Mendenhall, CL Pedrosa, MC Moseley, RH Hagedorn, CH Waters, B Chang, KM Morgan, TR Rossi, SJ Jeffers, LJ Wright, TL CA VA-HCV-001 Study Grp TI Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE community-based practice; dose reduction; hepatitis C; racial differences; therapy ID AFRICAN-AMERICANS; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; INITIAL TREATMENT; RANDOMIZED-TRIAL; VIRUS-INFECTION; US VETERANS; THERAPY; COMBINATION AB In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black patients have a lower SVR rate independent of genotype. We prospectively enrolled 785 patients (24.8% Black, 71.5% White, 3.7% others) who received interferon alpha-2b 3 MU three times weekly + RBV 1000-1200 mg/day for 24 weeks (GT-2/3) or 48 weeks (GT-1). Black patients were more commonly infected with GT-1 (86.8%vs 64.8%, P < 0.001) and less frequently had an SVR compared with non-Black patients (8.4%vs 21.6%, P < 0.001). Within GT-1, Black patients had a lower SVR rate than non-Black patients (6.1%vs 14.1%, P = 0.004) but not within GT-2/3 (50.0%vs 36.5%, P = 0.47). Black patients had lower baseline haemoglobin levels (14.8 vs 15.3 g/dL, P < 0.001) and neutrophil counts (2900 vs 4100/mm(3), P < 0.001) and required more frequent dose reductions of RBV (29.8%vs 18.5%, P < 0.001) and interferon (4.7%vs 1.6%, P = 0.012). However, dose reductions were not associated with lower SVR rates while early treatment discontinuations were (2.9%vs 25.7%, P < 0.001). Independent predictors of SVR were GT-1 [odds ratio (OR) 0.33; 95% confidence interval (CI) 0.20-0.55; P < 0.001], Black race (OR 0.45; 95% CI 0.22-0.93; P = 0.030), and advanced fibrosis, stages 3 + 4 (OR 0.53; 95% CI 0.31-0.92; P = 0.023). In conclusion, Black patients infected with HCV GT-1 (but not GT-2/3) have a lower SVR rate than non-Black patients. This is not explained by their lower baseline haemoglobin levels and neutrophil counts that lead to higher rates of ribavirin and interferon dose reductions. C1 Bronx Vet Adm Med Ctr, Infect Dis Sect 111F, Bronx, NY 10468 USA. Vet Affairs Med Ctr, New York, NY USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Vet Affairs Med Ctr, Iowa City, IA 52242 USA. Vet Affairs Med Ctr, Columbia, MO USA. Vet Affairs Med Ctr, Minneapolis, MN 55417 USA. Vet Affairs Med Ctr, Palo Alto, CA 94304 USA. Vet Affairs Med Ctr, Loma Linda, CA USA. Vet Affairs Med Ctr, Houston, TX 77030 USA. Vet Affairs Med Ctr, Denver, CO USA. Vet Affairs Med Ctr, Brooklyn, NY USA. Vet Affairs Med Ctr, Bay Pines, FL USA. Vet Affairs Med Ctr, Nashville, TN 37212 USA. Vet Affairs Med Ctr, Pittsburgh, PA USA. Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. Vet Affairs Med Ctr, Boston, MA USA. Vet Affairs Med Ctr, Ann Arbor, MI USA. Vet Affairs Med Ctr, Atlanta, GA 30033 USA. Vet Affairs Med Ctr, Memphis, TN USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Vet Affairs Med Ctr, Long Beach, CA USA. Vet Affairs Med Ctr, Miami, FL 33125 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Brau, N (reprint author), Bronx Vet Adm Med Ctr, Infect Dis Sect 111F, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM norbert.brau@med.va.gov NR 20 TC 30 Z9 30 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD APR PY 2006 VL 13 IS 4 BP 242 EP 249 DI 10.1111/j.1365-2893.2005.00682.x PG 8 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 022OJ UT WOS:000236065100005 PM 16611190 ER PT J AU Blackwell, T Yaffe, K Ancoli-Israel, S Scheider, JL Cauley, JA Hillier, TA Fink, HA Stone, KL AF Blackwell, T Yaffe, K Ancoli-Israel, S Scheider, JL Cauley, JA Hillier, TA Fink, HA Stone, KL CA Study Osteoporotic Fractures Grp TI Poor sleep is associated with impaired cognitive function in older women: The Study of Osteoporotic Fractures SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID JAPANESE-AMERICAN MEN; ALZHEIMERS-DISEASE; APNEA SYNDROME; BONE MASS; HEALTH; COMPLAINTS; DEMENTIA; INSOMNIA; PERFORMANCE; DYSFUNCTION AB Background. The association between objectively measured sleep and cognition among community-dwelling elderly persons remains understudied. This observational, cross-sectional analysis examined this association. Methods. Results are from 2932 women (mean age 83.5 years) in the Study of Osteoporotic Fractures between 2002 and 2004. Cognitive function was measured by Mini-Mental State Examination (MMSE) and Trail Making B Test (Trails B). Cognitive impairment was defined as MMSE < 26 or Trails B > 278 seconds. Sleep parameters measured objectively using actigraphy included total sleep time, sleep efficiency, sleep latency, wake after sleep onset (WASO), and total nap time. Results. There were 305 women (10.6%) with MMSE < 26 and 257 women (9.3%) with Trails B > 278 seconds. Compared with women with sleep efficiency >= 70%, those with < 70% had a higher risk of cognitive impairment (MMSE < 26 multivariate odds ratio [MOR] = 1.61; 95% confidence interval [CI], 1.20-2.16; Trails B > 278 MOR = 1.96; 95% CI, 1.43-2.67). Higher sleep latency was associated with higher risk of cognitive impairment (per half hour: MMSE < 26 MOR = 1.23; 95% CI, 1.13-1.33; Trails B > 278 MOR = 1.13; 95% CI, 1.04-1.24), as was higher WASO (per half hour: MMSE < 26 MOR = 1.15; 95% CI, 1.06-1.23: Trails B > 278 MOR = 1.24; 95% CI, 1.15-1.34). Women who napped >= 2 hours per day had a higher risk (MMSE < 26 MOR = 1.42; 95% CI, 1.05-1.93; Trails B > 278 MOR = 1.74; 95% CI, 1.26-2.40). There was no significant relationship for total sleep time. Conclusion. Objectively measured disturbed sleep was consistently related to poorer cognition. whereas total sleep time was not. This finding may suggest that it is disturbance of sleep rather than quantity that affects cognition. C1 SF Coordinating Ctr, San Francisco, CA 94107 USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. Kaiser Permanente Ctr Hlth Res, Portland, OR USA. VA Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA. VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. RP Blackwell, T (reprint author), SF Coordinating Ctr, 185 Berry St,Lobby 4,Suite 5700, San Francisco, CA 94107 USA. EM tblackwell@sfcc-cpmc.net RI Fink, Howard/F-3933-2012; Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NIA NIH HHS [R01 AG021918, AG05394, AG05407, AG08415, R01 AG026720]; NIAMS NIH HHS [AR35582, AR35583, AR35584] NR 44 TC 150 Z9 151 U1 3 U2 8 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2006 VL 61 IS 4 BP 405 EP 410 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 035OI UT WOS:000237010500014 PM 16611709 ER PT J AU Meeran, SM Mantena, SK Meleth, S Elmets, CA Katiyar, SK AF Meeran, SM Mantena, SK Meleth, S Elmets, CA Katiyar, SK TI Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID GREEN TEA POLYPHENOLS; IFN-GAMMA PRODUCTION; ULTRAVIOLET-RADIATION; INDUCED IMMUNOSUPPRESSION; CONTACT HYPERSENSITIVITY; DNA-REPAIR; IN-VIVO; IMMUNE SUPPRESSION; PYRIMIDINE DIMERS; SUNBURN CELL AB Solar UV radiation-induced immunosuppression is a risk factor for nonmelanoma skin cancer. Interleukin (IL)-12 has been shown to possess antitumor activity and inhibit the immunosuppresive effects of UV radiation in mice. In this study, we generated IL-12 knockout (KO) mice on a C3H/HeN background to characterize the role of IL-12 in photocarcinogenesis. After exposure of the mice to UVB (180 mJ/cm(2)) radiation thrice a week for 35 weeks, the development of UV induced tumors was more rapid and the tumor multiplicity and tumor size were significantly higher in IL-12 KO mice than their wild-type (WT) counterparts (P < 0.05-0.001). Moreover, the malignant transformation of UVB-induced papillomas to carcinomas was higher in IL-12 KO mice in terms of carcinoma incidence (55%, P < 0.001), carcinoma multiplicity (77%, P < 0.001), and carcinoma size (81%, P < 0.001). As IL-12 has the ability to repair UV-induced DNA damage, we determined this effect in our in vivo IL-12 KO mouse model. We found that UVB-induced DNA damage in the form of cyclobutane pyrimidine dimers was removed or repaired more rapidly in WT mice than IL-12 KO mice. Similarly, the UVB-induced sunburn cell formation is primarily a consequence of DNA damage. It was observed that UVB-induced sunburn cells were repaired rapidly in WT mice compared with IL-12 KO mice. The rapid removal or repair of UV-induced cyclobutane pyrimidine dimers or sunburn cells will result in reduced risk of photocarcinogenesis. Taken together, our data show that IL-12 deficiency is associated with the greater risk of photocarcinogenesis in mice, and this may be due to reduction in damaged DNA repair ability. C1 Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. Univ Alabama, Skin Dis Res Ctr, Birmingham, AL 35294 USA. Univ Alabama, Biostat & Bioinformat Unit, Birmingham, AL 35294 USA. Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU NCCIH NIH HHS [1 R01 AT002536]; NIAMS NIH HHS [AR050984-01] NR 43 TC 37 Z9 37 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 J9 MOL CANCER THER JI Mol. Cancer Ther. PD APR PY 2006 VL 5 IS 4 BP 825 EP 832 DI 10.1158/1535-7163.MCT-06-0003 PG 8 WC Oncology SC Oncology GA 041LU UT WOS:000237458500005 PM 16648552 ER PT J AU Song, CS Echchgadda, I Seo, YK Oh, T Kim, S Kim, SA Cho, SW Shi, LH Chatterjee, B AF Song, CS Echchgadda, I Seo, YK Oh, T Kim, S Kim, SA Cho, SW Shi, LH Chatterjee, B TI An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1) SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID HUMAN CYTOSOLIC SULFOTRANSFERASES; X-RECEPTOR PXR; DEHYDROEPIANDROSTERONE-SULFOTRANSFERASE; BILE-ACIDS; HYDROXYSTEROID SULFOTRANSFERASE; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; LIVER; INDUCTION AB The vitamin D receptor (VDR) regulates steroid and drug metabolism by inducing the genes encoding phase I and phase II enzymes. SULT2A1 is a liver- and intestine-expressed sulfo-conjugating enzyme that converts the alcohol-OH of neutral steroids, bile acids, and drugs to water-soluble sulfated metabolites. 1 alpha, 25-Dihydroxyvitamin D-3 [1,25-(OH)(2) D-3] induces SULT2A1 gene transcription after the recruitment of VDR to the vitamin D-responsive chromatin region of SULT2A1. A composite element in human SULT2A1 directs the 1,25-(OH)(2) D-3-mediated induction of natural and heterologous promoters. This element combines a VDR/retinoid X receptor-alpha-binding site [vitamin D response element ( VDRE)], which is an imperfect inverted repeat 2 of AGCTCA, and a CAAT/enhancer binding protein (C/EBP)-binding site located 9 bp downstream to VDRE. The binding sites were identified by EMSA, antibody supershift, and deoxyribonuclease I footprinting. C/EBP-alpha at the composite element plays an essential role in the VDR regulation of SULT2A1, because 1) induction was lost for promoters with inactivating mutations at the VDRE or C/EBP element; 2) SULT2A1 induction by 1,25( OH)(2) D-3 in C/ EBP-alpha-deficient cells required the expression of cotransfected C/EBP-alpha; and 3) C/EBP-beta did not substitute for C/EBP-alpha in this regulation. VDR and C/EBP-alpha were recruited concurrently to the composite element along with the coactivators p300, steroid receptor coactivator 1 (SRC-1), and SRC-2, but not SRC-3. VDR and C/EBP-alpha associated endogenously as a DNA-dependent, coimmunoprecipitable complex, which was detected at a markedly higher level in 1,25( OH)(2) D-3-treated cells. These results provide the first example of the essential role of the interaction in cis between C/EBP-alpha and VDR in directing 1,25( OH)(2) D-3-induced expression of a VDR target gene. C1 Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA. Audie L Murphy Mem Vet Affairs Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chatterjee, B (reprint author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM chatterjee@uthscsa.edu FU NIA NIH HHS [AG-10486] NR 46 TC 28 Z9 30 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD APR PY 2006 VL 20 IS 4 BP 795 EP 808 DI 10.1210/me.2005-0428 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 025UZ UT WOS:000236293700008 PM 16357103 ER PT J AU Kay, DM Zabetian, CP Factor, SA Nutt, JG Samii, A Griffith, A Bird, TD Kramer, P Higgins, DS Payami, H AF Kay, DM Zabetian, CP Factor, SA Nutt, JG Samii, A Griffith, A Bird, TD Kramer, P Higgins, DS Payami, H TI Parkinson's disease and LRRK2: Frequency of a common mutation in US movement disorder clinics SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; LRRK2 G2019S mutation; genotype-phenotype correlation; family history; age at onset; geography ID AUTOSOMAL-DOMINANT PARKINSONISM; G2019S MUTATION; GENE; IDENTIFICATION AB The G2019S mutation in the LRRK2 gene is reportedly a common cause of familial Parkinson's disease (PD) and may also have a significant role in nonfamilial PD. The objective of this study was to assess mutation carrier frequency in PD patients from movement disorder clinics in the United States, stratified by family history, age at onset, and geography, to determine carrier frequency in a large and well-characterized control Population; to examine segregation Of mutation in families of patients; and to correlate genotype with clinical phenotype. One thousand four hundred twenty-five unrelated PD patients from movement disorder clinics in Oregon, Washington, and New York and 1,647 unrelated controls were Studied. The G2019S mutation was detected using a TaqMan assay and verified by sequencing. Eighteen of 1.425 patients and one of 1.647 controls had the mutation. Carrier frequency (+/- 2SE) in patients was 0.013 +/- 0.006 overall, 0.030 +/- 0.019 in familial PD, 0.007 +/- 0.005 in nonfamilial PD, 0.016 +/- 0.013 in early-onset PD. and 0.012 +/- 0.007 in late-onset PD. Geographic differences were insignificant. Age at onset of mutation carriers, ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date. (C) 2006 Movement Disorder Society. C1 New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY 12201 USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU NIA NIH HHS [AG08017]; NINDS NIH HHS [K08-NS44138, NS R01-36960] NR 18 TC 55 Z9 58 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2006 VL 21 IS 4 BP 519 EP 523 DI 10.1002/mds.20751 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 036UV UT WOS:000237102300013 PM 16250030 ER PT J AU Jara, A von Hoveling, A Jara, X Burgos, ME Valdivieso, A Mezzano, S Felsenfeld, AJ AF Jara, A von Hoveling, A Jara, X Burgos, ME Valdivieso, A Mezzano, S Felsenfeld, AJ TI Effect of endothelin receptor antagonist on parathyroid gland growth, PTH values and cell proliferation in azotemic rats SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE bosentan; dietary phosphorus; endothelin; parathyroid hyperplasia ID SECONDARY HYPERPARATHYROIDISM; RENAL-FAILURE; PHOSPHORUS; P21(WAF1); SECRETION; HORMONE AB Background. A variety of stimuli are involved in the pathogenesis of parathyroid gland hyperplasia in renal failure. Recently, it was shown that blocking the signal from the endothelin-1 (ET-1) receptor (ETAR/ETBR) by a non-selective receptor antagonist, bosentan, reduced parathyroid cell proliferation, parathyroid gland hyperplasia and parathyroid hormone (PTH) levels in normal rats on a calcium deficient diet. Our goal was to determine whether in 5/6 nephrectomized (NPX) rats with developing or established hyperparathyroidism, the endothelin receptor blocker, bosentan, reduced the increase in parathyroid cell proliferation, parathyroid gland hyperplasia and PTH values. Methods. High (HPD, 1.2%) or normal phosphorus diets (PD) (NPD, 0.6%) were given to 5/6 NPX rats for 15 days (NPX15). In each dietary group, one-half the rats were given bosentan (B) i.p. 100 mg/kg/day. The four groups of rats were: (1) NPX15-1.2% P; (2) NPX15-1.2% P+B; (3) NPX15-0.6% P; and (4) NPX15-0.6% P+B. In a second study in which hyperparathyroidism was already established in 5/6 NPX rats fed a HPD for 15 days, rats were divided into two groups in which one group was maintained on a HPD and the other group was changed to very low PD (VLPD, < 0.05%) for an additional 15 days. In each dietary group, one-half the rats were given bosentan i.p. 100 mg/kg-day. The four groups of rats were: (1) NPX30-1.2% P; (2) NPX30-1.2% P+B; (3) NPX30-0.05% P and (4) NPX30-0.05% P+B. Parathyroid cell proliferation was measured by proliferating cell nuclear antigen (PCNA) staining and ET-1 expression by immunohistochemical techniques. Results. In the study of developing hyperparathyroidism, bosentan reduced ET-1 expression in the parathyroid glands of rats on the NPD and HPD (P < 0.05). But only in rats on the NPD did bosentan result in a reduced increase in parathyroid gland weight (P < 0.05). In the study of established hyperparathyroidism, in which 5/6 NPX rats were given a HPD for 15 days, bosentan started on day 15 reduced (P < 0.05) ET-1 expression in rats maintained for 15 additional days on the HPD or the VLPD. On the VLPD, parathyroid gland weight was less (P < 0.05) than that in rats on the HPD sacrificed at 15 or 30 days. Bosentan did not reduce parathyroid cell proliferation or parathyroid gland weight in rats maintained on the HPD or further reduce these parameters beyond that obtained with dietary phosphorus restriction. PTH values were lowest in the VLPD group, intermediate in the NPD group, and highest in the HPD group, but in none of the three groups did bosentan decrease PTH values. Conclusions. In azotemic rats with developing hyperparathyroidism, bosentan resulted in a reduced increase in parathyroid gland weight when dietary phosphorus content was normal. Despite a reduction in ET-1 expression in rats on a HPD with developing or established hyperparathyroidism, bosentan did not reduce the increase in parathyroid cell proliferation, parathyroid gland growth or PTH values. Thus, ET-1 blockade with bosentan did not prevent parathyroid gland growth in the azotemic rat. C1 Pontificia Univ Catolica Chile, Dept Nephrol, Santiago, Chile. Univ Austral Chile, Div Nephrol, Valdivia, Chile. W Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Jara, A (reprint author), Pontificia Univ Catolica Chile, Dept Nephrol, Lira 85, Santiago, Chile. EM ajara@med.puc.cl NR 17 TC 3 Z9 3 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD APR PY 2006 VL 21 IS 4 BP 917 EP 923 DI 10.1093/ndt/gfk006 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 025GS UT WOS:000236254000015 PM 16431896 ER PT J AU Lieu, SN Million, M Oh, DS Waschek, JA Tache, Y Pisegna, JR Germano, PM AF Lieu, SN Million, M Oh, DS Waschek, JA Tache, Y Pisegna, JR Germano, PM TI PACAP and its receptor, PAC1 exert a protective effect in preventing dextran sulfate sodium (DSS)-induced colitis SO NEUROPEPTIDES LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Dept Gastroenterol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0143-4179 J9 NEUROPEPTIDES JI Neuropeptides PD APR PY 2006 VL 40 IS 2 BP 153 EP 154 PG 2 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 046WU UT WOS:000237842600047 ER PT J AU Lieu, SN Oh, DS Lambrecht, N Yakubov, I Sachs, G Pisegna, JR Germano, PM AF Lieu, SN Oh, DS Lambrecht, N Yakubov, I Sachs, G Pisegna, JR Germano, PM TI PACAP activation of secretory and proliferative signaling pathways in BON cells is mediated through PKA, calmodulin and Ras SO NEUROPEPTIDES LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Pathol, David Geffen Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0143-4179 J9 NEUROPEPTIDES JI Neuropeptides PD APR PY 2006 VL 40 IS 2 BP 154 EP 154 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 046WU UT WOS:000237842600048 ER PT J AU Subak, LL Brown, JS Kraus, SR Brubaker, L Lin, F Richter, HE Bradley, CS Grady, D AF Subak, Leslee L. Brown, Jeanette S. Kraus, Stephen R. Brubaker, Linda Lin, Feng Richter, Holly E. Bradley, Catherine S. Grady, Deborah CA DAISy Grp TI The "costs" of urinary incontinence for women SO OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the American-Urogynecologic-Society CY SEP 15-17, 2005 CL Atlanta, GA SP Amer Urogynecol Soc ID WILLINGNESS-TO-PAY; QUALITY-OF-LIFE; URGE INCONTINENCE; INSTRUMENT; INDEX; CARE AB OBJECTIVE: To estimate costs of routine care for female urinary incontinence, health-related quality of life, and willingness to pay for incontinence improvement. METHODS: In a cross-sectional study at 5 U.S. sites, 293 incontinent women quantified supplies, laundry, and dry cleaning specifically for incontinence. Costs were calculated by multiplying resources used by national resource costs and presented in 2005 United States dollars ($2005). Health-related quality of life was estimated with the Health Utilities index. Participants estimated willingness to pay for 25-100% improvement in incontinence. Potential predictors of these outcomes were examined using multivariable linear regression. RESULTS: Mean age was 56 +/- 11 years; participants were racially diverse and had a broad range of incontinence severity. Nearly 90% reported incontinence-related costs. Median weekly cost (25%, 75% interquartile range) increased from $0.37 ($0, 4) for slight to $10.98 ($4, 21) for very severe incontinence. Costs increased with incontinence severity (P < .001). Costs were 2.4-fold higher for African American compared with white women (P < .001) and 65% higher for women with urge compared with those having stress incontinence (P < .001). More frequent incontinence was associated with lower Health Utilities Index score (mean 0.90 +/- 0.11 for weekly and 0.81 +/- 0.21 for daily incontinence; P = .02). Women were willing to pay a mean of $70 +/- $64 per month for complete resolution of incontinence, and willingness to pay increased with income and greater expected benefit. CONCLUSION: Women with severe urinary incontinence pay $900 annually for incontinence routine care, and incontinence is associated with a significant decrement in health-related quality of life. Effective incontinence treatment may decrease costs and improve quality of life. C1 Univ Calif San Francisco, Mt Zion Womens Hlth Clin Res Ctr, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94115 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Loyola Univ, Maywood, IL 60153 USA. Univ Alabama, Birmingham, AL USA. Univ Iowa, Iowa City, IA 52242 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. San Francisco Vet Affiars Med Ctr, San Francisco, CA USA. RP Subak, LL (reprint author), Univ Calif San Francisco, Mt Zion Womens Hlth Clin Res Ctr, Dept Obstet Gynecol & Reprod Sci, 1635 Diuvisadero St,Suite 600, San Francisco, CA 94115 USA. EM subakl@obgyn.ucsf.edu FU NIDDK NIH HHS [P50 DK064538] NR 29 TC 63 Z9 67 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2006 VL 107 IS 4 BP 908 EP 916 DI 10.1097/01.AOG.0000206213.48334.09 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 095GM UT WOS:000241296200025 PM 16582131 ER PT J AU Brown, KS Kane, MA AF Brown, KS Kane, MA TI Chemoprevention of squamous cell carcinoma of the oral cavity SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA LA English DT Article ID GROWTH-FACTOR RECEPTOR; 2ND PRIMARY TUMORS; NECK-CANCER PATIENTS; BETA-CAROTENE; RETINOIC ACID; VITAMIN-A; 13-CIS-RETINOIC ACID; PHARYNGEAL CANCER; RANDOMIZED-TRIAL; LUNG-CANCER AB The potential for chemoprevention of squamous cell carcinoma of the oral cavity has long been recognized. Its easily identifiable precursor lesions and the failure of local therapies to prevent progression of these lesions to cancer has fueled much of the interest in identifying an effective chemopreventive compound. Early optimism regarding retinoids has been tempered by concerns about toxicity and lack of long-term efficacy. Although several other compounds have been studied, none as yet have been shown to be safe and effective in large studies. Agents that target specific molecular carcinogenic pathways have shown promise. Chemoprevention of this disease remains an active area of investigation. C1 Denver Hlth Med Ctr, Denver, CO 80204 USA. Univ Colorado, Hlth Sci Ctr, Div Hematol & Oncol, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Brown, KS (reprint author), Denver Hlth Med Ctr, 660 Bannock St,MC 4000, Denver, CO 80204 USA. EM kevin.brown@dhha.org NR 81 TC 7 Z9 7 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0030-6665 J9 OTOLARYNG CLIN N AM JI Otolaryngol. Clin. N. Am. PD APR PY 2006 VL 39 IS 2 BP 349 EP + DI 10.1016/j.otc.2005.11.010 PG 16 WC Otorhinolaryngology SC Otorhinolaryngology GA 036JA UT WOS:000237066200009 PM 16580916 ER PT J AU Rifai, MA Moles, JK Lehman, LP Van der Linden, BJ AF Rifai, MA Moles, JK Lehman, LP Van der Linden, BJ TI Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders SO PSYCHOSOMATICS LA English DT Article ID ADDICTION SEVERITY INDEX; NONINJECTING DRUG-USERS; UNITED-STATES VETERANS; SERVICES TASK-FORCE; VIRUS-INFECTION; ALCOHOL-CONSUMPTION; DEPENDENT PATIENTS; LIVER-CIRRHOSIS; PLUS RIBAVIRIN; PREVALENCE AB The authors evaluated the association between hepatitis C virus ( HCV) seropositivity status and substance use treatment outcomes in an alcohol- and substance-dependent population undergoing rehabilitation. The second aim was to assess the impact of early screening for HCV infection and substance use treatment on HCV treatment outcomes. HCV-antibody testing of 338 patients attending a substance-use residential program was performed. HCV antibody status, lifetime comorbid psychiatric diagnoses, program completion rates, and 6-month abstinence rates after program discharge were assessed. HCV treatment outcomes were followed in patients who remained abstinent 6 months after completion of substance-use treatment. Almost one-fourth ( 23.1%) of patients were HCV antibody-positive. HCV-seropositive patients were more likely to complete the 28-day program and more likely to remain abstinent at 6 months after program discharge. HCV seropositive status was the strongest predictor for the likelihood of completing the program, and remaining abstinent for 6 months afterward. Patients with HCV who completed a substance-use treatment program were more likely to receive HCV treatment than substance-dependent patients with HCV who never attended a substance-use treatment program. Detecting HCV infection in the structured setting of substance-use treatment is ideal to initiate management of this infection, and it has a positive influence on the outcomes of both substance-use treatment and HCV treatment. C1 Univ Virginia, Sch Med, Salem, VA USA. Vet Affairs Med Ctr, Salem, VA USA. RP Rifai, MA (reprint author), Portland VA Med Ctr, NW Hepatitis C Res Ctr, POB 1034,P3MHADM, Portland, OR 97239 USA. EM AlyRifai@aol.com NR 44 TC 22 Z9 22 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD APR PY 2006 VL 47 IS 2 BP 112 EP 121 DI 10.1176/appi.psy.47.2.112 PG 10 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 017BR UT WOS:000235669600003 PM 16508022 ER PT J AU Hospenthal, MAC AF Hospenthal, MAC TI Diagnosis and management of idiopathic pulmonary fibrosis: Implications for respiratory care SO RESPIRATORY CARE LA English DT Article; Proceedings Paper CT 21st Annual New Horizons Symposium CY DEC 04, 2005 CL San Antonio, TX DE interstitial; lung diseases; pulmonary fibrosis; pulmonary function testing; fibrosing alveolitis; lung biopsy; management ID INTERSTITIAL LUNG-DISEASES; HAMMAN-RICH SYNDROME; PATHOGENESIS; ACCURACY; PNEUMONIA; BIOPSY; EPIDEMIOLOGY; ALVEOLITIS; THERAPY; SMOKING AB Although poorly understood, idiopathic pulmonary fibrosis is the most common of the idiopathic interstitial lung diseases. Its etiology is unknown, but how this fibrotic process develops in the lung has been studied over the last 60 years. It is a relatively rare disease, afflicting those 50-70 years of age, slightly more common among men than women, without racial predilection. The most common complaint is progressive shortness of breath. Pulmonary function testing reveals a restrictive ventilatory defect with a diminished diffusion capacity. The lungs demonstrate fibrotic and cystic areas interspersed with normal lung on radiographic and pathologic examination. No definitive medical treatment is available, although most patients are given trials of corticosteroids, alone or in combination with cytotoxic agents. On average, patients survive 2-4 years after diagnosis. Lung transplantation has been the only therapy shown to improve survival of those with idiopathic pulmonary fibrosis. C1 Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Hospenthal, MAC (reprint author), Audie Murphy Mem Vet Affairs Hosp, 7400 Merton Minter Blvd,111E, San Antonio, TX 78229 USA. EM hospenthal@uthscsa.edu NR 55 TC 4 Z9 5 U1 0 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESPIR CARE JI Respir. Care PD APR PY 2006 VL 51 IS 4 BP 382 EP 391 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 031SI UT WOS:000236723900004 PM 16563193 ER PT J AU Levine, SM Angel, LF AF Levine, SM Angel, LF TI The patient who has undergone lung transplantation: Implications for respiratory care SO RESPIRATORY CARE LA English DT Article; Proceedings Paper CT 21st Annual New Horizons Symposium CY DEC 04, 2005 CL San Antonio, TX DE lung transplantation; postoperative; rejection; obliterative bronchiolitis; post-operative management; patient assessment ID BRONCHIOLITIS-OBLITERANS-SYNDROME; ISHLT WORKING GROUP; HIGH-RESOLUTION CT; PRIMARY GRAFT FAILURE; INHALED NITRIC-OXIDE; QUALITY-OF-LIFE; HEART-LUNG; RISK-FACTORS; PULMONARY TRANSPLANTATION; INVASIVE ASPERGILLOSIS AB Lung transplantation is now performed in patients with end-stage pulmonary parenchymal or vascular lung disease. The process of evaluating a patient for transplantation, managing the patient during the peri-operative period, and caring for the patient following transplantation is complex. Lung-transplant recipients are prone to unique complications of lung transplantation, as well as general complications of an immunosuppressed host. This article reviews the indications for, expected outcomes of, and management of complications that can develop following lung transplantation. Respiratory therapists play an instrumental role in assisting in the management of this group of patients in the pretransplant and post-transplant periods, and in their long-term management. C1 Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Div Cardiothorac Surg, San Antonio, TX 78229 USA. RP Levine, SM (reprint author), Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM levines@uthscsa.edu NR 112 TC 0 Z9 0 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESPIR CARE JI Respir. Care PD APR PY 2006 VL 51 IS 4 BP 392 EP 402 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 031SI UT WOS:000236723900005 PM 16563192 ER PT J AU Lee, SH Wynn, JK Green, MF Kim, H Lee, KJ Nam, M Park, JK Chung, YC AF Lee, SH Wynn, JK Green, MF Kim, H Lee, KJ Nam, M Park, JK Chung, YC TI Quantitative EEG and low resolution electromagnetic tomography (LORETA) imaging of patients with persistent auditory hallucinations SO SCHIZOPHRENIA RESEARCH LA English DT Article DE auditory hallucination; schizophrenia; gamma and beta frequency oscillation; qEEG; LORETA ID CHRONIC-SCHIZOPHRENIA; CORTEX; BRAIN; SYNCHRONIZATION; OSCILLATIONS; GAMMA; NEUROANATOMY; POTENTIALS; INCREASES; VOICES AB Electrophysiological studies have demonstrated gamma and beta frequency oscillations in response to auditory stimuli. The purpose of this study was to test whether auditory hallucinations (AH) in schizophrenia patients reflect abnormalities in gamma and beta frequency oscillations and to investigate source. generators of these abnormalities. This theory was tested using quantitative electroencephalography (qEEG) and low-resolution electromagnetic tomography (LORETA) source imaging. Twenty-five schizophrenia patients with treatment refractory AH, lasting for at least 2 years, and 23 schizophrenia patients with non-AH (N-AH) in the past 2 years were recruited for the study. Spectral analysis of the qEEG and source imaging of frequency bands of artifact-free 30 s epochs were examined during rest. AH patients showed significantly increased beta I and beta 2 frequency amplitude compared with N-AH patients. Gamma and beta (2 and 3) frequencies were significantly correlated in AH but not in N-AH patients. Source imaging revealed significantly increased beta (I and 2) activity in the left inferior parietal lobule and the left medial frontal gyrus in AH versus N-AH patients. These results imply that AH is reflecting increased beta frequency oscillations with neural generators localized in speech-related areas. (c) 2006 Elsevier B.V. All rights reserved. C1 Inje Univ, Coll Med, Ilsanpaik Hosp, Dept Psychiat, Goyang 411706, South Korea. Univ Calif Los Angeles, Psychiat & Behav Sci, Los Angeles, CA USA. VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. RP Lee, SH (reprint author), Inje Univ, Coll Med, Ilsanpaik Hosp, Dept Psychiat, 2240 Daehwa Dong, Goyang 411706, South Korea. EM lshpss@hailmail.net RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 37 TC 46 Z9 47 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2006 VL 83 IS 2-3 BP 111 EP 119 DI 10.1016/j.schres.2005.11.025 PG 9 WC Psychiatry SC Psychiatry GA 035OW UT WOS:000237012200001 PM 16524699 ER PT J AU Taub, E Uswatte, G King, DK Morris, D Crago, JE Chatterjee, A AF Taub, E Uswatte, G King, DK Morris, D Crago, JE Chatterjee, A TI A placebo-controlled trial of constraint-induced movement therapy for upper extremity after stroke SO STROKE LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Physiological-Society CY APR, 2003 CL San Diego, CA SP Amer Physiol Soc DE controlled clinical trials; rehabilitation; stroke; treatment outcome ID MOTOR FUNCTION-TEST; LEARNED NONUSE; REHABILITATION; RELIABILITY AB Background and Purpose - Constraint-Induced Movement therapy (CI therapy) is a neurorehabilitation technique developed to improve use of the more affected upper extremity after stroke. A number of studies have reported positive effects for this intervention, but an experiment with a credible placebo control group has not yet been published. Methods - We conducted a placebo-controlled trial of CI therapy in patients with mild to moderate chronic ( mean = 4.5 years after stroke) motor deficit after stroke. The CI therapy group received intensive training ( shaping) of the more affected upper extremity for 6 hours per day on 10 consecutive weekdays, restraint of the less affected extremity for a target of 90% of waking hours during the 2-week treatment period, and application of a number of other techniques designed to produce transfer to the life situation. The placebo group received a program of physical fitness, cognitive, and relaxation exercises for the same length of time and with the same amount of therapist interaction as the experimental group. Results - After CI therapy, patients showed large ( Wolf Motor Function Test) to very large improvements in the functional use of their more affected arm in their daily lives ( Motor Activity Log; P < 0.0001). The changes persisted over the 2 years tested. Placebo subjects showed no significant changes. Conclusion - The results support the efficacy of CI therapy for rehabilitating upper extremity motor function in patients with chronic stroke. C1 Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. Univ Alabama, Dept Rehabil Serv, Birmingham, AL 35294 USA. Univ Alabama, Dept Phys Therapy, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. RP Taub, E (reprint author), Univ Alabama, Dept Psychol, 1530 3rd Ave S,CPM 712, Birmingham, AL 35294 USA. EM etaub@uab.edu RI Uswatte, Gitendra/C-4913-2009 FU NICHD NIH HHS [HD34273] NR 16 TC 200 Z9 226 U1 2 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2006 VL 37 IS 4 BP 1045 EP 1049 DI 10.1161/01.STR.0000206463.66461.97 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 025UJ UT WOS:000236292100027 PM 16514097 ER PT J AU Yenari, MA Xu, LJ Tang, XN Qiao, YL Giffard, RG AF Yenari, MA Xu, LJ Tang, XN Qiao, YL Giffard, RG TI Microglia potentiate damage to blood-brain barrier constituents - Improvement by minocycline in vivo and in vitro SO STROKE LA English DT Article DE blood-brain barrier; inflammation; ischemia; microglia ID CEREBRAL-ARTERY OCCLUSION; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; MILD HYPOTHERMIA; NADPH OXIDASE; HYPOXIA REOXYGENATION; EXPERIMENTAL STROKE; CORTICAL-NEURONS; ASTROGLIAL CELLS; ISCHEMIA AB Background - Blood - brain barrier (BBB) disruption after stroke can worsen ischemic injury by increasing edema and causing hemorrhage. We determined the effect of microglia on the BBB and its primary constituents, endothelial cells (ECs) and astrocytes, after ischemia using in vivo and in vitro models. Methods and Results - Primary astrocytes, ECs, or cocultures were prepared with or without added microglia. Primary ECs were more resistant to oxygen-glucose deprivation/reperfusion than astrocytes. ECs plus astrocytes showed intermediate vulnerability. Microglia added to cocultures nearly doubled cell death. This increase was prevented by minocycline and apocynin. In vivo, minocycline reduced infarct volume and neurological deficits and markedly reduced BBB disruption and hemorrhage in mice after experimental stroke. Conclusions - Inhibition of microglial activation may protect the brain after ischemic stroke by improving BBB viability and integrity. Microglial inhibitors may prove to be an important treatment adjunct to fibrinolysis. C1 Univ Calif San Francisco, VAMC, Dept Neurol, San Francisco, CA 94121 USA. Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, VAMC, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NIGMS NIH HHS [R01 GM49831]; NINDS NIH HHS [P01 NS37520, P50 NS14543, R01 NS40516] NR 41 TC 170 Z9 174 U1 2 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD APR PY 2006 VL 37 IS 4 BP 1087 EP 1093 DI 10.1161/01.STR.0000206281.77178.ac PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 025UJ UT WOS:000236292100035 PM 16497985 ER PT J AU Joseph, AM AF Joseph, AM TI Care coordination and telehealth technology in promoting self-management among chronically ill patients SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article AB With an increasingly complex healthcare system, the need to coordinate the care for chronically ill patient often goes unmet. This results in increased utilization of services at significant costs. In addition, providing patients with the tools to manage their own disease processes over the long term is also lacking in the healthcare environment. The Veterans Health Administration (VHA) approached these challenges by creating a Care Coordination program using technology to promote self management for veterans. Although a relatively new program, the Veterans Integrated Services Network (VISN) 7, has shown substantial gains in both decreasing the use of high cost care, such as emergency department (ED) visits and hospitalizations, as well as improving clinical outcomes with better glycemic control for patients with diabetes and improved lipid management for all patients. C1 Dept Vet Affairs, Atlanta, GA USA. RP Joseph, AM (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Amelia.joseph2@med.va.gov NR 7 TC 17 Z9 17 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD APR PY 2006 VL 12 IS 2 BP 156 EP 159 DI 10.1089/tmj.2006.12.156 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 044BT UT WOS:000237647800026 PM 16620170 ER PT J AU Galea, M Tumminia, J Garback, LM AF Galea, M Tumminia, J Garback, LM TI Telerehabilitation in spinal cord injury persons: A novel approach SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article ID NUTRITION INTERVENTION; TELEMEDICINE AB The care of a spinal cord injury (SCI) person constitutes a great challenge for the provider: SCI persons are mobility impaired, and they are prone to develop multiple comorbidities such as diabetes mellitus, hypertension, obesity, bladder infections, wounds, and depression. Furthermore, disease manifestations can be misleading depending on the level of injury. The utilization of telemedicine to monitor patients and deliver care has opened a new horizon for SCI persons. Several telehealth programs are now in use to monitor pressure ulcers and post-discharge rehabilitation in SCI persons. To answer the need for a more comprehensive approach to the multifaceted manifestation of SCI at the James J. Peters VAMC, we have started a customized telerehabilitation program. The program monitors the most common comorbidities of SCI, it is instrumental in the reintegration of the SCI person in the community, it offers individualized in-home rehabilitation programs, it addresses safety issues, and it offers counseling, weight reduction, and maintenance plans. A team of SCI specialists - including an internist, a registered nurse, a physical therapist, a nutritionist, a psychologist, and a recreational therapist - are available for weekly meetings with the patients. The programs are tailored to the patients' needs and agreed upon by both parties. Both messaging devices and videomonitors are utilized. An interdisciplinary template is used to record assessments and plans. Preliminary results are encouraging; coordination of the team and relative poor technology are some of the obstacles we have identified. Further evaluation is necessary to determine cost effectiveness. C1 James J Peters Vet Adm Med Ctr, Spinal Cord Injury Clin, Bronx, NY 10468 USA. RP Galea, M (reprint author), James J Peters Vet Adm Med Ctr, Spinal Cord Injury Clin, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM marinella.galea@med.va.gov NR 9 TC 20 Z9 22 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD APR PY 2006 VL 12 IS 2 BP 160 EP 162 DI 10.1089/tmj.2006.12.160 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 044BT UT WOS:000237647800027 PM 16620171 ER PT J AU Nguyen, TD Kim, US Perrine, SP AF Nguyen, TD Kim, US Perrine, SP TI Novel short chain fatty acids restore chloride secretion in cystic fibrosis SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE cystic fibrosis; Delta F508-CFTR; 2,2-dimethyl-butyrate; alpha-methylhydrocinnamic acid; iodide efflux; IB3-1 airway cells; butyrate derivatives; intracellular trafficking; chloride channel; chloride conductance ID ORAL SODIUM PHENYLBUTYRATE; EPITHELIAL-CELL LINE; FETAL-HEMOGLOBIN; CFTR FUNCTION; 4-PHENYLBUTYRATE; DELTA-F508-CFTR; ACTIVATION; EXPRESSION; MUTATIONS; INDUCTION AB Phenylalanine deletion at position 508 of the cystic fibrosis transmembrane conductance regulator (Delta F508-CFTR), the most common mutation in cystic fibrosis (CF), causes a misfolded protein exhibiting partial chloride conductance and impaired trafficking to the plasma membrane. 4-Phenylbutyrate corrects defective Delta F508-CFTR trafficking in vitro, but is not clinically efficacious. From a panel of short chain fatty acid derivatives, we showed that 2,2-dimethyl-butyrate (ST20) and alpha-methylhydrocinnamic acid (ST7), exhibiting high oral bioavailability and sustained plasma levels, correct the Delta F508-CFTR defect. Pre-incubation (>= 6 h) of CF 1B3-1 airway cells with >= 1 mM ST7 or ST20 restored the ability of 100 mu M forskolin to stimulate an I-125(-) efflux. This efflux was fully inhibited by NPPB, DPC, or glibenclamide, suggesting mediation through CFTR. Partial inhibition by DIDS suggests possible contribution from an additional CI- channel regulated by CFTR. Thus, ST7 and ST20 offer treatment potential for CF caused by the Delta F508 mutation. (c) 2006 Elsevier Inc. All rights reserved. C1 Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Boston Univ, Sch Med, Ctr Canc, Dept Pediat, Boston, MA 02118 USA. Boston Univ, Sch Med, Ctr Canc, Dept Med, Boston, MA 02118 USA. Boston Univ, Sch Med, Ctr Canc, Dept Pharmacol, Boston, MA 02118 USA. Boston Univ, Sch Med, Ctr Canc, Dept Expt Therapeut, Boston, MA 02118 USA. RP Nguyen, TD (reprint author), Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98108 USA. EM T1Nguyen@u.washington.edu FU NIDDK NIH HHS [DK-52962, DK-55885] NR 22 TC 8 Z9 8 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD MAR 31 PY 2006 VL 342 IS 1 BP 245 EP 252 DI 10.1016/j.bbrc.2006.01.127 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 018VV UT WOS:000235793800033 PM 16472777 ER PT J AU Taha, TA Hannun, YA Obeid, LM AF Taha, TA Hannun, YA Obeid, LM TI Sphingosine kinase: Biochemical and cellular regulation and role in disease SO JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Review DE angiogenesis; inflammation; sphingolipids; sphingosine kinase ID PROTEIN-COUPLED RECEPTORS; HUMAN ENDOTHELIAL-CELLS; FC-EPSILON-RI; FACTOR-INDUCED ACTIVATION; DENSITY-LIPOPROTEINS HDL; SMOOTH-MUSCLE-CELLS; BREAST-CANCER CELLS; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; HUMAN PLATELETS AB Sphingolipids have emerged as molecules whose metabolism is regulated leading to generation of bioactive products including ceramide, sphingosine, and sphingosine-I-phosphate. The balance between cellular levels of these bioactive products is increasingly recognized to be critical to cell regulation; whereby, ceramide and sphingosine cause apoptosis and growth arrest phenotypes, and sphingosine-1-phosphate mediates proliferative and angiogenic responses. Sphingosine kinase is a key enzyme in modulating the levels of these lipids and is emerging as an important and regulated enzyme. This review is geared at mechanisms of regulation of sphingosine kinase and the coming to light of its role in disease. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 171 Ashley Ave, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA 97132]; NHLBI NIH HHS [HL43707]; NIGMS NIH HHS [GM62887] NR 192 TC 186 Z9 198 U1 2 U2 9 PU SPRINGER SINGAPORE PTE LTD PI SINGAPORE PA #04-01 CENCON I, 1 TANNERY RD, SINGAPORE 347719, SINGAPORE SN 1225-8687 J9 J BIOCHEM MOL BIOL JI J. Biochem. Mol. Biol. PD MAR 31 PY 2006 VL 39 IS 2 BP 113 EP 131 PG 19 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 026LO UT WOS:000236340600001 PM 16584625 ER PT J AU Little, WC Freeman, GL AF Little, WC Freeman, GL TI Pericardial disease SO CIRCULATION LA English DT Article DE cardiac tamponade; pericarditis; pericardium ID EFFUSIVE-CONSTRICTIVE PERICARDITIS; VENTRICULAR DIASTOLIC COLLAPSE; ACUTE MYOCARDIAL-INFARCTION; CARDIAC TROPONIN-I; RESTRICTIVE CARDIOMYOPATHY; RECURRENT PERICARDITIS; DOPPLER-ECHOCARDIOGRAPHY; ETIOLOGIC DIAGNOSIS; INTRAPERICARDIAL TREATMENT; BALLOON PERICARDIOTOMY C1 Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Winston Salem, NC 27157 USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, Dept Physiol, San Antonio, TX USA. RP Little, WC (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM wlittle@wfubmc.edu NR 83 TC 136 Z9 156 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 28 PY 2006 VL 113 IS 12 BP 1622 EP 1632 DI 10.1161/CIRCULATIONAHA.105.561514 PG 11 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 025UO UT WOS:000236292600014 PM 16567581 ER PT J AU Chu, BC Yuan, C Takaya, N Shewchuk, JR Clowes, AW Hatsukami, TS AF Chu, BC Yuan, C Takaya, N Shewchuk, JR Clowes, AW Hatsukami, TS TI Serial high-spatial-resolution, multisequence magnetic resonance imaging studies identify fibrous cap rupture and penetrating ulcer into carotid atherosclerotic plaque SO CIRCULATION LA English DT Editorial Material C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA USA. RP Chu, BC (reprint author), Univ Washington, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA. EM chubc@u.washington.edu FU NHLBI NIH HHS [R01-HL-073401, R01-HL-61851] NR 4 TC 17 Z9 19 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 28 PY 2006 VL 113 IS 12 BP E660 EP E661 DI 10.1161/CIRCULATIONAHA.105.567255 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 025UO UT WOS:000236292600017 PM 16567574 ER PT J AU Burroughs, L Mielcarek, M Leisenring, W Sandmaier, BM Maloney, DG Baron, F Martin, PJ Flowers, MED Forman, SJ Chauncey, TR Bruno, B Storb, R AF Burroughs, L Mielcarek, M Leisenring, W Sandmaier, BM Maloney, DG Baron, F Martin, PJ Flowers, MED Forman, SJ Chauncey, TR Bruno, B Storb, R TI Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation SO TRANSPLANTATION LA English DT Article DE graft-versus-host disease; nonmyeloablative conditioning; allogeneic hematopoietic cell transplantation; cyclosporine ID BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; MATCHED RELATED DONORS; SEVERE APLASTIC-ANEMIA; TERM FOLLOW-UP; HEMATOLOGIC MALIGNANCIES; COMPARING METHOTREXATE; RANDOMIZED-TRIAL; UNRELATED DONORS; HUMAN RECIPIENTS AB Background. It is unknown whether the duration of systemic immunosuppressive treatment after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT) might influence the incidence, severity, timing, and/or corticosteroid-responsiveness of graft-versus-host disease (GVHD). Methods. We retrospectively analyzed outcomes among 185 patients with hematologic malignancies who were given grafts from HLA-matched related donors following conditioning with 2 Gy total body irradiation alone or in combination with fludarabine between December 1998 and March 2003. Postgrafting immunosuppression consisted of mycophenolate mofetil (days 0-27) in combination with 3 different cyclosporine (CSP) regimens: taper from (A) days 35 to 56 (n=107), (B) days 56 to 77 (n=35), and (C) days 56 to 180 (n=43). Results. The overall incidences of grades II-IV and III-IV acute GVHD, and extensive chronic GVHD were 52%,13%, and 56%, respectively. The duration of CSP prophylaxis did not significantly influence the overall rate of acute GVHD (grade II-IV), extensive chronic GVHD, or non-relapse mortality. However, prolonged administration of CSP (group C) was associated with a significantly decreased hazard of grades III-IV acute GVHD (HR 0.2, 95% CI [0.04, 0.9]) and with an increased likelihood of discontinuing all systemic immunosuppression (HR 2.4, 95% Cl [1.1, 5.2]) when compared to the shortest course of CSP (group A). Conclusion. Longer CSP duration decreased the risk of severe GVHD and increased the likelihood of discontinuing all systemic immunosuppression after nonmyeloablative HCT with HLA-matched related grafts. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Univ Washington, Dept Pediat, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA USA. Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Turin, Turin, Italy. RP Storb, R (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM rstorb@fhcrc.org FU NCI NIH HHS [CA 78902, CA 18029, CA 15704, P01 CA078902, K12 CA 076930]; NHLBI NIH HHS [HL 36444]; NIDDK NIH HHS [DK 064715] NR 34 TC 27 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD MAR 27 PY 2006 VL 81 IS 6 BP 818 EP 825 DI 10.1097/01.tp.0000203556.06145.5b PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 027UK UT WOS:000236440900002 PM 16570002 ER PT J AU Casarett, D Kapo, J Caplan, A AF Casarett, D Kapo, J Caplan, A TI Appropriate use of artificial nutrition and hydration - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 23 PY 2006 VL 354 IS 12 BP 1321 EP 1321 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 023ZH UT WOS:000236164200024 ER PT J AU Hunt, PW Deeks, SG Bangsberg, DR Moss, A Sinclair, E Liegler, T Bates, M Tsao, G Lampiris, H Hoh, R Martin, JN AF Hunt, PW Deeks, SG Bangsberg, DR Moss, A Sinclair, E Liegler, T Bates, M Tsao, G Lampiris, H Hoh, R Martin, JN TI The independent effect of drug resistance on T cell activation in HIV infection SO AIDS LA English DT Article; Proceedings Paper CT 11th Conference on Retroviruses and Opportunistic Infections CY FEB 08-11, 2004 CL San Francisco, CA DE HIV; antiretroviral therapy; drug resistance; T cell activation ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; PROTEASE INHIBITORS; VIRAL LOAD; LYMPHOCYTE ACTIVATION; CLINICAL PROGRESSION; COMBINATION THERAPY; DISEASE PROGRESSION; VIROLOGICAL FAILURE AB Objective: Antiretroviral-treated individuals with drug-resistant HIV experience slower CD4 cell count declines than untreated individuals, independent of degree of viremia. As immune activation independently predicts disease progression, we hypothesized that patients with drug-resistant viremia would have less immune activation than patients with wild-type viremia, independent of plasma HIV RNA levels and that these differences would not be explained by a direct drug effect of protease inhibitors. Methods: Percentages of activated (CD38/HLA-DR) T cells were compared between untreated participants with wild-type viremia and anti retroviral-treated participants with drug-resistant viremia, after adjusting for plasma HIV RNA levels among other factors associated with T cell activation. Changes in T cell activation were also assessed in subjects discontinuing protease inhibitors while continuing other antiretroviral medications. Results: Twenty-one untreated participants with wild-type viremia and 70 antiretroviral-treated participants with drug-resistant viremia were evaluated. Relative to untreated participants, those with drug-resistant viremia had 29% fewer activated CD4 (P = 0.051) and CD8 (P = 0.012) T cells after adjustment for plasma HIV RNA levels among other factors. There was no evidence for an early change in T cell activation among 13 Subjects with drug-resistant viremia interrupting protease inhibitors while continuing other antiretroviral medications, but a significant increase in T cell activation with complete or partial emergence of wild-type sequences in protease. Conclusions: Anti retroviral-treated patients with drug-resistant viremia have less T cell activation than untreated patients, independent of plasma HIV RNA level. Decreased ability of drug-resistant variants to cause T cell activation likely contributes to slower CD4 cell count declines among patients with drug-resistant viremia. (C) 2006 Lippincott Williams & Wilkins. C1 Univ Calif San Francisco, Posit Hlth Program, San Francisco Gen Hosp, San Francisco, CA 94110 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Virol Inc, San Francisco, CA USA. Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Gen Hosp, Gen Clin Res Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Epidemiol & Prevent Intervent Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Infect Dis, San Francisco, CA 94143 USA. RP Hunt, PW (reprint author), Univ Calif San Francisco, Posit Hlth Program, San Francisco Gen Hosp, Blg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA. EM phunt@php.ucsf.edu FU NCRR NIH HHS [5-MO1-RR00083-37]; NIAID NIH HHS [K23 AI 65244, R01 AI 52745, P30 AI27763]; NIMH NIH HHS [R01 MH054907, P30 MH59037, MH 54907, P30 MH62246] NR 56 TC 31 Z9 31 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAR 21 PY 2006 VL 20 IS 5 BP 691 EP 699 DI 10.1097/01.aids.0000216369.30948.18 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 027MZ UT WOS:000236421000008 PM 16514299 ER PT J AU Parimon, T Au, DH Martin, PJ Chien, JW AF Parimon, T Au, DH Martin, PJ Chien, JW TI A risk score for mortality after allogeneic hematopoietic cell transplantation SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID BONE-MARROW-TRANSPLANTATION; 2 IRRADIATION REGIMENS; RANDOMIZED-TRIAL; MYELOID-LEUKEMIA; FAILURE; VALUES; COHORT AB Background: Despite recent advances, mortality rates after allogeneic hematopoietic cell transplantation remain high and cannot be accurately predicted. Objective: To develop a reliable and valid predictor of all-cause mortality during the first 2 years after allogeneic hematopoietic cell transplantation. Design: Retrospective cohort. Setting: Tertiary hematopoietic cell transplantation center. Patients: Patients (n = 2802) who received a first hematopoietic cell transplant between 1990 and 2002 were assigned to a development group or a validation group. Measurements: Potential predictor variables were assessed with univariate and multivariable Cox proportional hazards methods to generate a prediction model. The c-statistic was calculated for 5 validation cohorts to assess model performance across early and late time periods and among patients with different diagnoses. Results: The authors constructed a 50-point Pretransplantation Assessment of Mortality (PAM) score that incorporated 8 pretransplantation clinical variables: patient age, donor type, disease risk, conditioning regimen, FEV(1), carbon monoxide diffusion capacity, serum creatinine level, and serum alanine aminotransferase concentration. The risk for death within 2 years for patients with PAM scores in the highest category was significantly higher than for those with scores in the lowest category. C-statistic values ranged from 0.69 to 0.76 for all validation cohorts. Limitations: The predictor model was not validated in an external cohort and is only useful for predicting the risk for death within the first 2 years after hematopoietic cell transplantation. Conclusions: Integrating pretransplantation clinical variables into a single score reliably predicts survival within 2 years after allogeneic hematopoietic cell transplantation. Accurate estimates of the risk for death may be useful in clinical trials and in epidemiologic studies. Such information can also be used to help physicians counsel patients regarding the expected outcomes of this potentially curative procedure. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Chien, JW (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Suite D5-280, Seattle, WA 98109 USA. EM jchien@fhcrc.org FU NHLBI NIH HHS [K23HL69860-01] NR 18 TC 99 Z9 100 U1 2 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 21 PY 2006 VL 144 IS 6 BP 407 EP 414 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 025FX UT WOS:000236251800004 PM 16549853 ER PT J AU Anand, BS Verstovsek, G Cole, G AF Anand, Bhupinder S. Verstovsek, Gordana Cole, George TI Tubulovillous adenoma of anal canal: A case report SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE tubulovillous adenoma; anal canal AB Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma. We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis. A 78-year-old white man presented with rectal bleeding of several months duration. Examination revealed a 4 cm friable mass attached to the anus by. a stalk. At surgery, the mass was grasped with a Babcock forceps and was resected using electrocautery. Microscopic examination revealed a tubulovillus adenoma with no areas of high grade dysplasia or malignant transformation. The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor. We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus. Although seen rarely, it is important to recognize and treat these tumors at an early stage because of their potential to transform into adenocarcinoma. (c) 2006 The WJG Press. All rights reserved. C1 Michael DeBakey Vet Adm Med Ctr, Dept Med, Houston, TX USA. Michael DeBakey Vet Adm Med Ctr, Dept Pathol, Houston, TX USA. Michael DeBakey Vet Adm Med Ctr, Dept Surg, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Anand, BS (reprint author), VA Med Ctr, Digest Dis Sect, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM ana0@flash.net NR 4 TC 4 Z9 4 U1 0 U2 0 PU W J G PRESS PI BEIJING PA PO BOX 2345, BEIJING 100023, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAR 21 PY 2006 VL 12 IS 11 BP 1780 EP 1781 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 076YZ UT WOS:000239995900021 PM 16586552 ER PT J AU Asch, SM Kerr, EA Keesey, J Adams, JL Setodji, CM Malik, S McGlynn, EA AF Asch, SM Kerr, EA Keesey, J Adams, JL Setodji, CM Malik, S McGlynn, EA TI Who is at greatest risk for receiving poor-quality health care? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OF-CARE; RACIAL-DIFFERENCES; PHYSICIAN COMMUNICATION; HEART-FAILURE; UNITED-STATES; BENEFICIARIES; INSURANCE; ADULTS; BLACK AB Background: American adults frequently do not receive recommended health care. The extent to which the quality of health care varies among sociodemographic groups is unknown. Methods: We used data from medical records and telephone interviews of a random sample of people living in 12 communities to assess the quality of care received by those who had made at least one visit to a health care provider during the previous two years. We constructed aggregate scores from 439 indicators of the quality of care for 30 chronic and acute conditions and for disease prevention. We estimated the rates at which members of different sociodemographic subgroups received recommended care, with adjustment for the number of chronic and acute conditions, use of health care services, and other sociodemographic characteristics. Results: Overall, participants received 54.9 percent of recommended care. Even after adjustment, there was only moderate variation in quality-of-care scores among sociodemographic subgroups. Women had higher overall scores than men (56.6 percent vs. 52.3 percent, P<0.001), and participants below the age of 31 years had higher scores than those over the age of 64 years (57.5 percent vs. 52.1 percent, P<0.001). Blacks (57.6 percent) and Hispanics (57.5 percent) had slightly higher scores than whites (54.1 percent, P<0.001 for both comparisons). Those with annual household incomes over $50,000 had higher scores than those with incomes of less than $15,000 (56.6 percent vs. 53.1 percent, P<0.001). Conclusions: The differences among sociodemographic subgroups in the observed quality of health care are small in comparison with the gap for each subgroup between observed and desirable quality of health care. Quality-improvement programs that focus solely on reducing disparities among sociodemographic subgroups may miss larger opportunities to improve care. C1 RAND Hlth, Santa Monica, CA 90407 USA. Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Vet Affairs Ann Arbor Hlth Care Syst, Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI USA. Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. Univ Calif Irvine, Dept Med, Div Cardiol, Irvine, CA 92717 USA. RP Asch, SM (reprint author), RAND Hlth, Santa Monica, CA 90407 USA. NR 32 TC 261 Z9 264 U1 1 U2 17 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 16 PY 2006 VL 354 IS 11 BP 1147 EP 1156 DI 10.1056/NEJMsa044464 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 021KI UT WOS:000235981700008 PM 16540615 ER PT J AU Musher, DM Logan, N Mehendiratta, V AF Musher, DM Logan, N Mehendiratta, V TI Epidemic Clostridium difficile SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID STRAIN C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 4 TC 11 Z9 12 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 16 PY 2006 VL 354 IS 11 BP 1199 EP 1200 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 021KI UT WOS:000235981700021 PM 16540624 ER PT J AU Rice, TL Palevsky, PM AF Rice, TL Palevsky, PM TI Preferred treatment of hyperkalemia SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Letter ID RENAL-FAILURE; HYPERGLYCEMIA C1 Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. Univ Dr Div, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Rice, TL (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 302 Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA. EM ricetl@upmc.edu; palevsky@pitt.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAR 15 PY 2006 VL 63 IS 6 BP 513 EP 513 DI 10.2146/ajhp050411 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 026XR UT WOS:000236377100012 PM 16522882 ER PT J AU Gharib, SA Liles, WC Matute-Bello, G Glenny, RW Martin, TR Altemeier, WA AF Gharib, SA Liles, WC Matute-Bello, G Glenny, RW Martin, TR Altemeier, WA TI Computational identification of key biological modules and transcription factors in acute lung injury SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE acute lung injury; gene network; microarray; transcription factor ID RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; GENE-ONTOLOGY; TIDAL VOLUMES; ACTIVATION; REGULATORS; CYP2E1; DAMAGE; CELLS; SP1 AB Rationale: Mechanical ventilation augments the acute lung injury (ALI) caused by bacterial products. The molecular pathogenesis of this synergistic interaction remains incompletely understood. Objective: We sought to develop a computational framework to systematically identify gene regulatory networks activated in ALI. Methods: We have developed a mouse model in which the combination of mechanical ventilation and intratracheal LPS produces significantly more injury to the lung than either insult alone. We used global gene ontology analysis to determine overrepresented biological modules and computational transcription factor analysis to identify putative regulatory factors involved in this model of ALI. Results: By integrating expression profiling with gene ontology and promoter analysis, we constructed a large-scale regulatory modular map of the important processes activated in ALI. This map assigned differentially expressed genes to highly overrepresented biological modules, including "defense response," "immune response," and "oxidoreductase activity." These modules were then systematically incorporated into a gene regulatory network that consisted of putative transcription factors, such as IFN-stimulated response element, IRF7, and Sp1, that may regulate critical processes involved in the pathogenesis of ALI. Conclusions: We present a novel, unbiased, and powerful computational approach to investigate the synergistic effects of mechanical ventilation and LPS in promoting ALI. Our methodology is applicable to any expression profiling experiment involving eukaryotic organisms. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Physiol, Seattle, WA 98195 USA. Univ Washington, Dept Biophys, Seattle, WA 98195 USA. Vet Affairs Puget Sound Healthcare Syst, Med Res Serv, Seattle, WA USA. RP Gharib, SA (reprint author), Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA. EM sagharib@u.washington.edu FU NHLBI NIH HHS [K08 HL071020] NR 29 TC 35 Z9 38 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 15 PY 2006 VL 173 IS 6 BP 653 EP 658 DI 10.1164/rccm.200509-1473OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 024FY UT WOS:000236182100012 PM 16387799 ER PT J AU Yang, SC Batra, RK Hillinger, S Reckamp, KL Strieter, RM Dubinett, SM Sharma, S AF Yang, SC Batra, RK Hillinger, S Reckamp, KL Strieter, RM Dubinett, SM Sharma, S TI Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma SO CANCER RESEARCH LA English DT Article ID COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; LUNG-CANCER; IN-VIVO; ANTITUMOR RESPONSES; IMMUNITY; ANTIGEN; LYMPHOCYTES; VACCINES AB The antitumor efficiency of dendritic cells transduced with an adenovirus vector expressing secondary lymphoid chemokine (CCL21) was evaluated in a murine model of spontaneous bronchoalveolar cell carcinoma. The transgenic mice (CC-10 TAg) express the SV40 large T antigen (TAg) under the Clara cell promoter, develop bilateral, multifocal, and pulmonary adenocarcinomas, and die at 4 months as a result of progressive pulmonary tumor burden. A single intratracheal administration of CCL21 gene-modified dendritic cells (DC-AdCCL21) led to a marked reduction in tumor burden with extensive mommuclear cell infiltration of the tumors. The reduction in tumor burden was accompanied by the enhanced elaboration of type I cytokines [IFN-gamma, interleukin (IL)-12, and granulocyte macrophage colony-stimulating factor] and antiangiogenic chemokines (CXCL9 and CXCL10) but a concomitant decrease in the immunosuppressive molecules (IL-10, transforming growth factor-P, prostaglandin E-2) in the tumor microenvironment. The DC-AdCCL21 therapy group revealed a significantly greater frequency of tumor-specific T cells releasing IFN-gamma, compared with the controls. Continuous therapy with weekly intranasal delivery of DC-AdCCL21 significantly prolonged median survival by > 7 weeks in CC10 TAg mice. Both innate natural killer and specific T-cell antitumor responses significantly increased following DC-AdCCL21 therapy. Significant reduction in tumor burden in a model in which tumors develop in an organ-specific manner provides a strong rationale for further evaluation of intrapulmonary-administered DC-AdCCL21 in regulation of tumor immunity and genetic immunotherapy for lung cancer. C1 Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Ctr Hlth Sci 37 131, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Dept Med, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA. Univ Zurich Hosp, CH-8091 Zurich, Switzerland. RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Ctr Hlth Sci 37 131, 10833 LeConte Ave, Los Angeles, CA 90095 USA. EM sharmasp@ucla.edu OI Batra, Raj K./0000-0002-1126-543X; Reckamp, Karen/0000-0002-9213-0325 FU NCI NIH HHS [P50 CA90388, R01 CA85686] NR 48 TC 48 Z9 52 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAR 15 PY 2006 VL 66 IS 6 BP 3205 EP 3213 DI 10.1158/0008-5472.CAN-05-3619 PG 9 WC Oncology SC Oncology GA 022ZA UT WOS:000236093500042 PM 16540672 ER PT J AU Gvilia, I Turner, A McGinty, D Szymusiak, R AF Gvilia, I Turner, A McGinty, D Szymusiak, R TI Preoptic area neurons and the homeostatic regulation of rapid eye movement sleep SO JOURNAL OF NEUROSCIENCE LA English DT Article DE sleep homeostasis; REM sleep; sleep deprivation; ventrolateral preoptic area; GABA; median preoptic nucleus ID DORSAL RAPHE NUCLEUS; SEROTONIN-CONTAINING NEURONS; WAKING DISCHARGE PATTERNS; MONOAMINERGIC CELL GROUPS; FREELY MOVING CATS; C-FOS; GABAERGIC INNERVATION; GALANINERGIC NEURONS; HYPOTHALAMIC NEURONS; PARADOXICAL SLEEP AB The median preoptic nucleus (MnPN) and the ventral lateral preoptic area (vlPOA) of the hypothalamus express sleep-related Fos immunoreactivity, and a subset of Fos-immunoreactive neurons (IRNs) in these nuclei contain glutamic acid decarboxylase (GAD), a marker of GABAergic cells. We recently showed that the numbers of Fos-positive (Fos +) and Fos + GAD-IRNs in both the MnPN and the vlPOA are positively correlated with the total amount of preceding sleep. The present study was designed to clarify whether or not activation of sleep-related neurons in the rat MnPN and vlPOA is associated with rapid eye movement (REM) sleep regulation. Expression of c-fos in MnPN and vlPOA neurons was examined under conditions of spontaneous sleep, REM sleep restriction, and REM sleep recovery after REM sleep restriction. Across all conditions, the number of Fos-IRNs was highest in REM-sleep- restricted rats displaying the highest levels of REM sleep homeostatic pressure/drive, i. e., those rats exhibiting the most frequent attempts to enter REM sleep. This finding provides the first evidence that activation of subsets of MnPN and vlPOA neurons is more strongly related to REM sleep pressure than to REM sleep amount. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Beritashvili Inst Physiol, GE-0160 Tbilisi, Rep of Georgia. RP Szymusiak, R (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, 16111 Plummer St, North Hills, CA 91343 USA. EM irmagvilia@hotmail.com; rszym@ucla.edu FU NHLBI NIH HHS [HL60296]; NIMH NIH HHS [MH63323] NR 35 TC 52 Z9 58 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 15 PY 2006 VL 26 IS 11 BP 3037 EP 3044 DI 10.1523/JNEUROSCI.4827-05.2006 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 021QU UT WOS:000236000400022 PM 16540582 ER PT J AU Shin, JM Homerin, M Domagala, F Ficheux, H Sachs, G AF Shin, JM Homerin, M Domagala, F Ficheux, H Sachs, G TI Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+-ATPase in vitro and in vivo SO BIOCHEMICAL PHARMACOLOGY LA English DT Article DE the gastric H,K-ATPase; tenatoprazole; binding stoichiometry; inhibition of acid secretion; proton pump inhibitor; omeprazole ID PROTON PUMP INHIBITORS; PLASMA HALF-LIFE; ACID-SECRETION; INTRAGASTRIC PH; HEALTHY-VOLUNTEERS; PARIETAL-CELL; OMEPRAZOLE; VESICLES; ATPASE; ESOMEPRAZOLE AB Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which is converted to the active sulfenamide or sulfenic acid by acid in the secretory canaliculus of the stimulated parietal cell of the stomach. This active species binds to lurninally accessible cysteines of the gastric H+,K+-ATPase resulting in disulfide formation and acid secretion inhibition. Tenatoprazole binds at the catalytic subunit of the gastric acid pump with a stoichiometry of 2.6 nmol mg(-1) of the enzyme in vitro. In vivo, maximum binding of tenatoprazole was 2.9 nmol mg(-1) of the enzyme at 2 h after IV administration. The binding sites of tenatoprazole were in the TM5/6 region at Cys813 and Cys822 as shown by tryptic and thermolysin digestion of the ATPase labeled by tenatoprazole. Decay of tenatoprazole binding on the gastric H+,K+-ATPase consisted of two components. One was relatively fast, with a half-life 3.9 h due to reversal of binding at cysteine 813, and the other was a plateau phase corresponding to ATPase turnover reflecting binding at cysteine 822 that also results in sustained inhibition in the presence of reducing agents in vitro. The stability of inhibition and the long plasma half-life of tenatoprazole should result in prolonged inhibition of acid secretion as compared to omeprazole. Further, the bioavailability of tenatoprazole was twofold greater in the (S)-tenatoprazole sodium salt hydrate form as compared to the free form in dogs which is due to differences in the crystal structure and hydrophobic nature of the two forms. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Membrane Biol Lab, Los Angeles, CA 90073 USA. Negma Lerads, F-78771 Magny Les Hameaux, France. RP Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol & Med, Los Angeles, CA 90024 USA. EM jaishin@ucla.edu; gsachs@ucla.edu FU NIDDK NIH HHS [DK46917, DK58333, DK53462] NR 35 TC 33 Z9 36 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0006-2952 EI 1873-2968 J9 BIOCHEM PHARMACOL JI Biochem. Pharmacol. PD MAR 14 PY 2006 VL 71 IS 6 BP 837 EP 849 DI 10.1016/j.bcp.2005.11.030 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 017WD UT WOS:000235723100014 PM 16405921 ER PT J AU Lambrecht, NWG Yakubov, I Zer, C Sachs, G AF Lambrecht, NWG Yakubov, I Zer, C Sachs, G TI Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion SO PHYSIOLOGICAL GENOMICS LA English DT Article DE entero-chromaffin-like cell; oligonucleotide expression microarray; transcriptome; apelin; APJ receptor ID ENTEROCHROMAFFIN-LIKE CELLS; FASTING RAT STOMACH; HUMAN APJ RECEPTOR; CIRCADIAN-RHYTHM; MOLECULAR-IDENTIFICATION; GASTROINTESTINAL-TRACT; INTRAGASTRIC ACIDITY; PEPTIDE PRECURSOR; ENERGY-BALANCE; DUODENAL-ULCER AB The gastric entero-chromaffin-like (ECL) cell plays a key regulatory role in peripheral regulation of acid secretion due to the release of histamine that stimulates acid secretion by the parietal cell. Studies in intact animals, gastric glands, and isolated cells after short-term culture have shown expression of stimulatory CCK2 and PAC1 and inhibitory SST2 and Gal1 receptors as well as histidine decarboxylase. However, the pattern of its gene expression as a neuroendocrine cell has not been explored. Comparison of gene expression by 95% pure ECL cells obtained by density gradient, elutriation, and fluorescence-assisted cell sorting with isolates of the intact fundic gastric epithelium ( i.e., "subtractive hybridization") identified a variety of additional expressed gene families characteristic of this neuroendocrine cell. These include genes 1) involved in neuropeptide synthesis and secretory vesicle exocytosis, 2) involved in control of inflammation, 3) implicated in healing of the epithelium, 4) encoding inhibitory G(i) protein-coupled receptors, 5) playing a role in neuroendocrine regulation of food intake, and 6) encoding proteins likely involved in maintenance of circadian rhythm, in addition to the ECL cell-specific genes histidine decarboxylase and monoamine transporter. Particularly, the inhibitory apelin receptor gene, APJ, was highly expressed in the ECL cell preparation. Because parietal cells express apelin, immunohistochemical and functional studies showed that there is an inhibitory feed back loop between the parietal and ECL cell during gastrin stimulation, providing evidence for a novel pathway of downregulation of acid secretion due to interaction between these two cell types. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Los Angeles, CA 90073 USA. RP Lambrecht, NWG (reprint author), Wadsworth VA Hosp, Bldg 113,Rm 325A, Los Angeles, CA 90073 USA. EM nilslam@ucla.edu OI Lambrecht, Nils/0000-0002-1275-1384 FU NIDDK NIH HHS [DK-53462, DK-46917, DK-58333] NR 72 TC 39 Z9 39 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD MAR 13 PY 2006 VL 25 IS 1 BP 153 EP 165 DI 10.1152/physiolgenomics.00271.2005 PG 13 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 031RW UT WOS:000236722700016 PM 16403840 ER PT J AU Saldarriaga, OA Travi, BL Park, W Perez, LE Melby, PC AF Saldarriaga, OA Travi, BL Park, W Perez, LE Melby, PC TI Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs SO VACCINE LA English DT Article DE visceral leishmaniasis; Leishmania donovani; Leishmania chagasi; vaccine; cellular immunity; interferon-gamma ID MURINE CUTANEOUS LEISHMANIASIS; CELLULAR IMMUNE-RESPONSE; CANINE KALA-AZAR; PROTECTIVE IMMUNITY; MAJOR VACCINE; DOUBLE-BLIND; IN-VIVO; ANTILEISHMANIAL ACTIVITY; CONFERS PROTECTION; ASYMPTOMATIC DOGS AB Vaccination of dogs, the domestic reservoir of Leishmania chagasi, could not only decrease the burden of canine visceral leishmaniasis (VL), but could also indirectly reduce the incidence of human VL. Intramuscular vaccination of foxhounds with a Leishmania multicomponent (10 antigen) DNA vaccine resulted in antigen-induced lymphoproliferative and IFN-gamma (but not IL-4) responses. This response was not augmented by co-administration of canine IL-12 or GM-CSF DNA adjuvants. The multicomponent DNA vaccine also induced a delayed type hypersensitivity (DTH) response to viable L. donovani promastigotes and led to a reduction of parasite burden in an in vitro intracellular infection model, and in the draining lymph node of dogs early after cutaneous challenge. Thus, the multicomponent DNA vaccine was effective in priming dogs for a parasite-specific type 1 cellular immune response, which was able to restrict parasite growth. (c) 2005 Elsevier Ltd. All rights reserved. C1 S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Res Ctr, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78285 USA. Ctr Int Entrenamiento & Invest Med, CIDEIM, Cali 5390, Colombia. RP Melby, PC (reprint author), S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Res Ctr, 7400 Merton Minter Dr,Mailstop 151, San Antonio, TX 78229 USA. EM melby@uthscsa.edu FU NIAID NIH HHS [AI48823] NR 73 TC 27 Z9 29 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAR 10 PY 2006 VL 24 IS 11 BP 1928 EP 1940 DI 10.1016/j.vaccine.2005.10.052 PG 13 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 025IR UT WOS:000236259600025 PM 16310897 ER PT J AU Pierce, A deWaal, E VanRemmen, H Richardson, A Chaudhuri, A AF Pierce, A deWaal, E VanRemmen, H Richardson, A Chaudhuri, A TI A novel approach for screening the proteome for changes in protein conformation SO BIOCHEMISTRY LA English DT Article ID CREATINE-KINASE; ACTIVE-SITE; SURFACE HYDROPHOBICITY; OXIDATIVE MODIFICATION; HYDROGEN-PEROXIDE; IN-VIVO; RHODANESE; INACTIVATION; BINDING; FLUORESCENCE AB Changes in surface hydrophobicity are generally considered as a sensitive indicator for monitoring the structural alterations of proteins that are often associated with changes in function. Currently, no technique has been developed to screen a complex mixture of proteins for changes in the conformation of specific proteins. In this study, we adapted a UV photolabeling approach, using an apolar fluorescent probe, 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid (BisANS), to monitor changes in surface hydrophobic domains in either purified rhodanese or skeletal muscle cytosolic proteins by urea-induced unfolding or in response to in vitro metal-catalyzed oxidation. Using two-dimensional polyacrylamide gel electrophoresis (2D PAGE), we identified two specific proteins in skeletal muscle cytosol that exhibited a marked loss of incorporation of BisANS after exposure to in vitro oxidative stress: creatine kinase (CK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We found that the activities of both enzymes were also reduced significantly in response to oxidative stress. We then determined if this method could detect changes in surface hydrophobicity in specific proteins arising from oxidative stress generated in vivo by muscle denervation. A loss in surface hydrophobic domains in CK and GAPDH was again observed as measured by the BisANS photoincorporation approach. In addition, the CK and GAPDH activity in denervated muscle was markedly reduced. These data demonstrate for the first time that this assay can screen a complex mixture of proteins for alterations in surface hydrophobic domains of individual proteins. C1 Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA. RP Chaudhuri, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chaudhuria@uthscsa.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU NIA NIH HHS [P01 AG19316, R01-AG23843] NR 46 TC 24 Z9 25 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD MAR 7 PY 2006 VL 45 IS 9 BP 3077 EP 3085 DI 10.1021/bi052031i PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 018VI UT WOS:000235792500034 PM 16503663 ER PT J AU Cowart, LA Hui, W AF Cowart, LA Hui, W TI Sphingolipid involvement in insulin sensitivity in C2C12 myotubes SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2006 Meeting CY APR 01-05, 2006 CL San Francisco, CA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 Med Univ S Carolina, Charleston, SC 29403 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2006 VL 20 IS 5 BP A1345 EP A1345 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 026GA UT WOS:000236326204414 ER PT J AU Zheng, Z Rumbaut, RE Burns, AR AF Zheng, Z Rumbaut, RE Burns, AR TI Transendothelial pressure inhibits neutrophil migration across IL1-treated endothelial cells: a role for nitric oxide. SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2006 Meeting CY APR 01-05, 2006 CL San Francisco, CA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2006 VL 20 IS 5 BP A1159 EP A1160 PN 2 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 026GA UT WOS:000236326203060 ER PT J AU Woo, JS Derleth, C Stratton, JR Levy, WC AF Woo, JS Derleth, C Stratton, JR Levy, WC TI The influence of age, gender, and training on exercise efficiency SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID POSTEXERCISE OXYGEN-CONSUMPTION; MAXIMAL AEROBIC CAPACITY; GAS-EXCHANGE KINETICS; HEART-FAILURE; MODERATE EXERCISE; SEDENTARY MEN; OLDER MEN; MUSCLE; YOUNG; DECLINE AB OBJECTIVES The aim of this study was to determine whether changes in oxygen efficiency occur with aging or exercise training in healthy young and older subjects. BACKGROUND Exercise capacity declines with age and improves with exercise training. Whether changes in oxygen efficiency, defined as the oxygen cost per unit work, contributes to the effects of aging or training has not yet been defined. METHODS Sixty-one healthy subjects were recruited into four groups of younger women (ages 20 to 33 years, n = 15), younger men (ages 20 to 30 years, n = 12), older women (ages 65 to 79 years, n = 16), and older men (ages 65 to 77 years, n = 18). All subjects under-went cardiopulmonary exercise testing to analyze aerobic parameters before and after three to six months of supervised aerobic exercise training. RESULTS Before training, younger subjects had a much higher exercise capacity, as shown by a 42% higher peak oxygen consumption (VO2) (ml/kg/min, p < 0.0001). This was associated with an 11% lower work VO2/W (P = 0.02) and an 8% higher efficiency than older subjects (p = 0.03). With training, older subjects displayed a larger increase in peak W/kg (+ 29% vs. +12%, p = 0.001), a larger decrease in work VO2/W (-24% vs. -2%, p < 0.0001), and a greater improvement in exercise efficiency (+30% vs. 2%, p < 0.0001) compared to the young. CONCLUSIONS Older age is associated with a decreased exercise efficiency and an increase in the oxygen cost of exercise, which contribute to a decreased exercise capacity. These age-related changes are reversed with exercise training, which improves efficiency to a greater degree in the elderly than in the young. C1 Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Cardiol, Seattle, WA USA. RP Levy, WC (reprint author), Univ Washington, Dept Internal Med, Box 356422,1959 NE Pacific St, Seattle, WA 98195 USA. EM levywc@u.washington.edu FU NIA NIH HHS [AG 15462] NR 36 TC 48 Z9 49 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 7 PY 2006 VL 47 IS 5 BP 1049 EP 1057 DI 10.1016/j.jacc.2005.09.066 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 018TN UT WOS:000235787800021 PM 16516092 ER PT J AU Coaxum, SD Gooz, M Baldys, A Garnovskaya, MN Raymond, JR AF Coaxum, SD Gooz, M Baldys, A Garnovskaya, MN Raymond, JR TI Epidermal growth factor activates Na+/H+ exchange in podocytes through a mechanism that involves janus kinase and calmodulin SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2006 Meeting CY APR 01-05, 2006 CL San Francisco, CA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 Med Univ S Carolina, Med Nephrol Div, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 6 PY 2006 VL 20 IS 4 BP A764 EP A764 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 024OW UT WOS:000236206506265 ER PT J AU Rhodes, ME Barkowski, KE Teets, BE Trice, MW Czambel, RK Rubin, RT AF Rhodes, ME Barkowski, KE Teets, BE Trice, MW Czambel, RK Rubin, RT TI Sexually diergic hypothalamic-pituitary-adrenal axis responses to single-dose nicotine alone and following continuous administration of nicotine by osmotic mini-pumps in rats SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2006 Meeting CY APR 01-05, 2006 CL San Francisco, CA SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut C1 St Vincent Coll, Dept Biol, Latrobe, PA 15650 USA. ASRI, Ctr Res Neurosci, Pittsburgh, PA 15212 USA. VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 6 PY 2006 VL 20 IS 4 BP A258 EP A258 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 024OW UT WOS:000236206502138 ER PT J AU Kilbourne, AM Pincus, HA Schutte, K Kirchner, JAE Haas, GL Yano, EM AF Kilbourne, AM Pincus, HA Schutte, K Kirchner, JAE Haas, GL Yano, EM TI Management of mental disorders in VA primary care practices SO ADMINISTRATION AND POLICY IN MENTAL HEALTH LA English DT Article DE depression; health services organization; mental disorders; mental health services; primary care ID UNITED-STATES; DEPRESSION; QUALITY; BURDEN; SYSTEM AB The association between facility-level organizational features and management of mental health services was assessed based on a survey of directors from 219 VA primary care facilities. Overall, 26.4% of VA primary care facilities referred patients with depression, while 72.6% and 46.1% referred patients with serious mental illness and substance use disorders, respectively Staffing mix (i.e., physician extenders such as nurse practitioners) was associated with a lesser likelihood of mental health referral. Managed care (preauthorization requirement) was associated with a greater likelihood of referral for depression. VA primary care programs, while tending to refer for more serious mental illnesses, may also be using mental health specialists and physician extenders to provide mental health care within general medical settings. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. RAND Univ Pittsburgh, Hlth Inst, Pittsburgh, PA USA. VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. VA Ctr Mental Healthcare & Outcomes Res, S Cent VA Mental Illness Res Educ Clin Ctr, Little Rock, AR 72114 USA. VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence 152, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Ctr Hlth Equ Res & Promot 151C, Univ Dr C, Pittsburgh, PA 15240 USA. EM Amy.Kilbourne@med.va.gov NR 19 TC 13 Z9 13 U1 0 U2 0 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD MAR PY 2006 VL 33 IS 2 BP 208 EP 214 DI 10.1007/s10488-006-0034-6 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 043ND UT WOS:000237607000007 PM 16477518 ER PT J AU Bogart, LM Fremont, AM Young, AS Pantoja, P Chinman, M Morton, S Koegel, P Sullivan, G Kanouse, DE AF Bogart, LM Fremont, AM Young, AS Pantoja, P Chinman, M Morton, S Koegel, P Sullivan, G Kanouse, DE TI Patterns of HIV care for patients with serious mental illness SO AIDS PATIENT CARE AND STDS LA English DT Article ID UNITED-STATES; ANTIRETROVIRAL TREATMENT; INFECTED PERSONS; CASE-MANAGEMENT; RISK BEHAVIORS; PEOPLE; AIDS; THERAPY; SEROPREVALENCE; INITIATION AB Individuals with serious mental illness are at higher risk for HIV than are members of the general population. Although studies have shown that individuals with serious mental illness experience less adequate care and worse physical health outcomes than comparable patients without serious mental illness, little is known about HIV care among individuals with serious mental illness who become infected with HIV. In the present study, we describe patterns of highly active antiretroviral treatment ( HAART) use and physician monitoring received by 154 patients with serious mental illness infected with HIV. Participants were recruited from mental health agencies in Los Angeles, California. Data from 762 HIV-only patients from a separate Western U. S. probability sample were used for comparison. High proportions of serious mental illness patients with HIV in our sample appeared to be receiving adequate HIV care. Fifty-one percent of all serious mental illness patients with serious mental illness with HIV were taking HAART, and the majority received close monitoring of their CD4 counts (84%) and viral loads (82%) throughout a 1-year period. HAART use and patterns of CD4 count and viral load monitoring did not differ significantly between patients with both serious mental illness and HIV, and patients with HIV only (all p > 0.05). Specialized programs providing assistance to serious mental illness populations with HIV may be helping to narrow health care disparities as a result of having serious mental illness. C1 RAND Corp, Santa Monica, CA 90407 USA. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Dept Vet Affairs Desert Pacific Mental Illness Re, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. VA S Cent Mental Illness Res Educ & Clin Ctr, N Little Rock, AR USA. Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. RP Bogart, LM (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM lbogart@rand.org RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU AHRQ HHS [U-01HS08578]; NIMH NIH HHS [P50 MH-54623, R01MH55936-05] NR 23 TC 13 Z9 13 U1 2 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAR PY 2006 VL 20 IS 3 BP 175 EP 182 DI 10.1089/apc.2006.20.175 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 029QN UT WOS:000236579600005 PM 16548714 ER PT J AU Mitchell, SH Reeves, JM Li, N Phillips, TJ AF Mitchell, SH Reeves, JM Li, N Phillips, TJ TI Delay discounting predicts behavioral sensitization to ethanol in outbred WSC mice SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE impulsivity; delay discounting; behavioral sensitization; locomotion; mice ID CONDITIONED PLACE PREFERENCE; ADJUSTING-AMOUNT PROCEDURE; RECOMBINANT INBRED MICE; LOCOMOTOR-ACTIVITY; VOLUNTARY ETHANOL; CHRONIC TOLERANCE; SELF-CONTROL; ALCOHOL; IMPULSIVITY; SENSITIVITY AB Background: Alcoholic individuals discount the value of future rewards more steeply than social drinkers, which is viewed as symptomatic of higher levels of impulsivity. However, the mechanisms underlying this difference are unknown. This study examined 2 hypotheses about the relationship between discounting and ethanol's effects in mice: (1) steep discounters are less sensitive to the initial stimulant-like effects of ethanol and (2) steep discounters exhibit greater behavioral adaptation to stimulant effects with repeated ethanol exposure. Methods: An adjusting amount procedure was used to assess discounting as a function of delay in ethanol-naive genetically heterogeneous WSC mice. Mice chose between a small amount of sucrose solution delivered immediately and 19.5 mu L delivered following a delay (0, 2, 4, 8, or 12 seconds, varied between sessions). Within sessions, the amount (mu L) of immediate sucrose was adjusted until animals became indifferent between the immediate and specific delayed reward. Hyperbolic discount functions were fitted to quantify the degree of delay discounting. Then, in a within-subjects design over 13 days, mice received a pattern of daily injections of saline or ethanol, and after certain treatments their locomotor activity was assessed for 15 minutes. Results: Animals with steeper discount functions (greater impulsivity) tended to exhibit less locomotor stimulation on their initial exposure to ethanol. However, steeper discounting was positively associated with increases in locomotor activity after repeated exposure (sensitization), indicating that steep discounters showed higher levels of sensitization to the stimulating effects of ethanol. Conclusions: These results suggest 2 behavioral effects of ethanol, associated with an increased risk for alcohol abuse, that are associated with variations in delay discounting. C1 Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Mitchell, SH (reprint author), Oregon Hlth Sci Univ, Dept Behav Neurosci, L470,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM mitchesu@ohsu.edu OI Mitchell, Suzanne/0000-0002-0225-7200 FU NIAAA NIH HHS [P50 AA10760, P60 AA010760] NR 43 TC 38 Z9 39 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAR PY 2006 VL 30 IS 3 BP 429 EP 437 DI 10.1111/j.1530-0277.2006.00047.x PG 9 WC Substance Abuse SC Substance Abuse GA 019EB UT WOS:000235817300005 PM 16499483 ER PT J AU Taylor, AN Tio, DL Bando, JK Romeo, HE Prolo, P AF Taylor, AN Tio, DL Bando, JK Romeo, HE Prolo, P TI Differential effects of alcohol consumption and withdrawal on circadian temperature and activity rhythms in Sprague-Dawley, Lewis, and Fischer male and female rats SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE ethanol dependence; biotelemetry; sex; inbred rat strains; corticotropin-releasing hormone ID CORTICOTROPIN-RELEASING HORMONE; SUPRACHIASMATIC NUCLEUS; LOCOMOTOR-ACTIVITY; BODY-TEMPERATURE; SEX-DIFFERENCES; TIME-SERIES; ETHANOL; RESPONSES; STRAINS; CORTICOSTERONE AB Background: Hypothalamic synthesis and secretion of corticotropin-releasing hormone (CRH), a putative mediator of various behavioral and physiological responses to ethanol (EtOH), is defective in inbred Lewis (LEW) rats in comparison with their genetically related inbred Fischer 344 (F344) and outbred Sprague-Dawley (S-D) strains. We aimed to characterize the effects of continuous EtOH consumption and withdrawal on circadian patterns of body temperature and spontaneous locomotor activity in males and females of these 3 strains. Methods: Adult LEW, F344, and S D males and randomly cycling females were fed an EtOH-containing liquid diet or the control (pair-fed or lab chow and water) diet for 14 days. Biotelemetric body temperature data for the last 3 days of EtOH diet feeding and the first 3 days of withdrawal were subjected to cosinor analysis of the circadian rhythm parameters of midline-estimating statistic of rhythm (MESOR), amplitude, and acrophase. Mean dark-phase activity during these periods was also computed. Results: In the control diet condition, the MESORs and amplitudes of LEW males were lower than those of F344 males. MESORs of rhythms of LEW females were lower than those of both F344 and S-D females. Ethanol consumption caused hypothermia with reduced MESORs and amplitudes of LEW and F344 males and amplitudes of F344 and S-D females. Upon withdrawal, MESORs of the males increased during each day as the amplitudes decreased, reflective of their initial withdrawal-induced dark-phase hypothermia, which was most pronounced in the LEW males, followed by light-phase hyperthermia. MESORs of females were not affected by withdrawal; their amplitudes were differentially affected. Acrophase of LEW males shifted from dark to light on the first day of withdrawal. All rats responded to EtOH exposure with a reduction of dark-phase spontaneous locomotor activity and an immediate increase upon withdrawal. Conclusions: Body temperature rhythms of the males were generally more affected by EtOH consumption and withdrawal than the females; within each sex, LEW and F344 rats differed significantly. The specific hormonal factors that mediate the differential temperature responses remain to be defined. C1 Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Taylor, AN (reprint author), Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM ataylor@mednet.ucla.edu FU NIAAA NIH HHS [AA09850] NR 51 TC 13 Z9 13 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAR PY 2006 VL 30 IS 3 BP 438 EP 447 DI 10.1111/j.1530-0277.2006.00048.x PG 10 WC Substance Abuse SC Substance Abuse GA 019EB UT WOS:000235817300006 PM 16499484 ER PT J AU Spertus, JA Peterson, E Rumsfeld, JS Jones, PG Decker, C Krumholz, H AF Spertus, JA Peterson, E Rumsfeld, JS Jones, PG Decker, C Krumholz, H CA Cardiovascular Outcomes Res Consor TI The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) - Evaluating the impact of myocardial infarction on patient outcomes SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROMES; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; QUALITY-OF-LIFE; HEART-ASSOCIATION; AMERICAN-COLLEGE; CARDIOVASCULAR-DISEASE; ARTERY DISEASE; HEALTH-STATUS; MANAGEMENT AB Background More information on the longitudinal care and outcomes of patients after myocardial infarction (MI) is needed to further improve the quality of MI care. The PREMIER study was designed to meet this need. Methods Patients with MI were prospectively screened and enrolled from 19 US centers between January 1, 2003, and June 28, 2004. Consenting patients had detailed chart abstractions of their medical history and processes of inpatient care, supplemented with a detailed, patient-centered interview. Centralized follow-up at 1, 6, and 12 months is being conducted to quantify patients' postdischarge care and outcomes, with a focus on their health status (symptoms, function, and quality of life). In 2003, detailed chart abstractions, devoid of all personal health information, were collected for patients eligible but not enrolled in PREMIER. Results Of 10911 patients screened, 3953 were eligible and 2498 enrolled into PREMIER. Few clinically significant differences between the total MI population and those enrolled into PREMIER were observed. Adherence to accepted processes of quality care, such as aspirin and beta-blockers on admission (96% and 91%) or discharge (96% and 93%), was high. One-month follow-up rates were high, with only 9% of patients being lost to follow-up. Conclusion PREMIER is a novel registry with detailed insights into patients' sociodemographic, clinical, and health status characteristics, as well as detailed monitoring of their inpatient and outpatient processes of care. Ultimately, PREMIER will describe patients' health status outcomes and identify determinants of these outcomes as an important step toward improving MI care. C1 Mid Amer Heart Inst, Kansas City, MO 64111 USA. Univ Missouri, Kansas City, MO USA. Yale Univ, New Haven, CT USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Colorado, Hlth Sci Ctr, Denver VA Med Ctr, Denver, CO USA. RP Spertus, JA (reprint author), Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM spertusj@umkc.edu FU AHRQ HHS [R-01 HS11282-01] NR 30 TC 80 Z9 83 U1 0 U2 4 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2006 VL 151 IS 3 BP 589 EP 597 DI 10.1016/j.ahj.2005.05.026 PG 17 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 026PF UT WOS:000236353900006 PM 16504619 ER PT J AU Rifai, MA Loftis, JM Hauser, P AF Rifai, MA Loftis, JM Hauser, P TI Hepatitis C treatment of veterans with psychiatric illness SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID INFECTION; DISORDERS; ELIGIBILITY; INTERFERON; HEALTH; RISK C1 Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97201 USA. Oregon Hlth Sci Univ, NW Hepatitis C Resource Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. Portland VA Med Ctr, JENS Lab, Portland, OR USA. RP Rifai, MA (reprint author), Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97201 USA. NR 10 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2006 VL 101 IS 3 BP 673 EP 674 DI 10.1111/j.1572-0241.2006.473_3.x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 016YD UT WOS:000235659500041 PM 16542298 ER PT J AU Norton, MC Skoog, I Toone, L Corcoran, C Tschanz, JAT Lisota, RD Hart, AD Zandi, PP Breitner, JCS Welsh-Bohmer, KA Steffens, DC AF Norton, MC Skoog, I Toone, L Corcoran, C Tschanz, JAT Lisota, RD Hart, AD Zandi, PP Breitner, JCS Welsh-Bohmer, KA Steffens, DC CA Cache County Investigators TI Three-year incidence of first-onset depressive syndrome in a population sample of older adults: The cache county study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 01-04, 2003 CL HONOLULU, HI SP Amer Assoc Geriatr Psychiat DE depression; epidemiology ID ELDERLY POPULATION; ALZHEIMERS-DISEASE; MENTAL-DISORDERS; MAJOR DEPRESSION; PREVALENCE; COMMUNITY; AD; EPIDEMIOLOGY; ANTAGONISTS; AGE AB Objective: Estimates of incidence of late-life depression vary greatly with few studies excluding demented cases through in-depth evaluation and most studies failing to control for the effect of mortality and interval treatment. In a large population-based study, the authors examined the effect on incidence of first-onset depressive syndrome to determine whether any gender or age differences in incidence are attenuated with inclusion of these additional measures. Method: Incidence rates of depressive syndrome per 1,000 person-years are presented for 2,877 nondemented elderly ( ages 65 to 100 years) residents of Cache County, Utah. Cases are identified by direct interview methods, by inference from prescription antidepressant medicine use, and by postmortem informant interview for decedents. Results: In-person interviews yielded incidence rates of first-onset depressive disorder (any type) of 13.09 for men and 19.44 for women. Inclusion of antidepressant users increased these figures to 15.55 for men and 23.30 for women. Addition of postmortem interview data yielded rates of 20.66 for men and 26.29 for women. Individuals with no history of depression had rates for major depression of 7.88 for men and 8.75 for women; minor depression rates were 19.23 for men and 24.46 for women (p = 0.691; effect for minor depression p < 0.0001). Age did not predict incidence. Conclusions: Incidence of first-onset major depression varies with data source and prior lifetime history of depression. Gender effects apparent in interview data are attenuated when postmortem information and pharmacotherapy were considered. C1 Utah State Univ, Dept Family Consumer & Human Dev, Logan, UT 84322 USA. Utah State Univ, Dept Psychol, Logan, UT 84322 USA. Utah State Univ, Dept Math & Stat, Logan, UT 84322 USA. Utah State Univ, Ctr Epidemiol Studies, Logan, UT 84322 USA. Gothenburg Univ, Sect Psychiat, Inst Clin Neurosci, S-41124 Gothenburg, Sweden. Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA. Johns Hopkins Univ, Dept Mental Hyg, Baltimore, MD 21218 USA. Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA. RP Norton, MC (reprint author), Utah State Univ, Dept Family Consumer & Human Dev, 2905 Old Main Hill, Logan, UT 84322 USA. EM mnorton@cc.usu.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU NIA NIH HHS [R01-AG-11380] NR 30 TC 32 Z9 33 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2006 VL 14 IS 3 BP 237 EP 245 DI 10.1097/01.JGP.0000196626.34881.42 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 016LE UT WOS:000235620900006 PM 16505128 ER PT J AU Chepenik, LG Ten Have, T Oslin, D Datto, C Zubritsky, C Katz, IR AF Chepenik, LG Ten Have, T Oslin, D Datto, C Zubritsky, C Katz, IR TI A daily diary study of late-life depression SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depressive disorders; minor depression; dysphoria; positive affect; diaries ID BEHAVIORAL HEALTH-CARE; CORTISOL SECRETION; RANDOMIZED-TRIAL; DAILY EVENTS; PRISM-E; DISORDER; MOOD; VARIABILITY; QUALITY; DISEASE AB Objective: The objective of this study was to use data from daily diaries to characterize the day-to-day variability in positive and negative affects, and the relationship between daily events and daily affects in primary care patients with late-life depression. Method: Daily diary data were obtained from primary care patients with major depression (N = 25) and other depressive disorders (N = 33); data from a two-week period were compared with those from elderly normal volunteer comparison subjects (N = 70) who participated in other studies. Results: There was significant day-to-day variability in negative affect in patients with major depression and other depressive disorders. Dysphoric days ( days with a negative affect ratings that occurred once every two weeks in normal subjects) represented 65.3% ( standard deviation [SD]: 37.1) of days in those with major depression and 50.6% (SD: 37.6) in those with other depression versus 7.7% (SD: 16.3) in normal subjects (F = 36.0, p < 0.001). The groups did not differ significantly in the number of positive and negative events reported, but the proportion of dysphoric days that occurred in association with negative events was greater in normal subjects than in those with major depression. Mixed-effects analyses demonstrated that patients with major depression had blunted positive affective responses to positive events, consistent with impairments in hedonic processes, and that patients with other depressions exhibited heightened negative affective responses to negative events, greater than those in normal subjects and patients with major depression. Conclusions: Diary methods demonstrated characteristics of late-life depression that have not been identified with assessment methods that have lower time resolution. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Katz, IR (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Rm 3001, Philadelphia, PA 19104 USA. EM katzi@mail.med.upenn.edu FU NIMH NIH HHS [R01 MH58349, MH66270] NR 26 TC 12 Z9 12 U1 1 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2006 VL 14 IS 3 BP 270 EP 279 DI 10.1097/01.JGP.0000194644.63245.42 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 016LE UT WOS:000235620900010 PM 16505132 ER PT J AU Hynes, DM Stroupe, KT Kaufman, JS Reda, DJ Peterman, A Browning, MM Huo, ZP Sorbara, D AF Hynes, DM Stroupe, KT Kaufman, JS Reda, DJ Peterman, A Browning, MM Huo, ZP Sorbara, D CA ESRD Cost Study Grp TI Adherence to guidelines for ESRD anemia management SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE erythropoietin; anemia management; end-stage renal disease (ESRD); clinical guidelines; veterans ID RED-CELL APLASIA; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; INTRAVENOUS EPOETIN; DIALYSIS PATIENTS; ERYTHROPOIETIN; THERAPY; IV AB Background. A costly component of end-stage renal disease care is anemia management with recombinant human erythropoietin. National Kidney Foundation clinical practice guidelines recommend that erythropoietin be administered subcutaneously, rather than intravenously, given that the target hemoglobin level can be maintained with a lower subcutaneous dose. Because reimbursement for erythropoietin differs for federal versus private-sector dialysis centers, we hypothesized different use patterns by facility type. Methods: Using data from a multisite prospective observational study of hemodialysis patients from 2001 to 2003, we examined compliance with erythropoietin administration guidelines across Veterans Affairs (VA) versus private-sector facilities and implications for erythropoietin dose, anemia management, and cost. Results: Erythropoietin was administered predominantly subcutaneously for 52% of patients in VA versus 15% in private-sector facilities (P<0.0001). Average adjusted weekly subcutaneous erythropoietin doses were 13,710 and 13,362 units at VA and private-sector facilities versus 19,453 and 21,237 units for intravenous erythropoietin (P=0.01), with corresponding hemoglobin levels of 11.55 and 12.34 g/dL (115.5 and 123.4 g/L) for subcutaneous and 11.38 and 11.91 g/dL (113.8 and 119.1 g/L) for intravenous erythropoietin (P=0.0002), respectively. Yearly erythropoietin costs per patient for subcutaneous administration were $7,129 and $6,948 at VA and private-sector facilities versus S10,116 and S11,043 for intravenous administration (P=0.01), respectively. Conclusion: We found greater guideline adherence at VA facilities compared with the private sector, with lower erythropoietin costs, although overall adherence is low. Anemia management was similar. Future research should examine how patient preferences and financial incentives impact on the wider use of subcutaneous erythropoietin administration. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA. Loyola Univ, Dept Med, Div Gen Internal Med, Maywood, IL 60153 USA. Univ Illinois, Dept Epidemiol & Biostat, Chicago, IL USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Vet Affairs Boston Healthcare Syst, Boston, MA USA. Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA. RP Hynes, DM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, POB 5000 151V, Hines, IL 60141 USA. EM denise.hynes@va.gov NR 19 TC 14 Z9 14 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2006 VL 47 IS 3 BP 455 EP 461 DI 10.1053/j.ajkd.2005.11.012 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 026FV UT WOS:000236325700012 PM 16490624 ER PT J AU Houldin, A Curtiss, CP Haylock, PJ AF Houldin, A Curtiss, CP Haylock, PJ TI Executive summary: The state of the science on nursing approaches to managing late and long-term sequelae of cancer and cancer treatment SO AMERICAN JOURNAL OF NURSING LA English DT Article ID SURVIVORSHIP; TRENDS; NATION C1 Univ Penn, Adult Oncol Nurse Practitioner Program, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Palliat Care Serv, Philadelphia, PA USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. RP Houldin, A (reprint author), Univ Penn, Adult Oncol Nurse Practitioner Program, Philadelphia, PA 19104 USA. EM houldin@nursing.upenn.edu; carol.curtiss@verizon.net; pjhaylock@indian-creek.net NR 13 TC 4 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD MAR PY 2006 VL 106 IS 3 BP 54 EP 59 PG 6 WC Nursing SC Nursing GA 016JI UT WOS:000235616100027 PM 16534393 ER PT J AU Czimmer, J Million, M Tache, Y AF Czimmer, J Million, M Tache, Y TI Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE adrenergic receptors; vagus; corticotropin; releasing hormone receptor ID CORTICOTROPIN-RELEASING-FACTOR; DORSAL RAPHE NUCLEUS; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; C-FOS EXPRESSION; PERIPHERAL UROCORTIN; FACTOR-RECEPTOR; CONSCIOUS RATS; STRESS; BRAIN; TRANSIT AB Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats. Am J Physiol Gastrointest Liver Physiol 290: G511-G518, 2006. First published Octobert 13, 2005; doi: 10.1152/ajpgi.00289.2005.-We characterized the influence of the selective corticotropin-releasing factor 2 (CRF2) receptor agonist human urocortin 2 (Ucn 2), injected intracisternally, on gastric emptying and its mechanism of action compared with intracisternal CRF or urocortin (Ucn 1) in conscious rats. The methylcellulose phenol red solution was gavaged 20 min after peptide injection, and gastric emptying was measured 20 min later. The intracisternal injection of Ucn 2 (0.1 and 1 mu g) and Ucn 1 (1 mu g) decreased gastric emptying to 37.8 +/- 6.9%, 23.1 +/- 8.6%, and 21.6 +/- 5.9%, respectively, compared with 58.4 +/- 3.8% after intracisternal vehicle. At lower doses, Ucn 2 (0.03 mu g) and Ucn 1 (0.1 mu g) had no effect. The CRF2 antagonist astressin(2)-B (3 mu g ic) antagonized intracisternal Ucn 2 (0.1 mu g) and CRF (0.3 mu g)-induced inhibition of gastric emptying. Vagotomy enhanced intracisternal Ucn 2 (0.1 or 1 mu g)-induced inhibition of gastric emptying compared with sham-operated group, whereas it blocked intracisternal CRF (1 mu g) inhibitory action (45.5 +/- 8.4% vs. 9.7 +/- 9.7%). Sympathetic blockade by bretylium prevented intracisternal and intracerebroventricular Ucn 2-induced delayed gastric emptying, whereas it did not influence intravenous Ucn 2-, intracisternal CRF-, and intracisternal Ucn 1-induced inhibition of gastric emptying. Prazosin abolished the intracisternal Ucn 2 inhibitory effect, whereas yohimbine and propranolol did not. None of the pretreatments modified basal gastric emptying. These data indicate that intracisternal Ucn 2 induced a central CRF2-mediated inhibition of gastric emptying involving sympathetic alpha(1)-adrenergic mechanisms independent from the vagus contrasting with the vagal-dependent inhibitory actions of CRF and Ucn 1. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, Dept Med, Los Angeles, CA USA. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE CNS Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [DK-41301, R01 DK-33061] NR 50 TC 39 Z9 40 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD MAR PY 2006 VL 290 IS 3 BP G511 EP G518 DI 10.1152/ajpgi.00289.2005 PG 8 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 011NP UT WOS:000235275500012 PM 16223946 ER PT J AU Kim, NH Rincon-Choles, H Bhandari, B Choudhury, GG Abboud, HE Gorin, Y AF Kim, NH Rincon-Choles, H Bhandari, B Choudhury, GG Abboud, HE Gorin, Y TI Redox dependence of glomerular epithelial cell hypertrophy in response to glucose SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE high glucose; angiotensin II; podocytes; reactive oxygen species; protein synthesis; hypertrophy ID SMOOTH-MUSCLE-CELLS; AKT/PROTEIN KINASE-B; ACTIVATED PROTEIN-KINASE; PROXIMAL TUBULAR CELLS; II-INDUCED ACTIVATION; ANGIOTENSIN-II; DIABETIC-NEPHROPATHY; MESANGIAL CELLS; PODOCYTE INJURY; NADPH OXIDASE AB Podocytes or glomerular epithelial cells ( GECs) are important targets of the diabetic microenvironment. Podocyte foot process effacement and widening, loss of GECs and hypertrophy are pathological features of this disease. ANG II and oxidative stress are key mediators of renal hypertrophy in diabetes. The cellular mechanisms responsible for GEC hypertrophy in diabetes are incompletely characterized. We investigated the effect of high glucose on protein synthesis and GEC hypertrophy. Exposure of GECs to high glucose dose dependently stimulated [ (3)H] leucine incorporation, but not [ (3)H] yhymidine incorporation. High glucose resulted in the activation of ERK1/2 and Akt/PKB. ERK1/2 pathway inhibitor or the dominant negative mutant of Akt/PKB inhibited high glucose-induced protein synthesis. High glucose elicited a rapid generation of reactive oxygen species ( ROS). The stimulatory effect of high glucose on ROS production, ERK1/2, and Akt/PKB activation was prevented by the antioxidants catalase, diphenylene iodonium, and N-acetylcysteine. Exposure of the cells to hydrogen peroxide mimicked the effects of high glucose. In addition, ANG II resulted in the activation of ERK1/2 and Akt/PKB and GEC hypertrophy. Moreover, high glucose and ANG II exhibited additive effects on ERK1/2 and Akt/PKB activation as well as protein synthesis. These additive responses were abolished by treatment of the cells with the antioxidants. These data demonstrate that high glucose stimulates GEC hypertrophy through a ROS-dependent activation of ERK1/2 and Akt/PKB. Enhanced ROS generation accounts for the additive effects of high glucose and ANG II, suggesting that this signaling cascade contributes to GEC injury in diabetes. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. Chonnam Natl Univ, Dept Med, Kwangju, South Korea. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Gorin, Y (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU NIDDK NIH HHS [DK-33665, DK-43988, DK-50190, DK-55815, P50 DK-61597] NR 54 TC 41 Z9 42 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 2006 VL 290 IS 3 BP F741 EP F751 DI 10.1152/ajprenal.00313.2005 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 009AE UT WOS:000235082700022 PM 16234311 ER PT J AU Subramanya, AR Yang, CL Zhu, XM Ellison, DH AF Subramanya, AR Yang, CL Zhu, XM Ellison, DH TI Dominant-negative regulation of WNK1 by its kidney-specific kinase-defective isoform SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE distal nephron; thiazide-sensitive sodium-chloride cotransporter; with-no-lysine kinases; aldosterone ID EPITHELIAL SODIUM-CHANNEL; NA-CL COTRANSPORTER; BLOOD-PRESSURE; HUMAN HYPERTENSION; MOLECULAR SWITCH; TRANSPORT; GENE; HYPERKALEMIA; REABSORPTION; ALDOSTERONE AB With-no-lysine kinase-1 (WNK1) gene mutations cause familial hyperkalemic hypertension (FHHt), a Mendelian disorder of excessive renal Na(+) and K(+) retention. Through its catalytic activity, full-length kinase-sufficient WNK1 (L-WNK1) suppresses its paralog, WNK4, thereby upregulating thiazide-sensitive Na-Cl cotransporter (NCC) activity. The predominant renal WNK1 isoform, KS-WNK1, expressed exclusively and at high levels in distal nephron, is a shorter kinase-defective product; the function of KS-WNK1 must therefore be kinase independent. Here, we report a novel role for KS-WNK1 as a dominant-negative regulator of L-WNK1. Na(+) transport studies in Xenopus laevis oocytes demonstrate that KS-WNK1 downregulates NCC activity indirectly, by inhibiting L-WNK1. KS-WNK1 also associates with L-WNK1 in protein complexes in oocytes and attenuates L-WNK1 kinase activity in vitro. These observations suggest that KS-WNK1 plays an essential role in the renal molecular switch regulating Na(+) and K(+) balance; they provide insight into the kidney-specific phenotype of FHHt. C1 Oregon Hlth Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [F32 DK 72865, R01 DK 51496] NR 29 TC 69 Z9 72 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 2006 VL 290 IS 3 BP F619 EP F624 DI 10.1152/ajprenal.00280.2005 PG 6 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 009AE UT WOS:000235082700008 PM 16204408 ER PT J AU Bowie, CR Reichenberg, A Patterson, TL Heaton, RK Harvey, PD AF Bowie, CR Reichenberg, A Patterson, TL Heaton, RK Harvey, PD TI Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 43rd Annual Meeting of the American-College-of-Neuropsychopharmacology CY DEC 12-16, 2004 CL San Juan, PR SP Vanderbilt Univ, Sch Med, Dept Psychiaty, Amer Coll Neuropsychopharmacol ID NEUROCOGNITIVE DEFICITS; MENTALLY-ILL; DISABILITY; MATRICS; TARGETS; SUPPORT; DISEASE; SKILLS; SCALE AB Objective: Impairments in adaptive life skills are a major source of disability in patients with schizophrenia. The relationship between adaptive life skills in realworld settings and performance on neuropsychological tests may be complicated by other factors that interfere with deployment of skills. Assessment of the ability to perform life skills under optimal conditions (i.e., assessment of functional capacity) has been proposed as a means to clarify these relationships. Method: The authors examined cross-sectional data from a study of the course of neuropsychological and adaptive life skills of older (age 50-85) schizophrenia patients (N=78). Functional capacity was examined with a performance-based measure (UCSD Performance-Based Skills Assessment), and case managers rated realworld adaptive functions ( i.e., interpersonal skills, work skills, and community activities). Neuropsychological performance was assessed with a comprehensive battery, while symptoms were assessed with patient self-report and clinical ratings. Results: Confirmatory path analyses were used to evaluate the effects of neuropsychological performance, functional capacity, and symptoms on the various domains of real-world functioning. Neuropsychological performance predicted functional capacity, which predicted all three domains of real-world functioning. Depression predicted interpersonal and work skills, while negative symptoms affected interpersonal skills independently of other predictors. Conclusions: Real-world adaptive life skills are predicted by neuropsychological performance, symptoms, and functional capacity. Neuropsychological performance contributes little to the prediction of real-world performance after accounting for functional capacity. In some domains, negative and depressive symptoms influenced real-world performance while not relating to functional capacity or neuropsychological performance. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Univ Calif San Diego, Med Ctr, Dept Psychiat, San Diego, CA 92103 USA. RP Bowie, CR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,4th Floor,Box 1230, New York, NY 10029 USA. EM christopher.bowie@mssm.edu FU NIMH NIH HHS [MH-36692, MH-63116] NR 37 TC 315 Z9 326 U1 3 U2 22 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAR PY 2006 VL 163 IS 3 BP 418 EP 425 DI 10.1176/appi.ajp.163.3.418 PG 8 WC Psychiatry SC Psychiatry GA 017XG UT WOS:000235726000014 PM 16513862 ER PT J AU Sergi, MJ Rassovsky, Y Nuechterlein, KH Green, MF AF Sergi, MJ Rassovsky, Y Nuechterlein, KH Green, MF TI Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT International-Congress-on-Schizophrenia-Research CY APR 03, 2005 CL Savannah, GA SP Int Congress Schizophrenia Res ID NEUROCOGNITIVE DEFICITS; AFFECT RECOGNITION; COGNITION; EMOTION; DISORDER; BEHAVIOR; MASKING; SCALE; MIND AB Objective: The potential of social cognition as a mediator of relations between neurocognition and functional status in schizophrenia has been suggested by correlational studies that link neurocognition to social cognition or link social cognition to functional status. The authors used structural equation modeling to test more directly whether one aspect of social cognition (social perception) mediates relations between basic visual perception and functional status in patients with schizophrenia. Method: Seventy-five outpatients with schizophrenia were administered measures of early visual processing (computerized visual masking procedures), social perception (Half Profile of Nonverbal Sensitivity), and functional status (Role Functioning Scale). Results: Structural equation modeling supported social perception as a mediator of relations between early visual processing and functional status in schizophrenia. The mediation model indicated that early visual processing is linked to functional status through social perception, thereby supporting a significant indirect relationship. The direct relationship between early visual processing and functional status was significant in a model that did not include social perception but was not significant in the mediation model that included social perception. Conclusions: Social cognition appears to be a key determinant of functional status in schizophrenia. Using a very basic measure of visual perception, the present study found that social perception mediates the influence of early visual processing on functional status in schizophrenia. C1 Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Sergi, MJ (reprint author), Calif State Univ Northridge, Dept Psychol, 18111 Nordhoff St, Northridge, CA 91330 USA. EM mark.sergi@csun.edu FU NIMH NIH HHS [MH-43292, MH-65707] NR 43 TC 165 Z9 169 U1 2 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAR PY 2006 VL 163 IS 3 BP 448 EP 454 DI 10.1176/appi.ajp.163.3.448 PG 7 WC Psychiatry SC Psychiatry GA 017XG UT WOS:000235726000018 PM 16513866 ER PT J AU Gruenewald, DA White, EJ AF Gruenewald, DA White, EJ TI The illness experience of older adults near the end of life: a systematic review SO ANESTHESIOLOGY CLINICS OF NORTH AMERICA LA English DT Article ID QUALITY-OF-LIFE; TERMINALLY-ILL; PATIENTS PERSPECTIVES; DYING PATIENTS; ELDERLY PATIENTS; DECISION-MAKING; PEOPLES VIEWS; LUNG-CANCER; CARE; PREFERENCES AB A systematic literature review identified qualitative studies of issues important to older people near the end of their lives, to develop a model of the illness experience near the end of life based on the views of older people. Six elements were identified from 40 studies that comprise a core domain of the experience of illness while dying: burden, Suffering, hope, dignity, decision making, and control and autonomy. These elements were interwoven with three main themes: contextual factors, perceptions and concerns, and response to illness. Collectively, the core domain and the three themes comprise a model of the experience of illness near the end of life. C1 Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv, Palliat Care & Hosp Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98108 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. RP Gruenewald, DA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Extended Care Serv, Palliat Care & Hosp Serv, S-182-GEC,1660 S Columbian Way, Seattle, WA 98108 USA. EM dgruen@u.washington.edu NR 43 TC 17 Z9 17 U1 1 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8537 J9 ANESTHESIOL CLIN N A JI Anesthesiol. Clin. N. Am. PD MAR PY 2006 VL 24 IS 1 BP 163 EP + DI 10.1016/j.atc.2005.12.003 PG 19 WC Anesthesiology SC Anesthesiology GA 021DD UT WOS:000235962800011 PM 16487901 ER PT J AU Abadie, JM Bankson, DD AF Abadie, JM Bankson, DD TI Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population SO ANNALS OF CLINICAL AND LABORATORY SCIENCE LA English DT Article DE light chains; monoclonal gammopathy; myeloma; electrophoresis; plasma cell dyscrasia ID MULTIPLE-MYELOMA; KAPPA AB This study evaluated serum. and l free light chain (FLC) concentrations in a Veterans Affairs (VA) population. We hypothesized that our older, mostly male, population should not differ in serum FLC ranges from levels previously established for younger male and female populations and that the assay would improve our screening protocol for plasma cell dyscrasias (PCD). Serum. and l FLC were assayed in 312 consecutive serum samples collected during a 16-week period from veterans whose clinical presentation indicated a need for serum protein electrophoresis (SPEP) analysis. We reviewed our laboratory information system (LIS) files to evaluate the patients' diagnoses and treatment status in conjunction with serum FLC levels. All assays and validation studies were conducted using an immunoturbidimetric method with a Roche/Hitachi 911 modular analytical system. The intra-assay variability (CV) was < 5%, based on 13 replicate assays of 4 control samples and 1 blank sample. Of the 312 patients, the SPEP results were normal in 235 and abnormal in 77. Of the 235 patients with normal SPEP results, 37 had abnormal FLC values and 20 of these were diagnosed as PCD. Of the 77 patients with abnormal SPEP results, only 9 had diagnoses unrelated to PCD. Using the FLC assay in conjunction with retrospective reviews of medical records, we obtained an 86% detection rate of PCD. This detection rate increased to 100% when both SPEP and FLC results were considered. In conclusion, this study documents an important role for serum FLC assays in diagnosing and monitoring PCD in a VA population. Our results support previously established serum FLC reference ranges that were obtained in younger, male and female populations. Using the serum FLC results in conjunction with SPEP results improves the sensitivity and specificity for managing VA patients whose clinical presentation indicates the need to evaluate PCD. C1 Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA. RP Abadie, JM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Pathol & Lab Med Serv, 1660 S Columbian Way S-113 Lab, Seattle, WA 98108 USA. EM judeabadie@medscape.com NR 13 TC 25 Z9 26 U1 0 U2 0 PU ASSN CLINICAL SCIENTISTS PI MIDDLEBURY PA PO BOX 1287, MIDDLEBURY, VT 05753 USA SN 0091-7370 J9 ANN CLIN LAB SCI JI Ann. Clin. Lab. Sci. PD SPR PY 2006 VL 36 IS 2 BP 157 EP 162 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 043LU UT WOS:000237603400006 PM 16682511 ER PT J AU Sung, SJ Conry, JM AF Sung, SJ Conry, JM TI Role of buprenorphine in the management of heroin addiction SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE addiction; buprenorphine; heroin; opioid ID METHADONE-MAINTENANCE INTERVENTIONS; OPIATE-DEPENDENT VOLUNTEERS; COST-EFFECTIVENESS; OPIOID DEPENDENCE; METAANALYSIS; BEHAVIOR AB OBJECTIVE: To review buprenorphine and explore its role in the treatment of heroin dependence. DATA SOURCES: Articles were identified through a search of MEDLINE (1966-February 2005) using the key terms buprenorphine, heroin, opioid, addiction, and methadone. DATA SYNTHESIS: Buprenorphine appears to provide potential advantages over methadone. Two Cochrane meta-analyses were evaluated on the use of buprenorphine in opioid dependence-one in the management of opioid dependence and the other in the management of opioid withdrawal. CONCLUSIONS: Buprenorphine offers several advantages for the treatment of heroin addiction. As maintenance treatment, buprenorphine is effective, but not more effective than methadone. In the management of opioid withdrawal, buprenorphine may be better tolerated than clonidine or methadone. C1 St Johns Univ, Coll Pharm & Allied Hlth Profess, Jamaica, NY 11439 USA. Bronx Vet Affairs Med Ctr, Dept Pharm, Bronx, NY USA. RP Conry, JM (reprint author), St Johns Univ, Coll Pharm & Allied Hlth Profess, St Alberts Hall,Rm 114,8000 Utopia Pkwy, Jamaica, NY 11439 USA. EM conryj@stjohns.edu NR 23 TC 12 Z9 12 U1 0 U2 2 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAR PY 2006 VL 40 IS 3 BP 501 EP 505 DI 10.1345/aph1G276 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 022JW UT WOS:000236052900017 PM 16434562 ER PT J AU Gerard, HC Whittum-Hudson, JA Schumacher, HR Hudson, AP AF Gerard, HC Whittum-Hudson, JA Schumacher, HR Hudson, AP TI Synovial Chlamydia trachomatis up regulates expression of a panel of genes similar to that transcribed by Mycobacterium tuberculosis during persistent infection SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID DIFFERENTIAL EXPRESSION; DEVELOPMENTAL CYCLE; GENOME SEQUENCE; PNEUMONIAE; DNA; MACROPHAGES; ARTHRITIS; PRODUCTS AB Background: Synovial tissues in patients with Chlamydia associated arthritis are persistently infected by C trachomatis, an organism for which genetic manipulation is not possible. M tuberculosis also engages in persistent infection, and because this bacterium is genetically tractable many groups have been able to define transcriptional characteristics of mycobacterial growth and persistence. Objective: To investigate whether the pattern of gene expression underlying chlamydial persistence is similar to that underlying mycobacterial persistence. Methods: 194 genes in M tuberculosis that are transcriptionally up regulated to support in vivo growth and persistence of that organism have previously been identified. Each of those genes was compared with the C trachomatis genome to identify orthologues. Expression of selected chlamydial orthologues so identified was assessed by real time RT-PCR in an in vitro model of chlamydial persistence and synovial tissues from patients who were PCR positive for C trachomatis at that site. Results: 67 C trachomatis genes were identified as being orthologous to mycobacterial persistence related genes, representing 35% of the genes tested. The chlamydial orthologues fell into similar metabolic and other categories as those in M tuberculosis. Expression of a majority of selected chlamydial orthologues was strongly up regulated in an in vitro model of chlamydial persistence and in synovial tissues of relevant patients, compared with their expression during active infection. Conclusions: These observations provide new insight into the molecular genetic basis underlying chlamydial persistence, and indicate that this information can be obtained, in some instances, by extrapolating observations made in other biological systems and/or organisms. C1 Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA. Univ Penn, Dept Med, Div Rheumatol, Sch Med, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Detroit, MI 48201 USA. RP Hudson, AP (reprint author), Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Gordon H Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA. EM ahudson@med.wayne.edu FU NIAID NIH HHS [AI-44493]; NIAMS NIH HHS [AR-47186, AR-42541] NR 27 TC 16 Z9 17 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD MAR PY 2006 VL 65 IS 3 BP 321 EP 327 DI 10.1136/ard.2005.042226 PG 7 WC Rheumatology SC Rheumatology GA 011NQ UT WOS:000235275600008 PM 16192289 ER PT J AU Mele, J Van Remmen, H Vijg, J Richardson, A AF Mele, James Van Remmen, Holly Vijg, Jan Richardson, Arlan TI Characterization of transgenic mice that overexpress both copper zinc superoxide dismutase and catalase SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID CELLULAR GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; DROSOPHILA-MELANOGASTER; MUTANT MICE; LIFE-SPAN; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; MEDIATED CYTOTOXICITY; ANTIOXIDANT ENZYMES; LIPID-PEROXIDATION AB Transgenic mice overexpressing both Cu/ZnSOD and catalase [Tg(SOD1/CAT)(+/o)] were used to evaluate the effects of overexpression of both genes against oxidative stress. Characterization of these transgenic mice revealed that catalase or Cu/ZnSOD activities were two- to fourfold higher in the tissues of transgenic mice compared to wild-type mice, and the activities of the other major antioxidant enzymes were not altered in the tissues of the transgenic mice. The murine embryonic fibroblasts (MEFs) from the Tg(SOD1/CAT)(+/o) and MEFs overexpressing Cu/ZnSOD were more resistant to paraquat cytotoxicity, relative to wild-type MEFs. The MEFs from Tg(SOD1/CAT)(+/o) tended to be more resistant (up to 2.25-fold) to paraquat cytotoxicity than MEFs overexpressing either Cu/ZnSOD or catalase alone. MEFs from Tg(CAT)(+/o) and Tg(SOD1/CAT)(+/o) were equally as resistant to hydrogen peroxide cytotoxicity. However, there were no significant differences in whole animal survival against either paraquat or gamma-radiation. C1 Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barchop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Geriatr Res, Educ & Clin Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Richardson, A (reprint author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM richardsona@uthscsa.edu FU NIA NIH HHS [P03 AG13319, P01 AG19316, P01 AG20591] NR 65 TC 33 Z9 33 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD MAR-APR PY 2006 VL 8 IS 3-4 BP 628 EP 638 DI 10.1089/ars.2006.8.628 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 042OZ UT WOS:000237539200036 PM 16677106 ER PT J AU Leverenz, JB Fishel, MA Peskind, ER Montine, TJ Nochlin, D Steinbart, E Raskind, MA Schellenberg, GD Bird, TD Tsuang, D AF Leverenz, JB Fishel, MA Peskind, ER Montine, TJ Nochlin, D Steinbart, E Raskind, MA Schellenberg, GD Bird, TD Tsuang, D TI Lewy body pathology in familial Alzheimer disease - Evidence for disease- and mutation-specific pathologic phenotype SO ARCHIVES OF NEUROLOGY LA English DT Article ID SPORADIC PARKINSONS-DISEASE; A-BETA DEPOSITION; ALPHA-SYNUCLEIN; NEUROFIBRILLARY CHANGES; CLINICAL-CRITERIA; APOLIPOPROTEIN-E; BODIES; DEMENTIA; PRESENILIN-1; BRAINS AB Background: The origin and significance of Lewy bodies and neurites (Lewy body pathology [LBP]) in Alzheimer disease (AD) are poorly understood. Objective: To examine LBP in the brainstem, limbic cortex, and neocortex of a large number of familial AD cases with mutations in 2 presenilin (PSEN) genes. Methods: Twenty-five familial AD cases with 9 known PSEN I mutations and 14 familial AD cases with a single PSEN 2 mutation (N1411) were examined for LBP using alpha-synuclein immunohistochemistry and sampling of multiple brainstem and cortical regions. Results: The amygdala was the most vulnerable site for LBP. In fact, virtually all (24 [96%] of 25 cases) of the PSEN 1 mutation cases had LBP in the amygdala. The PSEN 1 mutation cases also had more frequent LBP in the arnygdala and neocortex than those with the PSEN 2 mutation. However, within families with a single mutation of either PSEN I or PSEN 2, there was frequent variability of the LBP. Conclusion: These findings suggest that there are genetic influences on the presence of LBP in familial AD as demonstrated by the differences between PSEN I and PSEN 2 mutation cases. Results: The amygdala was the most vulnerable site for LBP. In fact, virtually all (24 [96%] of 25 cases) of the PSEN 1 mutation cases had LBP in the amygdala. The PSEN 1 mutation cases also had more frequent LBP in the amygdala and neocortex than those with the PSEN 2 mutation. However, within families with a single mutation of either PSEN I or PSEN 2, there was frequent variability of the LBP. Conclusion: These findings suggest that there are genetic influences on the presence of LBP in familial AD as demonstrated by the differences between PSEN I and PSEN 2 mutation cases. C1 Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Ctr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Res Educ & Clin Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. Univ Washington, Sch Med, Div Neuropathol, Dept Pathol, Seattle, WA USA. Univ Washington, Sch Med, Div Gerontol Geriatr, Dept Med, Seattle, WA USA. RP Leverenz, JB (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Ctr, 116MIRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM leverenz@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NINDS NIH HHS [R01 NS048595] NR 45 TC 50 Z9 52 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD MAR PY 2006 VL 63 IS 3 BP 370 EP 376 DI 10.1001/archneur.63.3.370 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 024ID UT WOS:000236187800008 PM 16533963 ER PT J AU Nosek, MA Hughes, RB Petersen, NJ Taylor, HB Robinson-Whelen, S Byrne, M Morgan, R AF Nosek, MA Hughes, RB Petersen, NJ Taylor, HB Robinson-Whelen, S Byrne, M Morgan, R TI Secondary conditions in a community-based sample of women with physical disabilities over a 1-year period SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE comorbidity; connective tissue diseases; disabled persons; joint diseases; multiple sclerosis; muscle weakness; nervous system; neurodegenerative diseases; neuromuscular diseases; obesity; pain; rehabilitation; rheumatic diseases; spinal cord injuries; trauma; women; women's health ID SPINAL-CORD-INJURY; INDEPENDENT LIVING CENTERS; UNITED-STATES; HEALTH; OUTCOMES; PEOPLE; GENDER; ADULTS AB Secondary conditions in a community-based sample of women with physical disabilities over a 1-year period. Arch Phys Med Rehabil 2006;87:320-7. Objective: To examine prevalence and predictors of secondary conditions in women with physical disabilities. Design: Cross-sectional. Setting: Women were recruited through private and public health clinics and various community organizations. Participants: A sample of 443 predominantly ethnic minority women with physical disabilities. Interventions: Not applicable. Main Outcome Measure: Health Conditions Checklist interference score. Results: Aggregated data over a 1-year period showed that nearly the entire sample reported interference from pain (94.5%) and fatigue (93.7%) and that at least three quarters of the sample reported problems with spasticity (85.4%), weakness (81.8%), sleep problems (80.2%), vision impairment (77.9%), and circulatory problems (77.9%). Obesity was substantially more prevalent in this sample (47.6%) than in the general population of women (34.0%). The mean number of secondary conditions per woman +/- standard deviation was 14.6 +/- 6.2 (range, 1-42), with 75% of the sample endorsing 10 or more conditions. On average, women reported experiencing 5.7 +/- 4.03 (range, 0-20) conditions that they rated as significant or chronic. A third (33.4%) of the variance in interference scores was accounted for in the regression analysis, with significant variance accounted for by race, disability type (women with joint and connective tissue disorders and women with postpolio reported the highest overall interference scores), greater functional limitations, and lower levels of general mental health. Conclusions: Secondary conditions in women with physical disabilities are substantially more problematic than reported previously in the literature. Further research is needed to determine health disparities of women with and without disabilities. Measurement issues and the clinical relevance of these findings are discussed. C1 Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33152 USA. Univ Texas, Hlth Sci Ctr, Div Dev Pediat, Houston, TX USA. RP Nosek, MA (reprint author), Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, 6550 Fannin,Ste 1421, Houston, TX 77030 USA. EM mnosek@bcm.tmc.edu RI Morgan, Robert/A-8577-2009 FU PHS HHS [R04/CCR618805] NR 34 TC 41 Z9 42 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 BP 320 EP 327 DI 10.1016/j.apmr.2005.11.003 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 021XZ UT WOS:000236020500003 PM 16500164 ER PT J AU Flood, KM Huang, ME Roberts, TL Pasquina, PF Nelson, VS Bryant, PR AF Flood, KM Huang, ME Roberts, TL Pasquina, PF Nelson, VS Bryant, PR TI Limb deficiency and prosthetic management. 2. Aging with limb loss SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE aging; amputation; artificial limbs; complications; outcome assessment (health care); rehabilitation ID AMPUTEE PATIENT; RISK-FACTORS; AMPUTATION; REHABILITATION; POPULATION; VETERANS; PAIN AB This self-directed learning module highlights the issues faced by people aging with limb loss. It is part of the study guide on limb deficiency and vascular rehabilitation in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This article specifically focuses on the impact that limb loss has on health and physical function throughout the life span. Case examples are used to illustrate what effect limb loss in childhood or young adulthood has on the incidence and management of new impairments or disease processes commonly associated with aging. Overall Article Objective: To discuss the impact of early-life limb loss on the incidence and management of physiologic and functional changes associated with aging. C1 VA Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, Pittsburgh, PA 15240 USA. Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. George E Wahlen Dept Vet Affairs Med Ctr, Phys Med & Rehabil Serv, Salt Lake City, UT USA. Walter Reed Army Med Ctr, Phys Med & Rehabil Serv, Washington, DC 20307 USA. Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. Good Shepherd Rehabil Hosp, Allentown, PA USA. RP Flood, KM (reprint author), VA Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, 132Y-A,Univ Dr C, Pittsburgh, PA 15240 USA. EM vze2zn62@verizon.net NR 33 TC 6 Z9 6 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 SU 1 BP S10 EP S14 DI 10.1016/j.apmr.2005.11.023 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 024PK UT WOS:000236208200003 PM 16500188 ER PT J AU Huang, ME Nelson, VS Flood, KM Roberts, TL Bryant, PR Pasquina, PF AF Huang, ME Nelson, VS Flood, KM Roberts, TL Bryant, PR Pasquina, PF TI Limb deficiency and prosthetic management. 3. Complex limb deficiency SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE amputation; artificial limbs; burns; multiple trauma; rehabilitation ID KNEE AMPUTATION LEVEL; ELECTRICAL BURNS; UPPER EXTREMITY; REHABILITATION; INJURIES; AMPUTEE; SALVAGE; SKIN AB This self-directed learning module highlights rehabilitation and prosthetic issues associated with complex limb deficiencies. It is part of the chapter on acquired limb deficiencies in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This article discusses rehabilitation and prosthetic management of patients with amputations for complex limb deficiencies secondary to trauma. Mechanisms of injury, prosthetic issues, prosthetic components, and potential problems in prosthetic fitting will be discussed. Overall Article Objective: To evaluate common problems associated with complex limb deficiency. C1 Northwestern Univ, Rehabil Inst Chicago, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. Vet Affairs Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, Pittsburgh, PA USA. George E Wahlen Dept Vet Affairs, Med Ctr, Phys Med & Rehabil Serv, Salt Lake City, UT USA. Good Shepherd Rehabil Hosp, Allentown, PA USA. Walter Reed Army Med Ctr, Phys Med & Rehabil Serv, Washington, DC 20307 USA. RP Huang, ME (reprint author), Northwestern Univ, Rehabil Inst Chicago, Feinberg Sch Med, Dept Phys Med & Rehabil, 345 E Super St, Chicago, IL 60611 USA. EM mhuang@ric.org NR 34 TC 2 Z9 2 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 SU 1 BP S15 EP S20 DI 10.1016/j.apmr.2005.11.024 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 024PK UT WOS:000236208200004 PM 16500189 ER PT J AU Nelson, VS Flood, KM Bryant, PR Huang, ME Pasquina, PF Roberts, TL AF Nelson, VS Flood, KM Bryant, PR Huang, ME Pasquina, PF Roberts, TL TI Limb deficiency and prosthetic management. 1. Decision making in prosthetic prescription and management SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE amputation; artificial limbs; limb deformities, congenital; prostheses and implants; rehabilitation AB Limb deficiency and prosthetic management. 1. Decision making in prosthetic prescription and management. C1 Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. Vet Affairs Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, Pittsburgh, PA USA. Good Shepherd Rehabil Hosp, Allentown, PA USA. Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. Walter Reed Army Med Ctr, Phys Med & Rehabil Serv, Washington, DC 20307 USA. George E Wahlen Dept Vet Affairs Med Ctr, Phys Med & Rehabil Serv, Salt Lake City, UT USA. RP Nelson, VS (reprint author), Dept PM&R, 325 E Eisenhower, Ann Arbor, MI 48108 USA. EM vsnelson@umich.edu NR 21 TC 16 Z9 17 U1 2 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 SU 1 BP S3 EP S9 DI 10.1016/j.apmr.2005.11.022 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 024PK UT WOS:000236208200002 PM 16500187 ER PT J AU Pasquina, PF Bryant, PR Huang, ME Roberts, TL Nelson, VS Flood, KM AF Pasquina, PF Bryant, PR Huang, ME Roberts, TL Nelson, VS Flood, KM TI Advances in amputee care SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Review DE amputation; prosthetics and implants; rehabilitation; review [publication type] ID DIFFERENT PROSTHETIC COMPONENTS; LOWER-LIMB AMPUTATIONS; TRANS-FEMORAL AMPUTEE; BELOW-KNEE AMPUTEES; QUALITY-OF-LIFE; ENERGY-EXPENDITURE; INTELLIGENT PROSTHESIS; TRANSFEMORAL AMPUTEES; HAND TRANSPLANTATION; OUTCOME MEASURE AB This self-directed learning module highlights the recent in novations in amputee care. It is part of the study guide on limb deficiency in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This focused review article describes the key elements of a successful comprehensive amputee program, the basic surgical considerations for upper- and lower-extremity amputation, and some of the more recent advances in prosthetic components. Further, an update is given on issues such as hand transplantation and the integration of robotics and artificial muscles for people with limb loss. Overall Article Objective: (a) To discuss current issues and advances in the care of patients with amputation, (b) to describe the key elements in designing a comprehensive amputee care program, and (c) to discuss surgical considerations of limb preservation and amputation levels. C1 Walter Reed Army Med Ctr, Sect 3J, Phys Med & Rehabil Serv, Washington, DC 20307 USA. Good Shepherd Rehabil Hosp, Allentown, PA USA. Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. George E Wahlen Dept Vet Affairs, Med Ctr, Salt Lake City, UT USA. Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. Vet Affairs Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, Pittsburgh, PA USA. RP Pasquina, PF (reprint author), Walter Reed Army Med Ctr, Sect 3J, Phys Med & Rehabil Serv, Bldg 2,6900 Georgia Ave, Washington, DC 20307 USA. EM Paul.Pasquina@NA.AMEDD.ARMY.MIL NR 86 TC 29 Z9 31 U1 2 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 SU 1 BP S34 EP S43 DI 10.1016/j.apmr.2005.11.026 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 024PK UT WOS:000236208200006 PM 16500191 ER PT J AU Roberts, TL Pasquina, PF Nelson, VS Flood, KM Bryant, PR Huang, ME AF Roberts, TL Pasquina, PF Nelson, VS Flood, KM Bryant, PR Huang, ME TI Limb deficiency and prosthetic management. 4. Comorbidities associated with limb loss SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE amputation; comorbidity; outcome assessment (health care); pain; rehabilitation ID PERIPHERAL-ARTERIAL-DISEASE; LOWER-EXTREMITY AMPUTATIONS; REHABILITATION; DEPRESSION; ADULTS; DISABILITY; AMPUTEES; PATIENT; POPULATION; PREVALENCE AB This self-directed learning module highlights common comorbidities found in people with amputations and their impact on functional outcome. It is part of the study guide on limb deficiency and vascular rehabilitation in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This article focuses on prosthetic considerations, functional outcome, and potential complications for a woman with the comorbidities of stroke and diabetes who experiences a dysvascular amputation. Formulation of the differential diagnosis, management of limb pain, and evaluation of the potential psychosocial issues arising after amputation are also discussed. Overall Article Objective: To analyze common comorbidities of people with amputations and to delineate their impact on functional outcome. C1 George E Wahlen Dept Vet Affairs, Med Ctr, Phys Med & Rehabil Serv, Salt Lake City, UT 84148 USA. Walter Reed Army Med Ctr, Phys Med & Rehabil Serv, Washington, DC 20307 USA. Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. Vet Affairs Pittsburgh Healthcare Syst, Phys Med & Rehabil Program, Pittsburgh, PA USA. Good Shepherd Rehabil Hosp, Allentown, PA USA. Northwestern Univ, Rehabil Inst Chicago, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. RP Roberts, TL (reprint author), George E Wahlen Dept Vet Affairs, Med Ctr, Phys Med & Rehabil Serv, 500 Foothill Blvd,117, Salt Lake City, UT 84148 USA. EM Toni.Roberts@med.va.gov NR 51 TC 11 Z9 11 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2006 VL 87 IS 3 SU 1 BP S21 EP S27 DI 10.1016/j.apmr.2005.11.025 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 024PK UT WOS:000236208200005 PM 16500190 ER PT J AU Samaha, FF Szapary, PO Iqbal, N Williams, MM Bloedon, LT Kochar, A Wolfe, ML Rader, DJ AF Samaha, FF Szapary, PO Iqbal, N Williams, MM Bloedon, LT Kochar, A Wolfe, ML Rader, DJ TI Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE adipocytokines; lipids; inflammation; lipoprotein metabolism; arteriosclerosis ID TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; IMPROVES GLYCEMIC CONTROL; ACTIVATED RECEPTOR-GAMMA; ARTERY-DISEASE PATIENTS; C-REACTIVE PROTEIN; ADIPOSE-TISSUE; PPAR-GAMMA; PIOGLITAZONE; METFORMIN AB Background - PPAR-gamma agonists improve insulin sensitivity and glycemic control in type 2 diabetes and may reduce atherosclerosis progression. Thus, PPAR-gamma agonists may be an effective therapy for metabolic syndrome. However, the full spectrum of potentially antiatherogenic mechanisms of PPAR-gamma agonists have not been fully tested in nondiabetic patients with metabolic syndrome. Methods and Results - We performed a prospective, double-blinded, placebo-controlled study of 60 nondiabetic subjects with low high-density lipoprotein cholesterol ( HDL-C) level and metabolic syndrome to rosiglitazone 8 mg daily or placebo for 12 weeks. We found no significant effect of rosiglitazone on HDL-C ( + 5.5% versus + 5.8%, P = 0.89), and an increase in total cholesterol ( + 8% versus + 1%; P = 0.03). Nevertheless, rosiglitazone significantly increased adiponectin ( + 168% versus + 25%; P = 0.001), and lowered resistin ( - 6% versus + 4%; P = 0.009), C- reactive protein ( - 32% versus + 36%, P = 0.002), interleukin ( IL)-6 ( - 22% versus + 4%, P < 0.001), and soluble tumor-necrosis factor-alpha receptor-2 ( - 5% versus + 7%, P < 0.001). Conclusions - These findings suggest that rosiglitazone, presumably through its PPAR-gamma agonist properties, has direct effects on inflammatory markers and adipokines in the absence of favorable lipid effects. These findings may help explain the mechanism underlying the possible antiatherosclerotic effects of rosiglitazone. C1 Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Div Cardiovasc, Dept Med, Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Cardiovasc Inst, Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. RP Samaha, FF (reprint author), Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM rick.samaha@med.va.gov FU NCRR NIH HHS [M01-RR00040] NR 30 TC 88 Z9 101 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAR PY 2006 VL 26 IS 3 BP 624 EP 630 DI 10.1161/01.ATV.0000200136.567196.30 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 012WW UT WOS:000235372600029 PM 16357312 ER PT J AU Cooper, RA AF Cooper, RA TI Adapting: Financial planning for a life with multiple sclerosis. SO ASSISTIVE TECHNOLOGY LA English DT Book Review C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA. EM rcooper@pitt.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PD SPR PY 2006 VL 18 IS 1 BP 122 EP 122 PG 1 WC Rehabilitation SC Rehabilitation GA 046UZ UT WOS:000237837900011 ER PT J AU Gould, GG Altamirano, AV Javors, MA Frazer, A AF Gould, GG Altamirano, AV Javors, MA Frazer, A TI A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters SO BIOLOGICAL PSYCHIATRY LA English DT Article DE serotonin transporter; norepinephrine transporter; dual uptake inhibitor; venlafaxine; amitriptyline; quantitative autoradiography ID REUPTAKE INHIBITOR VENLAFAXINE; SPECIES-SCANNING MUTAGENESIS; RAT-BRAIN; IN-VIVO; QUANTITATIVE AUTORADIOGRAPHY; CYTOCHROME-P450 ENZYMES; H-3 CYANOIMIPRAMINE; DRUG-INTERACTIONS; DORSAL RAPHE; UPTAKE SITES AB Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases NET binding sites. We hypothesized venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Alsom rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties. C1 Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Gould, GG (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gouldg@uthscsa.edu OI Gould, Georgianna/0000-0002-5470-8763 FU NIMH NIH HHS [MH57001] NR 57 TC 37 Z9 37 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2006 VL 59 IS 5 BP 408 EP 414 DI 10.1016/j.biopsych.2005.07.011 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 019PY UT WOS:000235850400004 PM 16140280 ER PT J AU Green, MF Nuechterlein, KH Breitmeyer, B Mintz, J AF Green, MF Nuechterlein, KH Breitmeyer, B Mintz, J TI Forward and backward visual masking in unaffected siblings of schizophrenic patients SO BIOLOGICAL PSYCHIATRY LA English DT Article DE visual masking; schizophrenia; vulnerability; visual processing; backward masking; siblings ID INFORMATION-PROCESSING DEFICITS; NEGATIVE-SYMPTOM SCHIZOPHRENIA; VULNERABILITY; CHANNELS; PERFORMANCE; MECHANISM; TRANSIENT; DISORDER; SYSTEM; MANIA AB Visual masking tasks assess the earliest stages of visual processing. This study examined visual masking performance for forward and backward masking tasks in siblings of schizophrenic patients and healthy comparison subjects. A staircase method was used to ensure that unmasked target identification was equivalent across subjects to eliminate differences due to discrimination of simple perceptual inputs. Four computerized visual masking tasks were administered to 43 siblings of patients and 42 normal comparison subjects. The tasks included: 1) locating a target; 2) identifying a target with a high-energy mask; 3) identifying a target with a low-energy mask; and 4) a paracontrast/metacontrast procedure with nonoverlapping target and mask. Across masking conditions, there was a significant group by forward/backward interaction, meaning that siblings showed a larger difference from control subjects in backward versus forward masking. This group difference was more pronounced in the location condition. These results support the theory that visual masking procedures may be indicators of vulnerability to schizophrenia. The pattern of findings in this report (larger group differences on backward versus forward masking and on the location condition) suggests that the activity of transient visual channels may be particularly linked to vulnerability. C1 Univ Calif Los Angeles, NPI, Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. Univ Houston, Dept Psychol, Houston, TX 77004 USA. RP Green, MF (reprint author), Univ Calif Los Angeles, NPI, Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Room 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu FU NIMH NIH HHS [MH-37705, MH-43292, MH-30911] NR 44 TC 29 Z9 30 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2006 VL 59 IS 5 BP 446 EP 451 DI 10.1016/j.biopsych.2005.06.035 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 019PY UT WOS:000235850400010 PM 16139818 ER PT J AU Didenko, VV Baskin, DS AF Didenko, VV Baskin, DS TI Horseradish peroxidase-driven fluorescent labeling of nanotubes with quantum dots SO BIOTECHNIQUES LA English DT Article ID WALLED CARBON NANOTUBES; VISUALIZATION AB We describe the first enzyme-driven technique for fluorescent labeling of single-wallet! carbon nanotubes (SWNTs). The labeling was performed via enzymatic biotinylation of nanotubes in the tyramide-horseradish peroxidase (HRP) reaction. Both direct and indirect-fluorescent labeling of SWNTS was achieved using either biotinvl tyramide or fuorescently tagged tyramides. Biotinylated SWNTs later reacted with streptavidin-conjugated fluorophores. Linking semiconductor nanocrystals, quantum clots (Q-clots), to the surface of nanotubes resulted in their fluorescent visualization, whereas conventional fluorophores bound to SWNTs directly or through biotin-streptavidin linkage, were completely quenched. Enzymatic biotinylation permits fluorescent visualization of carbon nanotubes, which could be useful flora number of biomedical applications. In addition, other organic molecules such as proteins, antibodies, or DNA can be conjugated to biotinylated SWNTs using this approach. C1 Baylor Coll Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Methodist Neurol Inst, Houston, TX USA. RP Didenko, VV (reprint author), 2002 Holcombe Blvd,Bldg 109,Room 204, Houston, TX 77030 USA. EM vdidenko@bcm.tmc.edu FU NIA NIH HHS [R03 AG022664, R03 AG022664-01] NR 13 TC 10 Z9 10 U1 1 U2 7 PU EATON PUBLISHING CO PI WESTBOROUGH PA ONE RESEARCH DRIVE, SUITE 400A, PO BOX 1070, WESTBOROUGH, MA 01581-6070 USA SN 0736-6205 J9 BIOTECHNIQUES JI Biotechniques PD MAR PY 2006 VL 40 IS 3 BP 295 EP + DI 10.2144/000112110 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 024QF UT WOS:000236210400007 PM 16568818 ER PT J AU Arango, JI Restrepo, A Schneider, DL Callander, NS Ochoa-Bayona, JL Restrepo, MI Bradshaw, P Patterson, J Freytes, CO AF Arango, JI Restrepo, A Schneider, DL Callander, NS Ochoa-Bayona, JL Restrepo, MI Bradshaw, P Patterson, J Freytes, CO TI Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma SO BONE MARROW TRANSPLANTATION LA English DT Article DE C. difficile-associated diarrhea; hematologic malignancies; autologous peripheral blood stem cell transplantation; high-dose chemotherapy ID ANTIBIOTIC-ASSOCIATED DIARRHEA; INFECTION; TOXIN; RECIPIENTS; ANTIBODY; COLITIS AB Diarrhea is a major cause of morbidity and discomfort for patients undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation (APBSCT). There are multiple causes of diarrhea in patients undergoing transplantation including antineoplastic chemotherapy, antimicrobials and infection, including Clostridium difficile as the most common pathogen involved. The purpose of this study was to determine the incidence of C. difficile-associated diarrhea (CDAD) 1 week before and 30 days after APBSCT, and to identify risk factors for the development of CDAD including diagnosis. Two hundred and forty-two patients underwent APBSCT for multiple myeloma and lymphoma between October 1996 and October 2001 in two teaching hospitals. Diarrhea was reported in 157 (64.9%) subjects. One hundred and thirty-five out of the 157 subjects were tested for the presence of C. difficile toxin A. These subjects constitute the study group. The incidence of CDAD was 15%. Two thirds of the patients who developed CDAD had multiple myeloma and one third had lymphoma; this difference did not attain statistical significance. The use of cephalosporins ( P = 0.03) and the use of intravenous vancomycin ( P = 0.02) were the only identified risk factors associated with the development of CDAD. Patients treated with paclitaxel as part of the mobilization regimen had a lower incidence of CDAD than patients who received hematopoietic growth factor only ( P = 0.01). C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Arango, JI (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, Mail Code 7880, San Antonio, TX 78229 USA. EM arangoj@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 NR 19 TC 34 Z9 35 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD MAR PY 2006 VL 37 IS 5 BP 517 EP 521 DI 10.1038/sj.bmt.1705269 PG 5 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 014RX UT WOS:000235498700012 PM 16435018 ER PT J AU Houldin, A Curtiss, CP Haylock, PJ AF Houldin, Arlene Curtiss, Carol P. Haylock, Pamela J. TI Executive summary SO CANCER NURSING LA English DT Editorial Material ID CANCER SURVIVORSHIP; TRENDS; NATION C1 Univ Penn, Sch Nursing, Adult Oncol Nurse Practitioner Program, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Palliat Care Serv, Philadelphia, PA USA. Univ Texas, Med Branch, Sch Nursing, Galveston, TX 77550 USA. RP Houldin, A (reprint author), Univ Penn, Sch Nursing, Adult Oncol Nurse Practitioner Program, Philadelphia, PA 19104 USA. EM bouldin@nursing.upenn.edu; carol.curtiss@verizon.net; pjhaylock@indian-creek.net NR 13 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0162-220X J9 CANCER NURS JI Cancer Nurs. PD MAR-APR PY 2006 VL 29 IS 2 SU S BP 6 EP 11 DI 10.1097/00002820-200603002-00003 PG 6 WC Oncology; Nursing SC Oncology; Nursing GA 097AY UT WOS:000241419800003 PM 16779948 ER PT J AU Ozdener, H Yee, KK Cao, J Brand, JG Teeter, JH Rawson, NE AF Ozdener, H Yee, KK Cao, J Brand, JG Teeter, JH Rawson, NE TI Characterization and long-term maintenance of rat taste cells in culture SO CHEMICAL SENSES LA English DT Article DE culture; gustducin; imaging; proliferation; taste receptor ID CIRCUMVALLATE PAPILLAE; ADHESION MOLECULE; BUD CELLS; FUNGIFORM PAPILLAE; RECEPTOR-CELLS; FINE STRUCTURE; TRANSDUCTION; EXPRESSION; INNERVATION; DENERVATION AB Taste cells have a limited life span and are replaced from a basal cell population, although the specific factors involved in this process are not well known. Short- and long-term cultures of other sensory cells have facilitated efforts to understand the signals involved in proliferation, differentiation, and senescence, yet few studies have reported successful primary culture protocols for taste cells. Furthermore, no studies have demonstrated both proliferation and differentiation in vitro. In this study, we have developed an in vitro culture system to maintain and utilize rat primary taste cells for more than 2 months without losing key molecular and biochemical features. Gustducin, phospholipase C-beta(2) (PLC-beta(2)), T1R3, and T2R5 mRNA were detected in the cultured cells by reverse transcriptase-polymerase chain reaction. Western blot analysis demonstrated gustducin and PLC-beta(2) expression in the same samples, which was confirmed by immunocytochemistry. Labeling with bromo-2-deoxyuridine (BrdU) demonstrated proliferation, and a subset of BrdU-labeled cells were also immunoreactive for either gustducin or PLC-beta(2), indicating differentiation of newly generated cells in vitro. Cultured cells also exhibited increases in intracellular calcium in response to several taste stimuli. These results indicate that taste cells from adult rats can be generated and maintained under the described conditions for at least 2 months. This system will enable further studies of the processes involved in proliferation, differentiation, and function of mammalian taste receptor cells in an in vitro preparation. C1 Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Ozdener, H (reprint author), Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA. EM hozdener@monell.org NR 44 TC 23 Z9 26 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X J9 CHEM SENSES JI Chem. Senses PD MAR PY 2006 VL 31 IS 3 BP 279 EP 290 DI 10.1093/chemse/bjj030 PG 12 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA 025GI UT WOS:000236252900011 PM 16452455 ER PT J AU Dominitz, JA Dire, CA Billingsley, KG Todd-Stenberg, JA AF Dominitz, JA Dire, CA Billingsley, KG Todd-Stenberg, JA TI Complications and antireflux medication use after antireflux surgery SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID LAPAROSCOPIC NISSEN FUNDOPLICATION; GASTROESOPHAGEAL-REFLUX DISEASE; QUALITY-OF-LIFE; VETERANS-AFFAIRS; SURGICAL THERAPY; FOLLOW-UP; TERM; POPULATION; PREVALENCE; EXPERIENCE AB Background & Aims: Although antireflux surgery is increasingly common, few studies have assessed the associated complications and health care use after surgery. The aim of this study was to estimate postoperative complications and continued use of antireflux medications and to identify predictors of complications. Methods: Through a review of the Department of Veterans Affairs administrative databases, all patients undergoing antireflux surgery from October 1, 1990, through January 29, 2001, were identified. Of 3367 patients identified, 22:2 were excluded as a result of a diagnosis of esophageal cancer, achalasia, or because there was no diagnosis related to gaistroesophageal reflux disease. Medication use was determined for 2406 patients who had a minimum of 1 year of follow-up, including :1 or more outpatient visits at least 6 months after surgery and during the time when national pharmacy records were available. Results: Dysphagia was recorded in:19.4%, dilation was performed in 6.4%, and a repeat antireflux surgery was performed in 2.3%. The surgical mortality rate was .8%. Prescriptions were dispensed repeatedly for H-2 receptor antagonists in 23.8%, proton pump inhibitors in 34.3%, and promotility agents in 9.2% of patients. Overall, 49.8% of patients received. at least 3 prescriptions for one of these medications. Conclusions: A moderate proportion of patients undergoing antireflux surgeries experienced complications and approximately 50% of patients received multiple prescriptions for antireflux medications at a median of 5 years of follow-up evaluation. Therefore, before surgery is performed, patients considering surgery should be counseled fully about the risk for complications and the likelihood of continued antireflux medication use. C1 VA Puget Sound Hlth Care Syst, Seattle Div S 111 Gastro, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S 111 Gastro, NW Hlth Serv Res & Dev Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jason.dominitz@va.gov OI Dominitz, Jason/0000-0002-8070-7086 NR 38 TC 40 Z9 41 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2006 VL 4 IS 3 BP 299 EP 305 DI 10.1016/j.cgh.2005.12.019 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 023AF UT WOS:000236096700010 PM 16527692 ER PT J AU El-Serag, HB Hampel, H Javadi, F AF El-Serag, HB Hampel, H Javadi, F TI The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Review ID NONALCOHOLIC FATTY LIVER; POPULATION-BASED COHORT; CHRONIC HEPATITIS-C; RISK-FACTORS; UNITED-STATES; NATURAL-HISTORY; CANCER-MORTALITY; VIRAL-HEPATITIS; VIRUS-INFECTION; US ADULTS AB Background & Aims: We conducted a systematic review and a meta-analysis to estimate the magnitude and determinants of association between diabetes and hepatocellular carcinoma (HCC). Methods: MEDLINE searches were conducted for published full studies (between January 1.966 and February 2005) that provided risk estimates and met criteria concerning the definition of exposure and outcomes. Two investigators independently performed standardized search and data abstraction. Unadjusted and adjusted odds ratios for individual outcomes Were obtained or calculated for each study and were synthesized using a random-effects model. Results: A total of 26 studies met our inclusion and exclusion criteria. Among 13 case-control studies, diabetes was associated significantly with HCC in 9 studies (pooled odds ratio, 2.5; 95% confidence interval, 1.8-3.5). Among 13 cohort studies, diabetes was associated significantly with HCC in 7 studies (pooled risk ratio, 2.5; 95% confidence interval, 1.9-.2). The results were relatively consistent in different populations, different geographic locations, and a variety of control groups. The signifiicant association between HCC and diabetes was independent of alcohol use or viral hepatitis in the :10 studies that examined these factors. Few studies adjusted for diet and obesity. Conclusions: Diabetes is associated with an increased risk for HIM However, more research is required to examine issues related to the duration and treatment of diabetes, and confounding by diet and obesity. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Texas, Sch Med, Dept Gastroenterol, Houston, TX USA. RP El-Serag, HB (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 41 TC 381 Z9 399 U1 4 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2006 VL 4 IS 3 BP 369 EP 380 DI 10.1016/j.cgh.2005.12.007 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 023AF UT WOS:000236096700020 PM 16527702 ER EF